
<html lang="en"     class="pb-page"  data-request-id="beb81c19-f925-467b-b360-0c2c52b67f3a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01307;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space" /></meta><meta name="dc.Creator" content="Adam G.  Schwaid" /></meta><meta name="dc.Creator" content="Kerrie B.  Spencer" /></meta><meta name="dc.Description" content="Inhibiting the NLRP3 inflammasome mediates inflammation in an extensive number of preclinical models. As excitement in this field has grown, several companies have recently initiated testing of dir..." /></meta><meta name="Description" content="Inhibiting the NLRP3 inflammasome mediates inflammation in an extensive number of preclinical models. As excitement in this field has grown, several companies have recently initiated testing of dir..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 22, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01307" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 The Authors. Published by American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01307" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01307" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01307" /></link>
        
    
    

<title>Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01307" /></meta><meta property="og:title" content="Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0009.jpeg" /></meta><meta property="og:description" content="Inhibiting the NLRP3 inflammasome mediates inflammation in an extensive number of preclinical models. As excitement in this field has grown, several companies have recently initiated testing of direct NLRP3 inhibitors in the clinic. At the same time, the NLRP3 inflammasome is part of a larger pro-inflammatory pathway, whose modulation is also being explored. Multiple targets in this pathway are already impinged upon by molecules that have been through clinical trials. These data, informed by the growing mechanistic understanding of the NLRP3 inflammasome in the preclinical space, provide a rich backdrop to assess the current state of the field. Here we explore attempts to inhibit the NLRP3 inflammasome in light of clinical and preclinical data around efficacy and safety." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Inhibiting the NLRP3 inflammasome mediates inflammation in an extensive number of preclinical models. As excitement in this field has grown, several companies have recently initiated testing of direct NLRP3 inhibitors in the clinic. At the same time, the NLRP3 inflammasome is part of a larger pro-inflammatory pathway, whose modulation is also being explored. Multiple targets in this pathway are already impinged upon by molecules that have been through clinical trials. These data, informed by the growing mechanistic understanding of the NLRP3 inflammasome in the preclinical space, provide a rich backdrop to assess the current state of the field. Here we explore attempts to inhibit the NLRP3 inflammasome in light of clinical and preclinical data around efficacy and safety." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0009.jpeg" /></meta><meta name="twitter:title" content="Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01307"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01307">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01307&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01307&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01307&amp;href=/doi/10.1021/acs.jmedchem.0c01307" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 101-122</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01176" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01459" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Adam G. Schwaid</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adam G. Schwaid</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adam+G.++Schwaid">Adam G. Schwaid</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2434-6148" title="Orcid link">http://orcid.org/0000-0003-2434-6148</a></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Kerrie B. Spencer</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kerrie B. Spencer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#640f0116160d013b1714010a07011624090116070f4a070b09"><span class="__cf_email__" data-cfemail="761d1304041f132905061318151304361b1304151d5815191b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kerrie+B.++Spencer">Kerrie B. Spencer</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01307&amp;href=/doi/10.1021%2Facs.jmedchem.0c01307" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 101–122</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 22, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 July 2020</li><li><span class="item_label"><b>Published</b> online</span>22 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01307" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01307</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D101%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAdam%2BG.%2BSchwaid%252C%2BKerrie%2BB.%2BSpencer%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D1%26contentID%3Dacs.jmedchem.0c01307%26title%3DStrategies%2Bfor%2BTargeting%2Bthe%2BNLRP3%2BInflammasome%2Bin%2Bthe%2BClinical%2Band%2BPreclinical%2BSpace%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D122%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01307"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1974</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01307" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;G. Schwaid&quot;},{&quot;first_name&quot;:&quot;Kerrie&quot;,&quot;last_name&quot;:&quot;B. Spencer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;101-122&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01307&quot;},&quot;abstract&quot;:&quot;Inhibiting the NLRP3 inflammasome mediates inflammation in an extensive number of preclinical models. As excitement in this field has grown, several companies have recently initiated testing of direct NLRP3 inhibitors in the clinic. At the same time, the NLRP3 inflammasome is part of a larger pro-inflammatory pathway, whose modulation is also being explored. Multiple targets in this pathway are already impinged upon by molecules that have been through clinical trials. These data, informed by the growing mechanistic understanding of the NLRP3 inflammasome in the preclinical space, provide a rich backdrop to assess the current state of the field. Here we explore attempts to inhibit the NLRP3 inflammasome in light of clinical and preclinical data around efficacy and safety.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01307&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01307" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01307&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01307" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01307&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01307" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01307&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01307&amp;href=/doi/10.1021/acs.jmedchem.0c01307" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01307" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01307" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01307%26sid%3Dliteratum%253Aachs%26pmid%3D33351619%26genre%3Darticle%26aulast%3DSchwaid%26date%3D2021%26atitle%3DStrategies%2Bfor%2BTargeting%2Bthe%2BNLRP3%2BInflammasome%2Bin%2Bthe%2BClinical%2Band%2BPreclinical%2BSpace%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D1%26spage%3D101%26epage%3D122%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291161" title="Inflammation">Inflammation</a>,</li><li><a href="/action/doSearch?ConceptID=290682" title="Post-translational modification">Post-translational modification</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/1" title="Go to Volume 64, Issue 1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/jmcmar.2021.64.issue-1/20210114/jmcmar.2021.64.issue-1.largecover.jpg" alt="Go to Volume 64, Issue 1"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibiting the NLRP3 inflammasome mediates inflammation in an extensive number of preclinical models. As excitement in this field has grown, several companies have recently initiated testing of direct NLRP3 inhibitors in the clinic. At the same time, the NLRP3 inflammasome is part of a larger pro-inflammatory pathway, whose modulation is also being explored. Multiple targets in this pathway are already impinged upon by molecules that have been through clinical trials. These data, informed by the growing mechanistic understanding of the NLRP3 inflammasome in the preclinical space, provide a rich backdrop to assess the current state of the field. Here we explore attempts to inhibit the NLRP3 inflammasome in light of clinical and preclinical data around efficacy and safety.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08084" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08084" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Targeting the NLRP3 inflammasome is an exploding field of research. Driven by extensive literature implicating the inflammasome in a range of different inflammatory conditions, numerous pharmaceutical and biotechnology companies have progressed compounds into clinical trials. Many different indications including nonalcoholic steatohepatitis (NASH), gout, Alzheimer’s disease, and Parkinson’s disease, among others are being targeted. In the past, attempts to inhibit the inflammasome focused on blocking the cytokines produced by inflammasome activation. This work had mixed results and limited commercial success. At present, most attempts to inhibit the NLRP3 inflammasome focus on compounds that directly bind to and inhibit NLRP3. Additionally, <i>in vitro</i> and <i>in vivo</i> studies suggest there are numerous additional strategies to perturb NLRP3 inflammasome function. These entail cellular mechanisms that regulate NLRP3 at the level of post-translational modifications and protein–protein interactions as well as strategies that look further upstream at events that trigger inflammasome activation. Several compounds that have been in clinical trials or are marketed drugs happen to inhibit proteins that are also purported to be critical to inflammasome function. Consequently, examining the data around some of these compounds may provide context for the clinical expectations that are reasonable from NLRP3 or other inflammasome inhibitors. Finally, we focus on what the safety implications are for direct NLRP3 inhibition based on preclinical data with a special interest in the effect of inhibiting NLRP3 on increased susceptibility to infection.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">The NLRP3 Inflammasome</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11227" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11227" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">NLRP3 is an inflammasome sensor protein that has been well studied in a number of disease contexts. Activation of NLRP3 leads to the formation of an oligomeric protein complex that includes ASC and caspase-1. This oligomeric protein complex is termed the “inflammasome”, and when the sensor protein in the complex is NLRP3, it is referred to as the NLRP3 inflammasome. Inflammasome formation can be triggered by the activation of other inflammasome sensor proteins, such as AIM2, NLRP1, or NLRC4, and in these cases the respective inflammasome sensor protein is part of the inflammasome oligomer. Some inflammasome sensors directly recognize damage associated molecular patterns (DAMPs) or pathogen associated molecular patterns (PAMPs).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> For example, NLRP1B recognizes anthrax lethal toxin, NLRC4 recognizes bacterial flagellin, and AIM2 recognizes cytosolic DNA.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> On the other hand, NLRP3 relies on intracellular second messengers rather than the direct detection of external stimuli. NLRP3 activation can be triggered by a variety of intracellular signals. Potassium efflux is one of the most well described triggers of NLRP3 inflammasome activation. NLRP3 is also known to respond to other intracellular signals such as reactive oxygen species (ROS) and cytoplasmic cathepsin activity.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The integration of multiple different inflammasome triggers into secondary messenger signals, like potassium efflux, may be why NLRP3 appears to be central to such a large variety of inflammatory conditions. Inflammasome activation is regulated by a complex molecular interplay beyond inflammasome sensor proteins. Understanding this pathway and its molecular interactions highlights other potential routes to drug the inflammasome.</div><div class="NLM_p">Inflammasome activation is mediated by two key steps: priming, often called signal 1, and activation, often called signal 2 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Priming consists of upregulation of inflammasome-related proteins including inflammasome sensor proteins, IL-1β and IL-18 through upregulation of NF-κB transcriptional activity. NF-κB transcriptional activity is highly regulated by numerous intracellular and extracellular mechanisms.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> NF-κB is held in an inactive state in the cytosol by IκB proteins. Post-translational modification or ubiquitination of IκB in response to signal transduction from extracellular stimuli leads to nuclear localization and activation of NF-κB. Bacterial components will activate NF-κB transcriptional activity through TLR binding and signal transduction through Myd88, IRAK, and TRAF6. Cytokines such as IL-1β and TNFα also activate NF-κB transcriptional activity as do other DAMPs such as S100a8/a9.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In the absence of NF-κB priming, many cells do not express enough inflammasome components for inflammasome activation upon signal 2 treatment. In particular, many cells do not express high levels of pro-IL-1β in the absence of signal 1. This leads to ASC speck formation upon signal 2, but without concomitant secretion of IL-1β. Numerous strategies to inhibit NF-κB activation have been described and are beyond the scope of this review.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. NLRP3 inflammasome pathway with nodes inhibited by clinical or marketed compounds highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Canonically, signal 2 triggers aggregation of an inflammasome sensor protein, with an inflammasome adaptor protein, and recruitment of caspase. In the case of NLRP3, signal 2 leads to the binding of NLRP3 to ASC and the recruitment of pro-caspase-1 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). This large protein aggregate appears as bright puncta in immunofluorescence assays. Aggregation of pro-caspase-1 leads to autoproteolysis and generates enzymatically active caspase-1. In turn, caspase-1 cleaves pro-IL-1β to IL-1β and gasdermin-D to N-terminal gasdermin-D. N-Terminal gasdermin-D forms membrane pores that lead to pyroptosis and secretion of IL-1β.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Initially, inhibitors of NLRP3 were discovered through phenotypic screening of a diaryl sulfonylurea library against interleukin 1 beta (IL-1β) secretion from human monocytes based on the observation that glyburide, a sulfonylurea, was an efficacious inhibitor.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Subsequently, these compounds were further optimized, and their mechanism was studied initially leading to the hypothesis that they functioned through inhibiting GST omega 1-1<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Further work led to the discovery that these compounds functioned through NLRP3 inhibition. One of these compounds derived from glyburide was renamed from CRID3 or CP456,773 to MCC950 and was found to be a potent inhibitor of the NLRP3 inflammasome<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). MCC950 was tested in the clinic for rheumatoid arthritis, but was not progressed possibly due to elevation of serum liver enzyme levels.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> MCC950 functions by binding to the Walker B motif in the NACHT domain of NLRP3 and blocking NLRP3-mediated ATP hydrolysis.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> MCC950 has since been used as a tool compound in a wide array of <i>in vitro</i> and <i>in vivo</i> studies that implicate NLRP3 in disease.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> This tool compound has been used in concert with a range of target validation techniques to show that NLRP3 is remarkable for its apparent activity in numerous disease contexts including cryopyrin associated periodic syndrome (CAPS), inflammatory bowel disease (IBD), NASH, gout, Alzheimer’s disease, and Parkinson’s disease.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and Targets of Inflammasome Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0007.gif" alt="" id="gr7" /></img><div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. NLRP3 inhibitors with structures in the public domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CAPS includes a range of autoimmune diseases including familial cold autoinflammatory syndrome and Muckle–Wells syndrome.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These rare genetic syndromes generally caused by gain-of-function (GOF) mutations in the NLRP3 gene, have symptoms including fever, rash, arthralgia, myalgia, fatigue, and conjunctivitis. CAPS patients have elevated secretion of IL-1β. At present, the treatments for CAPS are IL-1β blockers canakinumab and anakinra. It is hypothesized that directly inhibiting NLRP3 would also alleviate this disease. In support of this, MCC950 is efficacious in a model of CAPS, although the precise NLRP3 GOF mutation appears to be important for MCC950 efficacy.<a onclick="showRef(event, 'ref12 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref17">(12,17)</a> While CAPS is a rare disease with a small patient population, NLRP3 is also implicated in more common inflammatory diseases such as IBD, ulcerative colitis, and rheumatoid arthritis.</div><div class="NLM_p">In animal models of IBD, NLRP3 activation has been shown to lead to secretion of the cytokine IL-1β.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> While this cytokine secretion appears to have an impact on disease models in IBD, inflammasome activation may be driven to a greater extent through NOD2.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In the presence of NOD2, pharmacological inhibition of NLRP3 does not appear to ameliorate disease in a dextran sodium sulfate (DSS) model of IBD.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> On the other hand, NLRP3 appears to play a much more important role in a DSS-induced IBD model in NOD2 −/– animals.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> While the impact of NLRP3 in IBD may be unclear based on animal models of disease, human genetics points to a more significant role. Increased NLRP3 activity is reported in people harboring the V411I mutation in the NLRP3 interacting protein CARD8.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Moreover, treatment of patients harboring a CARD8 V411I mutation with canakinumab or anakinra appears promising.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Indirect inhibition of NLRP3 also may temper inflammation in IBD. For instance, the kinase NEK7 has been shown to stabilize and activate NLRP3. In turn, knockdown of NEK7 <i>in vitro</i> and <i>in vivo</i> attenuates DSS induced IBD in WT animals.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">NLRP3 inhibition is also being explored to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Elevated cholesterol and triglycerides are characteristic of patients with NASH.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Cholesterol crystals have been shown to activate the NLRP3 inflammasome <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Likewise, palmitic acid has been shown to activate NLRP3.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Ioannou et al. showed in obese diabetic Alms1 (foz/foz) mice fed a high fat diet, a model of NASH, that hepatic lipid droplets rich in cholesterol crystals led to recruitment and subsequent NLRP3 activation of Kupffer cells.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In this mouse model, cholesterol crystal accumulation in lipid droplets could be blocked by statin and ezetimibe treatment, and consequently NLRP3 activation could be ameliorated. MCC950 has been used in mouse models of NASH to directly interrogate the role of the NLRP3 inflammasome in this disease and reduce NAFLD pathology and fibrosis.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">Gout is a form of arthritis caused by the accumulation of uric acid crystals. Treatments for gout focus on blocking the production of uric acid by inhibiting xanthine oxidase with allopurinol.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> However, allopurinol treatment still leads to gout-flares. Therefore, patients are treated with anti-inflammatories, often NSAIDs or glucocorticoids, simultaneously.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Recently, it has been hypothesized that NLRP3 activation may contribute to disease pathology.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Uric acid crystals have been shown to activate the inflammasome <i>in vivo</i> and <i>in vitro</i>, and this activation is blocked by NLRP3 KO. Several strategies have been taken to block uric acid mediated inflammasome activation including β-hydroxybutyrate treatment to block IL-β secretion, purportedly through blocking inflammasome assembly, in neutrophils as well as caffeic acid treatment, which blocks inflammasome activation through ASC binding.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> The putative NLRP3 inhibitor OLT1177, also called dapansutrile, appears to be efficacious in preclinical models of gout, although the mechanism of this compound has not been elucidated as clearly as MCC950.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a></div><div class="NLM_p">As the role of neuroinflammation in neurodegeneration is increasingly recognized, the inflammasome has a growing importance in neuroscience. Gordon et al. showed that NLRP3 and ASC are upregulated in patients with Parkinson’s disease and demonstrated that α-synuclein elicited inflammasome activation followed by IL-1β secretion from primary rodent microglia.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> They demonstrated this process was mediated by NLRP3 using MCC950 and NLRP3 knockout cells and extended their work to several <i>in vivo</i> pharmacodynamic models of Parkinson’s disease. Likewise, Heneka et al. observed elevated levels of cleaved caspase-1 in brain lysates from patients with Alzheimer’s disease.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> APP/PS1 mice carrying mutations associated with familial Alzheimer’s were protected from loss of spatial memory and other pharmacodynamic markers of Alzheimer’s disease by caspase-1 or NLRP3 knockout. NLRP3 knockout also decreased deposition of amyloid-β. Furthermore, NLRP3 inflammasome activation has been shown to drive tau pathology. NLRP3 activation leads to tau hyperphosphorylation and aggregation.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p last">These reports suggest numerous indications for NLRP3 inhibitors and taken together lead to an understandably high level of excitement for the NLRP3 inhibitor field. Additional roles for the NLRP3 inflammasome in disease are still being explored. The number of connections between inflammation and disease along with the apparent centrality of NLRP3 to inflammasome activation promises numerous opportunities for NLRP3 inflammasome inhibition in the clinic. As one would expect, this has led to heavy investment in NLRP3 inhibitor research and development from several biotech and pharmaceutical companies. A number of these efforts are coming into focus as they reach the clinic.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Patent Landscape of NLRP3 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31330" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31330" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">As of November 2019, there were 104 documents submitted pertaining to potential therapeutic inflammasome modulators, including 22 granted patents.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Applications are predominantly focused on NLRP3 with IL-1/IL-1R, IL-18, NLRP1, and caspase-1 receiving considerable attention. Inflazome and IFM Therapeutics have the most patent applications filed with 10 or more each, followed by the companies Onxeo, Nodthera, University of Miami, and Trinity College Dublin with at least four filed applications. A search of patent applications published with the World Intellectual Property Organization (WIPO) since 2020 identified an additional 55 documents. Of these, the plurality was assigned to Novartis, Inflammasome Research, Inc., Inflazome Limited, and Innate Tumor Immunity, Inc. Since there is an 18-month delay between application submission and publication, it is anticipated that this number will continue to grow. The breadth and rate of growth of the patent landscape surrounding NLRP3 speak to the excitement in the field.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Direct NLRP3 Inhibitors in Clinical Trials</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00730" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00730" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Three companies have entered the clinic with NLRP3 inhibitors to date (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Olatec has presented phase II data for its compound dapansutrile in acute gout.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> This is, at the moment, the most clinically advanced NLRP3 inhibitor. In their study, dapansutrile decreased joint pain by greater than 50% at 3 days of treatment. Dapansutrile was dosed at 100, 300, 1000, or 2000 mg/day. Notably there was no increase in efficacy above the 300 mg/day dose, and treatment responses beyond 3 days were similar in all cohorts. Pain reduction at day 3 ranged from 56 to 68% in patients treated with ≥300 mg/day, which is similar to the pain reduction observed with NSAIDs or prednisolone.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> It is not clear if this will offer a competitive advantage as a single agent. Changes in cytokines were also measured. At the 300 mg/day or above, dose changes in plasma IL-6 were observed and at the 2000 mg/day dose a change in plasma IL-1β was observed between day one and three, although this change was not significant. To assess exposure levels, subjects were given 100, 300, or 1000 mg/day for eight consecutive days, which resulted in mean maximum plasma concentrations at steady state of 36.0, 118.6, and 310.9 μM, respectively. Despite reasonable exposure levels, the high doses required for efficacy may be indicative of polypharmacology resulting in incomplete inhibition of NLRP3 inflammasome activation. It is promising that toxicity was not observed at these high doses and high exposure levels above 300 μM. Chemically, dapansutrile is remarkably different from other NLRP3 inhibitors. Many patented compounds are structurally similar to the NLRP3 tool compound, MCC950. However, dapansutrile is a simple β-sulfonyl nitrile (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Nonetheless, Marchetti et al. demonstrated that dapansutrile inhibited IL-1β secretion and inflammasome activation in preclinical studies.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In studies with recombinant NLRP3 protein, the authors reported decreased ATP-hydrolysis activity in the presence of 1 μM or 10 μM of dapansutrile. To establish selectivity for the NLRP3 inflammasome, the authors show dapansutrile does not inhibit the AIM2 or NLRC4 inflammasomes.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Select List of NLRP3 Inhibitors in Clinical Trials</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">NCT identifier</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dapansutrile</td><td class="colsep0 rowsep0" align="left">Olatec</td><td class="colsep0 rowsep0" align="left">NLRP3 inhibitor</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">osteoarthritis, acute gout flare, heart failure</td><td class="colsep0 rowsep0" align="left">NCT03595371; NCT02104050; NCT01768975; NCT03534297</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Somalix</td><td class="colsep0 rowsep0" align="left">Inflazome</td><td class="colsep0 rowsep0" align="left">NLRP3 inhibitor</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">Parkinson’s disease; osteoarthritis; acute coronary syndromes; congestive heart failure; coronary artery disease</td><td class="colsep0 rowsep0" align="left">NCT04015076; NCT04338997; NCT04086602</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFM-2427</td><td class="colsep0 rowsep0" align="left">IFM Tre/Novartis</td><td class="colsep0 rowsep0" align="left">NLRP3 inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">Crohn’s disease, coronary artery disease, gout, NAFLD</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NT-0167</td><td class="colsep0 rowsep0" align="left">Nodthera</td><td class="colsep0 rowsep0" align="left">NLRP3 inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td><td class="colsep0 rowsep0" align="left">hepatic fibrosis; pulmonary fibrosis; NAFLD</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">none disclosed</td><td class="colsep0 rowsep0" align="left">Jecure/Genentech</td><td class="colsep0 rowsep0" align="left">NLRP3 inhibitor</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left">NASH, liver fibrosis</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div><div class="NLM_p">Novartis acquired IFM Tre in order to develop its portfolio of NLRP3 inhibitors. Prior to the acquisition, IFM has registered two phase I clinical trials in public databases for NLRP3 inhibitors with indications listed as coronary artery disease, gout, NAFLD, and Crohn’s disease, and has listed <i>ex vivo</i> measurements of IL-1β and IL-18 as exploratory pharmacodynamic biomarkers<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41−43)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). A patent from IFM discloses structures that are somewhat differentiated from MCC950 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). They retain a sulfonamide but replace the urea and tricyclic moiety with an acetamide linked to substituted phenyl. Of the compounds that they exemplify which are sub-micromolar, 2,6 alkyl substitutions are common along with halogenation at the 4 position. On the other side of the molecule, the pyrrole ring is exchanged for a variety of aromatic heterocycles with a preference for thiophenes and thiazoles.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Earlier patent filings disclose structures that appear similar to the MCC950 scaffold, suggesting that their clinical chemical matter has the same mode of action.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Sub-micromolar compounds exemplied in IFM’s patent US 2019/0119241.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inflazome, which was recently purchased by Roche, is the third company that has brought NLRP3 inhibitors to the clinic. They have taken the approach of generating three classes of compounds with distinct tissue distribution profiles for either central, peripheral, or gastrointestinal indications. Inzomelid, a CNS penetrant NLRP3 inhibitor, is being explored for Alzheimer’s disease, Parkinson’s disease, CAPS and amyotrophic lateral sclerosis (ALS) in phase Ib and have registered plans for a phase II trial in one or more of these indications. Conversely, somalix, another Inflazome compound, is a peripherally restricted NLRP3 inhibitor that has completed phase I trials in CAPS.<a onclick="showRef(event, 'ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48">(45−48)</a> Meanwhile, Inflazome has reported they are developing gut-restricted compounds.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Given the breadth of indications NLRP3 is involved in, this strategy may provide a way to tackle certain diseases without interfering with NLRP3 function in compartments that do not contribute to a particular disease. It is noteworthy that IFM has also indicated they are pursuing compounds with restricted distribution profiles suggesting a similar strategy. Inflazome has one granted patent which covers MCC950 and MCC7840<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Inflazome published 24 patent applications in 2019 and 6 to date of writing this review in 2020. All of their patent matter explores SAR around the sulfonylurea series of MCC950. From the 2019 patents, they explored the replacement of the tricyclic moiety with hydrophilic substituents building in polarity to likely improve the PK profile. Replacing the oxazole, Inflazome explored a wide variety of five- and six-membered heterocycles, substitutions, and alkyl connections to the sulfonamides.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54">(51−54)</a> Examples highlighted in this review were selected for good potency and PK properties reported within their patents (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). It is important to note that this is a small selection of the many exemplified compounds by Inflazome with good potency and PK data and is certainly not an exhaustive list or a list of their best compounds. Additionally, the patents do not identify inzomelid or somalix, and thus we are not presuming the structure of either of those clinical candidates.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Select compounds exemplifed in Inflazome’s patents reporting good potency and PK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two additional companies, Nodthera and Jecure (which has since been acquired by Genentech), have preclinical NLRP3 inhibitors as well (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The structures of the advanced preclinical compounds have not been disclosed, and there is no publicly available information on the precise mode of action of these compounds on the NLRP3 inflammasome. Jecure only has one patent, published in 2018.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The patent centers around MCC950-like chemical matter with variation primarily around the 5–6 bicyclic pyrazoles. The Jecure compounds 1 and 2 in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> were highlighted in the patent demonstrating NLRP3-dependent release of IL-1β in an acute in vivo LPS/ATP challenge model. Structures in early patents from Nodthera contain a tricyclic carbamate, but later patents also contain the tricyclic sulfonyl urea moiety (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). In their WO 2018/015445 A1 patent, they show examples with sub-micromolar potency that explore variations off of the pyrrole, replacing the oxazole of MCC950.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> A subsequent patent, WO2019/121691, has a large number of examples with sub-micromolar potency that replaces the pyrrole-sulfonamide with a tertiary sulfonamide predominantly connected to diazoles with a variety of substituents and aliphatic heterocycles.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Replacement of the diazoles with pyrimidine or isoxazole is also exemplified. Compounds claimed in patents by Jecure and Nodthera are structurally similar to MCC950, and so it appears plausible that they may function through a similar mechanism.<a onclick="showRef(event, 'ref14 ref55 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref14 ref55 ref58 ref59">(14,55,58,59)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Nodthera compounds exemplified in WO 2018/015445 A1 with sub-micromolar activity. (B) Example of a Nodthera compound claimed in WO2019/121691 that explores variations on the right-hand side of the molecule with sub-micromolar activity. (C) Compound exemplified in Jecure patent WO 2018/136890 A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The investment of multiple companies moving NLRP3 inhibitors into the clinic highlights the excitement in the field for NLRP3 as a therapeutic target. As compounds progress, it will be interesting to observe their differentiation in the clinic as the medicinal chemistry differentiation strategies have not been published, particularly considering the similar mode of action on NLRP3 and, in some cases, the similar chemical matter. In the meantime, it is interesting to consider data from clinical compounds and approved drugs that target the inflammasome pathway downstream of inflammasome activation.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">IL-1β Inhibition and Canakinumab</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Canakinumab (ACZ885, Ilaris) is a human anti-IL-1β monoclonal antibody developed by Novartis. Canakinumab is an extremely informative clinical asset as it has not only made it to market for select indications, but also completed a large phase III trial which garnered many insights into the efficacy and safety of IL-1β inhibition. The discovery and clinical development of canakinumab have been comprehensively reviewed.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> This antibody works by binding to and inhibiting the action of IL-1β, which normally triggers inflammation through binding to IL-1R. The CANTOS trial was the pivotal phase III trial for canakinumab as an anti-inflammatory therapy. Published in 2017,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> the results described efficacy in atherosclerosis, safety signals, and efficacy for additional symptoms and comorbidities seen in a population with chronic inflammation. The size of this trial, 10 061 patients, along with the randomized, double-blind placebo controlled, 48-month assessment of therapy, which included measurement of recurrent cardiovascular events, symptoms, and side effects enabled well-powered observations to support the study’s conclusions.</div><div class="NLM_p">From the CANTOS trial, canakinumab provided a clinical proof-of-concept that inhibiting inflammation could directly impact rate of recurrent cardiovascular events in patients with atherothrombosis. Canakinumab did not reduce lipids, and the efficacy was solely from the anti-inflammatory mechanisms. Although not a registered end point, it was observed that cancer mortality was significantly decreased in treatment groups. Specifically, a post hoc analysis revealed a significant lower incidence of lung cancer and fatalities from lung cancer in the 300 mg group.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> While total deaths were similar between all treatment groups and placebo, treatment groups had significantly more deaths from infection and sepsis. In the placebo group of 3344 patients, 1.8% experienced fatal infection or sepsis compared to the rate of occurrence with canakinumab treatment of 3.4% in the highest dosage group of 300 mg.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Additional nonfatal adverse events included neutropenia, which can lead to increased susceptibility to infection, and thrombocytopenia although no significant difference in hemorrhage.</div><div class="NLM_p">Additional efficacy and safety information from the many smaller trials in rare disease indications support canakinumab’s utility as an anti-inflammatory therapy. In 2009, canakinumab was approved for the treatment of CAPS, in adults and children 4 years of age and older including familial cold autoinflammatory syndrome and Muckle–Wells syndrome. This approval was based on a trial published by Lachmann et al. in which administration of canakinumab once every 8 weeks was associated with substantial control of inflammatory disease in children and adults with CAPS.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Clinical end points were combined into “flare-ups” which included the full range of symptoms these patients normally experience. A complete response to treatment was defined as a global assessment of no or minimal disease activity. Although the sample size in this trial was small, only 35 patients, the efficacy was so pronounced over a one-year span, that the drug was approved for CAPS patients.</div><div class="NLM_p">Consistent with the CANTOS trial, significant increase in infections was observed in the CAPS trial. However, the patient number was so small that it is difficult to interpret the significance. For example, one patient on canakinumab discontinued treatment due to recurrent urinary tract infections. One out of 35 is not enough to warrant concern, but infection risk is still noted even with such a small study. Importantly, no deaths or life-threatening adverse events (AEs) were seen. The approved label includes a warning of association with an increased incidence of serious infections.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">The efficacy of canakinumab observed across a wide range of symptoms and diseases gave the field confidence that decreasing systemic inflammation via the IL-1β axis has the potential to treat many common diseases, including cardiovascular events. The infection risk associated with doing so could impede progress in this space. Since multiple inflammasomes are known to produce IL-1β, it has been hypothesized that inhibiting NLRP3-mediated inflammasome response instead of IL-1β directly will ameliorate the risk of serious infection.</div><div class="NLM_p last">Diacerein is a small molecule reported to act by reducing IL-1β. Diacerein, an anthraquinone derivative, is a marketed drug approved for osteoarthritis.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The mechanism of action is generally attributed to blocking IL-1β release and more recently specified as NLRP3 inhibition. An analysis of the literature on clinical studies, meta-analyses, and postmarketing surveillance looked at both the efficacy and safety profiles of diacerein in the symptomatic treatment of knee and hip osteoarthritis.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> They confirmed a benefit especially for patients for whom NSAIDs and paracetamol are contraindicated. Side effects of diacerein include common gastrointestinal disorders such as diarrhea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. Severe infection risk was not highlighted and speaks to the potential for safety and efficacy of inhibiting IL-1β. More recently, TWi Biotechnology has registered AC-203, a topical formulation of 1% diacerein, in a clinical trial for epidermolysis bullosa simplex (EBS).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> EBS is a genetic condition causing the skin to be very fragile and to blister easily. The company claims the mechanism of action of diacerein is by inhibiting the NLRP3 inflammasome activation. The only publication from TWi Biotechnology is a patent with data showing that rhein, the active form of the prodrug, diacerein, can inhibit the expression of ASC and NLRP3 and prevent the formation of the NLRP3 inflammasome complex in PMA primed and MSU stimulated THP-1 cells with a from a fluorescence confocal microscopy readout.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">IL-1R Antagonism and Anakinra</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In addition to canakinumab, another approach to blocking IL-β signaling is IL-1R antagonism. Anakinra is a recombinant form of the endogenous IL-1R antagonist protein, IL-1RA. Anakinra blocks signaling of both IL-1α and IL-1β through IL-1R. It has also been explored extensively in the clinic and is currently an approved, albeit uncommonly prescribed drug.</div><div class="NLM_p">In 2001, anakinra was approved for use by the FDA for moderate to severe rheumatoid arthritis in patients who failed at least one other disease-modifying antirheumatic drug therapy. However, it has only moderate efficacy in this indication.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Of patients treated with anakinra, 38% reach an ACR20 versus 23% of placebo-treated patients. ACR20 is a response defined by a 20% improvement in tender and swollen joint counts and the same level of improvement in three of the five variables: patient/physician global assessment, pain scores, health assessment questionnaire score, and laboratory acute-phase reactants. However, anakinra is less efficacious in RA than anti-TNFα therapies and is not commonly prescribed for this indication.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Anakinra is also efficacious in CAPS.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Although it is used in the clinic for this indication, its short half-life of 4–6 h and the frequency of injection site reactions contribute to a preference for canakinumab, which has a half-life of 26 days.<a onclick="showRef(event, 'ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref69 ref70 ref71">(69−71)</a></div><div class="NLM_p">Overall, anakinra is safe. However, while the overall infection rate is unchanged, a 3-fold increase in serious infections from 0.6% to 1.8% of patients, but not overall infections, has been observed in anakinra-treated patients compared to placebo. Pneumonia was the most common serious infection observed with anakinra treatment.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Notably, this increase is not statistically significant, and further postapproval exploration of this safety finding is hindered by the limited clinical utilization of anakinra. In preclinical species combining anakinra with enteracept, a TNFα blocking therapy, the results of the combination therapy appeared additive or synergistic in models of RA.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> However, no additional efficacy was observed in clinical trials. The combination of anakinra and enteracept did increase the number of serious infections observed raising this incidence to 3.7% or 7.4% depending on the dose used (25 mg of enteracept QW or BIW with 100 mg/day anakinra).</div><div class="NLM_p">Since IL-1β secretion is a direct product of inflammasome activation, the insights from canakinumab and anakinra suggest the likelihood that inhibitors that directly block inflammasome activation will be efficacious in some indications. Notably, inflammasome activation from multiple different inflammasome sensor proteins contribute to IL-1β secretion. Targeting only a single inflammasome sensor protein may ameliorate some of the safety signals observed with anti-IL-1β therapy.</div><div class="NLM_p">LaRock et al. reviewed postmarketing surveillance on canakinumab and anakinra and found a low infection rate overall.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The exception to the low infection risk was severe invasive infections caused by Group A Streptococcus (GAS). This increased rate was significant with an ∼330-fold increase for patients receiving an IL-1β inhibitor. On the basis of both human and mouse (IL-1R–/– knock out mice and compound treated) data, the IL-1R antagonist anakinra correlated to a decrease in IL-1β signaling and allowed the increase in GAS growth and dissemination. The authors go on to hypothesize that blocking endogenous IL-1β maturation may not carry the same GAS infection risk as those that block receptor signaling.</div><div class="NLM_p last">Recently, the role of the NLRP3 inflammasome in COVID-19 induced acute respiratory distress syndrome (ARDS) has also come under scrutiny.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The SARS-CoV-2 proteins, orf3a, orf8a, and protein E have been shown to mediate potassium and calcium ion flux, which mediates NLRP3 inflammasome activation.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> High-dose anakinra was used in a small retrospective cohort study of 29 patients for the treatment of COVID-19 induced ARDS.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The investigators noted the short half-life of anakinra as an asset in this indication as it allowed for careful monitoring and discontinuation if needed. Anakinra treatment reduced C-reactive protein and increased overall survival at 21 days (90% vs 56%) compared to retrospective data.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> However, there was no difference in time to mechanical ventilation, which should temper excitement about the result. The small size of study, single study center, and retrospective nature of the analysis must be kept in mind when considering this data.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The large variation in reported mortality at the time of this analysis, 28–78% across reports, and the complicated clinical data following up other antibodies targeting inflammatory cytokines in COVID-19 induced ARDS treatment based on retrospective studies highlight the need for further studies before strong conclusions are drawn.<a onclick="showRef(event, 'ref76 ref77 ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref76 ref77 ref78 ref79">(76−79)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Clinical Landscape and Results for Caspase-1 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31671" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31671" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inhibiting caspase-1 is another route to block inflammasome signaling downstream of inflammasome activation. Pro-caspase-1 is a critical component of the inflammasome complex, and when activated to caspase-1, the cysteine protease cleaves pro-interleukin (IL-1β) and pro-IL-18 to their active cytokines and is the final step in the production of IL-1β and IL-18.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Additionally, caspase-1 leads to gasdermin-D cleavage, membrane pore formation, and pyroptosis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In the absence of caspase-1 activity, it has been shown in preclinical studies that inflammasome-mediated cell death can occur through caspase-8.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Small molecule and peptide mimetic caspase-1 inhibitors are a set of promising clinical compounds which have yet to deliver a marketed drug. Attempts to selectively inhibit caspase-1 or inhibit pan-caspase activity have not resulted in the report of a compound able to demonstrate sufficient efficacy and safety in the clinic.</div><div class="NLM_p">We will highlight the caspase-1 inhibitors VX-765 (belnacasan) and VX-740 (pralnacasan) as the most selective caspase-1 inhibitors that have advanced the furthest in the clinic (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). VX-740 was codeveloped by Aventis and Vertex. VX-740 is a prodrug converted to an active metabolite, VRT-18858, that inhibits caspase-1.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> While there is no human PK data published, preclinical studies show conversion to VRT-18858 in a pharmacodynamically active and therapeutically relevant range.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> In November 2003, Aventis and Vertex Pharmaceuticals announced that they had voluntarily discontinued the phase IIb clinical trials of VX-740 for rheumatoid arthritis due to results from an animal toxicity study that showed liver abnormalities after a nine-month exposure to VX-740 at high doses. They noted that no similar liver toxicity had been noted in human trials.<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> No further clinical trials were enrolled for VX-740.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Clinical Compounds That Impinge on the NLRP3 Inflammasome Pathway</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0008.gif" alt="" id="gr8" /></img><div></div></div><div class="NLM_p">VX-765 is structurally similar to VX-740 and is also a prodrug, which is converted to the active metabolite (VRT-043198) by plasma esterases. It was discovered and developed by Vertex for immune indications (undisclosed), epilepsy, and psoriasis. VRT-043198 acts by covalent modification of the catalytic cysteine residue in the active site of caspase-1. The selectivity for caspase-1 over other cysteine proteases is high for VRT-043198 with only caspase-4 inhibited at similar potency.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Preclinically, VX-765 demonstrated efficacy in animal models of inflammatory, arthritis, and skin diseases.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> VX-765 was tested in phase II trials for psoriasis and epilepsy indications, although notably not RA. In March 2011, Vertex reported data from the completed phase II trial in epilepsy.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> VX-765 was safe and moved into phase IIb; however, in 2012 it was discontinued. These data suggest the initial toxicity results observed with VX-740 were compound and not mechanism related. It is unclear why VX-765 is not clinically efficacious.</div><div class="NLM_p last">The only additional caspase inhibitors to enter the clinic were broad spectrum caspase inhibitors including IDN-6556 (emricasan) and GS-9450 (nivocasan).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Because of the nonspecificity of these compounds, it is unclear if any efficacy or safety observed is related to the inhibition of inflammasome signaling.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Inhibiting the NLRP3 Inflammasome Beyond Direct Binding</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Considering the pathway upstream and downstream of NLRP3 presents other opportunities to inhibit NLRP3 function. A range of proteins regulate inflammasome activation through direct binding, post-translational modification, or degradation of inflammasome proteins. One interesting protein with potential for future clinical significance is NEK7. Using mass spectrometry based pulldown experiments, NEK7 was found to directly bind to NLRP3 upon inflammasome activation by LPS or ATP.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The interaction between NLRP3 and NEK7 was found to be mediated by the NEK7 catalytic domain; however, mutations that perturb the catalytic activity of NEK7 do not affect the protein–protein interaction. Moreover, NEK7 is necessary for the activation of the NLRP3 inflammasome and formation of ASC specks in murine bone marrow derived macrophages (BMDM). This critical role is observed in experiments with a number of tested stimuli including ATP, nigericin, gramicidin, MSU, <span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-leucine methyl ester (LLOMe), silica, alum, and calcium pyrophosphate deposition (CPPd). Separately, NEK7 was also shown to be required for NLRP3 to respond to ROS.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Even the constitutively active NLRP3 gain of function mutant R258W requires NEK7 for inflammasome activation. NEK7 appears to bind multiple copies of NLRP3, which enables bridging of NLRP3 oligomers.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Remarkably, NEK7 has another interaction partner, NEK9, which is involved in mitosis. Since some cells express a limited amount of NEK7, NLRP3 inflammasome activation in such cells can only occur in interphase. Taken together, these data raise the question of whether NEK7 and its interaction with NLRP3 are a potential pharmacological target.</div><div class="NLM_p">The natural product oridonin has been reported to bind covalently to Cys279 in the NLRP3 NACHT domain as a Michael acceptor through an α,β unsaturated carbonyl<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Unlike many reported NLRP3 inhibitors, oridonin blocks the binding of NLRP3 to NEK7 instead of blocking the NLRP3 ATPase activity. In blocking the binding to NEK7, activation of the NLRP3 inflammasome by ATP, nigericin, and MSU is inhibited in BMDMs. Supporting this mechanism of action, mutation of Cys279 to alanine prevents oridonin-mediated inhibition of inflammasome activation.</div><div class="NLM_p">Post-translational modifications on NEK7 can also be manipulated to block NLRP3 inflammasome activation.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The glutathione transferase, GSTO1, removes glutathione from NEK7. This is necessary for NEK7 to mediate NLRP3 inflammasome activation. A chloroacetamide GSTO1 inhibitor, C1–27, was found to block NEK7 deglutathionylation and in turn block NLRP3 inflammasome activation <i>in vitro</i> and <i>in vivo</i> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Interestingly, C1–27 appeared to be more effective at blocking LPS/ATP activation of NLRP3 than LPS/nigericin.</div><div class="NLM_p">Another post-translational modification (PTM) that controls NLRP3 activity is phosphorylation.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Serine phosphorylation by JNK1 was shown to be necessary for inflammasome activation. Phosphorylation by PKD regulates NLRP3 subcellular localization, and PKA phosphorylation of NLRP3 has been shown to block its ATPase activity leading to inflammasome inhibition.<a onclick="showRef(event, 'ref94 ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref94 ref95 ref96 ref97">(94−97)</a> Phosphorylation of NLRP3 at serine 5 has also been shown to block the association of NLRP3 and ASC and dephosphorylation by PP2A has been shown to enable aggregation. Likewise, phosphorylation of ASC is important for inflammasome activation.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> ASC contains several putative phosphorylation sites. Tyrosine 146 (tyrosine 144 in mouse) has been shown to be important for ASC oligomerization. The kinases JNK1, Syk, Pyk2, and BTK have each been implicated in the phosphorylation of tyrosine 146, although it is difficult to determine if this phosphorylation is direct or downstream (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> BTK forms a protein–protein interaction with ASC and NLRP3 raising the likelihood that BTK-mediated phosphorylation is a direct event.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> BTK has additionally been shown to phosphorylate NLRP3.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> In <i>in vitro</i> phosphorylation assays, Pyk2 directly phosphorylates ASC. Each of these are potentially druggable nodes to modulate NLRP3 function.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Regulatory pathways of NLRP3 activation. (A) Routes leading to NLRP3 inflammasome activation. (B) Proximal proteins that regulate NLRP3 inflammasome components. (C) Integration of Syk and BTK into inflammasome activation and other downstream processes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ubiquitin-proteasome system is recognized as a druggable protein network.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Several drugs act through manipulating or inhibiting ubiquitin ligases or the proteasome.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The inflammasome is also regulated by a network of ubiquitin ligases (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Py et al. screened for compounds that blocked IL-1β secretion and found a compound, G5, that blocked NLRP3 inflammasome activation<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). They determined that G5 treatment led to accumulation of K63 and K48 polyubiquitin. Ultimately, they found this compound functions by blocking BRCC3 from deubiquitination of NLRP3. In the process of these experiments, they conducted immunoprecipitations to determine what deubiquitinases (DUBs) might interact with NLRP3 and found 43 DUBs. Of these, 12 were also capable of deubiquitinating NLRP3 when overexpressed. FBXL2 is an E3 ubiquitin ligase which ubiquitinylates NLRP3 on lysine 689. FBXL2 itself is regulated by another ubiquitin ligase, FBXO3. Consequently, NLRP3 inflammasome activation is post-translationally regulated both by FBXL2, which decreases NLRP3 levels, and FBXO3, which decreases FBXL2 levels resulting in an increase of NLRP3 levels. FBXO3 small molecule inhibitors, such as BC-1215, prevent degradation of FBXL2, and this leads to increased degradation of NLRP3<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). A phase I trial to test one of these molecules in IBD has been registered.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Additional studies have shown that dopamine can prevent NLRP3 inflammasome activation by MARCH7-mediated ubiquitination and degradation.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Notably, these studies also found two other E3s that were able to immunoprecipitate with NLRP3, CHIP, and UBR5. Separately, the ubiquitin ligase TRIM31 was found to lead to ubiquitination of K48 in NLRP3 and subsequent proteasomal degradation.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Interestingly, TRIM31 expression is also upregulated by LPS and IL-1β, although the kinetics of upregulation is slower than that of NLRP3, suggesting the possibility that TRIM31 is one mechanism the cell may use to terminate inflammasome signaling.</div><div class="NLM_p">Outside of directly regulating NLRP3, several of the known interacting proteins are also regulated by ubiquitination. DHX33 is a cytosolic dsRNA sensor that can interact with NLRP3 to trigger inflammasome activation.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> This protein–protein interaction is dependent on ubiquitination by TRIM33. Additionally, ASC abundance and inflammasome sensor interaction can be both positively and negatively affected by ubiquitination.<a onclick="showRef(event, 'ref110 ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref110 ref111 ref112">(110−112)</a> The existence of other deubiquitinating and ubiquitinating enzymes that associate with NLRP3 raises the question of whether there are additional ubiquitin-mediated axes to control NLRP3 function.</div><div class="NLM_p">Moving upstream of the inflammasome itself, the processes that lead to inflammasome activation can also be targeted for inhibition. There are three main routes that lead to NLRP3 inflammasome activation: lysosomal membrane permeabilization, ROS, and potassium efflux (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> These processes are interconnected, making it difficult to precisely pick apart the key initiating process activating the inflammasome. Nevertheless, a great deal of literature has focused on addressing this question.</div><div class="NLM_p">Lysosomal membrane permeabilization appears to be caused principally by particulate stimuli. Evidence indicates MSU, cholesterol crystals, silica, alum, and LLOMe all function through inducing lysosomal damage.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> In turn, lysosomal membrane permeabilization is hypothesized to activate the NLRP3 inflammasome by two main routes (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The first route is cathepsin release into the cytosol.<a onclick="showRef(event, 'ref23 ref114'); return false;" href="javascript:void(0);" class="ref ref23 ref114">(23,114)</a> Cathepsin inhibitors appear to block inflammasome activation from cholesterol and other particulates. This is often hypothesized to occur through inhibition of cathepsin B.<a onclick="showRef(event, 'ref113 ref115'); return false;" href="javascript:void(0);" class="ref ref113 ref115">(113,115)</a> However, it is difficult to conclude this with certainty due to the promiscuity of cathepsin B inhibitors and the discovery that the overexpression of other cathepsins can genetically compensate for the cathepsin knockout. It is unclear what substrate or scaffolding function cathepsins serve in the cytosol to activate the inflammasome. The second mechanism by which lysosomal membrane permeabilization appears to activate the inflammasome is by activation of upstream kinases.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Calcium flux from the lysosome can lead to activation of CAMKII, which leads to phosphorylation of TAK1 and subsequently phosphorylation of JNK, which activates the inflammasome as described above. Activation of the CAMKII pathway has been shown to be driven by some stimuli, such as MSU, but not others, such as ATP. Similarly, cathepsin inhibitors appear to have a greater effect on particulate stimuli, although results for some stimuli, such as nigericin, have been mixed in the literature. This discrepancy has been hypothesized to be a result of the different polypharmacology of nonselective cathepsin inhibitors. In addition to cathepsin inhibitors, CAMKII inhibitors and inhibitors of phagocytosis have been used to attenuate lysosomal membrane permeabilization-induced damage.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Additional approaches to decrease lysosomal rupture are also being investigated. For instance, dihydrolipoic acid treatment inhibits inflammasome activation in response to subarachnoid hemorrhage in rat by upregulating LAMP1 and decreasing signaling through CAMKII.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> As tools, ammonium chloride and chloroquine have been used as lysosomal neutralizing reagents, which appear to block inflammasome activation by inhibiting cathepsin activity.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a> Although lysosomal permeabilization is one pathway that can lead to inflammasome activation, it is interconnected with other mechanisms of inflammasome activation. For instance, ROS generation can lead to subsequent lysosomal permeabilization, and blocking potassium flux has also attenuated inflammasome activation from lysosomal permeabilization in some cases.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><div class="NLM_p">Studies that use mitochondrial toxins have shown an increase in ROS and subsequent activation of the NLRP3 inflammasome.<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121,122)</a> The mitophagy inhibitor 3-methyladenine also causes mitochondrial damage, an increase in ROS, and activation of the inflammasome. Similar experiments have been conducted in both macrophages and microglia. Likewise, knockout of autophagic proteins beclin and LC3B, leads to dysfunctional mitochondria, release of ROS and mitochondrial DNA, and inflammasome activation.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Knockdown of VDAC1 or VDAC2 or treatment with mito apocynin, a mitochondrial targeted antioxidant, blocks ROS induced inflammasome activation.<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121,122)</a> Conversely, mitochondrial depolarization through P2X7 prior to inflammasome priming can lead to deficient inflammasome post priming. This is hypothesized to be mediated by upregulated HIF-1α.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><div class="NLM_p">Potassium efflux is the third route to NLRP3 inflammasome activation. Potassium efflux appears to be a common underlying trigger of inflammasome activation, which is induced by many different inflammasome activators.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Indeed, the microbial toxins gramicidin and nigericin, which are commonly used as NLRP3 inflammasome activators in the literature, form potassium permeable pores in the cell membrane. Exogenous addition of high concentrations of potassium to cell culture media is able to block inflammasome activation from many different sources, supporting the critical role of potassium efflux in inflammasome activation.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The precise potassium channels involved in inflammasome activation are unclear. P2RX7 and TWIK-2 have both been proposed as important potassium channels in NLRP3 activation.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> TWIK-2 knockout or knockdown has been shown to block ATP but not nigericin triggered NLRP3 inflammasome activation. Quinine has been used to pharmacologically block TWIK-2 and achieve similar results; however, the data must be considered carefully in light of the polypharmacology of quinine. The data supports the possibility of inhibiting potassium efflux directly as another route to inhibiting inflammasome activation.</div><div class="NLM_p last">The NLRP3 inflammasome is regulated by a large range of processes including transcription, PTMs, PPIs, and upstream processes including LMP, ROS generation, and potassium efflux. In cell and animal models, many of these processes have been targeted pharmacologically and have efficaciously inhibited NLRP3 inflammasome activation, sometimes with specificity for individual signal 2 activators. The breadth of these processes supports the possibility of inhibiting NLRP3 inflammasome activation in the clinic with molecules that do not directly bind to NLRP3. It remains to be seen what advantages or disadvantages such avenues have compared to direct NLRP3 inhibitors. However, some anti-inflammatories in the clinic do appear to impinge upon the pathways described above. Comprehensive evaluation of the profiles of these compounds is valuable to keep in mind when considering the rationale for direct NLRP3 inhibitors.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Effects of Indirect NLRP3 Inhibitors in the Clinic</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00721" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00721" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Some of the mechanisms that have been described above which lead to the ablation of NLRP3 inflammasome activity have been explored in the clinic, albeit not with the aim of inhibiting the inflammasome (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Consequently, exploring the clinical data around these compounds with an eye toward inflammasome inhibition sheds valuable light on the mechanisms and outcomes of impinging on inflammasome pathways.</div><div class="NLM_p">BTK inhibitors are in the clinic principally for the treatment of chronic lymphocyte leukemia (CLL), although more recently BTK inhibitors are being explored for the treatment of autoimmune diseases.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> BTK is important for B-cell survival and essential for activation of several pathways downstream of the B-cell receptor that are important for CLL-survival.<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> As described above, BTK also activates the NLRP3 inflammasome by phosphorylation of both NLRP3 and ASC. This raises the question of whether BTK inhibitors block NLRP3 activation in patients and what effects that inhibition has clinically. Liu et al. observed that patients taking ibrutinib, an irreversible BTK inhibitor, had lower IL-1β secretion from peripheral blood mononuclear cells (PBMCs) after <i>ex vivo</i> stimulation suggesting <i>in vivo</i> effects of ibrutinib on the inflammasome.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Likewise, PBMCs from patients with X-linked agammaglobulinemia (XLA), a disease that harbors mutations in the BTK gene, exhibited lower inflammasome activation following <i>ex vivo</i> stimulation. Evobrutinib, another structurally similar, irreversible BTK inhibitor, has recently had positive phase II data in multiple sclerosis and showed a decrease in the number of gadolinium-enhancing lesions.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Fenebrutinib, a selective reversible BTK inhibitor, has shown some positive phase II data in rheumatoid arthritis. In patients who had an inadequate response to methotrexate alone, treatment with fenebrutinib increased ACR20 scores<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). This increase was comparable to the effect of the TNF-α antagonist antibody adalimumab (Humira) the standard of care. Efficacy is hypothesized to come from a mixture of effects on B-cells and myeloid cells. Keeping in mind that inhibiting BTK will affect a number of cell processes outside the inflammasome such as proliferation, survival, migration, angiogenesis, and cytokine production, attributing the efficacy of BTK inhibitors solely to decreasing inflammasome activation would not be accurate. While it is possible that some efficacy derives from inflammasome inhibition, the pleiotropic effects of BTK inhibitors make it difficult to conclude that this is entirely the case.</div><div class="NLM_p">IRAK4 transduces signaling from TLRs and IL-1R to activate NF-κB. In turn, this upregulates transcription of many NF-κB-dependent genes including those involved in the inflammasome.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> In recent years, inhibitors of IRAK4 have advanced to the clinic with four different companies currently conducting trials.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> IRAK4 inhibitors have been shown to dampen inflammasome activity by interfering with priming both <i>in vitro</i> and <i>in vivo</i>. In animal models, IRAK4 inhibitors have also been shown to decrease levels of secreted IL-1β, though they also have effects on other proinflammatory cytokines, such as IL-6, that are not secreted upon inflammasome activation.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> A Pfizer compound, PF-06650833, recently completed a phase IIb trial on rheumatoid arthritis and appeared efficacious based on the change from baseline in a simplified disease activity index<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). However, a full publication detailing these results is not currently available. It is not known to what degree of effect IRAK4 inhibitors have on inflammasome gene expression in humans and whether this contributes to clinical efficacy.</div><div class="NLM_p">Spleen tyrosine kinase (Syk) is a nonreceptor protein tyrosine kinase, which transmits B-cell antigen receptor or Fc-receptor signaling of hematopoietic cells and is implicated in many diseases also linked to inflammasome activation. We examined the impact of Syk inhibition on blockade of the inflammasome activation to see if clinical efficacy or safety signals of Syk inhibitors could be linked to the inflammasome phenotype. Activation of the numerous sites of phosphorylation on Syk leads to the activation of a set of signaling networks relevant to immune and autoimmune diseases. Syk, therefore, serves as a master regulator of inflammatory responses by immune cells, and as a result, inhibiting Syk activity decreases inflammation broadly and comprehensively.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> One recent report demonstrated the mechanism linking Syk to inflammasome secretion of IL-1β to be that of the NLRP3 inflammasome acting as a sensor and a regulator of the inflammatory response in diabetic nephropathy, resulting in cleavage of pro-caspase-1 and maturation of IL-1β. The phosphorylation of Syk may increase levels of pJNK and the expression of its downstream interactors, including NLRP3, caspase-1p20, ASC, and mIL-1β in high glucose-induced HK2 cells and RGMCs.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Additionally, the authors show that inhibition of Syk via small molecules (BAY61-3606) and Syk-siRNA were able to block this signaling cascade and decrease release of IL-1β. Additional reports support the key role for Syk signaling linked to NLRP3 functions and production of IL-1β during M. tuberculosis infection and fungal infections.<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140,141)</a> In recent years, 12 small molecule oral Syk inhibitors have entered the clinic for inflammatory disease indications, such as asthma, arthritis, and allergic diseases.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Syk signaling is involved in activation of immune cells, and inhibition of Syk is hypothesized to alleviate the autoimmune response.<a onclick="showRef(event, 'ref140 ref143'); return false;" href="javascript:void(0);" class="ref ref140 ref143">(140,143)</a> Despite early signals of efficacy, many of the phase II and III trials were withdrawn or terminated with no readout, and we are lacking publicly disclosed large portions of clinical data that could illuminate safety concerns or lack of therapeutic window. The discovery and development of Syk inhibitors have been comprehensively reviewed<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> detailing the biology of Syk inhibition, the landscape of disclosed small molecule inhibitors, the preclinical models, and early clinical results. An additional and more recent review covers the patent filings between 2010 and 2013 claiming Syk inhibitors and their paths in the clinic.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The author highlights the structural diversity and differences in kinase selectivity across the patent landscape. In addition to any efficacy, the failures in the clinic are of high interest to future efforts targeting the inflammasome as these could point to critical safety issues to avoid and demonstrate a clear lack of efficacy for diseases associated with chronic inflammation. Of the 12 Syk inhibitors that have entered the clinic, none have been brought to market for diseases with large patient populations.</div><div class="NLM_p">Fostamatinib (Tavalisse, R788) discovered by Rigel and developed by AstraZeneca, is the only marketed Syk inhibitor.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> It is currently marketed by Rigel for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Fostamatinib was the first Syk inhibitor to reach the clinic and showed early promise in a phase II trial in 457 patients with active rheumatoid arthritis despite methotrexate therapy. The phase IIb study, TASKi2, demonstrated that 67% of patients taking fostamatinib 100 mg twice daily achieved the primary efficacy end point at six months, which was significantly higher than placebo.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Hypertension was reported but deemed to be manageable with an appropriate medication. These exciting results kicked off a set of four phase III trials OSKIRA: Oral SyK Inhibition in Rheumatoid Arthritis.<a onclick="showRef(event, 'ref147 ref148 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref149 ref150">(147−150)</a> Despite statistically significant improvements in ACR20 response rates at 24 weeks for the 100 mg twice daily (BID) group and tolerable safety results in the OSKIRA phase III programs in patients with RA, AstraZeneca did not proceed with regulatory filings and returned the rights to fostamatinib to Rigel. An interesting perspective was published in 2019 of a systematic review and meta-analysis, looking into the safety and efficacy of multiple dosages of fostamatinib.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> They confirmed that across the 11 clinical trials including 3680 patients that fostamatinib was an effective and safe therapeutic medicine. For overall adverse events, a significant difference was found between fostamatinib 100 mg BID and placebo. Significant adverse events were found in gastrointestinal disorders, hepatobiliary disorders, infections and infestations, and musculoskeletal and connective tissue disorders. However, a marked increase in the frequency of serious infections and infestations was not found in the fostamatinib group compared to the placebo group. This observation does not track with the increase in serious infections seen in patients taking canakinumab, potentially differentiating the Syk inhibitor mechanism from inflammasome inhibition. With only moderate efficacy and some safety signals, there was concern about fostamatinib’s ability to compete in the RA market with adalimumab and tofacitinib.</div><div class="NLM_p">The lack of kinase selectivity of fostamatinib is critical in the interpretation of the clinical data and our effort to link clinical efficacy or safety to inflammasome inhibition. Fostamatinib (R788) is a prodrug of its active metabolite, R406. A comprehensive assessment of the in vitro pharmacological profiling of R406 has been described.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> The authors found that R406 binds to multiple kinases at therapeutically relevant concentrations. Extrapolating from the clinical PK data, they set a threshold of 150 nmol/L and identified 101 targets of R406 with greater potency, only one of which is not a kinase. While the major mechanism of fostamatinib may be Syk inhibition, we cannot rule out off-target or polypharmalogical effects of inhibiting 100 kinases.</div><div class="NLM_p">Following on the excitement of the phase II clinical data of fostamatinib, the next generation of Syk inhibitors aimed for higher selectivity, improved potency, and orally bioavailablility. MK-8457, a novel inhibitor of Syk and ZAP70, zetachain-associated protein kinase, was discontinued after two phase II trials were terminated due to high rates of serious infections. Cerdulatinib (PRT062070, RVT-502, BIIB-057), a dual Syk/JAK inhibitor codeveloped by Biogen and Portola, reported phase I data with PK and safety data in healthy volunteers.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> With a desirable PK profile, cerdulatinib was capable of safely, potently, and selectively suppressing Syk kinase function in humans following once-daily oral dosing. With the completion of that phase I trial, the phase II trials in systemic lupus erythematosus (SLE) and rheumatoid arthritis were planned but never initiated.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> The termination of these Syk inhibitors points to unfavorable safety signals, which could hinder further development of these drugs.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div><div class="NLM_p last">Overall, Syk inhibitors have pivoted away from early clinical indications (prior to the failure of fostamatinib in 2013) which focused on large patient populations with inflammatory indications such as asthma, rheumatoid arthritis, and thrombocytopenia to oncology indications. Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clinical trials for B-cell malignancies, acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL) and in combination regimens for these hematological malignancies<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Despite preclinical evidence linking Syk inhibition to inhibition of inflammasome activation, it is difficult to conclude whether any of the efficacy or safety signals can be attributed to attenuation of NLRP3 inflammasome activation.</div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">NLRP3 and Safety</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83367" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83367" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In many regards, NLRP3 appears to be the ideal drug target since it is aberrantly activated in many diseases with chronic inflammation. This leads one to ask why NLRP3 is evolutionarily maintained in the first place. There are no known loss of function (LOF) variants, and inflammasome sensors in other species can vary quite substantially. For instance, instead of NLRP1, mice express three paralogs, NLRP1a, NLRP1b, and NLRP1c, and five different allelic variants for NLRP1b.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> On the other hand, NLRP3 appears to be relatively conserved between species and responds to many of the same stimuli. In bats, dampened NLRP3 inflammasome activation has been associated with the existence of persistent viral reservoirs.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> In humans, NLRP3 may also be important for control of certain pathogens, in particular, RNA-based viruses.</div><div class="NLM_p">It has been reported that the NLRP3 inflammasome is activated by influenza A infection (IAV). Activation occurs through sensing of viral RNA and through the influenza protein M2, which is an ion channel.<a onclick="showRef(event, 'ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref158 ref159">(158,159)</a> Consequently, inhibition of NLRP3 effects host response to IAV infection.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> When mice are infected with a low inoculation of influenza A and treated with MCC950 the day after infection, MCC950 treated mice die after 6 days, whereas vehicle-treated mice or mice treated with MCC950 but not infected do not suffer any mortality up to 8 days, the last day measured in the study. With higher viral inoculation the difference between MCC950 treated and vehicle treated mice was smaller. WT mice died at 5 days, whereas MCC950 treated mice died at 4 days. On the other hand, animals that were infected with a high dose of influenza A and then treated with MCC950 at the height of viral infection showed better outcomes. This is likely due to prevention of cytokine storm and consequent damage to lung tissue from overactive NLRP3 response. These data point to the importance of NLRP3 activity to mount an initial response to infection. The authors posit that a scenario where an NLRP3 inhibitor is administered once infection has already developed is the more likely clinical scenario. In the case where NLRP3 inhibitors are employed to attenuate innate immune response to already developed infections, this may be true. However, in chronic diseases such as Parkinson’s disease or NASH where patients may be on NLRP3 inhibitors for years, it is unclear what effect this would have on influenza infection. It is a possibility that a small molecule medication could be terminated once an infection was observed. For instance, MCC950 has a half-life of only three and a half hours, although the clinical feasibility of this approach and what impact it would have on the course of disease have not been studied.</div><div class="NLM_p">In support of these data, studies with NLRP3 KO mice have also shown lesser responses and increased mortality upon IAV infection.<a onclick="showRef(event, 'ref159 ref161'); return false;" href="javascript:void(0);" class="ref ref159 ref161">(159,161)</a> Upon IAV infection, NLRP3 KO animals show reduced recruitment of neutrophils, monocytes, and dendritic cells, and increased epithelial necrosis with lung obstruction from necrotic debris. While viral titers between KO and WT were similar at 3 days post infection, at 7 days post infection, WT animals had lower viral titers than NLRP3 KO mice. Caspase-1 KO animals showed similar effects, whereas NLRC4 KO animals showed no difference from WT animals. Consistent with an important role of NLRP3 for response to IAV infection, NLRP3 GOF R258W mutant animals are resistant to IAV infection.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> These animals have increased survival in response to IAV infection, which is lost upon IL-1R knockout. Likewise, older mice have a decreased innate immune response and poorer survival upon IAV infection.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Stimulation with nigericin increased their inflammasome activity and improved their outcomes upon IAV infection. Taken together, these data indicate that functional NLRP3 activation upon IAV infection is important to mount a successful immune response.</div><div class="NLM_p">The NLRP3 inflammasome has also been shown to be important for response to <i>Streptococcus pneumoniae (S.P.)</i> infection.<a onclick="showRef(event, 'ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref164 ref165">(164,165)</a> In aged mice, NLRP3 knockout leads to much higher levels of mortality upon <i>S.P.</i> infection.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> In general, aged mice have impaired inflammasome activation and respond more poorly to <i>S. pneumoniae</i> infection. This response could be rescued by treatment with tauroursodeoxycholic acid treatment, which is an ER chaperone that upregulated NLRP3, ASC, caspase-1, and IL-1β secretion. Aged mice also respond poorly to secondary <i>S.P.</i> infection after IAV.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> In general, innate immune function appears to decline with age. While basal activity appears to increase, inducible activity appears to decrease.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><div class="NLM_p">NLRP3 also plays a role in defense against fungal infection. This has been demonstrated clearly with <i>Candida albicans</i>. The fungal peptide candidalysin activates the NLRP3 inflammasome in both mouse and human macrophages through potassium efflux.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> NLRP3 KO increases the number of colony forming units (CFU) upon <i>Candida albicans</i> infection in mice.<a onclick="showRef(event, 'ref141 ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref141 ref170 ref171">(141,170,171)</a> In mouse models of infection, survival is reduced in the absence of NLRP3 or other inflammasome components such as IL-1r1, ASC, or caspase-1.<a onclick="showRef(event, 'ref141 ref170'); return false;" href="javascript:void(0);" class="ref ref141 ref170">(141,170)</a> However, these studies have not been carried out with pharmacological inhibitors, limiting the ability extrapolate these results to a clinical scenario.</div><div class="NLM_p last">Studies have also shown a role for the NLRP3 inflammasome in adaptive immunity. Inflammasome activation also occurs in dendritic cells and T-cells. Ghiringhelli et al. showed that the NLRP3 inflammasome in dendritic cells is activated upon cancer cell death.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> In turn, this triggers secretion of IL-1β, priming CD8<sup>+</sup>T-cells, and secretion of IFN-γ. Knockout of inflammasome components NLRP3, P2RX7, or caspase-1 led to increased tumor size after oxaliplatin treatment compared to WT. Likewise, in CD4<sup>+</sup> cells NLRP3 function is required for IFN-γ secretion and T<sub>H</sub>1 response.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> MCC950 treatment prevents IFN-γ secretion from T<sub>H</sub>1 cells as does a caspase-1 inhibitor. Furthermore, CD4<sup>+</sup>T-cells from CAPS patients have increased IL-1β secretion and IFN-γ secretion. Both IL-1β and IFN-γ secretion were decreased with NLRP3 inhibitor treatment. CD3/CD28 activation of CD4<sup>+</sup> T-cells from NLRP3 KO mice led to secretion of only 25% as much IFN-γ as WT mouse CD4<sup>+</sup> T-cells <i>in vitro</i>. In response to lymphocyte choriomeningitis virus infection, CD4<sup>+</sup>T-cells that lacked NLRP3, IL1-R1, or IL-1α/IL-1β showed an impaired ability to generate IFN-γ<sup>+</sup> virus specific cells <i>in vivo</i>. These data point to the importance of this pathway as part of the innate and adaptive immune response to pathogen infection. This helps address the question of what the biological purpose of the NLRP3 inflammasome could be. It also highlights the need to tread cautiously as new drugs for this exciting target are tested.</div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">The NLRP1 Inflammasome</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73380" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73380" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Aside from NLRP3, there are numerous other inflammasome sensors, many of which are implicated in disease. In general, these are beyond the scope of this review; however, the NLRP1 inflammasome has been implicated in some of the same sterile inflammation as NLRP3, so merits it special mention. To date, there are no known small molecule tool compounds for NLRP1. In the preclinical space, there is one disclosure from IFM that covers compounds that modulate NLRP1, NLRP3, and dual NLRP1/3. However, no data for NLRP1 inhibition are shown.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> There is a report of a peptide, KSHV Orf63, shown to inhibit NLRP1. KSHV Orf63, a viral homologue of human NLRP1, blocked NLRP1-dependent innate immune responses, including caspase-1 activation and processing of interleukins IL-1β and IL-18. KSHV Orf63 is not NLRP1 selective and was also shown to interact with NLRP3 and NOD2.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> One additional publication from GSK presents a strategy for the identification of inhibitors of NLRP1. The authors performed a high-throughput screen for NLRP1 ATP-competitive inhibitors and confirmed hits in a fluorescent polarization assay, but failed to see any cellular activity for any of those hits.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Compared to the extensive patent and publication literature around NLRP3, the field is less enabled to study NLRP1 inhibition and lacks a small molecule tool compound to explore its biology. The discovery of specific small molecule tool compounds for inflammasomes outside of NLRP3 has the potential to open a new frontier in inflammasome biology.</div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The NLRP3 inflammasome is a promising drug target. The breadth of indications it is implicated in speak to the apparent centrality of this pathway. In the next several years, as the most advanced clinical assets begin to read out efficacy data, scientists, doctors, and patients will be watching to see how these expectations are borne out. A clear protective function of inhibiting the NLRP3 inflammasome in humans has not yet been proven. On the basis of the conservation of NLRP3, the lack of a described NLRP3 loss of function (LOF) variant in humans, reported infection AEs with some compounds that impinge or block aspects of the inflammasome, and the susceptibility of preclinical species to certain types of infection, the possibility of side effects from NLRP3 inhibition exists. At the same time, based on the efficacy of compounds that impinge on inflammasome activation or inhibit downstream products of inflammasome activation, there may be additional opportunities to inhibit the inflammasome through novel mechanisms or pathways that avoid directly inhibiting NLRP3 itself. Ultimately, this promises to be an exciting area of biology and drug discovery for years to come.</div></div><div class="NLM_back"><div class="NLM_notes" id="notes1">#<span class="title" id="d77875177e1108">Author Contributions</span><p class="last">A.G.S. and K.B.S. contributed equally.</p></div><div class="NLM_notes" id="notes2"><p class="first last">The authors declare the following competing financial interest(s): Adam Schwaid and Kerrie Spencer are employees of Merck & Co., Inc.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01307" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kerrie B. Spencer</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology, Merck &
Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#68030d1a1a010d371b180d060b0d1a28050d1a0b03460b0705"><span class="__cf_email__" data-cfemail="fe959b8c8c979ba18d8e9b909d9b8cbe939b8c9d95d09d9193">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam G. Schwaid</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology, Merck &
Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2434-6148" title="Orcid link">http://orcid.org/0000-0003-2434-6148</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.G.S. and K.B.S. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare the following competing financial interest(s): Adam Schwaid and Kerrie Spencer are employees of Merck & Co., Inc.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Adam G. Schwaid</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=BIO-d7e1634-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Adam G. Schwaid</b>, Ph.D., is an Associate Principal Scientist at Merck & Co., Inc., Boston, MA, USA, in the Chemical Biology group. His work primarily focuses on using chemical biology and chemoproteomics to identify and understand compound mechanisms of action and the protein targets of small molecules. Before joining Merck & Co., Inc. in 2016, Adam was a Senior Scientist at Pfizer where he used chemical biology to investigate cardiovascular, metabolic, and endocrine disease. He received his Ph.D. from the Department of Chemistry and Chemical Biology at Harvard University in Cambridge, MA.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Kerrie B. Spencer</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=BIO-d7e1639-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kerrie B. Spencer</b> is a Senior Scientist at Merck & Co., Inc., Boston, MA, USA, in the Chemical Biology group. Her current role applies her drug discovery experience to early space research projects principally in phenotypic screening, mechanism of action deconvolution, and target validation. Prior to joining the Chemical Biology group in 2016, Kerrie was a medicinal chemist at Merck & Co., Inc., Boston, MA, USA, contributing to projects in oncology, neuroscience, immunology, and metabolic diseases. She received her B.A. in chemistry from Boston University.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACR20</td><td class="NLM_def"><p class="first last">American College of Rheumatology 20% improvement on a scale of 28 intervals</p></td></tr><tr><td class="NLM_term">AIM2</td><td class="NLM_def"><p class="first last">absent in melanoma 2</p></td></tr><tr><td class="NLM_term">ASC</td><td class="NLM_def"><p class="first last">apoptosis-associated speck-like protein containing a CARD</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice daily</p></td></tr><tr><td class="NLM_term">BIW</td><td class="NLM_def"><p class="first last">twice weekly</p></td></tr><tr><td class="NLM_term">BMDM</td><td class="NLM_def"><p class="first last">bone marrow derived macrophages</p></td></tr><tr><td class="NLM_term">BRCC3</td><td class="NLM_def"><p class="first last">BRCA1-BRCA2-containing complex 3</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CAMKII</td><td class="NLM_def"><p class="first last">Ca<sup>2+</sup>/calmodulin-dependent protein kinase II</p></td></tr><tr><td class="NLM_term">CANTOS</td><td class="NLM_def"><p class="first last">Canakinumab Anti-inflammatory Thrombosis Outcomes Study</p></td></tr><tr><td class="NLM_term">CAPS</td><td class="NLM_def"><p class="first last">cryopyrin associated periodic syndrome</p></td></tr><tr><td class="NLM_term">CARD8</td><td class="NLM_def"><p class="first last">caspase activation and recruitment domain 8</p></td></tr><tr><td class="NLM_term">CFU</td><td class="NLM_def"><p class="first last">colony forming units</p></td></tr><tr><td class="NLM_term">CHIP</td><td class="NLM_def"><p class="first last">c terminus of HSC70-interacting protein</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocyte leukemia</p></td></tr><tr><td class="NLM_term">COVID-19</td><td class="NLM_def"><p class="first last">coronavirus disease 2019</p></td></tr><tr><td class="NLM_term">CPPd</td><td class="NLM_def"><p class="first last">calcium pyrophosphate deposition</p></td></tr><tr><td class="NLM_term">DAMP</td><td class="NLM_def"><p class="first last">damage associated molecular pattern</p></td></tr><tr><td class="NLM_term">DHX33</td><td class="NLM_def"><p class="first last">DEAH box protein 33</p></td></tr><tr><td class="NLM_term">dsRNA</td><td class="NLM_def"><p class="first last">double stranded ribonucleic acid</p></td></tr><tr><td class="NLM_term">DSS</td><td class="NLM_def"><p class="first last">dextran sodium sulfate</p></td></tr><tr><td class="NLM_term">DUB</td><td class="NLM_def"><p class="first last">deubiquitinase</p></td></tr><tr><td class="NLM_term">EBS</td><td class="NLM_def"><p class="first last">epidermolysis bullosa simplex</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">endoplasmic reticulum</p></td></tr><tr><td class="NLM_term">FBXL2</td><td class="NLM_def"><p class="first last">F-box/LRR-repeat protein 2</p></td></tr><tr><td class="NLM_term">FBXO3</td><td class="NLM_def"><p class="first last">F-box only protein 3</p></td></tr><tr><td class="NLM_term">GAS</td><td class="NLM_def"><p class="first last">group A streptococcus</p></td></tr><tr><td class="NLM_term">GOF</td><td class="NLM_def"><p class="first last">gain of function</p></td></tr><tr><td class="NLM_term">GSTO1</td><td class="NLM_def"><p class="first last">glutathione <i>S</i>-transferase omega 1</p></td></tr><tr><td class="NLM_term">HIF-1α</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor 1-alpha</p></td></tr><tr><td class="NLM_term">HK2</td><td class="NLM_def"><p class="first last">hexokinase 2</p></td></tr><tr><td class="NLM_term">IAV</td><td class="NLM_def"><p class="first last">influenza A infection</p></td></tr><tr><td class="NLM_term">IFN-γ</td><td class="NLM_def"><p class="first last">interferon gamma</p></td></tr><tr><td class="NLM_term">IL-6</td><td class="NLM_def"><p class="first last">interleukin 6</p></td></tr><tr><td class="NLM_term">IL-18</td><td class="NLM_def"><p class="first last">interleukin 18</p></td></tr><tr><td class="NLM_term">IL-1R</td><td class="NLM_def"><p class="first last">interleukin 1 receptor</p></td></tr><tr><td class="NLM_term">IL-1β</td><td class="NLM_def"><p class="first last">interleukin 1 beta</p></td></tr><tr><td class="NLM_term">IRAK4</td><td class="NLM_def"><p class="first last">interleukin-1 receptor-associated kinase 4</p></td></tr><tr><td class="NLM_term">ITP</td><td class="NLM_def"><p class="first last">immune thrombocytopenia</p></td></tr><tr><td class="NLM_term">IκB</td><td class="NLM_def"><p class="first last">inhibitor of nuclear factor kappa B</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">KO</td><td class="NLM_def"><p class="first last">knock out</p></td></tr><tr><td class="NLM_term">LAMP1</td><td class="NLM_def"><p class="first last">lysosomal-associated membrane protein 1</p></td></tr><tr><td class="NLM_term">LC3B</td><td class="NLM_def"><p class="first last">long-chain base protein 3</p></td></tr><tr><td class="NLM_term">LLOMe</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-leucine methyl ester</p></td></tr><tr><td class="NLM_term">LOF</td><td class="NLM_def"><p class="first last">loss of function</p></td></tr><tr><td class="NLM_term">MSU</td><td class="NLM_def"><p class="first last">monosodium urate</p></td></tr><tr><td class="NLM_term">Myd88</td><td class="NLM_def"><p class="first last">myeloid differentiation primary response 88</p></td></tr><tr><td class="NLM_term">NACHT</td><td class="NLM_def"><p class="first last">NAIP, CIITA, HET-E, and TP1</p></td></tr><tr><td class="NLM_term">NAFLD</td><td class="NLM_def"><p class="first last">nonalcoholic fatty liver disease</p></td></tr><tr><td class="NLM_term">NASH</td><td class="NLM_def"><p class="first last">nonalcoholic steatohepatitis</p></td></tr><tr><td class="NLM_term">NEK7</td><td class="NLM_def"><p class="first last">NIMA-related kinase 7</p></td></tr><tr><td class="NLM_term">NEK9</td><td class="NLM_def"><p class="first last">NIMA-related kinase 9</p></td></tr><tr><td class="NLM_term">NLRC4</td><td class="NLM_def"><p class="first last">NLR family CARD domain-containing protein 4</p></td></tr><tr><td class="NLM_term">NLRP1</td><td class="NLM_def"><p class="first last">NLR family pyrin domain containing 1</p></td></tr><tr><td class="NLM_term">NLRP3</td><td class="NLM_def"><p class="first last">NLR family pyrin domain containing 3</p></td></tr><tr><td class="NLM_term">NOD2</td><td class="NLM_def"><p class="first last">nucleotide-binding oligomerization domain-containing protein 2</p></td></tr><tr><td class="NLM_term">OSKIRA</td><td class="NLM_def"><p class="first last">Oral SyK Inhibition in Rheumatoid Arthritis</p></td></tr><tr><td class="NLM_term">P2RX7</td><td class="NLM_def"><p class="first last">P2X purinoceptor 7</p></td></tr><tr><td class="NLM_term">P2X7</td><td class="NLM_def"><p class="first last">P2X purinoceptor 7</p></td></tr><tr><td class="NLM_term">PAMP</td><td class="NLM_def"><p class="first last">pathogen associated molecular pattern</p></td></tr><tr><td class="NLM_term">PBMCs</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">PKD</td><td class="NLM_def"><p class="first last">polycystin 1</p></td></tr><tr><td class="NLM_term">PMA</td><td class="NLM_def"><p class="first last">phorbol 12-myristate 13-acetate</p></td></tr><tr><td class="NLM_term">PP2A</td><td class="NLM_def"><p class="first last">protein phosphatase 2</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">PTM</td><td class="NLM_def"><p class="first last">posttranslational modification</p></td></tr><tr><td class="NLM_term">Pyk2</td><td class="NLM_def"><p class="first last">protein tyrosine kinase 2 beta</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RGMCs</td><td class="NLM_def"><p class="first last">rat glomerular mesangial cells</p></td></tr><tr><td class="NLM_term"><i>S.P.</i></td><td class="NLM_def"><p class="first last"><i>Streptococcus pneumoniae</i></p></td></tr><tr><td class="NLM_term">S100a8/a9</td><td class="NLM_def"><p class="first last">S100 calcium-binding protein A8/A9</p></td></tr><tr><td class="NLM_term">SARS-CoV-2</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome coronavirus 2</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small interfering RNA</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">Syk</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term">TAK1</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase 7</p></td></tr><tr><td class="NLM_term">TASKi2</td><td class="NLM_def"><p class="first last">phase 2b clinical trials with R788</p></td></tr><tr><td class="NLM_term">TRAF6</td><td class="NLM_def"><p class="first last">TNF receptor associated factor 6</p></td></tr><tr><td class="NLM_term">TRIM31</td><td class="NLM_def"><p class="first last">tripartite motif-containing protein 31</p></td></tr><tr><td class="NLM_term">TWIK-2</td><td class="NLM_def"><p class="first last">tandem pore domain potassium channel 2</p></td></tr><tr><td class="NLM_term">UBR5</td><td class="NLM_def"><p class="first last">ubiquitin protein ligase E3 component N-recognin 5</p></td></tr><tr><td class="NLM_term">VDAC</td><td class="NLM_def"><p class="first last">voltage-dependent anion-selective channel</p></td></tr><tr><td class="NLM_term">WIPO</td><td class="NLM_def"><p class="first last">World Intellectual Property Organization</p></td></tr><tr><td class="NLM_term">XLA</td><td class="NLM_def"><p class="first last">X-linked agammaglobulinemia</p></td></tr><tr><td class="NLM_term">ZAP70</td><td class="NLM_def"><p class="first last">zetachain-associated protein kinase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 176 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jo, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasakawa, C.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms Regulating NLRP3 Inflammasome Activation</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1038/cmi.2015.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fcmi.2015.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26549800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Gms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=148-159&author=E.-K.+Joauthor=J.+K.+Kimauthor=D.-M.+Shinauthor=C.+Sasakawa&title=Molecular+Mechanisms+Regulating+NLRP3+Inflammasome+Activation&doi=10.1038%2Fcmi.2015.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms regulating NLRP3 inflammasome activation</span></div><div class="casAuthors">Jo, Eun-Kyeong; Kim, Jin Kyung; Shin, Dong-Min; Sasakawa, Chihiro</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-159</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">Inflammasomes are multi-protein signaling complexes that trigger the activation of inflammatory caspases and the maturation of interleukin-1β.  Among various inflammasome complexes, the NLRP3 inflammasome is best characterized and has been linked with various human autoinflammatory and autoimmune diseases.  Thus, the NLRP3 inflammasome may be a promising target for anti-inflammatory therapies.  In this review, we summarize the current understanding of the mechanisms by which the NLRP3 inflammasome is activated in the cytosol.  We also describe the binding partners of NLRP3 inflammasome complexes activating or inhibiting the inflammasome assembly.  Our knowledge of the mechanisms regulating NLRP3 inflammasome signaling and how these influence inflammatory responses offers further insight into potential therapeutic strategies to treat inflammatory diseases assocd. with dysregulation of the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBv_NNzcwFLVg90H21EOLACvtfcHk0lj3Qho0gXWyFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Gms7s%253D&md5=90c508a823912cf69f86cefac7aaaaec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2015.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2015.95%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DE.-K.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DShin%26aufirst%3DD.-M.%26aulast%3DSasakawa%26aufirst%3DC.%26atitle%3DMolecular%2520Mechanisms%2520Regulating%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2016%26volume%3D13%26spage%3D148%26epage%3D159%26doi%3D10.1038%2Fcmi.2015.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, J. P.-Y.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of NOD-like Receptor-Associated Inflammasome Activation</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2013.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2013.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24054327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVynu7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=432-441&author=H.+Wenauthor=E.+A.+Miaoauthor=J.+P.-Y.+Ting&title=Mechanisms+of+NOD-like+Receptor-Associated+Inflammasome+Activation&doi=10.1016%2Fj.immuni.2013.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of NOD-like Receptor-Associated Inflammasome Activation</span></div><div class="casAuthors">Wen, Haitao; Miao, Edward A.; Ting, Jenny P.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">432-441</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  A major function of a subfamily of NLR (nucleotide-binding domain, leucine-rich repeat contg., or NOD-like receptor) proteins is in inflammasome activation, which has been implicated in a multitude of disease models and human diseases.  This work will highlight key progress in understanding the mechanisms that activate the best-studied NLRs (NLRP3, NLRC4, NAIP, and NLRP1) and in uncovering inflammasome NLRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofkF9PnmcKNbVg90H21EOLACvtfcHk0lj3Qho0gXWyFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVynu7jE&md5=a3abf6999a40fe086584ccfb068f1b24</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2013.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2013.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DE.%2BA.%26aulast%3DTing%26aufirst%3DJ.%2BP.-Y.%26atitle%3DMechanisms%2520of%2520NOD-like%2520Receptor-Associated%2520Inflammasome%2520Activation%26jtitle%3DImmunity%26date%3D2013%26volume%3D39%26spage%3D432%26epage%3D441%26doi%3D10.1016%2Fj.immuni.2013.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, J. P.-Y.</span></span> <span> </span><span class="NLM_article-title">The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1038/s41577-019-0165-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41577-019-0165-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31036962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1SktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=477-489&author=K.+V.+Swansonauthor=M.+Dengauthor=J.+P.-Y.+Ting&title=The+NLRP3+Inflammasome%3A+Molecular+Activation+and+Regulation+to+Therapeutics&doi=10.1038%2Fs41577-019-0165-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP3 inflammasome: molecular activation and regulation to therapeutics</span></div><div class="casAuthors">Swanson, Karen V.; Deng, Meng; Ting, Jenny P.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">477-489</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  NLRP3 (NOD-, LRR- and pyrin domain-contg. protein 3) is an intracellular sensor that detects a broad range of microbial motifs, endogenous danger signals and environmental irritants, resulting in the formation and activation of the NLRP3 inflammasome.  Assembly of the NLRP3 inflammasome leads to caspase 1-dependent release of the pro-inflammatory cytokines IL-1β and IL-18, as well as to gasdermin D-mediated pyroptotic cell death.  Recent studies have revealed new regulators of the NLRP3 inflammasome, including new interacting or regulatory proteins, metabolic pathways and a regulatory mitochondrial hub.  In this Review, we present the mol., cell biol. and biochem. bases of NLRP3 activation and regulation and describe how this mechanistic understanding is leading to potential therapeutics that target the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW8T8C8vdzprVg90H21EOLACvtfcHk0lgxQ4mWCKjo9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1SktLw%253D&md5=f3acc6b5154d2ec4544aa54c2f3d7c4f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41577-019-0165-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41577-019-0165-0%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DK.%2BV.%26aulast%3DDeng%26aufirst%3DM.%26aulast%3DTing%26aufirst%3DJ.%2BP.-Y.%26atitle%3DThe%2520NLRP3%2520Inflammasome%253A%2520Molecular%2520Activation%2520and%2520Regulation%2520to%2520Therapeutics%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2019%26volume%3D19%26spage%3D477%26epage%3D489%26doi%3D10.1038%2Fs41577-019-0165-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Afonina, I. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyaert, R.</span></span> <span> </span><span class="NLM_article-title">Limiting Inflammation--the Negative Regulation of NF-κB and the NLRP3 Inflammasome</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1038/ni.3772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.3772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28722711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFyqtL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=861-869&issue=8&author=I.+S+Afoninaauthor=Z.+Zhongauthor=M.+Karinauthor=R.+Beyaert&title=Limiting+Inflammation%2D%2Dthe+Negative+Regulation+of+NF-%CE%BAB+and+the+NLRP3+Inflammasome&doi=10.1038%2Fni.3772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome</span></div><div class="casAuthors">Afonina, Inna S.; Zhong, Zhenyu; Karin, Michael; Beyaert, Rudi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">861-869</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A properly mounted immune response is indispensable for recognizing and eliminating danger arising from foreign invaders and tissue trauma.  However, the 'inflammatory fire' kindled by the host response must be tightly controlled to prevent it from spreading and causing irreparable damage.  Accordingly, acute inflammation is self-limiting and is normally attenuated after elimination of noxious stimuli, restoration of homeostasis and initiation of tissue repair.  However, unresolved inflammation may lead to the development of chronic autoimmune and degenerative diseases and cancer.  Here, we discuss the key mol. mechanisms that contribute to the self-limiting nature of inflammatory signaling, with emphasis on the neg. regulation of the NF-κB pathway and the NLRP3 inflammasome.  Understanding these neg. regulatory mechanisms should facilitate the development of much-needed therapeutic strategies for treatment of inflammatory and autoimmune pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLa1nlskoLxrVg90H21EOLACvtfcHk0lgxQ4mWCKjo9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFyqtL%252FO&md5=bf11b44362f40cd0327e51617564b4aa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fni.3772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3772%26sid%3Dliteratum%253Aachs%26aulast%3DAfonina%26aufirst%3DI.%2BS%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DBeyaert%26aufirst%3DR.%26atitle%3DLimiting%2520Inflammation--the%2520Negative%2520Regulation%2520of%2520NF-%25CE%25BAB%2520and%2520the%2520NLRP3%2520Inflammasome%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26issue%3D8%26spage%3D861%26epage%3D869%26doi%3D10.1038%2Fni.3772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauernfeind, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnemri, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes-Alnemri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">NF-kB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.0901363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19570822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFWgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=787-791&issue=2&author=F.+Bauernfeindauthor=G.+Horvathauthor=A.+Stutzauthor=E.+S.+Alnemriauthor=K.+MacDonaldauthor=D.+Speertauthor=T.+Fernandes-Alnemriauthor=J.+Wuauthor=B.+G.+Monksauthor=K.+A.+Fitzgeraldauthor=V.+Hornungauthor=E.+Latz&title=NF-kB+Activating+Pattern+Recognition+and+Cytokine+Receptors+License+NLRP3+Inflammasome+Activation+by+Regulating+NLRP3+Expression&doi=10.4049%2Fjimmunol.0901363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</span></div><div class="casAuthors">Bauernfeind, Franz G.; Horvath, Gabor; Stutz, Andrea; Alnemri, Emad S.; MacDonald, Kelly; Speert, David; Fernandes-Alnemri, Teresa; Wu, Jianghong; Monks, Brian G.; Fitzgerald, Katherine A.; Hornung, Veit; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">787-791</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The IL-1 family cytokines are regulated on transcriptional and posttranscriptional levels.  Pattern recognition and cytokine receptors control pro-IL-1β transcription whereas inflammasomes regulate the proteolytic processing of pro-IL-1β.  The NLRP3 inflammasome, however, assembles in response to extracellular ATP, pore-forming toxins, or crystals only in the presence of proinflammatory stimuli.  How the activation of gene transcription by signaling receptors enables NLRP3 activation remains elusive and controversial.  In this study, the authors show that cell priming through multiple signaling receptors induces NLRP3 expression, which the authors identified to be a crit. checkpoint for NLRP3 activation.  Signals provided by NF-κB activators are necessary but not sufficient for NLRP3 activation, and a second stimulus such as ATP or crystal-induced damage is required for NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUf4OrrejQ7Vg90H21EOLACvtfcHk0lgxQ4mWCKjo9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFWgt78%253D&md5=1b04c9f756bb70d6292bd8bd5507ee1f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901363%26sid%3Dliteratum%253Aachs%26aulast%3DBauernfeind%26aufirst%3DF.%26aulast%3DHorvath%26aufirst%3DG.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DAlnemri%26aufirst%3DE.%2BS.%26aulast%3DMacDonald%26aufirst%3DK.%26aulast%3DSpeert%26aufirst%3DD.%26aulast%3DFernandes-Alnemri%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DMonks%26aufirst%3DB.%2BG.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DHornung%26aufirst%3DV.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DNF-kB%2520Activating%2520Pattern%2520Recognition%2520and%2520Cytokine%2520Receptors%2520License%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Regulating%2520NLRP3%2520Expression%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26issue%3D2%26spage%3D787%26epage%3D791%26doi%3D10.4049%2Fjimmunol.0901363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapeton-Montes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardiff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, P. A.</span></span> <span> </span><span class="NLM_article-title">S100A8 and S100A9 Induce Cytokine Expression and Regulate the NLRP3 Inflammasome via ROS-Dependent Activation of NF-κB</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>), <span class="NLM_elocation-id">e72139</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0072138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.pone.0072138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24015211" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&issue=8&author=J.-C.+Simardauthor=A.+Cesaroauthor=J.+Chapeton-Montesauthor=M.+Tardiffauthor=F.+Antoineauthor=D.+Giradauthor=P.+A.+Tessier&title=S100A8+and+S100A9+Induce+Cytokine+Expression+and+Regulate+the+NLRP3+Inflammasome+via+ROS-Dependent+Activation+of+NF-%CE%BAB&doi=10.1371%2Fjournal.pone.0072138"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0072138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0072138%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DJ.-C.%26aulast%3DCesaro%26aufirst%3DA.%26aulast%3DChapeton-Montes%26aufirst%3DJ.%26aulast%3DTardiff%26aufirst%3DM.%26aulast%3DAntoine%26aufirst%3DF.%26aulast%3DGirad%26aufirst%3DD.%26aulast%3DTessier%26aufirst%3DP.%2BA.%26atitle%3DS100A8%2520and%2520S100A9%2520Induce%2520Cytokine%2520Expression%2520and%2520Regulate%2520the%2520NLRP3%2520Inflammasome%2520via%2520ROS-Dependent%2520Activation%2520of%2520NF-%25CE%25BAB%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D8%26doi%3D10.1371%2Fjournal.pone.0072138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, B. B.</span></span> <span> </span><span class="NLM_article-title">Inhibiting NF-κB Activation by Small Molecules as a Therapeutic Strategy</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1799</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2010.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.bbagrm.2010.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20493977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFahtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1799&publication_year=2010&pages=775-787&author=S.+C.+Guptaauthor=C.+Sundaramauthor=S.+Reuterauthor=B.+B.+Aggarwal&title=Inhibiting+NF-%CE%BAB+Activation+by+Small+Molecules+as+a+Therapeutic+Strategy&doi=10.1016%2Fj.bbagrm.2010.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting NF-κB activation by small molecules as a therapeutic strategy</span></div><div class="casAuthors">Gupta, Subash C.; Sundaram, Chitra; Reuter, Simone; Aggarwal, Bharat B.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1799</span>
        (<span class="NLM_cas:issue">10-12</span>),
    <span class="NLM_cas:pages">775-787</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Because nuclear factor-κB (NF-κB) is a ubiquitously expressed proinflammatory transcription factor that regulates the expression of over 500 genes involved in cellular transformation, survival, proliferation, invasion, angiogenesis, metastasis, and inflammation, the NF-κB signaling pathway has become a potential target for pharmacol. intervention.  A wide variety of agents can activate NF-κB through canonical and noncanonical pathways.  Canonical pathway involves various steps including the phosphorylation, ubiquitination, and degrdn. of the inhibitor of NF-κB (IκBα), which leads to the nuclear translocation of the p50-p65 subunits of NF-κB followed by p65 phosphorylation, acetylation and methylation, DNA binding, and gene transcription.  Thus, agents that can inhibit protein kinases, protein phosphatases, proteasomes, ubiquitination, acetylation, methylation, and DNA binding steps have been identified as NF-κB inhibitors.  Because of the crit. role of NF-κB in cancer and various chronic diseases, numerous inhibitors of NF-κB have been identified.  In this review, however, we describe only small mols. that suppress NF-κB activation, and the mechanism by which they block this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJfBI8lJJ4e7Vg90H21EOLACvtfcHk0lhk5g0Q26OHww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFahtLbI&md5=652d2f8de7b6141ef71f91acde907101</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2010.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2010.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%2BC.%26aulast%3DSundaram%26aufirst%3DC.%26aulast%3DReuter%26aufirst%3DS.%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26atitle%3DInhibiting%2520NF-%25CE%25BAB%2520Activation%2520by%2520Small%2520Molecules%2520as%2520a%2520Therapeutic%2520Strategy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2010%26volume%3D1799%26spage%3D775%26epage%3D787%26doi%3D10.1016%2Fj.bbagrm.2010.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">NF-κB, Inflammation, Immunity and Cancer: Coming of Age</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnri.2017.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29379212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=309-324&author=K.+Taniguchiauthor=M.+Karin&title=NF-%CE%BAB%2C+Inflammation%2C+Immunity+and+Cancer%3A+Coming+of+Age&doi=10.1038%2Fnri.2017.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB, inflammation, immunity and cancer: coming of age</span></div><div class="casAuthors">Taniguchi, Koji; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">309-324</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Fourteen years have passed since nuclear factor-κB (NF-κB) was first shown to serve as a mol. lynchpin that links persistent infections and chronic inflammation to increased cancer risk.  The young field of inflammation and cancer has now come of age, and inflammation has been recognized by the broad cancer research community as a hallmark and cause of cancer.  Here, we discuss how the initial discovery of a role for NF-κB in linking inflammation and cancer led to an improved understanding of tumor-elicited inflammation and its effects on anticancer immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbWVUEqQxv9rVg90H21EOLACvtfcHk0lhTYvfbO5vi_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yjtrk%253D&md5=02d3c489732baab402ddf87d18416bd6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.142%26sid%3Dliteratum%253Aachs%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DNF-%25CE%25BAB%252C%2520Inflammation%252C%2520Immunity%2520and%2520Cancer%253A%2520Coming%2520of%2520Age%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D309%26epage%3D324%26doi%3D10.1038%2Fnri.2017.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magupalli, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, J.</span></span> <span> </span><span class="NLM_article-title">Inflammasome-Activated Gasdermin D Causes Pyroptosis by Forming Membrane Pores</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1038/nature18629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature18629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27383986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFensL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=153-157&author=X.+Liuauthor=Z.+Zhangauthor=J.+Ruanauthor=Y.+Panauthor=V.+G.+Magupalliauthor=H.+Wuauthor=J.+Lieberman&title=Inflammasome-Activated+Gasdermin+D+Causes+Pyroptosis+by+Forming+Membrane+Pores&doi=10.1038%2Fnature18629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores</span></div><div class="casAuthors">Liu, Xing; Zhang, Zhibin; Ruan, Jianbin; Pan, Youdong; Magupalli, Venkat Giri; Wu, Hao; Lieberman, Judy</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7610</span>),
    <span class="NLM_cas:pages">153-158</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammatory caspases (caspases 1, 4, 5 and 11) are activated in response to microbial infection and danger signals.  When activated, they cleave mouse and human gasdermin D (GSDMD) after Asp276 and Asp275, resp., to generate an N-terminal cleavage product (GSDMD-NT) that triggers inflammatory death (pyroptosis) and release of inflammatory cytokines such as interleukin-1β.  Cleavage removes the C-terminal fragment (GSDMD-CT), which is thought to fold back on GSDMD-NT to inhibit its activation.  However, how GSDMD-NT causes cell death is unknown.  Here the authors show that GSDMD-NT oligomerizes in membranes to form pores that are visible by electron microscopy.  GSDMD-NT binds to phosphatidylinositol phosphates and phosphatidylserine (restricted to the cell membrane inner leaflet) and cardiolipin (present in the inner and outer leaflets of bacterial membranes).  Mutation of four evolutionarily conserved basic residues blocks GSDMD-NT oligomerization, membrane binding, pore formation and pyroptosis.  Because of its lipid-binding preferences, GSDMD-NT kills from within the cell, but does not harm neighboring mammalian cells when it is released during pyroptosis.  GSDMD-NT also kills cell-free bacteria in vitro and may have a direct bactericidal effect within the cytosol of host cells, but the importance of direct bacterial killing in controlling in vivo infection remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpcilGNbDUkrVg90H21EOLACvtfcHk0lhTYvfbO5vi_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFensL7K&md5=44ba5b0304b041c21b9a7d8f2f04651a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature18629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRuan%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DMagupalli%26aufirst%3DV.%2BG.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLieberman%26aufirst%3DJ.%26atitle%3DInflammasome-Activated%2520Gasdermin%2520D%2520Causes%2520Pyroptosis%2520by%2520Forming%2520Membrane%2520Pores%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D153%26epage%3D157%26doi%3D10.1038%2Fnature18629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perregaux, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcniff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laliberte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peurano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombroski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of a Novel Class of Interleukin-1 Post-Translational Processing Inhibitors</span>. <i>J. Pharmacol. Experimental Therapeutics</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>299</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=11561079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=187-197&issue=1&author=D.+G.+Perregauxauthor=P.+Mcniffauthor=R.+Laliberteauthor=N.+Hawrylukauthor=H.+Peuranoauthor=E.+Stamauthor=J.+Egglerauthor=R.+Griffithsauthor=M.+A.+Dombroskiauthor=C.+Gabel&title=Identification+and+Characterization+of+a+Novel+Class+of+Interleukin-1+Post-Translational+Processing+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors</span></div><div class="casAuthors">Perregaux, David G.; McNiff, Patricia; Laliberte, Ronald; Hawryluk, Natalie; Peurano, Heather; Stam, Ethan; Eggler, Jim; Griffiths, Richard; Dombroski, Mark A.; Gabel, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-197</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS)-activated monocytes and macrophages produce large quantities of pro-interleukin (IL)-1β but externalize little mature cytokine.  Efficient post-translational processing of the pro-cytokine occurs in vitro when these cells encounter a secretion stimulus such as ATP, cytolytic T cells, or hypotonic stress.  Each of these stimuli promotes rapid conversion of 31-kDa pro-IL-1β to its mature 17-kDa species and release of the 17-kDa cytokine.  In this study, two novel pharmacol. agents, CP-424,174 and CP-412,245, are identified as potent inhibitors of stimulus-coupled IL-1β post-translational processing.  These agents, both diarylsulfonylureas, block formation of mature IL-1β without increasing the amt. of pro-cytokine that is released extracellularly, and they inhibit independently of the secretion stimulus used.  Conditioned medium derived from LPS-activated/ATP-treated human monocytes maintained in the absence and presence of CP-424,174 contained comparable quantities of IL-6, tumor necrosis factor-α (TNFα), and IL-1RA, but 30-fold less IL-1β was generated in the test agent's presence.  As a result of this decrease, monocyte conditioned medium prepd. in the presence of CP-424,174 demonstrated a greatly diminished capacity to promote an IL-1-dependent response (induction of serum amyloid A synthesis by Hep3B cells).  Oral administration of CP-424,174 to mice resulted in inhibition of IL-1 in the absence of an effect on IL-6 and TNFα.  These novel agents, therefore, act as selective cytokine release inhibitors and define a new therapeutic approach for controlling IL-1 prodn. in inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnTnmtD12hMrVg90H21EOLACvtfcHk0lhTYvfbO5vi_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFWltL8%253D&md5=5da5f7fd4689c1dd7dc8e187a8f9d02f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerregaux%26aufirst%3DD.%2BG.%26aulast%3DMcniff%26aufirst%3DP.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DHawryluk%26aufirst%3DN.%26aulast%3DPeurano%26aufirst%3DH.%26aulast%3DStam%26aufirst%3DE.%26aulast%3DEggler%26aufirst%3DJ.%26aulast%3DGriffiths%26aufirst%3DR.%26aulast%3DDombroski%26aufirst%3DM.%2BA.%26aulast%3DGabel%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520a%2520Novel%2520Class%2520of%2520Interleukin-1%2520Post-Translational%2520Processing%2520Inhibitors%26jtitle%3DJ.%2520Pharmacol.%2520Experimental%2520Therapeutics%26date%3D2001%26volume%3D299%26issue%3D1%26spage%3D187%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laliberte, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perregaux, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peese, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombroski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span> <span> </span><span class="NLM_article-title">Glutathione <i>S-</i>Transferase Omega 1–1 is a Target of Cytokine Release Inhibitory Drugs and May Be Responsible for Their Effect on Interluekin-1β Posttranslational Processing</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">16567</span>– <span class="NLM_lpage">16578</span>, <span class="refDoi"> DOI: 10.1074/jbc.M211596200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1074%2Fjbc.M211596200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=12624100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVKnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=16567-16578&author=R.+E.+Laliberteauthor=D.+G.+Perregauxauthor=L.+R.+Hothauthor=P.+J.+Rosnerauthor=C.+K.+Jordanauthor=K.+M.+Peeseauthor=J.+F.+Egglerauthor=M.+A.+Dombroskiauthor=K.+F.+Geogheganauthor=C.+Gabel&title=Glutathione+S-Transferase+Omega+1%E2%80%931+is+a+Target+of+Cytokine+Release+Inhibitory+Drugs+and+May+Be+Responsible+for+Their+Effect+on+Interluekin-1%CE%B2+Posttranslational+Processing&doi=10.1074%2Fjbc.M211596200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione S-Transferase Omega 1-1 Is a Target of Cytokine Release Inhibitory Drugs and May Be Responsible for Their Effect on Interleukin-1β Posttranslational Processing</span></div><div class="casAuthors">Laliberte, Ronald E.; Perregaux, David G.; Hoth, Lise R.; Rosner, Philip J.; Jordan, Crystal K.; Peese, Kevin M.; Eggler, James. F.; Dombroski, Mark A.; Geoghegan, Kieran F.; Gabel, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">16567-16578</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Stimulus-induced posttranslational processing of human monocyte interleukin-1β (IL-1β) is accompanied by major changes to the intracellular ionic environment, activation of caspase-1, and cell death.  Certain diarylsulfonylureas inhibit this response, and are designated cytokine release inhibitory drugs (CRIDs).  CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved.  Affinity labeling with [14C]CRIDs and affinity chromatog. on immobilized CRID were used in seeking potential protein targets of their action.  Following treatment of intact human monocytes with an epoxide-bearing [14C]CRID, glutathione S-transferase (GST) Omega 1-1 was identified as a preferred target.  Moreover, labeling of this polypeptide correlated with irreversible inhibition of ATP-induced IL-1β posttranslational processing.  When exts. of human monocytic cells were chromatographed on a CRID affinity column, GST Omega 1-1 bound selectively to the affinity matrix and was eluted by sol. CRID.  Recombinant GST Omega 1-1 readily incorporated [14C]CRID epoxides, but labeling was negated by co-incubation with S-substituted glutathiones or by mutagenesis of the catalytic center Cys32 to alanine.  Peptide mapping by high performance liq. chromatog.-mass spectrometry also demonstrated that Cys32 was the site of modification.  Although S-alkylglutathiones did not arrest ATP-induced IL-1β posttranslational processing or inhibit [14C]CRID incorporation into cell-assocd. GST Omega 1-1, a glutathione-CRID adduct effectively demonstrated these attributes.  Therefore, the ability of CRIDs to arrest stimulus-induced IL-1β posttranslational processing may be attributable to their interaction with GST Omega 1-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkub8_wJ5lE7Vg90H21EOLACvtfcHk0ljXTB0SZGKCZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVKnsLs%253D&md5=bed10a4f698b571abda850217c44f379</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M211596200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M211596200%26sid%3Dliteratum%253Aachs%26aulast%3DLaliberte%26aufirst%3DR.%2BE.%26aulast%3DPerregaux%26aufirst%3DD.%2BG.%26aulast%3DHoth%26aufirst%3DL.%2BR.%26aulast%3DRosner%26aufirst%3DP.%2BJ.%26aulast%3DJordan%26aufirst%3DC.%2BK.%26aulast%3DPeese%26aufirst%3DK.%2BM.%26aulast%3DEggler%26aufirst%3DJ.%2BF.%26aulast%3DDombroski%26aufirst%3DM.%2BA.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DGabel%26aufirst%3DC.%26atitle%3DGlutathione%2520S-Transferase%2520Omega%25201%25E2%2580%25931%2520is%2520a%2520Target%2520of%2520Cytokine%2520Release%2520Inhibitory%2520Drugs%2520and%2520May%2520Be%2520Responsible%2520for%2520Their%2520Effect%2520on%2520Interluekin-1%25CE%25B2%2520Posttranslational%2520Processing%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D16567%26epage%3D16578%26doi%3D10.1074%2Fjbc.M211596200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coll, R. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, S. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Planillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inserra, M. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dungan, L. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croker, D. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haneklaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, C. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner, D. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K. H G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, S. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Neill, L. A J</span></span> <span> </span><span class="NLM_article-title">A Small-Molecule Inhibitor of the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1038/nm.3806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnm.3806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25686105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=248-255&issue=3&author=R.+C+Collauthor=A.+A+B+Robertsonauthor=J.+J.+Chaeauthor=S.+C+Higginsauthor=R.+Munoz-Planilloauthor=M.+C+Inserraauthor=I.+Vetterauthor=L.+S+Dunganauthor=B.+G+Monksauthor=A.+Stutzauthor=D.+E+Crokerauthor=M.+S+Butlerauthor=M.+Haneklausauthor=C.+E+Suttonauthor=G.+Nunezauthor=E.+Latzauthor=D.+L+Kastnerauthor=K.+H+G+Millsauthor=S.+L+Mastersauthor=K.+Schroderauthor=M.+A+Cooperauthor=L.+A+J+O%27Neill&title=A+Small-Molecule+Inhibitor+of+the+NLRP3+Inflammasome+for+the+Treatment+of+Inflammatory+Diseases&doi=10.1038%2Fnm.3806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases</span></div><div class="casAuthors">Coll, Rebecca C.; Robertson, Avril A. B.; Chae, Jae Jin; Higgins, Sarah C.; Munoz-Planillo, Raul; Inserra, Marco C.; Vetter, Irina; Dungan, Lara S.; Monks, Brian G.; Stutz, Andrea; Croker, Daniel E.; Butler, Mark S.; Haneklaus, Moritz; Sutton, Caroline E.; Nunez, Gabriel; Latz, Eicke; Kastner, Daniel L.; Mills, Kingston H. G.; Masters, Seth L.; Schroder, Kate; Cooper, Matthew A.; O'Neill, Luke A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-255</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The NOD-like receptor (NLR) family, pyrin domain-contg. protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-assocd. periodic syndrome (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis.  We describe the development of MCC950, a potent, selective, small-mol. inhibitor of NLRP3.  MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concns.  MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes.  MCC950 reduced interleukin-1β (IL-1β) prodn. in vivo and attenuated the severity of exptl. autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis.  Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle-Wells syndrome.  MCC950 is thus a potential therapeutic for NLRP3-assocd. syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBPny7QJdNA7Vg90H21EOLACvtfcHk0ljXTB0SZGKCZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSit7g%253D&md5=5ffe3683cc33ded3c3b18421e987cac5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm.3806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3806%26sid%3Dliteratum%253Aachs%26aulast%3DColl%26aufirst%3DR.%2BC%26aulast%3DRobertson%26aufirst%3DA.%2BA%2BB%26aulast%3DChae%26aufirst%3DJ.%2BJ.%26aulast%3DHiggins%26aufirst%3DS.%2BC%26aulast%3DMunoz-Planillo%26aufirst%3DR.%26aulast%3DInserra%26aufirst%3DM.%2BC%26aulast%3DVetter%26aufirst%3DI.%26aulast%3DDungan%26aufirst%3DL.%2BS%26aulast%3DMonks%26aufirst%3DB.%2BG%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DCroker%26aufirst%3DD.%2BE%26aulast%3DButler%26aufirst%3DM.%2BS%26aulast%3DHaneklaus%26aufirst%3DM.%26aulast%3DSutton%26aufirst%3DC.%2BE%26aulast%3DNunez%26aufirst%3DG.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DKastner%26aufirst%3DD.%2BL%26aulast%3DMills%26aufirst%3DK.%2BH%2BG%26aulast%3DMasters%26aufirst%3DS.%2BL%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DM.%2BA%26aulast%3DO%2527Neill%26aufirst%3DL.%2BA%2BJ%26atitle%3DA%2520Small-Molecule%2520Inhibitor%2520of%2520the%2520NLRP3%2520Inflammasome%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D3%26spage%3D248%26epage%3D255%26doi%3D10.1038%2Fnm.3806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangan, M. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roush, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Targeting the NLRP3 Inflammasome in Inflammatory Diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnrd.2018.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30026524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGlt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=588-606&author=M.+S.+J.+Manganauthor=E.+J.+Olhavaauthor=W.+R.+Roushauthor=H.+M.+Seidelauthor=G.+D.+Glickauthor=E.+Latz&title=Targeting+the+NLRP3+Inflammasome+in+Inflammatory+Diseases&doi=10.1038%2Fnrd.2018.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the NLRP3 inflammasome in inflammatory diseases</span></div><div class="casAuthors">Mangan, Matthew S. J.; Olhava, Edward J.; Roush, William R.; Seidel, H. Martin; Glick, Gary D.; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-606</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Danger signals are a hallmark of many common inflammatory diseases, and these stimuli can function to activate the cytosolic innate immune signalling receptor NLRP3 (NOD-, LRR- and pyrin domain-contg. 3).  Once activated, NLRP3 nucleates the assembly of an inflammasome, leading to caspase 1-mediated proteolytic activation of the interleukin-1β (IL-1β) family of cytokines, and induces an inflammatory, pyroptotic cell death.  Pharmacol. inhibition of NLRP3 activation results in potent therapeutic effects in a wide variety of rodent models of inflammatory diseases, effects that are mirrored by genetic ablation of NLRP3.  Although these findings highlight the potential of NLRP3 as a drug target, an understanding of NLRP3 structure and activation mechanisms is incomplete, which has hampered the discovery and development of novel therapeutics against this target.  Here, we review recent advances in our understanding of NLRP3 activation and regulation, highlight the evolving landscape of NLRP3 modulators and discuss opportunities for pharmacol. targeting NLRP3 with novel small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw2JAJ8RPRXrVg90H21EOLACvtfcHk0lj92UhcjWhVqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGlt7bM&md5=57b064477ea056dc859f6c90c4d00c36</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.97%26sid%3Dliteratum%253Aachs%26aulast%3DMangan%26aufirst%3DM.%2BS.%2BJ.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DRoush%26aufirst%3DW.%2BR.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DTargeting%2520the%2520NLRP3%2520Inflammasome%2520in%2520Inflammatory%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D588%26epage%3D606%26doi%3D10.1038%2Fnrd.2018.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coll, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamoshnikova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span> <span> </span><span class="NLM_article-title">MCC950 Directly Targets the NLRP3 ATP-Hydolysis Motif for Inflammasome Inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0277-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41589-019-0277-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31086327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=556-559&author=R.+C.+Collauthor=J.+R.+Hillauthor=C.+J.+Dayauthor=A.+Zamoshnikovaauthor=D.+Boucherauthor=N.+L.+Masseyauthor=J.+L.+Chittyauthor=J.+A.+Fraserauthor=M.+P.+Jenningsauthor=A.+A.+B.+Robertsonauthor=K.+Schroder&title=MCC950+Directly+Targets+the+NLRP3+ATP-Hydolysis+Motif+for+Inflammasome+Inhibition&doi=10.1038%2Fs41589-019-0277-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition</span></div><div class="casAuthors">Coll, Rebecca C.; Hill, James R.; Day, Christopher J.; Zamoshnikova, Alina; Boucher, Dave; Massey, Nicholas L.; Chitty, Jessica L.; Fraser, James A.; Jennings, Michael P.; Robertson, Avril A. B.; Schroder, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">556-559</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Inhibition of the NLRP3 inflammasome is a promising strategy for the development of new treatments for inflammatory diseases.  MCC950 is a potent and specific small-mol. inhibitor of the NLRP3 pathway, but its mol. target is not defined.  Here, we show that MCC950 directly interacts with the Walker B motif within the NLRP3 NACHT domain, thereby blocking ATP hydrolysis and inhibiting NLRP3 activation and inflammasome formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohNuLFaDJcpLVg90H21EOLACvtfcHk0lj92UhcjWhVqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqs73J&md5=9c898ea86dad48144379d2d0335e836f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0277-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0277-7%26sid%3Dliteratum%253Aachs%26aulast%3DColl%26aufirst%3DR.%2BC.%26aulast%3DHill%26aufirst%3DJ.%2BR.%26aulast%3DDay%26aufirst%3DC.%2BJ.%26aulast%3DZamoshnikova%26aufirst%3DA.%26aulast%3DBoucher%26aufirst%3DD.%26aulast%3DMassey%26aufirst%3DN.%2BL.%26aulast%3DChitty%26aufirst%3DJ.%2BL.%26aulast%3DFraser%26aufirst%3DJ.%2BA.%26aulast%3DJennings%26aufirst%3DM.%2BP.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DSchroder%26aufirst%3DK.%26atitle%3DMCC950%2520Directly%2520Targets%2520the%2520NLRP3%2520ATP-Hydolysis%2520Motif%2520for%2520Inflammasome%2520Inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D556%26epage%3D559%26doi%3D10.1038%2Fs41589-019-0277-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tapia-Abellan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angosto-Bazarra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Banaclocha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torre-Minguela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceron-Carrasco, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Sanchez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arostegui, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrin, P.</span></span> <span> </span><span class="NLM_article-title">MCC950 Closes the Active Conformation of NLRP3 to an Inactive State</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0278-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41589-019-0278-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31086329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=560-564&author=A.+Tapia-Abellanauthor=D.+Angosto-Bazarraauthor=H.+Martinez-Banaclochaauthor=C.+de+Torre-Minguelaauthor=J.+P.+Ceron-Carrascoauthor=H.+Perez-Sanchezauthor=J.+I.+Arosteguiauthor=P.+Pelegrin&title=MCC950+Closes+the+Active+Conformation+of+NLRP3+to+an+Inactive+State&doi=10.1038%2Fs41589-019-0278-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">MCC950 closes the active conformation of NLRP3 to an inactive state</span></div><div class="casAuthors">Tapia-Abellan, Ana; Angosto-Bazarra, Diego; Martinez-Banaclocha, Helios; de Torre-Minguela, Carlos; Ceron-Carrasco, Jose P.; Perez-Sanchez, Horacio; Arostegui, Juan I.; Pelegrin, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-564</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">NLRP3 (NOD-like receptor pyrin domain-contg. protein 3) is an innate immune sensor that contributes to the development of different diseases, including monogenic autoinflammatory syndromes, gout, atherosclerosis, and Alzheimer's disease.  The mol. sulfonylurea MCC950 is a NLRP3 inflammasome inhibitor with potential clin. utility.  However, the mechanism of action of MCC950 remains unknown.  Here, we characterize the mechanism of action of MCC950 in both wild-type and autoinflammatory-related NLRP3 mutants, and demonstrate that MCC950 closes the 'open' conformation of active NLRP3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogkRIxmyMRsLVg90H21EOLACvtfcHk0lgJ9WdU0NxGrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqs73M&md5=20eb8add8134e4dee7e0afa5add19792</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0278-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0278-6%26sid%3Dliteratum%253Aachs%26aulast%3DTapia-Abellan%26aufirst%3DA.%26aulast%3DAngosto-Bazarra%26aufirst%3DD.%26aulast%3DMartinez-Banaclocha%26aufirst%3DH.%26aulast%3Dde%2BTorre-Minguela%26aufirst%3DC.%26aulast%3DCeron-Carrasco%26aufirst%3DJ.%2BP.%26aulast%3DPerez-Sanchez%26aufirst%3DH.%26aulast%3DArostegui%26aufirst%3DJ.%2BI.%26aulast%3DPelegrin%26aufirst%3DP.%26atitle%3DMCC950%2520Closes%2520the%2520Active%2520Conformation%2520of%2520NLRP3%2520to%2520an%2520Inactive%2520State%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D560%26epage%3D564%26doi%3D10.1038%2Fs41589-019-0278-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booshehri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, H. M.</span></span> <span> </span><span class="NLM_article-title">CAPS and NLRP3</span>. <i>J. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1007/s10875-019-00638-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1007%2Fs10875-019-00638-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31077002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ks1Smsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=277-286&author=L.+M.+Booshehriauthor=H.+M.+Hoffman&title=CAPS+and+NLRP3&doi=10.1007%2Fs10875-019-00638-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">CAPS and NLRP3</span></div><div class="casAuthors">Booshehri Laela M; Hoffman Hal M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-286</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cryopyrin-associated periodic syndrome (CAPS) is a rare inherited autoinflammatory disorder characterized by systemic, cutaneous, musculoskeletal, and central nervous system inflammation.  Gain-of-function mutations in NLRP3 in CAPS patients lead to activation of the cryopyrin inflammasome, resulting in the inappropriate release of inflammatory cytokines including IL-1β and CAPS-related inflammatory symptoms.  Several mechanisms have been identified that are important for the normal regulation of the cryopyrin inflammasome in order to prevent uncontrolled inflammation.  Investigators have taken advantage of some of these pathways to develop and apply novel targeted therapies, which have resulted in improved quality of life for patients with this orphan disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRMGJG6VtPNz69zv1FsJFMfW6udTcc2eael5hRt1naE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ks1Smsw%253D%253D&md5=7c36b46229a77070d7d9db993a9ac519</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs10875-019-00638-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10875-019-00638-z%26sid%3Dliteratum%253Aachs%26aulast%3DBooshehri%26aufirst%3DL.%2BM.%26aulast%3DHoffman%26aufirst%3DH.%2BM.%26atitle%3DCAPS%2520and%2520NLRP3%26jtitle%3DJ.%2520Clin.%2520Immunol.%26date%3D2019%26volume%3D39%26spage%3D277%26epage%3D286%26doi%3D10.1007%2Fs10875-019-00638-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Walle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sácha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossoul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hauwermeiren, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saavedra, P. H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konvalinka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamkanfi, M.</span></span> <span> </span><span class="NLM_article-title">MCC950/CRID3 Potently Targets the NACHT Domain of Wild-Type NLRP3 but not Disease-Associated Mutants for Inflammasome Inhibition</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>), <span class="NLM_elocation-id">e3000354</span> <span class="refDoi"> DOI: 10.1371/journal.pbio.3000354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.pbio.3000354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31525186" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&issue=9&author=L.+Vande%0AWalleauthor=I.+B.+Stoweauthor=P.+S%C3%A1chaauthor=B.+L.+Leeauthor=D.+Demonauthor=A.+Fossoulauthor=F.+Van+Hauwermeirenauthor=P.+H.+V.+Saavedraauthor=P.+Simonauthor=V.+Subrtauthor=L.+Kostkaauthor=C.+E.+Stivalaauthor=V.+C.+Phamauthor=S.+T.+Stabenauthor=S.+Yamazoeauthor=J.+Konvalinkaauthor=N.+Kayagakiauthor=M.+Lamkanfi&title=MCC950%2FCRID3+Potently+Targets+the+NACHT+Domain+of+Wild-Type+NLRP3+but+not+Disease-Associated+Mutants+for+Inflammasome+Inhibition&doi=10.1371%2Fjournal.pbio.3000354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.3000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.3000354%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BWalle%26aufirst%3DL.%26aulast%3DStowe%26aufirst%3DI.%2BB.%26aulast%3DS%25C3%25A1cha%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DB.%2BL.%26aulast%3DDemon%26aufirst%3DD.%26aulast%3DFossoul%26aufirst%3DA.%26aulast%3DVan%2BHauwermeiren%26aufirst%3DF.%26aulast%3DSaavedra%26aufirst%3DP.%2BH.%2BV.%26aulast%3DSimon%26aufirst%3DP.%26aulast%3DSubrt%26aufirst%3DV.%26aulast%3DKostka%26aufirst%3DL.%26aulast%3DStivala%26aufirst%3DC.%2BE.%26aulast%3DPham%26aufirst%3DV.%2BC.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DYamazoe%26aufirst%3DS.%26aulast%3DKonvalinka%26aufirst%3DJ.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DLamkanfi%26aufirst%3DM.%26atitle%3DMCC950%252FCRID3%2520Potently%2520Targets%2520the%2520NACHT%2520Domain%2520of%2520Wild-Type%2520NLRP3%2520but%2520not%2520Disease-Associated%2520Mutants%2520for%2520Inflammasome%2520Inhibition%26jtitle%3DPLoS%2520Biol.%26date%3D2019%26volume%3D17%26issue%3D9%26doi%3D10.1371%2Fjournal.pbio.3000354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strober, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuss, I. J.</span></span> <span> </span><span class="NLM_article-title">The Role of NLRP3 and IL-1β in the Pathogenesis of Inflammatory Bowel Disease</span>. <i>Frontiers in Immunology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.02566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3389%2Ffimmu.2018.02566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29403488" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-9&author=L.+Maoauthor=A.+Kitaniauthor=W.+Stroberauthor=I.+J.+Fuss&title=The+Role+of+NLRP3+and+IL-1%CE%B2+in+the+Pathogenesis+of+Inflammatory+Bowel+Disease&doi=10.3389%2Ffimmu.2018.02566"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02566%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DL.%26aulast%3DKitani%26aufirst%3DA.%26aulast%3DStrober%26aufirst%3DW.%26aulast%3DFuss%26aufirst%3DI.%2BJ.%26atitle%3DThe%2520Role%2520of%2520NLRP3%2520and%2520IL-1%25CE%25B2%2520in%2520the%2520Pathogenesis%2520of%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DFrontiers%2520in%2520Immunology%26date%3D2018%26volume%3D9%26spage%3D1%26epage%3D9%26doi%3D10.3389%2Ffimmu.2018.02566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umiker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajami, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fregeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span> <span> </span><span class="NLM_article-title">The NLRP3 Inflammasome Mediates DSS-Induced Intestinal Inflammation in Nod2 Knockout Mice</span>. <i>Innate Immun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1177/1753425919826367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1177%2F1753425919826367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30774010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFWgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=132-143&issue=2&author=B.+Umikerauthor=H.-H.+Leeauthor=J.+Copeauthor=N.+J.+Ajamiauthor=J.-P.+Laineauthor=C.+Fregeauauthor=H.+Fergusonauthor=S.+E.+Alvesauthor=N.+Sciammettaauthor=M.+Kleinschekauthor=M.+Salmon&title=The+NLRP3+Inflammasome+Mediates+DSS-Induced+Intestinal+Inflammation+in+Nod2+Knockout+Mice&doi=10.1177%2F1753425919826367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP3 inflammasome mediates DSS-induced intestinal inflammation in Nod2 knockout mice</span></div><div class="casAuthors">Umiker, Benjamin; Lee, Hyun-Hee; Cope, Julia; Ajami, Nadim J.; Laine, Jean-Philippe; Fregeau, Christine; Ferguson, Heidi; Alves, Stephen E.; Sciammetta, Nunzio; Kleinschek, Melanie; Salmon, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Innate Immunity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">132-143</span>CODEN:
                <span class="NLM_cas:coden">IINMCB</span>;
        ISSN:<span class="NLM_cas:issn">1753-4259</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Crohn's disease (CD) is a chronic disorder of the gastrointestinal tract characterized by inflammation and intestinal epithelial injury.  Loss of function mutations in the intracellular bacterial sensor NOD2 are major risk factors for the development of CD.  In the absence of robust bacterial recognition by NOD2 an inflammatory cascade is initiated through alternative PRRs leading to CD.  In the present study, MCC950, a specific small mol. inhibitor of NLR pyrin domain-contg. protein 3 (NLRP3), abrogated dextran sodium sulfate (DSS)-induced intestinal inflammation in Nod2-/- mice.  NLRP3 inflammasome formation was obsd. at a higher rate in NOD2-deficient small intestinal lamina propria cells after insult by DSS.  NLRP3 complex formation led to an increase in IL-1β secretion in both the small intestine and colon of Nod2ko mice.  This increase in IL-1β secretion in the intestine was attenuated by MCC950 leading to decreased disease severity in Nod2ko mice.  Our work suggests that NLRP3 inflammasome activation may be a key driver of intestinal inflammation in the absence of functional NOD2.  NLRP3 pathway inhibition can prevent intestinal inflammation in the absence of robust NOD2 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRRizO0c3h27Vg90H21EOLACvtfcHk0lhFaVnSPNPLOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFWgsbc%253D&md5=738d2acab67571f7ebbff0d17aebe795</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1177%2F1753425919826367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1753425919826367%26sid%3Dliteratum%253Aachs%26aulast%3DUmiker%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DCope%26aufirst%3DJ.%26aulast%3DAjami%26aufirst%3DN.%2BJ.%26aulast%3DLaine%26aufirst%3DJ.-P.%26aulast%3DFregeau%26aufirst%3DC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DAlves%26aufirst%3DS.%2BE.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DKleinschek%26aufirst%3DM.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DThe%2520NLRP3%2520Inflammasome%2520Mediates%2520DSS-Induced%2520Intestinal%2520Inflammation%2520in%2520Nod2%2520Knockout%2520Mice%26jtitle%3DInnate%2520Immun.%26date%3D2019%26volume%3D25%26issue%3D2%26spage%3D132%26epage%3D143%26doi%3D10.1177%2F1753425919826367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Similuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oler, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albenberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quezado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery-Recht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuss, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strober, W.</span></span> <span> </span><span class="NLM_article-title">Loss-of-Function CARD8Mutation Causes NLRP3 Inflammasome Activation and Crohn’s Disease</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1172/JCI98642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1172%2FJCI98642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29408806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BC1MvotFOlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=1793-1806&issue=5&author=L.+Maoauthor=A.+Kitaniauthor=M.+Similukauthor=A.+J.+Olerauthor=L.+Albenbergauthor=J.+Kelsenauthor=A.+Aktayauthor=M.+Quezadoauthor=M.+Yaoauthor=K.+Montgomery-Rechtauthor=I.+J.+Fussauthor=W.+Strober&title=Loss-of-Function+CARD8Mutation+Causes+NLRP3+Inflammasome+Activation+and+Crohn%E2%80%99s+Disease&doi=10.1172%2FJCI98642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease</span></div><div class="casAuthors">Mao Liming; Kitani Atsushi; Yao Michael; Fuss Ivan J; Strober Warren; Similuk Morgan; Oler Andrew J; Albenberg Lindsey; Kelsen Judith; Aktay Atiye; Quezado Martha; Yao Michael; Montgomery-Recht Kim</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1793-1806</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In these studies, we evaluated the contribution of the NLRP3 inflammasome to Crohn's disease (CD) in a kindred containing individuals having a missense mutation in CARD8, a protein known to inhibit this inflammasome.  Whole exome sequencing and PCR studies identified the affected individuals as having a V44I mutation in a single allele of the T60 isoform of CARD8.  The serum levels of IL-1β in the affected individuals were increased compared with those in healthy controls, and their peripheral monocytes produced increased amounts of IL-1β when stimulated by NLRP3 activators.  Immunoblot studies probing the basis of these findings showed that mutated T60 CARD8 failed to downregulate the NLRP3 inflammasome because it did not bind to NLRP3 and inhibit its oligomerization.  In addition, these studies showed that mutated T60 CARD8 exerted a dominant-negative effect by its capacity to bind to and form oligomers with unmutated T60 or T48 CARD8 that impeded their binding to NLRP3.  Finally, inflammasome activation studies revealed that intact but not mutated CARD8 prevented NLRP3 deubiquitination and serine dephosphorylation.  CD due to a CARD8 mutation was not effectively treated by anti-TNF-α, but did respond to IL-1β inhibitors.  Thus, patients with anti-TNF-α-resistant CD may respond to this treatment option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ51eCIv3X5t4kFb3mqPUYDfW6udTcc2eZFsdZOC1Ogtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvotFOlsQ%253D%253D&md5=7897e01e868c27af9e771a870a40fe18</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI98642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI98642%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DL.%26aulast%3DKitani%26aufirst%3DA.%26aulast%3DSimiluk%26aufirst%3DM.%26aulast%3DOler%26aufirst%3DA.%2BJ.%26aulast%3DAlbenberg%26aufirst%3DL.%26aulast%3DKelsen%26aufirst%3DJ.%26aulast%3DAktay%26aufirst%3DA.%26aulast%3DQuezado%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DMontgomery-Recht%26aufirst%3DK.%26aulast%3DFuss%26aufirst%3DI.%2BJ.%26aulast%3DStrober%26aufirst%3DW.%26atitle%3DLoss-of-Function%2520CARD8Mutation%2520Causes%2520NLRP3%2520Inflammasome%2520Activation%2520and%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26issue%3D5%26spage%3D1793%26epage%3D1806%26doi%3D10.1172%2FJCI98642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span> <span> </span><span class="NLM_article-title">NEK7 Interacts with NLRP3 to Modulate the Pyroptosis in Inflammatory Bowel Disease via NF-κB Signaling</span>. <i>Cell Death and Disease</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">906</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s41419-019-2157-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41419-019-2157-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWmsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-12&issue=906&author=X.+Chenauthor=G.+Liuauthor=Y.+Yuanauthor=G.+Wuauthor=S.+Wangauthor=L.+Yuan&title=NEK7+Interacts+with+NLRP3+to+Modulate+the+Pyroptosis+in+Inflammatory+Bowel+Disease+via+NF-%CE%BAB+Signaling&doi=10.1038%2Fs41419-019-2157-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">FTY720 induces non-canonical phosphatidylserine externalization and cell death in acute myeloid leukemia</span></div><div class="casAuthors">Young, Megan M.; Bui, Van; Chen, Chong; Wang, Hong-Gang</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">FTY720 (fingolimod) is a FDA-approved sphingosine analog that is phosphorylated in vivo to modulate sphingosine-1-phosphate receptor (S1PR) signaling for immunosuppression in patients with refractory multiple sclerosis.  FTY720 also exhibits promising anticancer efficacy in several preclin. models.  While FTY720-induced cytotoxicity is not due to S1PR signaling, the mechanism remains unclear and is reported to occur through various cell death pathways.  Here, we performed a systematic, mechanistic study of FTY720-induced cell death in acute myeloid leukemia (AML).  We found that FTY720 induced cell death in a panel of genetically diverse AML cell lines that was accompanied by rapid phosphatidylserine (PS) externalization.  Importantly, FTY720-induced PS exposure was not due to any direct effects on plasma membrane integrity and was independent of canonical signaling by regulated cell death pathways known to activate lipid flip-flop, including caspase-dependent apoptosis/pyroptosis, necroptosis, ferroptosis, and reactive oxygen species-mediated cell death.  Notably, PS exposure required cellular vacuolization induced by defects in endocytic trafficking and was suppressed by the inhibition of PP2A and shedding of Annexin V-pos. subcellular particles.  Collectively, our studies reveal a non-canonical pathway underlying PS externalization and cell death in AML to provide mechanistic insight into the antitumor properties of FTY720.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTFJLrVn--C7Vg90H21EOLACvtfcHk0lih7iPHZMA6Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWmsrjM&md5=172806d536cf39d875417488aadbd493</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41419-019-2157-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-019-2157-1%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DL.%26atitle%3DNEK7%2520Interacts%2520with%2520NLRP3%2520to%2520Modulate%2520the%2520Pyroptosis%2520in%2520Inflammatory%2520Bowel%2520Disease%2520via%2520NF-%25CE%25BAB%2520Signaling%26jtitle%3DCell%2520Death%2520and%2520Disease%26date%3D2019%26volume%3D10%26issue%3D906%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs41419-019-2157-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannou, G. N.</span></span> <span> </span><span class="NLM_article-title">The Role of Cholesterol in the Pathogenesis of NASH</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2015.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.tem.2015.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26703097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=84-95&issue=2&author=G.+N.+Ioannou&title=The+Role+of+Cholesterol+in+the+Pathogenesis+of+NASH&doi=10.1016%2Fj.tem.2015.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">the role of cholesterol in the pathogenesis of NASH</span></div><div class="casAuthors">Ioannou, George N.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">84-95</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a subgroup of patients with nonalcoholic fatty liver disease (NAFLD), causing nonalcoholic steatohepatitis (NASH) and even progression to cirrhosis and hepatocellular carcinoma (HCC).  While the underlying mol. mechanisms responsible for the development of inflammation and fibrosis that characterize progressive NASH remain unclear, emerging evidence now suggests that hepatic free cholesterol (FC) is a major lipotoxic mol. crit. in the development of exptl. and human NASH.  In this review, we examine the effects of excess FC in hepatocytes, Kupffer cells (KCs), and hepatic stellate cells (HSCs), and the subcellular mechanisms by which excess FC can induce cellular toxicity or proinflammatory and profibrotic effects in these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc8NlE_FDOOLVg90H21EOLACvtfcHk0lih7iPHZMA6Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemtr%252FN&md5=6f2000afa1fdbe9874cec481daf57b2f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2015.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2015.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DIoannou%26aufirst%3DG.%2BN.%26atitle%3DThe%2520Role%2520of%2520Cholesterol%2520in%2520the%2520Pathogenesis%2520of%2520NASH%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2016%26volume%3D27%26issue%3D2%26spage%3D84%26epage%3D95%26doi%3D10.1016%2Fj.tem.2015.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duewell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayner, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirois, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vladimer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauernfeind, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abela, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnurr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espevik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasomes are Required for Atherogenesis and Activated by Cholesterol Crystals</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1361</span>, <span class="refDoi"> DOI: 10.1038/nature08938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature08938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20428172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltl2mu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=1357-1361&author=P.+Duewellauthor=H.+Konoauthor=K.+J.+Raynerauthor=C.+M.+Siroisauthor=G.+Vladimerauthor=F.+G.+Bauernfeindauthor=G.+S.+Abelaauthor=L.+Franchiauthor=G.+Nu%C3%B1ezauthor=M.+Schnurrauthor=T.+Espevikauthor=E.+Lienauthor=K.+A.+Fitzgeraldauthor=K.+L.+Rockauthor=K.+J.+Mooreauthor=S.+D.+Wrightauthor=V.+Hornungauthor=E.+Latz&title=NLRP3+Inflammasomes+are+Required+for+Atherogenesis+and+Activated+by+Cholesterol+Crystals&doi=10.1038%2Fnature08938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals</span></div><div class="casAuthors">Duewell, Peter; Kono, Hajime; Rayner, Katey J.; Sirois, Cherilyn M.; Vladimer, Gregory; Bauernfeind, Franz G.; Abela, George S.; Franchi, Luigi; Nunez, Gabriel; Schnurr, Max; Espevik, Terje; Lien, Egil; Fitzgerald, Katherine A.; Rock, Kenneth L.; Moore, Kathryn J.; Wright, Samuel D.; Hornung, Veit; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7293</span>),
    <span class="NLM_cas:pages">1357-1361</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inflammatory nature of atherosclerosis is well established but the agent(s) that incite inflammation in the artery wall remain largely unknown.  Germ-free animals are susceptible to atherosclerosis, suggesting that endogenous substances initiate the inflammation.  Mature atherosclerotic lesions contain macroscopic deposits of cholesterol crystals in the necrotic core, but their appearance late in atherogenesis had been thought to disqualify them as primary inflammatory stimuli.  However, using a new microscopic technique, the authors revealed that minute cholesterol crystals are present in early diet-induced atherosclerotic lesions and that their appearance in mice coincides with the first appearance of inflammatory cells.  Other cryst. substances can induce inflammation by stimulating the caspase-1-activating NLRP3 (NALP3 or cryopyrin) inflammasome, which results in cleavage and secretion of interleukin (IL)-1 family cytokines.  Here the authors show that cholesterol crystals activate the NLRP3 inflammasome in phagocytes in vitro in a process that involves phagolysosomal damage.  Similarly, when injected i.p., cholesterol crystals induce acute inflammation, which is impaired in mice deficient in components of the NLRP3 inflammasome, cathepsin B, cathepsin L or IL-1 mols.  Moreover, when mice deficient in low-d. lipoprotein receptor (LDLR) were bone-marrow transplanted with NLRP3-deficient, ASC (also known as PYCARD)-deficient or IL-1α/β-deficient bone marrow and fed on a high-cholesterol diet, they had markedly decreased early atherosclerosis and inflammasome-dependent IL-18 levels.  Minimally modified LDL can lead to cholesterol crystn. concomitant with NLRP3 inflammasome priming and activation in macrophages.  Although there is the possibility that oxidized LDL activates the NLRP3 inflammasome in vivo, the results demonstrate that cryst. cholesterol acts as an endogenous danger signal and its deposition in arteries or elsewhere is an early cause rather than a late consequence of inflammation.  These findings provide new insights into the pathogenesis of atherosclerosis and indicate new potential mol. targets for the therapy of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRFmxeie_MGrVg90H21EOLACvtfcHk0ljWArymjzw6-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltl2mu7w%253D&md5=593ac5b735c8d1151ae4f4b7861a3591</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnature08938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08938%26sid%3Dliteratum%253Aachs%26aulast%3DDuewell%26aufirst%3DP.%26aulast%3DKono%26aufirst%3DH.%26aulast%3DRayner%26aufirst%3DK.%2BJ.%26aulast%3DSirois%26aufirst%3DC.%2BM.%26aulast%3DVladimer%26aufirst%3DG.%26aulast%3DBauernfeind%26aufirst%3DF.%2BG.%26aulast%3DAbela%26aufirst%3DG.%2BS.%26aulast%3DFranchi%26aufirst%3DL.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DG.%26aulast%3DSchnurr%26aufirst%3DM.%26aulast%3DEspevik%26aufirst%3DT.%26aulast%3DLien%26aufirst%3DE.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DMoore%26aufirst%3DK.%2BJ.%26aulast%3DWright%26aufirst%3DS.%2BD.%26aulast%3DHornung%26aufirst%3DV.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DNLRP3%2520Inflammasomes%2520are%2520Required%2520for%2520Atherogenesis%2520and%2520Activated%2520by%2520Cholesterol%2520Crystals%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D1357%26epage%3D1361%26doi%3D10.1038%2Fnature08938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span> <span> </span><span class="NLM_article-title">Fatty Acid Activates NLRP3 Inflammasomes in Mouse Kupffer Cells through Mitochondrial DNA Release</span>. <i>Cell. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>332</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.cellimm.2018.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.cellimm.2018.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30103942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2ju77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2018&pages=111-120&author=J.+Panauthor=Z.+Ouauthor=C.+Caiauthor=P.+Liauthor=J.+Gongauthor=X.+Z.+Ruanauthor=K.+He&title=Fatty+Acid+Activates+NLRP3+Inflammasomes+in+Mouse+Kupffer+Cells+through+Mitochondrial+DNA+Release&doi=10.1016%2Fj.cellimm.2018.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release</span></div><div class="casAuthors">Pan, Junjiang; Ou, Zhibing; Cai, Can; Li, Peizhi; Gong, Jianping; Ruan, Xiong Z.; He, Kun</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-120</span>CODEN:
                <span class="NLM_cas:coden">CLIMB8</span>;
        ISSN:<span class="NLM_cas:issn">0008-8749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in many developed and developing countries worldwide.  It has been well established that the chronic sterile inflammation caused by the NLRP3 inflammasome is closely related to NAFLD development.  Kupffer cells (KCs) are involved in the pathogenesis of various liver diseases.  We used methionine choline-deficient diets to establish a mouse nonalcoholic steatohepatitis (NASH) model.  The expression and formation of the NLRP3 inflammasome in the KCs from the mouse and cell models were detd. by Western blotting and co-immunopptn.  Evidence of mitochondrial DNA (mtDNA) release was detd. by live cell labeling and imaging.  KCs and the NLRP3 inflammasome exerted proinflammatory effects on the development and progression of NASH through secretion of the proinflammatory cytokine IL-1β.  NLRP3, ASC and Caspase-1 protein expression levels in KCs from NASH mouse livers were significantly higher than those in KCs from NLRP3-/- mice, and the no. of NLRP3 inflammasome protein complexes was significantly higher in KCs from NASH mouse livers, whereas these protein complexes could not be formed in NLRP3-/- mice.  In in vitro expts., palmitic acid (PA) decreased the mitochondrial membrane potential and subsequently induced mtDNA release from the mitochondria to the cytoplasm.  NLRP3 inflammasome expression was substantially increased, and mtDNA-NLRP3 inflammasome complexes formed upon PA stimulation.  Our data suggest that mtDNA released from mitochondria during PA stimulation causes NLRP3 inflammasome activation, providing a missing link between NLRP3 inflammasome activation and NASH development, via binding of cytosolic mtDNA to the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmyOTPaAnxy7Vg90H21EOLACvtfcHk0liXK-DK-fQoWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2ju77P&md5=8e16b656e212522d9c3c68c0a176bdee</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cellimm.2018.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellimm.2018.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DRuan%26aufirst%3DX.%2BZ.%26aulast%3DHe%26aufirst%3DK.%26atitle%3DFatty%2520Acid%2520Activates%2520NLRP3%2520Inflammasomes%2520in%2520Mouse%2520Kupffer%2520Cells%2520through%2520Mitochondrial%2520DNA%2520Release%26jtitle%3DCell.%2520Immunol.%26date%3D2018%26volume%3D332%26spage%3D111%26epage%3D120%26doi%3D10.1016%2Fj.cellimm.2018.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannou, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rooyen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigh, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, G. C.</span></span> <span> </span><span class="NLM_article-title">Cholesterol-Lowering Drugs Cause Dissolution of Cholesterol Crystals and Disperse Kupffer Cell Crown-Like Structures During Resolution of NASH</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1194/jlr.M053785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1194%2Fjlr.M053785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25520429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVektLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=277-285&author=G.+N.+Ioannouauthor=D.+M.+Van+Rooyenauthor=C.+Savardauthor=W.+G.+Haighauthor=M.+M.+Yehauthor=N.+C.+Teohauthor=G.+C.+Farrell&title=Cholesterol-Lowering+Drugs+Cause+Dissolution+of+Cholesterol+Crystals+and+Disperse+Kupffer+Cell+Crown-Like+Structures+During+Resolution+of+NASH&doi=10.1194%2Fjlr.M053785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH</span></div><div class="casAuthors">Ioannou, George N.; Van Rooyen, Derrick M.; Savard, Christopher; Haigh, W. Geoffrey; Yeh, Matthew M.; Teoh, Narci C.; Farrell, Geoffrey C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-285</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">Cholesterol crystals form within hepatocyte lipid droplets in human and exptl. nonalcoholic steatohepatitis (NASH) and are the focus of crown-like structures (CLSs) of activated Kupffer cells (KCs).  Obese, diabetic Alms1 mutant (foz/foz) mice were a fed high-fat (23%) diet contg. 0.2% cholesterol for 16 wk and then assigned to four intervention groups for 8 wk: (a) vehicle control, (b) ezetimibe (5 mg/kg/day), (c) atorvastatin (20 mg/kg/day), or (d) ezetimibe and atorvastatin.  Livers of vehicle-treated mice developed fibrosing NASH with abundant cholesterol crystn. within lipid droplets calcd. to extend over 3.3% (SD, 2.2%) of liver surface area.  Hepatocyte lipid droplets with prominent cholesterol crystn. were surrounded by TNFα-pos. (activated) KCs forming CLSs (≥3 per high-power field).  KCs that formed CLSs stained pos. for NLRP3, implicating activation of the NLRP3 inflammasome in response to cholesterol crystals.  In contrast, foz/foz mice treated with ezetimibe and atorvastatin showed near-complete resoln. of cholesterol crystals [0.01% (SD, 0.02%) of surface area] and CLSs (0 per high-power field), with amelioration of fibrotic NASH.  Ezetimibe or atorvastatin alone had intermediate effects on cholesterol crystn., CLSs, and NASH.  These findings are consistent with a causative link between exposure of hepatocytes and KCs to cholesterol crystals and with the development of NASH possibly mediated by NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjZw2g3FBLhbVg90H21EOLACvtfcHk0liXK-DK-fQoWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVektLo%253D&md5=a943ccce06d08765bf81c8b631195dc8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1194%2Fjlr.M053785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.M053785%26sid%3Dliteratum%253Aachs%26aulast%3DIoannou%26aufirst%3DG.%2BN.%26aulast%3DVan%2BRooyen%26aufirst%3DD.%2BM.%26aulast%3DSavard%26aufirst%3DC.%26aulast%3DHaigh%26aufirst%3DW.%2BG.%26aulast%3DYeh%26aufirst%3DM.%2BM.%26aulast%3DTeoh%26aufirst%3DN.%2BC.%26aulast%3DFarrell%26aufirst%3DG.%2BC.%26atitle%3DCholesterol-Lowering%2520Drugs%2520Cause%2520Dissolution%2520of%2520Cholesterol%2520Crystals%2520and%2520Disperse%2520Kupffer%2520Cell%2520Crown-Like%2520Structures%2520During%2520Resolution%2520of%2520NASH%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2015%26volume%3D56%26spage%3D277%26epage%3D285%26doi%3D10.1194%2Fjlr.M053785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mridha, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wree, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rooyen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haczeyni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, N. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannou, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldstein, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, G. C.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Blockade Reduces Liver Inflammation and Fibrosis in Experimental NASH in Mice</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2017.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.jhep.2017.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28167322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFSiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1037-1046&author=A.+R.+Mridhaauthor=A.+Wreeauthor=A.+A.+B.+Robertsonauthor=M.+M.+Yehauthor=C.+D.+Johnsonauthor=D.+M.+Van+Rooyenauthor=F.+Haczeyniauthor=N.+C.-H.+Teohauthor=C.+Savardauthor=G.+N.+Ioannouauthor=S.+L.+Mastersauthor=K.+Schroderauthor=M.+A.+Cooperauthor=A.+E.+Feldsteinauthor=G.+C.+Farrell&title=NLRP3+Inflammasome+Blockade+Reduces+Liver+Inflammation+and+Fibrosis+in+Experimental+NASH+in+Mice&doi=10.1016%2Fj.jhep.2017.01.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice</span></div><div class="casAuthors">Mridha, Auvro R.; Wree, Alexander; Robertson, Avril A. B.; Yeh, Matthew M.; Johnson, Casey D.; Van Rooyen, Derrick M.; Haczeyni, Fahrettin; Teoh, Narci C.-H.; Savard, Christopher; Ioannou, George N.; Masters, Seth L.; Schroder, Kate; Cooper, Matthew A.; Feldstein, Ariel E.; Farrell, Geoffrey C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1037-1046</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alc. fatty liver disease (NAFLD).  We used the first small mol. NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.  We fed foz/foz and wild-type mice an atherogenic diet for 16 wk, gavaged MCC950 or vehicle until 24 wk, then detd. NAFLD phenotype.  In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6 wk and detd. the effects on liver fibrosis.  In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24 wk, in assocn. with cholesterol crystal formation and NASH pathol.; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased.  MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathol., and liver fibrosis.  In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the assocd. neutrophil migration.  MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered nos. of macrophages and neutrophils in the liver, and improved liver fibrosis.MCC950, an NLRP3 selective inhibitor, improved NAFLD pathol. and fibrosis in obese diabetic mice.  This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells.  MCC950 reduced liver fibrosis in MCD-fed mice.  Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.  Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alc. steatohepatitis (NASH), is the most common serious liver disease with no current treatment.  There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role.  Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH.  We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH.  This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH.  In addn., such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Eg3b8uiplbVg90H21EOLACvtfcHk0lhhcv7nu2H99Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFSiu7k%253D&md5=3daae9c7c7671aa0e3021b1f49f139d0</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2017.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2017.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DMridha%26aufirst%3DA.%2BR.%26aulast%3DWree%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DYeh%26aufirst%3DM.%2BM.%26aulast%3DJohnson%26aufirst%3DC.%2BD.%26aulast%3DVan%2BRooyen%26aufirst%3DD.%2BM.%26aulast%3DHaczeyni%26aufirst%3DF.%26aulast%3DTeoh%26aufirst%3DN.%2BC.-H.%26aulast%3DSavard%26aufirst%3DC.%26aulast%3DIoannou%26aufirst%3DG.%2BN.%26aulast%3DMasters%26aufirst%3DS.%2BL.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DFeldstein%26aufirst%3DA.%2BE.%26aulast%3DFarrell%26aufirst%3DG.%2BC.%26atitle%3DNLRP3%2520Inflammasome%2520Blockade%2520Reduces%2520Liver%2520Inflammation%2520and%2520Fibrosis%2520in%2520Experimental%2520NASH%2520in%2520Mice%26jtitle%3DJ.%2520Hepatol.%26date%3D2017%26volume%3D66%26spage%3D1037%26epage%3D1046%26doi%3D10.1016%2Fj.jhep.2017.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klinenberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfinger, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seegmiller, J. E.</span></span> <span> </span><span class="NLM_article-title">The Effectiveness of the Xanthine Oxidase Inhibitor Alloopurinol in the Treatment of Gout</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">647</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-62-4-639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.7326%2F0003-4819-62-4-639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=14274828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADyaF2MXptl2mtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1965&pages=639-647&issue=4&author=J.+R.+Klinenbergauthor=S.+E.+Goldfingerauthor=J.+E.+Seegmiller&title=The+Effectiveness+of+the+Xanthine+Oxidase+Inhibitor+Alloopurinol+in+the+Treatment+of+Gout&doi=10.7326%2F0003-4819-62-4-639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout</span></div><div class="casAuthors">Klinenberg, James R.; Goldfinger, Stephen E.; Seegmiller, J. Edwin</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Internal Medicine</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">639-47</span>CODEN:
                <span class="NLM_cas:coden">AIMEAS</span>;
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    </div><div class="casAbstract">Allopurinol (I) was well tolerated by 11 of 12 subjects and markedly decreased the plasma uric acid concn. and uric acid excretion.  The oxypurines xanthine and hypoxanthine largely replaced the deficit in uric acid excretion in both normal and gouty subjects.  Total purine excretion was affected to only a small extent by I administration.  Inhibition of xanthine oxidase is advantageous because the renal clearance of oxypurine is much greater than that of uric acid.  The resultant plasma oxypurine concns. do not exceed satn., hence tissue deposits are unlikely.  Allopurinol can be used in conjunction with uricosuric drugs to obtain max. total purine excretion and to allow unloading of large urate deposits.  It has a potential use in subjects with hyperuricemia and renal insufficiency who are refractory to uricosuric therapy and in gouty subjects who cannot tolerate other drugs which lower blood plasma urate concns.  20 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgW-RuFOFE3LVg90H21EOLACvtfcHk0lhhcv7nu2H99Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXptl2mtQ%253D%253D&md5=d0b67706e02a25ee383bf57501037652</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-62-4-639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-62-4-639%26sid%3Dliteratum%253Aachs%26aulast%3DKlinenberg%26aufirst%3DJ.%2BR.%26aulast%3DGoldfinger%26aufirst%3DS.%2BE.%26aulast%3DSeegmiller%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520Effectiveness%2520of%2520the%2520Xanthine%2520Oxidase%2520Inhibitor%2520Alloopurinol%2520in%2520the%2520Treatment%2520of%2520Gout%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D1965%26volume%3D62%26issue%3D4%26spage%3D639%26epage%3D647%26doi%3D10.7326%2F0003-4819-62-4-639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, J. J. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Lisdonk, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Riel, P. L. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Weel, C.</span></span> <span> </span><span class="NLM_article-title">Use of Oral Prednisolone or Naproxen for the Treatment of Gout Athritis: a Double-Blind, Randomised Equivalence Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1854</span>– <span class="NLM_lpage">1860</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)60799-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS0140-6736%2808%2960799-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=18514729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFKntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=1854-1860&author=J.+J.+E.+M.+Janssensauthor=M.+Janssenauthor=E.+H.+van+de+Lisdonkauthor=P.+L.+C.+M.+van+Rielauthor=C.+van+Weel&title=Use+of+Oral+Prednisolone+or+Naproxen+for+the+Treatment+of+Gout+Athritis%3A+a+Double-Blind%2C+Randomised+Equivalence+Trial&doi=10.1016%2FS0140-6736%2808%2960799-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial</span></div><div class="casAuthors">Janssens, Hein J. E. M.; Janssen, Matthijs; van de Lisdonk, Eloy H.; van Riel, Piet L. C. M.; van Weel, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">9627</span>),
    <span class="NLM_cas:pages">1854-1860</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Non-steroidal anti-inflammatory drugs and colchicine used to treat gout arthritis have gastrointestinal, renal, and cardiovascular adverse effects.  Systemic corticosteroids might be a beneficial alternative.  We investigated equivalence of naproxen and prednisolone in primary care.  We did a randomized clin. trial to test equivalence of prednisolone and naproxen for the treatment of monoarticular gout.  Primary-care patients with gout confirmed by presence of monosodium urate crystals were eligible: 120 patients were randomly assigned with computer-generated randomization to receive either prednisolone (35 mg once a day; n=60) or naproxen (500 mg twice a day; n=60), for 5 days.  Treatment was masked for both patients and physicians.  The primary outcome was pain measured on a 100 mm visual analog scale and the a priori margin for equivalence set at 10%.  Analyses were done per protocol and by intention to treat.  This study is registered as an International Std. Randomised Controlled Trial, no. ISRCTN14648181.  Data were incomplete for one patient in each treatment group, so per-protocol analyses included 59 patients in each group.  After 90 h the redn. in the pain score was 44.7 mm and 46.0 mm for prednisolone and naproxen, resp. (difference 1.3 mm; 95% CI -9.8 to 7.1), suggesting equivalence.  The difference in the size of change in pain was 1.57 mm (95% CI -8.65 to 11.78).  Adverse effects were similar between groups, minor, and resolved by 3 wk follow-up.  Thus, oral prednisolone and naproxen are equally effective in the initial treatment of gout arthritis over 4 days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsPRlPl63jObVg90H21EOLACvtfcHk0lhhcv7nu2H99Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFKntr4%253D&md5=282ab342933b2b607ccf03e55f1d1871</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960799-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960799-0%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DJ.%2BJ.%2BE.%2BM.%26aulast%3DJanssen%26aufirst%3DM.%26aulast%3Dvan%2Bde%2BLisdonk%26aufirst%3DE.%2BH.%26aulast%3Dvan%2BRiel%26aufirst%3DP.%2BL.%2BC.%2BM.%26aulast%3Dvan%2BWeel%26aufirst%3DC.%26atitle%3DUse%2520of%2520Oral%2520Prednisolone%2520or%2520Naproxen%2520for%2520the%2520Treatment%2520of%2520Gout%2520Athritis%253A%2520a%2520Double-Blind%252C%2520Randomised%2520Equivalence%2520Trial%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D1854%26epage%3D1860%26doi%3D10.1016%2FS0140-6736%2808%2960799-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollaston, W. H.</span></span> <span> </span><span class="NLM_article-title">XVII. On Gouty and Urinary Concentrations</span>. <i>Philosophical Transact.</i> <span class="NLM_year" style="font-weight: bold;">1797</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">386</span>– <span class="NLM_lpage">400</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1797&pages=386-400&author=W.+H.+Wollaston&title=XVII.+On+Gouty+and+Urinary+Concentrations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWollaston%26aufirst%3DW.%2BH.%26atitle%3DXVII.%2520On%2520Gouty%2520and%2520Urinary%2520Concentrations%26jtitle%3DPhilosophical%2520Transact.%26date%3D1797%26volume%3D87%26spage%3D386%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pétrilli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardivel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span> <span> </span><span class="NLM_article-title">Gout-Associated Uric Acid Crystals Activate the NALP3 Inflammasome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>440</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1038/nature04516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature04516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=16407889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFGitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=237-241&author=F.+Martinonauthor=V.+P%C3%A9trilliauthor=A.+Mayorauthor=A.+Tardivelauthor=J.+Tschopp&title=Gout-Associated+Uric+Acid+Crystals+Activate+the+NALP3+Inflammasome&doi=10.1038%2Fnature04516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Gout-associated uric acid crystals activate the NALP3 inflammasome</span></div><div class="casAuthors">Martinon, Fabio; Petrilli, Virginie; Mayor, Annick; Tardivel, Aubry; Tschopp, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7081</span>),
    <span class="NLM_cas:pages">237-241</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Development of the acute and chronic inflammatory responses known as gout and pseudogout are assocd. with the deposition of monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, resp., in joints and periarticular tissues.  Although MSU crystals were first identified as the etiol. agent of gout in the eighteenth century and more recently as a danger signal' released from dying cells, little is known about the mol. mechanisms underlying MSU- or CPPD-induced inflammation.  Here we show that MSU and CPPD engage the caspase-1-activating NALP3 (also called cryopyrin) inflammasome, resulting in the prodn. of active interleukin (IL)-1β and IL-18.  Macrophages from mice deficient in various components of the inflammasome such as caspase-1, ASC and NALP3 are defective in crystal-induced IL-1β activation.  Moreover, an impaired neutrophil influx is found in an in vivo model of crystal-induced peritonitis in inflammasome-deficient mice or mice deficient in the IL-1β receptor (IL-1R).  These findings provide insight into the mol. processes underlying the inflammatory conditions of gout and pseudogout, and further support a pivotal role of the inflammasome in several autoinflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Z0Lgw8VSWLVg90H21EOLACvtfcHk0lhdk12W7CYzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFGitLg%253D&md5=e8694a6dc4096b44f07442df6feb791f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnature04516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04516%26sid%3Dliteratum%253Aachs%26aulast%3DMartinon%26aufirst%3DF.%26aulast%3DP%25C3%25A9trilli%26aufirst%3DV.%26aulast%3DMayor%26aufirst%3DA.%26aulast%3DTardivel%26aufirst%3DA.%26aulast%3DTschopp%26aufirst%3DJ.%26atitle%3DGout-Associated%2520Uric%2520Acid%2520Crystals%2520Activate%2520the%2520NALP3%2520Inflammasome%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D237%26epage%3D241%26doi%3D10.1038%2Fnature04516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molony, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova-Roche, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. D.</span></span> <span> </span><span class="NLM_article-title">β-Hydroxybutyrate Deactivates Neutrophil Inflammasome to Relieve Gout Flares</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2077</span>– <span class="NLM_lpage">2087</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.celrep.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28249154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Ontbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=2077-2087&author=E.+L.+Goldbergauthor=J.+L.+Asherauthor=R.+D.+Molonyauthor=A.+C.+Shawauthor=C.+J.+Zeissauthor=C.+Wangauthor=L.+A.+Morozova-Rocheauthor=R.+I.+Herzogauthor=A.+Iwasakiauthor=V.+D.+Dixit&title=%CE%B2-Hydroxybutyrate+Deactivates+Neutrophil+Inflammasome+to+Relieve+Gout+Flares&doi=10.1016%2Fj.celrep.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares</span></div><div class="casAuthors">Goldberg, Emily L.; Asher, Jennifer L.; Molony, Ryan D.; Shaw, Albert C.; Zeiss, Caroline J.; Wang, Chao; Morozova-Roche, Ludmilla A.; Herzog, Raimund I.; Iwasaki, Akiko; Dixit, Vishwa Deep</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2077-2087</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Aging and lipotoxicity are two major risk factors for gout that are linked by the activation of the NLRP3 inflammasome.  Neutrophil-mediated prodn. of interleukin-1β (IL-1β) drives gouty flares that cause joint destruction, intense pain, and fever.  However, metabolites that impact neutrophil inflammasome remain unknown.  Here, we identified that ketogenic diet (KD) increases β-hydroxybutyrate (BHB) and alleviates urate crystal-induced gout without impairing immune defense against bacterial infection.  BHB inhibited NLRP3 inflammasome in S100A9 fibril-primed and urate crystal-activated macrophages, which serve to recruit inflammatory neutrophils in joints.  Consistent with reduced gouty flares in rats fed a ketogenic diet, BHB blocked IL-1β in neutrophils in a NLRP3-dependent manner in mice and humans irresp. of age.  Mechanistically, BHB inhibited the NLRP3 inflammasome in neutrophils by reducing priming and assembly steps.  Collectively, our studies show that BHB, a known alternate metabolic fuel, is also an anti-inflammatory mol. that may serve as a treatment for gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlbGyx7yQ7prVg90H21EOLACvtfcHk0lhdk12W7CYzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Ontbc%253D&md5=8c33a7438a868a2467916feb7925fd18</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DE.%2BL.%26aulast%3DAsher%26aufirst%3DJ.%2BL.%26aulast%3DMolony%26aufirst%3DR.%2BD.%26aulast%3DShaw%26aufirst%3DA.%2BC.%26aulast%3DZeiss%26aufirst%3DC.%2BJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMorozova-Roche%26aufirst%3DL.%2BA.%26aulast%3DHerzog%26aufirst%3DR.%2BI.%26aulast%3DIwasaki%26aufirst%3DA.%26aulast%3DDixit%26aufirst%3DV.%2BD.%26atitle%3D%25CE%25B2-Hydroxybutyrate%2520Deactivates%2520Neutrophil%2520Inflammasome%2520to%2520Relieve%2520Gout%2520Flares%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D2077%26epage%3D2087%26doi%3D10.1016%2Fj.celrep.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span> <span> </span><span class="NLM_article-title">Targeting ASC in NLRP3 Inflammasome by Caffeic Acid Phenethyl Ester: a Novel Strategy to Treat Acute Gout</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">38622</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1038/srep38622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fsrep38622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28442746" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1-11&issue=38622&author=H.+E.+Leeauthor=G.+Yangauthor=N.+D.+Kimauthor=S.+Jeongauthor=Y.+Jungauthor=J.+Y.+Choiauthor=H.+H.+Parkauthor=J.+Y.+Lee&title=Targeting+ASC+in+NLRP3+Inflammasome+by+Caffeic+Acid+Phenethyl+Ester%3A+a+Novel+Strategy+to+Treat+Acute+Gout&doi=10.1038%2Fsrep38622"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fsrep38622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep38622%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BE.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DJeong%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DJ.%2BY.%26aulast%3DPark%26aufirst%3DH.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26atitle%3DTargeting%2520ASC%2520in%2520NLRP3%2520Inflammasome%2520by%2520Caffeic%2520Acid%2520Phenethyl%2520Ester%253A%2520a%2520Novel%2520Strategy%2520to%2520Treat%2520Acute%2520Gout%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D38622%26spage%3D1%26epage%3D11%26doi%3D10.1038%2Fsrep38622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartzwelter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamboni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neff, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tengesdal, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemkov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessandro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrich, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scribner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skouras, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gattorno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janciauskiene, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubartelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span> <span> </span><span class="NLM_article-title">OLT1177, a β-Sulfonyl Nitrile Compound, Safe in Humans, Inhibits the NLRP3 Inflammasome and Reverses the Metabolic Cost of Inflammation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1073/pnas.1716095115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1073%2Fpnas.1716095115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWjtbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=1530-1539&issue=7&author=C.+Marchettiauthor=B.+Swartzwelterauthor=F.+Gamboniauthor=C.+P.+Neffauthor=K.+Richterauthor=T.+Azamauthor=S.+Cartaauthor=I.+W.+Tengesdalauthor=T.+Nemkovauthor=A.+D%E2%80%99Alessandroauthor=C.+Henryauthor=G.+S.+Jonesauthor=S.+A.+Goodrichauthor=J.+P.+St.+Laurentauthor=T.+M.+Jonesauthor=C.+L.+Scribnerauthor=R.+B.+Barrowauthor=R.+D.+Altmanauthor=D.+B.+Skourasauthor=M.+Gattornoauthor=V.+Grauauthor=S.+Janciauskieneauthor=A.+Rubartelliauthor=L.+A.+B.+Joostenauthor=C.+A.+Dinarello&title=OLT1177%2C+a+%CE%B2-Sulfonyl+Nitrile+Compound%2C+Safe+in+Humans%2C+Inhibits+the+NLRP3+Inflammasome+and+Reverses+the+Metabolic+Cost+of+Inflammation&doi=10.1073%2Fpnas.1716095115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation</span></div><div class="casAuthors">Marchetti, Carlo; Swartzwelter, Benjamin; Gamboni, Fabia; Neff, Charles P.; Richter, Katrin; Azam, Tania; Carta, Sonia; Tengesdal, Isak; Nemkov, Travis; DaAlessandro, Angelo; Henry, Curtis; Jones, Gerald S.; Goodrich, Scott A.; St. Laurent, Joseph P.; Jones, Terry M.; Scribner, Curtis L.; Barrow, Robert B.; Altman, Roy D.; Skouras, Damaris B.; Gattorno, Marco; Grau, Veronika; Janciauskiene, Sabina; Rubartelli, Anna; Joosten, Leo A. B.; Dinarello, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">E1530-E1539</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the NLRP3 inflammasome induces maturation of IL-1β and IL-18, both validated targets for treating acute and chronic inflammatory diseases.  Here, we demonstrate that OLT1177, an orally active β-sulfonyl nitrile mol., inhibits activation of the NLRP3 inflammasome.  In vitro, nanomolar concns. of OLT1177 reduced IL-1β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation.  The mol. showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3.  In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1β levels by 60% and IL-18 by 70% at concns. 100-fold lower in vitro than plasma concns. safely reached in humans.  OLT1177 also reduced IL-1β release and caspase-1 activity in freshly obtained human blood neutrophils.  In monocytes isolated from patients with cryopyrin-assocd. periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1β release by 84% and 36%.  Immunopptn. and FRET anal. demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization.  In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3.  Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1β precursor.  Steady-state levels of phosphorylated NF-κB and IkB kinase were significantly lowered in spleen cells from OLT1177-treated mice.  We obsd. reduced IL-1β content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metab. in OLT1177-treated mice challenged with LPS.  Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochem. or hematol. changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokLYw_bXy_NLVg90H21EOLACvtfcHk0liAvwxK8_Nwww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWjtbnO&md5=4c1c33730980ddd2cad26195f05efa08</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1716095115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1716095115%26sid%3Dliteratum%253Aachs%26aulast%3DMarchetti%26aufirst%3DC.%26aulast%3DSwartzwelter%26aufirst%3DB.%26aulast%3DGamboni%26aufirst%3DF.%26aulast%3DNeff%26aufirst%3DC.%2BP.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DAzam%26aufirst%3DT.%26aulast%3DCarta%26aufirst%3DS.%26aulast%3DTengesdal%26aufirst%3DI.%2BW.%26aulast%3DNemkov%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Alessandro%26aufirst%3DA.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DG.%2BS.%26aulast%3DGoodrich%26aufirst%3DS.%2BA.%26aulast%3DSt.%2BLaurent%26aufirst%3DJ.%2BP.%26aulast%3DJones%26aufirst%3DT.%2BM.%26aulast%3DScribner%26aufirst%3DC.%2BL.%26aulast%3DBarrow%26aufirst%3DR.%2BB.%26aulast%3DAltman%26aufirst%3DR.%2BD.%26aulast%3DSkouras%26aufirst%3DD.%2BB.%26aulast%3DGattorno%26aufirst%3DM.%26aulast%3DGrau%26aufirst%3DV.%26aulast%3DJanciauskiene%26aufirst%3DS.%26aulast%3DRubartelli%26aufirst%3DA.%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26atitle%3DOLT1177%252C%2520a%2520%25CE%25B2-Sulfonyl%2520Nitrile%2520Compound%252C%2520Safe%2520in%2520Humans%252C%2520Inhibits%2520the%2520NLRP3%2520Inflammasome%2520and%2520Reverses%2520the%2520Metabolic%2520Cost%2520of%2520Inflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D7%26spage%3D1530%26epage%3D1539%26doi%3D10.1073%2Fpnas.1716095115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartzwelter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenders, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tengesdal, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. B.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Inhibitor OLT1177 Suppresses Joint Inflammation in Murine Models of Acute Athritis</span>. <i>Arthritis Research & Therapy</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">169</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1186/s13075-018-1664-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1186%2Fs13075-018-1664-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29329602" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1-11&issue=169&author=C.+Marchettiauthor=B.+Swartzwelterauthor=M.+I.+Koendersauthor=T.+Azamauthor=I.+W.+Tengesdalauthor=N.+Powersauthor=D.+M.+de+Graafauthor=C.+A.+Dinarelloauthor=L.+A.+B.+Joosten&title=NLRP3+Inflammasome+Inhibitor+OLT1177+Suppresses+Joint+Inflammation+in+Murine+Models+of+Acute+Athritis&doi=10.1186%2Fs13075-018-1664-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs13075-018-1664-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-018-1664-2%26sid%3Dliteratum%253Aachs%26aulast%3DMarchetti%26aufirst%3DC.%26aulast%3DSwartzwelter%26aufirst%3DB.%26aulast%3DKoenders%26aufirst%3DM.%2BI.%26aulast%3DAzam%26aufirst%3DT.%26aulast%3DTengesdal%26aufirst%3DI.%2BW.%26aulast%3DPowers%26aufirst%3DN.%26aulast%3Dde%2BGraaf%26aufirst%3DD.%2BM.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26atitle%3DNLRP3%2520Inflammasome%2520Inhibitor%2520OLT1177%2520Suppresses%2520Joint%2520Inflammation%2520in%2520Murine%2520Models%2520of%2520Acute%2520Athritis%26jtitle%3DArthritis%2520Research%2520%2526%2520Therapy%26date%3D2018%26volume%3D20%26issue%3D169%26spage%3D1%26epage%3D11%26doi%3D10.1186%2Fs13075-018-1664-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albornoz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantovani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanthasamy, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, T. M.</span></span> <span> </span><span class="NLM_article-title">Inflammasome Inhibition Prevents α-Synuclein Pathology and Dopaminergic Neurodegeneration in Mice</span>. <i>Science Translational Medicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aah4066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fscitranslmed.aah4066" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1-12&author=R.+Gordonauthor=E.+A.+Albornozauthor=D.+C.+Christieauthor=M.+R.+Langleyauthor=V.+Kumarauthor=S.+Mantovaniauthor=A.+A.+B.+Robertsonauthor=M.+S.+Butlerauthor=D.+B.+Roweauthor=L.+A.+O%E2%80%99Neillauthor=A.+G.+Kanthasamyauthor=K.+Schroderauthor=M.+A.+Cooperauthor=T.+M.+Woodruff&title=Inflammasome+Inhibition+Prevents+%CE%B1-Synuclein+Pathology+and+Dopaminergic+Neurodegeneration+in+Mice&doi=10.1126%2Fscitranslmed.aah4066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aah4066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aah4066%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DAlbornoz%26aufirst%3DE.%2BA.%26aulast%3DChristie%26aufirst%3DD.%2BC.%26aulast%3DLangley%26aufirst%3DM.%2BR.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMantovani%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DButler%26aufirst%3DM.%2BS.%26aulast%3DRowe%26aufirst%3DD.%2BB.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.%26aulast%3DKanthasamy%26aufirst%3DA.%2BG.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DWoodruff%26aufirst%3DT.%2BM.%26atitle%3DInflammasome%2520Inhibition%2520Prevents%2520%25CE%25B1-Synuclein%2520Pathology%2520and%2520Dopaminergic%2520Neurodegeneration%2520in%2520Mice%26jtitle%3DScience%2520Translational%2520Medicine%26date%3D2018%26volume%3D10%26spage%3D1%26epage%3D12%26doi%3D10.1126%2Fscitranslmed.aah4066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delekate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-Saecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griep, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzeng, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelpi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D. T.</span></span> <span> </span><span class="NLM_article-title">NLRP3 is Activated in Alzheimer’s Disease and Contributes to Pathology in APP/PSA1Mice</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>493</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1038/nature11729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature11729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23254930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvV2ntLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=493&publication_year=2013&pages=674-678&author=M.+T.+Henekaauthor=M.+P.+Kummerauthor=A.+Stutzauthor=A.+Delekateauthor=S.+Schwartzauthor=A.+Vieira-Saeckerauthor=A.+Griepauthor=D.+Axtauthor=A.+Remusauthor=T.-C.+Tzengauthor=E.+Gelpiauthor=A.+Halleauthor=M.+Korteauthor=E.+Latzauthor=D.+T.+Golenbock&title=NLRP3+is+Activated+in+Alzheimer%E2%80%99s+Disease+and+Contributes+to+Pathology+in+APP%2FPSA1Mice&doi=10.1038%2Fnature11729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice</span></div><div class="casAuthors">Heneka, Michael T.; Kummer, Markus P.; Stutz, Andrea; Delekate, Andrea; Schwartz, Stephanie; Vieira-Saecker, Ana; Griep, Angelika; Axt, Daisy; Remus, Anita; Tzeng, Te-Chen; Gelpi, Ellen; Halle, Annett; Korte, Martin; Latz, Eicke; Golenbock, Douglas T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">493</span>
        (<span class="NLM_cas:issue">7434</span>),
    <span class="NLM_cas:pages">674-678</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alzheimer's disease is the world's most common dementing illness.  Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia.  Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events.  However, it remains unknown whether NLRP3 activation contributes to Alzheimer's disease in vivo.  Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer's disease, suggesting a role for the inflammasome in this neurodegenerative disease.  Nlrp3-/- or Casp1-/- mice carrying mutations assocd. with familial Alzheimer's disease were largely protected from loss of spatial memory and other sequelae assocd. with Alzheimer's disease, and demonstrated reduced brain caspase-1 and interleukin-1β activation as well as enhanced amyloid-β clearance.  Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-β in the APP/PS1 model of Alzheimer's disease.  These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer's disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc1Oe8w8wxWbVg90H21EOLACvtfcHk0lgyK4Jdp6ICXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvV2ntLfM&md5=382d9c04caad9c6d3e2431bf611bf9ff</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature11729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11729%26sid%3Dliteratum%253Aachs%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26aulast%3DKummer%26aufirst%3DM.%2BP.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DDelekate%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DVieira-Saecker%26aufirst%3DA.%26aulast%3DGriep%26aufirst%3DA.%26aulast%3DAxt%26aufirst%3DD.%26aulast%3DRemus%26aufirst%3DA.%26aulast%3DTzeng%26aufirst%3DT.-C.%26aulast%3DGelpi%26aufirst%3DE.%26aulast%3DHalle%26aufirst%3DA.%26aulast%3DKorte%26aufirst%3DM.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DGolenbock%26aufirst%3DD.%2BT.%26atitle%3DNLRP3%2520is%2520Activated%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520and%2520Contributes%2520to%2520Pathology%2520in%2520APP%252FPSA1Mice%26jtitle%3DNature%26date%3D2013%26volume%3D493%26spage%3D674%26epage%3D678%26doi%3D10.1038%2Fnature11729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ising, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venegas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-Saecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albasset, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griep, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosseron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stunden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Activation Drives Tau Pathology</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1769-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41586-019-1769-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31748742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2qt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=669-673&author=C.+Isingauthor=C.+Venegasauthor=S.+Zhangauthor=H.+Scheiblichauthor=S.+V.+Schmidtauthor=A.+Vieira-Saeckerauthor=S.+Schwartzauthor=S.+Albassetauthor=R.+M.+McManusauthor=D.+Tejeraauthor=A.+Griepauthor=F.+Santarelliauthor=F.+Brosseronauthor=S.+Opitzauthor=J.+Stundenauthor=M.+Mertenauthor=R.+Kayedauthor=D.+T.+Golenbockauthor=D.+Blumauthor=E.+Latzauthor=L.+Bueeauthor=M.+T.+Heneka&title=NLRP3+Inflammasome+Activation+Drives+Tau+Pathology&doi=10.1038%2Fs41586-019-1769-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome activation drives tau pathology</span></div><div class="casAuthors">Ising, Christina; Venegas, Carmen; Zhang, Shuangshuang; Scheiblich, Hannah; Schmidt, Susanne V.; Vieira-Saecker, Ana; Schwartz, Stephanie; Albasset, Shadi; McManus, Roisin M.; Tejera, Dario; Griep, Angelika; Santarelli, Francesco; Brosseron, Frederic; Opitz, Sabine; Stunden, James; Merten, Maximilian; Kayed, Rakez; Golenbock, Douglas T.; Blum, David; Latz, Eicke; Buee, Luc; Heneka, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7784</span>),
    <span class="NLM_cas:pages">669-673</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1.  The inflammasome inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2.  Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathol. in mice3, the precise effect on tau pathol. remains unknown.  Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases.  Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-contg. brain homogenates induced tau pathol. in an NLRP3-dependent manner.  These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer's disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCaPXz72o9VrVg90H21EOLACvtfcHk0lhJDWgDAFRxHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2qt7nE&md5=efd69ac9ce47699e362679c7c39265cc</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1769-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1769-z%26sid%3Dliteratum%253Aachs%26aulast%3DIsing%26aufirst%3DC.%26aulast%3DVenegas%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DScheiblich%26aufirst%3DH.%26aulast%3DSchmidt%26aufirst%3DS.%2BV.%26aulast%3DVieira-Saecker%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DAlbasset%26aufirst%3DS.%26aulast%3DMcManus%26aufirst%3DR.%2BM.%26aulast%3DTejera%26aufirst%3DD.%26aulast%3DGriep%26aufirst%3DA.%26aulast%3DSantarelli%26aufirst%3DF.%26aulast%3DBrosseron%26aufirst%3DF.%26aulast%3DOpitz%26aufirst%3DS.%26aulast%3DStunden%26aufirst%3DJ.%26aulast%3DMerten%26aufirst%3DM.%26aulast%3DKayed%26aufirst%3DR.%26aulast%3DGolenbock%26aufirst%3DD.%2BT.%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DBuee%26aufirst%3DL.%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26atitle%3DNLRP3%2520Inflammasome%2520Activation%2520Drives%2520Tau%2520Pathology%26jtitle%3DNature%26date%3D2019%26volume%3D575%26spage%3D669%26epage%3D673%26doi%3D10.1038%2Fs41586-019-1769-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowery, D.</span></span> <span> </span><span class="NLM_article-title">The Patent Landscape of Inflammasome Modulators</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">158</span>),  <span class="NLM_fpage">1474</span>– <span class="NLM_lpage">1784</span>, <span class="refDoi"> DOI: 10.1038/d41573-019-00200-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fd41573-019-00200-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=1474-1784&issue=158&author=B.+Leungauthor=D.+Lowery&title=The+Patent+Landscape+of+Inflammasome+Modulators&doi=10.1038%2Fd41573-019-00200-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fd41573-019-00200-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-019-00200-x%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DB.%26aulast%3DLowery%26aufirst%3DD.%26atitle%3DThe%2520Patent%2520Landscape%2520of%2520Inflammasome%2520Modulators%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26issue%3D158%26spage%3D1474%26epage%3D1784%26doi%3D10.1038%2Fd41573-019-00200-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluck, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comarniceanu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efdé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scribner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skouras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L.</span></span> <span> </span><span class="NLM_article-title">The First Phase 2A Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile (OLT1177), in Acute Gout</span>. <i>Annals of the Rheumatic Diseases</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2018-EWRR2019.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1136%2Fannrheumdis-2018-EWRR2019.142" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=70-71&author=T.+Jansenauthor=V.+Kluckauthor=M.+Janssenauthor=A.+Comarniceanuauthor=M.+Efd%C3%A9author=C.+Scribnerauthor=D.+Skourasauthor=C.+A.+Dinarelloauthor=L.+Joosten&title=The+First+Phase+2A+Proof-of-Concept+Study+of+a+Selective+NLRP3+Inflammasome+Inhibitor%2C+Dapansutrile+%28OLT1177%29%2C+in+Acute+Gout&doi=10.1136%2Fannrheumdis-2018-EWRR2019.142"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2018-EWRR2019.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2018-EWRR2019.142%26sid%3Dliteratum%253Aachs%26aulast%3DJansen%26aufirst%3DT.%26aulast%3DKluck%26aufirst%3DV.%26aulast%3DJanssen%26aufirst%3DM.%26aulast%3DComarniceanu%26aufirst%3DA.%26aulast%3DEfd%25C3%25A9%26aufirst%3DM.%26aulast%3DScribner%26aufirst%3DC.%26aulast%3DSkouras%26aufirst%3DD.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DJoosten%26aufirst%3DL.%26atitle%3DThe%2520First%2520Phase%25202A%2520Proof-of-Concept%2520Study%2520of%2520a%2520Selective%2520NLRP3%2520Inflammasome%2520Inhibitor%252C%2520Dapansutrile%2520%2528OLT1177%2529%252C%2520in%2520Acute%2520Gout%26jtitle%3DAnnals%2520of%2520the%2520Rheumatic%2520Diseases%26date%3D2019%26volume%3D78%26spage%3D70%26epage%3D71%26doi%3D10.1136%2Fannrheumdis-2018-EWRR2019.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klück, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, T. L. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comarniceanu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efdé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tengesdal, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schraa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleophas, M. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scribner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skouras, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. b.</span></span> <span> </span><span class="NLM_article-title">Dapansutrile, an Oral Selective NLRP3 Inflammasome Inhibitor, for Treatment of Gout Flares: An Open-Label, Dose-Adaptive, Proof-of-Concept, Phase 2a Trial</span>. <i>Lancet Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e270</span>– <span class="NLM_lpage">e280</span>, <span class="refDoi"> DOI: 10.1016/s2665-9913(20)30065-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930065-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=33005902" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=e270-e280&issue=5&author=V.+Kl%C3%BCckauthor=T.+L.+T.+A.+Jansenauthor=M.+Janssenauthor=A.+Comarniceanuauthor=M.+Efd%C3%A9author=I.+W.+Tengesdalauthor=K.+Schraaauthor=M.+C.+P.+Cleophasauthor=C.+L.+Scribnerauthor=D.+B.+Skourasauthor=C.+Marchettiauthor=C.+A.+Dinarelloauthor=L.+A.+b.+Joosten&title=Dapansutrile%2C+an+Oral+Selective+NLRP3+Inflammasome+Inhibitor%2C+for+Treatment+of+Gout+Flares%3A+An+Open-Label%2C+Dose-Adaptive%2C+Proof-of-Concept%2C+Phase+2a+Trial&doi=10.1016%2Fs2665-9913%2820%2930065-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930065-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930065-5%26sid%3Dliteratum%253Aachs%26aulast%3DKl%25C3%25BCck%26aufirst%3DV.%26aulast%3DJansen%26aufirst%3DT.%2BL.%2BT.%2BA.%26aulast%3DJanssen%26aufirst%3DM.%26aulast%3DComarniceanu%26aufirst%3DA.%26aulast%3DEfd%25C3%25A9%26aufirst%3DM.%26aulast%3DTengesdal%26aufirst%3DI.%2BW.%26aulast%3DSchraa%26aufirst%3DK.%26aulast%3DCleophas%26aufirst%3DM.%2BC.%2BP.%26aulast%3DScribner%26aufirst%3DC.%2BL.%26aulast%3DSkouras%26aufirst%3DD.%2BB.%26aulast%3DMarchetti%26aufirst%3DC.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2Bb.%26atitle%3DDapansutrile%252C%2520an%2520Oral%2520Selective%2520NLRP3%2520Inflammasome%2520Inhibitor%252C%2520for%2520Treatment%2520of%2520Gout%2520Flares%253A%2520An%2520Open-Label%252C%2520Dose-Adaptive%252C%2520Proof-of-Concept%252C%2520Phase%25202a%2520Trial%26jtitle%3DLancet%2520Rheumatol.%26date%3D2020%26volume%3D2%26issue%3D5%26spage%3De270%26epage%3De280%26doi%3D10.1016%2Fs2665-9913%2820%2930065-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misaghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izrael-Tomasevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmour, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamkanfi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kömüves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupp, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of NLRC4 is Critical for Inflammasome Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>490</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1038/nature11429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature11429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=22885697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOgtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2012&pages=539-542&author=Y.+Quauthor=S.+Misaghiauthor=A.+Izrael-Tomasevicauthor=K.+Newtonauthor=L.+L.+Gilmourauthor=M.+Lamkanfiauthor=S.+Louieauthor=N.+Kayagakiauthor=J.+Liuauthor=L.+K%C3%B6m%C3%BCvesauthor=J.+E.+Cuppauthor=D.+Arnottauthor=D.+Monackauthor=V.+M.+Dixit&title=Phosphorylation+of+NLRC4+is+Critical+for+Inflammasome+Activation&doi=10.1038%2Fnature11429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of NLRC4 is critical for inflammasome activation</span></div><div class="casAuthors">Qu, Yan; Misaghi, Shahram; Izrael-Tomasevic, Anita; Newton, Kim; Gilmour, Laurie L.; Lamkanfi, Mohamed; Louie, Salina; Kayagaki, Nobuhiko; Liu, Jinfeng; Koemueves, Laszlo; Cupp, James E.; Arnott, David; Monack, Denise; Dixit, Vishva M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">490</span>
        (<span class="NLM_cas:issue">7421</span>),
    <span class="NLM_cas:pages">539-542</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">NLRC4 is a cytosolic member of the NOD-like receptor family that is expressed in innate immune cells.  It senses indirectly bacterial flagellin and type III secretion systems, and responds by assembling an inflammasome complex that promotes caspase-1 activation and pyroptosis.  Here we use knock-in mice expressing NLRC4 with a carboxy-terminal 3×Flag tag to identify phosphorylation of NLRC4 on a single, evolutionarily conserved residue, Ser 533, following infection of macrophages with Salmonella enterica serovar Typhimurium (also known as Salmonella typhimurium).  Western blotting with a NLRC4 phospho-Ser 533 antibody confirmed that this post-translational modification occurs only in the presence of stimuli known to engage NLRC4 and not the related protein NLRP3 or AIM2.  Nlrc4-/- macrophages reconstituted with NLRC4 mutant S533A, unlike those reconstituted with wild-type NLRC4, did not activate caspase-1 and pyroptosis in response to S. typhimurium, indicating that S533 phosphorylation is crit. for NLRC4 inflammasome function.  Conversely, phosphomimetic NLRC4 S533D caused rapid macrophage pyroptosis without infection.  Biochem. purifn. of the NLRC4-phosphorylating activity and a screen of kinase inhibitors identified PRKCD (PKCδ) as a candidate NLRC4 kinase.  Recombinant PKCδ phosphorylated NLRC4 S533 in vitro, immunodepletion of PKCδ from macrophage lysates blocked NLRC4 S533 phosphorylation in vitro, and Prkcd-/- macrophages exhibited greatly attenuated caspase-1 activation and IL-1β secretion specifically in response to S. typhimurium.  Phosphorylation-defective NLRC4 S533A failed to recruit procaspase-1 and did not assemble inflammasome specks during S. typhimurium infection, so phosphorylation of NLRC4 S533 probably drives conformational changes necessary for NLRC4 inflammasome activity and host innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ9Hz_VCJo1LVg90H21EOLACvtfcHk0lhrMeu8fsdLvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOgtrzE&md5=5355b7dfc7fae0c367f8383dfe0cea96</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnature11429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11429%26sid%3Dliteratum%253Aachs%26aulast%3DQu%26aufirst%3DY.%26aulast%3DMisaghi%26aufirst%3DS.%26aulast%3DIzrael-Tomasevic%26aufirst%3DA.%26aulast%3DNewton%26aufirst%3DK.%26aulast%3DGilmour%26aufirst%3DL.%2BL.%26aulast%3DLamkanfi%26aufirst%3DM.%26aulast%3DLouie%26aufirst%3DS.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DK%25C3%25B6m%25C3%25BCves%26aufirst%3DL.%26aulast%3DCupp%26aufirst%3DJ.%2BE.%26aulast%3DArnott%26aufirst%3DD.%26aulast%3DMonack%26aufirst%3DD.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26atitle%3DPhosphorylation%2520of%2520NLRC4%2520is%2520Critical%2520for%2520Inflammasome%2520Activation%26jtitle%3DNature%26date%3D2012%26volume%3D490%26spage%3D539%26epage%3D542%26doi%3D10.1038%2Fnature11429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramlett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimshaw, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matuszkiewicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natala, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalevsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of TAK-659 and Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5947</span>– <span class="NLM_lpage">5950</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.bmcl.2016.10.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27839918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5947-5950&issue=24&author=B.+Lamauthor=Y.+Arikawaauthor=J.+Cramlettauthor=Q.+Dongauthor=R.+de+Jongauthor=V.+Feherauthor=C.+E.+Grimshawauthor=P.+J.+Farrellauthor=I.+D.+Hoffmanauthor=A.+Jenningsauthor=B.+Jonesauthor=J.+Matuszkiewiczauthor=J.+Miuraauthor=H.+Miyakeauthor=S.+R.+Natalaauthor=L.+Shiauthor=M.+Takahashiauthor=E.+Taylorauthor=C.+Wyrickauthor=J.+Yanoauthor=J.+Zalevskyauthor=Z.+Nie&title=Discovery+of+TAK-659+and+Orally+Available+Investigational+Inhibitor+of+Spleen+Tyrosine+Kinase+%28SYK%29&doi=10.1016%2Fj.bmcl.2016.10.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)</span></div><div class="casAuthors">Lam, Betty; Arikawa, Yasuyoshi; Cramlett, Joshua; Dong, Qing; de Jong, Ron; Feher, Victoria; Grimshaw, Charles E.; Farrell, Pamela J.; Hoffman, Isaac D.; Jennings, Andy; Jones, Benjamin; Matuszkiewicz, Jennifer; Miura, Joanne; Miyake, Hiroshi; Natala, Srinivasa Reddy; Shi, Lihong; Takahashi, Masashi; Taylor, Ewan; Wyrick, Corey; Yano, Jason; Zalevsky, Jonathan; Nie, Zhe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5947-5950</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spleen Tyrosine Kinase (SYK) is a non-receptor cytoplasmic tyrosine kinase that is primarily expressed in hematopoietic cells.  SYK is a key mediator for a variety of inflammatory cells, including B cells, mast cells, macrophages and neutrophils and therefore, an attractive approach for treatment of both inflammatory diseases and oncol. indications.  Using in house co-crystal structure information, and structure-based drug design, we designed and optimized a novel series of heteroarom. pyrrolidinone SYK inhibitors resulting in the selection of the development candidate TAK-659.  TAK-659 is currently undergoing Phase I clin. trials for advanced solid tumor and lymphoma malignancies, a Phase Ib study in advanced solid tumors in combination with nivolumab, and PhIb/II trials for relapsed/refractory AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMSKPjg5MH7Vg90H21EOLACvtfcHk0lhrMeu8fsdLvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3K&md5=baca5103b2feed622ae7381c90ce8f4c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.087%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DB.%26aulast%3DArikawa%26aufirst%3DY.%26aulast%3DCramlett%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3Dde%2BJong%26aufirst%3DR.%26aulast%3DFeher%26aufirst%3DV.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DFarrell%26aufirst%3DP.%2BJ.%26aulast%3DHoffman%26aufirst%3DI.%2BD.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DMatuszkiewicz%26aufirst%3DJ.%26aulast%3DMiura%26aufirst%3DJ.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DNatala%26aufirst%3DS.%2BR.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DWyrick%26aufirst%3DC.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DZalevsky%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520TAK-659%2520and%2520Orally%2520Available%2520Investigational%2520Inhibitor%2520of%2520Spleen%2520Tyrosine%2520Kinase%2520%2528SYK%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D24%26spage%3D5947%26epage%3D5950%26doi%3D10.1016%2Fj.bmcl.2016.10.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-362962,
A Phase
1, Double-Blind Placebo-Controlled Single Multiple Ascending Dose
Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
and Food Effects or IFM-2427 in Healthy Subjects.</i> <a href="https://citeline.informa.com/trials/details/362962?qId=6c9b6f61-bad0-48e6-9c80-d93c3eaa3a2e" class="extLink">https://citeline.informa.com/trials/details/362962?qId=6c9b6f61-bad0-48e6-9c80-d93c3eaa3a2e</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-362962%2C%0AA+Phase%0A1%2C+Double-Blind+Placebo-Controlled+Single+Multiple+Ascending+Dose%0AStudy+of+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+Pharmacodynamics%0Aand+Food+Effects+or+IFM-2427+in+Healthy+Subjects.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F362962%3FqId%3D6c9b6f61-bad0-48e6-9c80-d93c3eaa3a2e+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-362962%252C%250AA%2520Phase%250A1%252C%2520Double-Blind%2520Placebo-Controlled%2520Single%2520Multiple%2520Ascending%2520Dose%250AStudy%2520of%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520Pharmacodynamics%250Aand%2520Food%2520Effects%2520or%2520IFM-2427%2520in%2520Healthy%2520Subjects.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G.</span>; <span class="NLM_string-name">Gosh, S.</span>; <span class="NLM_string-name">Roush, W. R.</span>; <span class="NLM_string-name">Shen, D.-M.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Treating Conditions Associated with NLRP Activity</span>. WO <span class="NLM_patent">2019/023147</span>, Jan 31, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=G.+Glick&author=S.+Gosh&author=W.+R.+Roush&author=D.-M.+Shen&title=Compounds+and+Compositions+for+Treating+Conditions+Associated+with+NLRP+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGlick%26aufirst%3DG.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Treating%2520Conditions%2520Associated%2520with%2520NLRP%2520Activity%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-368867, A Phase
II Proof of Concept Study of Somalix to Address Clinical Unmet Needs
in Inflammatory Conditions Such as Arthritis and Cardiovascular Disease.</i> <a href="https://citeline.informa.com/trials/details/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13" class="extLink">https://citeline.informa.com/trials/details/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-368867%2C+A+Phase%0AII+Proof+of+Concept+Study+of+Somalix+to+Address+Clinical+Unmet+Needs%0Ain+Inflammatory+Conditions+Such+as+Arthritis+and+Cardiovascular+Disease.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F357081%3FqId%3Dbdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13+%28accessed+Apr+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-368867%252C%2520A%2520Phase%250AII%2520Proof%2520of%2520Concept%2520Study%2520of%2520Somalix%2520to%2520Address%2520Clinical%2520Unmet%2520Needs%250Ain%2520Inflammatory%2520Conditions%2520Such%2520as%2520Arthritis%2520and%2520Cardiovascular%2520Disease.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-360928, The Multiple
Proof of Concept Studies of Phase II Inzomelid in Patients with Parkinson’s
Disease.</i> <a href="https://citeline.informa.com/trials/details/360928?qId=79b241fb-63ac-4d15-a542-d6b6849d357c" class="extLink">https://citeline.informa.com/trials/details/360928?qId=79b241fb-63ac-4d15-a542-d6b6849d357c</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-360928%2C+The+Multiple%0AProof+of+Concept+Studies+of+Phase+II+Inzomelid+in+Patients+with+Parkinson%E2%80%99s%0ADisease.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F360928%3FqId%3D79b241fb-63ac-4d15-a542-d6b6849d357c+%28accessed+Apr+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-360928%252C%2520The%2520Multiple%250AProof%2520of%2520Concept%2520Studies%2520of%2520Phase%2520II%2520Inzomelid%2520in%2520Patients%2520with%2520Parkinson%25E2%2580%2599s%250ADisease.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-357081, A Phase
1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple
Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Food Effect of IZD334 in Healthy Adult Participants
as Well as an Open-Label Cohort to Confirm the Safety, Pharmacokinetics,
and Pharmacodynamics in Adult Patients With Cryopyrin-Associated Periodic
Syndromes.</i> <a href="https://citeline.informa.com/trials/details/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13" class="extLink">https://citeline.informa.com/trials/details/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-357081%2C+A+Phase%0A1%2C+Randomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Single+and+Multiple%0AAscending+Dose+Study+to+Determine+the+Safety%2C+Tolerability%2C+Pharmacokinetics%2C%0APharmacodynamics+and+Food+Effect+of+IZD334+in+Healthy+Adult+Participants%0Aas+Well+as+an+Open-Label+Cohort+to+Confirm+the+Safety%2C+Pharmacokinetics%2C%0Aand+Pharmacodynamics+in+Adult+Patients+With+Cryopyrin-Associated+Periodic%0ASyndromes.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F357081%3FqId%3Dbdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13+%28accessed+Apr+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-357081%252C%2520A%2520Phase%250A1%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Single%2520and%2520Multiple%250AAscending%2520Dose%2520Study%2520to%2520Determine%2520the%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%250APharmacodynamics%2520and%2520Food%2520Effect%2520of%2520IZD334%2520in%2520Healthy%2520Adult%2520Participants%250Aas%2520Well%2520as%2520an%2520Open-Label%2520Cohort%2520to%2520Confirm%2520the%2520Safety%252C%2520Pharmacokinetics%252C%250Aand%2520Pharmacodynamics%2520in%2520Adult%2520Patients%2520With%2520Cryopyrin-Associated%2520Periodic%250ASyndromes.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-353058, A Phase
1, Randomized, Double-Blind, Placebo Controlled, Single and Multiple
Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Food Effect of Inzomelid in Healthy Adult Participants
as Well as an Open Label Cohort to Confirm the Safety, Pharmacokinetics,
and Pharmacodynamics of Inzomelid in Adult Patients with Cryopyrin-Associated
Periodic Syndromes.</i> <a href="https://citeline.informa.com/trials/details/353058?qId=9029e7c5-e0d5-449a-851a-d762b6047856" class="extLink">https://citeline.informa.com/trials/details/353058?qId=9029e7c5-e0d5-449a-851a-d762b6047856</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-353058%2C+A+Phase%0A1%2C+Randomized%2C+Double-Blind%2C+Placebo+Controlled%2C+Single+and+Multiple%0AAscending+Dose+Study+to+Determine+the+Safety%2C+Tolerability%2C+Pharmacokinetics%2C%0APharmacodynamics+and+Food+Effect+of+Inzomelid+in+Healthy+Adult+Participants%0Aas+Well+as+an+Open+Label+Cohort+to+Confirm+the+Safety%2C+Pharmacokinetics%2C%0Aand+Pharmacodynamics+of+Inzomelid+in+Adult+Patients+with+Cryopyrin-Associated%0APeriodic+Syndromes.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F353058%3FqId%3D9029e7c5-e0d5-449a-851a-d762b6047856+%28accessed+Apr+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-353058%252C%2520A%2520Phase%250A1%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo%2520Controlled%252C%2520Single%2520and%2520Multiple%250AAscending%2520Dose%2520Study%2520to%2520Determine%2520the%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%250APharmacodynamics%2520and%2520Food%2520Effect%2520of%2520Inzomelid%2520in%2520Healthy%2520Adult%2520Participants%250Aas%2520Well%2520as%2520an%2520Open%2520Label%2520Cohort%2520to%2520Confirm%2520the%2520Safety%252C%2520Pharmacokinetics%252C%250Aand%2520Pharmacodynamics%2520of%2520Inzomelid%2520in%2520Adult%2520Patients%2520with%2520Cryopyrin-Associated%250APeriodic%2520Syndromes.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Inflazome</span>. <span> </span><span class="NLM_article-title">The Pipeline</span>. <a href="https://www.inflazome.com/pipeline" class="extLink">https://www.inflazome.com/pipeline</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Inflazome&title=The+Pipeline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520Pipeline%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L.</span>; <span class="NLM_string-name">Coll, R.</span>; <span class="NLM_string-name">Cooper, M.</span>; <span class="NLM_string-name">Robertson, A.</span>; <span class="NLM_string-name">Schroder, K.</span></span> <span> </span><span class="NLM_article-title">Sulfonylureas and Related Compounds and Use of Same</span>. WO <span class="NLM_patent">2016/131098</span>, Jan 21, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+O%E2%80%99Neill&author=R.+Coll&author=M.+Cooper&author=A.+Robertson&author=K.+Schroder&title=Sulfonylureas+and+Related+Compounds+and+Use+of+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%26atitle%3DSulfonylureas%2520and%2520Related%2520Compounds%2520and%2520Use%2520of%2520Same%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M.</span>; <span class="NLM_string-name">Miller, D.</span>; <span class="NLM_string-name">Macleod, A.</span>; <span class="NLM_string-name">Van Wiltenburg, J.</span>; <span class="NLM_string-name">Thom, S.</span>; <span class="NLM_string-name">St. Gallay, S.</span>; <span class="NLM_string-name">Shannon, J.</span>; <span class="NLM_string-name">Alanine, T.</span></span> <span> </span><span class="NLM_article-title">Novel Sulfonamide Carboxamide Compounds</span>. WO <span class="NLM_patent">2019/008025</span>, Jan 10, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Cooper&author=D.+Miller&author=A.+Macleod&author=J.+Van+Wiltenburg&author=S.+Thom&author=S.+St.+Gallay&author=J.+Shannon&author=T.+Alanine&title=Novel+Sulfonamide+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%26atitle%3DNovel%2520Sulfonamide%2520Carboxamide%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span>; <span class="NLM_string-name">Macleod, A.</span>; <span class="NLM_string-name">Van Wiltenburg, J.</span>; <span class="NLM_string-name">Thom, S.</span>; <span class="NLM_string-name">Shannon, J.</span></span> <span> </span><span class="NLM_article-title">Novel Sulfonamide Carboxamide Compounds</span>. WO <span class="NLM_patent">2019/034697</span>, Feb 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Miller&author=A.+Macleod&author=J.+Van+Wiltenburg&author=S.+Thom&author=J.+Shannon&title=Novel+Sulfonamide+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DD.%26atitle%3DNovel%2520Sulfonamide%2520Carboxamide%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M.</span>; <span class="NLM_string-name">Miller, D.</span>; <span class="NLM_string-name">Macleod, A.</span>; <span class="NLM_string-name">Van Wiltenburg, J.</span>; <span class="NLM_string-name">Thom, S.</span>; <span class="NLM_string-name">St. Gallay, S.</span>; <span class="NLM_string-name">Shannon, J.</span></span> <span> </span><span class="NLM_article-title">Novel Sulfonamide Carboxamide Compounds</span>. WO <span class="NLM_patent">2019/034686</span>, Feb 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Cooper&author=D.+Miller&author=A.+Macleod&author=J.+Van+Wiltenburg&author=S.+Thom&author=S.+St.+Gallay&author=J.+Shannon&title=Novel+Sulfonamide+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%26atitle%3DNovel%2520Sulfonamide%2520Carboxamide%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M.</span>; <span class="NLM_string-name">Miller, D.</span>; <span class="NLM_string-name">Macleod, A.</span>; <span class="NLM_string-name">Van Wiltenburg, J.</span>; <span class="NLM_string-name">Thom, S.</span>; <span class="NLM_string-name">St. Gallay, S.</span>; <span class="NLM_string-name">Shannon, J.</span></span> <span> </span><span class="NLM_article-title">Sulfonylureas and Sulfonylthioureas as NLRP3 Inhibitors</span>. WO <span class="NLM_patent">2019/034693</span>, Feb 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Cooper&author=D.+Miller&author=A.+Macleod&author=J.+Van+Wiltenburg&author=S.+Thom&author=S.+St.+Gallay&author=J.+Shannon&title=Sulfonylureas+and+Sulfonylthioureas+as+NLRP3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%26atitle%3DSulfonylureas%2520and%2520Sulfonylthioureas%2520as%2520NLRP3%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J. A.</span>; <span class="NLM_string-name">Veal, J. M.</span>; <span class="NLM_string-name">Trzoss, L. L.</span>; <span class="NLM_string-name">Mcbride, C.</span></span> <span> </span><span class="NLM_article-title">Chemical Compounds as Inhibitors of Interleukin-1 Activity</span>. WO <span class="NLM_patent">2018/136890</span>, Jul 26, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+A.+Stafford&author=J.+M.+Veal&author=L.+L.+Trzoss&author=C.+Mcbride&title=Chemical+Compounds+as+Inhibitors+of+Interleukin-1+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DChemical%2520Compounds%2520as%2520Inhibitors%2520of%2520Interleukin-1%2520Activity%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levenets, O.</span>; <span class="NLM_string-name">Galezowski, M.</span>; <span class="NLM_string-name">Bugaj, M.</span>; <span class="NLM_string-name">Woycie-Chowski, J.</span></span> <span> </span><span class="NLM_article-title">Sulfonyl Urea Derivatives and Their Use in the Control of Interleukin-1 Activity</span>. WO <span class="NLM_patent">20018/015445</span>, Jan 25, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=O.+Levenets&author=M.+Galezowski&author=M.+Bugaj&author=J.+Woycie-Chowski&title=Sulfonyl+Urea+Derivatives+and+Their+Use+in+the+Control+of+Interleukin-1+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLevenets%26aufirst%3DO.%26atitle%3DSulfonyl%2520Urea%2520Derivatives%2520and%2520Their%2520Use%2520in%2520the%2520Control%2520of%2520Interleukin-1%2520Activity%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, D.</span>; <span class="NLM_string-name">Watt, A. P.</span>; <span class="NLM_string-name">Bock, M. G.</span></span> <span> </span><span class="NLM_article-title">Sulphonyl Urea Derivatives as NLRP3 Inflammasome Modulators</span>. WO <span class="NLM_patent">2019/121691</span>, Jun 27, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Harrison&author=A.+P.+Watt&author=M.+G.+Bock&title=Sulphonyl+Urea+Derivatives+as+NLRP3+Inflammasome+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DD.%26atitle%3DSulphonyl%2520Urea%2520Derivatives%2520as%2520NLRP3%2520Inflammasome%2520Modulators%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span>; <span class="NLM_string-name">Watt, A. P.</span>; <span class="NLM_string-name">Porter, R. A.</span>; <span class="NLM_string-name">Harrison, D.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of the NLRP3 Inflammasome</span>. WO <span class="NLM_patent">2019/025467</span>, Feb 7, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+G.+Bock&author=A.+P.+Watt&author=R.+A.+Porter&author=D.+Harrison&title=Selective+Inhibitors+of+the+NLRP3+Inflammasome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DSelective%2520Inhibitors%2520of%2520the%2520NLRP3%2520Inflammasome%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Walle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossoul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hauwermeiren, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saavedra, P. H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konvalinka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamkanfi, M.</span></span> <span> </span><span class="NLM_article-title">MCC950/CRID3 Potently Targets the NACT Domain of Wild-Type NLRP3 but not Disease-Associated Mutants for Inflammasome Inhibition</span>. <i>PLOS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.3000354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.pbio.3000354" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=1-24&issue=9&author=L.+Vande%0AWalleauthor=I.+B.+Stoweauthor=P.+Sachaauthor=B.+L.+Leeauthor=D.+Demonauthor=A.+Fossoulauthor=F.+Van+Hauwermeirenauthor=P.+H.+V.+Saavedraauthor=P.+Simonauthor=V.+Subrtauthor=L.+Kostkaauthor=C.+E.+Stivalaauthor=V.+C.+Phamauthor=S.+T.+Stabenauthor=S.+Yamazoeauthor=J.+Konvalinkaauthor=N.+Kayagakiauthor=M.+Lamkanfi&title=MCC950%2FCRID3+Potently+Targets+the+NACT+Domain+of+Wild-Type+NLRP3+but+not+Disease-Associated+Mutants+for+Inflammasome+Inhibition&doi=10.1371%2Fjournal.pbio.3000354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.3000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.3000354%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BWalle%26aufirst%3DL.%26aulast%3DStowe%26aufirst%3DI.%2BB.%26aulast%3DSacha%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DB.%2BL.%26aulast%3DDemon%26aufirst%3DD.%26aulast%3DFossoul%26aufirst%3DA.%26aulast%3DVan%2BHauwermeiren%26aufirst%3DF.%26aulast%3DSaavedra%26aufirst%3DP.%2BH.%2BV.%26aulast%3DSimon%26aufirst%3DP.%26aulast%3DSubrt%26aufirst%3DV.%26aulast%3DKostka%26aufirst%3DL.%26aulast%3DStivala%26aufirst%3DC.%2BE.%26aulast%3DPham%26aufirst%3DV.%2BC.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DYamazoe%26aufirst%3DS.%26aulast%3DKonvalinka%26aufirst%3DJ.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DLamkanfi%26aufirst%3DM.%26atitle%3DMCC950%252FCRID3%2520Potently%2520Targets%2520the%2520NACT%2520Domain%2520of%2520Wild-Type%2520NLRP3%2520but%2520not%2520Disease-Associated%2520Mutants%2520for%2520Inflammasome%2520Inhibition%26jtitle%3DPLOS%2520Biol.%26date%3D2019%26volume%3D17%26issue%3D9%26spage%3D1%26epage%3D24%26doi%3D10.1371%2Fjournal.pbio.3000354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gram, H.</span></span> <span> </span><span class="NLM_article-title">The Long and Winding Road in Pharmaceutical Development of Canakinumab from Rare Genetic Autoinflammatory Syndromes to Myocardial Infarction and Cancer</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">104139</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.01.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.phrs.2019.01.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30648616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFylu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2020&pages=104139&author=H.+Gram&title=The+Long+and+Winding+Road+in+Pharmaceutical+Development+of+Canakinumab+from+Rare+Genetic+Autoinflammatory+Syndromes+to+Myocardial+Infarction+and+Cancer&doi=10.1016%2Fj.phrs.2019.01.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer</span></div><div class="casAuthors">Gram, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104139</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Interleukin-1beta (IL-1β) is an ancient and evolutionary conserved cytokine, which orchestrates innate immune responses triggered by infections in vertebrates.  While temporally limited induction of IL-1β protects the organism against traumatic or infectious insults, its chronic prodn. in unabated inflammation causes or enhances clin. manifestations of disease in almost all organ systems.  Therefore, pharmacol. targeting of IL-1β in a variety of clin. inflammatory conditions may provide symptomatic relief or profound disease modification.  The discovery of proteolytic processing of the inactive pro-IL-1β to mature, active and secreted IL-1β by the inflammasome/caspase 1 complex entailed a no. of drug discovery programs aiming towards low mol. wt. inhibitors across the Pharma industry.  Approved and marketed IL-1 pathway drugs today, however, are protein-based injectable drugs ("biologics") targeting either IL-1β, or the IL-1 receptor.  Canakinumab is a human monoclonal antibody that binds human IL-1β with high affinity and neutralizes its biol. activity.  This review describes the unique preclin. and clin. development journey of canakinumab starting from a rare genetic autoinflammatory disease and a systemic juvenile form of arthritis to further rare monogenetic periodic fever syndromes, and leading to non-orphan diseases, such as gout, myocardial infarction, and lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjXoqa7Hy42LVg90H21EOLACvtfcHk0liLH-cW51bF9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFylu78%253D&md5=6957795b40e29c715f423e6ac178bda0</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.01.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.01.023%26sid%3Dliteratum%253Aachs%26aulast%3DGram%26aufirst%3DH.%26atitle%3DThe%2520Long%2520and%2520Winding%2520Road%2520in%2520Pharmaceutical%2520Development%2520of%2520Canakinumab%2520from%2520Rare%2520Genetic%2520Autoinflammatory%2520Syndromes%2520to%2520Myocardial%2520Infarction%2520and%2520Cancer%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D154%26spage%3D104139%26doi%3D10.1016%2Fj.phrs.2019.01.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ridker, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFadyen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballantyne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastelein, J. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1707914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa1707914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28845751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1119-1131&author=P.+M.+Ridkerauthor=B.+M.+Everettauthor=T.+Thurenauthor=J.+G.+MacFadyenauthor=W.+H.+Changauthor=C.+Ballantyneauthor=F.+Fonsecaauthor=J.+Nicolauauthor=W.+Koenigauthor=S.+D.+Ankerauthor=J.+J.+P.+Kasteleinauthor=J.+H.+Cornel&title=Antiinflammatory+Therapy+with+Canakinumab+for+Atherosclerotic+Disease&doi=10.1056%2FNEJMoa1707914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Antiinflammatory therapy with canakinumab for atherosclerotic disease</span></div><div class="casAuthors">Ridker, P. M.; Everett, B. M.; Thuren, T.; MacFadyen, J. G.; Chang, W. H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S. D.; Kastelein, J. J. P.; Cornel, J. H.; Pais, P.; Pella, D.; Genest, J.; Cifkova, R.; Lorenzatti, A.; Forster, T.; Kobalava, Z.; Vida-Simiti, L.; Flather, M.; Shimokawa, H.; Ogawa, H.; Dellborg, M.; Rossi, P. R. F.; Troquay, R. P. T.; Libby, P.; Glynn, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1119-1131</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Exptl. and clin. data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease.  Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. methods We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per L.  The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered s.c. every 3 mo) with placebo.  The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. results At 48 mo, the median redn. from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group.  There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). conclusions Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 mo led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwYFxFQ_i_LVg90H21EOLACvtfcHk0liLH-cW51bF9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqurnE&md5=50570e06cca89d8b3f654333047f223d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1707914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1707914%26sid%3Dliteratum%253Aachs%26aulast%3DRidker%26aufirst%3DP.%2BM.%26aulast%3DEverett%26aufirst%3DB.%2BM.%26aulast%3DThuren%26aufirst%3DT.%26aulast%3DMacFadyen%26aufirst%3DJ.%2BG.%26aulast%3DChang%26aufirst%3DW.%2BH.%26aulast%3DBallantyne%26aufirst%3DC.%26aulast%3DFonseca%26aufirst%3DF.%26aulast%3DNicolau%26aufirst%3DJ.%26aulast%3DKoenig%26aufirst%3DW.%26aulast%3DAnker%26aufirst%3DS.%2BD.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%2BP.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26atitle%3DAntiinflammatory%2520Therapy%2520with%2520Canakinumab%2520for%2520Atherosclerotic%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1119%26epage%3D1131%26doi%3D10.1056%2FNEJMoa1707914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lachmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kone-Paut, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuemmerle-Deschner, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachulla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitton, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P. N.</span></span> <span> </span><span class="NLM_article-title">Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2416</span>– <span class="NLM_lpage">2425</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0810787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa0810787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19494217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=2416-2425&author=H.+J.+Lachmannauthor=I.+Kone-Pautauthor=J.+B.+Kuemmerle-Deschnerauthor=K.+S.+Leslieauthor=E.+Hachullaauthor=P.+Quartierauthor=X.+Gittonauthor=A.+Widmerauthor=N.+Patelauthor=P.+N.+Hawkins&title=Use+of+Canakinumab+in+the+Cryopyrin-Associated+Periodic+Syndrome&doi=10.1056%2FNEJMoa0810787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Use of canakinumab in the cryopyrin-associated periodic syndrome</span></div><div class="casAuthors">Lachmann, Helen J.; Kone-Paut, Isabelle; Kuemmerle-Deschner, Jasmin B.; Leslie, Kieron S.; Hachulla, Eric; Quartier, Pierre; Gitton, Xavier; Widmer, Albert; Patel, Neha; Hawkins, Philip N.; Madhoo, S.; Berthelot, J.-M.; Jorgensen, C.; Morell-Dubois, S.; Huriez, Claude; Mouy, R.; Marie, I.; Lacassagne, S.; Chaturvedi, R.; Vargas, C.; Block, J. A.; Smith, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2416-2425</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The cryopyrin-assocd. periodic syndrome (CAPS) is a rare inherited inflammatory disease assocd. with overprodn. of interleukin-1.  Canakinumab is a human anti-interleukin-1β monoclonal antibody.  We performed a three-part, 48-wk, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS.  In part 1, 35 patients received 150 mg of canakinumab s.c.  Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 wk for up to 24 wk.  After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab.  We evaluated therapeutic responses using disease-activity scores and anal. of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA).  In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab.  Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission.  Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P < 0.001).  At the end of part 2, median CRP and SAA values were normal (<10 mg per L for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P < 0.001 and P = 0.002, resp.).  Of the 31 patients, 28 (90%) completed part 3 in remission.  In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P = 0.03).  Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo.  Treatment with s.c. canakinumab once every 8 wk was assocd. with a rapid remission of symptoms in most patients with CAPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaTYjoHz3f7LVg90H21EOLACvtfcHk0liLH-cW51bF9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrk%253D&md5=38f4d5367e2d00843c0c4204edd6aada</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810787%26sid%3Dliteratum%253Aachs%26aulast%3DLachmann%26aufirst%3DH.%2BJ.%26aulast%3DKone-Paut%26aufirst%3DI.%26aulast%3DKuemmerle-Deschner%26aufirst%3DJ.%2BB.%26aulast%3DLeslie%26aufirst%3DK.%2BS.%26aulast%3DHachulla%26aufirst%3DE.%26aulast%3DQuartier%26aufirst%3DP.%26aulast%3DGitton%26aufirst%3DX.%26aulast%3DWidmer%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DHawkins%26aufirst%3DP.%2BN.%26atitle%3DUse%2520of%2520Canakinumab%2520in%2520the%2520Cryopyrin-Associated%2520Periodic%2520Syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D2416%26epage%3D2425%26doi%3D10.1056%2FNEJMoa0810787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">FDA</span>. <span> </span><span class="NLM_article-title">Highlights of Prescribing Information:
Ilaris (Canakinumab)</span>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf</a> (accessed Jun 9, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=FDA&title=Highlights+of+Prescribing+Information%3A%0AIlaris+%28Canakinumab%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DHighlights%2520of%2520Prescribing%2520Information%253A%250AIlaris%2520%2528Canakinumab%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavelka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruyère, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeb, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martel-Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfort, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reginster, J.-Y.</span></span> <span> </span><span class="NLM_article-title">Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1007/s40266-016-0347-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1007%2Fs40266-016-0347-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26849131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28Xitlyntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=75-85&author=K.+Pavelkaauthor=O.+Bruy%C3%A8reauthor=C.+Cooperauthor=J.+A.+Kanisauthor=B.+F.+Leebauthor=E.+Maheuauthor=J.+Martel-Pelletierauthor=J.+Monfortauthor=J.-P.+Pelletierauthor=R.+Rizzoliauthor=J.-Y.+Reginster&title=Diacerein%3A+Benefits%2C+Risks+and+Place+in+the+Management+of+Osteoarthritis.+An+Opinion-Based+Report+from+the+ESCEO&doi=10.1007%2Fs40266-016-0347-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO</span></div><div class="casAuthors">Pavelka, Karel; Bruyere, Olivier; Cooper, Cyrus; Kanis, John A.; Leeb, Burkhard F.; Maheu, Emmanuel; Martel-Pelletier, Johanne; Monfort, Jordi; Pelletier, Jean-Pierre; Rizzoli, Rene; Reginster, Jean-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane.  It has also recently been shown to have protective effects against subchondral bone remodelling.  Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clin. and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA.  Based on a literature review of clin. trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol.  Addnl., diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped.  The use of diacerein is assocd. with common gastrointestinal disorders such as soft stools and diarrhea, common mild skin reactions, and, uncommonly, hepatobiliary disorders.  However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions.  Therefore, the ESCEO concludes that the benefit-risk balance of diacerein remains pos. in the symptomatic treatment of hip and knee osteoarthritis.  Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacol. background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcgbKEWuefh7Vg90H21EOLACvtfcHk0li7jc9Dt5PukA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xitlyntbo%253D&md5=698383aa62dacd67da31fed815948cab</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs40266-016-0347-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40266-016-0347-4%26sid%3Dliteratum%253Aachs%26aulast%3DPavelka%26aufirst%3DK.%26aulast%3DBruy%25C3%25A8re%26aufirst%3DO.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKanis%26aufirst%3DJ.%2BA.%26aulast%3DLeeb%26aufirst%3DB.%2BF.%26aulast%3DMaheu%26aufirst%3DE.%26aulast%3DMartel-Pelletier%26aufirst%3DJ.%26aulast%3DMonfort%26aufirst%3DJ.%26aulast%3DPelletier%26aufirst%3DJ.-P.%26aulast%3DRizzoli%26aufirst%3DR.%26aulast%3DReginster%26aufirst%3DJ.-Y.%26atitle%3DDiacerein%253A%2520Benefits%252C%2520Risks%2520and%2520Place%2520in%2520the%2520Management%2520of%2520Osteoarthritis.%2520An%2520Opinion-Based%2520Report%2520from%2520the%2520ESCEO%26jtitle%3DDrugs%2520Aging%26date%3D2016%26volume%3D33%26spage%3D75%26epage%3D85%26doi%3D10.1007%2Fs40266-016-0347-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">TWi
Biotechnology</span> <span> </span><span class="NLM_article-title">Announces Last
Patient Enrolled in Phase 2 Proof-of-
Concept Study of AC-203 for Treatment of Epidermolysis Bullosa</span>. <a href="https://www.twibiotech.com/website/news_detail/46" class="extLink">https://www.twibiotech.com/website/news_detail/46</a> (accessed Jun 9, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=TWi%0ABiotechnology&title=Announces+Last%0APatient+Enrolled+in+Phase+2+Proof-of-%0AConcept+Study+of+AC-203+for+Treatment+of+Epidermolysis+Bullosa"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DAnnounces%2520Last%250APatient%2520Enrolled%2520in%2520Phase%25202%2520Proof-of-%250AConcept%2520Study%2520of%2520AC-203%2520for%2520Treatment%2520of%2520Epidermolysis%2520Bullosa%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-K.</span>; <span class="NLM_string-name">Lee, J.-Y.</span>; <span class="NLM_string-name">Lu, W.-S.</span></span> <span> </span><span class="NLM_article-title">Diacerein or Its Analogs for Inhibiting Expression of ASC, NLRP3, and/or Formation of NLRP3 Inflammasome Complex</span>. WO <span class="NLM_patent">2017/031161</span>, Feb 23, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.-K.+Chen&author=J.-Y.+Lee&author=W.-S.+Lu&title=Diacerein+or+Its+Analogs+for+Inhibiting+Expression+of+ASC%2C+NLRP3%2C+and%2For+Formation+of+NLRP3+Inflammasome+Complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.-K.%26atitle%3DDiacerein%2520or%2520Its%2520Analogs%2520for%2520Inhibiting%2520Expression%2520of%2520ASC%252C%2520NLRP3%252C%2520and%252For%2520Formation%2520of%2520NLRP3%2520Inflammasome%2520Complex%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. A.</span></span> <span> </span><span class="NLM_article-title">Anakinra for Rheumatoid Arthritis: A Systematic Review</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1118</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.3899/jrheum.090074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3899%2Fjrheum.090074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19447938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlSjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=1118-1125&issue=6&author=M.+Mertensauthor=J.+A.+Singh&title=Anakinra+for+Rheumatoid+Arthritis%3A+A+Systematic+Review&doi=10.3899%2Fjrheum.090074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Anakinra for rheumatoid arthritis: a systematic review</span></div><div class="casAuthors">Mertens, Marty; Singh, Jasvinder A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1118-1125</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  Objective. To perform a systematic review of clin. effectiveness and safety of anakinra in rheumatoid arthritis (RA).  Methods. We searched Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, and the ref. lists of included articles for randomized controlled trials comparing anakinra to placebo in adults with RA.  Results. Five trials involving 2846 patients, 781 randomized to placebo and 2065 to anakinra, were included.  There was a significant improvement in the no. of participants achieving American College of Rheumatol. (ACR)20 (38% vs 23%) treated with anakinra 50-150 mg daily vs. placebo after 24 wk.  ACR50 (18% vs 7%), ACR70 (7% vs 2%), Health Assessment Questionnaire, visual analog scale for pain, Larsen radiog. scores, and erythrocyte sedimentation rate all demonstrated significant improvement with anakinra vs. placebo as well.  There were no statistically significant differences noted in the no. of withdrawals, deaths, adverse events (total and serious), and infections (total and serious).  An increase in incidence of serious infections in anakinra vs. the placebo group (1.8% vs 0.6%) was noted that may be clin. significant.  Injection site reactions were significantly increased, occurring in 71% of anakinra vs. 28% of placebo group.  Conclusion. Anakinra is a relatively safe and modestly efficacious biol. therapy for RA.  More studies are needed to evaluate safety and efficacy, esp. in comparison to other therapies, and adverse event data for the longterm use of anakinra have yet to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7fgEptt9HDrVg90H21EOLACvtfcHk0lh34TrQeodjzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlSjt74%253D&md5=9a5a3085105c6e0cbe0c6a8a6eeafb71</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.090074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.090074%26sid%3Dliteratum%253Aachs%26aulast%3DMertens%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DJ.%2BA.%26atitle%3DAnakinra%2520for%2520Rheumatoid%2520Arthritis%253A%2520A%2520Systematic%2520Review%26jtitle%3DJ.%2520Rheumatol.%26date%3D2009%26volume%3D36%26issue%3D6%26spage%3D1118%26epage%3D1125%26doi%3D10.3899%2Fjrheum.090074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramírez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cañete, J. D.</span></span> <span> </span><span class="NLM_article-title">Anakinra for Treatmnt of Rheumatoid Arthritis: a Safety Evaluation</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1080/14740338.2018.1486819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1080%2F14740338.2018.1486819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29883212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=727-732&issue=7&author=J.+Ram%C3%ADrezauthor=J.+D.+Ca%C3%B1ete&title=Anakinra+for+Treatmnt+of+Rheumatoid+Arthritis%3A+a+Safety+Evaluation&doi=10.1080%2F14740338.2018.1486819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Anakinra for the treatment of rheumatoid arthritis: a safety evaluation</span></div><div class="casAuthors">Ramirez, Julio; Canete, Juan D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">727-732</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The anti-interleukin-1 receptor antagonist, anakinra, was approved for the treatment of rheumatoid arthritis (RA) more than 12 years ago.  However, its adverse effects are not well known.: We review the safety profile of anakinra, analyzing clin. trials, observational studies, and registry data.: Due to its lower efficacy compared with other biol. therapies approved for RA and its daily s.c. administration, anakinra is used only marginally for the treatment of RA.  This has limited the experience with this drug in RA, with a lack of data from long-term observational studies or registries.  From the five clin. trials performed, and given the unfeasibility of developing new studies of anakinra in RA, it may be concluded that site injection reactions, infections at higher doses (>100 mg), and immunogenicity are the most frequent adverse events related to anakinra administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolPB0ES8P-NrVg90H21EOLACvtfcHk0lh34TrQeodjzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrtr%252FJ&md5=39c1d67960e538bd77b82f3f2310c704</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1080%2F14740338.2018.1486819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2018.1486819%26sid%3Dliteratum%253Aachs%26aulast%3DRam%25C3%25ADrez%26aufirst%3DJ.%26aulast%3DCa%25C3%25B1ete%26aufirst%3DJ.%2BD.%26atitle%3DAnakinra%2520for%2520Treatmnt%2520of%2520Rheumatoid%2520Arthritis%253A%2520a%2520Safety%2520Evaluation%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2018%26volume%3D17%26issue%3D7%26spage%3D727%26epage%3D732%26doi%3D10.1080%2F14740338.2018.1486819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuemmerle-Deschner, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittkowski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrrell, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koetter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ummenhofer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koitschev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialkowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benseler, S. M.</span></span> <span> </span><span class="NLM_article-title">Treatment of Muckle-Wells Syndrome: Analysis of Two IL-1-Blocking Regimens</span>. <i>Arthritis Research & Therapy</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">R64</span>, <span class="refDoi"> DOI: 10.1186/ar4237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1186%2Far4237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23718630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlaqtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=R64&author=J.+B.+Kuemmerle-Deschnerauthor=H.+Wittkowskiauthor=P.+N.+Tyrrellauthor=I.+Koetterauthor=P.+Lohseauthor=K.+Ummenhoferauthor=F.+Reessauthor=S.+Hansmannauthor=A.+Koitschevauthor=C.+Deuterauthor=A.+Bialkowskiauthor=D.+Foellauthor=S.+M.+Benseler&title=Treatment+of+Muckle-Wells+Syndrome%3A+Analysis+of+Two+IL-1-Blocking+Regimens&doi=10.1186%2Far4237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens</span></div><div class="casAuthors">Kuemmerle-Deschner, Jasmin B.; Wittkowski, Helmut; Tyrrell, Pascal N.; Koetter, Ina; Lohse, Peter; Ummenhofer, Katharina; Reess, Fabian; Hansmann, Sandra; Koitschev, Assen; Deuter, Christoph; Bialkowski, Anja; Foell, Dirk; Benseler, Susanne M.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">R64</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Objectives: Muckle-Wells syndrome (MWS) is an autoinflammatory disease characterized by excessive interleukin-1 (IL-1) release, resulting in recurrent fevers, sensorineural hearing loss and amyloidosis.  IL-1 inhibition with anakinra, an IL-1 receptor antagonist, improves clin. symptoms and inflammatory markers.  Subclin. disease activity is commonly obsd.  Canakinumab, a fully human IgG1 anti-IL-1β monoclonal antibody, can abolish excess IL-1β.  The study aim was to analyze the efficacy and safety of these two anti-IL-1 therapies.  Methods: Two cohorts of patients with severe MWS and confirmed NLRP3 mutation were treated with anakinra and/or canakinumab.  Clin. and lab. features including ESR, CRP, SAA and the neutrophil marker S100A12 were detd. serially.  Disease activity was captured by MWS disease activity scores (MWS-DAS).  Remission was defined as MWS-DAS ≤5 plus normal CRP and SAA.  Treatment efficacy and safety were analyzed.  Results: The study included 12 anakinra- and 14 canakinumab-treated patients; the median age was 33.5 years (3.0 years to 72.0 years); 57% were female patients.  Both treatment regimens led to a significant redn. of clin. disease activity and inflammatory markers.  At last follow-up, 75% of anakinra-treated and 93% of canakinumab-treated patients achieved remission.  During follow-up, S100A12 levels mirrored recurrence of disease activity.  Both treatment regimens had favorable safety profiles.  Conclusions: IL-1 blockade is an effective and safe treatment in MWS patients.  MWS-DAS in combination with MWS inflammatory markers provides an excellent monitoring tool set.  Canakinumab led to a sustained control of disease activity even after secondary failure of anakinra therapy.  S100A12 may be a sensitive marker to detect subclin. disease activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRqKjXvEjbr7Vg90H21EOLACvtfcHk0lh34TrQeodjzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlaqtrfK&md5=7436cbbe87b2229b6710a378e6557b76</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1186%2Far4237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far4237%26sid%3Dliteratum%253Aachs%26aulast%3DKuemmerle-Deschner%26aufirst%3DJ.%2BB.%26aulast%3DWittkowski%26aufirst%3DH.%26aulast%3DTyrrell%26aufirst%3DP.%2BN.%26aulast%3DKoetter%26aufirst%3DI.%26aulast%3DLohse%26aufirst%3DP.%26aulast%3DUmmenhofer%26aufirst%3DK.%26aulast%3DReess%26aufirst%3DF.%26aulast%3DHansmann%26aufirst%3DS.%26aulast%3DKoitschev%26aufirst%3DA.%26aulast%3DDeuter%26aufirst%3DC.%26aulast%3DBialkowski%26aufirst%3DA.%26aulast%3DFoell%26aufirst%3DD.%26aulast%3DBenseler%26aufirst%3DS.%2BM.%26atitle%3DTreatment%2520of%2520Muckle-Wells%2520Syndrome%253A%2520Analysis%2520of%2520Two%2520IL-1-Blocking%2520Regimens%26jtitle%3DArthritis%2520Research%2520%2526%2520Therapy%26date%3D2013%26volume%3D15%26spage%3DR64%26doi%3D10.1186%2Far4237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baughman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of Anakinra in Subjects with Different Levels of Renal Function</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(03)00094-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS0009-9236%2803%2900094-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=12844139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFGhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2003&pages=85-94&issue=1&author=B.-B.+Yangauthor=S.+Baughmanauthor=J.+T.+Sullivan&title=Pharmacokinetics+of+Anakinra+in+Subjects+with+Different+Levels+of+Renal+Function&doi=10.1016%2FS0009-9236%2803%2900094-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of anakinra in subjects with different levels of renal function</span></div><div class="casAuthors">Yang, Bing-Bing; Baughman, Sharon; Sullivan, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Our objective was to assess the effects of decreased renal function and dialysis on anakinra pharmacokinetics.  In 2 sep. studies anakinra (1 mg/kg) was given i.v. to 12 healthy subjects and 20 subjects with end-stage renal disease undergoing dialysis.  In a third study anakinra (100 mg) was given s.c. to 30 subjects who had been assigned to 5 groups according to renal function, as follows: normal (creatinine clearance [CLcr] >80 mL/min), mildly impaired (CLcr = 50-80 mL/min), moderately impaired (CLcr = 30-49 mL/min), severely impaired (CLcr <30 mL/min), and end-stage renal disease undergoing hemodialysis.  Plasma samples were collected up to 96 h after dosing for anakinra measurement by enzyme-linked immunoassay.  The mean plasma clearance (CL) of anakinra after i.v. administration was reduced from 137 ± 21 mL/min in the healthy subjects to approx. 20 mL/min for the subjects with end-stage renal disease (P < .0001).  The removal of anakinra by dialysis was less than 2.5% of the dose administered.  Compared with mean anakinra clearance (CL/F) after s.c. administration in the group with normal renal function (170 ± 37 mL/min), CL/F was reduced by 16% in the mildly impaired group (142 ± 59 mL/min), by 50% in the moderately impaired group (84.5 ± 24.7 mL/min, P < .05), by 70% in the severely impaired group (51.5 ± 8.4 mL/min, P < .05), and by 75% in the group with end-stage renal disease (42.7 ± 4.7 mL/min, P < .05).  A significant correlation between anakinra CL/F and CLcr was obsd. [log(CL/F) = 1.65 + 0.0062 · CLcr; r2 = 0.718].  Anakinra is predominantly cleared renally in humans; the plasma clearance of anakinra decreased with decreasing renal function.  The dialysis process has a minimal effect on the removal of anakinra.  Our results suggest that a dose or schedule adjustment is indicated for persons with severe renal impairment or end-stage renal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojtjGG3lfq-LVg90H21EOLACvtfcHk0lgBqRPy7chWGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFGhsbo%253D&md5=8a84eaa96226bdd9af0634892ab58e7b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2803%2900094-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252803%252900094-8%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.-B.%26aulast%3DBaughman%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DJ.%2BT.%26atitle%3DPharmacokinetics%2520of%2520Anakinra%2520in%2520Subjects%2520with%2520Different%2520Levels%2520of%2520Renal%2520Function%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2003%26volume%3D74%26issue%3D1%26spage%3D85%26epage%3D94%26doi%3D10.1016%2FS0009-9236%2803%2900094-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannenbaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rordorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gram, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody</span>. <i>Clinical Pharmacokinetics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">e1</span>– <span class="NLM_lpage">e18</span>, <span class="refDoi"> DOI: 10.2165/11599820-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.2165%2F11599820-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=22550964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCmu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=e1-e18&author=A.+Chakrabortyauthor=S.+Tannenbaumauthor=C.+Rordorfauthor=P.+J.+Loweauthor=D.+Flochauthor=H.+Gramauthor=S.+Roy&title=Pharmacokinetic+and+Pharmacodynamic+Properties+of+Canakinumab%2C+a+Human+Anti-Interleukin-1%CE%B2+Monoclonal+Antibody&doi=10.2165%2F11599820-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody</span></div><div class="casAuthors">Chakraborty, Abhijit; Tannenbaum, Stacey; Rordorf, Christiane; Lowe, Philip J.; Floch, David; Gram, Hermann; Roy, Sandip</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1-e18</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Canakinumab is a high-affinity human monoclonal anti-interleukin-1β (IL-1β) antibody of the IgG1/κ isotype designed to bind and neutralize the activity of human IL-1β, a pro-inflammatory cytokine.  Canakinumab is currently being investigated on the premise that it would exert anti-inflammatory effects on a broad spectrum of diseases, driven by IL-1β.  This paper focuses on the anal. of the pharmacokinetic and pharmacodynamic data from the canakinumab clin. development program, describing results from the recently approved indication for the treatment of cryopyrin-assocd. periodic syndromes (CAPS) under the trade name ILARIS, as well as diseases such as rheumatoid arthritis, asthma and psoriasis.  Canakinumab displays pharmacokinetic properties typical of an IgG1 antibody.  In a CAPS patient weighing 70 kg, slow serum clearance (0.174 L/day) was obsd. with a low total vol. of distribution at steady state (6.0 L), resulting in a long elimination half-life of 26 days.  The s.c. abs. bioavailability was high (70%).  Canakinumab displays linear pharmacokinetics, with a dose-proportional increase in exposure and no evidence of accelerated clearance or time-dependent changes in pharmacokinetics following repeated administration was obsd.  The pharmacokinetics of canakinumab in various diseases (e.g. CAPS, rheumatoid arthritis, psoriasis or asthma) are comparable to those in healthy individuals.  No sex- or age-related pharmacokinetic differences were obsd. after correction for body wt.  An increase in total IL-1β was obsd. in both healthy subjects and all patient populations following canakinumab dosing, reflecting the ability of canakinumab to bind circulating IL-1β.  The kinetics of total IL-i.p. along with the pharmacokinetics of canakinumab were characterized by a population-based pharmacokinetic-binding model, where the apparent in vivo dissocn. const., signifying binding affinity of canakinumab to circulating IL-1β, was estd. at 1.07±0.173 nmol/L in CAPS patients.  During development of canakinumab a cell line change was introduced.  Pharmacokinetic characterization was performed in both animals and humans to assure that this manufg. change did not affect the pharmacokinetic/pharmacodynamic properties of canakinumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRcbP1lbqGe7Vg90H21EOLACvtfcHk0lgBqRPy7chWGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCmu7jL&md5=781a030dad736dea73fe542428185310</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2165%2F11599820-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11599820-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DTannenbaum%26aufirst%3DS.%26aulast%3DRordorf%26aufirst%3DC.%26aulast%3DLowe%26aufirst%3DP.%2BJ.%26aulast%3DFloch%26aufirst%3DD.%26aulast%3DGram%26aufirst%3DH.%26aulast%3DRoy%26aufirst%3DS.%26atitle%3DPharmacokinetic%2520and%2520Pharmacodynamic%2520Properties%2520of%2520Canakinumab%252C%2520a%2520Human%2520Anti-Interleukin-1%25CE%25B2%2520Monoclonal%2520Antibody%26jtitle%3DClinical%2520Pharmacokinetics%26date%3D2012%26volume%3D51%26spage%3De1%26epage%3De18%26doi%3D10.2165%2F11599820-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lium, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newmark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, P.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy with Etanercept and Anakinra in the Treatment of Patients with Rheumatoid Arthritis who have been Treated Unsuccessfully with Methotrexate</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1412</span>– <span class="NLM_lpage">1419</span>, <span class="refDoi"> DOI: 10.1002/art.20221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fart.20221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=15146410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=1412-1419&issue=5&author=M.+C.+Genoveseauthor=S.+Cohenauthor=L.+Morelandauthor=D.+Liumauthor=S.+Robbinsauthor=R.+Newmarkauthor=P.+Bekker&title=Combination+Therapy+with+Etanercept+and+Anakinra+in+the+Treatment+of+Patients+with+Rheumatoid+Arthritis+who+have+been+Treated+Unsuccessfully+with+Methotrexate&doi=10.1002%2Fart.20221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate</span></div><div class="casAuthors">Genovese, Mark C.; Cohen, Stanley; Moreland, Larry; Lium, Deborah; Robbins, Sean; Newmark, Richard; Bekker, Pirow; Block, S.; Borofsky, M.; Box, J.; Brasington, R.; Brodsky, A.; Bulpitt, K.; Caldwell, J.; Coalson, R.; Cush, J.; Deadhar, A.; Divittorio, G.; Fishman, A.; Greenwald, M.; Hurd, E.; Kay, J.; Kavanaugh, A.; Kohen, M.; Maestrello, S.; Malamet, R.; Mandel, D.; Martin, R.; Mathews, S.; Pearson, M.; Poiley, J.; Romano, T.; Roth, S.; Rutstein, J.; Schiff, M.; Schweitz, M.; Shergy, W.; Staley, H.; Sultany, G.; Surbeck, W.; Taborn, J.; Valen, P.; Valente, R.; Wallace, D.; Weidmann, C.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1412-1419</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The aim was to det. the potential for additive or synergistic effects of combination therapy with the selective anti-tumor necrosis factor α agent etanercept and the anti-interleukin-1 agent anakinra.  Two hundred forty-four patients in whom rheumatoid arthritis (RA) was active despite methotrexate therapy were treated with s.c. etanercept only (25 mg twice weekly), full-dosage etanercept (25 mg twice weekly) plus anakinra (100 mg/day), or half-dosage etanercept (25 mg once weekly) plus anakinra (100 mg/day) for 6 mo in a double-blind study at 41 centers in the US.  Patients had never previously received anticytokine therapy.  Patient response was measured with the American College of Rheumatol. (ACR) core set criteria, a health-related quality-of-life questionnaire, and the Disease Activity Score.  Safety was assessed by the no. of adverse events and clin. lab. values.  Plasma concns. of both agents and antibody formation against both agents were also assessed.  Combination therapy with etanercept plus anakinra provided no treatment benefit over etanercept alone, regardless of the regimen, but was assocd. with an increased safety risk.  Thirty-one percent of the patients treated with full-dosage etanercept plus anakinra achieved an ACR 50% response, compared with 41% of the patients treated with etanercept only.  This result was not statistically significant (P = 0.914).  The incidence of serious infections (0% for etanercept alone, 3.7-7.4% for combination therapy), injection-site reactions, and neutropenia was increased with combination therapy.  Combination therapy had no effect on the pharmacokinetics or immunogenicity of either agent.  Combination therapy with etanercept and anakinra provides no added benefit and an increased risk compared with etanercept alone and is not recommended for the treatment of patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotcT2gVGZY8rVg90H21EOLACvtfcHk0ligPD0dKWecYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFykurw%253D&md5=c465011f8a6f2dfd1bd7bc3a0477e51a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fart.20221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.20221%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DMoreland%26aufirst%3DL.%26aulast%3DLium%26aufirst%3DD.%26aulast%3DRobbins%26aufirst%3DS.%26aulast%3DNewmark%26aufirst%3DR.%26aulast%3DBekker%26aufirst%3DP.%26atitle%3DCombination%2520Therapy%2520with%2520Etanercept%2520and%2520Anakinra%2520in%2520the%2520Treatment%2520of%2520Patients%2520with%2520Rheumatoid%2520Arthritis%2520who%2520have%2520been%2520Treated%2520Unsuccessfully%2520with%2520Methotrexate%26jtitle%3DArthritis%2520Rheum.%26date%3D2004%26volume%3D50%26issue%3D5%26spage%3D1412%26epage%3D1419%26doi%3D10.1002%2Fart.20221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRock, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRock, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizet, V.</span></span> <span> </span><span class="NLM_article-title">IL-1β is an Innate Immune Sensor of Microbial Proteolysis</span>. <i>Science Immunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>), <span class="NLM_elocation-id">eaah3539</span> <span class="refDoi"> DOI: 10.1126/sciimmunol.aah3539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fsciimmunol.aah3539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28331908" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&issue=2&author=C.+N.+LaRockauthor=J.+Toddauthor=D.+L.+LaRockauthor=J.+Olsonauthor=A.+J.+O%E2%80%99Donoghueauthor=A.+A.+B.+Robertsonauthor=M.+A.+Cooperauthor=H.+M.+Hoffmanauthor=V.+Nizet&title=IL-1%CE%B2+is+an+Innate+Immune+Sensor+of+Microbial+Proteolysis&doi=10.1126%2Fsciimmunol.aah3539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1126%2Fsciimmunol.aah3539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciimmunol.aah3539%26sid%3Dliteratum%253Aachs%26aulast%3DLaRock%26aufirst%3DC.%2BN.%26aulast%3DTodd%26aufirst%3DJ.%26aulast%3DLaRock%26aufirst%3DD.%2BL.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%2BJ.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DHoffman%26aufirst%3DH.%2BM.%26aulast%3DNizet%26aufirst%3DV.%26atitle%3DIL-1%25CE%25B2%2520is%2520an%2520Innate%2520Immune%2520Sensor%2520of%2520Microbial%2520Proteolysis%26jtitle%3DScience%2520Immunology%26date%3D2016%26volume%3D1%26issue%3D2%26doi%3D10.1126%2Fsciimmunol.aah3539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span> <span> </span><span class="NLM_article-title">Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19</span>. <i>Frontiers in Immunology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.01021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3389%2Ffimmu.2020.01021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32038653" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1-5&author=A.+Shah&title=Novel+Coronavirus-Induced+NLRP3+Inflammasome+Activation%3A+A+Potential+Drug+Target+in+the+Treatment+of+COVID-19&doi=10.3389%2Ffimmu.2020.01021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.01021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.01021%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DA.%26atitle%3DNovel%2520Coronavirus-Induced%2520NLRP3%2520Inflammasome%2520Activation%253A%2520A%2520Potential%2520Drug%2520Target%2520in%2520the%2520Treatment%2520of%2520COVID-19%26jtitle%3DFrontiers%2520in%2520Immunology%26date%3D2020%26volume%3D11%26spage%3D1%26epage%3D5%26doi%3D10.3389%2Ffimmu.2020.01021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campochiaro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della-Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canetti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oltolini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglioni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassan Din, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boffini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomelleri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovere-Querini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Lucca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinenghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresoldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zangrillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpellini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagna, L.</span></span> <span> </span><span class="NLM_article-title">Interleukin-1 Blockade with High-Dose Anakinra in Patients with COVID-19, Acute Respiratory Distress Syndrome, and Hyperinflammation: A Retrospective Cohort Study</span>. <i>Lancet Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">E325</span>– <span class="NLM_lpage">E331</span>, <span class="refDoi"> DOI: 10.1016/S2665-9913(20)30127-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930127-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32501454" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=E325-E331&issue=6&author=G.+Cavalliauthor=G.+De+Lucaauthor=C.+Campochiaroauthor=E.+Della-Torreauthor=M.+Ripaauthor=D.+Canettiauthor=C.+Oltoliniauthor=B.+Castiglioniauthor=C.+Tassan+Dinauthor=N.+Boffiniauthor=A.+Tomelleriauthor=N.+Farinaauthor=A.+Ruggeriauthor=P.+Rovere-Queriniauthor=G.+Di+Luccaauthor=S.+Martinenghiauthor=R.+Scottiauthor=M.+Tresoldiauthor=F.+Ciceriauthor=G.+Landoniauthor=A.+Zangrilloauthor=P.+Scarpelliniauthor=L.+Dagna&title=Interleukin-1+Blockade+with+High-Dose+Anakinra+in+Patients+with+COVID-19%2C+Acute+Respiratory+Distress+Syndrome%2C+and+Hyperinflammation%3A+A+Retrospective+Cohort+Study&doi=10.1016%2FS2665-9913%2820%2930127-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930127-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930127-2%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DG.%26aulast%3DDe%2BLuca%26aufirst%3DG.%26aulast%3DCampochiaro%26aufirst%3DC.%26aulast%3DDella-Torre%26aufirst%3DE.%26aulast%3DRipa%26aufirst%3DM.%26aulast%3DCanetti%26aufirst%3DD.%26aulast%3DOltolini%26aufirst%3DC.%26aulast%3DCastiglioni%26aufirst%3DB.%26aulast%3DTassan%2BDin%26aufirst%3DC.%26aulast%3DBoffini%26aufirst%3DN.%26aulast%3DTomelleri%26aufirst%3DA.%26aulast%3DFarina%26aufirst%3DN.%26aulast%3DRuggeri%26aufirst%3DA.%26aulast%3DRovere-Querini%26aufirst%3DP.%26aulast%3DDi%2BLucca%26aufirst%3DG.%26aulast%3DMartinenghi%26aufirst%3DS.%26aulast%3DScotti%26aufirst%3DR.%26aulast%3DTresoldi%26aufirst%3DM.%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DLandoni%26aufirst%3DG.%26aulast%3DZangrillo%26aufirst%3DA.%26aulast%3DScarpellini%26aufirst%3DP.%26aulast%3DDagna%26aufirst%3DL.%26atitle%3DInterleukin-1%2520Blockade%2520with%2520High-Dose%2520Anakinra%2520in%2520Patients%2520with%2520COVID-19%252C%2520Acute%2520Respiratory%2520Distress%2520Syndrome%252C%2520and%2520Hyperinflammation%253A%2520A%2520Retrospective%2520Cohort%2520Study%26jtitle%3DLancet%2520Rheumatology%26date%3D2020%26volume%3D2%26issue%3D6%26spage%3DE325%26epage%3DE331%26doi%3D10.1016%2FS2665-9913%2820%2930127-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kernan, K. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canna, S. W</span></span> <span> </span><span class="NLM_article-title">Should COVID-19 Take Advice From Rheumatologists</span>. <i>Lancet Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">E310</span>– <span class="NLM_lpage">E311</span>, <span class="refDoi"> DOI: 10.1016/S2665-9913(20)30129-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930129-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32501452" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=E310-E311&issue=6&author=K.+F+Kernanauthor=S.+W+Canna&title=Should+COVID-19+Take+Advice+From+Rheumatologists&doi=10.1016%2FS2665-9913%2820%2930129-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930129-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930129-6%26sid%3Dliteratum%253Aachs%26aulast%3DKernan%26aufirst%3DK.%2BF%26aulast%3DCanna%26aufirst%3DS.%2BW%26atitle%3DShould%2520COVID-19%2520Take%2520Advice%2520From%2520Rheumatologists%26jtitle%3DLancet%2520Rheumatology%26date%3D2020%26volume%3D2%26issue%3D6%26spage%3DE310%26epage%3DE311%26doi%3D10.1016%2FS2665-9913%2820%2930129-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Roche’s</span> <span> </span><span class="NLM_article-title">Phase III EMPACTA Study Showed Actemra/RoActemra
Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalised
Patients with COVID-19 Associated Pneumonia</span>. <a href="https://www.roche.com/media/releases/med-cor-2020-09-18.htm" class="extLink">https://www.roche.com/media/releases/med-cor-2020-09-18.htm</a> (accessed Sep 27, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Roche%E2%80%99s&title=Phase+III+EMPACTA+Study+Showed+Actemra%2FRoActemra%0AReduced+the+Likelihood+of+Needing+Mechanical+Ventilation+in+Hospitalised%0APatients+with+COVID-19+Associated+Pneumonia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DPhase%2520III%2520EMPACTA%2520Study%2520Showed%2520Actemra%252FRoActemra%250AReduced%2520the%2520Likelihood%2520of%2520Needing%2520Mechanical%2520Ventilation%2520in%2520Hospitalised%250APatients%2520with%2520COVID-19%2520Associated%2520Pneumonia%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guaraldi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meschiari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzi-Lepri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Gaetano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzzolante, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corradi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaniere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabbi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedeschi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartoletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugioni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrangelo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossarizza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pea, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvarani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussini, C.</span></span> <span> </span><span class="NLM_article-title">Tocilizumab in Patients with Severe COVID-19; a Retrospective Cohort Study</span>. <i>Lancet Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">E474</span>– <span class="NLM_lpage">E484</span>, <span class="refDoi"> DOI: 10.1016/S2665-9913(20)30173-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930173-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32835257" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=E474-E484&issue=8&author=G.+Guaraldiauthor=M.+Meschiariauthor=A.+Cozzi-Lepriauthor=J.+Milicauthor=R.+Tonelliauthor=M.+Menozziauthor=E.+Franceschiniauthor=G.+Cuomoauthor=G.+Orlandoauthor=V.+Borghiauthor=A.+Santoroauthor=M.+Di+Gaetanoauthor=C.+Puzzolanteauthor=F.+Carliauthor=A.+Bediniauthor=L.+Corradiauthor=R.+Fantiniauthor=I.+Castaniereauthor=L.+Tabbiauthor=M.+Girardisauthor=S.+Tedeschiauthor=M.+Giannellaauthor=M.+Bartolettiauthor=R.+Pascaleauthor=G.+Dolciauthor=L.+Brugioniauthor=A.+Pietrangeloauthor=A.+Cossarizzaauthor=F.+Peaauthor=E.+Cliniauthor=C.+Salvaraniauthor=M.+Massariauthor=P.+L.+Vialeauthor=C.+Mussini&title=Tocilizumab+in+Patients+with+Severe+COVID-19%3B+a+Retrospective+Cohort+Study&doi=10.1016%2FS2665-9913%2820%2930173-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930173-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930173-9%26sid%3Dliteratum%253Aachs%26aulast%3DGuaraldi%26aufirst%3DG.%26aulast%3DMeschiari%26aufirst%3DM.%26aulast%3DCozzi-Lepri%26aufirst%3DA.%26aulast%3DMilic%26aufirst%3DJ.%26aulast%3DTonelli%26aufirst%3DR.%26aulast%3DMenozzi%26aufirst%3DM.%26aulast%3DFranceschini%26aufirst%3DE.%26aulast%3DCuomo%26aufirst%3DG.%26aulast%3DOrlando%26aufirst%3DG.%26aulast%3DBorghi%26aufirst%3DV.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DDi%2BGaetano%26aufirst%3DM.%26aulast%3DPuzzolante%26aufirst%3DC.%26aulast%3DCarli%26aufirst%3DF.%26aulast%3DBedini%26aufirst%3DA.%26aulast%3DCorradi%26aufirst%3DL.%26aulast%3DFantini%26aufirst%3DR.%26aulast%3DCastaniere%26aufirst%3DI.%26aulast%3DTabbi%26aufirst%3DL.%26aulast%3DGirardis%26aufirst%3DM.%26aulast%3DTedeschi%26aufirst%3DS.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DBartoletti%26aufirst%3DM.%26aulast%3DPascale%26aufirst%3DR.%26aulast%3DDolci%26aufirst%3DG.%26aulast%3DBrugioni%26aufirst%3DL.%26aulast%3DPietrangelo%26aufirst%3DA.%26aulast%3DCossarizza%26aufirst%3DA.%26aulast%3DPea%26aufirst%3DF.%26aulast%3DClini%26aufirst%3DE.%26aulast%3DSalvarani%26aufirst%3DC.%26aulast%3DMassari%26aufirst%3DM.%26aulast%3DViale%26aufirst%3DP.%2BL.%26aulast%3DMussini%26aufirst%3DC.%26atitle%3DTocilizumab%2520in%2520Patients%2520with%2520Severe%2520COVID-19%253B%2520a%2520Retrospective%2520Cohort%2520Study%26jtitle%3DLancet%2520Rheumatology%26date%3D2020%26volume%3D2%26issue%3D8%26spage%3DE474%26epage%3DE484%26doi%3D10.1016%2FS2665-9913%2820%2930173-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furlow, B.</span></span> <span> </span><span class="NLM_article-title">COVACTA Trial Raises Questions About Tocilizumab’s Benefit in COVID-19</span>. <i>Lancet Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">E592</span>, <span class="refDoi"> DOI: 10.1016/S2665-9913(20)30313-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930313-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32929415" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=E592&issue=10&author=B.+Furlow&title=COVACTA+Trial+Raises+Questions+About+Tocilizumab%E2%80%99s+Benefit+in+COVID-19&doi=10.1016%2FS2665-9913%2820%2930313-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930313-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930313-1%26sid%3Dliteratum%253Aachs%26aulast%3DFurlow%26aufirst%3DB.%26atitle%3DCOVACTA%2520Trial%2520Raises%2520Questions%2520About%2520Tocilizumab%25E2%2580%2599s%2520Benefit%2520in%2520COVID-19%26jtitle%3DLancet%2520Rheumatology%26date%3D2020%26volume%3D2%26issue%3D10%26spage%3DE592%26doi%3D10.1016%2FS2665-9913%2820%2930313-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathinam, V. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span> <span> </span><span class="NLM_article-title">Inflammasome Complexes: Emerging Mechanisms and Effector Functions</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.cell.2016.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27153493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslKitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=792-800&issue=4&author=V.+A.+K.+Rathinamauthor=K.+A.+Fitzgerald&title=Inflammasome+Complexes%3A+Emerging+Mechanisms+and+Effector+Functions&doi=10.1016%2Fj.cell.2016.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammasome Complexes: Emerging Mechanisms and Effector Functions</span></div><div class="casAuthors">Rathinam, Vijay A. K.; Fitzgerald, Katherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">792-800</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Canonical activation of the inflammasome is crit. to promote caspase-1-dependent maturation of the proinflammatory cytokines IL-1β and IL-18, as well as to induce pyroptotic cell death in response to pathogens and endogenous danger signals.  Recent discoveries, however, are beginning to unveil new components of the inflammasome machinery as well as the full spectrum of inflammasome functions, extending their influence beyond canonical functions to regulation of eicosanoid storm, autophagy, and metab.  In addn., the receptor components of the inflammasome can also regulate diverse biol. processes, such as cellular proliferation, gene transcription, and tumorigenesis, all of which are independent of their inflammasome complex-forming capabilities.  Here, we review these recent advances that are shaping our understanding of the complex biol. of the inflammasome and its constituents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThWvwaIho17Vg90H21EOLACvtfcHk0lj0S716o1eZKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslKitrY%253D&md5=f95e0d0bbe9e3c412caaf4b7ed3d9fdd</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DRathinam%26aufirst%3DV.%2BA.%2BK.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26atitle%3DInflammasome%2520Complexes%253A%2520Emerging%2520Mechanisms%2520and%2520Effector%2520Functions%26jtitle%3DCell%26date%3D2016%26volume%3D165%26issue%3D4%26spage%3D792%26epage%3D800%26doi%3D10.1016%2Fj.cell.2016.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GroB, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreier, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ćiković, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodenkamp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Médard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naumann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GroB, O.</span></span> <span> </span><span class="NLM_article-title">The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis and IL-1 Release in the Absence of Caspase-1 Protease Activity</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3846</span>– <span class="NLM_lpage">3859</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2017.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.celrep.2017.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29281832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVeksb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=3846-3859&author=K.+S.+Schneiderauthor=C.+J.+GroBauthor=R.+F.+Dreierauthor=B.+S.+Sallerauthor=R.+Mishraauthor=O.+Gorkaauthor=R.+Heiligauthor=E.+Meunierauthor=M.+S.+Dickauthor=T.+%C4%86ikovi%C4%87author=J.+Sodenkampauthor=G.+M%C3%A9dardauthor=R.+Naumannauthor=J.+Rulandauthor=B.+Kusterauthor=P.+Brozauthor=O.+GroB&title=The+Inflammasome+Drives+GSDMD-Independent+Secondary+Pyroptosis+and+IL-1+Release+in+the+Absence+of+Caspase-1+Protease+Activity&doi=10.1016%2Fj.celrep.2017.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis and IL-1 Release in the Absence of Caspase-1 Protease Activity</span></div><div class="casAuthors">Schneider, Katharina S.; Gross, Christina J.; Dreier, Roland F.; Saller, Benedikt S.; Mishra, Ritu; Gorka, Oliver; Heilig, Rosalie; Meunier, Etienne; Dick, Mathias S.; Cikovic, Tamara; Sodenkamp, Jan; Medard, Guillaume; Naumann, Ronald; Ruland, Juergen; Kuster, Bernhard; Broz, Petr; Gross, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3846-3859</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inflammasomes activate the protease caspase-1, which cleaves interleukin-1β and interleukin-18 to generate the mature cytokines and controls their secretion and a form of inflammatory cell death called pyroptosis.  By generating mice expressing enzymically inactive caspase-1C284A, we provide genetic evidence that caspase-1 protease activity is required for canonical IL-1 secretion, pyroptosis, and inflammasome-mediated immunity.  In caspase-1-deficient cells, caspase-8 can be activated at the inflammasome.  Using mice either lacking the pyroptosis effector gasdermin D (GSDMD) or expressing caspase-1C284A, we found that GSDMD-dependent pyroptosis prevented caspase-8 activation at the inflammasome.  In the absence of GSDMD-dependent pyroptosis, the inflammasome engaged a delayed, alternative form of lytic cell death that was accompanied by the release of large amts. of mature IL-1 and contributed to host protection.  Features of this cell death modality distinguished it from apoptosis, suggesting it may represent a distinct form of pro-inflammatory regulated necrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbq43d0I8bIbVg90H21EOLACvtfcHk0ljFmq4YuYpwrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVeksb%252FE&md5=71fe5e84799fe99f7d56789f147051d4</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DK.%2BS.%26aulast%3DGroB%26aufirst%3DC.%2BJ.%26aulast%3DDreier%26aufirst%3DR.%2BF.%26aulast%3DSaller%26aufirst%3DB.%2BS.%26aulast%3DMishra%26aufirst%3DR.%26aulast%3DGorka%26aufirst%3DO.%26aulast%3DHeilig%26aufirst%3DR.%26aulast%3DMeunier%26aufirst%3DE.%26aulast%3DDick%26aufirst%3DM.%2BS.%26aulast%3D%25C4%2586ikovi%25C4%2587%26aufirst%3DT.%26aulast%3DSodenkamp%26aufirst%3DJ.%26aulast%3DM%25C3%25A9dard%26aufirst%3DG.%26aulast%3DNaumann%26aufirst%3DR.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DBroz%26aufirst%3DP.%26aulast%3DGroB%26aufirst%3DO.%26atitle%3DThe%2520Inflammasome%2520Drives%2520GSDMD-Independent%2520Secondary%2520Pyroptosis%2520and%2520IL-1%2520Release%2520in%2520the%2520Absence%2520of%2520Caspase-1%2520Protease%2520Activity%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D21%26spage%3D3846%26epage%3D3859%26doi%3D10.1016%2Fj.celrep.2017.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ku, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybuck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randle, J.</span></span> <span> </span><span class="NLM_article-title">Selective Interleukin-1β Converting Enzyme (ICE/Caspase-1) Inhibition with Pralnacasan (HMR 3480/VX-740) Reduces Inflammation and Joint Destruction in Murine Type II Collagen-Induced Arthritis (CIA)</span>. <i>Arthritis Rheumatism</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">S241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=11212168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=S241&issue=9&author=G.+Kuauthor=P.+Fordauthor=S.+Raybuckauthor=M.+Hardingauthor=J.+Randle&title=Selective+Interleukin-1%CE%B2+Converting+Enzyme+%28ICE%2FCaspase-1%29+Inhibition+with+Pralnacasan+%28HMR+3480%2FVX-740%29+Reduces+Inflammation+and+Joint+Destruction+in+Murine+Type+II+Collagen-Induced+Arthritis+%28CIA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKu%26aufirst%3DG.%26aulast%3DFord%26aufirst%3DP.%26aulast%3DRaybuck%26aufirst%3DS.%26aulast%3DHarding%26aufirst%3DM.%26aulast%3DRandle%26aufirst%3DJ.%26atitle%3DSelective%2520Interleukin-1%25CE%25B2%2520Converting%2520Enzyme%2520%2528ICE%252FCaspase-1%2529%2520Inhibition%2520with%2520Pralnacasan%2520%2528HMR%25203480%252FVX-740%2529%2520Reduces%2520Inflammation%2520and%2520Joint%2520Destruction%2520in%2520Murine%2520Type%2520II%2520Collagen-Induced%2520Arthritis%2520%2528CIA%2529%26jtitle%3DArthritis%2520Rheumatism%26date%3D2001%26volume%3D44%26issue%3D9%26spage%3DS241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolphi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verzijl, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Kraan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berg, W.</span></span> <span> </span><span class="NLM_article-title">Pralnacasan, an Inhibitor of Interleukin-1 Converting Enzyme, Reduces Joint Damage in Two Murine Models of Osteoarthritis</span>. <i>Osteo Arthritis and Cartilage</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1016/S1063-4584(03)00153-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS1063-4584%2803%2900153-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=13129693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BD3svjsFOhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=738-746&author=K.+Rudolphiauthor=N.+Gerwinauthor=N.+Verzijlauthor=P.+van+der+Kraanauthor=W.+van+den+Berg&title=Pralnacasan%2C+an+Inhibitor+of+Interleukin-1+Converting+Enzyme%2C+Reduces+Joint+Damage+in+Two+Murine+Models+of+Osteoarthritis&doi=10.1016%2FS1063-4584%2803%2900153-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis</span></div><div class="casAuthors">Rudolphi K; Gerwin N; Verzijl N; van der Kraan P; van den Berg W</div><div class="citationInfo"><span class="NLM_cas:title">Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">738-46</span>
        ISSN:<span class="NLM_cas:issn">1063-4584</span>.
    </div><div class="casAbstract">OBJECTIVE:  To study the effect of pralnacasan, the orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE), RU 36384/VRT-18858, on joint damage in two mouse models of knee osteoarthritis (OA).  DESIGN:  In a collagenase-induced OA model, pralnacasan was given orally by gavage to female Balb/c mice at 0, 12.5, 25 and 50 mg/kg twice a day.  In the second study, pralnacasan was tested in male STR/1N mice, which develop OA spontaneously, by administering food-drug mixtures ad libitum at concentrations of 0, 700 and 4200 ppm (mg/kg food).  OA joint damage was assessed by a semi-quantitative histopathological score in both studies.  In the STR/1N mouse study, urinary levels of collagen cross-links hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) were determined by high-pressure liquid chromatography at baseline, after 3 and 6 weeks of treatment and RU 36384/VRT-18858 plasma concentrations was measured after 6 weeks.  RESULTS:  In both studies, the mice developed moderate to severe knee joint OA in the medial joint compartments (tibial plateau and femoral condyle), the non-treated control groups showing median histopathological scores from 18 to 21 of a maximal score of 32.  Pralnacasan was well tolerated.  At the doses of 12.5 and 50 mg/kg in collagenase-induced OA and at the high dose of 4200 ppm in STR/1N mice pralnacasan treatment significantly reduced OA by 13-22%.  In the STR/1N mice, urinary levels of HP cross-links and the ratio of HP/LP, which are indicators of joint damage in OA, were significantly reduced in the high dose group by 59 and 84%, respectively.  CONCLUSIONS:  The ICE inhibitor pralnacasan reduced joint damage in two experimental models of OA and has the potential to become a disease-modifying drug for the treatment of OA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS00eZqsMAAocjl5L8hwNX0fW6udTcc2ea-LUE0bG8eKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svjsFOhtg%253D%253D&md5=ec8e69c841b711bb5c56cb1f9ac983c3</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS1063-4584%2803%2900153-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1063-4584%252803%252900153-5%26sid%3Dliteratum%253Aachs%26aulast%3DRudolphi%26aufirst%3DK.%26aulast%3DGerwin%26aufirst%3DN.%26aulast%3DVerzijl%26aufirst%3DN.%26aulast%3Dvan%2Bder%2BKraan%26aufirst%3DP.%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DW.%26atitle%3DPralnacasan%252C%2520an%2520Inhibitor%2520of%2520Interleukin-1%2520Converting%2520Enzyme%252C%2520Reduces%2520Joint%2520Damage%2520in%2520Two%2520Murine%2520Models%2520of%2520Osteoarthritis%26jtitle%3DOsteo%2520Arthritis%2520and%2520Cartilage%26date%3D2003%26volume%3D11%26spage%3D738%26epage%3D746%26doi%3D10.1016%2FS1063-4584%2803%2900153-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span> </span><span class="NLM_article-title">Aventis and Vertex Pharmaceuticals Voluntarily
Discontinue Phase
IIb Clinical Trials of Pralnacasan in Rheumatoid Arthritis: Phase
II Activities Temporarily Suspended While Unexpected Toxicology Results
Analyzed</span>. <a href="https://www.sec.gov/Archives/edgar/data/875320/000110465903025360/a03-5139_1ex99d1.htm" class="extLink">https://www.sec.gov/Archives/edgar/data/875320/000110465903025360/a03-5139_1ex99d1.htm</a> (accessed Jun 9, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Aventis+and+Vertex+Pharmaceuticals+Voluntarily%0ADiscontinue+Phase%0AIIb+Clinical+Trials+of+Pralnacasan+in+Rheumatoid+Arthritis%3A+Phase%0AII+Activities+Temporarily+Suspended+While+Unexpected+Toxicology+Results%0AAnalyzed.+https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F875320%2F000110465903025360%2Fa03-5139_1ex99d1.htm+%28accessed+Jun+9%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAventis%2520and%2520Vertex%2520Pharmaceuticals%2520Voluntarily%250ADiscontinue%2520Phase%250AIIb%2520Clinical%2520Trials%2520of%2520Pralnacasan%2520in%2520Rheumatoid%2520Arthritis%253A%2520Phase%250AII%2520Activities%2520Temporarily%2520Suspended%2520While%2520Unexpected%2520Toxicology%2520Results%250AAnalyzed%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wannamaker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charifson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germann, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randle, J. C. R.</span></span> <span> </span><span class="NLM_article-title">(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL-18</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>321</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.111344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1124%2Fjpet.106.111344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=17289835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFehtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=509-516&issue=2&author=W.+Wannamakerauthor=R.+Daviesauthor=M.+Namchukauthor=J.+Pollardauthor=P.+Fordauthor=G.+Kuauthor=C.+Deckerauthor=P.+Charifsonauthor=P.+Weberauthor=U.+A.+Germannauthor=K.+Kuidaauthor=J.+C.+R.+Randle&title=%28S%29-1-%28%28S%29-2-%7B%5B1-%284-Amino-3-chloro-phenyl%29-methanoyl%5D-amino%7D-3%2C3-dimethyl-butanoyl%29-pyrrolidine-2-carboxylic+acid+%28%282R%2C3S%29-2-ethoxy-5-oxo-tetrahydro-furan-3-yl%29-amide+%28VX-765%29%2C+an+Orally+Available+Selective+Interleukin+%28IL%29-Converting+Enzyme%2FCaspase-1+Inhibitor%2C+Exhibits+Potent+Anti-Inflammatory+Activities+by+Inhibiting+the+Release+of+IL-1%CE%B2+and+IL-18&doi=10.1124%2Fjpet.106.111344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-1-((S)-2-{[1-(4-Amino-3-chlorophenyl)methanoyl]amino}-3,3-dimethylbutanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18</span></div><div class="casAuthors">Wannamaker, Woods; Davies, Robert; Namchuk, Mark; Pollard, John; Ford, Pamella; Ku, George; Decker, Caroline; Charifson, Paul; Weber, Peter; Germann, Ursula A.; Kuida, Keisuke; Randle, John C. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">509-516</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">VX-765 is an orally absorbed prodrug of (S)-3-({1-[(S)-1-((S)-2-{[1-(4-amino-3-chlorophenyl)methanoyl]amino}-3,3-dimethyl-butanoyl)pyrrolidin-2-yl]-methanoyl}amino)-4-oxobutyric acid (VRT-043198), a potent and selective inhibitor of interleukin-converting enzyme/caspase-1 subfamily caspases.  VRT-043198 exhibits 100- to 10,000-fold selectivity against other caspase-3 and -6 to -9.  The therapeutic potential of VX-765 was assessed by detg. the effects of VRT-043198 on cytokine release by monocytes in vitro and of orally administered VX-765 in several animal models in vivo.  In cultures of peripheral blood mononuclear cells and whole blood from healthy subjects stimulated with bacterial products, VRT-043198 inhibited the release of interleukin (IL)-1β and IL-18, but it had little effect on the release of several other cytokines, including IL-1α, tumor necrosis factor-α, IL-6 and IL-8.  In contrast, VRT-043198 had little or no demonstrable activity in cellular models of apoptosis, and it did not affect the proliferation of activated primary T cells or T-cell lines.  VX-765 was efficiently converted to VRT-043198 when administered orally to mice, and it inhibited lipopolysaccharide-induced cytokine secretion.  In addn., VX-765 reduced disease severity and the expression of inflammatory mediators in models of rheumatoid arthritis and skin inflammation.  These data suggest that VX-765 is a novel cytokine inhibitor useful for treatment of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUYnZtQc6cNrVg90H21EOLACvtfcHk0lhNVlWEwSPhXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFehtLY%253D&md5=f310c20314ee44357acd3027105a8b6a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.111344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.111344%26sid%3Dliteratum%253Aachs%26aulast%3DWannamaker%26aufirst%3DW.%26aulast%3DDavies%26aufirst%3DR.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DFord%26aufirst%3DP.%26aulast%3DKu%26aufirst%3DG.%26aulast%3DDecker%26aufirst%3DC.%26aulast%3DCharifson%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DP.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DKuida%26aufirst%3DK.%26aulast%3DRandle%26aufirst%3DJ.%2BC.%2BR.%26atitle%3D%2528S%2529-1-%2528%2528S%2529-2-%257B%255B1-%25284-Amino-3-chloro-phenyl%2529-methanoyl%255D-amino%257D-3%252C3-dimethyl-butanoyl%2529-pyrrolidine-2-carboxylic%2520acid%2520%2528%25282R%252C3S%2529-2-ethoxy-5-oxo-tetrahydro-furan-3-yl%2529-amide%2520%2528VX-765%2529%252C%2520an%2520Orally%2520Available%2520Selective%2520Interleukin%2520%2528IL%2529-Converting%2520Enzyme%252FCaspase-1%2520Inhibitor%252C%2520Exhibits%2520Potent%2520Anti-Inflammatory%2520Activities%2520by%2520Inhibiting%2520the%2520Release%2520of%2520IL-1%25CE%25B2%2520and%2520IL-18%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26issue%3D2%26spage%3D509%26epage%3D516%26doi%3D10.1124%2Fjpet.106.111344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kudelova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischmannova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matalova, E.</span></span> <span> </span><span class="NLM_article-title">Pharmalogical Caspase Inhibitors: Research Towards Therapeutic Perspectives</span>. <i>J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26348072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVymurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=473-482&issue=4&author=J.+Kudelovaauthor=J.+Fleischmannovaauthor=E.+Adamovaauthor=E.+Matalova&title=Pharmalogical+Caspase+Inhibitors%3A+Research+Towards+Therapeutic+Perspectives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological caspase inhibitors: research towards therapeutic perspectives</span></div><div class="casAuthors">Kudelova, J.; Fleischmannova, J.; Adamova, E.; Matalova, E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">473-482</span>CODEN:
                <span class="NLM_cas:coden">JPHPEI</span>;
        ISSN:<span class="NLM_cas:issn">0867-5910</span>.
    
            (<span class="NLM_cas:orgname">Polish Physiological Society</span>)
        </div><div class="casAbstract">Caspases are key mols. of apoptosis and the inflammatory response.  Up-regulation of the caspase cascade contributes to human pathologies such as neurodegenerative and immune disorders.  Thus, blocking the excessive apoptosis by pharmacol. inhibitors seems promising for therapeutic interventions in such diseases, Caspase inhibitors, both natural and artificial, have been used as research tools and have helped to define the role of the individual caspases in apoptosis and in non-apoptotic processes.  Moreover, some caspase inhibitors have demonstrated their therapeutic efficiency in the redn. of cell death and inflammation in animal models of human diseases, however, no drug based on caspase inhibition has been approved on the market until now.  Thus, the development of therapeutic approaches that specifically target caspases remains a great challenge and is now the focus of intense biol. and clin. interest.  Here, we provide a brief review of recent knowledge about pharmacol. caspase inhibitors with special focus on their proposed clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW1AVlhbjjVrVg90H21EOLACvtfcHk0lhNVlWEwSPhXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVymurzF&md5=e4ccc2a8861545154b9bce6882112772</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKudelova%26aufirst%3DJ.%26aulast%3DFleischmannova%26aufirst%3DJ.%26aulast%3DAdamova%26aufirst%3DE.%26aulast%3DMatalova%26aufirst%3DE.%26atitle%3DPharmalogical%2520Caspase%2520Inhibitors%253A%2520Research%2520Towards%2520Therapeutic%2520Perspectives%26jtitle%3DJ.%2520Physiol.%2520Pharmacol.%26date%3D2015%26volume%3D66%26issue%3D4%26spage%3D473%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Vertex</span>. <span> </span><span class="NLM_article-title">Vertex Announces Completion of Phase 2 Study of
VX-765 in People with Epilepsy Who Did Not Respond to Previous Treatment
- Results Support Continued Development of VX-765 in People with Treatment-Resistant
Epilepsy</span>. <a href="https://investors.vrtx.com/static-files/99195d36-42be-4e2a-a2b3-b0d632ba31c7" class="extLink">https://investors.vrtx.com/static-files/99195d36-42be-4e2a-a2b3-b0d632ba31c7</a> (accessed Jun 9, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Vertex&title=Vertex+Announces+Completion+of+Phase+2+Study+of%0AVX-765+in+People+with+Epilepsy+Who+Did+Not+Respond+to+Previous+Treatment%0A-+Results+Support+Continued+Development+of+VX-765+in+People+with+Treatment-Resistant%0AEpilepsy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DVertex%2520Announces%2520Completion%2520of%2520Phase%25202%2520Study%2520of%250AVX-765%2520in%2520People%2520with%2520Epilepsy%2520Who%2520Did%2520Not%2520Respond%2520to%2520Previous%2520Treatment%250A-%2520Results%2520Support%2520Continued%2520Development%2520of%2520VX-765%2520in%2520People%2520with%2520Treatment-Resistant%250AEpilepsy%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, G.</span></span> <span> </span><span class="NLM_article-title">NEK7 is an Essential Mediator of NLRP3 Activation Downstream of Potassium Efflux</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nature16959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature16959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26814970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2016&pages=354-357&author=Y.+Heauthor=M.+Y.+Zengauthor=D.+Yangauthor=B.+Motroauthor=G.+N%C3%BA%C3%B1ez&title=NEK7+is+an+Essential+Mediator+of+NLRP3+Activation+Downstream+of+Potassium+Efflux&doi=10.1038%2Fnature16959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux</span></div><div class="casAuthors">He, Yuan; Zeng, Melody Y.; Yang, Dahai; Motro, Benny; Nunez, Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">7590</span>),
    <span class="NLM_cas:pages">354-357</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammasomes are intracellular protein complexes that drive the activation of inflammatory caspases.  So far, four inflammasomes involving NLRP1, NLRP3, NLRC4 and AIM2 have been described that recruit the common adaptor protein ASC to activate caspase-1, leading to the secretion of mature IL-1β and IL-18 proteins.  The NLRP3 inflammasome has been implicated in the pathogenesis of several acquired inflammatory diseases as well as cryopyrin-assocd. periodic fever syndromes (CAPS) caused by inherited NLRP3 mutations.  Potassium efflux is a common step that is essential for NLRP3 inflammasome activation induced by many stimuli.  Despite extensive investigation, the mol. mechanism leading to NLRP3 activation in response to potassium efflux remains unknown.  Here the authors report the identification of NEK7, a member of the family of mammalian NIMA-related kinases (NEK proteins), as an NLRP3-binding protein that acts downstream of potassium efflux to regulate NLRP3 oligomerization and activation.  In the absence of NEK7, caspase-1 activation and IL-1β release were abrogated in response to signals that activate NLRP3, but not NLRC4 or AIM2 inflammasomes.  NLRP3-activating stimuli promoted the NLRP3-NEK7 interaction in a process that was dependent on potassium efflux.  NLRP3 assocd. with the catalytic domain of NEK7, but the catalytic activity of NEK7 was shown to be dispensable for activation of the NLRP3 inflammasome.  Activated macrophages formed a high-mol.-mass NLRP3-NEK7 complex, which, along with ASC oligomerization and ASC speck formation, was abrogated in the absence of NEK7.  NEK7 was required for macrophages contg. the CAPS-assocd. NLRP3(R258W) activating mutation to activate caspase-1.  Mouse chimeras reconstituted with wild-type, Nek7-/- or Nlrp3-/- hematopoietic cells showed that NEK7 was required for NLRP3 inflammasome activation in vivo.  These studies demonstrate that NEK7 is an essential protein that acts downstream of potassium efflux to mediate NLRP3 inflammasome assembly and activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcHD1JcxOIqrVg90H21EOLACvtfcHk0lg0oMQktQjMnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyitbY%253D&md5=ff385d4ed4c8d8861059772c2cb26f19</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnature16959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16959%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DM.%2BY.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DMotro%26aufirst%3DB.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DG.%26atitle%3DNEK7%2520is%2520an%2520Essential%2520Mediator%2520of%2520NLRP3%2520Activation%2520Downstream%2520of%2520Potassium%2520Efflux%26jtitle%3DNature%26date%3D2016%26volume%3D530%26spage%3D354%26epage%3D357%26doi%3D10.1038%2Fnature16959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groß, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettmarshausen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittlein, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, P.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikovic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartjes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smollich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A.B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Supprian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traidl-Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perocchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groß, O.</span></span> <span> </span><span class="NLM_article-title">K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">773</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2016.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2016.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27692612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOmtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=761-773&author=C.+J.+Gro%C3%9Fauthor=R.+Mishraauthor=K.+S.+Schneiderauthor=G.+Medardauthor=J.+Wettmarshausenauthor=D.+C.+Dittleinauthor=H.+Shiauthor=O.+Gorkaauthor=P.-A.+Koenigauthor=S.+Frommauthor=G.+Magnaniauthor=T.+Cikovicauthor=L.+Hartjesauthor=J.+Smollichauthor=A.+A.B.+Robertsonauthor=M.+A.+Cooperauthor=M.+Schmidt-Supprianauthor=M.+Schusterauthor=K.+Schroderauthor=P.+Brozauthor=C.+Traidl-Hoffmannauthor=B.+Beutlerauthor=B.+Kusterauthor=J.+Rulandauthor=S.+Schneiderauthor=F.+Perocchiauthor=O.+Gro%C3%9F&title=K%2B+Efflux-Independent+NLRP3+Inflammasome+Activation+by+Small+Molecules+Targeting+Mitochondria&doi=10.1016%2Fj.immuni.2016.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria</span></div><div class="casAuthors">Gross, Christina J.; Mishra, Ritu; Schneider, Katharina S.; Medard, Guillaume; Wettmarshausen, Jennifer; Dittlein, Daniela C.; Shi, Hexin; Gorka, Oliver; Koenig, Paul-Albert; Fromm, Stephan; Magnani, Giovanni; Cikovic, Tamara; Hartjes, Lara; Smollich, Joachim; Robertson, Avril A. B.; Cooper, Matthew A.; Schmidt-Supprian, Marc; Schuster, Michael; Schroder, Kate; Broz, Petr; Traidl-Hoffmann, Claudia; Beutler, Bruce; Kuster, Bernhard; Ruland, Juergen; Schneider, Sabine; Perocchi, Fabiana; Gross, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">761-773</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Imiquimod is a small-mol. ligand of Toll-like receptor-7 (TLR7) that is licensed for the treatment of viral infections and cancers of the skin.  Imiquimod has TLR7-independent activities that are mechanistically unexplained, including NLRP3 inflammasome activation in myeloid cells and apoptosis induction in cancer cells.  We investigated the mechanism of inflammasome activation by imiquimod and the related mol. CL097 and detd. that K+ efflux was dispensable for NLRP3 activation by these compds.  Imiquimod and CL097 inhibited the quinone oxidoreductases NQO2 and mitochondrial Complex I.  This induced a burst of reactive oxygen species (ROS) and thiol oxidn., and led to NLRP3 activation via NEK7, a recently identified component of this inflammasome.  Metabolic consequences of Complex I inhibition and endolysosomal effects of imiquimod might also contribute to NLRP3 activation.  Our results reveal a K+ efflux-independent mechanism for NLRP3 activation and identify targets of imiquimod that might be clin. relevant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpx4Y3DNW0vbVg90H21EOLACvtfcHk0ljLXZfKoE7-ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOmtLzJ&md5=e39d1a51cafcecd59f5ab8f2f9d35ff1</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DGro%25C3%259F%26aufirst%3DC.%2BJ.%26aulast%3DMishra%26aufirst%3DR.%26aulast%3DSchneider%26aufirst%3DK.%2BS.%26aulast%3DMedard%26aufirst%3DG.%26aulast%3DWettmarshausen%26aufirst%3DJ.%26aulast%3DDittlein%26aufirst%3DD.%2BC.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DGorka%26aufirst%3DO.%26aulast%3DKoenig%26aufirst%3DP.-A.%26aulast%3DFromm%26aufirst%3DS.%26aulast%3DMagnani%26aufirst%3DG.%26aulast%3DCikovic%26aufirst%3DT.%26aulast%3DHartjes%26aufirst%3DL.%26aulast%3DSmollich%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DA.%2BA.B.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DSchmidt-Supprian%26aufirst%3DM.%26aulast%3DSchuster%26aufirst%3DM.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DBroz%26aufirst%3DP.%26aulast%3DTraidl-Hoffmann%26aufirst%3DC.%26aulast%3DBeutler%26aufirst%3DB.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DPerocchi%26aufirst%3DF.%26aulast%3DGro%25C3%259F%26aufirst%3DO.%26atitle%3DK%252B%2520Efflux-Independent%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Small%2520Molecules%2520Targeting%2520Mitochondria%26jtitle%3DImmunity%26date%3D2016%26volume%3D45%26spage%3D761%26epage%3D773%26doi%3D10.1016%2Fj.immuni.2016.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magupalli, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauenstein, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span> <span> </span><span class="NLM_article-title">Structural Mechanism for NEK7-licensed Activation of NLRP3 Inflammasome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>570</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1295-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41586-019-1295-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31189953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKgs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=570&publication_year=2019&pages=338-343&author=H.+Sharifauthor=L.+Wangauthor=W.+L.+Wangauthor=V.+G.+Magupalliauthor=L.+Andreevaauthor=Q.+Qiaoauthor=A.+V.+Hauensteinauthor=Z.+Wuauthor=G.+Nunezauthor=Y.+Maoauthor=H.+Wu&title=Structural+Mechanism+for+NEK7-licensed+Activation+of+NLRP3+Inflammasome&doi=10.1038%2Fs41586-019-1295-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome</span></div><div class="casAuthors">Sharif, Humayun; Wang, Li; Wang, Wei Li; Magupalli, Venkat Giri; Andreeva, Liudmila; Qiao, Qi; Hauenstein, Arthur V.; Wu, Zhaolong; Nunez, Gabriel; Mao, Youdong; Wu, Hao</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">570</span>
        (<span class="NLM_cas:issue">7761</span>),
    <span class="NLM_cas:pages">338-343</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome can be activated by stimuli that include nigericin, uric acid crystals, amyloid-β fibrils and extracellular ATP.  The mitotic kinase NEK7 licenses the assembly and activation of the NLRP3 inflammasome in interphase.  Here we report a cryo-electron microscopy structure of inactive human NLRP3 in complex with NEK7, at a resoln. of 3.8 Å.  The earring-shaped NLRP3 consists of curved leucine-rich-repeat and globular NACHT domains, and the C-terminal lobe of NEK7 nestles against both NLRP3 domains.  Structural recognition between NLRP3 and NEK7 is confirmed by mutagenesis both in vitro and in cells.  Modeling of an active NLRP3-NEK7 conformation based on the NLRC4 inflammasome predicts an addnl. contact between an NLRP3-bound NEK7 and a neighboring NLRP3.  Mutations to this interface abolish the ability of NEK7 or NLRP3 to rescue NLRP3 activation in NEK7-knockout or NLRP3-knockout cells.  These data suggest that NEK7 bridges adjacent NLRP3 subunits with bipartite interactions to mediate the activation of the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKz2yqOHis9bVg90H21EOLACvtfcHk0ljLXZfKoE7-ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKgs7vP&md5=e6d535e4d91e360ce82c1f4327e10e24</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1295-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1295-z%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DMagupalli%26aufirst%3DV.%2BG.%26aulast%3DAndreeva%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DQ.%26aulast%3DHauenstein%26aufirst%3DA.%2BV.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DNunez%26aufirst%3DG.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DH.%26atitle%3DStructural%2520Mechanism%2520for%2520NEK7-licensed%2520Activation%2520of%2520NLRP3%2520Inflammasome%26jtitle%3DNature%26date%3D2019%26volume%3D570%26spage%3D338%26epage%3D343%26doi%3D10.1038%2Fs41586-019-1295-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span> <span> </span><span class="NLM_article-title">Oridonin is a Covalent NLRP3 Inhibitor with Strong Anti-Inflammasome Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2550</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04947-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41467-018-04947-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29317637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGqurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-12&issue=2550&author=H.+Heauthor=H.+Jiangauthor=Y.+Chenauthor=J.+Yeauthor=A.+Wangauthor=C.+Wangauthor=Q.+Liuauthor=G.+Liangauthor=X.+Dengauthor=W.+Jiangauthor=R.+Zhou&title=Oridonin+is+a+Covalent+NLRP3+Inhibitor+with+Strong+Anti-Inflammasome+Activity&doi=10.1038%2Fs41467-018-04947-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of pancreatic acinar cell carcinoma by Roux-en-Y Gastric Bypass Surgery</span></div><div class="casAuthors">He, Rui; Yin, Yue; Yin, Wenzhen; Li, Yin; Zhao, Jing; Zhang, Weizhen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Roux-en-Y Gastric Bypass Surgery (RYGB) prevents the occurrence of pancreatic cell acinar carcinoma (ACC) in male and female Ngn3-Tsc1-/- mice.  Ngn3 directed Cre deletion of Tsc1 gene induced the development of pancreatic ACC.  The transgenic mice with sham surgery demonstrated a cancer incidence of 96.7 ± 3.35% and survival rate of 67.0 ± 1.4% at the age of 300 days.  Metastasis to liver and kidney was obsd. in 69.7 ± 9.7% and 44.3 ± 8.01% of these animals, resp.  All animals with RYGB performed at the age of 16 wk survived free of pancreatic ACC up to the age of 300 days.  RYGB significantly attenuated the activation of mTORC1 signaling and inhibition of tumor suppressor genes: p21, p27, and p53 in pancreatic ACC.  Our studies demonstrate that bariatric surgery may limit the occurrence and growth of pancreatic ACC through the suppression of mTORC1 signaling in pancreas.  RYGB shows promise for intervention of both metabolic dysfunction and organ cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMD0P4M0bQ37Vg90H21EOLACvtfcHk0ljLXZfKoE7-ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGqurbI&md5=fbfeff076ac7a0336e3bce1fce8967bd</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04947-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04947-6%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DR.%26atitle%3DOridonin%2520is%2520a%2520Covalent%2520NLRP3%2520Inhibitor%2520with%2520Strong%2520Anti-Inflammasome%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D2550%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs41467-018-04947-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooftman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaslona, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runtsch, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGettrick, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diskin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundararaj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarotto, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlstrom, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palsson-McDermott, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corr, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K. H.G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R. J.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Board, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L. A.J.</span></span> <span> </span><span class="NLM_article-title">Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.08.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.celrep.2019.08.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31577945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSqtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=151-161&issue=1&author=M.+M.+Hughesauthor=A.+Hooftmanauthor=S.+Angiariauthor=P.+Tummalaauthor=Z.+Zaslonaauthor=M.+C.+Runtschauthor=A.+F.+McGettrickauthor=C.+E.+Suttonauthor=C.+Diskinauthor=M.+Rookeauthor=S.+Takahashiauthor=S.+Sundararajauthor=M.+G.+Casarottoauthor=J.+E.+Dahlstromauthor=E.+M.+Palsson-McDermottauthor=S.+C.+Corrauthor=K.+H.G.+Millsauthor=R.+J.S.+Prestonauthor=N.+Neamatiauthor=Y.+Xieauthor=J.+B.+Baellauthor=P.+G.+Boardauthor=L.+A.J.+O%E2%80%99Neill&title=Glutathione+Transferase+Omega-1+Regulates+NLRP3+Inflammasome+Activation+through+NEK7+Deglutathionylation&doi=10.1016%2Fj.celrep.2019.08.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation</span></div><div class="casAuthors">Hughes, Mark M.; Hooftman, Alexander; Angiari, Stefano; Tummala, Padmaja; Zaslona, Zbigniew; Runtsch, Marah C.; McGettrick, Anne F.; Sutton, Caroline E.; Diskin, Ciana; Rooke, Melissa; Takahashi, Shuhei; Sundararaj, Srinivasan; Casarotto, Marco G.; Dahlstrom, Jane E.; Palsson-McDermott, Eva M.; Corr, Sinead C.; Mills, Kingston H. G.; Preston, Roger J. S.; Neamati, Nouri; Xie, Yiyue; Baell, Jonathan B.; Board, Philip G.; O'Neill, Luke A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-161.e5</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome is a cytosolic complex sensing phagocytosed material and various damage-assocd. mol. patterns, triggering prodn. of the pro-inflammatory cytokines interleukin-1 beta (IL)-β and IL-18 and promoting pyroptosis.  Here, we characterize glutathione transferase omega 1-1 (GSTO1-1), a constitutive deglutathionylating enzyme, as a regulator of the NLRP3 inflammasome.  Using a small mol. inhibitor of GSTO1-1 termed C1-27, endogenous GSTO1-1 knockdown, and GSTO1-1-/- mice, we report that GSTO1-1 is involved in NLRP3 inflammasome activation.  Mechanistically, GSTO1-1 deglutathionylates cysteine 253 in NIMA related kinase 7 (NEK7) to promote NLRP3 activation.  We therefore identify GSTO1-1 as an NLRP3 inflammasome regulator, which has potential as a drug target to limit NLRP3-mediated inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIyA9WP4EQdbVg90H21EOLACvtfcHk0ljLn4Fn7HYXRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSqtrjM&md5=0c3de58791a8b626ec0b2204736f5a3c</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.08.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.08.072%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DM.%2BM.%26aulast%3DHooftman%26aufirst%3DA.%26aulast%3DAngiari%26aufirst%3DS.%26aulast%3DTummala%26aufirst%3DP.%26aulast%3DZaslona%26aufirst%3DZ.%26aulast%3DRuntsch%26aufirst%3DM.%2BC.%26aulast%3DMcGettrick%26aufirst%3DA.%2BF.%26aulast%3DSutton%26aufirst%3DC.%2BE.%26aulast%3DDiskin%26aufirst%3DC.%26aulast%3DRooke%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DSundararaj%26aufirst%3DS.%26aulast%3DCasarotto%26aufirst%3DM.%2BG.%26aulast%3DDahlstrom%26aufirst%3DJ.%2BE.%26aulast%3DPalsson-McDermott%26aufirst%3DE.%2BM.%26aulast%3DCorr%26aufirst%3DS.%2BC.%26aulast%3DMills%26aufirst%3DK.%2BH.G.%26aulast%3DPreston%26aufirst%3DR.%2BJ.S.%26aulast%3DNeamati%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DBoard%26aufirst%3DP.%2BG.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.J.%26atitle%3DGlutathione%2520Transferase%2520Omega-1%2520Regulates%2520NLRP3%2520Inflammasome%2520Activation%2520through%2520NEK7%2520Deglutathionylation%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D29%26issue%3D1%26spage%3D151%26epage%3D161%26doi%3D10.1016%2Fj.celrep.2019.08.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span> <span> </span><span class="NLM_article-title">Regulation of NLRP3 Inflammasome by Phosphorylation</span>. <i>Frontiers in Immunology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2305</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.02305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3389%2Ffimmu.2018.02305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29403488" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-9&issue=2305&author=N.+Songauthor=T.+Li&title=Regulation+of+NLRP3+Inflammasome+by+Phosphorylation&doi=10.3389%2Ffimmu.2018.02305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02305%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DT.%26atitle%3DRegulation%2520of%2520NLRP3%2520Inflammasome%2520by%2520Phosphorylation%26jtitle%3DFrontiers%2520in%2520Immunology%26date%3D2018%26volume%3D9%26issue%3D2305%26spage%3D1%26epage%3D9%26doi%3D10.3389%2Ffimmu.2018.02305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortimer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadee, K.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Inhibition is Disrupted in a Group of Auto-Inflammatory Disease CAPS Mutations</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1176</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1038/ni.3538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.3538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27548431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlyisLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=1176-1186&issue=10&author=L.+Mortimerauthor=F.+Moreauauthor=J.+A.+MacDonaldauthor=K.+Chadee&title=NLRP3+Inflammasome+Inhibition+is+Disrupted+in+a+Group+of+Auto-Inflammatory+Disease+CAPS+Mutations&doi=10.1038%2Fni.3538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations</span></div><div class="casAuthors">Mortimer, Leanne; Moreau, France; MacDonald, Justin A.; Chadee, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1176-1186</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammasomes are positioned to rapidly escalate the intensity of inflammation by activating interleukin (IL)-1β, IL-18 and cell death by pyroptosis.  However, neg. regulation of inflammasomes remains poorly understood, as is the signaling cascade that dampens inflammasome activity.  We found that rapid NLRP3 inflammasome activation was directly inhibited by protein kinase A (PKA), which was induced by prostaglandin E2 (PGE2) signaling via the PGE2 receptor E-prostanoid 4 (EP4).  PKA directly phosphorylated the cytoplasmic receptor NLRP3 and attenuated its ATPase function.  We found that Ser295 in human NLRP3 was crit. for rapid inhibition and PKA phosphorylation.  Mutations in NLRP3-encoding residues adjacent to Ser295 have been linked to the inflammatory disease CAPS (cryopyrin-assocd. periodic syndromes).  NLRP3-S295A phenocopied the human CAPS mutants.  These data suggest that neg. regulation at Ser295 is crit. for restraining the NLRP3 inflammasome and identify a mol. basis for CAPS-assocd. NLRP3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy0USzArMZsbVg90H21EOLACvtfcHk0lgbb_JyXNdZGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlyisLjJ&md5=167971f60f807175bbb69a14158c688d</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fni.3538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3538%26sid%3Dliteratum%253Aachs%26aulast%3DMortimer%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DF.%26aulast%3DMacDonald%26aufirst%3DJ.%2BA.%26aulast%3DChadee%26aufirst%3DK.%26atitle%3DNLRP3%2520Inflammasome%2520Inhibition%2520is%2520Disrupted%2520in%2520a%2520Group%2520of%2520Auto-Inflammatory%2520Disease%2520CAPS%2520Mutations%26jtitle%3DNat.%2520Immunol.%26date%3D2016%26volume%3D17%26issue%3D10%26spage%3D1176%26epage%3D1186%26doi%3D10.1038%2Fni.3538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meszaros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.-t.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fatima
Magliarelli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihlan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig Gamez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goginashvili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielska, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebersold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, R.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase D at the Golgi Controls the NLRP3 Inflammasome Activation</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>214</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2671</span>– <span class="NLM_lpage">2693</span>, <span class="refDoi"> DOI: 10.1084/jem.20162040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1084%2Fjem.20162040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28716882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlemtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2017&pages=2671-2693&issue=9&author=Z.+Zhangauthor=G.+Meszarosauthor=W.-t.+Heauthor=Y.+Xuauthor=H.+de+Fatima%0AMagliarelliauthor=L.+Maillyauthor=M.+Mihlanauthor=Y.+Liuauthor=M.+Puig+Gamezauthor=A.+Goginashviliauthor=A.+Pasquierauthor=O.+Bielskaauthor=B.+Nevenauthor=P.+Quartierauthor=R.+Aebersoldauthor=T.+F.+Baumertauthor=P.+Georgelauthor=J.+Hanauthor=R.+Ricci&title=Protein+Kinase+D+at+the+Golgi+Controls+the+NLRP3+Inflammasome+Activation&doi=10.1084%2Fjem.20162040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase D at the Golgi controls NLRP3 inflammasome activation</span></div><div class="casAuthors">Zhang, Zhirong; Meszaros, Gergo; He, Wan-ting; Xu, Yanfang; Magliarelli, Helena de Fatima; Mailly, Laurent; Mihlan, Michael; Liu, Yansheng; Gamez, Marta Puig; Goginashvili, Alexander; Pasquier, Adrien; Bielska, Olga; Neven, Benedicte; Quartier, Pierre; Aebersold, Rudolf; Baumert, Thomas F.; Georgel, Philippe; Han, Jiahuai; Ricci, Romeo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2671-2693</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The inflammasomes are multiprotein complexs sensing tissue damage and infectious agents to initiate innate immune responses.  Different inflammasomes contg. distinct sensor mols. exist.  The NLRP3 inflammasome is unique as it detects a variety of danger signals.  It has been reported that NLRP3 is recruited to mitochondria-assocd. endoplasmic reticulum membranes (MAMs) and is activated by MAM-derived effectors.  Here, we show that in response to inflammasome activators, MAMs localize adjacent to Golgi membranes.  Diacylglycerol (DAG) at the Golgi rapidly increases, recruiting protein kinase D (PKD), a key effector of DAG.  Upon PKD inactivation, self-oligomerized NLRP3 is retained at MAMs adjacent to Golgi, blocking assembly of the active inflammasome.  Importantly, phosphorylation of NLRP3 by PKD at the Golgi is sufficient to release NLRP3 from MAMs, resulting in assembly of the active inflammasome.  Moreover, PKD inhibition prevents inflammasome autoactivation in peripheral blood mononuclear cells from patients carrying NLRP3 mutations.  Hence, Golgi-mediated PKD signaling is required and sufficient for NLRP3 inflammasome activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Soi3wqOjdLVg90H21EOLACvtfcHk0lgbb_JyXNdZGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlemtbk%253D&md5=c2947be57cbac9abeb28d859ecd15188</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1084%2Fjem.20162040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20162040%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DMeszaros%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DW.-t.%26aulast%3DXu%26aufirst%3DY.%26aulast%3Dde%2BFatima%2BMagliarelli%26aufirst%3DH.%26aulast%3DMailly%26aufirst%3DL.%26aulast%3DMihlan%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPuig%2BGamez%26aufirst%3DM.%26aulast%3DGoginashvili%26aufirst%3DA.%26aulast%3DPasquier%26aufirst%3DA.%26aulast%3DBielska%26aufirst%3DO.%26aulast%3DNeven%26aufirst%3DB.%26aulast%3DQuartier%26aufirst%3DP.%26aulast%3DAebersold%26aufirst%3DR.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26aulast%3DGeorgel%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DRicci%26aufirst%3DR.%26atitle%3DProtein%2520Kinase%2520D%2520at%2520the%2520Golgi%2520Controls%2520the%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2017%26volume%3D214%26issue%3D9%26spage%3D2671%26epage%3D2693%26doi%3D10.1084%2Fjem.20162040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Phosphorylation is an Essential Priming Event for Inflammasome Activation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2017.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.molcel.2017.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28943315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGnsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2017&pages=185-197&issue=1&author=N.+Songauthor=Z.-S.+Liuauthor=W.+Xueauthor=Z.-F.+Baiauthor=Q.-Y.+Wangauthor=J.+Daiauthor=X.+Liuauthor=Y.-J.+Huangauthor=H.+Caiauthor=X.-Y.+Zhanauthor=Q.-Y.+Hanauthor=H.+Wangauthor=Y.+Chenauthor=H.-Y.+Liauthor=A.-L.+Liauthor=X.-M.+Zhangauthor=T.+Zhouauthor=T.+Li&title=NLRP3+Phosphorylation+is+an+Essential+Priming+Event+for+Inflammasome+Activation&doi=10.1016%2Fj.molcel.2017.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation</span></div><div class="casAuthors">Song, Nan; Liu, Zhao-Shan; Xue, Wen; Bai, Zhao-Fang; Wang, Qian-Yi; Dai, Jiang; Liu, Xin; Huang, Yi-Jiao; Cai, Hong; Zhan, Xiao-Yan; Han, Qiu-Ying; Wang, Hongxia; Chen, Yuan; Li, Hui-Yan; Li, Ai-Ling; Zhang, Xue-Min; Zhou, Tao; Li, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-197.e6</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Many infections and stress signals can rapidly activate the NLRP3 inflammasome to elicit robust inflammatory responses.  This activation requires a priming step, which is thought to be mainly for upregulating NLRP3 transcription.  However, recent studies report that the NLRP3 inflammasome can be activated independently of transcription, suggesting that the priming process has unknown essential regulatory steps.  Here, we report that JNK1-mediated NLRP3 phosphorylation at S194 is a crit. priming event and is essential for NLRP3 inflammasome activation.  We show that NLRP3 inflammasome activation is disrupted in NLRP3-S194A knockin mice.  JNK1-mediated NLRP3 S194 phosphorylation is crit. for NLRP3 deubiquitination and facilitates its self-assocn. and the subsequent inflammasome assembly.  Importantly, we demonstrate that blocking S194 phosphorylation prevents NLRP3 inflammasome activation in cryopyrin-assocd. periodic syndromes (CAPS).  Thus, our study reveals a key priming mol. event that is a prerequisite for NLRP3 inflammasome activation.  Inhibiting NLRP3 phosphorylation could be an effective treatment for NLRP3-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNwg8-xqO4bVg90H21EOLACvtfcHk0lgoQGUerm0sRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGnsrfN&md5=4baadedcf6fcebbe7e0e77345000f1a6</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2017.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DZ.-S.%26aulast%3DXue%26aufirst%3DW.%26aulast%3DBai%26aufirst%3DZ.-F.%26aulast%3DWang%26aufirst%3DQ.-Y.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.-J.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DZhan%26aufirst%3DX.-Y.%26aulast%3DHan%26aufirst%3DQ.-Y.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.-Y.%26aulast%3DLi%26aufirst%3DA.-L.%26aulast%3DZhang%26aufirst%3DX.-M.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DT.%26atitle%3DNLRP3%2520Phosphorylation%2520is%2520an%2520Essential%2520Priming%2520Event%2520for%2520Inflammasome%2520Activation%26jtitle%3DMol.%2520Cell%26date%3D2017%26volume%3D68%26issue%3D1%26spage%3D185%26epage%3D197%26doi%3D10.1016%2Fj.molcel.2017.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Ray, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkschulte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meissner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Assembly is Regulated by Phosphorylation of the Pyrin Domain</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>214</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1725</span>– <span class="NLM_lpage">1736</span>, <span class="refDoi"> DOI: 10.1084/jem.20160933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1084%2Fjem.20160933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28465465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OgsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2017&pages=1725-1736&issue=6&author=A.+Stutzauthor=C.+Kolbeauthor=R.+Stahlauthor=G.+Horvathauthor=B.+Franklinauthor=O.+van+Rayauthor=R.+Brinkschulteauthor=M.+Geyerauthor=F.+Meissnerauthor=E.+Latz&title=NLRP3+Inflammasome+Assembly+is+Regulated+by+Phosphorylation+of+the+Pyrin+Domain&doi=10.1084%2Fjem.20160933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain</span></div><div class="casAuthors">Stutz, Andrea; Kolbe, Carl-Christian; Stahl, Rainer; Horvath, Gabor L.; Franklin, Bernardo S.; Ray, Olivia van; Brinkschulte, Rebecca; Geyer, Matthias; Meissner, Felix; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1725-1736</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">NLRP3 is a cytosolic pattern recognition receptor that senses microbes and endogenous danger signals.  Upon activation, NLRP3 forms an inflammasome with the adapter ASC, resulting in caspase-1 activation, release of proinflammatory cytokines and cell death.  How NLRP3 activation is regulated by transcriptional and posttranslational mechanisms to prevent aberrant activation remains incompletely understood.  Here, we identify three conserved phosphorylation sites in NLRP3 and demonstrate that NLRP3 activation is controlled by phosphorylation of its pyrin domain (PYD).  Phosphomimetic residues in NLRP3 PYD abrogate inflammasome activation and structural modeling indicates that phosphorylation of the PYD regulates charge-charge interaction between two PYDs that are essential for NLRP3 activation.  Phosphatase 2A (PP2A) inhibition or knock-down drastically reduces NLRP3 activation, showing that PP2A can license inflammasome assembly via dephosphorylating NLRP3 PYD.  These results propose that the balance between kinases and phosphatases acting on the NLRP3 PYD is crit. for NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCB_CjTHBGDLVg90H21EOLACvtfcHk0lgoQGUerm0sRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OgsbrL&md5=ded2d910f713c60f11d41a766ca8d9ab</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1084%2Fjem.20160933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20160933%26sid%3Dliteratum%253Aachs%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DKolbe%26aufirst%3DC.%26aulast%3DStahl%26aufirst%3DR.%26aulast%3DHorvath%26aufirst%3DG.%26aulast%3DFranklin%26aufirst%3DB.%26aulast%3Dvan%2BRay%26aufirst%3DO.%26aulast%3DBrinkschulte%26aufirst%3DR.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DMeissner%26aufirst%3DF.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DNLRP3%2520Inflammasome%2520Assembly%2520is%2520Regulated%2520by%2520Phosphorylation%2520of%2520the%2520Pyrin%2520Domain%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2017%26volume%3D214%26issue%3D6%26spage%3D1725%26epage%3D1736%26doi%3D10.1084%2Fjem.20160933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Cuellar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweighoffer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuyama, M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of the Adaptor ASC Acts as a Molecular Switch that Controls the Formation of Speck-Like Aggregates and Inflammasome Activity</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1255</span>, <span class="refDoi"> DOI: 10.1038/ni.2749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.2749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24185614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWisbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1247-1255&issue=12&author=H.+Haraauthor=K.+Tsuchiyaauthor=I.+Kawamuraauthor=R.+Fangauthor=E.+Hernandez-Cuellarauthor=Y.+Shenauthor=J.+Mizuguchiauthor=E.+Schweighofferauthor=V.+Tybulewiczauthor=M.+Mitsuyama&title=Phosphorylation+of+the+Adaptor+ASC+Acts+as+a+Molecular+Switch+that+Controls+the+Formation+of+Speck-Like+Aggregates+and+Inflammasome+Activity&doi=10.1038%2Fni.2749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity</span></div><div class="casAuthors">Hara, Hideki; Tsuchiya, Kohsuke; Kawamura, Ikuo; Fang, Rendong; Hernandez-Cuellar, Eduardo; Shen, Yanna; Mizuguchi, Junichiro; Schweighoffer, Edina; Tybulewicz, Victor; Mitsuyama, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1247-1255</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inflammasome adaptor ASC contributes to innate immunity through the activation of caspase-1.  Here we found that signaling pathways dependent on the kinases Syk and Jnk were required for the activation of caspase-1 via the ASC-dependent inflammasomes NLRP3 and AIM2.  Inhibition of Syk or Jnk abolished the formation of ASC specks without affecting the interaction of ASC with NLRP3.  ASC was phosphorylated during inflammasome activation in a Syk- and Jnk-dependent manner, which suggested that Syk and Jnk are upstream of ASC phosphorylation.  Moreover, phosphorylation of Tyr144 in mouse ASC was crit. for speck formation and caspase-1 activation.  Our results suggest that phosphorylation of ASC controls inflammasome activity through the formation of ASC specks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriBevVIrORmrVg90H21EOLACvtfcHk0lhRuZ4rhhAUrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWisbvI&md5=2ad63f6ef21b319a29cd41d9b48a2ae2</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fni.2749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2749%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DH.%26aulast%3DTsuchiya%26aufirst%3DK.%26aulast%3DKawamura%26aufirst%3DI.%26aulast%3DFang%26aufirst%3DR.%26aulast%3DHernandez-Cuellar%26aufirst%3DE.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DMizuguchi%26aufirst%3DJ.%26aulast%3DSchweighoffer%26aufirst%3DE.%26aulast%3DTybulewicz%26aufirst%3DV.%26aulast%3DMitsuyama%26aufirst%3DM.%26atitle%3DPhosphorylation%2520of%2520the%2520Adaptor%2520ASC%2520Acts%2520as%2520a%2520Molecular%2520Switch%2520that%2520Controls%2520the%2520Formation%2520of%2520Speck-Like%2520Aggregates%2520and%2520Inflammasome%2520Activity%26jtitle%3DNat.%2520Immunol.%26date%3D2013%26volume%3D14%26issue%3D12%26spage%3D1247%26epage%3D1255%26doi%3D10.1038%2Fni.2749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, I.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun-Nan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojcius, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-C.</span></span> <span> </span><span class="NLM_article-title">Pyk2 Activates the NLRP3 Inflammasome by Directly Phosphorylating ASC and Contributes to Inflammasome-Dependent Peritonitis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">36214</span>, <span class="refDoi"> DOI: 10.1038/srep36214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fsrep36214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27796369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVSitLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=36214&author=I.-C.+Chungauthor=O.+Chun-Nanauthor=S.-N.+Yuanauthor=H.-P.+Liauthor=J.-T.+Chenauthor=H.-R.+Shiehauthor=Y.-J.+Chenauthor=D.+M.+Ojciusauthor=C.-L.+Chuauthor=J.+S.+Yuauthor=Y.-S.+Changauthor=L.-C.+Chen&title=Pyk2+Activates+the+NLRP3+Inflammasome+by+Directly+Phosphorylating+ASC+and+Contributes+to+Inflammasome-Dependent+Peritonitis&doi=10.1038%2Fsrep36214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis</span></div><div class="casAuthors">Chung, I-Che; OuYang, Chun-Nan; Yuan, Sheng-Ning; Li, Hsin-Pai; Chen, Jeng-Ting; Shieh, Hui-Ru; Chen, Yu-Jen; Ojcius, David M.; Chu, Ching-Liang; Yu, Jau-Song; Chang, Yu-Sun; Chen, Lih-Chyang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36214</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inflammasome adaptor protein, ASC, contributes to both innate immune responses and inflammatory diseases via self-oligomerization, which leads to the activation of the protease, caspase-1.  Here, we report that the cytosolic tyrosine kinases, FAK and Pyk2, are differentially involved in NLRP3 and AIM2 inflammasome activation.  The inhibition of FAK and Pyk2 with RNA interference or chem. inhibitors dramatically abolished ASC oligomerization, caspase-1 activation, and IL-1β secretion in response to NLRP3 or AIM2 stimulation.  Pyk2 is phosphorylated by the kinase Syk and relocalizes to the ASC specks upon NLRP3 inflammasome activation.  Pyk2, but not FAK, could directly phosphorylate ASC at Tyr146, and only the phosphorylated ASC could participate in speck formation and trigger IL-1β secretion.  Moreover, the clin.-trial-tested Pyk2/FAK dual inhibitor PF-562271 reduced monosodium urate-mediated peritonitis, a disease model used for studying the consequences of NLRP3 activation.  Our results suggest that although Pyk2 and FAK are involved in inflammasome activation, only Pyk2 directly phosphorylates ASC and brings ASC into an oligomerization-competent state by allowing Tyr146 phosphorylation to participate ASC speck formation and subsequent NLRP3 inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJECFWqBMP-bVg90H21EOLACvtfcHk0lhRuZ4rhhAUrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVSitLvJ&md5=aaa6bbbd0e347e2425a9e740efc01399</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fsrep36214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep36214%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DI.-C.%26aulast%3DChun-Nan%26aufirst%3DO.%26aulast%3DYuan%26aufirst%3DS.-N.%26aulast%3DLi%26aufirst%3DH.-P.%26aulast%3DChen%26aufirst%3DJ.-T.%26aulast%3DShieh%26aufirst%3DH.-R.%26aulast%3DChen%26aufirst%3DY.-J.%26aulast%3DOjcius%26aufirst%3DD.%2BM.%26aulast%3DChu%26aufirst%3DC.-L.%26aulast%3DYu%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DY.-S.%26aulast%3DChen%26aufirst%3DL.-C.%26atitle%3DPyk2%2520Activates%2520the%2520NLRP3%2520Inflammasome%2520by%2520Directly%2520Phosphorylating%2520ASC%2520and%2520Contributes%2520to%2520Inflammasome-Dependent%2520Peritonitis%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D36214%26doi%3D10.1038%2Fsrep36214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shichita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, R.</span></span> <span> </span><span class="NLM_article-title">Burton’s Tyrosine Kinase is Essential for NLRP3 Inflammasome Activation and Contributes to Ischaemic Brain Injury</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">7360</span>, <span class="refDoi"> DOI: 10.1038/ncomms8360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fncomms8360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26059659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbit1ersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7360&author=M.+Itoauthor=T.+Shichitaauthor=M.+Okadaauthor=R.+Komineauthor=Y.+Noguchiauthor=A.+Yoshimuraauthor=R.+Morita&title=Burton%E2%80%99s+Tyrosine+Kinase+is+Essential+for+NLRP3+Inflammasome+Activation+and+Contributes+to+Ischaemic+Brain+Injury&doi=10.1038%2Fncomms8360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury</span></div><div class="casAuthors">Ito Minako; Okada Masahiro; Komine Ritsuko; Noguchi Yoshiko; Yoshimura Akihiko; Morita Rimpei; Shichita Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7360</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammasome activation has been implicated in various inflammatory diseases including post-ischaemic inflammation after stroke.  Inflammasomes mediate activation of caspase-1, which subsequently induces secretion of pro-inflammatory cytokines such as IL-1β and IL-18, as well as a form of cell death called pyroptosis.  In this study, we report that Bruton's tyrosine kinase (BTK) is an essential component of the NLRP3 inflammasome, in which BTK physically interacts with ASC and NLRP3.  Inhibition of BTK by pharmacological or genetic means severely impairs activation of the NLRP3 inflammasome.  The FDA-approved BTK inhibitor ibrutinib (PCI-32765) efficiently suppresses infarct volume growth and neurological damage in a brain ischaemia/reperfusion model in mice.  Ibrutinib inhibits maturation of IL-1β by suppressing caspase-1 activation in infiltrating macrophages and neutrophils in the infarcted area of ischaemic brain.  Our study indicates that BTK is essential for NLRP3 inflammasome activation and could be a potent therapeutic target in ischaemic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpx_DiGIJ5y8jl5L8hwNX0fW6udTcc2eYgRFX4RISs6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbit1ersg%253D%253D&md5=b3062eadbae9cd02ae356cbb8fb54ed2</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fncomms8360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8360%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DM.%26aulast%3DShichita%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DKomine%26aufirst%3DR.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DYoshimura%26aufirst%3DA.%26aulast%3DMorita%26aufirst%3DR.%26atitle%3DBurton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520is%2520Essential%2520for%2520NLRP3%2520Inflammasome%2520Activation%2520and%2520Contributes%2520to%2520Ischaemic%2520Brain%2520Injury%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7360%26doi%3D10.1038%2Fncomms8360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, Z. A.</span>; <span class="NLM_string-name">Liu, X.</span>; <span class="NLM_string-name">Dickhöfer, S.</span>; <span class="NLM_string-name">Kalbacher, H.</span>; <span class="NLM_string-name">Bosch, K.</span>; <span class="NLM_string-name">Andreeva, L.</span>; <span class="NLM_string-name">Marcu, A.</span>; <span class="NLM_string-name">Stevanovic, S.</span>; <span class="NLM_string-name">Mangan, M.</span>; <span class="NLM_string-name">Düwell, P.</span>; <span class="NLM_string-name">Lovotti, M.</span>; <span class="NLM_string-name">Herster, F.</span>; <span class="NLM_string-name">Löffler, M. W.</span>; <span class="NLM_string-name">Shankar, S.</span>; <span class="NLM_string-name">Tapia-Abellán, A.</span>; <span class="NLM_string-name">Wolz, O.-O.</span>; <span class="NLM_string-name">Schilling, N. A.</span>; <span class="NLM_string-name">Kümmerle-Deschner, J.</span>; <span class="NLM_string-name">Wagner, S.</span>; <span class="NLM_string-name">Delor, A.</span>; <span class="NLM_string-name">Grimbacher, B.</span>; <span class="NLM_string-name">Wu, H.</span>; <span class="NLM_string-name">Latz, E.</span>; <span class="NLM_string-name">Weber, A. N. R.</span></span>, <span> </span><span class="NLM_article-title">BTK Operates a Phospho-Tyrosine Switch to Regulate NLRP3 Inflammasome Activity</span> <i>bioRxiv</i> <span class="NLM_year">2019</span>, <span class="refDoi"> DOI: 10.1101/864702</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1101%2F864702" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Z.+A.+Bittner&author=X.+Liu&author=S.+Dickh%C3%B6fer&author=H.+Kalbacher&author=K.+Bosch&author=L.+Andreeva&author=A.+Marcu&author=S.+Stevanovic&author=M.+Mangan&author=P.+D%C3%BCwell&author=M.+Lovotti&author=F.+Herster&author=M.+W.+L%C3%B6ffler&author=S.+Shankar&author=A.+Tapia-Abell%C3%A1n&author=O.-O.+Wolz&author=N.+A.+Schilling&author=J.+K%C3%BCmmerle-Deschner&author=S.+Wagner&author=A.+Delor&author=B.+Grimbacher&author=H.+Wu&author=E.+Latz&author=A.+N.+R.+Weber&title=bioRxiv"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1101%2F864702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1101%252F864702%26sid%3Dliteratum%253Aachs%26aulast%3DBittner%26aufirst%3DZ.%2BA.%26atitle%3DBTK%2520Operates%2520a%2520Phospho-Tyrosine%2520Switch%2520to%2520Regulate%2520NLRP3%2520Inflammasome%2520Activity%26btitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F864702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bedford, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-like Protein Conjugation and the Ubiquitin-Proteasome System as Drug Targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1038/nrd3321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnrd3321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21151032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFChtLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=29-46&author=L.+Bedfordauthor=J.+Loweauthor=L.+R.+Dickauthor=J.+Mayerauthor=J.+E.+Brownell&title=Ubiquitin-like+Protein+Conjugation+and+the+Ubiquitin-Proteasome+System+as+Drug+Targets&doi=10.1038%2Fnrd3321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets</span></div><div class="casAuthors">Bedford, Lynn; Lowe, James; Dick, Lawrence R.; Mayer, R. John; Brownell, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-46</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system (UPS) and ubiquitin-like protein (UBL) conjugation pathways are integral to cellular protein homeostasis.  The growing recognition of the fundamental importance of these pathways to normal cell function and in disease has prompted an in-depth search for small-mol. inhibitors that selectively block the function of these pathways.  However, our limited understanding of the mol. mechanisms and biol. consequences of UBL conjugation is a significant hurdle to identifying drug-like inhibitors of enzyme targets within these pathways.  Here, we highlight recent advances in understanding the role of some of these enzymes and how these new insights may be the key to developing novel therapeutics for diseases including immuno-inflammatory disorders, cancer, infectious diseases, cardiovascular disease and neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkz-kR-1J0ELVg90H21EOLACvtfcHk0lh7K45pZ4rNcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFChtLjE&md5=99e49846be907b138ca87bebc5ee91ee</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnrd3321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3321%26sid%3Dliteratum%253Aachs%26aulast%3DBedford%26aufirst%3DL.%26aulast%3DLowe%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26atitle%3DUbiquitin-like%2520Protein%2520Conjugation%2520and%2520the%2520Ubiquitin-Proteasome%2520System%2520as%2520Drug%2520Targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D29%26epage%3D46%26doi%3D10.1038%2Fnrd3321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a Primary Target of Thalidomide Teratogenicity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1350</span>, <span class="refDoi"> DOI: 10.1126/science.1177319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fscience.1177319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20223979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=1345-1350&author=T.+Itoauthor=H.+Andoauthor=T.+Suzukiauthor=T.+Oguraauthor=K.+Hottaauthor=Y.+Imamuraauthor=Y.+Yamaguchiauthor=H.+Handa&title=Identification+of+a+Primary+Target+of+Thalidomide+Teratogenicity&doi=10.1126%2Fscience.1177319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Primary Target of Thalidomide Teratogenicity</span></div><div class="casAuthors">Ito, Takumi; Ando, Hideki; Suzuki, Takayuki; Ogura, Toshihiko; Hotta, Kentaro; Imamura, Yoshimasa; Yamaguchi, Yuki; Handa, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5971</span>),
    <span class="NLM_cas:pages">1345-1350</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects.  Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental defects is unknown.  Here, we identified cereblon (CRBN) as a thalidomide-binding protein.  CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.  Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the assocd. ubiquitin ligase activity.  This study reveals a basis for thalidomide teratogenicity and may contribute to the development of new thalidomide derivs. without teratogenic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPC_7RXLkfabVg90H21EOLACvtfcHk0lgw7En030I2_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFensrs%253D&md5=4565a67837e0ec34ede2c93c1036f312</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1126%2Fscience.1177319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1177319%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DHotta%26aufirst%3DK.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520Primary%2520Target%2520of%2520Thalidomide%2520Teratogenicity%26jtitle%3DScience%26date%3D2010%26volume%3D327%26spage%3D1345%26epage%3D1350%26doi%3D10.1126%2Fscience.1177319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Py, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakifahmetoglu-Norberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span> <span> </span><span class="NLM_article-title">Deubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2012.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.molcel.2012.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23246432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCku7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=331-338&author=B.+F.+Pyauthor=M.-S.+Kimauthor=H.+Vakifahmetoglu-Norbergauthor=J.+Yuan&title=Deubiquitination+of+NLRP3+by+BRCC3+Critically+Regulates+Inflammasome+Activity&doi=10.1016%2Fj.molcel.2012.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Deubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity</span></div><div class="casAuthors">Py, Benedicte F.; Kim, Mi-Sung; Vakifahmetoglu-Norberg, Helin; Yuan, Junying</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-338</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">NLRP3 is an important pattern recognition receptor involved in mediating inflammasome activation in response to viral and bacterial infections as well as various proinflammatory stimuli assocd. with tissue damage or malfunction.  Upon activation, NLRP3 assembles a multimeric inflammasome complex comprising the adaptor ASC and the effector pro-caspase-1 to mediate the activation of caspase-1.  Although NLRP3 expression is induced by the NF-κB pathway, the posttranscriptional mol. mechanism controlling the activation of NLRP3 remains elusive.  Using both pharmacol. and mol. approaches, we show that the activation of NLRP3 inflammasome is regulated by a deubiquitination mechanism.  We further identify the deubiquitinating enzyme, BRCC3, as a crit. regulator of NLRP3 activity by promoting its deubiquitination and characterizing NLRP3 as a substrate for the cytosolic BRCC3-contg. BRISC complex.  Our results elucidate a regulatory mechanism involving BRCC3-dependent NLRP3 regulation and highlight NLRP3 ubiquitination as a potential therapeutic target for inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4BbAkb645obVg90H21EOLACvtfcHk0lgw7En030I2_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCku7nL&md5=b84aeaec7e762a36b39abd55d705b30b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DPy%26aufirst%3DB.%2BF.%26aulast%3DKim%26aufirst%3DM.-S.%26aulast%3DVakifahmetoglu-Norberg%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DJ.%26atitle%3DDeubiquitination%2520of%2520NLRP3%2520by%2520BRCC3%2520Critically%2520Regulates%2520Inflammasome%2520Activity%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D49%26spage%3D331%26epage%3D338%26doi%3D10.1016%2Fj.molcel.2012.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lear, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajbhandari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snavely, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulick, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallampalli, R. K.</span></span> <span> </span><span class="NLM_article-title">Lipopolysaccharide Primes the NALP3 Inflammasome by Inhibiting its Ubiquitination and Degradation Mediated by SCF<sup>FBXL2</sup> E3 Ligase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">18123</span>– <span class="NLM_lpage">18133</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1074%2Fjbc.M115.645549" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=18123-18133&issue=29&author=S.+Hanauthor=T.+B.+Learauthor=J.+A.+Jeromeauthor=S.+Rajbhandariauthor=C.+A.+Snavelyauthor=D.+L.+Gulickauthor=K.+f.+Gibsonauthor=C.+Zhouauthor=B.+B.+Chenauthor=R.+K.+Mallampalli&title=Lipopolysaccharide+Primes+the+NALP3+Inflammasome+by+Inhibiting+its+Ubiquitination+and+Degradation+Mediated+by+SCFFBXL2+E3+Ligase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.645549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.645549%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DLear%26aufirst%3DT.%2BB.%26aulast%3DJerome%26aufirst%3DJ.%2BA.%26aulast%3DRajbhandari%26aufirst%3DS.%26aulast%3DSnavely%26aufirst%3DC.%2BA.%26aulast%3DGulick%26aufirst%3DD.%2BL.%26aulast%3DGibson%26aufirst%3DK.%2Bf.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DB.%2BB.%26aulast%3DMallampalli%26aufirst%3DR.%2BK.%26atitle%3DLipopolysaccharide%2520Primes%2520the%2520NALP3%2520Inflammasome%2520by%2520Inhibiting%2520its%2520Ubiquitination%2520and%2520Degradation%2520Mediated%2520by%2520SCFFBXL2%2520E3%2520Ligase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26issue%3D29%26spage%3D18123%26epage%3D18133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-328626, A Clinical
Study to Evaluate KT-1002 for the Treatment of Inflammatory Bowel
Disease, including Ulcerative Colitis and Crohn’s Disease.</i> <a href="https://citeline.informa.com/trials/details/328626?qId=f03d3d1b-94a9-4c09-b53f-543447fe5ea0" class="extLink">https://citeline.informa.com/trials/details/328626?qId=f03d3d1b-94a9-4c09-b53f-543447fe5ea0</a> (accessed Apr 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-328626%2C+A+Clinical%0AStudy+to+Evaluate+KT-1002+for+the+Treatment+of+Inflammatory+Bowel%0ADisease%2C+including+Ulcerative+Colitis+and+Crohn%E2%80%99s+Disease.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F328626%3FqId%3Df03d3d1b-94a9-4c09-b53f-543447fe5ea0+%28accessed+Apr+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-328626%252C%2520A%2520Clinical%250AStudy%2520to%2520Evaluate%2520KT-1002%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Bowel%250ADisease%252C%2520including%2520Ulcerative%2520Colitis%2520and%2520Crohn%25E2%2580%2599s%2520Disease.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span> <span> </span><span class="NLM_article-title">Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 Inflammation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.11.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.cell.2014.11.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25594175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2lsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2015&pages=62-73&author=Y.+Yanauthor=W.+Jiangauthor=L.+Liuauthor=X.+Wangauthor=C.+Dingauthor=Z.+Tianauthor=R.+Zhou&title=Dopamine+Controls+Systemic+Inflammation+through+Inhibition+of+NLRP3+Inflammation&doi=10.1016%2Fj.cell.2014.11.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome</span></div><div class="casAuthors">Yan, Yiqing; Jiang, Wei; Liu, Lei; Wang, Xiaqiong; Ding, Chen; Tian, Zhigang; Zhou, Rongbin</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">62-73</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inflammasomes are involved in diverse inflammatory diseases, so the activation of inflammasomes needs to be tightly controlled to prevent excessive inflammation.  However, the endogenous regulatory mechanisms of inflammasome activation are still unclear.  Here, we report that the neurotransmitter dopamine (DA) inhibits NLRP3 inflammasome activation via dopamine D1 receptor (DRD1).  DRD1 signaling neg. regulates NLRP3 inflammasome via a second messenger cyclic adenosine monophosphate (cAMP), which binds to NLRP3 and promotes its ubiquitination and degrdn. via the E3 ubiquitin ligase MARCH7.  Importantly, in vivo data show that DA and DRD1 signaling prevent NLRP3 inflammasome-dependent inflammation, including neurotoxin-induced neuroinflammation, LPS-induced systemic inflammation, and monosodium urate crystal (MSU)-induced peritoneal inflammation.  Taken together, our results reveal an endogenous mechanism of inflammasome regulation and suggest DRD1 as a potential target for the treatment of NLRP3 inflammasome-driven diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCoi1PYLt3vrVg90H21EOLACvtfcHk0liZqIMZvSjchw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2lsbc%253D&md5=48b1a2b5a54fef680343cd3294dc6b8e</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.11.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.11.047%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DR.%26atitle%3DDopamine%2520Controls%2520Systemic%2520Inflammation%2520through%2520Inhibition%2520of%2520NLRP3%2520Inflammation%26jtitle%3DCell%26date%3D2015%26volume%3D160%26spage%3D62%26epage%3D73%26doi%3D10.1016%2Fj.cell.2014.11.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span> <span> </span><span class="NLM_article-title">The E3 Ubiquitin Ligase TRIM31 Attenuates NLRP3 Inflammasome Activation by Promoting Proteasomal Degradation of NLRP3</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13727</span>, <span class="refDoi"> DOI: 10.1038/ncomms13727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fncomms13727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27929086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13727&author=H.+Songauthor=B.+Liuauthor=W.+Huaiauthor=Z.+Yuauthor=W.+Wangauthor=J.+Zhaoauthor=L.+Hanauthor=G.+Jiangauthor=L.+Zhangauthor=C.+Gaoauthor=W.+Zhao&title=The+E3+Ubiquitin+Ligase+TRIM31+Attenuates+NLRP3+Inflammasome+Activation+by+Promoting+Proteasomal+Degradation+of+NLRP3&doi=10.1038%2Fncomms13727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3</span></div><div class="casAuthors">Song, Hui; Liu, Bingyu; Huai, Wanwan; Yu, Zhongxia; Wang, Wenwen; Zhao, Jing; Han, Lihui; Jiang, Guosheng; Zhang, Lining; Gao, Chengjiang; Zhao, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13727</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome has a fundamental role in host defense against microbial pathogens and its deregulation may cause diverse inflammatory diseases.  NLRP3 protein expression is a rate-limiting step for inflammasome activation, thus its expression must be tightly controlled to maintain immune homeostasis and avoid detrimental effects.  However, how NLRP3 expression is regulated remains largely unknown.  In this study, we identify E3 ubiquitin ligase TRIM31 as a feedback suppressor of NLRP3 inflammasome.  TRIM31 directly binds to NLRP3, promotes K48-linked polyubiquitination and proteasomal degrdn. of NLRP3.  Consequently, TRIM31 deficiency enhances NLRP3 inflammasome activation and aggravates alum-induced peritonitis in vivo.  Furthermore, TRIM31 deficiency attenuates the severity of dextran sodium sulfate (DSS)-induced colitis, an inflammatory bowel diseases model in which NLRP3 possesses protective roles.  Thus, our research describes a mechanism by which TRIM31 limits NLRP3 inflammasome activity under physiol. conditions and suggests TRIM31 as a potential therapeutic target for the intervention of NLRP3 inflammasome related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5QK_RwuJAsrVg90H21EOLACvtfcHk0liZqIMZvSjchw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamsb7I&md5=e788f0dbe7b67ad95c72efcf19f97e4e</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fncomms13727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13727%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHuai%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DW.%26atitle%3DThe%2520E3%2520Ubiquitin%2520Ligase%2520TRIM31%2520Attenuates%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Promoting%2520Proteasomal%2520Degradation%2520of%2520NLRP3%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13727%26doi%3D10.1038%2Fncomms13727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitoma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tricot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-J.</span></span> <span> </span><span class="NLM_article-title">The E3 Ubiquitin Ligase Tripartite Motif 33 Is Essential for Cytosolic RNA-Induced NLRP3 Inflammasome Activation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">3676</span>– <span class="NLM_lpage">3682</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1401448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1401448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25172487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOnsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=3676-3682&author=L.+Wengauthor=H.+Mitomaauthor=C.+Tricotauthor=M.+Baoauthor=Y.+Liuauthor=Z.+Zhangauthor=Y.-J.+Liu&title=The+E3+Ubiquitin+Ligase+Tripartite+Motif+33+Is+Essential+for+Cytosolic+RNA-Induced+NLRP3+Inflammasome+Activation&doi=10.4049%2Fjimmunol.1401448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">The E3 Ubiquitin Ligase Tripartite Motif 33 Is Essential for Cytosolic RNA-Induced NLRP3 Inflammasome Activation</span></div><div class="casAuthors">Weng, Leiyun; Mitoma, Hiroki; Trichot, Coline; Bao, Musheng; Liu, Ying; Zhang, Zhiqiang; Liu, Yong-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3676-3682</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">NLRP3 is a key component of caspase-activating macromol. protein complexes called inflammasomes.  It has been found that DHX33 is a cytosolic dsRNA sensor for the NLRP3 inflammasome, which induces caspase-1-dependent prodn. of IL-1β and IL-18 upon activation.  However, how the cytosolic dsRNAs induce the interaction between DHX33 and the NLRP3 inflammasome remains unknown.  In this study, we report that TRIM33, a member of the tripartite motif (TRIM) family, can bind DHX33 directly and induce DHX33 ubiquitination via the lysine 218 upon dsRNA stimulation.  Knocking down of TRIM33 abolished the dsRNA-induced NLRP3 inflammasome activation in both THP-1-derived macrophages and human monocyte-derived macrophages.  The ubiquitination of DHX33 by TRIM33 is lysine 63 specific and is required for the formation of the DHX33-NLRP3 inflammasome complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_35cBrT67FLVg90H21EOLACvtfcHk0lh-tsR9o35KDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOnsLjJ&md5=8570f79500d90db7c6ab0ea49cb009be</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1401448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1401448%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DL.%26aulast%3DMitoma%26aufirst%3DH.%26aulast%3DTricot%26aufirst%3DC.%26aulast%3DBao%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.-J.%26atitle%3DThe%2520E3%2520Ubiquitin%2520Ligase%2520Tripartite%2520Motif%252033%2520Is%2520Essential%2520for%2520Cytosolic%2520RNA-Induced%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D3676%26epage%3D3682%26doi%3D10.4049%2Fjimmunol.1401448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. H.</span></span> <span> </span><span class="NLM_article-title">The Deubiquitinating Enzyme, Ubiquitin-Specific Peptidase 50, Regulates Inflammasome Activation by Targeting the ASC Adaptor Protein</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>591</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2F1873-3468.12558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28094437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=591&publication_year=2017&pages=479-490&author=J.+Y.+Leeauthor=D.+Seoauthor=J.+Youauthor=S.+Chungauthor=J.+S.+Parkauthor=J.-H.+Leeauthor=S.+M.+Jungauthor=Y.+S.+Leeauthor=S.+H.+Park&title=The+Deubiquitinating+Enzyme%2C+Ubiquitin-Specific+Peptidase+50%2C+Regulates+Inflammasome+Activation+by+Targeting+the+ASC+Adaptor+Protein&doi=10.1002%2F1873-3468.12558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">The deubiquitinating enzyme, ubiquitin-specific peptidase 50, regulates inflammasome activation by targeting the ASC adaptor protein</span></div><div class="casAuthors">Lee, Jae Young; Seo, Dongyeob; You, Jiyeon; Chung, Sehee; Park, Jin Seok; Lee, Ji-Hyung; Jung, Su Myung; Lee, Youn Sook; Park, Seok Hee</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">591</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-490</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">NOD-like receptor family protein 3 (NLRP3)-mediated inflammasome activation promotes caspase-1-dependent prodn. of interleukin-1β (IL-1β) and requires the adaptor protein ASC.  Compared with the priming and activation mechanisms of the inflammasome signaling pathway, post-translational ubiquitination/deubiquitination mechanisms controlling inflammasome activation have not been clearly addressed.  The authors here demonstrate that the deubiquitinating enzyme USP50 binds to the ASC protein and subsequently regulates the inflammasome signaling pathway by deubiquitinating the lysine 63-linked polyubiquitination of ASC.  USP50 knockdown in human THP-1 cells and mouse bone marrow-derived macrophages shows a significant decrease in procaspase-1 cleavage, resulting in a reduced secretion of IL-1β and interleukin-18 (IL-18) upon treatment with NLRP3 stimuli and a redn. in ASC speck formation and oligomerization.  Thus, the authors elucidate a novel regulatory mechanism of the inflammasome signaling pathway mediated by the USP50 deubiquitinating enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYuk8j74_iFLVg90H21EOLACvtfcHk0lh-tsR9o35KDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kms7k%253D&md5=ec89d85ff5039871a81d88417e944ec1</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12558%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DSeo%26aufirst%3DD.%26aulast%3DYou%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DJung%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BH.%26atitle%3DThe%2520Deubiquitinating%2520Enzyme%252C%2520Ubiquitin-Specific%2520Peptidase%252050%252C%2520Regulates%2520Inflammasome%2520Activation%2520by%2520Targeting%2520the%2520ASC%2520Adaptor%2520Protein%26jtitle%3DFEBS%2520Lett.%26date%3D2017%26volume%3D591%26spage%3D479%26epage%3D490%26doi%3D10.1002%2F1873-3468.12558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castano-Rodriguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjuanes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, D.-Y.</span></span> <span> </span><span class="NLM_article-title">Severe Acute Respiratory Syndrome Coronavirus ORF3a Protein Activates the NLRP3 Inflammasome by Promoting TRAF3-Dependent Ubiquitination of ASC</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">8865</span>– <span class="NLM_lpage">8877</span>, <span class="refDoi"> DOI: 10.1096/fj.201802418R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1096%2Ffj.201802418R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31034780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVWnsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=8865-8877&issue=8&author=K.-L.+Siuauthor=K.-S.+Yuenauthor=C.+Castano-Rodriguezauthor=Z.-W.+Yeauthor=M.-L.+Yeungauthor=S.-Y.+Fungauthor=S.+Yuanauthor=C.-P.+Chanauthor=K.-Y.+Yuenauthor=L.+Enjuanesauthor=D.-Y.+Jin&title=Severe+Acute+Respiratory+Syndrome+Coronavirus+ORF3a+Protein+Activates+the+NLRP3+Inflammasome+by+Promoting+TRAF3-Dependent+Ubiquitination+of+ASC&doi=10.1096%2Ffj.201802418R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC</span></div><div class="casAuthors">Siu, Kam-Leung; Yuen, Kit-San; Castano-Rodriguez, Carlos; Ye, Zi-Wei; Yeung, Man-Lung; Fung, Sin-Yee; Yuan, Shuofeng; Chan, Chi-Ping; Yuen, Kwok-Yung; Enjuanes, Luis; Jin, Dong-Yan</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">8865-8877</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus (SARS-CoV) is capable of inducing a storm of proinflammatory cytokines.  In this study, we show that the SARS-CoV open reading frame 3a (ORF3a) accessory protein activates the NLRP3 inflammasome by promoting TNF receptor-assocd. factor 3 (TRAF3)-mediated ubiquitination of apoptosis-assocd. speck-like protein contg. a caspase recruitment domain (ASC).  SARS-CoV and its ORF3a protein were found to be potent activators of pro-IL-1b gene transcription and protein maturation, the 2 signals required for activation of the NLRP3 inflammasome.  ORF3a induced pro-IL-1b transcription through activation of NF-kB, which was mediated by TRAF3-dependent ubiquitination and processing of p105.  ORF3a induced elevation of IL-1b secretion was independent of its ion channel activity or absent in melanoma 2 but required NLRP3, ASC, and TRAF3.  ORF3a interacted with TRAF3 and ASC, colocalized with them in discrete punctate structures in the cytoplasm, and facilitated ASC speck formation.  TRAF3-dependent K63-linked ubiquitination of ASC was more pronounced in SARS-CoV-infected cells or when ORF3a was expressed.  Taken together, our findings reveal a new mechanism by which SARS-CoV ORF3a protein activates NF-kB and the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of p105 and ASC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PzhM5DkKdLVg90H21EOLACvtfcHk0lh-tsR9o35KDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVWnsLrP&md5=f5b36378f985b3e16047b00a0e5e5bde</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1096%2Ffj.201802418R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201802418R%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DK.-L.%26aulast%3DYuen%26aufirst%3DK.-S.%26aulast%3DCastano-Rodriguez%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DZ.-W.%26aulast%3DYeung%26aufirst%3DM.-L.%26aulast%3DFung%26aufirst%3DS.-Y.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DC.-P.%26aulast%3DYuen%26aufirst%3DK.-Y.%26aulast%3DEnjuanes%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DD.-Y.%26atitle%3DSevere%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520ORF3a%2520Protein%2520Activates%2520the%2520NLRP3%2520Inflammasome%2520by%2520Promoting%2520TRAF3-Dependent%2520Ubiquitination%2520of%2520ASC%26jtitle%3DFASEB%2520J.%26date%3D2019%26volume%3D33%26issue%3D8%26spage%3D8865%26epage%3D8877%26doi%3D10.1096%2Ffj.201802418R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-H.</span>; <span class="NLM_string-name">Lee, Y.</span>; <span class="NLM_string-name">Suh, G. Y.</span>; <span class="NLM_string-name">Lee, Y.-S.</span></span>, <span> </span><span class="NLM_article-title">Mul I Suppresses NLRP3 Inflammasome Activation Through Ubiquitination and Degradation of ASC</span>.  <i>bioRxiv</i> <span class="NLM_year">2019</span> <span class="refDoi"> DOI: 10.1101/830380</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1101%2F830380" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=H.-H.+Kim&author=Y.+Lee&author=G.+Y.+Suh&author=Y.-S.+Lee&title=bioRxiv"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1101%2F830380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1101%252F830380%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.-H.%26atitle%3DMul%2520I%2520Suppresses%2520NLRP3%2520Inflammasome%2520Activation%2520Through%2520Ubiquitination%2520and%2520Degradation%2520of%2520ASC%26btitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F830380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campden, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">The Role of Lysosomal Cysteine Cathepsins in NLRP3 Inflammasome Activation</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>670</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2019.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.abb.2019.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30807742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFOqu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=670&publication_year=2019&pages=32-42&author=R.+I.+Campdenauthor=Y.+Zhang&title=The+Role+of+Lysosomal+Cysteine+Cathepsins+in+NLRP3+Inflammasome+Activation&doi=10.1016%2Fj.abb.2019.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation</span></div><div class="casAuthors">Campden, Rhiannon I.; Zhang, Yifei</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">670</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Lysosomal cysteine cathepsins are a family of proteases that are involved in a myriad of cellular processes from proteolytic degrdn. in the lysosome to bone resorption.  These proteins mature following the cleavage of a pro-domain in the lysosome to become either exo- or endo-peptidases.  The cathepsins B, C, L, S and Z have been implicated in NLRP3 inflammasome activation following their activation with ATP, monosodium urate, silica crystals, or bacterial components, among others.  These five cathepsins have both compensatory and independent functions in NLRP3 inflammasome activation.  There is much evidence in the literature to support the release of cathepsin B following lysosomal membrane degrdn. which leads to NLRP3 inflammasome activation.  This is likely due to a hitherto unidentified role of this protein in the cytoplasm, although other interactions with autophagy proteins and within lysosomes have been proposed.  Cathepsin C is involved in the processing of neutrophil IL-1β through processing of upstream proteases.  Cathepsin Z is non-redundantly required for NLRP3 inflammasome activation following nigericin, ATP and monosodium urate activation.  Lysosomal cysteine cathepsins are members of a diverse and complementary family, and likely share both overlapping and independent functions in NLRP3 inflammasome activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQjAezZNN_wbVg90H21EOLACvtfcHk0lhSEe0fduzqpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFOqu74%253D&md5=1f05b83dc71939a82985ab9b97d46f7b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2019.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2019.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DCampden%26aufirst%3DR.%2BI.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DThe%2520Role%2520of%2520Lysosomal%2520Cysteine%2520Cathepsins%2520in%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2019%26volume%3D670%26spage%3D32%26epage%3D42%26doi%3D10.1016%2Fj.abb.2019.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajamäki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappalainen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öörni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Välimäki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matikainen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovanen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eklund, K. K.</span></span> <span> </span><span class="NLM_article-title">Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>), <span class="NLM_elocation-id">e11765</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0011765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.pone.0011765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20668705" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&issue=7&author=K.+Rajam%C3%A4kiauthor=J.+Lappalainenauthor=K.+%C3%96%C3%B6rniauthor=E.+V%C3%A4lim%C3%A4kiauthor=S.+Matikainenauthor=P.+T.+Kovanenauthor=K.+K.+Eklund&title=Cholesterol+Crystals+Activate+the+NLRP3+Inflammasome+in+Human+Macrophages%3A+A+Novel+Link+between+Cholesterol+Metabolism+and+Inflammation&doi=10.1371%2Fjournal.pone.0011765"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0011765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0011765%26sid%3Dliteratum%253Aachs%26aulast%3DRajam%25C3%25A4ki%26aufirst%3DK.%26aulast%3DLappalainen%26aufirst%3DJ.%26aulast%3D%25C3%2596%25C3%25B6rni%26aufirst%3DK.%26aulast%3DV%25C3%25A4lim%25C3%25A4ki%26aufirst%3DE.%26aulast%3DMatikainen%26aufirst%3DS.%26aulast%3DKovanen%26aufirst%3DP.%2BT.%26aulast%3DEklund%26aufirst%3DK.%2BK.%26atitle%3DCholesterol%2520Crystals%2520Activate%2520the%2520NLRP3%2520Inflammasome%2520in%2520Human%2520Macrophages%253A%2520A%2520Novel%2520Link%2520between%2520Cholesterol%2520Metabolism%2520and%2520Inflammation%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26issue%3D7%26doi%3D10.1371%2Fjournal.pone.0011765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbert, J. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span> <span> </span><span class="NLM_article-title">Multiple Cathepsins Promote Pro-IL-1β Synthesis and NLRP3-Mediated IL-1β Activation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">1685</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1500509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1500509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26195813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12gt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2015&pages=1685-1697&author=G.+M.+Orlowskiauthor=J.+d.+Colbertauthor=S.+Sharmaauthor=M.+Bogyoauthor=S.+A.+Robertsonauthor=K.+L.+Rock&title=Multiple+Cathepsins+Promote+Pro-IL-1%CE%B2+Synthesis+and+NLRP3-Mediated+IL-1%CE%B2+Activation&doi=10.4049%2Fjimmunol.1500509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Cathepsins Promote Pro-IL-1β Synthesis and NLRP3-Mediated IL-1β Activation</span></div><div class="casAuthors">Orlowski, Gregory M.; Colbert, Jeff D.; Sharma, Shruti; Bogyo, Matthew; Robertson, Stephanie A.; Rock, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1685-1697</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Sterile particles induce robust inflammatory responses that underlie the pathogenesis of diseases like silicosis, gout, and atherosclerosis.  A key cytokine mediating this response is IL-1β.  The generation of bioactive IL-1β by sterile particles is mediated by the NOD-like receptor contg. a pyrin domain 3 (NLRP3) inflammasome, although exactly how this occurs is incompletely resolved.  Prior studies have found that the cathepsin B inhibitor, Ca074Me, suppresses this response, supporting a model whereby ingested particles disrupt lysosomes and release cathepsin B into the cytosol, somehow activating NLRP3.  However, reports that cathepsin B-deficient macrophages have no defect in particle-induced IL-1β generation have questioned cathepsin B's involvement.  In this study, we examine the hypothesis that multiple redundant cathepsins (not just cathepsin B) mediate this process by evaluating IL-1β generation in murine macrophages, singly or multiply deficient in cathepsins B, L, C, S and X. Using an activity-based probe, we measure specific cathepsin activity in living cells, documenting compensatory changes in cathepsin-deficient cells, and Ca074Me's dose-dependent cathepsin inhibition profile is analyzed in parallel with its suppression of particle-induced IL-1β secretion.  Also, we evaluate endogenous cathepsin inhibitors cystatins C and B. Surprisingly, we find that multiple redundant cathepsins, inhibited by Ca074Me and cystatins, promote pro-IL-1β synthesis, and to our knowledge, we provide the first evidence that cathepsin X plays a nonredundant role in nonparticulate NLRP3 activation.  Finally, we find cathepsin inhibitors selectively block particle-induced NLRP3 activation, independently of suppressing pro-IL-1β synthesis.  Altogether, we demonstrate that both small mol. and endogenous cathepsin inhibitors suppress particle-induced IL-1β secretion, implicating roles for multiple cathepsins in both pro-IL-1β synthesis and NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohBFbAHtRb3rVg90H21EOLACvtfcHk0ljKb5x8BbNF5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12gt7zN&md5=a0e28826ce30c80aa0f9f3d941c6c396</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1500509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1500509%26sid%3Dliteratum%253Aachs%26aulast%3DOrlowski%26aufirst%3DG.%2BM.%26aulast%3DColbert%26aufirst%3DJ.%2Bd.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DBogyo%26aufirst%3DM.%26aulast%3DRobertson%26aufirst%3DS.%2BA.%26aulast%3DRock%26aufirst%3DK.%2BL.%26atitle%3DMultiple%2520Cathepsins%2520Promote%2520Pro-IL-1%25CE%25B2%2520Synthesis%2520and%2520NLRP3-Mediated%2520IL-1%25CE%25B2%2520Activation%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D195%26spage%3D1685%26epage%3D1697%26doi%3D10.4049%2Fjimmunol.1500509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichijo, H.</span></span> <span> </span><span class="NLM_article-title">The Lysosome Rupture-activated TAK1-JNK Pathway Regulates NLRP3 Inflammasome Activation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">32926</span>– <span class="NLM_lpage">32936</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.579961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1074%2Fjbc.M114.579961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25288801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKkt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=32926-32936&issue=47&author=M.+Okadaauthor=A.+Matsuzawaauthor=A.+Yoshimuraauthor=H.+Ichijo&title=The+Lysosome+Rupture-activated+TAK1-JNK+Pathway+Regulates+NLRP3+Inflammasome+Activation&doi=10.1074%2Fjbc.M114.579961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation</span></div><div class="casAuthors">Okada, Masahiro; Matsuzawa, Atsushi; Yoshimura, Akihiko; Ichijo, Hidenori</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">32926-32936</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Lysosome rupture triggers NLRP3 inflammasome activation in macrophages.  However, the underlying mechanism is not fully understood.  Here we showed that the TAK1-JNK pathway, a MAPK signaling pathway, is activated through lysosome rupture and that this activation is necessary for the complete activation of the NLRP3 inflammasome through the oligomerization of an adapter protein, apoptosis-assocd. speck-like protein contg. a caspase recruitment domain (ASC).  We also revealed that the activation of the TAK1-JNK pathway is sustained through Ca2+ ions and that calcium/calmodulin-dependent protein kinase type II functions upstream of the TAK1-JNK pathway and specifically regulates lysosome rupture-induced NLRP3 inflammasome activation.  These data suggest a novel role for the TAK1-JNK pathway as a crit. regulator of NLRP3 inflammasome activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplzjRjZXbuS7Vg90H21EOLACvtfcHk0ljKb5x8BbNF5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKkt7rF&md5=a6885a1a5a1ef95eb984777e4dfa808b</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.579961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.579961%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DMatsuzawa%26aufirst%3DA.%26aulast%3DYoshimura%26aufirst%3DA.%26aulast%3DIchijo%26aufirst%3DH.%26atitle%3DThe%2520Lysosome%2520Rupture-activated%2520TAK1-JNK%2520Pathway%2520Regulates%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D47%26spage%3D32926%26epage%3D32936%26doi%3D10.1074%2Fjbc.M114.579961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enkhjargal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaguit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span> <span> </span><span class="NLM_article-title">Dihydrolipoic Acid Inhibits Lysosomal Rupture and NLRP3 Through Lysosome-Associated Membrane Protein-1/Calcium/Calmodulin-Dependent Protein Kinase II/TAK1 Pathways After Subarachnoid Hemorrhage in Rat</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1161/STROKEAHA.117.018593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1161%2FSTROKEAHA.117.018593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29273596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=175-183&issue=1&author=K.+Zhouauthor=B.+Enkhjargalauthor=Z.+Xieauthor=C.+Sunauthor=L.+Wuauthor=J.+Malaguitauthor=S.+Chenauthor=J.+Tangauthor=J.+Zhangauthor=J.+H.+Zhang&title=Dihydrolipoic+Acid+Inhibits+Lysosomal+Rupture+and+NLRP3+Through+Lysosome-Associated+Membrane+Protein-1%2FCalcium%2FCalmodulin-Dependent+Protein+Kinase+II%2FTAK1+Pathways+After+Subarachnoid+Hemorrhage+in+Rat&doi=10.1161%2FSTROKEAHA.117.018593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydrolipoic acid inhibits lysosomal rupture and nlrp3 through lysosome-associated membrane protein-1/calcium/calmodulin-dependent protein kinase ii/tak1 pathways after subarachnoid hemorrhage in rat</span></div><div class="casAuthors">Zhou, Keren; Enkhjargal, Budbazar; Xie, Zhiyi; Sun, Chengmei; Wu, Lingyun; Malaguit, Jay; Chen, Sheng; Tang, Jiping; Zhang, Jianmin; Zhang, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-183</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND AND PURPOSE-: The NLRP3 (nucleotide binding and oligomerization domain-like receptor family pyrin domain-contg. 3) inflammasome is a crucial component of the inflammatory response in early brain injury after subarachnoid hemorrhage (SAH).  In this study, we investigated a role of dihydrolipoic acid (DHLA) in lysosomal rupture, NLRP3 activation, and detd. the underlying pathway.  METHODS-: SAH was induced by endovascular perforation in male Sprague-Dawley rats.  DHLA was administered i.p. 1 h after SAH.  Small interfering RNA for lysosome-assocd. membrane protein-1 and CaMKIIα (calcium/calmodulin-dependent protein kinase II α) was administered through intracerebroventricular 48 h before SAH induction.  SAH grade evaluation, short- and long-term neurol. function testing, Western blot, and immunofluorescence staining expts. were performed.  RESULTS-: DHLA treatment increased the expression of lysosome-assocd. membrane protein-1 and decreased phosphorylated CaMKIIα and NLRP3 inflammasome, thereby alleviating neurol. deficits after SAH.  Lysosome-assocd. membrane protein-1 small interfering RNA abolished the neuroprotective effects of DHLA and increased the level of phosphorylated CaMKIIα, p-TAK1 (phosphorylated transforming growth factor-β-activated kinase), p-JNK (phosphorylated c-Jun-N-terminal kinase), and NLRP3 inflammasome.  CaMKIIα small interfering RNA downregulated the expression of p-TAK1, p-JNK, and NLRP3 and improved the neurobehavior after SAH.  CONCLUSIONS-: DHLA treatment improved neurofunction and alleviated inflammation through the lysosome-assocd. membrane protein-1/CaMKII/TAK1 pathway in early brain injury after SAH.  DHLA may provide a promising treatment to alleviate early brain injury after SAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8EwUm0EBjL7Vg90H21EOLACvtfcHk0liI_6tU6a1iBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2ksrc%253D&md5=3fe7d21a458b66d817c6847279a1168b</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.117.018593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.117.018593%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DK.%26aulast%3DEnkhjargal%26aufirst%3DB.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DMalaguit%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26atitle%3DDihydrolipoic%2520Acid%2520Inhibits%2520Lysosomal%2520Rupture%2520and%2520NLRP3%2520Through%2520Lysosome-Associated%2520Membrane%2520Protein-1%252FCalcium%252FCalmodulin-Dependent%2520Protein%2520Kinase%2520II%252FTAK1%2520Pathways%2520After%2520Subarachnoid%2520Hemorrhage%2520in%2520Rat%26jtitle%3DStroke%26date%3D2018%26volume%3D49%26issue%3D1%26spage%3D175%26epage%3D183%26doi%3D10.1161%2FSTROKEAHA.117.018593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.-C.</span></span> <span> </span><span class="NLM_article-title">Hydroxychloroquine Attenuates Renal Ischemia/Reperfusion Injury by Inhibiting Cathepsin Mediated NLRP3 Inflammasome Activation</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">351</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29298988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSms7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-14&issue=351&author=T.-T.+Tangauthor=M.-M.+Panauthor=Y.+Wenauthor=B.+Wangauthor=Z.-L.+Liauthor=M.+Wuauthor=F.-M.+Wangauthor=S.+D.+Crowleyauthor=B.-C.+Liu&title=Hydroxychloroquine+Attenuates+Renal+Ischemia%2FReperfusion+Injury+by+Inhibiting+Cathepsin+Mediated+NLRP3+Inflammasome+Activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA</span></div><div class="casAuthors">Tang, Jianming; Zhong, Guangsheng; Zhang, Haibo; Yu, Bo; Wei, Fangqiang; Luo, Liming; kang, Yao; Wu, Jianhui; Jiang, Jiaxiang; Li, Yucheng; Wu, Shuqiang; Jia, Yongshi; Liang, Xiaodong; Bi, Aihong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Conventional therapies and novel mol. targeted therapies against breast cancer have gained great advances over the past two decades.  However, poor prognosis and low survival rate are far from expectation for improvement, particularly in patients with triple neg. breast cancer (TNBC).  Here, we found that lncRNA DANCR was significantly overregulated in TNBC tissues and cell lines compared with normal breast tissues or other type of breast cancer.  Knockdown of DANCR suppressed TNBC proliferation both in vitro and in vivo.  Further study of underlying mechanisms demonstrated that DANCR bound with RXRA and increased its serine 49/78 phosphorylation via GSK3β, resulting in activating PIK3CA transcription, and subsequently enhanced PI3K/AKT signaling and TNBC tumorigenesis.  Taken together, our findings identified DANCR as an pro-oncogene and uncovered a new working pattern of lncRNA to mediate TNBC tumorigenesis, which may be a potential therapeutic target for improving treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc1dh6prybH7Vg90H21EOLACvtfcHk0liI_6tU6a1iBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSms7jE&md5=fdca54208fbbe946f8a119cc51288d7f</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DT.-T.%26aulast%3DPan%26aufirst%3DM.-M.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DZ.-L.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.-M.%26aulast%3DCrowley%26aufirst%3DS.%2BD.%26aulast%3DLiu%26aufirst%3DB.-C.%26atitle%3DHydroxychloroquine%2520Attenuates%2520Renal%2520Ischemia%252FReperfusion%2520Injury%2520by%2520Inhibiting%2520Cathepsin%2520Mediated%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26issue%3D351%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Arcy Hart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. R.</span></span> <span> </span><span class="NLM_article-title">Ammonia Inhibits Phagosome-Lysosome Fusion in Macrophages</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1038/286079a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2F286079a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=6993961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADyaL3cXls1Wrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1980&pages=79-80&author=A.+H.+Gordonauthor=P.+D%27Arcy+Hartauthor=M.+R.+Young&title=Ammonia+Inhibits+Phagosome-Lysosome+Fusion+in+Macrophages&doi=10.1038%2F286079a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Ammonia inhibits phagosome-lysosome fusion in macrophages</span></div><div class="casAuthors">Gordon, A. H.; D'Arcy Hart, P.; Young, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5768</span>),
    <span class="NLM_cas:pages">79-80</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">NH3 inhibited phagosome-lysosome fusion (P-LF) induced in mouse peritoneal macrophages by ingestion of Saccharomyces cerevisiae.  Mycobacterium tuberculosis Produced sufficient NH3 (≤20 mM) when grown in vitro to account for most or all of the fusion-inhibitory effect of its culture fluid in this yeast system.  Thus, M. tuberculosis may inhibit P-LF by the prodn. of NH3 or relevant amines within phagosomes of macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx4A85F2voyrVg90H21EOLACvtfcHk0lgV-_P90IXx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXls1Wrurw%253D&md5=b3da688cb26ebc0c2116a3cd337b41eb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2F286079a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F286079a0%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DA.%2BH.%26aulast%3DD%2527Arcy%2BHart%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DM.%2BR.%26atitle%3DAmmonia%2520Inhibits%2520Phagosome-Lysosome%2520Fusion%2520in%2520Macrophages%26jtitle%3DNature%26date%3D1980%26volume%3D286%26spage%3D79%26epage%3D80%26doi%3D10.1038%2F286079a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heid, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter, R. D.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Reactive Oxygen Species Induces NLRP3-Dependent Lysosmal Damage and Inflammasome Activation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5230</span>– <span class="NLM_lpage">5238</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1301490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24089192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWlsL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=5230-5238&issue=10&author=M.+E.+Heidauthor=P.+A.+Keyelauthor=C.+Kamgaauthor=S.+Shivaauthor=S.+C.+Watkinsauthor=R.+D.+Salter&title=Mitochondrial+Reactive+Oxygen+Species+Induces+NLRP3-Dependent+Lysosmal+Damage+and+Inflammasome+Activation&doi=10.4049%2Fjimmunol.1301490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Reactive Oxygen Species Induces NLRP3-Dependent Lysosomal Damage and Inflammasome Activation</span></div><div class="casAuthors">Heid, Michelle E.; Keyel, Peter A.; Kamga, Christelle; Shiva, Sruti; Watkins, Simon C.; Salter, Russell D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5230-5238</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The nucleotide-binding oligomerization domain-like receptor family, pyrin domain-contg. 3 (NLRP3) inflammasome drives many inflammatory processes and mediates IL-1 family cytokine release.  Inflammasome activators typically damage cells and may release lysosomal and mitochondrial products into the cytosol.  Macrophages triggered by the NLRP3 inflammasome activator nigericin show reduced mitochondrial function and decreased cellular ATP.  Release of mitochondrial reactive oxygen species (ROS) leads to subsequent lysosomal membrane permeabilization (LMP).  NLRP3-deficient macrophages show comparable reduced mitochondrial function and ATP loss, but maintain lysosomal acidity, demonstrating that LMP is NLRP3 dependent.  A subset of wild-type macrophages undergo subsequent mitochondrial membrane permeabilization and die.  Both LMP and mitochondrial membrane permeabilization are inhibited by potassium, scavenging mitochondrial ROS, or NLRP3 deficiency, but are unaffected by cathepsin B or caspase-1 inhibitors.  In contrast, IL-1β secretion is ablated by potassium, scavenging mitochondrial ROS, and both cathepsin B and caspase-1 inhibition.  These results demonstrate interplay between lysosomes and mitochondria that sustain NLRP3 activation and distinguish cell death from IL-1β release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj5uO2tzJX_7Vg90H21EOLACvtfcHk0lgV-_P90IXx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWlsL%252FL&md5=f8016a549ebfb06742c3a4140349704a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301490%26sid%3Dliteratum%253Aachs%26aulast%3DHeid%26aufirst%3DM.%2BE.%26aulast%3DKeyel%26aufirst%3DP.%2BA.%26aulast%3DKamga%26aufirst%3DC.%26aulast%3DShiva%26aufirst%3DS.%26aulast%3DWatkins%26aufirst%3DS.%2BC.%26aulast%3DSalter%26aufirst%3DR.%2BD.%26atitle%3DMitochondrial%2520Reactive%2520Oxygen%2520Species%2520Induces%2520NLRP3-Dependent%2520Lysosmal%2520Damage%2520and%2520Inflammasome%2520Activation%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26issue%3D10%26spage%3D5230%26epage%3D5238%26doi%3D10.4049%2Fjimmunol.1301490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorbara, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardin, S. E.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial ROS Fuel the Inflammasome</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1038/cr.2011.20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fcr.2011.20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21283134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BC3MvhtlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=558-560&author=M.+T.+Sorbaraauthor=S.+E.+Girardin&title=Mitochondrial+ROS+Fuel+the+Inflammasome&doi=10.1038%2Fcr.2011.20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial ROS fuel the inflammasome</span></div><div class="casAuthors">Sorbara Matthew T; Girardin Stephen E</div><div class="citationInfo"><span class="NLM_cas:title">Cell research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">558-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToLlA23qka5EkUaC_kzhvyfW6udTcc2eb4hqI0BAsYB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvhtlGqug%253D%253D&md5=007c030ae99fce66aa11f93289391f5d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fcr.2011.20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2011.20%26sid%3Dliteratum%253Aachs%26aulast%3DSorbara%26aufirst%3DM.%2BT.%26aulast%3DGirardin%26aufirst%3DS.%2BE.%26atitle%3DMitochondrial%2520ROS%2520Fuel%2520the%2520Inflammasome%26jtitle%3DCell%2520Res.%26date%3D2011%26volume%3D21%26spage%3D558%26epage%3D560%26doi%3D10.1038%2Fcr.2011.20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span> <span> </span><span class="NLM_article-title">A Role for Mitochondria in NLRP3 Inflammasome Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1038/nature09663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature09663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21124315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2nsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=221-225&author=R.+Zhouauthor=A.+S.+Yazdiauthor=P.+Menuauthor=J.+Tschopp&title=A+Role+for+Mitochondria+in+NLRP3+Inflammasome+Activation&doi=10.1038%2Fnature09663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A role for mitochondria in NLRP3 inflammasome activation</span></div><div class="casAuthors">Zhou, Rong-Bin; Yazdi, Amir S.; Menu, Philippe; Tschopp, Jurg</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">221-225</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An inflammatory response initiated by the NLRP3 inflammasome is triggered by a variety of situations of host 'danger', including infection and metabolic dysregulation.  Previous studies suggested that NLRP3 inflammasome activity is neg. regulated by autophagy and pos. regulated by reactive oxygen species (ROS) derived from an uncharacterized organelle.  Here we show that mitophagy/autophagy blockade leads to the accumulation of damaged, ROS-generating mitochondria, and this in turn activates the NLRP3 inflammasome.  Resting NLRP3 localizes to endoplasmic reticulum structures, whereas on inflammasome activation both NLRP3 and its adaptor ASC redistribute to the perinuclear space where they colocalize with endoplasmic reticulum and mitochondria organelle clusters.  Notably, both ROS generation and inflammasome activation are suppressed when mitochondrial activity is dysregulated by inhibition of the voltage-dependent anion channel.  This indicates that NLRP3 inflammasome senses mitochondrial dysfunction and may explain the frequent assocn. of mitochondrial damage with inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2S_8r04FZELVg90H21EOLACvtfcHk0lh0iRLPnqzBGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2nsLrE&md5=f1a13fa2ad8568fbd6c9467121aa1d9d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnature09663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09663%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DYazdi%26aufirst%3DA.%2BS.%26aulast%3DMenu%26aufirst%3DP.%26aulast%3DTschopp%26aufirst%3DJ.%26atitle%3DA%2520Role%2520for%2520Mitochondria%2520in%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D221%26epage%3D225%26doi%3D10.1038%2Fnature09663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakahira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haspel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinam, V. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolinay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englert, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernadas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryter, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, A. M. K.</span></span> <span> </span><span class="NLM_article-title">Autophagy Proteins Regulate Innate Immune Responses by Inhibiting the Release of Mitochondrial DNA Mediated by the NLRP3 Inflammasome</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1038/ni.1980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.1980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21151103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGgtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=222-230&author=K.+Nakahiraauthor=J.+A.+Haspelauthor=V.+A.+K.+Rathinamauthor=S.-J.+Leeauthor=T.+Dolinayauthor=H.+C.+Lamauthor=J.+A.+Englertauthor=M.+Rabinovitchauthor=M.+Cernadasauthor=H.+P.+Kimauthor=K.+A.+Fitzgeraldauthor=S.+W.+Ryterauthor=A.+M.+K.+Choi&title=Autophagy+Proteins+Regulate+Innate+Immune+Responses+by+Inhibiting+the+Release+of+Mitochondrial+DNA+Mediated+by+the+NLRP3+Inflammasome&doi=10.1038%2Fni.1980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome</span></div><div class="casAuthors">Nakahira, Ki-Ichi; Haspel, Jeffrey Adam; Rathinam, Vijay A. K.; Lee, Seon-Jin; Dolinay, Tamas; Lam, Hilaire C.; Englert, Joshua A.; Rabinovitch, Marlene; Cernadas, Manuela; Kim, Hong-Pyo; Fitzgerald, Katherine A.; Ryter, Stefan W.; Choi, Augustine M.-K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-230</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Autophagy, a cellular process for organelle and protein turnover, regulates innate immune responses.  Here we demonstrate that depletion of the autophagic proteins LC3B and beclin 1 enhanced the activation of caspase-1 and secretion of interleukin-1β (IL-1β) and IL-18.  Depletion of autophagic proteins promoted the accumulation of dysfunctional mitochondria and cytosolic translocation of mitochondrial DNA (mtDNA) in response to lipopolysaccharide (LPS) and ATP in macrophages.  Release of mtDNA into the cytosol depended on the NALP3 inflammasome and mitochondrial reactive oxygen species (ROS).  Cytosolic mtDNA contributed to the secretion of IL-1β and IL-18 in response to LPS and ATP.  LC3B-deficient mice produced more caspase-1-dependent cytokines in two sepsis models and were susceptible to LPS-induced mortality.  Our study suggests that autophagic proteins regulate NALP3-dependent inflammation by preserving mitochondrial integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA9JFQ4PVrk7Vg90H21EOLACvtfcHk0lh0iRLPnqzBGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGgtrzE&md5=acce38793034d600b469a8a2b6b4ee0d</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fni.1980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1980%26sid%3Dliteratum%253Aachs%26aulast%3DNakahira%26aufirst%3DK.%26aulast%3DHaspel%26aufirst%3DJ.%2BA.%26aulast%3DRathinam%26aufirst%3DV.%2BA.%2BK.%26aulast%3DLee%26aufirst%3DS.-J.%26aulast%3DDolinay%26aufirst%3DT.%26aulast%3DLam%26aufirst%3DH.%2BC.%26aulast%3DEnglert%26aufirst%3DJ.%2BA.%26aulast%3DRabinovitch%26aufirst%3DM.%26aulast%3DCernadas%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%2BP.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DRyter%26aufirst%3DS.%2BW.%26aulast%3DChoi%26aufirst%3DA.%2BM.%2BK.%26atitle%3DAutophagy%2520Proteins%2520Regulate%2520Innate%2520Immune%2520Responses%2520by%2520Inhibiting%2520the%2520Release%2520of%2520Mitochondrial%2520DNA%2520Mediated%2520by%2520the%2520NLRP3%2520Inflammasome%26jtitle%3DNat.%2520Immunol.%26date%3D2011%26volume%3D12%26spage%3D222%26epage%3D230%26doi%3D10.1038%2Fni.1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-García, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Banaclocha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angosto-Bazarra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torre-Minguela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baroja-Mazo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcón-Vila, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Alarcón, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amores-Iniesta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Sánchez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercole, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Lisorge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Pacheco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Gil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adriouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch-Nolte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luján, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta-Villegas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrilla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Palenciano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrin, P.</span></span> <span> </span><span class="NLM_article-title">P2X7 Receptor Induces Mitochondrial Failure in Monocytes and Compromises NLRP3 Inflammasome Activation During Sepsis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2711</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-10626-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41467-019-10626-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31221993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BB3M3ptVaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2711&author=J.+J.+Mart%C3%ADnez-Garc%C3%ADaauthor=H.+Mart%C3%ADnez-Banaclochaauthor=D.+Angosto-Bazarraauthor=C.+de+Torre-Minguelaauthor=A.+Baroja-Mazoauthor=C.+Alarc%C3%B3n-Vilaauthor=L.+Mart%C3%ADnez-Alarc%C3%B3nauthor=J.+Amores-Iniestaauthor=F.+Mart%C3%ADn-S%C3%A1nchezauthor=G.+A.+Ercoleauthor=C.+M.+Mart%C3%ADnezauthor=A.+Gonz%C3%A1lez-Lisorgeauthor=J.+Fern%C3%A1ndez-Pachecoauthor=P.+Mart%C3%ADnez-Gilauthor=S.+Adriouchauthor=F.+Koch-Nolteauthor=J.+Luj%C3%A1nauthor=F.+Acosta-Villegasauthor=P.+Parrillaauthor=C.+Garc%C3%ADa-Palencianoauthor=P.+Pelegrin&title=P2X7+Receptor+Induces+Mitochondrial+Failure+in+Monocytes+and+Compromises+NLRP3+Inflammasome+Activation+During+Sepsis&doi=10.1038%2Fs41467-019-10626-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis</span></div><div class="casAuthors">Martinez-Garcia Juan Jose; Martinez-Banaclocha Helios; Angosto-Bazarra Diego; de Torre-Minguela Carlos; Baroja-Mazo Alberto; Alarcon-Vila Cristina; Martinez-Alarcon Laura; Amores-Iniesta Joaquin; Martin-Sanchez Fatima; Parrilla Pascual; Pelegrin Pablo; Ercole Giovanni A; Gonzalez-Lisorge Ada; Fernandez-Pacheco Jose; Martinez-Gil Piedad; Acosta-Villegas Francisco; Garcia-Palenciano Carlos; Martinez Carlos M; Adriouch Sahil; Koch-Nolte Friedrich; Lujan Juan; Parrilla Pascual</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2711</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sepsis is characterized by a systemic inflammatory response followed by immunosuppression of the host.  Metabolic defects and mitochondrial failure are common in immunocompromised patients with sepsis.  The NLRP3 inflammasome is important for establishing an inflammatory response after activation by the purinergic P2X7 receptor.  Here, we study a cohort of individuals with intra-abdominal origin sepsis and show that patient monocytes have impaired NLRP3 activation by the P2X7 receptor.  Furthermore, most sepsis-related deaths are among patients whose NLRP3 activation is profoundly altered.  In monocytes from sepsis patients, the P2X7 receptor is associated with mitochondrial dysfunction.  Furthermore, activation of the P2X7 receptor results in mitochondrial damage, which in turn inhibits NLRP3 activation by HIF-1α.  We show that mortality increases in a mouse model of sepsis when the P2X7 receptor is activated in vivo.  These data reveal a molecular mechanism initiated by the P2X7 receptor that contributes to NLRP3 impairment during infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTcVKXbfvKN7GbPKh4T9eAfW6udTcc2ebr-YUH3W9uwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3ptVaisA%253D%253D&md5=c42379ba9783f43d78d277fba2b0c34b</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-10626-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-10626-x%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez-Garc%25C3%25ADa%26aufirst%3DJ.%2BJ.%26aulast%3DMart%25C3%25ADnez-Banaclocha%26aufirst%3DH.%26aulast%3DAngosto-Bazarra%26aufirst%3DD.%26aulast%3Dde%2BTorre-Minguela%26aufirst%3DC.%26aulast%3DBaroja-Mazo%26aufirst%3DA.%26aulast%3DAlarc%25C3%25B3n-Vila%26aufirst%3DC.%26aulast%3DMart%25C3%25ADnez-Alarc%25C3%25B3n%26aufirst%3DL.%26aulast%3DAmores-Iniesta%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADn-S%25C3%25A1nchez%26aufirst%3DF.%26aulast%3DErcole%26aufirst%3DG.%2BA.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DC.%2BM.%26aulast%3DGonz%25C3%25A1lez-Lisorge%26aufirst%3DA.%26aulast%3DFern%25C3%25A1ndez-Pacheco%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADnez-Gil%26aufirst%3DP.%26aulast%3DAdriouch%26aufirst%3DS.%26aulast%3DKoch-Nolte%26aufirst%3DF.%26aulast%3DLuj%25C3%25A1n%26aufirst%3DJ.%26aulast%3DAcosta-Villegas%26aufirst%3DF.%26aulast%3DParrilla%26aufirst%3DP.%26aulast%3DGarc%25C3%25ADa-Palenciano%26aufirst%3DC.%26aulast%3DPelegrin%26aufirst%3DP.%26atitle%3DP2X7%2520Receptor%2520Induces%2520Mitochondrial%2520Failure%2520in%2520Monocytes%2520and%2520Compromises%2520NLRP3%2520Inflammasome%2520Activation%2520During%2520Sepsis%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D2711%26doi%3D10.1038%2Fs41467-019-10626-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pétrilli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dostert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span> <span> </span><span class="NLM_article-title">Activation of the NALP3 Inflammasome is Triggered by Low Intracellular Potassium Concentration</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1583</span>– <span class="NLM_lpage">1589</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4402195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fsj.cdd.4402195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=17599094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptFymurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1583-1589&author=V.+P%C3%A9trilliauthor=S.+Papinauthor=C.+Dostertauthor=A.+Mayorauthor=F.+Martinonauthor=J.+Tschopp&title=Activation+of+the+NALP3+Inflammasome+is+Triggered+by+Low+Intracellular+Potassium+Concentration&doi=10.1038%2Fsj.cdd.4402195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration</span></div><div class="casAuthors">Petrilli, V.; Papin, S.; Dostert, C.; Mayor, A.; Martinon, F.; Tschopp, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1583-1589</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammasomes are Nod-like receptor(NLR)- and caspase-1-contg. cytoplasmic multiprotein complexes, which upon their assembly, process and activate the proinflammatory cytokines interleukin (IL)-1β and IL-18.  The inflammasomes harboring the NLR members NALP1, NALP3 and IPAF have been best characterized.  While the IPAF inflammasome is activated by bacterial flagellin, activation of the NALP3 inflammasome is triggered not only by several microbial components, but also by a plethora of danger-assocd. host mols. such as uric acid.  How NALP3 senses these chem. unrelated activators is not known.  Here, we provide evidence that activation of NALP3, but not of the IPAF inflammasome, is blocked by inhibiting K+ efflux from cells.  Low intracellular K+ is also a requirement for NALP1 inflammasome activation by lethal toxin of Bacillus anthracis.  In vitro, NALP inflammasome assembly and caspase-1 recruitment occurs spontaneously at K+ concns. below 90 mM, but is prevented at higher concns.  Thus, low intracellular K+ may be the least common trigger of NALP-inflammasome activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_dQ8Ub0nztrVg90H21EOLACvtfcHk0lisMJb9spxQZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptFymurg%253D&md5=2bfb251f0e7b7d90ebed564cbd63c90f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4402195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4402195%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9trilli%26aufirst%3DV.%26aulast%3DPapin%26aufirst%3DS.%26aulast%3DDostert%26aufirst%3DC.%26aulast%3DMayor%26aufirst%3DA.%26aulast%3DMartinon%26aufirst%3DF.%26aulast%3DTschopp%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520the%2520NALP3%2520Inflammasome%2520is%2520Triggered%2520by%2520Low%2520Intracellular%2520Potassium%2520Concentration%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2007%26volume%3D14%26spage%3D1583%26epage%3D1589%26doi%3D10.1038%2Fsj.cdd.4402195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Planillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuffa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Colón, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajendiran, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, G.</span></span> <span> </span><span class="NLM_article-title">K<sup>+</sup> Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1142</span>– <span class="NLM_lpage">1153</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2013.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2013.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23809161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaitb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=1142-1153&author=R.+Mu%C3%B1oz-Planilloauthor=P.+Kuffaauthor=G.+Mart%C3%ADnez-Col%C3%B3nauthor=B.+L.+Smithauthor=T.+M.+Rajendiranauthor=G.+N%C3%BA%C3%B1ez&title=K%2B+Efflux+Is+the+Common+Trigger+of+NLRP3+Inflammasome+Activation+by+Bacterial+Toxins+and+Particulate+Matter&doi=10.1016%2Fj.immuni.2013.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">K+ Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter</span></div><div class="casAuthors">Munoz-Planillo, Raul; Kuffa, Peter; Martinez-Colon, Giovanny; Smith, Brenna L.; Rajendiran, Thekkelnaycke M.; Nunez, Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1142-1153</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome is an important component of the innate immune system.  However, its mechanism of activation remains largely unknown.  We show that NLRP3 activators including bacterial pore-forming toxins, nigericin, ATP, and particulate matter caused mitochondrial perturbation or the opening of a large membrane pore, but this was not required for NLRP3 activation.  Furthermore, reactive oxygen species generation or a change in cell vol. was not necessary for NLRP3 activation.  Instead, the only common activity induced by all NLRP3 agonists was the permeation of the cell membrane to K+ and Na+.  Notably, redn. of the intracellular K+ concn. was sufficient to activate NLRP3, whereas an increase in intracellular Na+ modulated but was not strictly required for inflammasome activation.  These results provide a unifying model for the activation of the NLRP3 inflammasome in which a drop in cytosolic K+ is the common step that is necessary and sufficient for caspase-1 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj2o5NsEXmVLVg90H21EOLACvtfcHk0lisMJb9spxQZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaitb3M&md5=5532eee6c2f44c06f67df63ea73f3a1e</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2013.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2013.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz-Planillo%26aufirst%3DR.%26aulast%3DKuffa%26aufirst%3DP.%26aulast%3DMart%25C3%25ADnez-Col%25C3%25B3n%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DB.%2BL.%26aulast%3DRajendiran%26aufirst%3DT.%2BM.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DG.%26atitle%3DK%252B%2520Efflux%2520Is%2520the%2520Common%2520Trigger%2520of%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Bacterial%2520Toxins%2520and%2520Particulate%2520Matter%26jtitle%3DImmunity%26date%3D2013%26volume%3D38%26spage%3D1142%26epage%3D1153%26doi%3D10.1016%2Fj.immuni.2013.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malireddi, R.K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kometani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, T.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, A. B.</span></span> <span> </span><span class="NLM_article-title">The TWIK2 Potassium Efflux Channel in Macrophages Mediates NLRP3 Inflammasome Induced Inflammation</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2018.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2018.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29958799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Smu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=56-65&issue=1&author=A.+Diauthor=S.+Xiongauthor=Z.+Yeauthor=R.K.+S.+Malireddiauthor=S.+Kometaniauthor=M.+Zhongauthor=M.+Mittalauthor=Z.+Hongauthor=T.-D.+Kannegantiauthor=J.+Rehmanauthor=A.+B.+Malik&title=The+TWIK2+Potassium+Efflux+Channel+in+Macrophages+Mediates+NLRP3+Inflammasome+Induced+Inflammation&doi=10.1016%2Fj.immuni.2018.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation</span></div><div class="casAuthors">Di, Anke; Xiong, Shiqin; Ye, Zhiming; Malireddi, R. K. Subbarao; Kometani, Satoshi; Zhong, Ming; Mittal, Manish; Hong, Zhigang; Kanneganti, Thirumala-Devi; Rehman, Jalees; Malik, Asrar B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-65.e4</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Potassium (K+) efflux across the plasma membrane is thought to be an essential mechanism for ATP-induced NLRP3 inflammasome activation, yet the identity of the efflux channel has remained elusive.  Here we identified the two-pore domain K+ channel (K2P) TWIK2 as the K+ efflux channel triggering NLRP3 inflammasome activation.  Deletion of Kcnk6 (encoding TWIK2) prevented NLRP3 activation in macrophages and suppressed sepsis-induced lung inflammation.  Adoptive transfer of Kcnk6-/- macrophages into mouse airways after macrophage depletion also prevented inflammatory lung injury.  The K+ efflux channel TWIK2 in macrophages has a fundamental role in activating the NLRP3 inflammasome and consequently mediates inflammation, pointing to TWIK2 as a potential target for anti-inflammatory therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG6-0jm_OakLVg90H21EOLACvtfcHk0lisMJb9spxQZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Smu7vK&md5=81c9a6a77acc1fbda934ede3f5379585</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2018.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2018.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DA.%26aulast%3DXiong%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DMalireddi%26aufirst%3DR.K.%2BS.%26aulast%3DKometani%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DMittal%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DKanneganti%26aufirst%3DT.-D.%26aulast%3DRehman%26aufirst%3DJ.%26aulast%3DMalik%26aufirst%3DA.%2BB.%26atitle%3DThe%2520TWIK2%2520Potassium%2520Efflux%2520Channel%2520in%2520Macrophages%2520Mediates%2520NLRP3%2520Inflammasome%2520Induced%2520Inflammation%26jtitle%3DImmunity%26date%3D2018%26volume%3D49%26issue%3D1%26spage%3D56%26epage%3D65%26doi%3D10.1016%2Fj.immuni.2018.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&issue=1&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+Heeremaauthor=A.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lj8fGJs1dgHeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26issue%3D1%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittaluga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lih, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkre, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shustov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vose, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elstrom, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habermann, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munneke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1038/nm.3884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnm.3884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26193343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=922-926&issue=8&author=W.+H.+Wilsonauthor=R.+M.+Youngauthor=R.+Schmitzauthor=Y.+Yangauthor=S.+Pittalugaauthor=G.+Wrightauthor=C.-J.+Lihauthor=P.+M.+Williamsauthor=A.+L.+Shafferauthor=J.+Gerecitanoauthor=S.+de+Vosauthor=A.+Goyauthor=V.+P.+Kenkreauthor=P.+M.+Barrauthor=K.+A.+Blumauthor=A.+Shustovauthor=R.+Advaniauthor=N.+H.+Fowlerauthor=J.+M.+Voseauthor=R.+L.+Elstromauthor=T.+M.+Habermannauthor=J.+C.+Barrientosauthor=J.+McGreivyauthor=M.+Fardisauthor=B.+Y.+Changauthor=F.+Clowauthor=B.+Munnekeauthor=D.+Moussaauthor=D.+M.+Beaupreauthor=L.+M.+Staudt&title=Targeting+B+Cell+Receptor+Signaling+with+Ibrutinib+in+Diffuse+Large+B+Cell+Lymphoma&doi=10.1038%2Fnm.3884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span></div><div class="casAuthors">Wilson, Wyndham H.; Young, Ryan M.; Schmitz, Roland; Yang, Yandan; Pittaluga, Stefania; Wright, George; Lih, Chih-Jian; Williams, P. Mickey; Shaffer, Arthur L.; Gerecitano, John; de Vos, Sven; Goy, Andre; Kenkre, Vaishalee P.; Barr, Paul M.; Blum, Kristie A.; Shustov, Andrei; Advani, Ranjana; Fowler, Nathan H.; Vose, Julie M.; Elstrom, Rebecca L.; Habermann, Thomas M.; Barrientos, Jacqueline C.; McGreivy, Jesse; Fardis, Maria; Chang, Betty Y.; Clow, Fong; Munneke, Brian; Moussa, Davina; Beaupre, Darrin M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">922-926</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The two major subtypes of diffuse large B cell lymphoma (DLBCL)-activated B cell-like (ABC) and germinal center B cell-like (GCB)-arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling.  The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies.  We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling.  In a phase 1/2 clin. trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106).  ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), esp. those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways.  However, the highest no. of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms.  These results support the selective development of ibrutinib for the treatment of ABC DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpryc32RWzm77Vg90H21EOLACvtfcHk0liC9fLxPthRKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK&md5=d3342e8baa16eb379eed112c21d0b4ba</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnm.3884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3884%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DLih%26aufirst%3DC.-J.%26aulast%3DWilliams%26aufirst%3DP.%2BM.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DGerecitano%26aufirst%3DJ.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DKenkre%26aufirst%3DV.%2BP.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DShustov%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DElstrom%26aufirst%3DR.%2BL.%26aulast%3DHabermann%26aufirst%3DT.%2BM.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DMoussa%26aufirst%3DD.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520B%2520Cell%2520Receptor%2520Signaling%2520with%2520Ibrutinib%2520in%2520Diffuse%2520Large%2520B%2520Cell%2520Lymphoma%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D8%26spage%3D922%26epage%3D926%26doi%3D10.1038%2Fnm.3884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal
Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammeijer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s Tyrosine Kinase in B Cell and Malignancies</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0779-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1186%2Fs12943-018-0779-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29455639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=57&author=S.+Pal%0ASinghauthor=F.+Dammeijerauthor=R.+W.+Hendriks&title=Role+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+B+Cell+and+Malignancies&doi=10.1186%2Fs12943-018-0779-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in B cells and malignancies</span></div><div class="casAuthors">Pal Singh Simar; Dammeijer Floris; Hendriks Rudi W; Pal Singh Simar; Pal Singh Simar; Dammeijer Floris; Dammeijer Floris</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies.  BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells.  Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR).  More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies.  In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions.  Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016.  To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies.  BTK inhibition has molecular effects beyond its classic role in BCR signaling.  These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches.  Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.  As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors.  Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses.  In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp0F3T0LEJd4vKgEt20y1XfW6udTcc2eYsGs3HkKrchrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D&md5=de1ba14dc19e6a123c21b89f1f4133f4</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0779-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0779-z%26sid%3Dliteratum%253Aachs%26aulast%3DPal%2BSingh%26aufirst%3DS.%26aulast%3DDammeijer%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B%2520Cell%2520and%2520Malignancies%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D57%26doi%3D10.1186%2Fs12943-018-0779-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichulik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolz, O.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, T.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickhöfer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daiber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Münzenmayer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kümmerle-Deschner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz-Wachtel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walz, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimbacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. N. R.</span></span> <span> </span><span class="NLM_article-title">Human NACHT, LRR, and PYD Domain-Containing Protein 3 (NLRP3) Inflammasome Activity is Regulated by and Potentially Targetable Through Bruton Tyrosine Kinase</span>. <i>Mechanisms of Allergy/Immunology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2017.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.jaci.2017.01.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=1054-1067&issue=4&author=X.+Liuauthor=T.+Pichulikauthor=O.-O.+Wolzauthor=T.-M.+Dangauthor=A.+Stutzauthor=C.+Dillenauthor=M.+D.+Garciaauthor=H.+Krausauthor=S.+Dickh%C3%B6ferauthor=E.+Daiberauthor=L.+M%C3%BCnzenmayerauthor=S.+Wahlauthor=N.+Rieberauthor=J.+K%C3%BCmmerle-Deschnerauthor=A.+S.+Yazdiauthor=M.+Franz-Wachtelauthor=B.+Macekauthor=M.+Radsakauthor=S.+Vogelauthor=B.+Schulteauthor=J.+S.+Walzauthor=D.+Hartlauthor=E.+Latzauthor=S.+Stilgenbauerauthor=B.+Grimbacherauthor=L.+Millerauthor=C.+Brunnerauthor=C.+Wolzauthor=A.+N.+R.+Weber&title=Human+NACHT%2C+LRR%2C+and+PYD+Domain-Containing+Protein+3+%28NLRP3%29+Inflammasome+Activity+is+Regulated+by+and+Potentially+Targetable+Through+Bruton+Tyrosine+Kinase&doi=10.1016%2Fj.jaci.2017.01.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2017.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2017.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DPichulik%26aufirst%3DT.%26aulast%3DWolz%26aufirst%3DO.-O.%26aulast%3DDang%26aufirst%3DT.-M.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DDillen%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DM.%2BD.%26aulast%3DKraus%26aufirst%3DH.%26aulast%3DDickh%25C3%25B6fer%26aufirst%3DS.%26aulast%3DDaiber%26aufirst%3DE.%26aulast%3DM%25C3%25BCnzenmayer%26aufirst%3DL.%26aulast%3DWahl%26aufirst%3DS.%26aulast%3DRieber%26aufirst%3DN.%26aulast%3DK%25C3%25BCmmerle-Deschner%26aufirst%3DJ.%26aulast%3DYazdi%26aufirst%3DA.%2BS.%26aulast%3DFranz-Wachtel%26aufirst%3DM.%26aulast%3DMacek%26aufirst%3DB.%26aulast%3DRadsak%26aufirst%3DM.%26aulast%3DVogel%26aufirst%3DS.%26aulast%3DSchulte%26aufirst%3DB.%26aulast%3DWalz%26aufirst%3DJ.%2BS.%26aulast%3DHartl%26aufirst%3DD.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DGrimbacher%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DL.%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DWolz%26aufirst%3DC.%26aulast%3DWeber%26aufirst%3DA.%2BN.%2BR.%26atitle%3DHuman%2520NACHT%252C%2520LRR%252C%2520and%2520PYD%2520Domain-Containing%2520Protein%25203%2520%2528NLRP3%2529%2520Inflammasome%2520Activity%2520is%2520Regulated%2520by%2520and%2520Potentially%2520Targetable%2520Through%2520Bruton%2520Tyrosine%2520Kinase%26jtitle%3DMechanisms%2520of%2520Allergy%252FImmunology%26date%3D2017%26volume%3D140%26issue%3D4%26spage%3D1054%26epage%3D1067%26doi%3D10.1016%2Fj.jaci.2017.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staikov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piasecka-Stryczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangond, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolinsky, J.</span></span> <span> </span><span class="NLM_article-title">Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">2406</span>– <span class="NLM_lpage">2147</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa1901981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31075187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2406-2147&issue=25&author=X.+Montalbanauthor=D.+L.+Arnoldauthor=M.+s.+Weberauthor=I.+Staikovauthor=K.+Piasecka-Stryczynskaauthor=J.+Willmerauthor=E.+C.+Martinauthor=F.+Dangondauthor=S.+Syedauthor=J.+Wolinsky&title=Placebo-Controlled+Trial+of+an+Oral+BTK+Inhibitor+in+Multiple+Sclerosis&doi=10.1056%2FNEJMoa1901981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis</span></div><div class="casAuthors">Montalban, Xavier; Arnold, Douglas L.; Weber, Martin S.; Staikov, Ivan; Piasecka-Stryczynska, Karolina; Willmer, Jonathan; Martin, Emily C.; Dangond, Fernando; Syed, Sana; Wolinsky, Jerry S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2406-2417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis.  Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo. methods In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label di-Me fumarate (DMF) as a ref.  The primary end point was the total (cumulative) no. of gadolinium-enhancing lesions identified on T1-weighted magnetic resonance imaging at weeks 12, 16, 20, and 24.  Key secondary end points included the annualized relapse rate and change from baseline in the score on the Expanded Disability Status Scale (EDSS). results A total of 267 patients were randomly assigned to a trial group.  The mean (±SD) total no. of gadolinium-enhancing lesions during weeks 12 through 24 was 3.85 ± 5.44 in the placebo group, 4.06 ± 8.02 in the evobrutinib 25-mg group, 1.69 ± 4.69 in the evobrutinib 75-mg once-daily group, 1.15 ± 3.70 in the evobrutinib 75-mg twice-daily group, and 4.78 ± 22.05 in the DMF group.  The baseline adjusted rate ratios for the total no. of lesions over time as compared with placebo were 1.45 in the evobrutinib 25-mg group (P = 0.32), 0.30 in the evobrutinib 75-mg once-daily group (P = 0.005), and 0.44 in the evobrutinib 75-mg twice-daily group (P = 0.06).  The unadjusted annualized relapse rate at week 24 was 0.37 in the placebo group, 0.57 in the evobrutinib 25-mg group, 0.13 in the evobrutinib 75-mg once-daily group, 0.08 in the evobrutinib 75-mg twice-daily group, and 0.20 in the DMF group.  There was no significant effect of trial group on the change from baseline in the EDSS score.  Elevations in liver aminotransferase values were obsd. with evobrutinib. conclusions Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo.  There was no significant difference with placebo for either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor in the annualized relapse rate or disability progression at any dose.  Longer and larger trials are required to det. the effect and risks of evobrutinib in patients with multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBCts7AZpkC7Vg90H21EOLACvtfcHk0lgCNRvhkh8n9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGqurs%253D&md5=86489e8fe1c2130c8ab46986f0b52881</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901981%26sid%3Dliteratum%253Aachs%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DArnold%26aufirst%3DD.%2BL.%26aulast%3DWeber%26aufirst%3DM.%2Bs.%26aulast%3DStaikov%26aufirst%3DI.%26aulast%3DPiasecka-Stryczynska%26aufirst%3DK.%26aulast%3DWillmer%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DE.%2BC.%26aulast%3DDangond%26aufirst%3DF.%26aulast%3DSyed%26aufirst%3DS.%26aulast%3DWolinsky%26aufirst%3DJ.%26atitle%3DPlacebo-Controlled%2520Trial%2520of%2520an%2520Oral%2520BTK%2520Inhibitor%2520in%2520Multiple%2520Sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D25%26spage%3D2406%26epage%3D2147%26doi%3D10.1056%2FNEJMoa1901981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuckwell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsumoto, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damjanov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedkov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinn, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Bind, Phase II Trial (ANDES Study)</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1435</span>– <span class="NLM_lpage">1446</span>, <span class="refDoi"> DOI: 10.1002/art.41275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fart.41275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGitLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=1435-1446&issue=9&author=S.+Cohenauthor=K.+Tuckwellauthor=T.+R.+Katsumotoauthor=R.+Zhaoauthor=J.+Galanterauthor=C.+Leeauthor=J.+Raeauthor=B.+Tothauthor=N.+Ramamoorthiauthor=J.+A.+Hackneyauthor=A.+Bermanauthor=N.+Damjanovauthor=D.+Fedkovauthor=S.+Jekaauthor=L.+W.+Chinnauthor=M.+J.+Townsendauthor=A.+M.+Morimotoauthor=M.+C.+Genovese&title=Fenebrutinib+versus+Placebo+or+Adalimumab+in+Rheumatoid+Arthritis%3A+A+Randomized%2C+Double-Bind%2C+Phase+II+Trial+%28ANDES+Study%29&doi=10.1002%2Fart.41275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial</span></div><div class="casAuthors">Cohen, Stanley; Tuckwell, Katie; Katsumoto, Tamiko R.; Zhao, Rui; Galanter, Joshua; Lee, Chin; Rae, Julie; Toth, Balazs; Ramamoorthi, Nandhini; Hackney, Jason A.; Berman, Alberto; Damjanov, Nemanja; Fedkov, Dmytro; Jeka, Slawomir; Chinn, Leslie W.; Townsend, Michael J.; Morimoto, Alyssa M.; Genovese, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1435-1446</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA).  Methods : Patients with RA and an inadequate response to methotrexate (MTX) (cohort 1; n = 480) were randomized to receive fenebrutinib (50 mg once daily, 150 mg once daily, or 200 mg twice daily), adalimumab (40 mg every other week), or placebo.  Patients with RA and an inadequate response to tumor necrosis factor inhibitors received fenebrutinib (200 mg twice daily) or placebo.  Both cohorts continued MTX therapy.  Results : In cohort 1, the percentages of patients in whom American College of Rheumatol. 50% improvement criteria (ACR50) was achieved at week 12 were similar in the fenebrutinib 50 mg once daily and placebo groups, and were higher in the fenebrutinib 150 mg once daily group (28%) and 200 mg twice daily group (35%) than in the placebo group (15%) (P = 0.016 and P = 0.0003, resp.).  Fenebrutinib 200 mg twice daily and adalimumab (36%) were comparable (P = 0.81).  Fenebrutinib and adalimumab caused overlapping as well as distinct changes in B cell and myeloid biomarkers.  Conclusion : Fenebrutinib demonstrates efficacy comparable to adalimumab in patients with an inadequate response to MTX, and safety consistent with existing immunomodulatory therapies for RA.  These data support targeting both B and myeloid cells via this novel mechanism for potential efficacy in the treatment of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovM47ed5ph-7Vg90H21EOLACvtfcHk0lig0zMHneL35w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGitLjM&md5=4ab180d321fb58498e0d115e9043ebf3</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1002%2Fart.41275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.41275%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DTuckwell%26aufirst%3DK.%26aulast%3DKatsumoto%26aufirst%3DT.%2BR.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DGalanter%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRae%26aufirst%3DJ.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DBerman%26aufirst%3DA.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DFedkov%26aufirst%3DD.%26aulast%3DJeka%26aufirst%3DS.%26aulast%3DChinn%26aufirst%3DL.%2BW.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DMorimoto%26aufirst%3DA.%2BM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DFenebrutinib%2520versus%2520Placebo%2520or%2520Adalimumab%2520in%2520Rheumatoid%2520Arthritis%253A%2520A%2520Randomized%252C%2520Double-Bind%252C%2520Phase%2520II%2520Trial%2520%2528ANDES%2520Study%2529%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2020%26volume%3D72%26issue%3D9%26spage%3D1435%26epage%3D1446%26doi%3D10.1002%2Fart.41275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauernfeind, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnemri, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes-Alnemri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Recepotrs License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.0901363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19570822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFWgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=787-791&author=F.+Bauernfeindauthor=G.+Horvathauthor=A.+Stutzauthor=E.+S.+Alnemriauthor=K.+MacDonaldauthor=D.+Speertauthor=T.+Fernandes-Alnemriauthor=J.+Wuauthor=B.+G.+Monksauthor=K.+A.+Fitzgeraldauthor=V.+Hornungauthor=E.+Latz&title=Cutting+Edge%3A+NF-%CE%BAB+Activating+Pattern+Recognition+and+Cytokine+Recepotrs+License+NLRP3+Inflammasome+Activation+by+Regulating+NLRP3+Expression&doi=10.4049%2Fjimmunol.0901363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</span></div><div class="casAuthors">Bauernfeind, Franz G.; Horvath, Gabor; Stutz, Andrea; Alnemri, Emad S.; MacDonald, Kelly; Speert, David; Fernandes-Alnemri, Teresa; Wu, Jianghong; Monks, Brian G.; Fitzgerald, Katherine A.; Hornung, Veit; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">787-791</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The IL-1 family cytokines are regulated on transcriptional and posttranscriptional levels.  Pattern recognition and cytokine receptors control pro-IL-1β transcription whereas inflammasomes regulate the proteolytic processing of pro-IL-1β.  The NLRP3 inflammasome, however, assembles in response to extracellular ATP, pore-forming toxins, or crystals only in the presence of proinflammatory stimuli.  How the activation of gene transcription by signaling receptors enables NLRP3 activation remains elusive and controversial.  In this study, the authors show that cell priming through multiple signaling receptors induces NLRP3 expression, which the authors identified to be a crit. checkpoint for NLRP3 activation.  Signals provided by NF-κB activators are necessary but not sufficient for NLRP3 activation, and a second stimulus such as ATP or crystal-induced damage is required for NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUf4OrrejQ7Vg90H21EOLACvtfcHk0lig0zMHneL35w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFWgt78%253D&md5=1b04c9f756bb70d6292bd8bd5507ee1f</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901363%26sid%3Dliteratum%253Aachs%26aulast%3DBauernfeind%26aufirst%3DF.%26aulast%3DHorvath%26aufirst%3DG.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DAlnemri%26aufirst%3DE.%2BS.%26aulast%3DMacDonald%26aufirst%3DK.%26aulast%3DSpeert%26aufirst%3DD.%26aulast%3DFernandes-Alnemri%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DMonks%26aufirst%3DB.%2BG.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DHornung%26aufirst%3DV.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DCutting%2520Edge%253A%2520NF-%25CE%25BAB%2520Activating%2520Pattern%2520Recognition%2520and%2520Cytokine%2520Recepotrs%2520License%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Regulating%2520NLRP3%2520Expression%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D787%26epage%3D791%26doi%3D10.4049%2Fjimmunol.0901363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning-Bennett, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abuhelwa, A. Y.</span></span> <span> </span><span class="NLM_article-title">Investigational IRAK-4 Inhibitors for the Treatment of Rheumatoid Athritis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1080/13543784.2020.1752660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1080%2F13543784.2020.1752660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32255710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVWqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=475-482&issue=5&author=M.+D.+Wieseauthor=A.+T.+Manning-Bennettauthor=A.+Y.+Abuhelwa&title=Investigational+IRAK-4+Inhibitors+for+the+Treatment+of+Rheumatoid+Athritis&doi=10.1080%2F13543784.2020.1752660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Wiese, Michael D.; Manning-Bennett, Arkady T.; Abuhelwa, Ahmad Y.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">475-482</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Rheumatoid arthritis (RA) is a chronic inflammatory auto-immune disease that can lead to permanent disability and deformity.  Despite current treatment modalities, many patients are still unable to reach remission.  Interleukin-1 receptor-assocd. kinase 4 (IRAK-4) inhibitors are novel agents designed to suppress immune signaling pathways involved in inflammation and joint destruction in RA.  Four IRAK-4 inhibitors have entered clin. trials.: This review summarizes the current stage of development of IRAK-4 inhibitors in clin. trials, detailing their chem., pharmacokinetics, and therapeutic potential in the treatment of RA.  PubMed, Embase and restricted Google searches were conducted using the term 'IRAK-4', and publicly accessible clin. trial databases were reviewed.: IRAK-4 inhibitors are an exciting therapeutic option in RA management because unlike other targeted disease-modifying agents, they target the innate immune system.  The role of IRAK-4 as a key component of Toll/Interleukin-1 receptor signaling and its potential for a low rate of infectious complications is particularly exciting and this may facilitate their use in combination treatment.  A key aspect of upcoming clin. trials will be the identification of biomarkers predictive of treatment efficacy, which will help to define if and how they will be used in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrpVAIiTis27Vg90H21EOLACvtfcHk0lj7oXbgTD11Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVWqtL8%253D&md5=e0f764411673764a188bb6e2d6bcba24</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1080%2F13543784.2020.1752660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2020.1752660%26sid%3Dliteratum%253Aachs%26aulast%3DWiese%26aufirst%3DM.%2BD.%26aulast%3DManning-Bennett%26aufirst%3DA.%2BT.%26aulast%3DAbuhelwa%26aufirst%3DA.%2BY.%26atitle%3DInvestigational%2520IRAK-4%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Athritis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2020%26volume%3D29%26issue%3D5%26spage%3D475%26epage%3D482%26doi%3D10.1080%2F13543784.2020.1752660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulshian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bober, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlisi, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossetta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=677-682&author=W.+T.+McElroyauthor=Z.+Tanauthor=G.+Hoauthor=S.+Paliwalauthor=G.+Liauthor=M.+W.+Seganishauthor=D.+Tulshianauthor=J.+Tataauthor=T.+O.+Fischmannauthor=C.+Sondeyauthor=H.+Bianauthor=L.+Boberauthor=J.+Jacksonauthor=C.+G.+Garlisiauthor=K.+Devitoauthor=J.+Fossettaauthor=D.+Lundellauthor=X.+Niu&title=Potent+and+Selective+Amidopyrazole+Inhibitors+of+IRAK4+That+Are+Efficacious+in+a+Rodent+Model+of+Inflammation&doi=10.1021%2Facsmedchemlett.5b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation</span></div><div class="casAuthors">McElroy, William T.; Tan, Zheng; Ho, Ginny; Paliwal, Sunil; Li, Guoqing; Seganish, W. Michael; Tulshian, Deen; Tata, James; Fischmann, Thierry O.; Sondey, Christopher; Bian, Hong; Bober, Loretta; Jackson, James; Garlisi, Charles G.; Devito, Kristine; Fossetta, James; Lundell, Daniel; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-682</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IRAK4 is a crit. upstream kinase in the IL-1R/TLR signaling pathway.  Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders.  A screening campaign identified a pyrazole class of IRAK4 inhibitors that were detd. by X-ray crystallog. to exhibit an unusual binding mode.  SAR efforts focused on the identification of a potent and selective inhibitor with good aq. soly. and rodent pharmacokinetics.  Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogs generally having good rodent oral exposure but poor soly.  N-Alkyl piperidines exhibited excellent soly. and reduced exposure.  Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active.  Piperazine 32 was a potent enzyme inhibitor with good cellular activity.  Compd. 32 reduced the in vivo prodn. of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSA2VYtAf07Vg90H21EOLACvtfcHk0ljVnyretZ6B7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D&md5=2203ad720b478a6e415d7d9df3e82106</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00106%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DG.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSeganish%26aufirst%3DM.%2BW.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DBober%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DPotent%2520and%2520Selective%2520Amidopyrazole%2520Inhibitors%2520of%2520IRAK4%2520That%2520Are%2520Efficacious%2520in%2520a%2520Rodent%2520Model%2520of%2520Inflammation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D677%26epage%3D682%26doi%3D10.1021%2Facsmedchemlett.5b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danto, S. I.</span>; <span class="NLM_string-name">Shojaee, N.</span>; <span class="NLM_string-name">Singh, R. S. P.</span>; <span class="NLM_string-name">Manukyan, Z.</span>; <span class="NLM_string-name">Mancuso, J.</span>; <span class="NLM_string-name">Peeva, E.</span>; <span class="NLM_string-name">Vincent, M.</span>; <span class="NLM_string-name">Beebe, J.</span></span> <span> </span><span class="NLM_article-title">In Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate</span>,  <i>2019 ACR/ARP Annual Meeting</i>, <span class="NLM_publisher-loc">Atlanta, GA</span>, November 8–13; Atlanta, Georgia, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+I.+Danto&author=N.+Shojaee&author=R.+S.+P.+Singh&author=Z.+Manukyan&author=J.+Mancuso&author=E.+Peeva&author=M.+Vincent&author=J.+Beebe&title=In+Efficacy+and+Safety+of+the+Selective+Interleukin-1+Receptor+Associated+Kinase+4+Inhibitor%2C+PF-06650833%2C+in+Patients+with+Active+Rheumatoid+Arthritis+and+Inadequate+Response+to+Methotrexate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DDanto%26aufirst%3DS.%2BI.%26atitle%3DIn%2520Efficacy%2520and%2520Safety%2520of%2520the%2520Selective%2520Interleukin-1%2520Receptor%2520Associated%2520Kinase%25204%2520Inhibitor%252C%2520PF-06650833%252C%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%2520and%2520Inadequate%2520Response%2520to%2520Methotrexate%26jtitle%3D2019%2520ACR%252FARP%2520Annual%2520Meeting%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3614</span>– <span class="NLM_lpage">3643</span>, <span class="refDoi"> DOI: 10.1021/jm201271b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201271b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3614-3643&author=R.+Singhauthor=E.+S.+Masudaauthor=D.+G.+Payan&title=Discovery+and+Development+of+Spleen+Tyrosine+Kinase+%28SYK%29+Inhibitors&doi=10.1021%2Fjm201271b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span></div><div class="casAuthors">Singh, Rajinder; Masuda, Esteban S.; Payan, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3614-3643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (SYK) is a member of the cytoplasmic protein tyrosine kinase (PTK) family and has been identified as an important target for the development of therapeutics for the treatment of allergic and autoimmune diseases.  Maladies resulting from chronic inflammation and autoimmune dysfunction include, asthma, rheumatoid arthritis (RA), Crohn's disease, systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP).  SYK has garnered substantial attention because of its importance as a key signal transduction regulator through antigen and Fc receptors in hematopoietic cells.  Recently SYK has entered the mainstream of potential pharmaceutical targets with a no. of inhibitor classes being reported in the literature.  The true potential as a validated target for inhibition by small mols. has been investigated in the last few years, with the emergence of advanced clin. trial data.  Structurally SYK possesses a tandem N-terminal Src homol. 2 domains (SH2), referred to as N-SH2 and C-SH2 domains, followed by a C-terminal kinase domain and most closely related to ZAP-70.  The multiple phosphorylation sites on SYK are fundamental structural prerequisites for its diverse functional activity.  Overall, these phosphorylation sites contribute to maintaining the kinase in an inactivated state.  In addn., they are implicated in events leading to primary activation of the kinase catalytic domain, amplification of this activity, and the orchestrated phosphorylation of multiple substrates.  Utilization of the numerous sites of phosphorylation on SYK leads to the activation of a multitude of signaling networks relevant to immune and autoimmune maladies.  SYK serves as a master regulator of inflammatory responses in a multitude of immune cells and as a result, inhibiting SYK activity dampens inflammation broadly and comprehensively.  The validation of SYK as an effective target for therapeutic intervention in autoimmune and inflammatory disorders has picked up pace over the last decade.  In particular, this has been attributable to the recognition of key biol. findings, coupled with successful small mol. inhibitors of SYK that have shown early indications of clin. efficacy in diverse autoimmune and inflammatory diseases.  SYK as a target has gained reinforcement with the successful completion of several Phase 2 clin. studies in RA, ITP and B-cell lymphoma.  Addnl. clin. studies are under way that may further emphasize the position of SYK as a therapeutically relevant target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp363qA4V4g-rVg90H21EOLACvtfcHk0ljVnyretZ6B7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D&md5=1b51e1b658842f2b562d533edb05e685</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjm201271b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201271b%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Spleen%2520Tyrosine%2520Kinase%2520%2528SYK%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3614%26epage%3D3643%26doi%3D10.1021%2Fjm201271b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Men, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Spleen Tyrosine Kinase Promotes NLR Family Pyrin Domain Containing 3 Inflammasome-Mediated IL-1β Secretion via c-Jun N-Terminal Kinase Activation and Cell Apoptosis During Diabetic Nephropathy</span>. <i>Molecular Medicine Reports</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1995</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.3892/mmr.2018.9164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3892%2Fmmr.2018.9164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29901140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=1995-2008&author=Y.+Qiaoauthor=X.+Tianauthor=L.+Menauthor=S.+Liauthor=Y.+Chenauthor=M.+Xueauthor=Y.+Huauthor=P.+Zhouauthor=G.+Longauthor=Y.+Shiauthor=R.+Liuauthor=Y.+Liuauthor=Z.+Qiauthor=Y.+Cuiauthor=Y.+Shen&title=Spleen+Tyrosine+Kinase+Promotes+NLR+Family+Pyrin+Domain+Containing+3+Inflammasome-Mediated+IL-1%CE%B2+Secretion+via+c-Jun+N-Terminal+Kinase+Activation+and+Cell+Apoptosis+During+Diabetic+Nephropathy&doi=10.3892%2Fmmr.2018.9164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Spleen tyrosine kinase promotes NLR family pyrin domain containing 3 inflammasome-mediated IL-1β secretion via c-Jun N-terminal kinase activation and cell apoptosis during diabetic nephropathy</span></div><div class="casAuthors">Qiao, Yingchun; Tian, Xixi; Men, Li; Li, Shengyu; Chen, Yufeng; Xue, Meiting; Hu, Yahui; Zhou, Pengfei; Long, Guangfeng; Shi, Yue; Liu, Ruiqing; Liu, Yunde; Qi, Zhi; Cui, Yujie; Shen, Yanna</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1995-2008</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Diabetic nephropathy (DN) is a serious complication of diabetes and can cause an increased mortality risk.  It was previously reported that NLR family pyrin domain contg. 3 (NLRP3) inflammasome is involved in the pathogenesis of diabetes.  However, the underlying mechanism is not clearly understood.  In the present study, the effects of spleen tyrosine kinase (Syk) and c-Jun N-terminal kinase (JNK) on the NLRP3 inflammasome were examd. in vivo and in vitro.  Sprague-Dawley rats were injected i.p. with streptozotocin (65 mg/kg) to induce diabetes.  HK2 cells and rat glomerular mesangial cells (RGMCs) were examd. to detect the expression of JNK and NLRP3 inflammasome-assocd. proteins following treatment with a Syk inhibitor or Syk-small interfering (si)RNA in a high glucose condition.  In the present study, it was revealed that the protein and mRNA expression levels of NLRP3 inflammasome-assocd. mols. and the downstream mature interleukin (IL)-1β were upregulated in vivo and in vitro.  The Syk inhibitor and Syk-siRNA suppressed high glucose-induced JNK activation, and subsequently downregulated the activation of the NLRP3 inflammasome and mature IL-1β in HK2 cells and RGMCs.  Therefore, the present results detd. that high glucose-induced activation of the NLRP3 inflammasome is mediated by Syk/JNK activation, which subsequently increased the protein expression level of IL-1β and mature IL-1β.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoNxBctyuDDbVg90H21EOLACvtfcHk0ljSOw6EjuqKtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjtrbI&md5=cf317a7edf88708cc66649e1f8f8b4b5</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2018.9164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2018.9164%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DMen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DLong%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DSpleen%2520Tyrosine%2520Kinase%2520Promotes%2520NLR%2520Family%2520Pyrin%2520Domain%2520Containing%25203%2520Inflammasome-Mediated%2520IL-1%25CE%25B2%2520Secretion%2520via%2520c-Jun%2520N-Terminal%2520Kinase%2520Activation%2520and%2520Cell%2520Apoptosis%2520During%2520Diabetic%2520Nephropathy%26jtitle%3DMolecular%2520Medicine%2520Reports%26date%3D2018%26volume%3D18%26spage%3D1995%26epage%3D2008%26doi%3D10.3892%2Fmmr.2018.9164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R. J.</span></span> <span> </span><span class="NLM_article-title">Critical Role for NLRP3 in Necrotic Death Triggered by Mycobacterium Tuberculosis</span>. <i>Cell. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1371</span>– <span class="NLM_lpage">1384</span>, <span class="refDoi"> DOI: 10.1111/j.1462-5822.2011.01625.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1111%2Fj.1462-5822.2011.01625.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21740493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWqsbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1371-1384&issue=9&author=K.-W.+Wongauthor=W.+R.+J.+Jacobs&title=Critical+Role+for+NLRP3+in+Necrotic+Death+Triggered+by+Mycobacterium+Tuberculosis&doi=10.1111%2Fj.1462-5822.2011.01625.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis</span></div><div class="casAuthors">Wong, Ka-Wing; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1371-1384</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Induction of necrotic death in macrophages is a primary virulence determinant of Mycobacterium tuberculosis.  The ESX-1 secretion system and its substrate ESAT-6 are required for M. tuberculosis to induce necrosis, but host factors that mediate the ESAT-6-promoted necrosis remain unknown.  Here we report that ESAT-6-promoted necrotic death in THP-1 human macrophages is dependent on the NLRP3 inflammasome, as shown by RNA interference and pharmacol. inhibitions.  Phagosomes contg. ESAT-6-expressing M. tuberculosis recruit markers previously assocd. with damaged phagosomal membrane, such as galectin-3 and ubiquitinated protein aggregates.  In addn., ESAT-6 promoted lysosomal permeabilization by M. tuberculosis.  ESAT-6 mutants defective for ubiquitination were unable to trigger NLRP3 activation and necrotic death.  Furthermore, Syk tyrosine kinase, recently implicated in NLRP3 activation during fungal and malarial infections, was necessary for mediating the ESAT-6-promoted necrosis and NLRP3 activation.  Our results thus link phagosomal damage and Syk activity to NLRP3-mediated necrotic death triggered by M. tuberculosis ESAT-6 during infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0eSC-Ojhsg7Vg90H21EOLACvtfcHk0ljSOw6EjuqKtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWqsbjM&md5=d297c676ebdbd640d4ce9ffb10116bb3</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1111%2Fj.1462-5822.2011.01625.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1462-5822.2011.01625.x%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.-W.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%2BJ.%26atitle%3DCritical%2520Role%2520for%2520NLRP3%2520in%2520Necrotic%2520Death%2520Triggered%2520by%2520Mycobacterium%2520Tuberculosis%26jtitle%3DCell.%2520Microbiol.%26date%3D2011%26volume%3D13%26issue%3D9%26spage%3D1371%26epage%3D1384%26doi%3D10.1111%2Fj.1462-5822.2011.01625.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poeck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bscheider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dostert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannesschläger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardivel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweighoffer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mocsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span> <span> </span><span class="NLM_article-title">Syk Kinase Signalling Couples to the Nlrp3 Inflammasome for Anti-Fungal Host Defence</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>459</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1038/nature07965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature07965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19339971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvV2ksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2009&pages=433-436&author=O.+Grossauthor=H.+Poeckauthor=M.+Bscheiderauthor=C.+Dostertauthor=N.+Hannesschl%C3%A4gerauthor=S.+Endresauthor=G.+Hartmannauthor=A.+Tardivelauthor=E.+Schweighofferauthor=V.+Tybulewiczauthor=A.+Mocsaiauthor=J.+Tschoppauthor=J.+Ruland&title=Syk+Kinase+Signalling+Couples+to+the+Nlrp3+Inflammasome+for+Anti-Fungal+Host+Defence&doi=10.1038%2Fnature07965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence</span></div><div class="casAuthors">Gross, Olaf; Poeck, Hendrik; Bscheider, Michael; Dostert, Catherine; Hannesschlaeger, Nicole; Endres, Stefan; Hartmann, Gunther; Tardivel, Aubry; Schweighoffer, Edina; Tybulewicz, Victor; Mocsai, Attila; Tschopp, Juerg; Ruland, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">7245</span>),
    <span class="NLM_cas:pages">433-436</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fungal infections represent a serious threat, particularly in immunocompromised patients.  Interleukin-1β (IL-1β) is a key pro-inflammatory factor in innate antifungal immunity.  The mechanism by which the mammalian immune system regulates IL-1β prodn. after fungal recognition is unclear.  Two signals are generally required for IL-1β prodn.: an NF-κB-dependent signal that induces the synthesis of pro-IL-1β (p35), and a second signal that triggers proteolytic pro-IL-1β processing to produce bioactive IL-1β (p17) via Caspase-1-contg. multiprotein complexes called inflammasomes.  Here we demonstrate that the tyrosine kinase Syk, operating downstream of several immunoreceptor tyrosine-based activation motif (ITAM)-coupled fungal pattern recognition receptors, controls both pro-IL-1β synthesis and inflammasome activation after cell stimulation with Candida albicans.  Whereas Syk signalling for pro-IL-1β synthesis selectively uses the Card9 pathway, inflammasome activation by the fungus involves reactive oxygen species prodn. and potassium efflux.  Genetic deletion or pharmalogical inhibition of Syk selectively abrogated inflammasome activation by C. albicans but not by inflammasome activators such as Salmonella typhimurium or the bacterial toxin nigericin.  Nlrp3 (also known as NALP3) was identified as the crit. NOD-like receptor family member that transduces the fungal recognition signal to the inflammasome adaptor Asc (Pycard) for Caspase-1 (Casp1) activation and pro-IL-1β processing.  Consistent with an essential role for Nlrp3 inflammasomes in antifungal immunity, we show that Nlrp3-deficient mice are hypersusceptible to Candida albicans infection.  Thus, our results demonstrate the mol. basis for IL-1β prodn. after fungal infection and identify a crucial function for the Nlrp3 inflammasome in mammalian host defense in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK4a_GDL8lrrVg90H21EOLACvtfcHk0lha2eQUZhlGuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvV2ksLs%253D&md5=7a8d5d412df3bcd7e34dc5e6affe7a42</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1038%2Fnature07965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07965%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DO.%26aulast%3DPoeck%26aufirst%3DH.%26aulast%3DBscheider%26aufirst%3DM.%26aulast%3DDostert%26aufirst%3DC.%26aulast%3DHannesschl%25C3%25A4ger%26aufirst%3DN.%26aulast%3DEndres%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DG.%26aulast%3DTardivel%26aufirst%3DA.%26aulast%3DSchweighoffer%26aufirst%3DE.%26aulast%3DTybulewicz%26aufirst%3DV.%26aulast%3DMocsai%26aufirst%3DA.%26aulast%3DTschopp%26aufirst%3DJ.%26aulast%3DRuland%26aufirst%3DJ.%26atitle%3DSyk%2520Kinase%2520Signalling%2520Couples%2520to%2520the%2520Nlrp3%2520Inflammasome%2520for%2520Anti-Fungal%2520Host%2520Defence%26jtitle%3DNature%26date%3D2009%26volume%3D459%26spage%3D433%26epage%3D436%26doi%3D10.1038%2Fnature07965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Spleen Tyrosine Kinase Inhibitors: A Review of the Patent Literature 2010 - 2013</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.890184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1517%2F13543776.2014.890184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24555683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=573-595&issue=5&author=P.+Norman&title=Spleen+Tyrosine+Kinase+Inhibitors%3A+A+Review+of+the+Patent+Literature+2010+-+2013&doi=10.1517%2F13543776.2014.890184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">573-595</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The non-receptor tyrosine kinase, spleen tyrosine kinase (Syk), is primarily expressed in hematopoietic cells and appears to be particularly important in B cells.  Syk is involved in signal transduction processes and appears to regulate allergic, inflammatory and autoimmune responses.  It also appears to play a significant role in the development of haematol. malignancies.  Inhibitors of Syk are potentially useful in treating asthma, rheumatoid arthritis, lupus, chronic lymphocytic leukemia and lymphomas.  Areas covered: This article reviews the increasing no. of patent filings between 2010 and 2013 claiming Syk inhibitors and focuses on the multiple structural classes of Syk inhibitors disclosed.  It also comments on recent developments with Syk inhibitors, both clin. results and licensing deals.  Expert opinion: The increased interest in the identification of Syk inhibitors has seen a sharp increase in patent filings claiming such compds.  However, the no. of these is well below that of filings relating to other pro-inflammatory kinases (p38, JAK).  These filings have also claimed an increasingly diverse range of chem. classes moving away from the 2,4-diaminopyrimidine motif present in drugs such as fostamatinib and PRT-06207.  Many of the claimed compds. are Syk inhibitors with potencies considerably better than fostamatinib.  However, good kinase selectivity is also likely to be essential if a Syk inhibitor is to prove useful enough to emulate the JAK inhibitor tofacitinib in gaining marketing authorization.  Recent clin. failures with Syk inhibitors are expected to result in a decrease in the rate of patent filings claiming Syk inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKOmjQYSJAsbVg90H21EOLACvtfcHk0lha2eQUZhlGuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu7o%253D&md5=6db9860a438ced1374f5b8727e3cd420</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.890184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.890184%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DSpleen%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520A%2520Review%2520of%2520the%2520Patent%2520Literature%25202010%2520-%25202013%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26issue%3D5%26spage%3D573%26epage%3D595%26doi%3D10.1517%2F13543776.2014.890184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braselmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlaar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span> <span> </span><span class="NLM_article-title">R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>319</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.109058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1124%2Fjpet.106.109058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=16946104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2006&pages=998-1008&issue=3&author=S.+Braselmannauthor=V.+Taylorauthor=H.+Zhaoauthor=S.+Wangauthor=C.+Sylvainauthor=M.+Baluomauthor=K.+Quauthor=E.+Herlaarauthor=A.+Lauauthor=C.+Youngauthor=B.+R.+Wongauthor=S.+Lovellauthor=T.+Sunauthor=G.+Parkauthor=A.+Argadeauthor=S.+Jurcevicauthor=P.+Pineauthor=R.+Singhauthor=E.+B.+Grossbardauthor=D.+G.+Payanauthor=E.+S.+Masuda&title=R406%2C+an+Orally+Available+Spleen+Tyrosine+Kinase+Inhibitor+Blocks+Fc+Receptor+Signaling+and+Reduces+Immune+Complex-Mediated+Inflammation&doi=10.1124%2Fjpet.106.109058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation</span></div><div class="casAuthors">Braselmann, Sylvia; Taylor, Vanessa; Zhao, Haoran; Wang, Su; Sylvain, Catherine; Baluom, Muhammad; Qu, Kunbin; Herlaar, Ellen; Lau, Angela; Young, Chi; Wong, Brian R.; Lovell, Scott; Sun, Thomas; Park, Gary; Argade, Ankush; Jurcevic, Stipo; Pine, Polly; Singh, Rajinder; Grossbard, Elliott B.; Payan, Donald G.; Masuda, Esteban S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">998-1008</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent compelling evidence has lead to renewed interest in the role of antibodies and immune complexes in the pathogenesis of several autoimmune disorders, such as rheumatoid arthritis.  These immune complexes, consisting of autoantibodies to self-antigens, can mediate inflammatory responses largely through binding and activating the Ig Fc receptors (FcRs).  Using cell-based structure activity relationships with cultured human mast cells, we have identified the small mol. R406 [N4-(2,2-dimethyl-3-oxo-4H-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2- (3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine] as a potent inhibitor of IgE (IgE)- and IgG-mediated activation of Fc receptor signaling (EC50 for degranulation = 56-64 nM).  Here we show that the primary target for R406 is the spleen tyrosine kinase (Syk), which plays a key role in the signaling of activating Fc receptors and the B-cell receptor (BCR).  R406 inhibited phosphorylation of Syk substrate linker for activation of T cells in mast cells and B-cell linker protein/SLP65 in B cells.  R406 bound to the ATP binding pocket of Syk and inhibited its kinase activity as an ATP-competitive inhibitor (Ki = 30 nM).  Furthermore, R406 blocked Syk-dependent FcR-mediated activation of monocytes/macrophages and neutrophils and BCR-mediated activation of B lymphocytes.  R406 was selective as assessed using a large panel of Syk-independent cell-based assays representing both specific and general signaling pathways.  Consistent with Syk inhibition, oral administration of R406 to mice reduced immune complex-mediated inflammation in a reverse-passive Arthus reaction and two antibody-induced arthritis models.  Finally, we report a first-in-human study showing that R406 is orally bioavailable, achieving exposures capable of inhibiting Syk-dependent IgE-mediated basophil activation.  Collectively, the results show R406 potential for modulating Syk activity in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohoeT9BJQAyLVg90H21EOLACvtfcHk0ljWJ9nwpaFfGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltL7P&md5=18fea516041ea075d2123158f321a186</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.109058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.109058%26sid%3Dliteratum%253Aachs%26aulast%3DBraselmann%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DK.%26aulast%3DHerlaar%26aufirst%3DE.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DB.%2BR.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DArgade%26aufirst%3DA.%26aulast%3DJurcevic%26aufirst%3DS.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26atitle%3DR406%252C%2520an%2520Orally%2520Available%2520Spleen%2520Tyrosine%2520Kinase%2520Inhibitor%2520Blocks%2520Fc%2520Receptor%2520Signaling%2520and%2520Reduces%2520Immune%2520Complex-Mediated%2520Inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D319%26issue%3D3%26spage%3D998%26epage%3D1008%26doi%3D10.1124%2Fjpet.106.109058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pine, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoettler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banquerigo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahn, E.</span></span> <span> </span><span class="NLM_article-title">Inflammation and Bone Erosion are Suppressed in Models of Rheumatoid Arthritis Following Treatment with a Novel Syk Inhibitor</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2007.03.543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.clim.2007.03.543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=17537677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1eltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2007&pages=244-257&issue=3&author=P.+R.+Pineauthor=B.+Changauthor=N.+Schoettlerauthor=M.+L.+Banquerigoauthor=S.+Wangauthor=A.+Lauauthor=F.+Zhaoauthor=E.+B.+Grossbardauthor=D.+G.+Payanauthor=E.+Brahn&title=Inflammation+and+Bone+Erosion+are+Suppressed+in+Models+of+Rheumatoid+Arthritis+Following+Treatment+with+a+Novel+Syk+Inhibitor&doi=10.1016%2Fj.clim.2007.03.543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor</span></div><div class="casAuthors">Pine, Polly R.; Chang, Betty; Schoettler, Nathan; Banquerigo, Mona L.; Wang, Su; Lau, Angela; Zhao, Feifei; Grossbard, Elliott B.; Payan, Donald G.; Brahn, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-257</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in inflammatory cells, is essential for immune complex-mediated signal transduction initiated by activated receptors for IgG.  In collagen-induced arthritis, R788/R406, a novel and potent small mol. Syk inhibitor suppressed clin. arthritis, bone erosions, pannus formation, and synovitis.  Serum anti-collagen type II antibody levels were unaltered, while the half-life of exogenous antibody was extended when co-administered with R406.  Expression of the targeted kinase (Syk) in synovial tissue correlated with the joint level of inflammatory cell infiltrates and was virtually undetectable in treated rats.  Syk inhibition suppressed synovial cytokines and cartilage oligomeric matrix protein (COMP) in serum, suggesting a sensitive and reliable biomarker for R406 activity.  These results highlight the role of activating Fcgamma receptors in inflammatory synovitis and suggest that interruption of the signaling cascade with a novel Syk inhibitor may be a useful addn. to immunosuppressive disease-modifying anti-rheumatic drugs currently used in the treatment of human autoimmune diseases such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Nm2XObIb37Vg90H21EOLACvtfcHk0lgJ7pgPHQdEAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1eltb0%253D&md5=98b5020fb23cc209e5b7c322024748fb</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2007.03.543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2007.03.543%26sid%3Dliteratum%253Aachs%26aulast%3DPine%26aufirst%3DP.%2BR.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DSchoettler%26aufirst%3DN.%26aulast%3DBanquerigo%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DBrahn%26aufirst%3DE.%26atitle%3DInflammation%2520and%2520Bone%2520Erosion%2520are%2520Suppressed%2520in%2520Models%2520of%2520Rheumatoid%2520Arthritis%2520Following%2520Treatment%2520with%2520a%2520Novel%2520Syk%2520Inhibitor%26jtitle%3DClin.%2520Immunol.%26date%3D2007%26volume%3D124%26issue%3D3%26spage%3D244%26epage%3D257%26doi%3D10.1016%2Fj.clim.2007.03.543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bussel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treliński, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homenda, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windyga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivcheva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalafallah, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaja, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovtsov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duliege, A.-M.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1002/ajh.25125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fajh.25125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29696684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ylur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=921-930&issue=7&author=J.+Busselauthor=D.+M.+Arnoldauthor=E.+Grossbardauthor=J.+Mayerauthor=J.+Treli%C5%84skiauthor=W.+Homendaauthor=A.+Hellmannauthor=J.+Windygaauthor=L.+Sivchevaauthor=A.+A.+Khalafallahauthor=F.+Zajaauthor=N.+Cooperauthor=V.+Markovtsovauthor=H.+Zayedauthor=A.-M.+Duliege&title=Fostamatinib+for+the+Treatment+of+Adult+Persistent+and+Chronic+Immune+Thrombocytopenia%3A+Results+of+Two+Phase+3%2C+Randomized%2C+Placebo-Controlled+Trials&doi=10.1002%2Fajh.25125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials</span></div><div class="casAuthors">Bussel, James; Arnold, Donald M.; Grossbard, Elliot; Mayer, Jiri; Trelinski, Jacek; Homenda, Wojciech; Hellmann, Andrzej; Windyga, Jerzy; Sivcheva, Liliya; Khalafallah, Alhossain A.; Zaja, Francesco; Cooper, Nichola; Markovtsov, Vadim; Zayed, Hany; Duliege, Anne-Marie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">921-930</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP).  Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses in a phase 2 ITP study.  In two parallel, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n = 101) or placebo (n = 49) at 100 mg BID for 24 wk with a dose increase in nonresponders to 150 mg BID after 4 wk.  The primary endpoint was stable response (platelets ≥50 000/μL at ≥4 of 6 biweekly visits, weeks 14-24, without rescue therapy).  Baseline median platelet count was 16 000/μL; median duration of ITP was 8.5 years.  Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003).  Overall responses (defined retrospectively as ≥1 platelet count ≥50 000/μL within the first 12 wk on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P = .0006).  Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 wk.  The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%).  Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti-motility agents).  Fostamatinib produced clin.-meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab.  Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXWLFmFwBPrLVg90H21EOLACvtfcHk0lgJ7pgPHQdEAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ylur%252FF&md5=06dff53ac5d8e7752b760844f9f22384</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2Fajh.25125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.25125%26sid%3Dliteratum%253Aachs%26aulast%3DBussel%26aufirst%3DJ.%26aulast%3DArnold%26aufirst%3DD.%2BM.%26aulast%3DGrossbard%26aufirst%3DE.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DTreli%25C5%2584ski%26aufirst%3DJ.%26aulast%3DHomenda%26aufirst%3DW.%26aulast%3DHellmann%26aufirst%3DA.%26aulast%3DWindyga%26aufirst%3DJ.%26aulast%3DSivcheva%26aufirst%3DL.%26aulast%3DKhalafallah%26aufirst%3DA.%2BA.%26aulast%3DZaja%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DMarkovtsov%26aufirst%3DV.%26aulast%3DZayed%26aufirst%3DH.%26aulast%3DDuliege%26aufirst%3DA.-M.%26atitle%3DFostamatinib%2520for%2520the%2520Treatment%2520of%2520Adult%2520Persistent%2520and%2520Chronic%2520Immune%2520Thrombocytopenia%253A%2520Results%2520of%2520Two%2520Phase%25203%252C%2520Randomized%252C%2520Placebo-Controlled%2520Trials%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2018%26volume%3D93%26issue%3D7%26spage%3D921%26epage%3D930%26doi%3D10.1002%2Fajh.25125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magilavy, D. B.</span></span> <span> </span><span class="NLM_article-title">An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1312</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1000500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa1000500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20879879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WqsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1303-1312&author=M.+E.+Weinblattauthor=A.+Kavanaughauthor=M.+C.+Genoveseauthor=T.+K.+Musserauthor=E.+B.+Grossbardauthor=D.+B.+Magilavy&title=An+Oral+Spleen+Tyrosine+Kinase+%28Syk%29+Inhibitor+for+Rheumatoid+Arthritis&doi=10.1056%2FNEJMoa1000500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">An oral spleen tyrosine kinase (SyK) inhibitor for rheumatoid arthritis</span></div><div class="casAuthors">Weinblatt, Michael E.; Kavanaugh, Arthur; Genovese, Mark C.; Musser, Theresa K.; Grossbard, Elliott B.; Magilavy, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1303-1312</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND  Spleen tyrosine kinase (Syk) is an important modulator of immune signaling.  The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy.  METHODS  We enrolled 457 patients who had active rheumatoid arthritis despite long-term methotrexate therapy in a 6-mo, double-blind, placebo-controlled trial.  The primary outcome was the American College of Rheumatol. (ACR) 20 response (which indicates at least a 20% redn. in the no. of both tender and swollen joints and improvement in at least three of five other criteria) at month 6.  RESULTS  R788, at a dose of 100 mg twice daily and at a dose of 150 mg once daily, was significantly superior to placebo at month 6 (ACR 20 response rates of 67% and 57%, resp., vs. 35%; P < 0.001 for the comparison of both doses with placebo).  It was also significantly superior with respect to ACR 50, which indicates at least a 50% improvement (43% and 32% vs. 19%; P < 0.001 for the comparison of the 100-mg dose with placebo, P = 0.007 for the comparison of the 150-mg dose with placebo) and ACR70 (28% and 14% vs. 10%; P < 0.001 for the comparison of the 100-mg dose with placebo, P = 0.34 for the comparison of the 150-mg dose with placebo).  A clin. significant effect was noted by the end of the first week of treatment.  Adverse effects included diarrhea (in 19% of subjects taking the 100-mg dose of R788 vs. 3% of those taking placebo), upper respiratory infections (14% vs. 7%), and neutropenia (60/% vs. 1%0/).  R788 was assocd. with an increase in systolic blood pressure of approx. 3 mm Hg between baseline and month 1, as compared with a decrease of 2 mm Hg with placebo; 23% of the patients taking R788 vs. 7% of the patients receiving placebo required the initiation of or a change in antihypertensive therapy.  CONCLUSIONS  In this phase 2 study, a Syk inhibitor reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia.  Addnl. studies will be needed to further assess the safety and efficacy of Syk-inhibition therapy in patients with rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv0QGXE3rZiLVg90H21EOLACvtfcHk0lj3dtsF6VWEnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WqsLfI&md5=f6da21edb34b0fe9858b6d7bbfd6f0b4</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1000500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1000500%26sid%3Dliteratum%253Aachs%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DMusser%26aufirst%3DT.%2BK.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DMagilavy%26aufirst%3DD.%2BB.%26atitle%3DAn%2520Oral%2520Spleen%2520Tyrosine%2520Kinase%2520%2528Syk%2529%2520Inhibitor%2520for%2520Rheumatoid%2520Arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1303%26epage%3D1312%26doi%3D10.1056%2FNEJMoa1000500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-120302, (OSKIRA-2):
A Phase III, Multi-center, Randomised, Double-Blind, Placebo-Controlled,
Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium
in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs
Oral SYK Inhibition in Rheumatoid Arthritis (OSKIRA) - 2 Study.</i> <a href="https://citeline.informa.com/trials/details/120302?qId=c470e1cf-5602-472d-af98-cf9e6aad4f7a" class="extLink">https://citeline.informa.com/trials/details/120302?qId=c470e1cf-5602-472d-af98-cf9e6aad4f7a</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-120302%2C+%28OSKIRA-2%29%3A%0AA+Phase+III%2C+Multi-center%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C%0AParallel+Group+Study+of+Two+Dosing+Regimens+of+Fostamatinib+Disodium%0Ain+Rheumatoid+Arthritis+Patients+with+an+Inadequate+Response+to+DMARDs%0AOral+SYK+Inhibition+in+Rheumatoid+Arthritis+%28OSKIRA%29+-+2+Study.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F120302%3FqId%3Dc470e1cf-5602-472d-af98-cf9e6aad4f7a+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-120302%252C%2520%2528OSKIRA-2%2529%253A%250AA%2520Phase%2520III%252C%2520Multi-center%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%250AParallel%2520Group%2520Study%2520of%2520Two%2520Dosing%2520Regimens%2520of%2520Fostamatinib%2520Disodium%250Ain%2520Rheumatoid%2520Arthritis%2520Patients%2520with%2520an%2520Inadequate%2520Response%2520to%2520DMARDs%250AOral%2520SYK%2520Inhibition%2520in%2520Rheumatoid%2520Arthritis%2520%2528OSKIRA%2529%2520-%25202%2520Study.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-134518 (OSKIRA-3):
A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled,
Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium
in Rheumatoid Arthritis Patients with Inadequate Response to a TNF-alpha
Antagonist.</i> <a href="https://citeline.informa.com/trials/details/120302?qId=c470e1cf-5602-472d-af98-cf9e6aad4f7a" class="extLink">https://citeline.informa.com/trials/details/120302?qId=c470e1cf-5602-472d-af98-cf9e6aad4f7a</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-134518+%28OSKIRA-3%29%3A%0AA+Phase+III%2C+Multi-centre%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C%0AParallel+Group+Study+of+Two+Dosing+Regimens+of+Fostamatinib+Disodium%0Ain+Rheumatoid+Arthritis+Patients+with+Inadequate+Response+to+a+TNF-alpha%0AAntagonist.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F120302%3FqId%3Dc470e1cf-5602-472d-af98-cf9e6aad4f7a+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-134518%2520%2528OSKIRA-3%2529%253A%250AA%2520Phase%2520III%252C%2520Multi-centre%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%250AParallel%2520Group%2520Study%2520of%2520Two%2520Dosing%2520Regimens%2520of%2520Fostamatinib%2520Disodium%250Ain%2520Rheumatoid%2520Arthritis%2520Patients%2520with%2520Inadequate%2520Response%2520to%2520a%2520TNF-alpha%250AAntagonist.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-134522, (OSKIRA-1):
A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled,
Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium
in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate
OSKIRA: Oral Syk Inhibition in Rheumatoid Arthritis.</i> <a href="https://citeline.informa.com/trials/details/134522?qId=ad330157-7712-4ed5-826c-f50e8aadddfc" class="extLink">https://citeline.informa.com/trials/details/134522?qId=ad330157-7712-4ed5-826c-f50e8aadddfc</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-134522%2C+%28OSKIRA-1%29%3A%0AA+Phase+III%2C+Multi-centre%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C%0AParallel+Group+Study+of+Two+Dosing+Regimens+of+Fostamatinib+Disodium%0Ain+Rheumatoid+Arthritis+Patients+with+an+Inadequate+Response+to+Methotrexate%0AOSKIRA%3A+Oral+Syk+Inhibition+in+Rheumatoid+Arthritis.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F134522%3FqId%3Dad330157-7712-4ed5-826c-f50e8aadddfc+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-134522%252C%2520%2528OSKIRA-1%2529%253A%250AA%2520Phase%2520III%252C%2520Multi-centre%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%250AParallel%2520Group%2520Study%2520of%2520Two%2520Dosing%2520Regimens%2520of%2520Fostamatinib%2520Disodium%250Ain%2520Rheumatoid%2520Arthritis%2520Patients%2520with%2520an%2520Inadequate%2520Response%2520to%2520Methotrexate%250AOSKIRA%253A%2520Oral%2520Syk%2520Inhibition%2520in%2520Rheumatoid%2520Arthritis.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-136490, A Long-Term
Extension Study to Assess the Safety and Efficacy of Fostamatinib
Disodium (FosD) in the Treatment of Rheumatoid Arthritis.</i> <a href="https://citeline.informa.com/trials/details/136490?qId=67e62c4f-b508-4d9b-8ef9-37ba0a61c0e1" class="extLink">https://citeline.informa.com/trials/details/136490?qId=67e62c4f-b508-4d9b-8ef9-37ba0a61c0e1</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-136490%2C+A+Long-Term%0AExtension+Study+to+Assess+the+Safety+and+Efficacy+of+Fostamatinib%0ADisodium+%28FosD%29+in+the+Treatment+of+Rheumatoid+Arthritis.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F136490%3FqId%3D67e62c4f-b508-4d9b-8ef9-37ba0a61c0e1+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-136490%252C%2520A%2520Long-Term%250AExtension%2520Study%2520to%2520Assess%2520the%2520Safety%2520and%2520Efficacy%2520of%2520Fostamatinib%250ADisodium%2520%2528FosD%2529%2520in%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span>; <span class="NLM_string-name">Jiang, X.</span>; <span class="NLM_string-name">Qin, D.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Yang, J.</span>; <span class="NLM_string-name">Wu, A.</span>; <span class="NLM_string-name">Huang, F.</span>; <span class="NLM_string-name">Ye, Y.</span>; <span class="NLM_string-name">Wu, J.</span></span>, <span> </span><span class="NLM_article-title">Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</span>.  <i>Frontiers in Pharmacology</i> <span class="NLM_year">2019</span>,  <span class="NLM_volume">10</span> (<span class="NLM_issue">897</span>), <span class="refDoi"> DOI: 10.3389/fphar.2019.00897</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3389%2Ffphar.2019.00897" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Kang&author=X.+Jiang&author=D.+Qin&author=L.+Wang&author=J.+Yang&author=A.+Wu&author=F.+Huang&author=Y.+Ye&author=J.+Wu&title=Frontiers+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.3389%252Ffphar.2019.00897%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Multiple%2520Dosages%2520of%2520Fostamatinib%2520in%2520Adult%2520Patients%2520With%2520Rheumatoid%2520Arthritis%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26btitle%3DFrontiers%2520in%2520Pharmacology%26date%3D2019%26volume%3D10%26issue%3D897%26doi%3D10.3389%2Ffphar.2019.00897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rolf, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldman-Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellawell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braddock, M.</span></span> <span> </span><span class="NLM_article-title">In Vitro Pharmacological Profiling of R406 Identifies Molecular Targets Underlying the Clinical Effects of Fostamatinib</span>. <i>Pharmacology Res. Perspectives</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e00175</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fprp2.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26516587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&issue=5&author=M.+G.+Rolfauthor=J.+O.+Curwenauthor=M.+Veldman-Jonesauthor=C.+Eberleinauthor=J.+Wangauthor=A.+Harmerauthor=C.+J.+Hellawellauthor=M.+Braddock&title=In+Vitro+Pharmacological+Profiling+of+R406+Identifies+Molecular+Targets+Underlying+the+Clinical+Effects+of+Fostamatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib</span></div><div class="casAuthors">Rolf, Michael G.; Curwen, Jon O.; Veldman-Jones, Margaret; Eberlein, Cath; Wang, Jianyan; Harmer, Alex; Hellawell, Caroline J.; Braddock, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology Research & Perspectives</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e00175/1-e00175/12</span>CODEN:
                <span class="NLM_cas:coden">PRPHCA</span>;
        ISSN:<span class="NLM_cas:issn">2052-1707</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Off-target pharmacol. may contribute to both adverse and beneficial effects of a new drug.  In vitro pharmacol. profiling is often applied early in drug discovery; there are fewer reports addressing the relevance of broad profiles to clin. adverse effects.  Here, we have characterized the pharmacol. profile of the active metabolite of fostamatinib, R406, linking an understanding of drug selectivity to the increase in blood pressure obsd. in clin. studies.  R406 was profiled in a broad range of in vitro assays to generate a comprehensive pharmacol. profile and key targets were further investigated using functional and cellular assay systems.  A combination of traditional literature searches and text-mining approaches established potential mechanistic links between the profile of R406 and clin. side effects.  R406 was selective outside the kinase domain, with only antagonist activity at the adenosine A3 receptor in the range relevant to clin. effects.  R406 was less selective in the kinase domain, having activity at many protein kinases at therapeutically relevant concns. when tested in multiple in vitro systems.  Systematic literature analyses identified KDR as the probable target underlying the blood pressure increase obsd. in patients.  While the in vitro pharmacol. profile of R406 suggests a lack of selectivity among kinases, a combination of classical searching and text-mining approaches rationalized the complex profile establishing linkage between off-target pharmacol. and clin. obsd. effects.  These results demonstrate the utility of in vitro pharmacol. profiling for a compd. in late-stage clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYLaOYcHUvq7Vg90H21EOLACvtfcHk0likRnbg40vWAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjurvJ&md5=101df05b530d6928568bd3b8b2f651fa</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fprp2.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.175%26sid%3Dliteratum%253Aachs%26aulast%3DRolf%26aufirst%3DM.%2BG.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DVeldman-Jones%26aufirst%3DM.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHarmer%26aufirst%3DA.%26aulast%3DHellawell%26aufirst%3DC.%2BJ.%26aulast%3DBraddock%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Pharmacological%2520Profiling%2520of%2520R406%2520Identifies%2520Molecular%2520Targets%2520Underlying%2520the%2520Clinical%2520Effects%2520of%2520Fostamatinib%26jtitle%3DPharmacology%2520Res.%2520Perspectives%26date%3D2015%26volume%3D3%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberstock-Debic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gretler, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span> <span> </span><span class="NLM_article-title">PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1002/jcph.794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fjcph.794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27406873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlSrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=194-210&issue=2&author=G.+Coffeyauthor=A.+Raniauthor=A.+Betzauthor=Y.+Pakauthor=H.+Haberstock-Debicauthor=A.+Pandeyauthor=S.+Hollenbachauthor=D.+D.+Gretlerauthor=T.+Mantauthor=S.+Jurcevicauthor=U.+Sinha&title=PRT062607+Achieves+Complete+Inhibition+of+the+Spleen+Tyrosine+Kinase+at+Tolerated+Exposures+Following+Oral+Dosing+in+Healthy+Volunteers&doi=10.1002%2Fjcph.794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers</span></div><div class="casAuthors">Coffey, Greg; Rani, Aradhana; Betz, Andreas; Pak, Yvonne; Haberstock-Debic, Helena; Pandey, Anjali; Hollenbach, Stanley; Gretler, Daniel D.; Mant, Tim; Jurcevic, Stipo; Sinha, Uma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">194-210</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it an intriguing target for the treatment of inflammatory and autoimmune disorders as well as certain B-cell malignancies.  We have previously reported on the discovery and preclin. characterization of PRT062607, a potent and highly selective inhibitor of SYK that exhibits robust anti-inflammatory activity in a variety of animal models.  Here we present data from our first human studies aimed at characterizing the pharmacokinetics (PK), pharmacodynamics (PD), and safety of PRT062607 in healthy volunteers following single and multiple oral administrations.  PRT062607 demonstrated a favorable PK profile and the ability to completely inhibit SYK activity in multiple whole-blood assays.  The PD half-life in the more sensitive assays was approx. 24 h and returned to predose levels by 72 h.  Selectivity for SYK was obsd. at all dose levels tested.  Anal. of the PK/PD relationship indicated an IC50 of 324 nM for inhibition of B-cell antigen receptor-mediated B-cell activation and 205 nM for inhibition of FcεRI-mediated basophil degranulation.  PRT062607 was safe and well tolerated across the entire range of doses.  Clin. PK/PD was related to in vivo anti-inflammatory activity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concns. may be safely achieved in humans for the treatment of autoimmune disease.  PRT062607 has a desirable PK profile and is capable of safely, potently, and selectively suppressing SYK kinase function in humans following once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCmfMLrtasGbVg90H21EOLACvtfcHk0ljuarxsAT1cEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlSrtw%253D%253D&md5=93d8c5128dbd3d21a51335941f06a8c1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1002%2Fjcph.794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.794%26sid%3Dliteratum%253Aachs%26aulast%3DCoffey%26aufirst%3DG.%26aulast%3DRani%26aufirst%3DA.%26aulast%3DBetz%26aufirst%3DA.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DGretler%26aufirst%3DD.%2BD.%26aulast%3DMant%26aufirst%3DT.%26aulast%3DJurcevic%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DU.%26atitle%3DPRT062607%2520Achieves%2520Complete%2520Inhibition%2520of%2520the%2520Spleen%2520Tyrosine%2520Kinase%2520at%2520Tolerated%2520Exposures%2520Following%2520Oral%2520Dosing%2520in%2520Healthy%2520Volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D57%26issue%3D2%26spage%3D194%26epage%3D210%26doi%3D10.1002%2Fjcph.794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-174235,
A Phase
II Trial of Syk Inhibitor for Systemic Lupus Erythematosus.</i> <a href="https://citeline.informa.com/trials/details/174235?qId=06f0e751-f3d6-4797-9193-ae485615c160" class="extLink">https://citeline.informa.com/trials/details/174235?qId=06f0e751-f3d6-4797-9193-ae485615c160</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-174235%2C%0AA+Phase%0AII+Trial+of+Syk+Inhibitor+for+Systemic+Lupus+Erythematosus.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F174235%3FqId%3D06f0e751-f3d6-4797-9193-ae485615c160+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-174235%252C%250AA%2520Phase%250AII%2520Trial%2520of%2520Syk%2520Inhibitor%2520for%2520Systemic%2520Lupus%2520Erythematosus.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamorska-Dyga, A.</span></span> <span> </span><span class="NLM_article-title">Syk Inhibitors in Clinical Development for Hematological Malignancies</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">145</span>, <span class="refDoi"> DOI: 10.1186/s13045-017-0512-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1186%2Fs13045-017-0512-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28754125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2gsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=145&author=D.+Liuauthor=A.+Mamorska-Dyga&title=Syk+Inhibitors+in+Clinical+Development+for+Hematological+Malignancies&doi=10.1186%2Fs13045-017-0512-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Syk inhibitors in clinical development for hematological malignancies</span></div><div class="casAuthors">Liu, Delong; Mamorska-Dyga, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145/1-145/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells.  Syk was recognized as a crit. element in the B-cell receptor signaling pathway.  Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors.  Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clin. trials.  The second generation compd., entospletinib, showed promising results in clin. trials against B-cell malignancies, mainly chronic lymphoid leukemia.  Syk inhibitors are being evaluated in combination regimens in multiple malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI4gAk4MLv-7Vg90H21EOLACvtfcHk0ljuarxsAT1cEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2gsrbJ&md5=ed423c793913414c2966af15bd4457c4</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1186%2Fs13045-017-0512-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-017-0512-1%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMamorska-Dyga%26aufirst%3DA.%26atitle%3DSyk%2520Inhibitors%2520in%2520Clinical%2520Development%2520for%2520Hematological%2520Malignancies%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D10%26spage%3D145%26doi%3D10.1186%2Fs13045-017-0512-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chavarría-Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vance, R. E.</span></span> <span> </span><span class="NLM_article-title">The NLRP1 Inflammasomes</span>. <i>Immunological Reviews</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>265</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1111/imr.12283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1111%2Fimr.12283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25879281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1Sqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=2015&pages=22-34&author=J.+Chavarr%C3%ADa-Smithauthor=R.+E.+Vance&title=The+NLRP1+Inflammasomes&doi=10.1111%2Fimr.12283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP1 inflammasomes</span></div><div class="casAuthors">Chavarria-Smith, Joseph; Vance, Russell E.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-34</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Inflammasomes are cytosolic protein complexes that serve as platforms for the recruitment and activation of the pro-inflammatory CASPASE-1 protease.  CASPASE-1 activation leads to processing and maturation of the cytokines interleukin-1β and interleukin-18 and a lytic form of cell death termed pyroptosis.  Inflammasome assembly is initiated by cytosolic sensors in response to microbial infections.  Many of these sensors, including NLRP1 (NLR family, pyrin domain contg. 1), are described to form an inflammasome, but until recently, the mechanism of inflammasome activation and its physiol. functions in host defense have remained unclear.  In the last few years, important advances in our understanding of NLRP1 biol. have been achieved.  In this review, we discuss the activation of NLRP1 by various stimuli, including Bacillus anthracis lethal toxin, Toxoplasma gondii, muramyl dipeptide, and host intracellular ATP depletion.  The role NLRP1 plays in pathogen recognition and resistance during infection is also discussed, as is the regulation of NLRP1 by host and viral proteins.  We conclude by discussing the unexpected differences in the mechanism of NLRP1 inflammasome activation, as compared to the activation of other inflammasomes, such as the NAIP (NLR family, apoptosis inhibitory protein)/NLRC4 inflammasomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqrHKpelBISrVg90H21EOLACvtfcHk0liOQsIowH1_pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1Sqtb8%253D&md5=4ff66ff30ba1136982dab3cf8d8b8cab</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1111%2Fimr.12283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12283%26sid%3Dliteratum%253Aachs%26aulast%3DChavarr%25C3%25ADa-Smith%26aufirst%3DJ.%26aulast%3DVance%26aufirst%3DR.%2BE.%26atitle%3DThe%2520NLRP1%2520Inflammasomes%26jtitle%3DImmunological%2520Reviews%26date%3D2015%26volume%3D265%26spage%3D22%26epage%3D34%26doi%3D10.1111%2Fimr.12283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, J. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobota, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutertre, C.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginhoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irving, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-F.</span></span> <span> </span><span class="NLM_article-title">Dampened NLRP3-Mediated Inflammation in Bats and Implications for a Special Viral Reservoir Host</span>. <i>Nature Microbiology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1038/s41564-019-0371-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41564-019-0371-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30804542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsVyrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=789-799&author=M.+Ahnauthor=D.+E.+Andersonauthor=Q.+Zhangauthor=C.+W.+Tanauthor=B.+L.+Limauthor=K.+Lukoauthor=M.+Wenauthor=W.+N.+Chiaauthor=S.+Maniauthor=L.+C.+Wangauthor=J.+H.+J.+Ngauthor=R.+M.+Sobotaauthor=C.-A.+Dutertreauthor=F.+Ginhouxauthor=Z.-L.+Shiauthor=A.+T.+Irvingauthor=L.-F.+Wang&title=Dampened+NLRP3-Mediated+Inflammation+in+Bats+and+Implications+for+a+Special+Viral+Reservoir+Host&doi=10.1038%2Fs41564-019-0371-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host</span></div><div class="casAuthors">Ahn, Matae; Anderson, Danielle E.; Zhang, Qian; Tan, Chee Wah; Lim, Beng Lee; Luko, Katarina; Wen, Ming; Chia, Wan Ni; Mani, Shailendra; Wang, Loo Chien; Ng, Justin Han Jia; Sobota, Radoslaw M.; Dutertre, Charles-Antoine; Ginhoux, Florent; Shi, Zheng-Li; Irving, Aaron T.; Wang, Lin-Fa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">789-799</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Bats are special in their ability to host emerging viruses.  As the only flying mammal, bats endure high metabolic rates yet exhibit elongated lifespans.  It is currently unclear whether these unique features are interlinked.  The important inflammasome sensor, NLR family pyrin domain contg. 3 (NLRP3), has been linked to both viral-induced and age-related inflammation.  Here, we report significantly dampened activation of the NLRP3 inflammasome in bat primary immune cells compared to human or mouse counterparts.  Lower induction of apoptosis-assocd. speck-like protein contg. a CARD (ASC) speck formation and secretion of interleukin-1β in response to both 'sterile' stimuli and infection with multiple zoonotic viruses including influenza A virus (-single-stranded (ss) RNA), Melaka virus (PRV3M, double-stranded RNA) and Middle East respiratory syndrome coronavirus (+ssRNA) was obsd.  Importantly, this redn. of inflammation had no impact on the overall viral loads.  We identified dampened transcriptional priming, a novel splice variant and an altered leucine-rich repeat domain of bat NLRP3 as the cause.  Our results elucidate an important mechanism through which bats dampen inflammation with implications for longevity and unique viral reservoir status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTDTFm3XuF_LVg90H21EOLACvtfcHk0liOQsIowH1_pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsVyrtbo%253D&md5=35f29689eb0fde042b548c36402fed02</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1038%2Fs41564-019-0371-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41564-019-0371-3%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DD.%2BE.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTan%26aufirst%3DC.%2BW.%26aulast%3DLim%26aufirst%3DB.%2BL.%26aulast%3DLuko%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DM.%26aulast%3DChia%26aufirst%3DW.%2BN.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%2BC.%26aulast%3DNg%26aufirst%3DJ.%2BH.%2BJ.%26aulast%3DSobota%26aufirst%3DR.%2BM.%26aulast%3DDutertre%26aufirst%3DC.-A.%26aulast%3DGinhoux%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DZ.-L.%26aulast%3DIrving%26aufirst%3DA.%2BT.%26aulast%3DWang%26aufirst%3DL.-F.%26atitle%3DDampened%2520NLRP3-Mediated%2520Inflammation%2520in%2520Bats%2520and%2520Implications%2520for%2520a%2520Special%2520Viral%2520Reservoir%2520Host%26jtitle%3DNature%2520Microbiology%26date%3D2019%26volume%3D4%26spage%3D789%26epage%3D799%26doi%3D10.1038%2Fs41564-019-0371-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichinohe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span> <span> </span><span class="NLM_article-title">Influenza Virus Activates Inflammasomes via its Intracellular M2 Ion Channel</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/ni.1861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.1861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20383149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFaks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=404-410&issue=5&author=T.+Ichinoheauthor=I.+K.+Pangauthor=A.+Iwasaki&title=Influenza+Virus+Activates+Inflammasomes+via+its+Intracellular+M2+Ion+Channel&doi=10.1038%2Fni.1861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus activates inflammasomes via its intracellular M2 ion channel</span></div><div class="casAuthors">Ichinohe, Takeshi; Pang, Iris K.; Iwasaki, Akiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-410</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza virus, a neg.-stranded RNA virus that causes severe illness in humans and animals, stimulates the inflammasome through the Nod-like receptor NLRP3.  However, the mechanism by which influenza virus activates the NLRP3 inflammasome is unknown.  Here the authors show that the influenza virus M2 protein, a proton-selective ion channel important in viral pathogenesis, stimulates the NLRP3 inflammasome pathway.  M2 channel activity was required for the activation of inflammasomes by influenza and was sufficient to activate inflammasomes in primed macrophages and dendritic cells.  M2-induced activation of inflammasomes required its localization to the Golgi app. and was dependent on the pH gradient.  The authors' results show a mechanism by which influenza virus infection activates inflammasomes and identify the sensing of disturbances in intracellular ionic concns. as a previously unknown pathogen-recognition pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkq1MNEoVjp7Vg90H21EOLACvtfcHk0ljggpIrUvK5tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFaks7Y%253D&md5=4b772dca3cb7b7fc9229e40e0636278c</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1038%2Fni.1861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1861%26sid%3Dliteratum%253Aachs%26aulast%3DIchinohe%26aufirst%3DT.%26aulast%3DPang%26aufirst%3DI.%2BK.%26aulast%3DIwasaki%26aufirst%3DA.%26atitle%3DInfluenza%2520Virus%2520Activates%2520Inflammasomes%2520via%2520its%2520Intracellular%2520M2%2520Ion%2520Channel%26jtitle%3DNat.%2520Immunol.%26date%3D2010%26volume%3D11%26issue%3D5%26spage%3D404%26epage%3D410%26doi%3D10.1038%2Fni.1861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scull, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holl, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElvania-TeKippe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taxman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickles, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, J. P.-Y.</span></span> <span> </span><span class="NLM_article-title">The NLRP3 Inflammasome Mediates In Vivo Innate Immunity to Influenza A Virus through Recognition of Viral RNA</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2009.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2009.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19362020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Sqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=556-565&issue=4&author=I.+C.+Allenauthor=M.+A.+Scullauthor=C.+B.+Mooreauthor=E.+K.+Hollauthor=E.+McElvania-TeKippeauthor=D.+J.+Taxmanauthor=E.+H.+Guthrieauthor=R.+J.+Picklesauthor=J.+P.-Y.+Ting&title=The+NLRP3+Inflammasome+Mediates+In+Vivo+Innate+Immunity+to+Influenza+A+Virus+through+Recognition+of+Viral+RNA&doi=10.1016%2Fj.immuni.2009.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA</span></div><div class="casAuthors">Allen, Irving C.; Scull, Margaret A.; Moore, Chris B.; Holl, Eda K.; McElvania-TeKippe, Erin; Taxman, Debra J.; Guthrie, Elizabeth H.; Pickles, Raymond J.; Ting, Jenny P.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The nucleotide-binding domain and leucine-rich-repeat-contg. (NLR) family of pattern-recognition mols. mediate host immunity to various pathogenic stimuli.  However, in vivo evidence for the involvement of NLR proteins in viral sensing has not been widely investigated and remains controversial.  As a test of the physiol. role of the NLR mol. NLRP3 during RNA viral infection, we explored the in vivo role of NLRP3 inflammasome components during influenza virus infection.  Mice lacking Nlrp3, Pycard, or caspase-1, but not Nlrc4, exhibited dramatically increased mortality and a reduced immune response after exposure to the influenza virus.  Utilizing analogs of dsRNA (poly(I:C)) and ssRNA (ssRNA40), we demonstrated that an NLRP3-mediated response could be activated by RNA species.  Mechanistically, NLRP3 inflammasome activation by the influenza virus was dependent on lysosomal maturation and reactive oxygen species (ROS).  Inhibition of ROS induction eliminated IL-1β prodn. in animals during influenza infection.  Together, these data place the NLRP3 inflammasome as an essential component in host defense against influenza infection through the sensing of viral RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYN46-nyFYCLVg90H21EOLACvtfcHk0ljggpIrUvK5tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Sqsr8%253D&md5=b5478e1b5b21ca5531c7ca833fa83ce1</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2009.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2009.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DI.%2BC.%26aulast%3DScull%26aufirst%3DM.%2BA.%26aulast%3DMoore%26aufirst%3DC.%2BB.%26aulast%3DHoll%26aufirst%3DE.%2BK.%26aulast%3DMcElvania-TeKippe%26aufirst%3DE.%26aulast%3DTaxman%26aufirst%3DD.%2BJ.%26aulast%3DGuthrie%26aufirst%3DE.%2BH.%26aulast%3DPickles%26aufirst%3DR.%2BJ.%26aulast%3DTing%26aufirst%3DJ.%2BP.-Y.%26atitle%3DThe%2520NLRP3%2520Inflammasome%2520Mediates%2520In%2520Vivo%2520Innate%2520Immunity%2520to%2520Influenza%2520A%2520Virus%2520through%2520Recognition%2520of%2520Viral%2520RNA%26jtitle%3DImmunity%26date%3D2009%26volume%3D30%26issue%3D4%26spage%3D556%26epage%3D565%26doi%3D10.1016%2Fj.immuni.2009.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tate, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, J. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzog, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansell, A.</span></span> <span> </span><span class="NLM_article-title">Reassessing the Role of the NLRP3 Inflammasome During Pathogenic Influenza A Virus Infection via Temporal Inhibition</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">27912</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1038/srep27912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fsrep27912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28442746" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1-8&issue=27912&author=M.+D.+Tateauthor=J.+D.+H.+Ongauthor=J.+K.+Dowlingauthor=J.+L.+McAuleyauthor=A.+B.+Robertsonauthor=E.+Latzauthor=G.+R.+Drummondauthor=M.+A.+Cooperauthor=P.+J.+Hertzogauthor=A.+Mansell&title=Reassessing+the+Role+of+the+NLRP3+Inflammasome+During+Pathogenic+Influenza+A+Virus+Infection+via+Temporal+Inhibition&doi=10.1038%2Fsrep27912"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fsrep27912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep27912%26sid%3Dliteratum%253Aachs%26aulast%3DTate%26aufirst%3DM.%2BD.%26aulast%3DOng%26aufirst%3DJ.%2BD.%2BH.%26aulast%3DDowling%26aufirst%3DJ.%2BK.%26aulast%3DMcAuley%26aufirst%3DJ.%2BL.%26aulast%3DRobertson%26aufirst%3DA.%2BB.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DDrummond%26aufirst%3DG.%2BR.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DHertzog%26aufirst%3DP.%2BJ.%26aulast%3DMansell%26aufirst%3DA.%26atitle%3DReassessing%2520the%2520Role%2520of%2520the%2520NLRP3%2520Inflammasome%2520During%2520Pathogenic%2520Influenza%2520A%2520Virus%2520Infection%2520via%2520Temporal%2520Inhibition%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D27912%26spage%3D1%26epage%3D8%26doi%3D10.1038%2Fsrep27912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldridge, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellebedy, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamkanfi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webby, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, T.-D.</span></span> <span> </span><span class="NLM_article-title">The Intracellular Sensor NLRP3Mediates Key Innate and Healing Responses to Infleunza A Virus via the Regulation of Caspase-1</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2009.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2009.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19362023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Sqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=566-575&author=P.+G.+Thomasauthor=P.+Dashauthor=J.+R.+Aldridgeauthor=A.+H.+Ellebedyauthor=C.+Reynoldsauthor=A.+J.+Funkauthor=W.+J.+Martinauthor=M.+Lamkanfiauthor=R.+J.+Webbyauthor=K.+L.+Boydauthor=P.+C.+Dohertyauthor=T.-D.+Kanneganti&title=The+Intracellular+Sensor+NLRP3Mediates+Key+Innate+and+Healing+Responses+to+Infleunza+A+Virus+via+the+Regulation+of+Caspase-1&doi=10.1016%2Fj.immuni.2009.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1</span></div><div class="casAuthors">Thomas, Paul G.; Dash, Pradyot; Aldridge, Jerry R., Jr.; Ellebedy, Ali H.; Reynolds, Cory; Funk, Amy J.; Martin, William J.; Lamkanfi, Mohamed; Webby, Richard J.; Boyd, Kelli L.; Doherty, Peter C.; Kanneganti, Thirumala-Devi</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">566-575</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Virus-induced interleukin-1β (IL-1β) and IL-18 prodn. in macrophages are mediated via caspase-1 pathway.  Multiple microbial components, including viral RNA, are thought to trigger assembly of the cryopyrin inflammasome resulting in caspase-1 activation.  Here, we demonstrated that Nlrp3-/- and Casp1-/- mice were more susceptible than wild-type mice after infection with a pathogenic influenza A virus.  This enhanced morbidity correlated with decreased neutrophil and monocyte recruitment and reduced cytokine and chemokine prodn.  Despite the effect on innate immunity, cryopyrin-deficiency was not assocd. with any obvious defect in virus control or on the later emergence of the adaptive response.  Early epithelial necrosis was, however, more severe in the infected mutants, with extensive collagen deposition leading to later respiratory compromise.  These findings reveal a function of the cryopyrin inflammasome in healing responses.  Thus, cryopyrin and caspase-1 are central to both innate immunity and to moderating lung pathol. in influenza pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplgvzh5pP-PLVg90H21EOLACvtfcHk0lgomu077kgEBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Sqsrw%253D&md5=fcfb5b235b4f0316c6d30661747c2b47</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2009.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2009.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DP.%2BG.%26aulast%3DDash%26aufirst%3DP.%26aulast%3DAldridge%26aufirst%3DJ.%2BR.%26aulast%3DEllebedy%26aufirst%3DA.%2BH.%26aulast%3DReynolds%26aufirst%3DC.%26aulast%3DFunk%26aufirst%3DA.%2BJ.%26aulast%3DMartin%26aufirst%3DW.%2BJ.%26aulast%3DLamkanfi%26aufirst%3DM.%26aulast%3DWebby%26aufirst%3DR.%2BJ.%26aulast%3DBoyd%26aufirst%3DK.%2BL.%26aulast%3DDoherty%26aufirst%3DP.%2BC.%26aulast%3DKanneganti%26aufirst%3DT.-D.%26atitle%3DThe%2520Intracellular%2520Sensor%2520NLRP3Mediates%2520Key%2520Innate%2520and%2520Healing%2520Responses%2520to%2520Infleunza%2520A%2520Virus%2520via%2520the%2520Regulation%2520of%2520Caspase-1%26jtitle%3DImmunity%26date%3D2009%26volume%3D30%26spage%3D566%26epage%3D575%26doi%3D10.1016%2Fj.immuni.2009.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, G.</span></span> <span> </span><span class="NLM_article-title">Hyperactivation of the NLRP3 Inflammasome Protects Mice Against Influenza A Virus Infection via IL-1β Mediated Neutrophil Recruitment</span>. <i>Cytokine+</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2019.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.cyto.2019.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31055218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVCnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=115-124&author=J.+Niuauthor=S.+Wuauthor=M.+Chenauthor=K.+Xuauthor=Q.+Guoauthor=A.+Luauthor=L.+Zhaoauthor=B.+Sunauthor=G.+Meng&title=Hyperactivation+of+the+NLRP3+Inflammasome+Protects+Mice+Against+Influenza+A+Virus+Infection+via+IL-1%CE%B2+Mediated+Neutrophil+Recruitment&doi=10.1016%2Fj.cyto.2019.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactivation of the NLRP3 inflammasome protects mice against influenza A virus infection via IL-1β mediated neutrophil recruitment</span></div><div class="casAuthors">Niu, Junling; Wu, Shuxian; Chen, Mingkuan; Xu, Ke; Guo, Qiuhong; Lu, Ailing; Zhao, Liping; Sun, Bing; Meng, Guangxun</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-124</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Host innate immune system is crit. for combating invading microbes including Influenza A virus (IAV).  As an important arm of the innate immunity, the NLRP3 inflammasome has been found essential for protecting host against IAV challenge, while the mechanism remained elusive.  Here we found that mice carrying a gain-of-function mutation in the Nlrp3 gene (Nlrp3R258W) are strongly resistant to IAV infection.  Upon H1N1 IAV infection, the Nlrp3R258W mice exhibited decreased wt. loss, increased survival rate and attenuated lung damage compared with WT littermate controls.  Mechanistically, the resistance of Nlrp3R258W mice to IAV infection was dependent on IL-1β-mediated neutrophil recruitment.  Upon IAV infection, mice carrying the Nlrp3R258W mutation produced more IL-1β than WT mice in the lung, which enhanced neutrophil recruitment locally.  The recruited neutrophils facilitated IAV clearance, so that the viral load in Nlrp3R258W mice was lower than that in control mice.  Conversely, neutrophil depletion in Nlrp3R258W mice compromised IAV clearance.  Taken together, our results demonstrate a previously undescribed mechanism by which hyperactivation of the NLRP3 Inflammasome protects mice from IAV infection through IL-1β mediated neutrophil recruitment, thus suggest that pos. fine tuning the physiol. function of NLRP3 inflammasome can be beneficial for a mammalian host against IAV challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0kuu-_n6EX7Vg90H21EOLACvtfcHk0lgomu077kgEBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVCnt7w%253D&md5=35dfd7dc7cfe2edaef4273782f54f97e</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2019.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2019.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DMeng%26aufirst%3DG.%26atitle%3DHyperactivation%2520of%2520the%2520NLRP3%2520Inflammasome%2520Protects%2520Mice%2520Against%2520Influenza%2520A%2520Virus%2520Infection%2520via%2520IL-1%25CE%25B2%2520Mediated%2520Neutrophil%2520Recruitment%26jtitle%3DCytokine%252B%26date%3D2019%26volume%3D120%26spage%3D115%26epage%3D124%26doi%3D10.1016%2Fj.cyto.2019.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stout-Delgado, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirali, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, K. S.</span></span> <span> </span><span class="NLM_article-title">Impaired NLRP3 Inflammasome Function in Elderly Mice during Influenza Infection is Rescued by Treatment with Nigericin</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">2815</span>– <span class="NLM_lpage">2824</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1103051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1103051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=22327078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1GntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2012&pages=2815-2824&author=H.+W.+Stout-Delgadoauthor=S.+E.+Vaughanauthor=A.+C.+Shiraliauthor=R.+J.+Jaramilloauthor=K.+S.+Harrod&title=Impaired+NLRP3+Inflammasome+Function+in+Elderly+Mice+during+Influenza+Infection+is+Rescued+by+Treatment+with+Nigericin&doi=10.4049%2Fjimmunol.1103051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired NLRP3 Inflammasome Function in Elderly Mice during Influenza Infection Is Rescued by Treatment with Nigericin</span></div><div class="casAuthors">Stout-Delgado, Heather W.; Vaughan, Sarah E.; Shirali, Anushree C.; Jaramillo, Richard J.; Harrod, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2815-2824</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome is activated in the lung during influenza viral infection; however, the impact of aging on inflammasome function during influenza infection has not been examd.  In this study, we show that elderly mice infected with a mouse-adapted strain of influenza produced lower levels of IL-1β during in vitro and in vivo infection.  Dendritic cells from elderly mice exhibited decreased expression of ASC, NLRP3, and capase-1 but increased expression of pro-IL-1β, pro-IL-18, and pro-IL-33 compared with dendritic cells from young infected mice.  Treatment with nigericin during influenza infection augmented IL-1β prodn., increased caspase-1 activity, and decreased morbidity and mortality in elderly mice.  Our study demonstrates for the first time, to our knowledge, that during influenza viral infection, elderly mice have impaired NLRP3 inflammasome activity and that treatment with nigericin rescues NLRP3 activation in elderly hosts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopYLpyTCR137Vg90H21EOLACvtfcHk0lgiOAH5FlBTlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1GntLs%253D&md5=d65e75a5db34e23c8fe60c6b694d29c6</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1103051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1103051%26sid%3Dliteratum%253Aachs%26aulast%3DStout-Delgado%26aufirst%3DH.%2BW.%26aulast%3DVaughan%26aufirst%3DS.%2BE.%26aulast%3DShirali%26aufirst%3DA.%2BC.%26aulast%3DJaramillo%26aufirst%3DR.%2BJ.%26aulast%3DHarrod%26aufirst%3DK.%2BS.%26atitle%3DImpaired%2520NLRP3%2520Inflammasome%2520Function%2520in%2520Elderly%2520Mice%2520during%2520Influenza%2520Infection%2520is%2520Rescued%2520by%2520Treatment%2520with%2520Nigericin%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D188%26spage%3D2815%26epage%3D2824%26doi%3D10.4049%2Fjimmunol.1103051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNeela, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neill, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeaton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Rachkidy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLoughlin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrilli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrew, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadioglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavelle, E. C.</span></span> <span> </span><span class="NLM_article-title">Pneumolysin Activates the NLRP3 Inflammasome and Promotes Proinflammatory Cytokines Independently of TLR4</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>), <span class="NLM_elocation-id">e1001191</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1001191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.ppat.1001191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21085613" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&issue=11&author=E.+A.+McNeelaauthor=A.+Burkeauthor=D.+R.+Neillauthor=C.+Baxterauthor=V.+E.+Fernandesauthor=D.+Ferreiraauthor=S.+Smeatonauthor=R.+El-Rachkidyauthor=R.+M.+McLoughlinauthor=A.+Moriauthor=B.+Moranauthor=K.+A.+Fitzgeraldauthor=J.+Tschoppauthor=V.+Petrilliauthor=P.+W.+Andrewauthor=A.+Kadiogluauthor=E.+C.+Lavelle&title=Pneumolysin+Activates+the+NLRP3+Inflammasome+and+Promotes+Proinflammatory+Cytokines+Independently+of+TLR4&doi=10.1371%2Fjournal.ppat.1001191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001191%26sid%3Dliteratum%253Aachs%26aulast%3DMcNeela%26aufirst%3DE.%2BA.%26aulast%3DBurke%26aufirst%3DA.%26aulast%3DNeill%26aufirst%3DD.%2BR.%26aulast%3DBaxter%26aufirst%3DC.%26aulast%3DFernandes%26aufirst%3DV.%2BE.%26aulast%3DFerreira%26aufirst%3DD.%26aulast%3DSmeaton%26aufirst%3DS.%26aulast%3DEl-Rachkidy%26aufirst%3DR.%26aulast%3DMcLoughlin%26aufirst%3DR.%2BM.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DMoran%26aufirst%3DB.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DTschopp%26aufirst%3DJ.%26aulast%3DPetrilli%26aufirst%3DV.%26aulast%3DAndrew%26aufirst%3DP.%2BW.%26aulast%3DKadioglu%26aufirst%3DA.%26aulast%3DLavelle%26aufirst%3DE.%2BC.%26atitle%3DPneumolysin%2520Activates%2520the%2520NLRP3%2520Inflammasome%2520and%2520Promotes%2520Proinflammatory%2520Cytokines%2520Independently%2520of%2520TLR4%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26issue%3D11%26doi%3D10.1371%2Fjournal.ppat.1001191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witzenrath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pache, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutbier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabeling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reppe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meixenberger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorhoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trendelenburg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimesaat, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bereswill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suttorp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, B.</span></span> <span> </span><span class="NLM_article-title">The NLRP3 Inflammasome is Differentially Activated by Pneumolysin Variants and Contributes to Host Defense in Pneumococcal Pneumonia</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1003143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1003143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21646297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvValtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=434-440&author=M.+Witzenrathauthor=F.+Pacheauthor=D.+Lorenzauthor=U.+Koppeauthor=B.+Gutbierauthor=C.+Tabelingauthor=K.+Reppeauthor=K.+Meixenbergerauthor=A.+Dorhoiauthor=J.+Maauthor=A.+Holmesauthor=G.+Trendelenburgauthor=M.+M.+Heimesaatauthor=S.+Bereswillauthor=M.+van+der+Lindenauthor=J.+Tschoppauthor=T.+J.+Mitchellauthor=N.+Suttorpauthor=B.+Opitz&title=The+NLRP3+Inflammasome+is+Differentially+Activated+by+Pneumolysin+Variants+and+Contributes+to+Host+Defense+in+Pneumococcal+Pneumonia&doi=10.4049%2Fjimmunol.1003143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP3 Inflammasome Is Differentially Activated by Pneumolysin Variants and Contributes to Host Defense in Pneumococcal Pneumonia</span></div><div class="casAuthors">Witzenrath, Martin; Pache, Florence; Lorenz, Daniel; Koppe, Uwe; Gutbier, Birgitt; Tabeling, Christoph; Reppe, Katrin; Meixenberger, Karolin; Dorhoi, Anca; Ma, Jiangtao; Holmes, Ashleigh; Trendelenburg, George; Heimesaat, Markus M.; Bereswill, Stefan; van der Linden, Mark; Tschopp, Juerg; Mitchell, Timothy J.; Suttorp, Norbert; Opitz, Bastian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">434-440</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Streptococcus pneumoniae is a leading cause of pneumonia, meningitis, and sepsis.  Pneumococci can be divided into >90 serotypes that show differences in the pathogenicity and invasiveness.  We tested the hypotheses that the innate immune inflammasome pathway is involved in fighting pneumococcal pneumonia and that some invasive pneumococcal types are not recognized by this pathway.  We show that human and murine mononuclear cells responded to S. pneumoniae expressing hemolytic pneumolysin by producing IL-1β.  This IL-1β prodn. depended on the NOD-like receptor family, pyrin domain contg. 3 (NLRP3) inflammasome.  Some serotype 1, serotype 8, and serotype 7F bacteria, which have previously been assocd. with increased invasiveness and with prodn. of toxins with reduced hemolytic activity, or bacterial mutants lacking pneumolysin did not stimulate notable IL-1β prodn.  We further found that NLRP3 was beneficial for mice during pneumonia caused by pneumococci expressing hemolytic pneumolysin and was involved in cytokine prodn. and maintenance of the pulmonary microvascular barrier.  Overall, the inflammasome pathway is protective in pneumonia caused by pneumococci expressing hemolytic toxin but is not activated by clin. important pneumococcal sequence types causing invasive disease.  The study indicates that a virulence factor polymorphism may substantially affect the recognition of bacteria by the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTyHkIuuS577Vg90H21EOLACvtfcHk0lgIV2pR9-gusQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvValtL8%253D&md5=8e2ba1fb62ee9126e53fad5ead63b204</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1003143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1003143%26sid%3Dliteratum%253Aachs%26aulast%3DWitzenrath%26aufirst%3DM.%26aulast%3DPache%26aufirst%3DF.%26aulast%3DLorenz%26aufirst%3DD.%26aulast%3DKoppe%26aufirst%3DU.%26aulast%3DGutbier%26aufirst%3DB.%26aulast%3DTabeling%26aufirst%3DC.%26aulast%3DReppe%26aufirst%3DK.%26aulast%3DMeixenberger%26aufirst%3DK.%26aulast%3DDorhoi%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DHolmes%26aufirst%3DA.%26aulast%3DTrendelenburg%26aufirst%3DG.%26aulast%3DHeimesaat%26aufirst%3DM.%2BM.%26aulast%3DBereswill%26aufirst%3DS.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DM.%26aulast%3DTschopp%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DT.%2BJ.%26aulast%3DSuttorp%26aufirst%3DN.%26aulast%3DOpitz%26aufirst%3DB.%26atitle%3DThe%2520NLRP3%2520Inflammasome%2520is%2520Differentially%2520Activated%2520by%2520Pneumolysin%2520Variants%2520and%2520Contributes%2520to%2520Host%2520Defense%2520in%2520Pneumococcal%2520Pneumonia%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D434%26epage%3D440%26doi%3D10.4049%2Fjimmunol.1003143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, A. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout-Delgado, H. W.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Activation in Aged Macrophages is Diminished During <i>Streptococcus Pneumoniae</i> Infection</span>. <i>American Journal of Physiology-Lung Cellular and Molecular Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">L372</span>– <span class="NLM_lpage">L387</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00393.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1152%2Fajplung.00393.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29097427" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2018&pages=L372-L387&author=S.+J.+Choauthor=K.+Rooneyauthor=A.+M.+K.+Choiauthor=H.+W.+Stout-Delgado&title=NLRP3+Inflammasome+Activation+in+Aged+Macrophages+is+Diminished+During+Streptococcus+Pneumoniae+Infection&doi=10.1152%2Fajplung.00393.2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00393.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00393.2017%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DRooney%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DA.%2BM.%2BK.%26aulast%3DStout-Delgado%26aufirst%3DH.%2BW.%26atitle%3DNLRP3%2520Inflammasome%2520Activation%2520in%2520Aged%2520Macrophages%2520is%2520Diminished%2520During%2520Streptococcus%2520Pneumoniae%2520Infection%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Lung%2520Cellular%2520and%2520Molecular%2520Pharmacology%26date%3D2018%26volume%3D314%26spage%3DL372%26epage%3DL387%26doi%3D10.1152%2Fajplung.00393.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plataki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitzel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout-Delgado, H.</span></span> <span> </span><span class="NLM_article-title">Decreased NLRP3 Inflammasome Expression in Aged Lung may Contribute to Increased Susceptibility to Secondary <i>Streptococcus Pneumoniae</i> Infection</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/j.exger.2017.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.exger.2017.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29203400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCis73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2018&pages=40-46&author=S.+J.+Choauthor=M.+Platakiauthor=D.+Mitzelauthor=G.+Lowryauthor=K.+Rooneyauthor=H.+Stout-Delgado&title=Decreased+NLRP3+Inflammasome+Expression+in+Aged+Lung+may+Contribute+to+Increased+Susceptibility+to+Secondary+Streptococcus+Pneumoniae+Infection&doi=10.1016%2Fj.exger.2017.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased NLRP3 inflammasome expression in aged lung may contribute to increased susceptibility to secondary Streptococcus pneumoniae infection</span></div><div class="casAuthors">Cho, Soo Jung; Plataki, Maria; Mitzel, Dana; Lowry, Gena; Rooney, Kristen; Stout-Delgado, Heather</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-46</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Post-viral pneumococcal pneumonia is a leading morbidity and mortality in older patients (≥ 65 years of age).  The goal of our current study is to understand the impact of chronol. aging on innate immune responses to a secondary, post viral infection with Streptococcus pneumoniae, a causative agent of bacterial pneumonia.  Using aged murine models of infection, our findings demonstrate increased morbidity and mortality in aged mice within 48 h post-secondary S. pneumoniae infection.  Increased susceptibility of aged mice was assocd. with decreased TLR1, TLR6, and TLR9 mRNA expression and diminished IL1β mRNA expression.  Examn. of NLRP3 inflammasome expression illustrated decreased NLRP3 mRNA expression and decreased IL1β prodn. in aged lung in response to secondary S. pneumoniae infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKor62qdna7Vg90H21EOLACvtfcHk0lheI68SoSutkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCis73P&md5=844f92d658146ae4dd300908770c61c1</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.exger.2017.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exger.2017.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DPlataki%26aufirst%3DM.%26aulast%3DMitzel%26aufirst%3DD.%26aulast%3DLowry%26aufirst%3DG.%26aulast%3DRooney%26aufirst%3DK.%26aulast%3DStout-Delgado%26aufirst%3DH.%26atitle%3DDecreased%2520NLRP3%2520Inflammasome%2520Expression%2520in%2520Aged%2520Lung%2520may%2520Contribute%2520to%2520Increased%2520Susceptibility%2520to%2520Secondary%2520Streptococcus%2520Pneumoniae%2520Infection%26jtitle%3DExp.%2520Gerontol.%26date%3D2018%26volume%3D105%26spage%3D40%26epage%3D46%26doi%3D10.1016%2Fj.exger.2017.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molony, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malawista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. R.</span></span> <span> </span><span class="NLM_article-title">Reduced Dynamic Range of Antiviral Innate Immune Responses in Aging</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.exger.2017.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.exger.2017.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28822811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2gtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2018&pages=130-135&issue=1&author=R.+D.+Molonyauthor=A.+Malawistaauthor=R.+R.+Montgomery&title=Reduced+Dynamic+Range+of+Antiviral+Innate+Immune+Responses+in+Aging&doi=10.1016%2Fj.exger.2017.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced dynamic range of antiviral innate immune responses in aging</span></div><div class="casAuthors">Molony, Ryan D.; Malawista, Anna; Montgomery, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">130-135</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The worldwide population aged ≥ 65 years is increasing and the av. life span is expected to increase another 10 years by 2050.  This extended lifespan is assocd. with a progressive decline in immune function and a paradoxical state of low-grade, chronic inflammation that may contribute to susceptibility to viral infection, and reduced responses to vaccination.  Here we review the effects of aging on innate immune responses to viral pathogens including elements of recognition, signaling, and prodn. of inflammatory mediators.  We specifically focus on age-related changes in key pattern recognition receptor signaling pathways, converging on altered cytokine responses, including a notable impairment of antiviral interferon responses.  We highlight an emergent change in innate immunity that arises during aging - the dampening of the dynamic range of responses to multiple sources of stimulation - which may underlie reduced efficiency of immune responses in aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWBTuv1dkmvrVg90H21EOLACvtfcHk0lheI68SoSutkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2gtbrI&md5=6a5fa872cf191e85a9139f4fcff9c11c</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.exger.2017.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exger.2017.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DMolony%26aufirst%3DR.%2BD.%26aulast%3DMalawista%26aufirst%3DA.%26aulast%3DMontgomery%26aufirst%3DR.%2BR.%26atitle%3DReduced%2520Dynamic%2520Range%2520of%2520Antiviral%2520Innate%2520Immune%2520Responses%2520in%2520Aging%26jtitle%3DExp.%2520Gerontol.%26date%3D2018%26volume%3D107%26issue%3D1%26spage%3D130%26epage%3D135%26doi%3D10.1016%2Fj.exger.2017.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, P.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresnigt, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lionakis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groß, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naglik, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hube, B.</span></span> <span> </span><span class="NLM_article-title">The Fungal Peptide Toxin Candidalysin Activates the NLRP3 Inflammasome and Causes Cytolysis in Mononuclear Phagocytes</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4260</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06607-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41467-018-06607-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30323213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BB3czpsFCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4260&author=L.+Kasperauthor=A.+Konigauthor=P.-A.+Koenigauthor=M.+S.+Gresnigtauthor=J.+Westmanauthor=R.+A.+Drummondauthor=M.+S.+Lionakisauthor=O.+Gro%C3%9Fauthor=J.+Rulandauthor=J.+R.+Naglikauthor=B.+Hube&title=The+Fungal+Peptide+Toxin+Candidalysin+Activates+the+NLRP3+Inflammasome+and+Causes+Cytolysis+in+Mononuclear+Phagocytes&doi=10.1038%2Fs41467-018-06607-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes</span></div><div class="casAuthors">Kasper Lydia; Konig Annika; Gresnigt Mark S; Hube Bernhard; Koenig Paul-Albert; Ruland Jurgen; Westman Johannes; Drummond Rebecca A; Lionakis Michail S; Drummond Rebecca A; Gross Olaf; Ruland Jurgen; Ruland Jurgen; Ruland Jurgen; Naglik Julian R; Hube Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4260</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Clearance of invading microbes requires phagocytes of the innate immune system.  However, successful pathogens have evolved sophisticated strategies to evade immune killing.  The opportunistic human fungal pathogen Candida albicans is efficiently phagocytosed by macrophages, but causes inflammasome activation, host cytolysis, and escapes after hypha formation.  Previous studies suggest that macrophage lysis by C. albicans results from early inflammasome-dependent cell death (pyroptosis), late damage due to glucose depletion and membrane piercing by growing hyphae.  Here we show that Candidalysin, a cytolytic peptide toxin encoded by the hypha-associated gene ECE1, is both a central trigger for NLRP3 inflammasome-dependent caspase-1 activation via potassium efflux and a key driver of inflammasome-independent cytolysis of macrophages and dendritic cells upon infection with C. albicans.  This suggests that Candidalysin-induced cell damage is a third mechanism of C. albicans-mediated mononuclear phagocyte cell death in addition to damage caused by pyroptosis and the growth of glucose-consuming hyphae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdAjzJJAvn4bFU0A1HOshhfW6udTcc2eaQJ0QcODTR2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czpsFCrtg%253D%253D&md5=48e1088c5fcb6cc21a3e8e336fbdf161</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06607-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06607-1%26sid%3Dliteratum%253Aachs%26aulast%3DKasper%26aufirst%3DL.%26aulast%3DKonig%26aufirst%3DA.%26aulast%3DKoenig%26aufirst%3DP.-A.%26aulast%3DGresnigt%26aufirst%3DM.%2BS.%26aulast%3DWestman%26aufirst%3DJ.%26aulast%3DDrummond%26aufirst%3DR.%2BA.%26aulast%3DLionakis%26aufirst%3DM.%2BS.%26aulast%3DGro%25C3%259F%26aufirst%3DO.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DNaglik%26aufirst%3DJ.%2BR.%26aulast%3DHube%26aufirst%3DB.%26atitle%3DThe%2520Fungal%2520Peptide%2520Toxin%2520Candidalysin%2520Activates%2520the%2520NLRP3%2520Inflammasome%2520and%2520Causes%2520Cytolysis%2520in%2520Mononuclear%2520Phagocytes%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4260%26doi%3D10.1038%2Fs41467-018-06607-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hise, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomalka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span> <span> </span><span class="NLM_article-title">An Essential Role for the NLRP3 Inflammasome in Host Defense Against the Human Fungal Pathogen <i>Candida Albicans</i></span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2009.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.chom.2009.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19454352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVClu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=487-497&author=A.+G.+Hiseauthor=J.+Tomalkaauthor=S.+Ganesanauthor=K.+Patelauthor=B.+A.+Hallauthor=G.+D.+Brownauthor=K.+A.+Fitzgerald&title=An+Essential+Role+for+the+NLRP3+Inflammasome+in+Host+Defense+Against+the+Human+Fungal+Pathogen+Candida+Albicans&doi=10.1016%2Fj.chom.2009.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans</span></div><div class="casAuthors">Hise, Amy G.; Tomalka, Jeffrey; Ganesan, Sandhya; Patel, Krupen; Hall, Brian A.; Brown, Gordon D.; Fitzgerald, Katherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">487-497</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">C. albicans is an opportunistic fungal pathogen causing life-threatening mucosal and systemic infections in immunocompromised humans.  Using a murine model of mucosal Candida infection, the authors investigated the role of the proinflammatory cytokine IL-1β in host defense to C. albicans.  They found that the synthesis, processing, and release of IL-1β in response to Candida are tightly controlled and first require transcriptional induction, followed by a second signal leading to caspase-1-mediated cleavage of the pro-IL-1β cytokine.  The known fungal pattern recognition receptors TLR2 and Dectin-1 regulate IL-1β gene transcription, whereas the NLRP3-contg. proinflammatory multiprotein complex, the NLRP3 inflammasome, controls caspase-1-mediated cleavage of pro-IL-1β.  Furthermore, the authors show that TLR2, Dectin-1, and NLRP3 are essential for defense against dissemination of mucosal infection and mortality in vivo.  Therefore, in addn. to sensing bacterial and viral pathogens, the NLRP3 inflammasome senses fungal pathogens and is crit. in host defense against Candida.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBcuTfQ1A1BbVg90H21EOLACvtfcHk0lhiCw-DlpYZFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVClu7c%253D&md5=b4a08e1bfcc1ac2f3e7c73ab7fd380be</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2009.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2009.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DHise%26aufirst%3DA.%2BG.%26aulast%3DTomalka%26aufirst%3DJ.%26aulast%3DGanesan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DB.%2BA.%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26atitle%3DAn%2520Essential%2520Role%2520for%2520the%2520NLRP3%2520Inflammasome%2520in%2520Host%2520Defense%2520Against%2520the%2520Human%2520Fungal%2520Pathogen%2520Candida%2520Albicans%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2009%26volume%3D5%26spage%3D487%26epage%3D497%26doi%3D10.1016%2Fj.chom.2009.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutterwala, F. S.</span></span> <span> </span><span class="NLM_article-title">Cutting Edge: <i>Candida albicans</i> Hyphae Formation Triggers Activation of the NLRP3 Inflammasome</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">3578</span>– <span class="NLM_lpage">3581</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.0901323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19684085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOmur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=3578-3581&issue=6&author=S.+Jolyauthor=N.+Maauthor=J.+J.+Sadlerauthor=D.+R.+Sollauthor=S.+L.+Casselauthor=F.+S.+Sutterwala&title=Cutting+Edge%3A+Candida+albicans+Hyphae+Formation+Triggers+Activation+of+the+NLRP3+Inflammasome&doi=10.4049%2Fjimmunol.0901323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Cutting Edge: Candida albicans Hyphae Formation Triggers Activation of the Nlrp3 Inflammasome</span></div><div class="casAuthors">Joly, Sophie; Ma, Ning; Sadler, Jeffrey J.; Soll, David R.; Cassel, Suzanne L.; Sutterwala, Fayyaz S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3578-3581</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The proinflammatory cytokine IL-1β plays an important role in antifungal immunity; however, the mechanisms by which fungal pathogens trigger IL-1β secretion are unclear.  In this study we show that infection with Candida albicans is sensed by the Nlrp3 inflammasome, resulting in the subsequent release of IL-1β.  The ability of C. albicans to switch from a unicellular yeast form into a filamentous form is essential for activation of the Nlrp3 inflammasome, as C. albicans mutants incapable of forming hyphae were defective in their ability to induce macrophage IL-1β secretion.  Nlrp3-deficient mice also demonstrated increased susceptibility to infection with C. albicans, which is consistent with a key role for Nlrp3 in innate immune responses to the pathogen C. albicans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYPsaZsfDXGrVg90H21EOLACvtfcHk0ljqPOjmgg7LkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOmur3E&md5=2637b6909de303851a9f097797fd2d56</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901323%26sid%3Dliteratum%253Aachs%26aulast%3DJoly%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DN.%26aulast%3DSadler%26aufirst%3DJ.%2BJ.%26aulast%3DSoll%26aufirst%3DD.%2BR.%26aulast%3DCassel%26aufirst%3DS.%2BL.%26aulast%3DSutterwala%26aufirst%3DF.%2BS.%26atitle%3DCutting%2520Edge%253A%2520Candida%2520albicans%2520Hyphae%2520Formation%2520Triggers%2520Activation%2520of%2520the%2520NLRP3%2520Inflammasome%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26issue%3D6%26spage%3D3578%26epage%3D3581%26doi%3D10.4049%2Fjimmunol.0901323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiringhelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apetoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesniere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aymeric, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermaelen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaretakis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfettini, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlemmer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasdemir, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Génin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryffel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanellopoulos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lidereau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitvogel, L.</span></span> <span> </span><span class="NLM_article-title">Activation of the NLRP3 Inflammasome in Dendritic Cells Induces IL-1β-Dependent Adaptive Immunity Against Tumors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1038/nm.2028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnm.2028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19767732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGjt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1170-1178&issue=10&author=F.+Ghiringhelliauthor=L.+Apetohauthor=A.+Tesniereauthor=L.+Aymericauthor=Y.+Maauthor=C.+Ortizauthor=K.+Vermaelenauthor=T.+Panaretakisauthor=G.+Mignotauthor=E.+Ullrichauthor=J.-L.+Perfettiniauthor=F.+Schlemmerauthor=E.+Tasdemirauthor=M.+Uhlauthor=P.+G%C3%A9ninauthor=A.+Civasauthor=B.+Ryffelauthor=J.+Kanellopoulosauthor=J.+Tschoppauthor=F.+Andr%C3%A9author=R.+Lidereauauthor=N.+M.+McLaughlinauthor=N.+M.+Haynesauthor=M.+J.+Smythauthor=G.+Kroemerauthor=L.+Zitvogel&title=Activation+of+the+NLRP3+Inflammasome+in+Dendritic+Cells+Induces+IL-1%CE%B2-Dependent+Adaptive+Immunity+Against+Tumors&doi=10.1038%2Fnm.2028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors</span></div><div class="casAuthors">Ghiringhelli, Francois; Apetoh, Lionel; Tesniere, Antoine; Aymeric, Laetitia; Ma, Yuting; Ortiz, Carla; Vermaelen, Karim; Panaretakis, Theocharis; Mignot, Gregoire; Ullrich, Evelyn; Perfettini, Jean-Luc; Schlemmer, Frederic; Tasdemir, Ezgi; Uhl, Martin; Genin, Pierre; Civas, Ahmet; Ryffel, Bernhard; Kanellopoulos, Jean; Tschopp, Juerg; Andre, Fabrice; Lidereau, Rosette; McLaughlin, Nicole M.; Haynes, Nicole M.; Smyth, Mark J.; Kroemer, Guido; Zitvogel, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1170-1178</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The therapeutic efficacy of anticancer chemotherapies may depend on dendritic cells (DCs), which present antigens from dying cancer cells to prime tumor-specific interferon-γ (IFN-γ)-producing T lymphocytes.  Here the authors show that dying tumor cells release ATP, which then acts on P2X7 purinergic receptors from DCs and triggers the NOD-like receptor family, pyrin domain contg.-3 protein (NLRP3)-dependent caspase-1 activation complex ('inflammasome'), allowing for the secretion of interleukin-1β (IL-1β).  The priming of IFN-γ-producing CD8+ T cells by dying tumor cells fails in the absence of a functional IL-1 receptor 1 and in Nlpr3-deficient (Nlrp3-/-) or caspase-1-deficient (Casp-1-/-) mice unless exogenous IL-1β is provided.  Accordingly, anticancer chemotherapy turned out to be inefficient against tumors established in purinergic receptor P2rx7-/- or Nlrp3-/- or Casp1-/- hosts.  Anthracycline-treated individuals with breast cancer carrying a loss-of-function allele of P2RX7 developed metastatic disease more rapidly than individuals bearing the normal allele.  These results indicate that the NLRP3 inflammasome links the innate and adaptive immune responses against dying tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGi-AQIhQXaLVg90H21EOLACvtfcHk0ljqPOjmgg7LkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGjt7rK&md5=78dfc1d52fcccd8fd2081aeb82274599</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fnm.2028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2028%26sid%3Dliteratum%253Aachs%26aulast%3DGhiringhelli%26aufirst%3DF.%26aulast%3DApetoh%26aufirst%3DL.%26aulast%3DTesniere%26aufirst%3DA.%26aulast%3DAymeric%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DOrtiz%26aufirst%3DC.%26aulast%3DVermaelen%26aufirst%3DK.%26aulast%3DPanaretakis%26aufirst%3DT.%26aulast%3DMignot%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DE.%26aulast%3DPerfettini%26aufirst%3DJ.-L.%26aulast%3DSchlemmer%26aufirst%3DF.%26aulast%3DTasdemir%26aufirst%3DE.%26aulast%3DUhl%26aufirst%3DM.%26aulast%3DG%25C3%25A9nin%26aufirst%3DP.%26aulast%3DCivas%26aufirst%3DA.%26aulast%3DRyffel%26aufirst%3DB.%26aulast%3DKanellopoulos%26aufirst%3DJ.%26aulast%3DTschopp%26aufirst%3DJ.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DLidereau%26aufirst%3DR.%26aulast%3DMcLaughlin%26aufirst%3DN.%2BM.%26aulast%3DHaynes%26aufirst%3DN.%2BM.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DZitvogel%26aufirst%3DL.%26atitle%3DActivation%2520of%2520the%2520NLRP3%2520Inflammasome%2520in%2520Dendritic%2520Cells%2520Induces%2520IL-1%25CE%25B2-Dependent%2520Adaptive%2520Immunity%2520Against%2520Tumors%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26issue%3D10%26spage%3D1170%26epage%3D1178%26doi%3D10.1038%2Fnm.2028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arbore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spolski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheinheimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ONeill, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coll, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afzali, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Barber, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, C.</span></span> <span> </span><span class="NLM_article-title">T Helper 1 Immunity Requires Complement-Driven NLRP3 Inflammasome Activity in CD4<sup>+</sup>T Cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">6292</span>), <span class="NLM_elocation-id">aad1210</span> <span class="refDoi"> DOI: 10.1126/science.aad1210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fscience.aad1210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27313051" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2016&issue=6292&author=G.+Arboreauthor=E.+E.+Westauthor=R.+Spolskiauthor=A.+A.+B.+Robertsonauthor=A.+Klosauthor=C.+Rheinheimerauthor=P.+Dutowauthor=T.+M.+Woodruffauthor=Z.+X.+Yuauthor=L.+A.+ONeillauthor=R.+C.+Collauthor=A.+Sherauthor=W.+J.+Leonardauthor=J.+Kohlauthor=P.+Monkauthor=M.+A.+Cooperauthor=M.+Arnoauthor=B.+Afzaliauthor=H.+J.+Lachmannauthor=A.+P.+Copeauthor=K.+D.+Mayer-Barberauthor=C.+Kemper&title=T+Helper+1+Immunity+Requires+Complement-Driven+NLRP3+Inflammasome+Activity+in+CD4%2BT+Cells&doi=10.1126%2Fscience.aad1210"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad1210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad1210%26sid%3Dliteratum%253Aachs%26aulast%3DArbore%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DE.%2BE.%26aulast%3DSpolski%26aufirst%3DR.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DKlos%26aufirst%3DA.%26aulast%3DRheinheimer%26aufirst%3DC.%26aulast%3DDutow%26aufirst%3DP.%26aulast%3DWoodruff%26aufirst%3DT.%2BM.%26aulast%3DYu%26aufirst%3DZ.%2BX.%26aulast%3DONeill%26aufirst%3DL.%2BA.%26aulast%3DColl%26aufirst%3DR.%2BC.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26aulast%3DKohl%26aufirst%3DJ.%26aulast%3DMonk%26aufirst%3DP.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DArno%26aufirst%3DM.%26aulast%3DAfzali%26aufirst%3DB.%26aulast%3DLachmann%26aufirst%3DH.%2BJ.%26aulast%3DCope%26aufirst%3DA.%2BP.%26aulast%3DMayer-Barber%26aufirst%3DK.%2BD.%26aulast%3DKemper%26aufirst%3DC.%26atitle%3DT%2520Helper%25201%2520Immunity%2520Requires%2520Complement-Driven%2520NLRP3%2520Inflammasome%2520Activity%2520in%2520CD4%252BT%2520Cells%26jtitle%3DScience%26date%3D2016%26volume%3D352%26issue%3D6292%26doi%3D10.1126%2Fscience.aad1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span>; <span class="NLM_string-name">Ghosh, S.</span>; <span class="NLM_string-name">Roush, W. R.</span>; <span class="NLM_string-name">Shen, D.-M.</span>; <span class="NLM_string-name">Katz, J.</span>; <span class="NLM_string-name">Seidel, H. M.</span></span> <span> </span><span class="NLM_article-title">Sulphonamides and Compositions Thereof for Treating Conditions Associated with NLRP Activity</span>. WO <span class="NLM_patent">2019/079119</span>, Apr 25, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+Venkatraman&author=S.+Ghosh&author=W.+R.+Roush&author=D.-M.+Shen&author=J.+Katz&author=H.+M.+Seidel&title=Sulphonamides+and+Compositions+Thereof+for+Treating+Conditions+Associated+with+NLRP+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DSulphonamides%2520and%2520Compositions%2520Thereof%2520for%2520Treating%2520Conditions%2520Associated%2520with%2520NLRP%2520Activity%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taxman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, J. P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damania, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Viral NLR Homolog that Inhibits the Inflammasome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>331</i></span> (<span class="NLM_issue">6015</span>),  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1126/science.1199478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fscience.1199478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21252346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsVequw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2011&pages=330-334&issue=6015&author=S.+M.+Gregoryauthor=B.+K.+Davisauthor=J.+A.+Westauthor=D.+J.+Taxmanauthor=S.-i.+Matsuzawaauthor=J.+C.+Reedauthor=J.+P.+Y.+Tingauthor=B.+Damania&title=Discovery+of+a+Viral+NLR+Homolog+that+Inhibits+the+Inflammasome&doi=10.1126%2Fscience.1199478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Viral NLR Homolog that Inhibits the Inflammasome</span></div><div class="casAuthors">Gregory, Sean M.; Davis, Beckley K.; West, John A.; Taxman, Debra J.; Matsuzawa, Shu-ichi; Reed, John C.; Ting, Jenny P. Y.; Damania, Blossom</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">6015</span>),
    <span class="NLM_cas:pages">330-334</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The NLR (nucleotide binding and oligomerization, leucine-rich repeat) family of proteins senses microbial infections and activates the inflammasome, a multiprotein complex that promotes microbial clearance.  Kaposi's sarcoma-assocd. herpesvirus (KSHV) is linked to several human malignancies.  The authors found that KSHV Orf63 is a viral homolog of human NLRP1.  Orf63 blocked NLRP1-dependent innate immune responses, including caspase-1 activation and processing of interleukins IL-1β and IL-18.  KSHV Orf63 interacted with NLRP1, NLRP3, and NOD2.  Inhibition of Orf63 expression resulted in increased expression of IL-1β during the KSHV life cycle.  Furthermore, inhibition of NLRP1 was necessary for efficient reactivation and generation of progeny virus.  The viral homolog subverts the function of cellular NLRs, which suggests that modulation of NLR-mediated innate immunity is important for the lifelong persistence of herpesviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDjH5iE_d2_rVg90H21EOLACvtfcHk0lha7Iu7hM6jNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsVequw%253D%253D&md5=0403fdf36556d47c935d6cb962779c3b</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1126%2Fscience.1199478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1199478%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DS.%2BM.%26aulast%3DDavis%26aufirst%3DB.%2BK.%26aulast%3DWest%26aufirst%3DJ.%2BA.%26aulast%3DTaxman%26aufirst%3DD.%2BJ.%26aulast%3DMatsuzawa%26aufirst%3DS.-i.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DTing%26aufirst%3DJ.%2BP.%2BY.%26aulast%3DDamania%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520a%2520Viral%2520NLR%2520Homolog%2520that%2520Inhibits%2520the%2520Inflammasome%26jtitle%3DScience%26date%3D2011%26volume%3D331%26issue%3D6015%26spage%3D330%26epage%3D334%26doi%3D10.1126%2Fscience.1199478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duraiswami, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornwald, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span> <span> </span><span class="NLM_article-title">High Throughput Screening Identifies ATP-Competitive Inhibitors of the NLRP1 Inflammasome</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2739</span>– <span class="NLM_lpage">2743</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.bmcl.2015.05.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26022841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2739-2743&issue=14&author=P.+A.+Harrisauthor=C.+Duraiswamiauthor=D.+T.+Fisherauthor=J.+Fornwaldauthor=S.+J.+Hoffmanauthor=G.+Hofmannauthor=M.+Jiangauthor=R.+Lehrauthor=P.+M.+McCormickauthor=L.+Nickelsauthor=B.+Schwartzauthor=Z.+Wuauthor=G.+Zhangauthor=R.+W.+Marquisauthor=J.+Bertinauthor=P.+J.+Gough&title=High+Throughput+Screening+Identifies+ATP-Competitive+Inhibitors+of+the+NLRP1+Inflammasome&doi=10.1016%2Fj.bmcl.2015.05.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput screening identifies ATP-competitive inhibitors of the NLRP1 inflammasome</span></div><div class="casAuthors">Harris, Philip A.; Duraiswami, Chaya; Fisher, Donald T.; Fornwald, James; Hoffman, Sandra J.; Hofmann, Glenn; Jiang, Ming; Lehr, Ruth; McCormick, Patricia M.; Nickels, Leng; Schwartz, Benjamin; Wu, Zining; Zhang, Guofeng; Marquis, Robert W.; Bertin, John; Gough, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2739-2743</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nod-like receptors (NLRs) are cytoplasmic pattern recognition receptors that are promising targets for the development of anti-inflammatory therapeutics.  Drug discovery efforts targeting NLRs have been hampered by their inherent tendency to form aggregates making protein generation and the development of screening assays very challenging.  Herein we report the results of an HTS screen of NLR family member NLRP1 (NLR family, pyrin domain-contg. 1) which was achieved through the large scale generation of recombinant GST-His-Thrombin-NLRP1 protein.  The screen led to the identification of a diverse set of ATP competitive inhibitors with micromolar potencies.  Activity of these hits was confirmed in a FP binding assay, and two homol. models were employed to predict the possible binding mode of the leading series and facilitate further lead-optimization.  These results highlight a promising strategy for the identification of inhibitors of NLR family members which are rapidly emerging as key drivers of inflammation in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb4l4eWn7-vLVg90H21EOLACvtfcHk0lgzCY7Sbp_xxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVert78%253D&md5=5c248a57f2ac7178ade9259b6e5adb11</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.032%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DDuraiswami%26aufirst%3DC.%26aulast%3DFisher%26aufirst%3DD.%2BT.%26aulast%3DFornwald%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DS.%2BJ.%26aulast%3DHofmann%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DLehr%26aufirst%3DR.%26aulast%3DMcCormick%26aufirst%3DP.%2BM.%26aulast%3DNickels%26aufirst%3DL.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26atitle%3DHigh%2520Throughput%2520Screening%2520Identifies%2520ATP-Competitive%2520Inhibitors%2520of%2520the%2520NLRP1%2520Inflammasome%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D14%26spage%3D2739%26epage%3D2743%26doi%3D10.1016%2Fj.bmcl.2015.05.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Hu  Yue</span>, <span class="hlFld-ContribAuthor ">Ping  Sun</span>, <span class="hlFld-ContribAuthor ">Lei  Hua</span>, <span class="hlFld-ContribAuthor ">Shuli  Liang</span>, <span class="hlFld-ContribAuthor ">Yitao  Ou</span>, <span class="hlFld-ContribAuthor ">Dan  Wu</span>, <span class="hlFld-ContribAuthor ">Xinyi  Wu</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Ying  Hao</span>, <span class="hlFld-ContribAuthor ">Wenhui  Hu</span>, <span class="hlFld-ContribAuthor ">Zhongjin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>219 </em>, 113417. <a href="https://doi.org/10.1016/j.ejmech.2021.113417" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113417%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bchalcone%252Banalogues%252Bas%252Bnovel%252BNLRP3%252Binflammasome%252Binhibitors%252Bwith%252Bpotent%252Banti-inflammation%252Bactivities%26aulast%3DZhang%26aufirst%3DCheng%26date%3D2021%26volume%3D219%26spage%3D113417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoqing  Wang</span>, <span class="hlFld-ContribAuthor ">Yafei  Liu</span>, <span class="hlFld-ContribAuthor ">Xingchun  Han</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>, <span class="hlFld-ContribAuthor ">Wei  Zhu</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Haixia  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>44 </em>, 128101. <a href="https://doi.org/10.1016/j.bmcl.2021.128101" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128101%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BII%252529%25253A%252BNucleic%252Bacid%252Bsensing%252Bantagonists%252Band%252Binhibitors%26aulast%3DWang%26aufirst%3DXiaoqing%26date%3D2021%26volume%3D44%26spage%3D128101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silke  Miller</span>, <span class="hlFld-ContribAuthor ">Maria-Jesus  Blanco</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 871-886. <a href="https://doi.org/10.1039/D1MD00036E" title="DOI URL">https://doi.org/10.1039/D1MD00036E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00036E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00036E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSmall%252Bmolecule%252Btherapeutics%252Bfor%252Bneuroinflammation-mediated%252Bneurodegenerative%252Bdisorders%26aulast%3DMiller%26aufirst%3DSilke%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D6%26spage%3D871%26epage%3D886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanwan  Li</span>, <span class="hlFld-ContribAuthor ">Zhongqiang  Cao</span>, <span class="hlFld-ContribAuthor ">Junjie  Cheng</span>, <span class="hlFld-ContribAuthor ">Feiyu  Chen</span>, <span class="hlFld-ContribAuthor ">Shuai  Li</span>, <span class="hlFld-ContribAuthor ">Yiwei  Huang</span>, <span class="hlFld-ContribAuthor ">Long Tai  Zheng</span>, <span class="hlFld-ContribAuthor ">Na  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N-phenyl-1-(phenylsulfonamido)cyclopropane-1-carboxamide analogs as NLRP3 inflammasome inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>30 </em>
                                    (6)
                                     , 1294-1308. <a href="https://doi.org/10.1007/s00044-021-02740-7" title="DOI URL">https://doi.org/10.1007/s00044-021-02740-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-021-02740-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-021-02740-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDiscovery%252Bof%252BN-phenyl-1-%252528phenylsulfonamido%252529cyclopropane-1-carboxamide%252Banalogs%252Bas%252BNLRP3%252Binflammasome%252Binhibitors%26aulast%3DLi%26aufirst%3DWanwan%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D6%26spage%3D1294%26epage%3D1308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eduardo Felipe Alves  Fernandes</span>, <span class="hlFld-ContribAuthor ">Dennis  Özcelik</span>. </span><span class="cited-content_cbyCitation_article-title">Imaging Biomarkers for Monitoring the Inflammatory Redox Landscape in the Brain. </span><span class="cited-content_cbyCitation_journal-name">Antioxidants</span><span> <strong>2021,</strong> <em>10 </em>
                                    (4)
                                     , 528. <a href="https://doi.org/10.3390/antiox10040528" title="DOI URL">https://doi.org/10.3390/antiox10040528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antiox10040528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantiox10040528%26sid%3Dliteratum%253Aachs%26jtitle%3DAntioxidants%26atitle%3DImaging%252BBiomarkers%252Bfor%252BMonitoring%252Bthe%252BInflammatory%252BRedox%252BLandscape%252Bin%252Bthe%252BBrain%26aulast%3DFernandes%26aufirst%3DEduardo%2BFelipe%2BAlves%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D4%26spage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. NLRP3 inflammasome pathway with nodes inhibited by clinical or marketed compounds highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. NLRP3 inhibitors with structures in the public domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Sub-micromolar compounds exemplied in IFM’s patent US 2019/0119241.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Select compounds exemplifed in Inflazome’s patents reporting good potency and PK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Nodthera compounds exemplified in WO 2018/015445 A1 with sub-micromolar activity. (B) Example of a Nodthera compound claimed in WO2019/121691 that explores variations on the right-hand side of the molecule with sub-micromolar activity. (C) Compound exemplified in Jecure patent WO 2018/136890 A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/medium/jm0c01307_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Regulatory pathways of NLRP3 activation. (A) Routes leading to NLRP3 inflammasome activation. (B) Proximal proteins that regulate NLRP3 inflammasome components. (C) Integration of Syk and BTK into inflammasome activation and other downstream processes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01307/20210107/images/large/jm0c01307_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01307&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 176 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jo, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasakawa, C.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms Regulating NLRP3 Inflammasome Activation</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1038/cmi.2015.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fcmi.2015.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26549800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Gms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=148-159&author=E.-K.+Joauthor=J.+K.+Kimauthor=D.-M.+Shinauthor=C.+Sasakawa&title=Molecular+Mechanisms+Regulating+NLRP3+Inflammasome+Activation&doi=10.1038%2Fcmi.2015.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms regulating NLRP3 inflammasome activation</span></div><div class="casAuthors">Jo, Eun-Kyeong; Kim, Jin Kyung; Shin, Dong-Min; Sasakawa, Chihiro</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-159</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">Inflammasomes are multi-protein signaling complexes that trigger the activation of inflammatory caspases and the maturation of interleukin-1β.  Among various inflammasome complexes, the NLRP3 inflammasome is best characterized and has been linked with various human autoinflammatory and autoimmune diseases.  Thus, the NLRP3 inflammasome may be a promising target for anti-inflammatory therapies.  In this review, we summarize the current understanding of the mechanisms by which the NLRP3 inflammasome is activated in the cytosol.  We also describe the binding partners of NLRP3 inflammasome complexes activating or inhibiting the inflammasome assembly.  Our knowledge of the mechanisms regulating NLRP3 inflammasome signaling and how these influence inflammatory responses offers further insight into potential therapeutic strategies to treat inflammatory diseases assocd. with dysregulation of the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBv_NNzcwFLVg90H21EOLACvtfcHk0lgTG6BfbtO0rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Gms7s%253D&md5=90c508a823912cf69f86cefac7aaaaec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2015.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2015.95%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DE.-K.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DShin%26aufirst%3DD.-M.%26aulast%3DSasakawa%26aufirst%3DC.%26atitle%3DMolecular%2520Mechanisms%2520Regulating%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2016%26volume%3D13%26spage%3D148%26epage%3D159%26doi%3D10.1038%2Fcmi.2015.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, J. P.-Y.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of NOD-like Receptor-Associated Inflammasome Activation</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2013.08.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2013.08.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24054327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVynu7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=432-441&author=H.+Wenauthor=E.+A.+Miaoauthor=J.+P.-Y.+Ting&title=Mechanisms+of+NOD-like+Receptor-Associated+Inflammasome+Activation&doi=10.1016%2Fj.immuni.2013.08.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of NOD-like Receptor-Associated Inflammasome Activation</span></div><div class="casAuthors">Wen, Haitao; Miao, Edward A.; Ting, Jenny P.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">432-441</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  A major function of a subfamily of NLR (nucleotide-binding domain, leucine-rich repeat contg., or NOD-like receptor) proteins is in inflammasome activation, which has been implicated in a multitude of disease models and human diseases.  This work will highlight key progress in understanding the mechanisms that activate the best-studied NLRs (NLRP3, NLRC4, NAIP, and NLRP1) and in uncovering inflammasome NLRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofkF9PnmcKNbVg90H21EOLACvtfcHk0lhC4K2bpLiuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVynu7jE&md5=a3abf6999a40fe086584ccfb068f1b24</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2013.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2013.08.037%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DE.%2BA.%26aulast%3DTing%26aufirst%3DJ.%2BP.-Y.%26atitle%3DMechanisms%2520of%2520NOD-like%2520Receptor-Associated%2520Inflammasome%2520Activation%26jtitle%3DImmunity%26date%3D2013%26volume%3D39%26spage%3D432%26epage%3D441%26doi%3D10.1016%2Fj.immuni.2013.08.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, J. P.-Y.</span></span> <span> </span><span class="NLM_article-title">The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1038/s41577-019-0165-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41577-019-0165-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31036962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1SktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=477-489&author=K.+V.+Swansonauthor=M.+Dengauthor=J.+P.-Y.+Ting&title=The+NLRP3+Inflammasome%3A+Molecular+Activation+and+Regulation+to+Therapeutics&doi=10.1038%2Fs41577-019-0165-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP3 inflammasome: molecular activation and regulation to therapeutics</span></div><div class="casAuthors">Swanson, Karen V.; Deng, Meng; Ting, Jenny P.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">477-489</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  NLRP3 (NOD-, LRR- and pyrin domain-contg. protein 3) is an intracellular sensor that detects a broad range of microbial motifs, endogenous danger signals and environmental irritants, resulting in the formation and activation of the NLRP3 inflammasome.  Assembly of the NLRP3 inflammasome leads to caspase 1-dependent release of the pro-inflammatory cytokines IL-1β and IL-18, as well as to gasdermin D-mediated pyroptotic cell death.  Recent studies have revealed new regulators of the NLRP3 inflammasome, including new interacting or regulatory proteins, metabolic pathways and a regulatory mitochondrial hub.  In this Review, we present the mol., cell biol. and biochem. bases of NLRP3 activation and regulation and describe how this mechanistic understanding is leading to potential therapeutics that target the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW8T8C8vdzprVg90H21EOLACvtfcHk0lhC4K2bpLiuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1SktLw%253D&md5=f3acc6b5154d2ec4544aa54c2f3d7c4f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41577-019-0165-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41577-019-0165-0%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DK.%2BV.%26aulast%3DDeng%26aufirst%3DM.%26aulast%3DTing%26aufirst%3DJ.%2BP.-Y.%26atitle%3DThe%2520NLRP3%2520Inflammasome%253A%2520Molecular%2520Activation%2520and%2520Regulation%2520to%2520Therapeutics%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2019%26volume%3D19%26spage%3D477%26epage%3D489%26doi%3D10.1038%2Fs41577-019-0165-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Afonina, I. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyaert, R.</span></span> <span> </span><span class="NLM_article-title">Limiting Inflammation--the Negative Regulation of NF-κB and the NLRP3 Inflammasome</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1038/ni.3772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.3772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28722711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFyqtL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=861-869&issue=8&author=I.+S+Afoninaauthor=Z.+Zhongauthor=M.+Karinauthor=R.+Beyaert&title=Limiting+Inflammation%2D%2Dthe+Negative+Regulation+of+NF-%CE%BAB+and+the+NLRP3+Inflammasome&doi=10.1038%2Fni.3772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome</span></div><div class="casAuthors">Afonina, Inna S.; Zhong, Zhenyu; Karin, Michael; Beyaert, Rudi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">861-869</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A properly mounted immune response is indispensable for recognizing and eliminating danger arising from foreign invaders and tissue trauma.  However, the 'inflammatory fire' kindled by the host response must be tightly controlled to prevent it from spreading and causing irreparable damage.  Accordingly, acute inflammation is self-limiting and is normally attenuated after elimination of noxious stimuli, restoration of homeostasis and initiation of tissue repair.  However, unresolved inflammation may lead to the development of chronic autoimmune and degenerative diseases and cancer.  Here, we discuss the key mol. mechanisms that contribute to the self-limiting nature of inflammatory signaling, with emphasis on the neg. regulation of the NF-κB pathway and the NLRP3 inflammasome.  Understanding these neg. regulatory mechanisms should facilitate the development of much-needed therapeutic strategies for treatment of inflammatory and autoimmune pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLa1nlskoLxrVg90H21EOLACvtfcHk0lgD4LYu_thPiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFyqtL%252FO&md5=bf11b44362f40cd0327e51617564b4aa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fni.3772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3772%26sid%3Dliteratum%253Aachs%26aulast%3DAfonina%26aufirst%3DI.%2BS%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DBeyaert%26aufirst%3DR.%26atitle%3DLimiting%2520Inflammation--the%2520Negative%2520Regulation%2520of%2520NF-%25CE%25BAB%2520and%2520the%2520NLRP3%2520Inflammasome%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26issue%3D8%26spage%3D861%26epage%3D869%26doi%3D10.1038%2Fni.3772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauernfeind, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnemri, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes-Alnemri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">NF-kB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.0901363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19570822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFWgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=787-791&issue=2&author=F.+Bauernfeindauthor=G.+Horvathauthor=A.+Stutzauthor=E.+S.+Alnemriauthor=K.+MacDonaldauthor=D.+Speertauthor=T.+Fernandes-Alnemriauthor=J.+Wuauthor=B.+G.+Monksauthor=K.+A.+Fitzgeraldauthor=V.+Hornungauthor=E.+Latz&title=NF-kB+Activating+Pattern+Recognition+and+Cytokine+Receptors+License+NLRP3+Inflammasome+Activation+by+Regulating+NLRP3+Expression&doi=10.4049%2Fjimmunol.0901363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</span></div><div class="casAuthors">Bauernfeind, Franz G.; Horvath, Gabor; Stutz, Andrea; Alnemri, Emad S.; MacDonald, Kelly; Speert, David; Fernandes-Alnemri, Teresa; Wu, Jianghong; Monks, Brian G.; Fitzgerald, Katherine A.; Hornung, Veit; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">787-791</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The IL-1 family cytokines are regulated on transcriptional and posttranscriptional levels.  Pattern recognition and cytokine receptors control pro-IL-1β transcription whereas inflammasomes regulate the proteolytic processing of pro-IL-1β.  The NLRP3 inflammasome, however, assembles in response to extracellular ATP, pore-forming toxins, or crystals only in the presence of proinflammatory stimuli.  How the activation of gene transcription by signaling receptors enables NLRP3 activation remains elusive and controversial.  In this study, the authors show that cell priming through multiple signaling receptors induces NLRP3 expression, which the authors identified to be a crit. checkpoint for NLRP3 activation.  Signals provided by NF-κB activators are necessary but not sufficient for NLRP3 activation, and a second stimulus such as ATP or crystal-induced damage is required for NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUf4OrrejQ7Vg90H21EOLACvtfcHk0lhbmVgWEy2UIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFWgt78%253D&md5=1b04c9f756bb70d6292bd8bd5507ee1f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901363%26sid%3Dliteratum%253Aachs%26aulast%3DBauernfeind%26aufirst%3DF.%26aulast%3DHorvath%26aufirst%3DG.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DAlnemri%26aufirst%3DE.%2BS.%26aulast%3DMacDonald%26aufirst%3DK.%26aulast%3DSpeert%26aufirst%3DD.%26aulast%3DFernandes-Alnemri%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DMonks%26aufirst%3DB.%2BG.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DHornung%26aufirst%3DV.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DNF-kB%2520Activating%2520Pattern%2520Recognition%2520and%2520Cytokine%2520Receptors%2520License%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Regulating%2520NLRP3%2520Expression%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26issue%3D2%26spage%3D787%26epage%3D791%26doi%3D10.4049%2Fjimmunol.0901363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapeton-Montes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardiff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, P. A.</span></span> <span> </span><span class="NLM_article-title">S100A8 and S100A9 Induce Cytokine Expression and Regulate the NLRP3 Inflammasome via ROS-Dependent Activation of NF-κB</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>), <span class="NLM_elocation-id">e72139</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0072138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.pone.0072138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24015211" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&issue=8&author=J.-C.+Simardauthor=A.+Cesaroauthor=J.+Chapeton-Montesauthor=M.+Tardiffauthor=F.+Antoineauthor=D.+Giradauthor=P.+A.+Tessier&title=S100A8+and+S100A9+Induce+Cytokine+Expression+and+Regulate+the+NLRP3+Inflammasome+via+ROS-Dependent+Activation+of+NF-%CE%BAB&doi=10.1371%2Fjournal.pone.0072138"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0072138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0072138%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DJ.-C.%26aulast%3DCesaro%26aufirst%3DA.%26aulast%3DChapeton-Montes%26aufirst%3DJ.%26aulast%3DTardiff%26aufirst%3DM.%26aulast%3DAntoine%26aufirst%3DF.%26aulast%3DGirad%26aufirst%3DD.%26aulast%3DTessier%26aufirst%3DP.%2BA.%26atitle%3DS100A8%2520and%2520S100A9%2520Induce%2520Cytokine%2520Expression%2520and%2520Regulate%2520the%2520NLRP3%2520Inflammasome%2520via%2520ROS-Dependent%2520Activation%2520of%2520NF-%25CE%25BAB%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D8%26doi%3D10.1371%2Fjournal.pone.0072138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, B. B.</span></span> <span> </span><span class="NLM_article-title">Inhibiting NF-κB Activation by Small Molecules as a Therapeutic Strategy</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1799</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2010.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.bbagrm.2010.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20493977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFahtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1799&publication_year=2010&pages=775-787&author=S.+C.+Guptaauthor=C.+Sundaramauthor=S.+Reuterauthor=B.+B.+Aggarwal&title=Inhibiting+NF-%CE%BAB+Activation+by+Small+Molecules+as+a+Therapeutic+Strategy&doi=10.1016%2Fj.bbagrm.2010.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting NF-κB activation by small molecules as a therapeutic strategy</span></div><div class="casAuthors">Gupta, Subash C.; Sundaram, Chitra; Reuter, Simone; Aggarwal, Bharat B.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1799</span>
        (<span class="NLM_cas:issue">10-12</span>),
    <span class="NLM_cas:pages">775-787</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Because nuclear factor-κB (NF-κB) is a ubiquitously expressed proinflammatory transcription factor that regulates the expression of over 500 genes involved in cellular transformation, survival, proliferation, invasion, angiogenesis, metastasis, and inflammation, the NF-κB signaling pathway has become a potential target for pharmacol. intervention.  A wide variety of agents can activate NF-κB through canonical and noncanonical pathways.  Canonical pathway involves various steps including the phosphorylation, ubiquitination, and degrdn. of the inhibitor of NF-κB (IκBα), which leads to the nuclear translocation of the p50-p65 subunits of NF-κB followed by p65 phosphorylation, acetylation and methylation, DNA binding, and gene transcription.  Thus, agents that can inhibit protein kinases, protein phosphatases, proteasomes, ubiquitination, acetylation, methylation, and DNA binding steps have been identified as NF-κB inhibitors.  Because of the crit. role of NF-κB in cancer and various chronic diseases, numerous inhibitors of NF-κB have been identified.  In this review, however, we describe only small mols. that suppress NF-κB activation, and the mechanism by which they block this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJfBI8lJJ4e7Vg90H21EOLACvtfcHk0lj9zo3Lrz7WZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFahtLbI&md5=652d2f8de7b6141ef71f91acde907101</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2010.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2010.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%2BC.%26aulast%3DSundaram%26aufirst%3DC.%26aulast%3DReuter%26aufirst%3DS.%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26atitle%3DInhibiting%2520NF-%25CE%25BAB%2520Activation%2520by%2520Small%2520Molecules%2520as%2520a%2520Therapeutic%2520Strategy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2010%26volume%3D1799%26spage%3D775%26epage%3D787%26doi%3D10.1016%2Fj.bbagrm.2010.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">NF-κB, Inflammation, Immunity and Cancer: Coming of Age</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnri.2017.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29379212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=309-324&author=K.+Taniguchiauthor=M.+Karin&title=NF-%CE%BAB%2C+Inflammation%2C+Immunity+and+Cancer%3A+Coming+of+Age&doi=10.1038%2Fnri.2017.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB, inflammation, immunity and cancer: coming of age</span></div><div class="casAuthors">Taniguchi, Koji; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">309-324</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Fourteen years have passed since nuclear factor-κB (NF-κB) was first shown to serve as a mol. lynchpin that links persistent infections and chronic inflammation to increased cancer risk.  The young field of inflammation and cancer has now come of age, and inflammation has been recognized by the broad cancer research community as a hallmark and cause of cancer.  Here, we discuss how the initial discovery of a role for NF-κB in linking inflammation and cancer led to an improved understanding of tumor-elicited inflammation and its effects on anticancer immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbWVUEqQxv9rVg90H21EOLACvtfcHk0lj9zo3Lrz7WZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yjtrk%253D&md5=02d3c489732baab402ddf87d18416bd6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.142%26sid%3Dliteratum%253Aachs%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DNF-%25CE%25BAB%252C%2520Inflammation%252C%2520Immunity%2520and%2520Cancer%253A%2520Coming%2520of%2520Age%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D309%26epage%3D324%26doi%3D10.1038%2Fnri.2017.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magupalli, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, J.</span></span> <span> </span><span class="NLM_article-title">Inflammasome-Activated Gasdermin D Causes Pyroptosis by Forming Membrane Pores</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1038/nature18629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature18629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27383986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFensL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=153-157&author=X.+Liuauthor=Z.+Zhangauthor=J.+Ruanauthor=Y.+Panauthor=V.+G.+Magupalliauthor=H.+Wuauthor=J.+Lieberman&title=Inflammasome-Activated+Gasdermin+D+Causes+Pyroptosis+by+Forming+Membrane+Pores&doi=10.1038%2Fnature18629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores</span></div><div class="casAuthors">Liu, Xing; Zhang, Zhibin; Ruan, Jianbin; Pan, Youdong; Magupalli, Venkat Giri; Wu, Hao; Lieberman, Judy</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7610</span>),
    <span class="NLM_cas:pages">153-158</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammatory caspases (caspases 1, 4, 5 and 11) are activated in response to microbial infection and danger signals.  When activated, they cleave mouse and human gasdermin D (GSDMD) after Asp276 and Asp275, resp., to generate an N-terminal cleavage product (GSDMD-NT) that triggers inflammatory death (pyroptosis) and release of inflammatory cytokines such as interleukin-1β.  Cleavage removes the C-terminal fragment (GSDMD-CT), which is thought to fold back on GSDMD-NT to inhibit its activation.  However, how GSDMD-NT causes cell death is unknown.  Here the authors show that GSDMD-NT oligomerizes in membranes to form pores that are visible by electron microscopy.  GSDMD-NT binds to phosphatidylinositol phosphates and phosphatidylserine (restricted to the cell membrane inner leaflet) and cardiolipin (present in the inner and outer leaflets of bacterial membranes).  Mutation of four evolutionarily conserved basic residues blocks GSDMD-NT oligomerization, membrane binding, pore formation and pyroptosis.  Because of its lipid-binding preferences, GSDMD-NT kills from within the cell, but does not harm neighboring mammalian cells when it is released during pyroptosis.  GSDMD-NT also kills cell-free bacteria in vitro and may have a direct bactericidal effect within the cytosol of host cells, but the importance of direct bacterial killing in controlling in vivo infection remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpcilGNbDUkrVg90H21EOLACvtfcHk0lj9zo3Lrz7WZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFensL7K&md5=44ba5b0304b041c21b9a7d8f2f04651a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature18629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRuan%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DMagupalli%26aufirst%3DV.%2BG.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLieberman%26aufirst%3DJ.%26atitle%3DInflammasome-Activated%2520Gasdermin%2520D%2520Causes%2520Pyroptosis%2520by%2520Forming%2520Membrane%2520Pores%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D153%26epage%3D157%26doi%3D10.1038%2Fnature18629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perregaux, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcniff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laliberte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peurano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombroski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of a Novel Class of Interleukin-1 Post-Translational Processing Inhibitors</span>. <i>J. Pharmacol. Experimental Therapeutics</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>299</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=11561079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=187-197&issue=1&author=D.+G.+Perregauxauthor=P.+Mcniffauthor=R.+Laliberteauthor=N.+Hawrylukauthor=H.+Peuranoauthor=E.+Stamauthor=J.+Egglerauthor=R.+Griffithsauthor=M.+A.+Dombroskiauthor=C.+Gabel&title=Identification+and+Characterization+of+a+Novel+Class+of+Interleukin-1+Post-Translational+Processing+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors</span></div><div class="casAuthors">Perregaux, David G.; McNiff, Patricia; Laliberte, Ronald; Hawryluk, Natalie; Peurano, Heather; Stam, Ethan; Eggler, Jim; Griffiths, Richard; Dombroski, Mark A.; Gabel, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-197</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS)-activated monocytes and macrophages produce large quantities of pro-interleukin (IL)-1β but externalize little mature cytokine.  Efficient post-translational processing of the pro-cytokine occurs in vitro when these cells encounter a secretion stimulus such as ATP, cytolytic T cells, or hypotonic stress.  Each of these stimuli promotes rapid conversion of 31-kDa pro-IL-1β to its mature 17-kDa species and release of the 17-kDa cytokine.  In this study, two novel pharmacol. agents, CP-424,174 and CP-412,245, are identified as potent inhibitors of stimulus-coupled IL-1β post-translational processing.  These agents, both diarylsulfonylureas, block formation of mature IL-1β without increasing the amt. of pro-cytokine that is released extracellularly, and they inhibit independently of the secretion stimulus used.  Conditioned medium derived from LPS-activated/ATP-treated human monocytes maintained in the absence and presence of CP-424,174 contained comparable quantities of IL-6, tumor necrosis factor-α (TNFα), and IL-1RA, but 30-fold less IL-1β was generated in the test agent's presence.  As a result of this decrease, monocyte conditioned medium prepd. in the presence of CP-424,174 demonstrated a greatly diminished capacity to promote an IL-1-dependent response (induction of serum amyloid A synthesis by Hep3B cells).  Oral administration of CP-424,174 to mice resulted in inhibition of IL-1 in the absence of an effect on IL-6 and TNFα.  These novel agents, therefore, act as selective cytokine release inhibitors and define a new therapeutic approach for controlling IL-1 prodn. in inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnTnmtD12hMrVg90H21EOLACvtfcHk0lgCyDBedCLgeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFWltL8%253D&md5=5da5f7fd4689c1dd7dc8e187a8f9d02f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerregaux%26aufirst%3DD.%2BG.%26aulast%3DMcniff%26aufirst%3DP.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DHawryluk%26aufirst%3DN.%26aulast%3DPeurano%26aufirst%3DH.%26aulast%3DStam%26aufirst%3DE.%26aulast%3DEggler%26aufirst%3DJ.%26aulast%3DGriffiths%26aufirst%3DR.%26aulast%3DDombroski%26aufirst%3DM.%2BA.%26aulast%3DGabel%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520a%2520Novel%2520Class%2520of%2520Interleukin-1%2520Post-Translational%2520Processing%2520Inhibitors%26jtitle%3DJ.%2520Pharmacol.%2520Experimental%2520Therapeutics%26date%3D2001%26volume%3D299%26issue%3D1%26spage%3D187%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laliberte, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perregaux, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peese, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggler, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombroski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span> <span> </span><span class="NLM_article-title">Glutathione <i>S-</i>Transferase Omega 1–1 is a Target of Cytokine Release Inhibitory Drugs and May Be Responsible for Their Effect on Interluekin-1β Posttranslational Processing</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">16567</span>– <span class="NLM_lpage">16578</span>, <span class="refDoi"> DOI: 10.1074/jbc.M211596200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1074%2Fjbc.M211596200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=12624100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVKnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=16567-16578&author=R.+E.+Laliberteauthor=D.+G.+Perregauxauthor=L.+R.+Hothauthor=P.+J.+Rosnerauthor=C.+K.+Jordanauthor=K.+M.+Peeseauthor=J.+F.+Egglerauthor=M.+A.+Dombroskiauthor=K.+F.+Geogheganauthor=C.+Gabel&title=Glutathione+S-Transferase+Omega+1%E2%80%931+is+a+Target+of+Cytokine+Release+Inhibitory+Drugs+and+May+Be+Responsible+for+Their+Effect+on+Interluekin-1%CE%B2+Posttranslational+Processing&doi=10.1074%2Fjbc.M211596200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione S-Transferase Omega 1-1 Is a Target of Cytokine Release Inhibitory Drugs and May Be Responsible for Their Effect on Interleukin-1β Posttranslational Processing</span></div><div class="casAuthors">Laliberte, Ronald E.; Perregaux, David G.; Hoth, Lise R.; Rosner, Philip J.; Jordan, Crystal K.; Peese, Kevin M.; Eggler, James. F.; Dombroski, Mark A.; Geoghegan, Kieran F.; Gabel, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">16567-16578</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Stimulus-induced posttranslational processing of human monocyte interleukin-1β (IL-1β) is accompanied by major changes to the intracellular ionic environment, activation of caspase-1, and cell death.  Certain diarylsulfonylureas inhibit this response, and are designated cytokine release inhibitory drugs (CRIDs).  CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved.  Affinity labeling with [14C]CRIDs and affinity chromatog. on immobilized CRID were used in seeking potential protein targets of their action.  Following treatment of intact human monocytes with an epoxide-bearing [14C]CRID, glutathione S-transferase (GST) Omega 1-1 was identified as a preferred target.  Moreover, labeling of this polypeptide correlated with irreversible inhibition of ATP-induced IL-1β posttranslational processing.  When exts. of human monocytic cells were chromatographed on a CRID affinity column, GST Omega 1-1 bound selectively to the affinity matrix and was eluted by sol. CRID.  Recombinant GST Omega 1-1 readily incorporated [14C]CRID epoxides, but labeling was negated by co-incubation with S-substituted glutathiones or by mutagenesis of the catalytic center Cys32 to alanine.  Peptide mapping by high performance liq. chromatog.-mass spectrometry also demonstrated that Cys32 was the site of modification.  Although S-alkylglutathiones did not arrest ATP-induced IL-1β posttranslational processing or inhibit [14C]CRID incorporation into cell-assocd. GST Omega 1-1, a glutathione-CRID adduct effectively demonstrated these attributes.  Therefore, the ability of CRIDs to arrest stimulus-induced IL-1β posttranslational processing may be attributable to their interaction with GST Omega 1-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkub8_wJ5lE7Vg90H21EOLACvtfcHk0lgCyDBedCLgeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVKnsLs%253D&md5=bed10a4f698b571abda850217c44f379</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M211596200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M211596200%26sid%3Dliteratum%253Aachs%26aulast%3DLaliberte%26aufirst%3DR.%2BE.%26aulast%3DPerregaux%26aufirst%3DD.%2BG.%26aulast%3DHoth%26aufirst%3DL.%2BR.%26aulast%3DRosner%26aufirst%3DP.%2BJ.%26aulast%3DJordan%26aufirst%3DC.%2BK.%26aulast%3DPeese%26aufirst%3DK.%2BM.%26aulast%3DEggler%26aufirst%3DJ.%2BF.%26aulast%3DDombroski%26aufirst%3DM.%2BA.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DGabel%26aufirst%3DC.%26atitle%3DGlutathione%2520S-Transferase%2520Omega%25201%25E2%2580%25931%2520is%2520a%2520Target%2520of%2520Cytokine%2520Release%2520Inhibitory%2520Drugs%2520and%2520May%2520Be%2520Responsible%2520for%2520Their%2520Effect%2520on%2520Interluekin-1%25CE%25B2%2520Posttranslational%2520Processing%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D16567%26epage%3D16578%26doi%3D10.1074%2Fjbc.M211596200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coll, R. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, S. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Planillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inserra, M. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dungan, L. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croker, D. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haneklaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, C. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner, D. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K. H G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, S. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Neill, L. A J</span></span> <span> </span><span class="NLM_article-title">A Small-Molecule Inhibitor of the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1038/nm.3806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnm.3806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25686105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=248-255&issue=3&author=R.+C+Collauthor=A.+A+B+Robertsonauthor=J.+J.+Chaeauthor=S.+C+Higginsauthor=R.+Munoz-Planilloauthor=M.+C+Inserraauthor=I.+Vetterauthor=L.+S+Dunganauthor=B.+G+Monksauthor=A.+Stutzauthor=D.+E+Crokerauthor=M.+S+Butlerauthor=M.+Haneklausauthor=C.+E+Suttonauthor=G.+Nunezauthor=E.+Latzauthor=D.+L+Kastnerauthor=K.+H+G+Millsauthor=S.+L+Mastersauthor=K.+Schroderauthor=M.+A+Cooperauthor=L.+A+J+O%27Neill&title=A+Small-Molecule+Inhibitor+of+the+NLRP3+Inflammasome+for+the+Treatment+of+Inflammatory+Diseases&doi=10.1038%2Fnm.3806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases</span></div><div class="casAuthors">Coll, Rebecca C.; Robertson, Avril A. B.; Chae, Jae Jin; Higgins, Sarah C.; Munoz-Planillo, Raul; Inserra, Marco C.; Vetter, Irina; Dungan, Lara S.; Monks, Brian G.; Stutz, Andrea; Croker, Daniel E.; Butler, Mark S.; Haneklaus, Moritz; Sutton, Caroline E.; Nunez, Gabriel; Latz, Eicke; Kastner, Daniel L.; Mills, Kingston H. G.; Masters, Seth L.; Schroder, Kate; Cooper, Matthew A.; O'Neill, Luke A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-255</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The NOD-like receptor (NLR) family, pyrin domain-contg. protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-assocd. periodic syndrome (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis.  We describe the development of MCC950, a potent, selective, small-mol. inhibitor of NLRP3.  MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concns.  MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes.  MCC950 reduced interleukin-1β (IL-1β) prodn. in vivo and attenuated the severity of exptl. autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis.  Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle-Wells syndrome.  MCC950 is thus a potential therapeutic for NLRP3-assocd. syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBPny7QJdNA7Vg90H21EOLACvtfcHk0lj-SEs8Xo16zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSit7g%253D&md5=5ffe3683cc33ded3c3b18421e987cac5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm.3806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3806%26sid%3Dliteratum%253Aachs%26aulast%3DColl%26aufirst%3DR.%2BC%26aulast%3DRobertson%26aufirst%3DA.%2BA%2BB%26aulast%3DChae%26aufirst%3DJ.%2BJ.%26aulast%3DHiggins%26aufirst%3DS.%2BC%26aulast%3DMunoz-Planillo%26aufirst%3DR.%26aulast%3DInserra%26aufirst%3DM.%2BC%26aulast%3DVetter%26aufirst%3DI.%26aulast%3DDungan%26aufirst%3DL.%2BS%26aulast%3DMonks%26aufirst%3DB.%2BG%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DCroker%26aufirst%3DD.%2BE%26aulast%3DButler%26aufirst%3DM.%2BS%26aulast%3DHaneklaus%26aufirst%3DM.%26aulast%3DSutton%26aufirst%3DC.%2BE%26aulast%3DNunez%26aufirst%3DG.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DKastner%26aufirst%3DD.%2BL%26aulast%3DMills%26aufirst%3DK.%2BH%2BG%26aulast%3DMasters%26aufirst%3DS.%2BL%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DM.%2BA%26aulast%3DO%2527Neill%26aufirst%3DL.%2BA%2BJ%26atitle%3DA%2520Small-Molecule%2520Inhibitor%2520of%2520the%2520NLRP3%2520Inflammasome%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D3%26spage%3D248%26epage%3D255%26doi%3D10.1038%2Fnm.3806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangan, M. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roush, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Targeting the NLRP3 Inflammasome in Inflammatory Diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnrd.2018.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30026524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGlt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=588-606&author=M.+S.+J.+Manganauthor=E.+J.+Olhavaauthor=W.+R.+Roushauthor=H.+M.+Seidelauthor=G.+D.+Glickauthor=E.+Latz&title=Targeting+the+NLRP3+Inflammasome+in+Inflammatory+Diseases&doi=10.1038%2Fnrd.2018.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the NLRP3 inflammasome in inflammatory diseases</span></div><div class="casAuthors">Mangan, Matthew S. J.; Olhava, Edward J.; Roush, William R.; Seidel, H. Martin; Glick, Gary D.; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-606</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Danger signals are a hallmark of many common inflammatory diseases, and these stimuli can function to activate the cytosolic innate immune signalling receptor NLRP3 (NOD-, LRR- and pyrin domain-contg. 3).  Once activated, NLRP3 nucleates the assembly of an inflammasome, leading to caspase 1-mediated proteolytic activation of the interleukin-1β (IL-1β) family of cytokines, and induces an inflammatory, pyroptotic cell death.  Pharmacol. inhibition of NLRP3 activation results in potent therapeutic effects in a wide variety of rodent models of inflammatory diseases, effects that are mirrored by genetic ablation of NLRP3.  Although these findings highlight the potential of NLRP3 as a drug target, an understanding of NLRP3 structure and activation mechanisms is incomplete, which has hampered the discovery and development of novel therapeutics against this target.  Here, we review recent advances in our understanding of NLRP3 activation and regulation, highlight the evolving landscape of NLRP3 modulators and discuss opportunities for pharmacol. targeting NLRP3 with novel small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw2JAJ8RPRXrVg90H21EOLACvtfcHk0liJVf443Uic8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGlt7bM&md5=57b064477ea056dc859f6c90c4d00c36</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.97%26sid%3Dliteratum%253Aachs%26aulast%3DMangan%26aufirst%3DM.%2BS.%2BJ.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DRoush%26aufirst%3DW.%2BR.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DTargeting%2520the%2520NLRP3%2520Inflammasome%2520in%2520Inflammatory%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D588%26epage%3D606%26doi%3D10.1038%2Fnrd.2018.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coll, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamoshnikova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span> <span> </span><span class="NLM_article-title">MCC950 Directly Targets the NLRP3 ATP-Hydolysis Motif for Inflammasome Inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0277-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41589-019-0277-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31086327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=556-559&author=R.+C.+Collauthor=J.+R.+Hillauthor=C.+J.+Dayauthor=A.+Zamoshnikovaauthor=D.+Boucherauthor=N.+L.+Masseyauthor=J.+L.+Chittyauthor=J.+A.+Fraserauthor=M.+P.+Jenningsauthor=A.+A.+B.+Robertsonauthor=K.+Schroder&title=MCC950+Directly+Targets+the+NLRP3+ATP-Hydolysis+Motif+for+Inflammasome+Inhibition&doi=10.1038%2Fs41589-019-0277-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition</span></div><div class="casAuthors">Coll, Rebecca C.; Hill, James R.; Day, Christopher J.; Zamoshnikova, Alina; Boucher, Dave; Massey, Nicholas L.; Chitty, Jessica L.; Fraser, James A.; Jennings, Michael P.; Robertson, Avril A. B.; Schroder, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">556-559</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Inhibition of the NLRP3 inflammasome is a promising strategy for the development of new treatments for inflammatory diseases.  MCC950 is a potent and specific small-mol. inhibitor of the NLRP3 pathway, but its mol. target is not defined.  Here, we show that MCC950 directly interacts with the Walker B motif within the NLRP3 NACHT domain, thereby blocking ATP hydrolysis and inhibiting NLRP3 activation and inflammasome formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohNuLFaDJcpLVg90H21EOLACvtfcHk0liJVf443Uic8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqs73J&md5=9c898ea86dad48144379d2d0335e836f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0277-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0277-7%26sid%3Dliteratum%253Aachs%26aulast%3DColl%26aufirst%3DR.%2BC.%26aulast%3DHill%26aufirst%3DJ.%2BR.%26aulast%3DDay%26aufirst%3DC.%2BJ.%26aulast%3DZamoshnikova%26aufirst%3DA.%26aulast%3DBoucher%26aufirst%3DD.%26aulast%3DMassey%26aufirst%3DN.%2BL.%26aulast%3DChitty%26aufirst%3DJ.%2BL.%26aulast%3DFraser%26aufirst%3DJ.%2BA.%26aulast%3DJennings%26aufirst%3DM.%2BP.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DSchroder%26aufirst%3DK.%26atitle%3DMCC950%2520Directly%2520Targets%2520the%2520NLRP3%2520ATP-Hydolysis%2520Motif%2520for%2520Inflammasome%2520Inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D556%26epage%3D559%26doi%3D10.1038%2Fs41589-019-0277-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tapia-Abellan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angosto-Bazarra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Banaclocha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torre-Minguela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceron-Carrasco, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Sanchez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arostegui, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrin, P.</span></span> <span> </span><span class="NLM_article-title">MCC950 Closes the Active Conformation of NLRP3 to an Inactive State</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0278-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41589-019-0278-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31086329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=560-564&author=A.+Tapia-Abellanauthor=D.+Angosto-Bazarraauthor=H.+Martinez-Banaclochaauthor=C.+de+Torre-Minguelaauthor=J.+P.+Ceron-Carrascoauthor=H.+Perez-Sanchezauthor=J.+I.+Arosteguiauthor=P.+Pelegrin&title=MCC950+Closes+the+Active+Conformation+of+NLRP3+to+an+Inactive+State&doi=10.1038%2Fs41589-019-0278-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">MCC950 closes the active conformation of NLRP3 to an inactive state</span></div><div class="casAuthors">Tapia-Abellan, Ana; Angosto-Bazarra, Diego; Martinez-Banaclocha, Helios; de Torre-Minguela, Carlos; Ceron-Carrasco, Jose P.; Perez-Sanchez, Horacio; Arostegui, Juan I.; Pelegrin, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-564</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">NLRP3 (NOD-like receptor pyrin domain-contg. protein 3) is an innate immune sensor that contributes to the development of different diseases, including monogenic autoinflammatory syndromes, gout, atherosclerosis, and Alzheimer's disease.  The mol. sulfonylurea MCC950 is a NLRP3 inflammasome inhibitor with potential clin. utility.  However, the mechanism of action of MCC950 remains unknown.  Here, we characterize the mechanism of action of MCC950 in both wild-type and autoinflammatory-related NLRP3 mutants, and demonstrate that MCC950 closes the 'open' conformation of active NLRP3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogkRIxmyMRsLVg90H21EOLACvtfcHk0liJVf443Uic8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqs73M&md5=20eb8add8134e4dee7e0afa5add19792</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0278-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0278-6%26sid%3Dliteratum%253Aachs%26aulast%3DTapia-Abellan%26aufirst%3DA.%26aulast%3DAngosto-Bazarra%26aufirst%3DD.%26aulast%3DMartinez-Banaclocha%26aufirst%3DH.%26aulast%3Dde%2BTorre-Minguela%26aufirst%3DC.%26aulast%3DCeron-Carrasco%26aufirst%3DJ.%2BP.%26aulast%3DPerez-Sanchez%26aufirst%3DH.%26aulast%3DArostegui%26aufirst%3DJ.%2BI.%26aulast%3DPelegrin%26aufirst%3DP.%26atitle%3DMCC950%2520Closes%2520the%2520Active%2520Conformation%2520of%2520NLRP3%2520to%2520an%2520Inactive%2520State%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D560%26epage%3D564%26doi%3D10.1038%2Fs41589-019-0278-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booshehri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, H. M.</span></span> <span> </span><span class="NLM_article-title">CAPS and NLRP3</span>. <i>J. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1007/s10875-019-00638-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1007%2Fs10875-019-00638-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31077002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ks1Smsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=277-286&author=L.+M.+Booshehriauthor=H.+M.+Hoffman&title=CAPS+and+NLRP3&doi=10.1007%2Fs10875-019-00638-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">CAPS and NLRP3</span></div><div class="casAuthors">Booshehri Laela M; Hoffman Hal M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-286</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cryopyrin-associated periodic syndrome (CAPS) is a rare inherited autoinflammatory disorder characterized by systemic, cutaneous, musculoskeletal, and central nervous system inflammation.  Gain-of-function mutations in NLRP3 in CAPS patients lead to activation of the cryopyrin inflammasome, resulting in the inappropriate release of inflammatory cytokines including IL-1β and CAPS-related inflammatory symptoms.  Several mechanisms have been identified that are important for the normal regulation of the cryopyrin inflammasome in order to prevent uncontrolled inflammation.  Investigators have taken advantage of some of these pathways to develop and apply novel targeted therapies, which have resulted in improved quality of life for patients with this orphan disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRMGJG6VtPNz69zv1FsJFMfW6udTcc2eZ3H-If7O0Wcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ks1Smsw%253D%253D&md5=7c36b46229a77070d7d9db993a9ac519</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs10875-019-00638-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10875-019-00638-z%26sid%3Dliteratum%253Aachs%26aulast%3DBooshehri%26aufirst%3DL.%2BM.%26aulast%3DHoffman%26aufirst%3DH.%2BM.%26atitle%3DCAPS%2520and%2520NLRP3%26jtitle%3DJ.%2520Clin.%2520Immunol.%26date%3D2019%26volume%3D39%26spage%3D277%26epage%3D286%26doi%3D10.1007%2Fs10875-019-00638-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Walle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sácha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossoul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hauwermeiren, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saavedra, P. H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konvalinka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamkanfi, M.</span></span> <span> </span><span class="NLM_article-title">MCC950/CRID3 Potently Targets the NACHT Domain of Wild-Type NLRP3 but not Disease-Associated Mutants for Inflammasome Inhibition</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>), <span class="NLM_elocation-id">e3000354</span> <span class="refDoi"> DOI: 10.1371/journal.pbio.3000354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.pbio.3000354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31525186" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&issue=9&author=L.+Vande%0AWalleauthor=I.+B.+Stoweauthor=P.+S%C3%A1chaauthor=B.+L.+Leeauthor=D.+Demonauthor=A.+Fossoulauthor=F.+Van+Hauwermeirenauthor=P.+H.+V.+Saavedraauthor=P.+Simonauthor=V.+Subrtauthor=L.+Kostkaauthor=C.+E.+Stivalaauthor=V.+C.+Phamauthor=S.+T.+Stabenauthor=S.+Yamazoeauthor=J.+Konvalinkaauthor=N.+Kayagakiauthor=M.+Lamkanfi&title=MCC950%2FCRID3+Potently+Targets+the+NACHT+Domain+of+Wild-Type+NLRP3+but+not+Disease-Associated+Mutants+for+Inflammasome+Inhibition&doi=10.1371%2Fjournal.pbio.3000354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.3000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.3000354%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BWalle%26aufirst%3DL.%26aulast%3DStowe%26aufirst%3DI.%2BB.%26aulast%3DS%25C3%25A1cha%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DB.%2BL.%26aulast%3DDemon%26aufirst%3DD.%26aulast%3DFossoul%26aufirst%3DA.%26aulast%3DVan%2BHauwermeiren%26aufirst%3DF.%26aulast%3DSaavedra%26aufirst%3DP.%2BH.%2BV.%26aulast%3DSimon%26aufirst%3DP.%26aulast%3DSubrt%26aufirst%3DV.%26aulast%3DKostka%26aufirst%3DL.%26aulast%3DStivala%26aufirst%3DC.%2BE.%26aulast%3DPham%26aufirst%3DV.%2BC.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DYamazoe%26aufirst%3DS.%26aulast%3DKonvalinka%26aufirst%3DJ.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DLamkanfi%26aufirst%3DM.%26atitle%3DMCC950%252FCRID3%2520Potently%2520Targets%2520the%2520NACHT%2520Domain%2520of%2520Wild-Type%2520NLRP3%2520but%2520not%2520Disease-Associated%2520Mutants%2520for%2520Inflammasome%2520Inhibition%26jtitle%3DPLoS%2520Biol.%26date%3D2019%26volume%3D17%26issue%3D9%26doi%3D10.1371%2Fjournal.pbio.3000354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strober, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuss, I. J.</span></span> <span> </span><span class="NLM_article-title">The Role of NLRP3 and IL-1β in the Pathogenesis of Inflammatory Bowel Disease</span>. <i>Frontiers in Immunology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.02566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3389%2Ffimmu.2018.02566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29403488" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-9&author=L.+Maoauthor=A.+Kitaniauthor=W.+Stroberauthor=I.+J.+Fuss&title=The+Role+of+NLRP3+and+IL-1%CE%B2+in+the+Pathogenesis+of+Inflammatory+Bowel+Disease&doi=10.3389%2Ffimmu.2018.02566"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02566%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DL.%26aulast%3DKitani%26aufirst%3DA.%26aulast%3DStrober%26aufirst%3DW.%26aulast%3DFuss%26aufirst%3DI.%2BJ.%26atitle%3DThe%2520Role%2520of%2520NLRP3%2520and%2520IL-1%25CE%25B2%2520in%2520the%2520Pathogenesis%2520of%2520Inflammatory%2520Bowel%2520Disease%26jtitle%3DFrontiers%2520in%2520Immunology%26date%3D2018%26volume%3D9%26spage%3D1%26epage%3D9%26doi%3D10.3389%2Ffimmu.2018.02566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umiker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajami, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fregeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span> <span> </span><span class="NLM_article-title">The NLRP3 Inflammasome Mediates DSS-Induced Intestinal Inflammation in Nod2 Knockout Mice</span>. <i>Innate Immun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1177/1753425919826367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1177%2F1753425919826367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30774010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFWgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=132-143&issue=2&author=B.+Umikerauthor=H.-H.+Leeauthor=J.+Copeauthor=N.+J.+Ajamiauthor=J.-P.+Laineauthor=C.+Fregeauauthor=H.+Fergusonauthor=S.+E.+Alvesauthor=N.+Sciammettaauthor=M.+Kleinschekauthor=M.+Salmon&title=The+NLRP3+Inflammasome+Mediates+DSS-Induced+Intestinal+Inflammation+in+Nod2+Knockout+Mice&doi=10.1177%2F1753425919826367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP3 inflammasome mediates DSS-induced intestinal inflammation in Nod2 knockout mice</span></div><div class="casAuthors">Umiker, Benjamin; Lee, Hyun-Hee; Cope, Julia; Ajami, Nadim J.; Laine, Jean-Philippe; Fregeau, Christine; Ferguson, Heidi; Alves, Stephen E.; Sciammetta, Nunzio; Kleinschek, Melanie; Salmon, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Innate Immunity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">132-143</span>CODEN:
                <span class="NLM_cas:coden">IINMCB</span>;
        ISSN:<span class="NLM_cas:issn">1753-4259</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Crohn's disease (CD) is a chronic disorder of the gastrointestinal tract characterized by inflammation and intestinal epithelial injury.  Loss of function mutations in the intracellular bacterial sensor NOD2 are major risk factors for the development of CD.  In the absence of robust bacterial recognition by NOD2 an inflammatory cascade is initiated through alternative PRRs leading to CD.  In the present study, MCC950, a specific small mol. inhibitor of NLR pyrin domain-contg. protein 3 (NLRP3), abrogated dextran sodium sulfate (DSS)-induced intestinal inflammation in Nod2-/- mice.  NLRP3 inflammasome formation was obsd. at a higher rate in NOD2-deficient small intestinal lamina propria cells after insult by DSS.  NLRP3 complex formation led to an increase in IL-1β secretion in both the small intestine and colon of Nod2ko mice.  This increase in IL-1β secretion in the intestine was attenuated by MCC950 leading to decreased disease severity in Nod2ko mice.  Our work suggests that NLRP3 inflammasome activation may be a key driver of intestinal inflammation in the absence of functional NOD2.  NLRP3 pathway inhibition can prevent intestinal inflammation in the absence of robust NOD2 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRRizO0c3h27Vg90H21EOLACvtfcHk0lh_0K4DmEeeOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFWgsbc%253D&md5=738d2acab67571f7ebbff0d17aebe795</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1177%2F1753425919826367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1753425919826367%26sid%3Dliteratum%253Aachs%26aulast%3DUmiker%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DCope%26aufirst%3DJ.%26aulast%3DAjami%26aufirst%3DN.%2BJ.%26aulast%3DLaine%26aufirst%3DJ.-P.%26aulast%3DFregeau%26aufirst%3DC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DAlves%26aufirst%3DS.%2BE.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DKleinschek%26aufirst%3DM.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DThe%2520NLRP3%2520Inflammasome%2520Mediates%2520DSS-Induced%2520Intestinal%2520Inflammation%2520in%2520Nod2%2520Knockout%2520Mice%26jtitle%3DInnate%2520Immun.%26date%3D2019%26volume%3D25%26issue%3D2%26spage%3D132%26epage%3D143%26doi%3D10.1177%2F1753425919826367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Similuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oler, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albenberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quezado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery-Recht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuss, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strober, W.</span></span> <span> </span><span class="NLM_article-title">Loss-of-Function CARD8Mutation Causes NLRP3 Inflammasome Activation and Crohn’s Disease</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1172/JCI98642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1172%2FJCI98642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29408806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BC1MvotFOlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=1793-1806&issue=5&author=L.+Maoauthor=A.+Kitaniauthor=M.+Similukauthor=A.+J.+Olerauthor=L.+Albenbergauthor=J.+Kelsenauthor=A.+Aktayauthor=M.+Quezadoauthor=M.+Yaoauthor=K.+Montgomery-Rechtauthor=I.+J.+Fussauthor=W.+Strober&title=Loss-of-Function+CARD8Mutation+Causes+NLRP3+Inflammasome+Activation+and+Crohn%E2%80%99s+Disease&doi=10.1172%2FJCI98642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease</span></div><div class="casAuthors">Mao Liming; Kitani Atsushi; Yao Michael; Fuss Ivan J; Strober Warren; Similuk Morgan; Oler Andrew J; Albenberg Lindsey; Kelsen Judith; Aktay Atiye; Quezado Martha; Yao Michael; Montgomery-Recht Kim</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1793-1806</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In these studies, we evaluated the contribution of the NLRP3 inflammasome to Crohn's disease (CD) in a kindred containing individuals having a missense mutation in CARD8, a protein known to inhibit this inflammasome.  Whole exome sequencing and PCR studies identified the affected individuals as having a V44I mutation in a single allele of the T60 isoform of CARD8.  The serum levels of IL-1β in the affected individuals were increased compared with those in healthy controls, and their peripheral monocytes produced increased amounts of IL-1β when stimulated by NLRP3 activators.  Immunoblot studies probing the basis of these findings showed that mutated T60 CARD8 failed to downregulate the NLRP3 inflammasome because it did not bind to NLRP3 and inhibit its oligomerization.  In addition, these studies showed that mutated T60 CARD8 exerted a dominant-negative effect by its capacity to bind to and form oligomers with unmutated T60 or T48 CARD8 that impeded their binding to NLRP3.  Finally, inflammasome activation studies revealed that intact but not mutated CARD8 prevented NLRP3 deubiquitination and serine dephosphorylation.  CD due to a CARD8 mutation was not effectively treated by anti-TNF-α, but did respond to IL-1β inhibitors.  Thus, patients with anti-TNF-α-resistant CD may respond to this treatment option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ51eCIv3X5t4kFb3mqPUYDfW6udTcc2eZ7dJc1D5H4Zrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvotFOlsQ%253D%253D&md5=7897e01e868c27af9e771a870a40fe18</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI98642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI98642%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DL.%26aulast%3DKitani%26aufirst%3DA.%26aulast%3DSimiluk%26aufirst%3DM.%26aulast%3DOler%26aufirst%3DA.%2BJ.%26aulast%3DAlbenberg%26aufirst%3DL.%26aulast%3DKelsen%26aufirst%3DJ.%26aulast%3DAktay%26aufirst%3DA.%26aulast%3DQuezado%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DMontgomery-Recht%26aufirst%3DK.%26aulast%3DFuss%26aufirst%3DI.%2BJ.%26aulast%3DStrober%26aufirst%3DW.%26atitle%3DLoss-of-Function%2520CARD8Mutation%2520Causes%2520NLRP3%2520Inflammasome%2520Activation%2520and%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26issue%3D5%26spage%3D1793%26epage%3D1806%26doi%3D10.1172%2FJCI98642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span> <span> </span><span class="NLM_article-title">NEK7 Interacts with NLRP3 to Modulate the Pyroptosis in Inflammatory Bowel Disease via NF-κB Signaling</span>. <i>Cell Death and Disease</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">906</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s41419-019-2157-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41419-019-2157-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWmsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-12&issue=906&author=X.+Chenauthor=G.+Liuauthor=Y.+Yuanauthor=G.+Wuauthor=S.+Wangauthor=L.+Yuan&title=NEK7+Interacts+with+NLRP3+to+Modulate+the+Pyroptosis+in+Inflammatory+Bowel+Disease+via+NF-%CE%BAB+Signaling&doi=10.1038%2Fs41419-019-2157-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">FTY720 induces non-canonical phosphatidylserine externalization and cell death in acute myeloid leukemia</span></div><div class="casAuthors">Young, Megan M.; Bui, Van; Chen, Chong; Wang, Hong-Gang</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">FTY720 (fingolimod) is a FDA-approved sphingosine analog that is phosphorylated in vivo to modulate sphingosine-1-phosphate receptor (S1PR) signaling for immunosuppression in patients with refractory multiple sclerosis.  FTY720 also exhibits promising anticancer efficacy in several preclin. models.  While FTY720-induced cytotoxicity is not due to S1PR signaling, the mechanism remains unclear and is reported to occur through various cell death pathways.  Here, we performed a systematic, mechanistic study of FTY720-induced cell death in acute myeloid leukemia (AML).  We found that FTY720 induced cell death in a panel of genetically diverse AML cell lines that was accompanied by rapid phosphatidylserine (PS) externalization.  Importantly, FTY720-induced PS exposure was not due to any direct effects on plasma membrane integrity and was independent of canonical signaling by regulated cell death pathways known to activate lipid flip-flop, including caspase-dependent apoptosis/pyroptosis, necroptosis, ferroptosis, and reactive oxygen species-mediated cell death.  Notably, PS exposure required cellular vacuolization induced by defects in endocytic trafficking and was suppressed by the inhibition of PP2A and shedding of Annexin V-pos. subcellular particles.  Collectively, our studies reveal a non-canonical pathway underlying PS externalization and cell death in AML to provide mechanistic insight into the antitumor properties of FTY720.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTFJLrVn--C7Vg90H21EOLACvtfcHk0lg2C33D_z2xfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWmsrjM&md5=172806d536cf39d875417488aadbd493</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41419-019-2157-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-019-2157-1%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DL.%26atitle%3DNEK7%2520Interacts%2520with%2520NLRP3%2520to%2520Modulate%2520the%2520Pyroptosis%2520in%2520Inflammatory%2520Bowel%2520Disease%2520via%2520NF-%25CE%25BAB%2520Signaling%26jtitle%3DCell%2520Death%2520and%2520Disease%26date%3D2019%26volume%3D10%26issue%3D906%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs41419-019-2157-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannou, G. N.</span></span> <span> </span><span class="NLM_article-title">The Role of Cholesterol in the Pathogenesis of NASH</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2015.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.tem.2015.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26703097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=84-95&issue=2&author=G.+N.+Ioannou&title=The+Role+of+Cholesterol+in+the+Pathogenesis+of+NASH&doi=10.1016%2Fj.tem.2015.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">the role of cholesterol in the pathogenesis of NASH</span></div><div class="casAuthors">Ioannou, George N.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">84-95</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a subgroup of patients with nonalcoholic fatty liver disease (NAFLD), causing nonalcoholic steatohepatitis (NASH) and even progression to cirrhosis and hepatocellular carcinoma (HCC).  While the underlying mol. mechanisms responsible for the development of inflammation and fibrosis that characterize progressive NASH remain unclear, emerging evidence now suggests that hepatic free cholesterol (FC) is a major lipotoxic mol. crit. in the development of exptl. and human NASH.  In this review, we examine the effects of excess FC in hepatocytes, Kupffer cells (KCs), and hepatic stellate cells (HSCs), and the subcellular mechanisms by which excess FC can induce cellular toxicity or proinflammatory and profibrotic effects in these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc8NlE_FDOOLVg90H21EOLACvtfcHk0lg2C33D_z2xfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemtr%252FN&md5=6f2000afa1fdbe9874cec481daf57b2f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2015.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2015.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DIoannou%26aufirst%3DG.%2BN.%26atitle%3DThe%2520Role%2520of%2520Cholesterol%2520in%2520the%2520Pathogenesis%2520of%2520NASH%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2016%26volume%3D27%26issue%3D2%26spage%3D84%26epage%3D95%26doi%3D10.1016%2Fj.tem.2015.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duewell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayner, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirois, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vladimer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauernfeind, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abela, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnurr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espevik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasomes are Required for Atherogenesis and Activated by Cholesterol Crystals</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1361</span>, <span class="refDoi"> DOI: 10.1038/nature08938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature08938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20428172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltl2mu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=1357-1361&author=P.+Duewellauthor=H.+Konoauthor=K.+J.+Raynerauthor=C.+M.+Siroisauthor=G.+Vladimerauthor=F.+G.+Bauernfeindauthor=G.+S.+Abelaauthor=L.+Franchiauthor=G.+Nu%C3%B1ezauthor=M.+Schnurrauthor=T.+Espevikauthor=E.+Lienauthor=K.+A.+Fitzgeraldauthor=K.+L.+Rockauthor=K.+J.+Mooreauthor=S.+D.+Wrightauthor=V.+Hornungauthor=E.+Latz&title=NLRP3+Inflammasomes+are+Required+for+Atherogenesis+and+Activated+by+Cholesterol+Crystals&doi=10.1038%2Fnature08938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals</span></div><div class="casAuthors">Duewell, Peter; Kono, Hajime; Rayner, Katey J.; Sirois, Cherilyn M.; Vladimer, Gregory; Bauernfeind, Franz G.; Abela, George S.; Franchi, Luigi; Nunez, Gabriel; Schnurr, Max; Espevik, Terje; Lien, Egil; Fitzgerald, Katherine A.; Rock, Kenneth L.; Moore, Kathryn J.; Wright, Samuel D.; Hornung, Veit; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7293</span>),
    <span class="NLM_cas:pages">1357-1361</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inflammatory nature of atherosclerosis is well established but the agent(s) that incite inflammation in the artery wall remain largely unknown.  Germ-free animals are susceptible to atherosclerosis, suggesting that endogenous substances initiate the inflammation.  Mature atherosclerotic lesions contain macroscopic deposits of cholesterol crystals in the necrotic core, but their appearance late in atherogenesis had been thought to disqualify them as primary inflammatory stimuli.  However, using a new microscopic technique, the authors revealed that minute cholesterol crystals are present in early diet-induced atherosclerotic lesions and that their appearance in mice coincides with the first appearance of inflammatory cells.  Other cryst. substances can induce inflammation by stimulating the caspase-1-activating NLRP3 (NALP3 or cryopyrin) inflammasome, which results in cleavage and secretion of interleukin (IL)-1 family cytokines.  Here the authors show that cholesterol crystals activate the NLRP3 inflammasome in phagocytes in vitro in a process that involves phagolysosomal damage.  Similarly, when injected i.p., cholesterol crystals induce acute inflammation, which is impaired in mice deficient in components of the NLRP3 inflammasome, cathepsin B, cathepsin L or IL-1 mols.  Moreover, when mice deficient in low-d. lipoprotein receptor (LDLR) were bone-marrow transplanted with NLRP3-deficient, ASC (also known as PYCARD)-deficient or IL-1α/β-deficient bone marrow and fed on a high-cholesterol diet, they had markedly decreased early atherosclerosis and inflammasome-dependent IL-18 levels.  Minimally modified LDL can lead to cholesterol crystn. concomitant with NLRP3 inflammasome priming and activation in macrophages.  Although there is the possibility that oxidized LDL activates the NLRP3 inflammasome in vivo, the results demonstrate that cryst. cholesterol acts as an endogenous danger signal and its deposition in arteries or elsewhere is an early cause rather than a late consequence of inflammation.  These findings provide new insights into the pathogenesis of atherosclerosis and indicate new potential mol. targets for the therapy of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRFmxeie_MGrVg90H21EOLACvtfcHk0lg2C33D_z2xfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltl2mu7w%253D&md5=593ac5b735c8d1151ae4f4b7861a3591</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnature08938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08938%26sid%3Dliteratum%253Aachs%26aulast%3DDuewell%26aufirst%3DP.%26aulast%3DKono%26aufirst%3DH.%26aulast%3DRayner%26aufirst%3DK.%2BJ.%26aulast%3DSirois%26aufirst%3DC.%2BM.%26aulast%3DVladimer%26aufirst%3DG.%26aulast%3DBauernfeind%26aufirst%3DF.%2BG.%26aulast%3DAbela%26aufirst%3DG.%2BS.%26aulast%3DFranchi%26aufirst%3DL.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DG.%26aulast%3DSchnurr%26aufirst%3DM.%26aulast%3DEspevik%26aufirst%3DT.%26aulast%3DLien%26aufirst%3DE.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DMoore%26aufirst%3DK.%2BJ.%26aulast%3DWright%26aufirst%3DS.%2BD.%26aulast%3DHornung%26aufirst%3DV.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DNLRP3%2520Inflammasomes%2520are%2520Required%2520for%2520Atherogenesis%2520and%2520Activated%2520by%2520Cholesterol%2520Crystals%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D1357%26epage%3D1361%26doi%3D10.1038%2Fnature08938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span> <span> </span><span class="NLM_article-title">Fatty Acid Activates NLRP3 Inflammasomes in Mouse Kupffer Cells through Mitochondrial DNA Release</span>. <i>Cell. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>332</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.cellimm.2018.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.cellimm.2018.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30103942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2ju77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2018&pages=111-120&author=J.+Panauthor=Z.+Ouauthor=C.+Caiauthor=P.+Liauthor=J.+Gongauthor=X.+Z.+Ruanauthor=K.+He&title=Fatty+Acid+Activates+NLRP3+Inflammasomes+in+Mouse+Kupffer+Cells+through+Mitochondrial+DNA+Release&doi=10.1016%2Fj.cellimm.2018.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release</span></div><div class="casAuthors">Pan, Junjiang; Ou, Zhibing; Cai, Can; Li, Peizhi; Gong, Jianping; Ruan, Xiong Z.; He, Kun</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-120</span>CODEN:
                <span class="NLM_cas:coden">CLIMB8</span>;
        ISSN:<span class="NLM_cas:issn">0008-8749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in many developed and developing countries worldwide.  It has been well established that the chronic sterile inflammation caused by the NLRP3 inflammasome is closely related to NAFLD development.  Kupffer cells (KCs) are involved in the pathogenesis of various liver diseases.  We used methionine choline-deficient diets to establish a mouse nonalcoholic steatohepatitis (NASH) model.  The expression and formation of the NLRP3 inflammasome in the KCs from the mouse and cell models were detd. by Western blotting and co-immunopptn.  Evidence of mitochondrial DNA (mtDNA) release was detd. by live cell labeling and imaging.  KCs and the NLRP3 inflammasome exerted proinflammatory effects on the development and progression of NASH through secretion of the proinflammatory cytokine IL-1β.  NLRP3, ASC and Caspase-1 protein expression levels in KCs from NASH mouse livers were significantly higher than those in KCs from NLRP3-/- mice, and the no. of NLRP3 inflammasome protein complexes was significantly higher in KCs from NASH mouse livers, whereas these protein complexes could not be formed in NLRP3-/- mice.  In in vitro expts., palmitic acid (PA) decreased the mitochondrial membrane potential and subsequently induced mtDNA release from the mitochondria to the cytoplasm.  NLRP3 inflammasome expression was substantially increased, and mtDNA-NLRP3 inflammasome complexes formed upon PA stimulation.  Our data suggest that mtDNA released from mitochondria during PA stimulation causes NLRP3 inflammasome activation, providing a missing link between NLRP3 inflammasome activation and NASH development, via binding of cytosolic mtDNA to the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmyOTPaAnxy7Vg90H21EOLACvtfcHk0lhG4Z0SrES-PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2ju77P&md5=8e16b656e212522d9c3c68c0a176bdee</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cellimm.2018.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellimm.2018.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DRuan%26aufirst%3DX.%2BZ.%26aulast%3DHe%26aufirst%3DK.%26atitle%3DFatty%2520Acid%2520Activates%2520NLRP3%2520Inflammasomes%2520in%2520Mouse%2520Kupffer%2520Cells%2520through%2520Mitochondrial%2520DNA%2520Release%26jtitle%3DCell.%2520Immunol.%26date%3D2018%26volume%3D332%26spage%3D111%26epage%3D120%26doi%3D10.1016%2Fj.cellimm.2018.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannou, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rooyen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigh, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, G. C.</span></span> <span> </span><span class="NLM_article-title">Cholesterol-Lowering Drugs Cause Dissolution of Cholesterol Crystals and Disperse Kupffer Cell Crown-Like Structures During Resolution of NASH</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1194/jlr.M053785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1194%2Fjlr.M053785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25520429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVektLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=277-285&author=G.+N.+Ioannouauthor=D.+M.+Van+Rooyenauthor=C.+Savardauthor=W.+G.+Haighauthor=M.+M.+Yehauthor=N.+C.+Teohauthor=G.+C.+Farrell&title=Cholesterol-Lowering+Drugs+Cause+Dissolution+of+Cholesterol+Crystals+and+Disperse+Kupffer+Cell+Crown-Like+Structures+During+Resolution+of+NASH&doi=10.1194%2Fjlr.M053785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH</span></div><div class="casAuthors">Ioannou, George N.; Van Rooyen, Derrick M.; Savard, Christopher; Haigh, W. Geoffrey; Yeh, Matthew M.; Teoh, Narci C.; Farrell, Geoffrey C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-285</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">Cholesterol crystals form within hepatocyte lipid droplets in human and exptl. nonalcoholic steatohepatitis (NASH) and are the focus of crown-like structures (CLSs) of activated Kupffer cells (KCs).  Obese, diabetic Alms1 mutant (foz/foz) mice were a fed high-fat (23%) diet contg. 0.2% cholesterol for 16 wk and then assigned to four intervention groups for 8 wk: (a) vehicle control, (b) ezetimibe (5 mg/kg/day), (c) atorvastatin (20 mg/kg/day), or (d) ezetimibe and atorvastatin.  Livers of vehicle-treated mice developed fibrosing NASH with abundant cholesterol crystn. within lipid droplets calcd. to extend over 3.3% (SD, 2.2%) of liver surface area.  Hepatocyte lipid droplets with prominent cholesterol crystn. were surrounded by TNFα-pos. (activated) KCs forming CLSs (≥3 per high-power field).  KCs that formed CLSs stained pos. for NLRP3, implicating activation of the NLRP3 inflammasome in response to cholesterol crystals.  In contrast, foz/foz mice treated with ezetimibe and atorvastatin showed near-complete resoln. of cholesterol crystals [0.01% (SD, 0.02%) of surface area] and CLSs (0 per high-power field), with amelioration of fibrotic NASH.  Ezetimibe or atorvastatin alone had intermediate effects on cholesterol crystn., CLSs, and NASH.  These findings are consistent with a causative link between exposure of hepatocytes and KCs to cholesterol crystals and with the development of NASH possibly mediated by NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjZw2g3FBLhbVg90H21EOLACvtfcHk0lhG4Z0SrES-PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVektLo%253D&md5=a943ccce06d08765bf81c8b631195dc8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1194%2Fjlr.M053785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.M053785%26sid%3Dliteratum%253Aachs%26aulast%3DIoannou%26aufirst%3DG.%2BN.%26aulast%3DVan%2BRooyen%26aufirst%3DD.%2BM.%26aulast%3DSavard%26aufirst%3DC.%26aulast%3DHaigh%26aufirst%3DW.%2BG.%26aulast%3DYeh%26aufirst%3DM.%2BM.%26aulast%3DTeoh%26aufirst%3DN.%2BC.%26aulast%3DFarrell%26aufirst%3DG.%2BC.%26atitle%3DCholesterol-Lowering%2520Drugs%2520Cause%2520Dissolution%2520of%2520Cholesterol%2520Crystals%2520and%2520Disperse%2520Kupffer%2520Cell%2520Crown-Like%2520Structures%2520During%2520Resolution%2520of%2520NASH%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2015%26volume%3D56%26spage%3D277%26epage%3D285%26doi%3D10.1194%2Fjlr.M053785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mridha, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wree, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rooyen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haczeyni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, N. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannou, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldstein, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, G. C.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Blockade Reduces Liver Inflammation and Fibrosis in Experimental NASH in Mice</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2017.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.jhep.2017.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28167322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFSiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1037-1046&author=A.+R.+Mridhaauthor=A.+Wreeauthor=A.+A.+B.+Robertsonauthor=M.+M.+Yehauthor=C.+D.+Johnsonauthor=D.+M.+Van+Rooyenauthor=F.+Haczeyniauthor=N.+C.-H.+Teohauthor=C.+Savardauthor=G.+N.+Ioannouauthor=S.+L.+Mastersauthor=K.+Schroderauthor=M.+A.+Cooperauthor=A.+E.+Feldsteinauthor=G.+C.+Farrell&title=NLRP3+Inflammasome+Blockade+Reduces+Liver+Inflammation+and+Fibrosis+in+Experimental+NASH+in+Mice&doi=10.1016%2Fj.jhep.2017.01.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice</span></div><div class="casAuthors">Mridha, Auvro R.; Wree, Alexander; Robertson, Avril A. B.; Yeh, Matthew M.; Johnson, Casey D.; Van Rooyen, Derrick M.; Haczeyni, Fahrettin; Teoh, Narci C.-H.; Savard, Christopher; Ioannou, George N.; Masters, Seth L.; Schroder, Kate; Cooper, Matthew A.; Feldstein, Ariel E.; Farrell, Geoffrey C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1037-1046</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alc. fatty liver disease (NAFLD).  We used the first small mol. NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.  We fed foz/foz and wild-type mice an atherogenic diet for 16 wk, gavaged MCC950 or vehicle until 24 wk, then detd. NAFLD phenotype.  In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6 wk and detd. the effects on liver fibrosis.  In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24 wk, in assocn. with cholesterol crystal formation and NASH pathol.; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased.  MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathol., and liver fibrosis.  In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the assocd. neutrophil migration.  MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered nos. of macrophages and neutrophils in the liver, and improved liver fibrosis.MCC950, an NLRP3 selective inhibitor, improved NAFLD pathol. and fibrosis in obese diabetic mice.  This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells.  MCC950 reduced liver fibrosis in MCD-fed mice.  Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.  Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alc. steatohepatitis (NASH), is the most common serious liver disease with no current treatment.  There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role.  Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH.  We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH.  This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH.  In addn., such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Eg3b8uiplbVg90H21EOLACvtfcHk0lhUi1QGKdEAyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFSiu7k%253D&md5=3daae9c7c7671aa0e3021b1f49f139d0</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2017.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2017.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DMridha%26aufirst%3DA.%2BR.%26aulast%3DWree%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DYeh%26aufirst%3DM.%2BM.%26aulast%3DJohnson%26aufirst%3DC.%2BD.%26aulast%3DVan%2BRooyen%26aufirst%3DD.%2BM.%26aulast%3DHaczeyni%26aufirst%3DF.%26aulast%3DTeoh%26aufirst%3DN.%2BC.-H.%26aulast%3DSavard%26aufirst%3DC.%26aulast%3DIoannou%26aufirst%3DG.%2BN.%26aulast%3DMasters%26aufirst%3DS.%2BL.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DFeldstein%26aufirst%3DA.%2BE.%26aulast%3DFarrell%26aufirst%3DG.%2BC.%26atitle%3DNLRP3%2520Inflammasome%2520Blockade%2520Reduces%2520Liver%2520Inflammation%2520and%2520Fibrosis%2520in%2520Experimental%2520NASH%2520in%2520Mice%26jtitle%3DJ.%2520Hepatol.%26date%3D2017%26volume%3D66%26spage%3D1037%26epage%3D1046%26doi%3D10.1016%2Fj.jhep.2017.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klinenberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfinger, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seegmiller, J. E.</span></span> <span> </span><span class="NLM_article-title">The Effectiveness of the Xanthine Oxidase Inhibitor Alloopurinol in the Treatment of Gout</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">647</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-62-4-639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.7326%2F0003-4819-62-4-639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=14274828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADyaF2MXptl2mtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1965&pages=639-647&issue=4&author=J.+R.+Klinenbergauthor=S.+E.+Goldfingerauthor=J.+E.+Seegmiller&title=The+Effectiveness+of+the+Xanthine+Oxidase+Inhibitor+Alloopurinol+in+the+Treatment+of+Gout&doi=10.7326%2F0003-4819-62-4-639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout</span></div><div class="casAuthors">Klinenberg, James R.; Goldfinger, Stephen E.; Seegmiller, J. Edwin</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Internal Medicine</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">639-47</span>CODEN:
                <span class="NLM_cas:coden">AIMEAS</span>;
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    </div><div class="casAbstract">Allopurinol (I) was well tolerated by 11 of 12 subjects and markedly decreased the plasma uric acid concn. and uric acid excretion.  The oxypurines xanthine and hypoxanthine largely replaced the deficit in uric acid excretion in both normal and gouty subjects.  Total purine excretion was affected to only a small extent by I administration.  Inhibition of xanthine oxidase is advantageous because the renal clearance of oxypurine is much greater than that of uric acid.  The resultant plasma oxypurine concns. do not exceed satn., hence tissue deposits are unlikely.  Allopurinol can be used in conjunction with uricosuric drugs to obtain max. total purine excretion and to allow unloading of large urate deposits.  It has a potential use in subjects with hyperuricemia and renal insufficiency who are refractory to uricosuric therapy and in gouty subjects who cannot tolerate other drugs which lower blood plasma urate concns.  20 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgW-RuFOFE3LVg90H21EOLACvtfcHk0lhUi1QGKdEAyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXptl2mtQ%253D%253D&md5=d0b67706e02a25ee383bf57501037652</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-62-4-639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-62-4-639%26sid%3Dliteratum%253Aachs%26aulast%3DKlinenberg%26aufirst%3DJ.%2BR.%26aulast%3DGoldfinger%26aufirst%3DS.%2BE.%26aulast%3DSeegmiller%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520Effectiveness%2520of%2520the%2520Xanthine%2520Oxidase%2520Inhibitor%2520Alloopurinol%2520in%2520the%2520Treatment%2520of%2520Gout%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D1965%26volume%3D62%26issue%3D4%26spage%3D639%26epage%3D647%26doi%3D10.7326%2F0003-4819-62-4-639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, J. J. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Lisdonk, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Riel, P. L. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Weel, C.</span></span> <span> </span><span class="NLM_article-title">Use of Oral Prednisolone or Naproxen for the Treatment of Gout Athritis: a Double-Blind, Randomised Equivalence Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1854</span>– <span class="NLM_lpage">1860</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)60799-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS0140-6736%2808%2960799-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=18514729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFKntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=1854-1860&author=J.+J.+E.+M.+Janssensauthor=M.+Janssenauthor=E.+H.+van+de+Lisdonkauthor=P.+L.+C.+M.+van+Rielauthor=C.+van+Weel&title=Use+of+Oral+Prednisolone+or+Naproxen+for+the+Treatment+of+Gout+Athritis%3A+a+Double-Blind%2C+Randomised+Equivalence+Trial&doi=10.1016%2FS0140-6736%2808%2960799-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial</span></div><div class="casAuthors">Janssens, Hein J. E. M.; Janssen, Matthijs; van de Lisdonk, Eloy H.; van Riel, Piet L. C. M.; van Weel, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">9627</span>),
    <span class="NLM_cas:pages">1854-1860</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Non-steroidal anti-inflammatory drugs and colchicine used to treat gout arthritis have gastrointestinal, renal, and cardiovascular adverse effects.  Systemic corticosteroids might be a beneficial alternative.  We investigated equivalence of naproxen and prednisolone in primary care.  We did a randomized clin. trial to test equivalence of prednisolone and naproxen for the treatment of monoarticular gout.  Primary-care patients with gout confirmed by presence of monosodium urate crystals were eligible: 120 patients were randomly assigned with computer-generated randomization to receive either prednisolone (35 mg once a day; n=60) or naproxen (500 mg twice a day; n=60), for 5 days.  Treatment was masked for both patients and physicians.  The primary outcome was pain measured on a 100 mm visual analog scale and the a priori margin for equivalence set at 10%.  Analyses were done per protocol and by intention to treat.  This study is registered as an International Std. Randomised Controlled Trial, no. ISRCTN14648181.  Data were incomplete for one patient in each treatment group, so per-protocol analyses included 59 patients in each group.  After 90 h the redn. in the pain score was 44.7 mm and 46.0 mm for prednisolone and naproxen, resp. (difference 1.3 mm; 95% CI -9.8 to 7.1), suggesting equivalence.  The difference in the size of change in pain was 1.57 mm (95% CI -8.65 to 11.78).  Adverse effects were similar between groups, minor, and resolved by 3 wk follow-up.  Thus, oral prednisolone and naproxen are equally effective in the initial treatment of gout arthritis over 4 days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsPRlPl63jObVg90H21EOLACvtfcHk0lhUi1QGKdEAyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFKntr4%253D&md5=282ab342933b2b607ccf03e55f1d1871</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960799-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960799-0%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DJ.%2BJ.%2BE.%2BM.%26aulast%3DJanssen%26aufirst%3DM.%26aulast%3Dvan%2Bde%2BLisdonk%26aufirst%3DE.%2BH.%26aulast%3Dvan%2BRiel%26aufirst%3DP.%2BL.%2BC.%2BM.%26aulast%3Dvan%2BWeel%26aufirst%3DC.%26atitle%3DUse%2520of%2520Oral%2520Prednisolone%2520or%2520Naproxen%2520for%2520the%2520Treatment%2520of%2520Gout%2520Athritis%253A%2520a%2520Double-Blind%252C%2520Randomised%2520Equivalence%2520Trial%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D1854%26epage%3D1860%26doi%3D10.1016%2FS0140-6736%2808%2960799-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollaston, W. H.</span></span> <span> </span><span class="NLM_article-title">XVII. On Gouty and Urinary Concentrations</span>. <i>Philosophical Transact.</i> <span class="NLM_year" style="font-weight: bold;">1797</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">386</span>– <span class="NLM_lpage">400</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1797&pages=386-400&author=W.+H.+Wollaston&title=XVII.+On+Gouty+and+Urinary+Concentrations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWollaston%26aufirst%3DW.%2BH.%26atitle%3DXVII.%2520On%2520Gouty%2520and%2520Urinary%2520Concentrations%26jtitle%3DPhilosophical%2520Transact.%26date%3D1797%26volume%3D87%26spage%3D386%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pétrilli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardivel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span> <span> </span><span class="NLM_article-title">Gout-Associated Uric Acid Crystals Activate the NALP3 Inflammasome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>440</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1038/nature04516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature04516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=16407889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFGitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=237-241&author=F.+Martinonauthor=V.+P%C3%A9trilliauthor=A.+Mayorauthor=A.+Tardivelauthor=J.+Tschopp&title=Gout-Associated+Uric+Acid+Crystals+Activate+the+NALP3+Inflammasome&doi=10.1038%2Fnature04516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Gout-associated uric acid crystals activate the NALP3 inflammasome</span></div><div class="casAuthors">Martinon, Fabio; Petrilli, Virginie; Mayor, Annick; Tardivel, Aubry; Tschopp, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7081</span>),
    <span class="NLM_cas:pages">237-241</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Development of the acute and chronic inflammatory responses known as gout and pseudogout are assocd. with the deposition of monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, resp., in joints and periarticular tissues.  Although MSU crystals were first identified as the etiol. agent of gout in the eighteenth century and more recently as a danger signal' released from dying cells, little is known about the mol. mechanisms underlying MSU- or CPPD-induced inflammation.  Here we show that MSU and CPPD engage the caspase-1-activating NALP3 (also called cryopyrin) inflammasome, resulting in the prodn. of active interleukin (IL)-1β and IL-18.  Macrophages from mice deficient in various components of the inflammasome such as caspase-1, ASC and NALP3 are defective in crystal-induced IL-1β activation.  Moreover, an impaired neutrophil influx is found in an in vivo model of crystal-induced peritonitis in inflammasome-deficient mice or mice deficient in the IL-1β receptor (IL-1R).  These findings provide insight into the mol. processes underlying the inflammatory conditions of gout and pseudogout, and further support a pivotal role of the inflammasome in several autoinflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Z0Lgw8VSWLVg90H21EOLACvtfcHk0lhpBIvL3UwXJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFGitLg%253D&md5=e8694a6dc4096b44f07442df6feb791f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnature04516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04516%26sid%3Dliteratum%253Aachs%26aulast%3DMartinon%26aufirst%3DF.%26aulast%3DP%25C3%25A9trilli%26aufirst%3DV.%26aulast%3DMayor%26aufirst%3DA.%26aulast%3DTardivel%26aufirst%3DA.%26aulast%3DTschopp%26aufirst%3DJ.%26atitle%3DGout-Associated%2520Uric%2520Acid%2520Crystals%2520Activate%2520the%2520NALP3%2520Inflammasome%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D237%26epage%3D241%26doi%3D10.1038%2Fnature04516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molony, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova-Roche, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. D.</span></span> <span> </span><span class="NLM_article-title">β-Hydroxybutyrate Deactivates Neutrophil Inflammasome to Relieve Gout Flares</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2077</span>– <span class="NLM_lpage">2087</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.celrep.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28249154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Ontbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=2077-2087&author=E.+L.+Goldbergauthor=J.+L.+Asherauthor=R.+D.+Molonyauthor=A.+C.+Shawauthor=C.+J.+Zeissauthor=C.+Wangauthor=L.+A.+Morozova-Rocheauthor=R.+I.+Herzogauthor=A.+Iwasakiauthor=V.+D.+Dixit&title=%CE%B2-Hydroxybutyrate+Deactivates+Neutrophil+Inflammasome+to+Relieve+Gout+Flares&doi=10.1016%2Fj.celrep.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares</span></div><div class="casAuthors">Goldberg, Emily L.; Asher, Jennifer L.; Molony, Ryan D.; Shaw, Albert C.; Zeiss, Caroline J.; Wang, Chao; Morozova-Roche, Ludmilla A.; Herzog, Raimund I.; Iwasaki, Akiko; Dixit, Vishwa Deep</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2077-2087</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Aging and lipotoxicity are two major risk factors for gout that are linked by the activation of the NLRP3 inflammasome.  Neutrophil-mediated prodn. of interleukin-1β (IL-1β) drives gouty flares that cause joint destruction, intense pain, and fever.  However, metabolites that impact neutrophil inflammasome remain unknown.  Here, we identified that ketogenic diet (KD) increases β-hydroxybutyrate (BHB) and alleviates urate crystal-induced gout without impairing immune defense against bacterial infection.  BHB inhibited NLRP3 inflammasome in S100A9 fibril-primed and urate crystal-activated macrophages, which serve to recruit inflammatory neutrophils in joints.  Consistent with reduced gouty flares in rats fed a ketogenic diet, BHB blocked IL-1β in neutrophils in a NLRP3-dependent manner in mice and humans irresp. of age.  Mechanistically, BHB inhibited the NLRP3 inflammasome in neutrophils by reducing priming and assembly steps.  Collectively, our studies show that BHB, a known alternate metabolic fuel, is also an anti-inflammatory mol. that may serve as a treatment for gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlbGyx7yQ7prVg90H21EOLACvtfcHk0lhpBIvL3UwXJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Ontbc%253D&md5=8c33a7438a868a2467916feb7925fd18</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DE.%2BL.%26aulast%3DAsher%26aufirst%3DJ.%2BL.%26aulast%3DMolony%26aufirst%3DR.%2BD.%26aulast%3DShaw%26aufirst%3DA.%2BC.%26aulast%3DZeiss%26aufirst%3DC.%2BJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMorozova-Roche%26aufirst%3DL.%2BA.%26aulast%3DHerzog%26aufirst%3DR.%2BI.%26aulast%3DIwasaki%26aufirst%3DA.%26aulast%3DDixit%26aufirst%3DV.%2BD.%26atitle%3D%25CE%25B2-Hydroxybutyrate%2520Deactivates%2520Neutrophil%2520Inflammasome%2520to%2520Relieve%2520Gout%2520Flares%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D2077%26epage%3D2087%26doi%3D10.1016%2Fj.celrep.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span> <span> </span><span class="NLM_article-title">Targeting ASC in NLRP3 Inflammasome by Caffeic Acid Phenethyl Ester: a Novel Strategy to Treat Acute Gout</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">38622</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1038/srep38622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fsrep38622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28442746" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1-11&issue=38622&author=H.+E.+Leeauthor=G.+Yangauthor=N.+D.+Kimauthor=S.+Jeongauthor=Y.+Jungauthor=J.+Y.+Choiauthor=H.+H.+Parkauthor=J.+Y.+Lee&title=Targeting+ASC+in+NLRP3+Inflammasome+by+Caffeic+Acid+Phenethyl+Ester%3A+a+Novel+Strategy+to+Treat+Acute+Gout&doi=10.1038%2Fsrep38622"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fsrep38622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep38622%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BE.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DJeong%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DJ.%2BY.%26aulast%3DPark%26aufirst%3DH.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26atitle%3DTargeting%2520ASC%2520in%2520NLRP3%2520Inflammasome%2520by%2520Caffeic%2520Acid%2520Phenethyl%2520Ester%253A%2520a%2520Novel%2520Strategy%2520to%2520Treat%2520Acute%2520Gout%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D38622%26spage%3D1%26epage%3D11%26doi%3D10.1038%2Fsrep38622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartzwelter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamboni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neff, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tengesdal, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemkov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessandro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrich, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scribner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skouras, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gattorno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janciauskiene, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubartelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span> <span> </span><span class="NLM_article-title">OLT1177, a β-Sulfonyl Nitrile Compound, Safe in Humans, Inhibits the NLRP3 Inflammasome and Reverses the Metabolic Cost of Inflammation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1073/pnas.1716095115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1073%2Fpnas.1716095115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWjtbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=1530-1539&issue=7&author=C.+Marchettiauthor=B.+Swartzwelterauthor=F.+Gamboniauthor=C.+P.+Neffauthor=K.+Richterauthor=T.+Azamauthor=S.+Cartaauthor=I.+W.+Tengesdalauthor=T.+Nemkovauthor=A.+D%E2%80%99Alessandroauthor=C.+Henryauthor=G.+S.+Jonesauthor=S.+A.+Goodrichauthor=J.+P.+St.+Laurentauthor=T.+M.+Jonesauthor=C.+L.+Scribnerauthor=R.+B.+Barrowauthor=R.+D.+Altmanauthor=D.+B.+Skourasauthor=M.+Gattornoauthor=V.+Grauauthor=S.+Janciauskieneauthor=A.+Rubartelliauthor=L.+A.+B.+Joostenauthor=C.+A.+Dinarello&title=OLT1177%2C+a+%CE%B2-Sulfonyl+Nitrile+Compound%2C+Safe+in+Humans%2C+Inhibits+the+NLRP3+Inflammasome+and+Reverses+the+Metabolic+Cost+of+Inflammation&doi=10.1073%2Fpnas.1716095115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation</span></div><div class="casAuthors">Marchetti, Carlo; Swartzwelter, Benjamin; Gamboni, Fabia; Neff, Charles P.; Richter, Katrin; Azam, Tania; Carta, Sonia; Tengesdal, Isak; Nemkov, Travis; DaAlessandro, Angelo; Henry, Curtis; Jones, Gerald S.; Goodrich, Scott A.; St. Laurent, Joseph P.; Jones, Terry M.; Scribner, Curtis L.; Barrow, Robert B.; Altman, Roy D.; Skouras, Damaris B.; Gattorno, Marco; Grau, Veronika; Janciauskiene, Sabina; Rubartelli, Anna; Joosten, Leo A. B.; Dinarello, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">E1530-E1539</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the NLRP3 inflammasome induces maturation of IL-1β and IL-18, both validated targets for treating acute and chronic inflammatory diseases.  Here, we demonstrate that OLT1177, an orally active β-sulfonyl nitrile mol., inhibits activation of the NLRP3 inflammasome.  In vitro, nanomolar concns. of OLT1177 reduced IL-1β and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation.  The mol. showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3.  In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1β levels by 60% and IL-18 by 70% at concns. 100-fold lower in vitro than plasma concns. safely reached in humans.  OLT1177 also reduced IL-1β release and caspase-1 activity in freshly obtained human blood neutrophils.  In monocytes isolated from patients with cryopyrin-assocd. periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1β release by 84% and 36%.  Immunopptn. and FRET anal. demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization.  In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3.  Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1β precursor.  Steady-state levels of phosphorylated NF-κB and IkB kinase were significantly lowered in spleen cells from OLT1177-treated mice.  We obsd. reduced IL-1β content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metab. in OLT1177-treated mice challenged with LPS.  Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochem. or hematol. changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokLYw_bXy_NLVg90H21EOLACvtfcHk0lhmrcMkXT24DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWjtbnO&md5=4c1c33730980ddd2cad26195f05efa08</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1716095115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1716095115%26sid%3Dliteratum%253Aachs%26aulast%3DMarchetti%26aufirst%3DC.%26aulast%3DSwartzwelter%26aufirst%3DB.%26aulast%3DGamboni%26aufirst%3DF.%26aulast%3DNeff%26aufirst%3DC.%2BP.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DAzam%26aufirst%3DT.%26aulast%3DCarta%26aufirst%3DS.%26aulast%3DTengesdal%26aufirst%3DI.%2BW.%26aulast%3DNemkov%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Alessandro%26aufirst%3DA.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DG.%2BS.%26aulast%3DGoodrich%26aufirst%3DS.%2BA.%26aulast%3DSt.%2BLaurent%26aufirst%3DJ.%2BP.%26aulast%3DJones%26aufirst%3DT.%2BM.%26aulast%3DScribner%26aufirst%3DC.%2BL.%26aulast%3DBarrow%26aufirst%3DR.%2BB.%26aulast%3DAltman%26aufirst%3DR.%2BD.%26aulast%3DSkouras%26aufirst%3DD.%2BB.%26aulast%3DGattorno%26aufirst%3DM.%26aulast%3DGrau%26aufirst%3DV.%26aulast%3DJanciauskiene%26aufirst%3DS.%26aulast%3DRubartelli%26aufirst%3DA.%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26atitle%3DOLT1177%252C%2520a%2520%25CE%25B2-Sulfonyl%2520Nitrile%2520Compound%252C%2520Safe%2520in%2520Humans%252C%2520Inhibits%2520the%2520NLRP3%2520Inflammasome%2520and%2520Reverses%2520the%2520Metabolic%2520Cost%2520of%2520Inflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D7%26spage%3D1530%26epage%3D1539%26doi%3D10.1073%2Fpnas.1716095115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartzwelter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenders, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tengesdal, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. B.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Inhibitor OLT1177 Suppresses Joint Inflammation in Murine Models of Acute Athritis</span>. <i>Arthritis Research & Therapy</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">169</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1186/s13075-018-1664-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1186%2Fs13075-018-1664-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29329602" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1-11&issue=169&author=C.+Marchettiauthor=B.+Swartzwelterauthor=M.+I.+Koendersauthor=T.+Azamauthor=I.+W.+Tengesdalauthor=N.+Powersauthor=D.+M.+de+Graafauthor=C.+A.+Dinarelloauthor=L.+A.+B.+Joosten&title=NLRP3+Inflammasome+Inhibitor+OLT1177+Suppresses+Joint+Inflammation+in+Murine+Models+of+Acute+Athritis&doi=10.1186%2Fs13075-018-1664-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs13075-018-1664-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-018-1664-2%26sid%3Dliteratum%253Aachs%26aulast%3DMarchetti%26aufirst%3DC.%26aulast%3DSwartzwelter%26aufirst%3DB.%26aulast%3DKoenders%26aufirst%3DM.%2BI.%26aulast%3DAzam%26aufirst%3DT.%26aulast%3DTengesdal%26aufirst%3DI.%2BW.%26aulast%3DPowers%26aufirst%3DN.%26aulast%3Dde%2BGraaf%26aufirst%3DD.%2BM.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26atitle%3DNLRP3%2520Inflammasome%2520Inhibitor%2520OLT1177%2520Suppresses%2520Joint%2520Inflammation%2520in%2520Murine%2520Models%2520of%2520Acute%2520Athritis%26jtitle%3DArthritis%2520Research%2520%2526%2520Therapy%26date%3D2018%26volume%3D20%26issue%3D169%26spage%3D1%26epage%3D11%26doi%3D10.1186%2Fs13075-018-1664-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albornoz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantovani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanthasamy, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, T. M.</span></span> <span> </span><span class="NLM_article-title">Inflammasome Inhibition Prevents α-Synuclein Pathology and Dopaminergic Neurodegeneration in Mice</span>. <i>Science Translational Medicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aah4066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fscitranslmed.aah4066" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1-12&author=R.+Gordonauthor=E.+A.+Albornozauthor=D.+C.+Christieauthor=M.+R.+Langleyauthor=V.+Kumarauthor=S.+Mantovaniauthor=A.+A.+B.+Robertsonauthor=M.+S.+Butlerauthor=D.+B.+Roweauthor=L.+A.+O%E2%80%99Neillauthor=A.+G.+Kanthasamyauthor=K.+Schroderauthor=M.+A.+Cooperauthor=T.+M.+Woodruff&title=Inflammasome+Inhibition+Prevents+%CE%B1-Synuclein+Pathology+and+Dopaminergic+Neurodegeneration+in+Mice&doi=10.1126%2Fscitranslmed.aah4066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aah4066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aah4066%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DAlbornoz%26aufirst%3DE.%2BA.%26aulast%3DChristie%26aufirst%3DD.%2BC.%26aulast%3DLangley%26aufirst%3DM.%2BR.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMantovani%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DButler%26aufirst%3DM.%2BS.%26aulast%3DRowe%26aufirst%3DD.%2BB.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.%26aulast%3DKanthasamy%26aufirst%3DA.%2BG.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DWoodruff%26aufirst%3DT.%2BM.%26atitle%3DInflammasome%2520Inhibition%2520Prevents%2520%25CE%25B1-Synuclein%2520Pathology%2520and%2520Dopaminergic%2520Neurodegeneration%2520in%2520Mice%26jtitle%3DScience%2520Translational%2520Medicine%26date%3D2018%26volume%3D10%26spage%3D1%26epage%3D12%26doi%3D10.1126%2Fscitranslmed.aah4066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delekate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-Saecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griep, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzeng, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelpi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D. T.</span></span> <span> </span><span class="NLM_article-title">NLRP3 is Activated in Alzheimer’s Disease and Contributes to Pathology in APP/PSA1Mice</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>493</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1038/nature11729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature11729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23254930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvV2ntLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=493&publication_year=2013&pages=674-678&author=M.+T.+Henekaauthor=M.+P.+Kummerauthor=A.+Stutzauthor=A.+Delekateauthor=S.+Schwartzauthor=A.+Vieira-Saeckerauthor=A.+Griepauthor=D.+Axtauthor=A.+Remusauthor=T.-C.+Tzengauthor=E.+Gelpiauthor=A.+Halleauthor=M.+Korteauthor=E.+Latzauthor=D.+T.+Golenbock&title=NLRP3+is+Activated+in+Alzheimer%E2%80%99s+Disease+and+Contributes+to+Pathology+in+APP%2FPSA1Mice&doi=10.1038%2Fnature11729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice</span></div><div class="casAuthors">Heneka, Michael T.; Kummer, Markus P.; Stutz, Andrea; Delekate, Andrea; Schwartz, Stephanie; Vieira-Saecker, Ana; Griep, Angelika; Axt, Daisy; Remus, Anita; Tzeng, Te-Chen; Gelpi, Ellen; Halle, Annett; Korte, Martin; Latz, Eicke; Golenbock, Douglas T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">493</span>
        (<span class="NLM_cas:issue">7434</span>),
    <span class="NLM_cas:pages">674-678</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alzheimer's disease is the world's most common dementing illness.  Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia.  Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events.  However, it remains unknown whether NLRP3 activation contributes to Alzheimer's disease in vivo.  Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer's disease, suggesting a role for the inflammasome in this neurodegenerative disease.  Nlrp3-/- or Casp1-/- mice carrying mutations assocd. with familial Alzheimer's disease were largely protected from loss of spatial memory and other sequelae assocd. with Alzheimer's disease, and demonstrated reduced brain caspase-1 and interleukin-1β activation as well as enhanced amyloid-β clearance.  Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-β in the APP/PS1 model of Alzheimer's disease.  These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer's disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc1Oe8w8wxWbVg90H21EOLACvtfcHk0lhE_LDmUknAlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvV2ntLfM&md5=382d9c04caad9c6d3e2431bf611bf9ff</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature11729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11729%26sid%3Dliteratum%253Aachs%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26aulast%3DKummer%26aufirst%3DM.%2BP.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DDelekate%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DVieira-Saecker%26aufirst%3DA.%26aulast%3DGriep%26aufirst%3DA.%26aulast%3DAxt%26aufirst%3DD.%26aulast%3DRemus%26aufirst%3DA.%26aulast%3DTzeng%26aufirst%3DT.-C.%26aulast%3DGelpi%26aufirst%3DE.%26aulast%3DHalle%26aufirst%3DA.%26aulast%3DKorte%26aufirst%3DM.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DGolenbock%26aufirst%3DD.%2BT.%26atitle%3DNLRP3%2520is%2520Activated%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520and%2520Contributes%2520to%2520Pathology%2520in%2520APP%252FPSA1Mice%26jtitle%3DNature%26date%3D2013%26volume%3D493%26spage%3D674%26epage%3D678%26doi%3D10.1038%2Fnature11729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ising, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venegas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira-Saecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albasset, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griep, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosseron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stunden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Activation Drives Tau Pathology</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>575</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1769-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41586-019-1769-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31748742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2qt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=575&publication_year=2019&pages=669-673&author=C.+Isingauthor=C.+Venegasauthor=S.+Zhangauthor=H.+Scheiblichauthor=S.+V.+Schmidtauthor=A.+Vieira-Saeckerauthor=S.+Schwartzauthor=S.+Albassetauthor=R.+M.+McManusauthor=D.+Tejeraauthor=A.+Griepauthor=F.+Santarelliauthor=F.+Brosseronauthor=S.+Opitzauthor=J.+Stundenauthor=M.+Mertenauthor=R.+Kayedauthor=D.+T.+Golenbockauthor=D.+Blumauthor=E.+Latzauthor=L.+Bueeauthor=M.+T.+Heneka&title=NLRP3+Inflammasome+Activation+Drives+Tau+Pathology&doi=10.1038%2Fs41586-019-1769-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome activation drives tau pathology</span></div><div class="casAuthors">Ising, Christina; Venegas, Carmen; Zhang, Shuangshuang; Scheiblich, Hannah; Schmidt, Susanne V.; Vieira-Saecker, Ana; Schwartz, Stephanie; Albasset, Shadi; McManus, Roisin M.; Tejera, Dario; Griep, Angelika; Santarelli, Francesco; Brosseron, Frederic; Opitz, Sabine; Stunden, James; Merten, Maximilian; Kayed, Rakez; Golenbock, Douglas T.; Blum, David; Latz, Eicke; Buee, Luc; Heneka, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">575</span>
        (<span class="NLM_cas:issue">7784</span>),
    <span class="NLM_cas:pages">669-673</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1.  The inflammasome inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2.  Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathol. in mice3, the precise effect on tau pathol. remains unknown.  Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases.  Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-contg. brain homogenates induced tau pathol. in an NLRP3-dependent manner.  These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer's disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCaPXz72o9VrVg90H21EOLACvtfcHk0ljk3eEVmqOjmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2qt7nE&md5=efd69ac9ce47699e362679c7c39265cc</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1769-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1769-z%26sid%3Dliteratum%253Aachs%26aulast%3DIsing%26aufirst%3DC.%26aulast%3DVenegas%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DScheiblich%26aufirst%3DH.%26aulast%3DSchmidt%26aufirst%3DS.%2BV.%26aulast%3DVieira-Saecker%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DAlbasset%26aufirst%3DS.%26aulast%3DMcManus%26aufirst%3DR.%2BM.%26aulast%3DTejera%26aufirst%3DD.%26aulast%3DGriep%26aufirst%3DA.%26aulast%3DSantarelli%26aufirst%3DF.%26aulast%3DBrosseron%26aufirst%3DF.%26aulast%3DOpitz%26aufirst%3DS.%26aulast%3DStunden%26aufirst%3DJ.%26aulast%3DMerten%26aufirst%3DM.%26aulast%3DKayed%26aufirst%3DR.%26aulast%3DGolenbock%26aufirst%3DD.%2BT.%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DBuee%26aufirst%3DL.%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26atitle%3DNLRP3%2520Inflammasome%2520Activation%2520Drives%2520Tau%2520Pathology%26jtitle%3DNature%26date%3D2019%26volume%3D575%26spage%3D669%26epage%3D673%26doi%3D10.1038%2Fs41586-019-1769-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowery, D.</span></span> <span> </span><span class="NLM_article-title">The Patent Landscape of Inflammasome Modulators</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">158</span>),  <span class="NLM_fpage">1474</span>– <span class="NLM_lpage">1784</span>, <span class="refDoi"> DOI: 10.1038/d41573-019-00200-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fd41573-019-00200-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=1474-1784&issue=158&author=B.+Leungauthor=D.+Lowery&title=The+Patent+Landscape+of+Inflammasome+Modulators&doi=10.1038%2Fd41573-019-00200-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fd41573-019-00200-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-019-00200-x%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DB.%26aulast%3DLowery%26aufirst%3DD.%26atitle%3DThe%2520Patent%2520Landscape%2520of%2520Inflammasome%2520Modulators%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26issue%3D158%26spage%3D1474%26epage%3D1784%26doi%3D10.1038%2Fd41573-019-00200-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluck, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comarniceanu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efdé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scribner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skouras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L.</span></span> <span> </span><span class="NLM_article-title">The First Phase 2A Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile (OLT1177), in Acute Gout</span>. <i>Annals of the Rheumatic Diseases</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2018-EWRR2019.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1136%2Fannrheumdis-2018-EWRR2019.142" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=70-71&author=T.+Jansenauthor=V.+Kluckauthor=M.+Janssenauthor=A.+Comarniceanuauthor=M.+Efd%C3%A9author=C.+Scribnerauthor=D.+Skourasauthor=C.+A.+Dinarelloauthor=L.+Joosten&title=The+First+Phase+2A+Proof-of-Concept+Study+of+a+Selective+NLRP3+Inflammasome+Inhibitor%2C+Dapansutrile+%28OLT1177%29%2C+in+Acute+Gout&doi=10.1136%2Fannrheumdis-2018-EWRR2019.142"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2018-EWRR2019.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2018-EWRR2019.142%26sid%3Dliteratum%253Aachs%26aulast%3DJansen%26aufirst%3DT.%26aulast%3DKluck%26aufirst%3DV.%26aulast%3DJanssen%26aufirst%3DM.%26aulast%3DComarniceanu%26aufirst%3DA.%26aulast%3DEfd%25C3%25A9%26aufirst%3DM.%26aulast%3DScribner%26aufirst%3DC.%26aulast%3DSkouras%26aufirst%3DD.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DJoosten%26aufirst%3DL.%26atitle%3DThe%2520First%2520Phase%25202A%2520Proof-of-Concept%2520Study%2520of%2520a%2520Selective%2520NLRP3%2520Inflammasome%2520Inhibitor%252C%2520Dapansutrile%2520%2528OLT1177%2529%252C%2520in%2520Acute%2520Gout%26jtitle%3DAnnals%2520of%2520the%2520Rheumatic%2520Diseases%26date%3D2019%26volume%3D78%26spage%3D70%26epage%3D71%26doi%3D10.1136%2Fannrheumdis-2018-EWRR2019.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klück, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, T. L. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comarniceanu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efdé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tengesdal, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schraa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleophas, M. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scribner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skouras, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosten, L. A. b.</span></span> <span> </span><span class="NLM_article-title">Dapansutrile, an Oral Selective NLRP3 Inflammasome Inhibitor, for Treatment of Gout Flares: An Open-Label, Dose-Adaptive, Proof-of-Concept, Phase 2a Trial</span>. <i>Lancet Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e270</span>– <span class="NLM_lpage">e280</span>, <span class="refDoi"> DOI: 10.1016/s2665-9913(20)30065-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930065-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=33005902" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=e270-e280&issue=5&author=V.+Kl%C3%BCckauthor=T.+L.+T.+A.+Jansenauthor=M.+Janssenauthor=A.+Comarniceanuauthor=M.+Efd%C3%A9author=I.+W.+Tengesdalauthor=K.+Schraaauthor=M.+C.+P.+Cleophasauthor=C.+L.+Scribnerauthor=D.+B.+Skourasauthor=C.+Marchettiauthor=C.+A.+Dinarelloauthor=L.+A.+b.+Joosten&title=Dapansutrile%2C+an+Oral+Selective+NLRP3+Inflammasome+Inhibitor%2C+for+Treatment+of+Gout+Flares%3A+An+Open-Label%2C+Dose-Adaptive%2C+Proof-of-Concept%2C+Phase+2a+Trial&doi=10.1016%2Fs2665-9913%2820%2930065-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930065-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930065-5%26sid%3Dliteratum%253Aachs%26aulast%3DKl%25C3%25BCck%26aufirst%3DV.%26aulast%3DJansen%26aufirst%3DT.%2BL.%2BT.%2BA.%26aulast%3DJanssen%26aufirst%3DM.%26aulast%3DComarniceanu%26aufirst%3DA.%26aulast%3DEfd%25C3%25A9%26aufirst%3DM.%26aulast%3DTengesdal%26aufirst%3DI.%2BW.%26aulast%3DSchraa%26aufirst%3DK.%26aulast%3DCleophas%26aufirst%3DM.%2BC.%2BP.%26aulast%3DScribner%26aufirst%3DC.%2BL.%26aulast%3DSkouras%26aufirst%3DD.%2BB.%26aulast%3DMarchetti%26aufirst%3DC.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2Bb.%26atitle%3DDapansutrile%252C%2520an%2520Oral%2520Selective%2520NLRP3%2520Inflammasome%2520Inhibitor%252C%2520for%2520Treatment%2520of%2520Gout%2520Flares%253A%2520An%2520Open-Label%252C%2520Dose-Adaptive%252C%2520Proof-of-Concept%252C%2520Phase%25202a%2520Trial%26jtitle%3DLancet%2520Rheumatol.%26date%3D2020%26volume%3D2%26issue%3D5%26spage%3De270%26epage%3De280%26doi%3D10.1016%2Fs2665-9913%2820%2930065-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misaghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izrael-Tomasevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmour, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamkanfi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kömüves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupp, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, V. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of NLRC4 is Critical for Inflammasome Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>490</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1038/nature11429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature11429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=22885697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOgtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2012&pages=539-542&author=Y.+Quauthor=S.+Misaghiauthor=A.+Izrael-Tomasevicauthor=K.+Newtonauthor=L.+L.+Gilmourauthor=M.+Lamkanfiauthor=S.+Louieauthor=N.+Kayagakiauthor=J.+Liuauthor=L.+K%C3%B6m%C3%BCvesauthor=J.+E.+Cuppauthor=D.+Arnottauthor=D.+Monackauthor=V.+M.+Dixit&title=Phosphorylation+of+NLRC4+is+Critical+for+Inflammasome+Activation&doi=10.1038%2Fnature11429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of NLRC4 is critical for inflammasome activation</span></div><div class="casAuthors">Qu, Yan; Misaghi, Shahram; Izrael-Tomasevic, Anita; Newton, Kim; Gilmour, Laurie L.; Lamkanfi, Mohamed; Louie, Salina; Kayagaki, Nobuhiko; Liu, Jinfeng; Koemueves, Laszlo; Cupp, James E.; Arnott, David; Monack, Denise; Dixit, Vishva M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">490</span>
        (<span class="NLM_cas:issue">7421</span>),
    <span class="NLM_cas:pages">539-542</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">NLRC4 is a cytosolic member of the NOD-like receptor family that is expressed in innate immune cells.  It senses indirectly bacterial flagellin and type III secretion systems, and responds by assembling an inflammasome complex that promotes caspase-1 activation and pyroptosis.  Here we use knock-in mice expressing NLRC4 with a carboxy-terminal 3×Flag tag to identify phosphorylation of NLRC4 on a single, evolutionarily conserved residue, Ser 533, following infection of macrophages with Salmonella enterica serovar Typhimurium (also known as Salmonella typhimurium).  Western blotting with a NLRC4 phospho-Ser 533 antibody confirmed that this post-translational modification occurs only in the presence of stimuli known to engage NLRC4 and not the related protein NLRP3 or AIM2.  Nlrc4-/- macrophages reconstituted with NLRC4 mutant S533A, unlike those reconstituted with wild-type NLRC4, did not activate caspase-1 and pyroptosis in response to S. typhimurium, indicating that S533 phosphorylation is crit. for NLRC4 inflammasome function.  Conversely, phosphomimetic NLRC4 S533D caused rapid macrophage pyroptosis without infection.  Biochem. purifn. of the NLRC4-phosphorylating activity and a screen of kinase inhibitors identified PRKCD (PKCδ) as a candidate NLRC4 kinase.  Recombinant PKCδ phosphorylated NLRC4 S533 in vitro, immunodepletion of PKCδ from macrophage lysates blocked NLRC4 S533 phosphorylation in vitro, and Prkcd-/- macrophages exhibited greatly attenuated caspase-1 activation and IL-1β secretion specifically in response to S. typhimurium.  Phosphorylation-defective NLRC4 S533A failed to recruit procaspase-1 and did not assemble inflammasome specks during S. typhimurium infection, so phosphorylation of NLRC4 S533 probably drives conformational changes necessary for NLRC4 inflammasome activity and host innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ9Hz_VCJo1LVg90H21EOLACvtfcHk0lhsJb2UR5zg1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOgtrzE&md5=5355b7dfc7fae0c367f8383dfe0cea96</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnature11429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11429%26sid%3Dliteratum%253Aachs%26aulast%3DQu%26aufirst%3DY.%26aulast%3DMisaghi%26aufirst%3DS.%26aulast%3DIzrael-Tomasevic%26aufirst%3DA.%26aulast%3DNewton%26aufirst%3DK.%26aulast%3DGilmour%26aufirst%3DL.%2BL.%26aulast%3DLamkanfi%26aufirst%3DM.%26aulast%3DLouie%26aufirst%3DS.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DK%25C3%25B6m%25C3%25BCves%26aufirst%3DL.%26aulast%3DCupp%26aufirst%3DJ.%2BE.%26aulast%3DArnott%26aufirst%3DD.%26aulast%3DMonack%26aufirst%3DD.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26atitle%3DPhosphorylation%2520of%2520NLRC4%2520is%2520Critical%2520for%2520Inflammasome%2520Activation%26jtitle%3DNature%26date%3D2012%26volume%3D490%26spage%3D539%26epage%3D542%26doi%3D10.1038%2Fnature11429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramlett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimshaw, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matuszkiewicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natala, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalevsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of TAK-659 and Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5947</span>– <span class="NLM_lpage">5950</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.bmcl.2016.10.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27839918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5947-5950&issue=24&author=B.+Lamauthor=Y.+Arikawaauthor=J.+Cramlettauthor=Q.+Dongauthor=R.+de+Jongauthor=V.+Feherauthor=C.+E.+Grimshawauthor=P.+J.+Farrellauthor=I.+D.+Hoffmanauthor=A.+Jenningsauthor=B.+Jonesauthor=J.+Matuszkiewiczauthor=J.+Miuraauthor=H.+Miyakeauthor=S.+R.+Natalaauthor=L.+Shiauthor=M.+Takahashiauthor=E.+Taylorauthor=C.+Wyrickauthor=J.+Yanoauthor=J.+Zalevskyauthor=Z.+Nie&title=Discovery+of+TAK-659+and+Orally+Available+Investigational+Inhibitor+of+Spleen+Tyrosine+Kinase+%28SYK%29&doi=10.1016%2Fj.bmcl.2016.10.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)</span></div><div class="casAuthors">Lam, Betty; Arikawa, Yasuyoshi; Cramlett, Joshua; Dong, Qing; de Jong, Ron; Feher, Victoria; Grimshaw, Charles E.; Farrell, Pamela J.; Hoffman, Isaac D.; Jennings, Andy; Jones, Benjamin; Matuszkiewicz, Jennifer; Miura, Joanne; Miyake, Hiroshi; Natala, Srinivasa Reddy; Shi, Lihong; Takahashi, Masashi; Taylor, Ewan; Wyrick, Corey; Yano, Jason; Zalevsky, Jonathan; Nie, Zhe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5947-5950</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spleen Tyrosine Kinase (SYK) is a non-receptor cytoplasmic tyrosine kinase that is primarily expressed in hematopoietic cells.  SYK is a key mediator for a variety of inflammatory cells, including B cells, mast cells, macrophages and neutrophils and therefore, an attractive approach for treatment of both inflammatory diseases and oncol. indications.  Using in house co-crystal structure information, and structure-based drug design, we designed and optimized a novel series of heteroarom. pyrrolidinone SYK inhibitors resulting in the selection of the development candidate TAK-659.  TAK-659 is currently undergoing Phase I clin. trials for advanced solid tumor and lymphoma malignancies, a Phase Ib study in advanced solid tumors in combination with nivolumab, and PhIb/II trials for relapsed/refractory AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMSKPjg5MH7Vg90H21EOLACvtfcHk0lgR-PIvgkWnjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3K&md5=baca5103b2feed622ae7381c90ce8f4c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.087%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DB.%26aulast%3DArikawa%26aufirst%3DY.%26aulast%3DCramlett%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3Dde%2BJong%26aufirst%3DR.%26aulast%3DFeher%26aufirst%3DV.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DFarrell%26aufirst%3DP.%2BJ.%26aulast%3DHoffman%26aufirst%3DI.%2BD.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DMatuszkiewicz%26aufirst%3DJ.%26aulast%3DMiura%26aufirst%3DJ.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DNatala%26aufirst%3DS.%2BR.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DWyrick%26aufirst%3DC.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DZalevsky%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520TAK-659%2520and%2520Orally%2520Available%2520Investigational%2520Inhibitor%2520of%2520Spleen%2520Tyrosine%2520Kinase%2520%2528SYK%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D24%26spage%3D5947%26epage%3D5950%26doi%3D10.1016%2Fj.bmcl.2016.10.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-362962,
A Phase
1, Double-Blind Placebo-Controlled Single Multiple Ascending Dose
Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
and Food Effects or IFM-2427 in Healthy Subjects.</i> <a href="https://citeline.informa.com/trials/details/362962?qId=6c9b6f61-bad0-48e6-9c80-d93c3eaa3a2e" class="extLink">https://citeline.informa.com/trials/details/362962?qId=6c9b6f61-bad0-48e6-9c80-d93c3eaa3a2e</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-362962%2C%0AA+Phase%0A1%2C+Double-Blind+Placebo-Controlled+Single+Multiple+Ascending+Dose%0AStudy+of+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+Pharmacodynamics%0Aand+Food+Effects+or+IFM-2427+in+Healthy+Subjects.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F362962%3FqId%3D6c9b6f61-bad0-48e6-9c80-d93c3eaa3a2e+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-362962%252C%250AA%2520Phase%250A1%252C%2520Double-Blind%2520Placebo-Controlled%2520Single%2520Multiple%2520Ascending%2520Dose%250AStudy%2520of%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520Pharmacodynamics%250Aand%2520Food%2520Effects%2520or%2520IFM-2427%2520in%2520Healthy%2520Subjects.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G.</span>; <span class="NLM_string-name">Gosh, S.</span>; <span class="NLM_string-name">Roush, W. R.</span>; <span class="NLM_string-name">Shen, D.-M.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions for Treating Conditions Associated with NLRP Activity</span>. WO <span class="NLM_patent">2019/023147</span>, Jan 31, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=G.+Glick&author=S.+Gosh&author=W.+R.+Roush&author=D.-M.+Shen&title=Compounds+and+Compositions+for+Treating+Conditions+Associated+with+NLRP+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGlick%26aufirst%3DG.%26atitle%3DCompounds%2520and%2520Compositions%2520for%2520Treating%2520Conditions%2520Associated%2520with%2520NLRP%2520Activity%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-368867, A Phase
II Proof of Concept Study of Somalix to Address Clinical Unmet Needs
in Inflammatory Conditions Such as Arthritis and Cardiovascular Disease.</i> <a href="https://citeline.informa.com/trials/details/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13" class="extLink">https://citeline.informa.com/trials/details/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-368867%2C+A+Phase%0AII+Proof+of+Concept+Study+of+Somalix+to+Address+Clinical+Unmet+Needs%0Ain+Inflammatory+Conditions+Such+as+Arthritis+and+Cardiovascular+Disease.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F357081%3FqId%3Dbdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13+%28accessed+Apr+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-368867%252C%2520A%2520Phase%250AII%2520Proof%2520of%2520Concept%2520Study%2520of%2520Somalix%2520to%2520Address%2520Clinical%2520Unmet%2520Needs%250Ain%2520Inflammatory%2520Conditions%2520Such%2520as%2520Arthritis%2520and%2520Cardiovascular%2520Disease.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-360928, The Multiple
Proof of Concept Studies of Phase II Inzomelid in Patients with Parkinson’s
Disease.</i> <a href="https://citeline.informa.com/trials/details/360928?qId=79b241fb-63ac-4d15-a542-d6b6849d357c" class="extLink">https://citeline.informa.com/trials/details/360928?qId=79b241fb-63ac-4d15-a542-d6b6849d357c</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-360928%2C+The+Multiple%0AProof+of+Concept+Studies+of+Phase+II+Inzomelid+in+Patients+with+Parkinson%E2%80%99s%0ADisease.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F360928%3FqId%3D79b241fb-63ac-4d15-a542-d6b6849d357c+%28accessed+Apr+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-360928%252C%2520The%2520Multiple%250AProof%2520of%2520Concept%2520Studies%2520of%2520Phase%2520II%2520Inzomelid%2520in%2520Patients%2520with%2520Parkinson%25E2%2580%2599s%250ADisease.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-357081, A Phase
1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple
Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Food Effect of IZD334 in Healthy Adult Participants
as Well as an Open-Label Cohort to Confirm the Safety, Pharmacokinetics,
and Pharmacodynamics in Adult Patients With Cryopyrin-Associated Periodic
Syndromes.</i> <a href="https://citeline.informa.com/trials/details/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13" class="extLink">https://citeline.informa.com/trials/details/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-357081%2C+A+Phase%0A1%2C+Randomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Single+and+Multiple%0AAscending+Dose+Study+to+Determine+the+Safety%2C+Tolerability%2C+Pharmacokinetics%2C%0APharmacodynamics+and+Food+Effect+of+IZD334+in+Healthy+Adult+Participants%0Aas+Well+as+an+Open-Label+Cohort+to+Confirm+the+Safety%2C+Pharmacokinetics%2C%0Aand+Pharmacodynamics+in+Adult+Patients+With+Cryopyrin-Associated+Periodic%0ASyndromes.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F357081%3FqId%3Dbdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13+%28accessed+Apr+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-357081%252C%2520A%2520Phase%250A1%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Single%2520and%2520Multiple%250AAscending%2520Dose%2520Study%2520to%2520Determine%2520the%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%250APharmacodynamics%2520and%2520Food%2520Effect%2520of%2520IZD334%2520in%2520Healthy%2520Adult%2520Participants%250Aas%2520Well%2520as%2520an%2520Open-Label%2520Cohort%2520to%2520Confirm%2520the%2520Safety%252C%2520Pharmacokinetics%252C%250Aand%2520Pharmacodynamics%2520in%2520Adult%2520Patients%2520With%2520Cryopyrin-Associated%2520Periodic%250ASyndromes.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-353058, A Phase
1, Randomized, Double-Blind, Placebo Controlled, Single and Multiple
Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Food Effect of Inzomelid in Healthy Adult Participants
as Well as an Open Label Cohort to Confirm the Safety, Pharmacokinetics,
and Pharmacodynamics of Inzomelid in Adult Patients with Cryopyrin-Associated
Periodic Syndromes.</i> <a href="https://citeline.informa.com/trials/details/353058?qId=9029e7c5-e0d5-449a-851a-d762b6047856" class="extLink">https://citeline.informa.com/trials/details/353058?qId=9029e7c5-e0d5-449a-851a-d762b6047856</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-353058%2C+A+Phase%0A1%2C+Randomized%2C+Double-Blind%2C+Placebo+Controlled%2C+Single+and+Multiple%0AAscending+Dose+Study+to+Determine+the+Safety%2C+Tolerability%2C+Pharmacokinetics%2C%0APharmacodynamics+and+Food+Effect+of+Inzomelid+in+Healthy+Adult+Participants%0Aas+Well+as+an+Open+Label+Cohort+to+Confirm+the+Safety%2C+Pharmacokinetics%2C%0Aand+Pharmacodynamics+of+Inzomelid+in+Adult+Patients+with+Cryopyrin-Associated%0APeriodic+Syndromes.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F353058%3FqId%3D9029e7c5-e0d5-449a-851a-d762b6047856+%28accessed+Apr+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-353058%252C%2520A%2520Phase%250A1%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo%2520Controlled%252C%2520Single%2520and%2520Multiple%250AAscending%2520Dose%2520Study%2520to%2520Determine%2520the%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%250APharmacodynamics%2520and%2520Food%2520Effect%2520of%2520Inzomelid%2520in%2520Healthy%2520Adult%2520Participants%250Aas%2520Well%2520as%2520an%2520Open%2520Label%2520Cohort%2520to%2520Confirm%2520the%2520Safety%252C%2520Pharmacokinetics%252C%250Aand%2520Pharmacodynamics%2520of%2520Inzomelid%2520in%2520Adult%2520Patients%2520with%2520Cryopyrin-Associated%250APeriodic%2520Syndromes.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Inflazome</span>. <span> </span><span class="NLM_article-title">The Pipeline</span>. <a href="https://www.inflazome.com/pipeline" class="extLink">https://www.inflazome.com/pipeline</a> (accessed Apr 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Inflazome&title=The+Pipeline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520Pipeline%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L.</span>; <span class="NLM_string-name">Coll, R.</span>; <span class="NLM_string-name">Cooper, M.</span>; <span class="NLM_string-name">Robertson, A.</span>; <span class="NLM_string-name">Schroder, K.</span></span> <span> </span><span class="NLM_article-title">Sulfonylureas and Related Compounds and Use of Same</span>. WO <span class="NLM_patent">2016/131098</span>, Jan 21, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+O%E2%80%99Neill&author=R.+Coll&author=M.+Cooper&author=A.+Robertson&author=K.+Schroder&title=Sulfonylureas+and+Related+Compounds+and+Use+of+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%26atitle%3DSulfonylureas%2520and%2520Related%2520Compounds%2520and%2520Use%2520of%2520Same%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M.</span>; <span class="NLM_string-name">Miller, D.</span>; <span class="NLM_string-name">Macleod, A.</span>; <span class="NLM_string-name">Van Wiltenburg, J.</span>; <span class="NLM_string-name">Thom, S.</span>; <span class="NLM_string-name">St. Gallay, S.</span>; <span class="NLM_string-name">Shannon, J.</span>; <span class="NLM_string-name">Alanine, T.</span></span> <span> </span><span class="NLM_article-title">Novel Sulfonamide Carboxamide Compounds</span>. WO <span class="NLM_patent">2019/008025</span>, Jan 10, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Cooper&author=D.+Miller&author=A.+Macleod&author=J.+Van+Wiltenburg&author=S.+Thom&author=S.+St.+Gallay&author=J.+Shannon&author=T.+Alanine&title=Novel+Sulfonamide+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%26atitle%3DNovel%2520Sulfonamide%2520Carboxamide%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span>; <span class="NLM_string-name">Macleod, A.</span>; <span class="NLM_string-name">Van Wiltenburg, J.</span>; <span class="NLM_string-name">Thom, S.</span>; <span class="NLM_string-name">Shannon, J.</span></span> <span> </span><span class="NLM_article-title">Novel Sulfonamide Carboxamide Compounds</span>. WO <span class="NLM_patent">2019/034697</span>, Feb 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Miller&author=A.+Macleod&author=J.+Van+Wiltenburg&author=S.+Thom&author=J.+Shannon&title=Novel+Sulfonamide+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DD.%26atitle%3DNovel%2520Sulfonamide%2520Carboxamide%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M.</span>; <span class="NLM_string-name">Miller, D.</span>; <span class="NLM_string-name">Macleod, A.</span>; <span class="NLM_string-name">Van Wiltenburg, J.</span>; <span class="NLM_string-name">Thom, S.</span>; <span class="NLM_string-name">St. Gallay, S.</span>; <span class="NLM_string-name">Shannon, J.</span></span> <span> </span><span class="NLM_article-title">Novel Sulfonamide Carboxamide Compounds</span>. WO <span class="NLM_patent">2019/034686</span>, Feb 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Cooper&author=D.+Miller&author=A.+Macleod&author=J.+Van+Wiltenburg&author=S.+Thom&author=S.+St.+Gallay&author=J.+Shannon&title=Novel+Sulfonamide+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%26atitle%3DNovel%2520Sulfonamide%2520Carboxamide%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M.</span>; <span class="NLM_string-name">Miller, D.</span>; <span class="NLM_string-name">Macleod, A.</span>; <span class="NLM_string-name">Van Wiltenburg, J.</span>; <span class="NLM_string-name">Thom, S.</span>; <span class="NLM_string-name">St. Gallay, S.</span>; <span class="NLM_string-name">Shannon, J.</span></span> <span> </span><span class="NLM_article-title">Sulfonylureas and Sulfonylthioureas as NLRP3 Inhibitors</span>. WO <span class="NLM_patent">2019/034693</span>, Feb 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Cooper&author=D.+Miller&author=A.+Macleod&author=J.+Van+Wiltenburg&author=S.+Thom&author=S.+St.+Gallay&author=J.+Shannon&title=Sulfonylureas+and+Sulfonylthioureas+as+NLRP3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%26atitle%3DSulfonylureas%2520and%2520Sulfonylthioureas%2520as%2520NLRP3%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J. A.</span>; <span class="NLM_string-name">Veal, J. M.</span>; <span class="NLM_string-name">Trzoss, L. L.</span>; <span class="NLM_string-name">Mcbride, C.</span></span> <span> </span><span class="NLM_article-title">Chemical Compounds as Inhibitors of Interleukin-1 Activity</span>. WO <span class="NLM_patent">2018/136890</span>, Jul 26, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+A.+Stafford&author=J.+M.+Veal&author=L.+L.+Trzoss&author=C.+Mcbride&title=Chemical+Compounds+as+Inhibitors+of+Interleukin-1+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DChemical%2520Compounds%2520as%2520Inhibitors%2520of%2520Interleukin-1%2520Activity%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levenets, O.</span>; <span class="NLM_string-name">Galezowski, M.</span>; <span class="NLM_string-name">Bugaj, M.</span>; <span class="NLM_string-name">Woycie-Chowski, J.</span></span> <span> </span><span class="NLM_article-title">Sulfonyl Urea Derivatives and Their Use in the Control of Interleukin-1 Activity</span>. WO <span class="NLM_patent">20018/015445</span>, Jan 25, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=O.+Levenets&author=M.+Galezowski&author=M.+Bugaj&author=J.+Woycie-Chowski&title=Sulfonyl+Urea+Derivatives+and+Their+Use+in+the+Control+of+Interleukin-1+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLevenets%26aufirst%3DO.%26atitle%3DSulfonyl%2520Urea%2520Derivatives%2520and%2520Their%2520Use%2520in%2520the%2520Control%2520of%2520Interleukin-1%2520Activity%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, D.</span>; <span class="NLM_string-name">Watt, A. P.</span>; <span class="NLM_string-name">Bock, M. G.</span></span> <span> </span><span class="NLM_article-title">Sulphonyl Urea Derivatives as NLRP3 Inflammasome Modulators</span>. WO <span class="NLM_patent">2019/121691</span>, Jun 27, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Harrison&author=A.+P.+Watt&author=M.+G.+Bock&title=Sulphonyl+Urea+Derivatives+as+NLRP3+Inflammasome+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DD.%26atitle%3DSulphonyl%2520Urea%2520Derivatives%2520as%2520NLRP3%2520Inflammasome%2520Modulators%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span>; <span class="NLM_string-name">Watt, A. P.</span>; <span class="NLM_string-name">Porter, R. A.</span>; <span class="NLM_string-name">Harrison, D.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of the NLRP3 Inflammasome</span>. WO <span class="NLM_patent">2019/025467</span>, Feb 7, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+G.+Bock&author=A.+P.+Watt&author=R.+A.+Porter&author=D.+Harrison&title=Selective+Inhibitors+of+the+NLRP3+Inflammasome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DSelective%2520Inhibitors%2520of%2520the%2520NLRP3%2520Inflammasome%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Walle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossoul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hauwermeiren, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saavedra, P. H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konvalinka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamkanfi, M.</span></span> <span> </span><span class="NLM_article-title">MCC950/CRID3 Potently Targets the NACT Domain of Wild-Type NLRP3 but not Disease-Associated Mutants for Inflammasome Inhibition</span>. <i>PLOS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.3000354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.pbio.3000354" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=1-24&issue=9&author=L.+Vande%0AWalleauthor=I.+B.+Stoweauthor=P.+Sachaauthor=B.+L.+Leeauthor=D.+Demonauthor=A.+Fossoulauthor=F.+Van+Hauwermeirenauthor=P.+H.+V.+Saavedraauthor=P.+Simonauthor=V.+Subrtauthor=L.+Kostkaauthor=C.+E.+Stivalaauthor=V.+C.+Phamauthor=S.+T.+Stabenauthor=S.+Yamazoeauthor=J.+Konvalinkaauthor=N.+Kayagakiauthor=M.+Lamkanfi&title=MCC950%2FCRID3+Potently+Targets+the+NACT+Domain+of+Wild-Type+NLRP3+but+not+Disease-Associated+Mutants+for+Inflammasome+Inhibition&doi=10.1371%2Fjournal.pbio.3000354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.3000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.3000354%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BWalle%26aufirst%3DL.%26aulast%3DStowe%26aufirst%3DI.%2BB.%26aulast%3DSacha%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DB.%2BL.%26aulast%3DDemon%26aufirst%3DD.%26aulast%3DFossoul%26aufirst%3DA.%26aulast%3DVan%2BHauwermeiren%26aufirst%3DF.%26aulast%3DSaavedra%26aufirst%3DP.%2BH.%2BV.%26aulast%3DSimon%26aufirst%3DP.%26aulast%3DSubrt%26aufirst%3DV.%26aulast%3DKostka%26aufirst%3DL.%26aulast%3DStivala%26aufirst%3DC.%2BE.%26aulast%3DPham%26aufirst%3DV.%2BC.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DYamazoe%26aufirst%3DS.%26aulast%3DKonvalinka%26aufirst%3DJ.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DLamkanfi%26aufirst%3DM.%26atitle%3DMCC950%252FCRID3%2520Potently%2520Targets%2520the%2520NACT%2520Domain%2520of%2520Wild-Type%2520NLRP3%2520but%2520not%2520Disease-Associated%2520Mutants%2520for%2520Inflammasome%2520Inhibition%26jtitle%3DPLOS%2520Biol.%26date%3D2019%26volume%3D17%26issue%3D9%26spage%3D1%26epage%3D24%26doi%3D10.1371%2Fjournal.pbio.3000354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gram, H.</span></span> <span> </span><span class="NLM_article-title">The Long and Winding Road in Pharmaceutical Development of Canakinumab from Rare Genetic Autoinflammatory Syndromes to Myocardial Infarction and Cancer</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">104139</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.01.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.phrs.2019.01.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30648616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFylu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2020&pages=104139&author=H.+Gram&title=The+Long+and+Winding+Road+in+Pharmaceutical+Development+of+Canakinumab+from+Rare+Genetic+Autoinflammatory+Syndromes+to+Myocardial+Infarction+and+Cancer&doi=10.1016%2Fj.phrs.2019.01.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer</span></div><div class="casAuthors">Gram, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104139</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Interleukin-1beta (IL-1β) is an ancient and evolutionary conserved cytokine, which orchestrates innate immune responses triggered by infections in vertebrates.  While temporally limited induction of IL-1β protects the organism against traumatic or infectious insults, its chronic prodn. in unabated inflammation causes or enhances clin. manifestations of disease in almost all organ systems.  Therefore, pharmacol. targeting of IL-1β in a variety of clin. inflammatory conditions may provide symptomatic relief or profound disease modification.  The discovery of proteolytic processing of the inactive pro-IL-1β to mature, active and secreted IL-1β by the inflammasome/caspase 1 complex entailed a no. of drug discovery programs aiming towards low mol. wt. inhibitors across the Pharma industry.  Approved and marketed IL-1 pathway drugs today, however, are protein-based injectable drugs ("biologics") targeting either IL-1β, or the IL-1 receptor.  Canakinumab is a human monoclonal antibody that binds human IL-1β with high affinity and neutralizes its biol. activity.  This review describes the unique preclin. and clin. development journey of canakinumab starting from a rare genetic autoinflammatory disease and a systemic juvenile form of arthritis to further rare monogenetic periodic fever syndromes, and leading to non-orphan diseases, such as gout, myocardial infarction, and lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjXoqa7Hy42LVg90H21EOLACvtfcHk0lgUSdy8tCGYGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFylu78%253D&md5=6957795b40e29c715f423e6ac178bda0</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.01.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.01.023%26sid%3Dliteratum%253Aachs%26aulast%3DGram%26aufirst%3DH.%26atitle%3DThe%2520Long%2520and%2520Winding%2520Road%2520in%2520Pharmaceutical%2520Development%2520of%2520Canakinumab%2520from%2520Rare%2520Genetic%2520Autoinflammatory%2520Syndromes%2520to%2520Myocardial%2520Infarction%2520and%2520Cancer%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D154%26spage%3D104139%26doi%3D10.1016%2Fj.phrs.2019.01.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ridker, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFadyen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballantyne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastelein, J. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1707914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa1707914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28845751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1119-1131&author=P.+M.+Ridkerauthor=B.+M.+Everettauthor=T.+Thurenauthor=J.+G.+MacFadyenauthor=W.+H.+Changauthor=C.+Ballantyneauthor=F.+Fonsecaauthor=J.+Nicolauauthor=W.+Koenigauthor=S.+D.+Ankerauthor=J.+J.+P.+Kasteleinauthor=J.+H.+Cornel&title=Antiinflammatory+Therapy+with+Canakinumab+for+Atherosclerotic+Disease&doi=10.1056%2FNEJMoa1707914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Antiinflammatory therapy with canakinumab for atherosclerotic disease</span></div><div class="casAuthors">Ridker, P. M.; Everett, B. M.; Thuren, T.; MacFadyen, J. G.; Chang, W. H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S. D.; Kastelein, J. J. P.; Cornel, J. H.; Pais, P.; Pella, D.; Genest, J.; Cifkova, R.; Lorenzatti, A.; Forster, T.; Kobalava, Z.; Vida-Simiti, L.; Flather, M.; Shimokawa, H.; Ogawa, H.; Dellborg, M.; Rossi, P. R. F.; Troquay, R. P. T.; Libby, P.; Glynn, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1119-1131</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Exptl. and clin. data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease.  Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. methods We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per L.  The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered s.c. every 3 mo) with placebo.  The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. results At 48 mo, the median redn. from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group.  There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). conclusions Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 mo led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwYFxFQ_i_LVg90H21EOLACvtfcHk0lgUSdy8tCGYGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqurnE&md5=50570e06cca89d8b3f654333047f223d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1707914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1707914%26sid%3Dliteratum%253Aachs%26aulast%3DRidker%26aufirst%3DP.%2BM.%26aulast%3DEverett%26aufirst%3DB.%2BM.%26aulast%3DThuren%26aufirst%3DT.%26aulast%3DMacFadyen%26aufirst%3DJ.%2BG.%26aulast%3DChang%26aufirst%3DW.%2BH.%26aulast%3DBallantyne%26aufirst%3DC.%26aulast%3DFonseca%26aufirst%3DF.%26aulast%3DNicolau%26aufirst%3DJ.%26aulast%3DKoenig%26aufirst%3DW.%26aulast%3DAnker%26aufirst%3DS.%2BD.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%2BP.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26atitle%3DAntiinflammatory%2520Therapy%2520with%2520Canakinumab%2520for%2520Atherosclerotic%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1119%26epage%3D1131%26doi%3D10.1056%2FNEJMoa1707914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lachmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kone-Paut, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuemmerle-Deschner, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachulla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitton, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P. N.</span></span> <span> </span><span class="NLM_article-title">Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2416</span>– <span class="NLM_lpage">2425</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0810787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa0810787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19494217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=2416-2425&author=H.+J.+Lachmannauthor=I.+Kone-Pautauthor=J.+B.+Kuemmerle-Deschnerauthor=K.+S.+Leslieauthor=E.+Hachullaauthor=P.+Quartierauthor=X.+Gittonauthor=A.+Widmerauthor=N.+Patelauthor=P.+N.+Hawkins&title=Use+of+Canakinumab+in+the+Cryopyrin-Associated+Periodic+Syndrome&doi=10.1056%2FNEJMoa0810787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Use of canakinumab in the cryopyrin-associated periodic syndrome</span></div><div class="casAuthors">Lachmann, Helen J.; Kone-Paut, Isabelle; Kuemmerle-Deschner, Jasmin B.; Leslie, Kieron S.; Hachulla, Eric; Quartier, Pierre; Gitton, Xavier; Widmer, Albert; Patel, Neha; Hawkins, Philip N.; Madhoo, S.; Berthelot, J.-M.; Jorgensen, C.; Morell-Dubois, S.; Huriez, Claude; Mouy, R.; Marie, I.; Lacassagne, S.; Chaturvedi, R.; Vargas, C.; Block, J. A.; Smith, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2416-2425</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The cryopyrin-assocd. periodic syndrome (CAPS) is a rare inherited inflammatory disease assocd. with overprodn. of interleukin-1.  Canakinumab is a human anti-interleukin-1β monoclonal antibody.  We performed a three-part, 48-wk, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS.  In part 1, 35 patients received 150 mg of canakinumab s.c.  Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 wk for up to 24 wk.  After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab.  We evaluated therapeutic responses using disease-activity scores and anal. of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA).  In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab.  Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission.  Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P < 0.001).  At the end of part 2, median CRP and SAA values were normal (<10 mg per L for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P < 0.001 and P = 0.002, resp.).  Of the 31 patients, 28 (90%) completed part 3 in remission.  In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P = 0.03).  Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo.  Treatment with s.c. canakinumab once every 8 wk was assocd. with a rapid remission of symptoms in most patients with CAPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaTYjoHz3f7LVg90H21EOLACvtfcHk0lhOrklwf4d-7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrk%253D&md5=38f4d5367e2d00843c0c4204edd6aada</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810787%26sid%3Dliteratum%253Aachs%26aulast%3DLachmann%26aufirst%3DH.%2BJ.%26aulast%3DKone-Paut%26aufirst%3DI.%26aulast%3DKuemmerle-Deschner%26aufirst%3DJ.%2BB.%26aulast%3DLeslie%26aufirst%3DK.%2BS.%26aulast%3DHachulla%26aufirst%3DE.%26aulast%3DQuartier%26aufirst%3DP.%26aulast%3DGitton%26aufirst%3DX.%26aulast%3DWidmer%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DHawkins%26aufirst%3DP.%2BN.%26atitle%3DUse%2520of%2520Canakinumab%2520in%2520the%2520Cryopyrin-Associated%2520Periodic%2520Syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D2416%26epage%3D2425%26doi%3D10.1056%2FNEJMoa0810787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">FDA</span>. <span> </span><span class="NLM_article-title">Highlights of Prescribing Information:
Ilaris (Canakinumab)</span>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf</a> (accessed Jun 9, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=FDA&title=Highlights+of+Prescribing+Information%3A%0AIlaris+%28Canakinumab%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DHighlights%2520of%2520Prescribing%2520Information%253A%250AIlaris%2520%2528Canakinumab%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavelka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruyère, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeb, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martel-Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfort, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reginster, J.-Y.</span></span> <span> </span><span class="NLM_article-title">Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1007/s40266-016-0347-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1007%2Fs40266-016-0347-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26849131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28Xitlyntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=75-85&author=K.+Pavelkaauthor=O.+Bruy%C3%A8reauthor=C.+Cooperauthor=J.+A.+Kanisauthor=B.+F.+Leebauthor=E.+Maheuauthor=J.+Martel-Pelletierauthor=J.+Monfortauthor=J.-P.+Pelletierauthor=R.+Rizzoliauthor=J.-Y.+Reginster&title=Diacerein%3A+Benefits%2C+Risks+and+Place+in+the+Management+of+Osteoarthritis.+An+Opinion-Based+Report+from+the+ESCEO&doi=10.1007%2Fs40266-016-0347-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO</span></div><div class="casAuthors">Pavelka, Karel; Bruyere, Olivier; Cooper, Cyrus; Kanis, John A.; Leeb, Burkhard F.; Maheu, Emmanuel; Martel-Pelletier, Johanne; Monfort, Jordi; Pelletier, Jean-Pierre; Rizzoli, Rene; Reginster, Jean-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane.  It has also recently been shown to have protective effects against subchondral bone remodelling.  Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clin. and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA.  Based on a literature review of clin. trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol.  Addnl., diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped.  The use of diacerein is assocd. with common gastrointestinal disorders such as soft stools and diarrhea, common mild skin reactions, and, uncommonly, hepatobiliary disorders.  However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions.  Therefore, the ESCEO concludes that the benefit-risk balance of diacerein remains pos. in the symptomatic treatment of hip and knee osteoarthritis.  Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacol. background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcgbKEWuefh7Vg90H21EOLACvtfcHk0ljbl1VCUaaXbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xitlyntbo%253D&md5=698383aa62dacd67da31fed815948cab</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs40266-016-0347-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40266-016-0347-4%26sid%3Dliteratum%253Aachs%26aulast%3DPavelka%26aufirst%3DK.%26aulast%3DBruy%25C3%25A8re%26aufirst%3DO.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKanis%26aufirst%3DJ.%2BA.%26aulast%3DLeeb%26aufirst%3DB.%2BF.%26aulast%3DMaheu%26aufirst%3DE.%26aulast%3DMartel-Pelletier%26aufirst%3DJ.%26aulast%3DMonfort%26aufirst%3DJ.%26aulast%3DPelletier%26aufirst%3DJ.-P.%26aulast%3DRizzoli%26aufirst%3DR.%26aulast%3DReginster%26aufirst%3DJ.-Y.%26atitle%3DDiacerein%253A%2520Benefits%252C%2520Risks%2520and%2520Place%2520in%2520the%2520Management%2520of%2520Osteoarthritis.%2520An%2520Opinion-Based%2520Report%2520from%2520the%2520ESCEO%26jtitle%3DDrugs%2520Aging%26date%3D2016%26volume%3D33%26spage%3D75%26epage%3D85%26doi%3D10.1007%2Fs40266-016-0347-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">TWi
Biotechnology</span> <span> </span><span class="NLM_article-title">Announces Last
Patient Enrolled in Phase 2 Proof-of-
Concept Study of AC-203 for Treatment of Epidermolysis Bullosa</span>. <a href="https://www.twibiotech.com/website/news_detail/46" class="extLink">https://www.twibiotech.com/website/news_detail/46</a> (accessed Jun 9, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=TWi%0ABiotechnology&title=Announces+Last%0APatient+Enrolled+in+Phase+2+Proof-of-%0AConcept+Study+of+AC-203+for+Treatment+of+Epidermolysis+Bullosa"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DAnnounces%2520Last%250APatient%2520Enrolled%2520in%2520Phase%25202%2520Proof-of-%250AConcept%2520Study%2520of%2520AC-203%2520for%2520Treatment%2520of%2520Epidermolysis%2520Bullosa%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-K.</span>; <span class="NLM_string-name">Lee, J.-Y.</span>; <span class="NLM_string-name">Lu, W.-S.</span></span> <span> </span><span class="NLM_article-title">Diacerein or Its Analogs for Inhibiting Expression of ASC, NLRP3, and/or Formation of NLRP3 Inflammasome Complex</span>. WO <span class="NLM_patent">2017/031161</span>, Feb 23, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.-K.+Chen&author=J.-Y.+Lee&author=W.-S.+Lu&title=Diacerein+or+Its+Analogs+for+Inhibiting+Expression+of+ASC%2C+NLRP3%2C+and%2For+Formation+of+NLRP3+Inflammasome+Complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.-K.%26atitle%3DDiacerein%2520or%2520Its%2520Analogs%2520for%2520Inhibiting%2520Expression%2520of%2520ASC%252C%2520NLRP3%252C%2520and%252For%2520Formation%2520of%2520NLRP3%2520Inflammasome%2520Complex%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. A.</span></span> <span> </span><span class="NLM_article-title">Anakinra for Rheumatoid Arthritis: A Systematic Review</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1118</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.3899/jrheum.090074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3899%2Fjrheum.090074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19447938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlSjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=1118-1125&issue=6&author=M.+Mertensauthor=J.+A.+Singh&title=Anakinra+for+Rheumatoid+Arthritis%3A+A+Systematic+Review&doi=10.3899%2Fjrheum.090074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Anakinra for rheumatoid arthritis: a systematic review</span></div><div class="casAuthors">Mertens, Marty; Singh, Jasvinder A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1118-1125</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  Objective. To perform a systematic review of clin. effectiveness and safety of anakinra in rheumatoid arthritis (RA).  Methods. We searched Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, and the ref. lists of included articles for randomized controlled trials comparing anakinra to placebo in adults with RA.  Results. Five trials involving 2846 patients, 781 randomized to placebo and 2065 to anakinra, were included.  There was a significant improvement in the no. of participants achieving American College of Rheumatol. (ACR)20 (38% vs 23%) treated with anakinra 50-150 mg daily vs. placebo after 24 wk.  ACR50 (18% vs 7%), ACR70 (7% vs 2%), Health Assessment Questionnaire, visual analog scale for pain, Larsen radiog. scores, and erythrocyte sedimentation rate all demonstrated significant improvement with anakinra vs. placebo as well.  There were no statistically significant differences noted in the no. of withdrawals, deaths, adverse events (total and serious), and infections (total and serious).  An increase in incidence of serious infections in anakinra vs. the placebo group (1.8% vs 0.6%) was noted that may be clin. significant.  Injection site reactions were significantly increased, occurring in 71% of anakinra vs. 28% of placebo group.  Conclusion. Anakinra is a relatively safe and modestly efficacious biol. therapy for RA.  More studies are needed to evaluate safety and efficacy, esp. in comparison to other therapies, and adverse event data for the longterm use of anakinra have yet to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7fgEptt9HDrVg90H21EOLACvtfcHk0ljbl1VCUaaXbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlSjt74%253D&md5=9a5a3085105c6e0cbe0c6a8a6eeafb71</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.090074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.090074%26sid%3Dliteratum%253Aachs%26aulast%3DMertens%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DJ.%2BA.%26atitle%3DAnakinra%2520for%2520Rheumatoid%2520Arthritis%253A%2520A%2520Systematic%2520Review%26jtitle%3DJ.%2520Rheumatol.%26date%3D2009%26volume%3D36%26issue%3D6%26spage%3D1118%26epage%3D1125%26doi%3D10.3899%2Fjrheum.090074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramírez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cañete, J. D.</span></span> <span> </span><span class="NLM_article-title">Anakinra for Treatmnt of Rheumatoid Arthritis: a Safety Evaluation</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1080/14740338.2018.1486819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1080%2F14740338.2018.1486819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29883212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=727-732&issue=7&author=J.+Ram%C3%ADrezauthor=J.+D.+Ca%C3%B1ete&title=Anakinra+for+Treatmnt+of+Rheumatoid+Arthritis%3A+a+Safety+Evaluation&doi=10.1080%2F14740338.2018.1486819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Anakinra for the treatment of rheumatoid arthritis: a safety evaluation</span></div><div class="casAuthors">Ramirez, Julio; Canete, Juan D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">727-732</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The anti-interleukin-1 receptor antagonist, anakinra, was approved for the treatment of rheumatoid arthritis (RA) more than 12 years ago.  However, its adverse effects are not well known.: We review the safety profile of anakinra, analyzing clin. trials, observational studies, and registry data.: Due to its lower efficacy compared with other biol. therapies approved for RA and its daily s.c. administration, anakinra is used only marginally for the treatment of RA.  This has limited the experience with this drug in RA, with a lack of data from long-term observational studies or registries.  From the five clin. trials performed, and given the unfeasibility of developing new studies of anakinra in RA, it may be concluded that site injection reactions, infections at higher doses (>100 mg), and immunogenicity are the most frequent adverse events related to anakinra administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolPB0ES8P-NrVg90H21EOLACvtfcHk0lhOixyXJRZGzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrtr%252FJ&md5=39c1d67960e538bd77b82f3f2310c704</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1080%2F14740338.2018.1486819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2018.1486819%26sid%3Dliteratum%253Aachs%26aulast%3DRam%25C3%25ADrez%26aufirst%3DJ.%26aulast%3DCa%25C3%25B1ete%26aufirst%3DJ.%2BD.%26atitle%3DAnakinra%2520for%2520Treatmnt%2520of%2520Rheumatoid%2520Arthritis%253A%2520a%2520Safety%2520Evaluation%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2018%26volume%3D17%26issue%3D7%26spage%3D727%26epage%3D732%26doi%3D10.1080%2F14740338.2018.1486819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuemmerle-Deschner, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittkowski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrrell, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koetter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ummenhofer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koitschev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialkowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benseler, S. M.</span></span> <span> </span><span class="NLM_article-title">Treatment of Muckle-Wells Syndrome: Analysis of Two IL-1-Blocking Regimens</span>. <i>Arthritis Research & Therapy</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">R64</span>, <span class="refDoi"> DOI: 10.1186/ar4237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1186%2Far4237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23718630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlaqtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=R64&author=J.+B.+Kuemmerle-Deschnerauthor=H.+Wittkowskiauthor=P.+N.+Tyrrellauthor=I.+Koetterauthor=P.+Lohseauthor=K.+Ummenhoferauthor=F.+Reessauthor=S.+Hansmannauthor=A.+Koitschevauthor=C.+Deuterauthor=A.+Bialkowskiauthor=D.+Foellauthor=S.+M.+Benseler&title=Treatment+of+Muckle-Wells+Syndrome%3A+Analysis+of+Two+IL-1-Blocking+Regimens&doi=10.1186%2Far4237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens</span></div><div class="casAuthors">Kuemmerle-Deschner, Jasmin B.; Wittkowski, Helmut; Tyrrell, Pascal N.; Koetter, Ina; Lohse, Peter; Ummenhofer, Katharina; Reess, Fabian; Hansmann, Sandra; Koitschev, Assen; Deuter, Christoph; Bialkowski, Anja; Foell, Dirk; Benseler, Susanne M.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">R64</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Objectives: Muckle-Wells syndrome (MWS) is an autoinflammatory disease characterized by excessive interleukin-1 (IL-1) release, resulting in recurrent fevers, sensorineural hearing loss and amyloidosis.  IL-1 inhibition with anakinra, an IL-1 receptor antagonist, improves clin. symptoms and inflammatory markers.  Subclin. disease activity is commonly obsd.  Canakinumab, a fully human IgG1 anti-IL-1β monoclonal antibody, can abolish excess IL-1β.  The study aim was to analyze the efficacy and safety of these two anti-IL-1 therapies.  Methods: Two cohorts of patients with severe MWS and confirmed NLRP3 mutation were treated with anakinra and/or canakinumab.  Clin. and lab. features including ESR, CRP, SAA and the neutrophil marker S100A12 were detd. serially.  Disease activity was captured by MWS disease activity scores (MWS-DAS).  Remission was defined as MWS-DAS ≤5 plus normal CRP and SAA.  Treatment efficacy and safety were analyzed.  Results: The study included 12 anakinra- and 14 canakinumab-treated patients; the median age was 33.5 years (3.0 years to 72.0 years); 57% were female patients.  Both treatment regimens led to a significant redn. of clin. disease activity and inflammatory markers.  At last follow-up, 75% of anakinra-treated and 93% of canakinumab-treated patients achieved remission.  During follow-up, S100A12 levels mirrored recurrence of disease activity.  Both treatment regimens had favorable safety profiles.  Conclusions: IL-1 blockade is an effective and safe treatment in MWS patients.  MWS-DAS in combination with MWS inflammatory markers provides an excellent monitoring tool set.  Canakinumab led to a sustained control of disease activity even after secondary failure of anakinra therapy.  S100A12 may be a sensitive marker to detect subclin. disease activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRqKjXvEjbr7Vg90H21EOLACvtfcHk0lhOixyXJRZGzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlaqtrfK&md5=7436cbbe87b2229b6710a378e6557b76</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1186%2Far4237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far4237%26sid%3Dliteratum%253Aachs%26aulast%3DKuemmerle-Deschner%26aufirst%3DJ.%2BB.%26aulast%3DWittkowski%26aufirst%3DH.%26aulast%3DTyrrell%26aufirst%3DP.%2BN.%26aulast%3DKoetter%26aufirst%3DI.%26aulast%3DLohse%26aufirst%3DP.%26aulast%3DUmmenhofer%26aufirst%3DK.%26aulast%3DReess%26aufirst%3DF.%26aulast%3DHansmann%26aufirst%3DS.%26aulast%3DKoitschev%26aufirst%3DA.%26aulast%3DDeuter%26aufirst%3DC.%26aulast%3DBialkowski%26aufirst%3DA.%26aulast%3DFoell%26aufirst%3DD.%26aulast%3DBenseler%26aufirst%3DS.%2BM.%26atitle%3DTreatment%2520of%2520Muckle-Wells%2520Syndrome%253A%2520Analysis%2520of%2520Two%2520IL-1-Blocking%2520Regimens%26jtitle%3DArthritis%2520Research%2520%2526%2520Therapy%26date%3D2013%26volume%3D15%26spage%3DR64%26doi%3D10.1186%2Far4237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baughman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of Anakinra in Subjects with Different Levels of Renal Function</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(03)00094-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS0009-9236%2803%2900094-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=12844139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFGhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2003&pages=85-94&issue=1&author=B.-B.+Yangauthor=S.+Baughmanauthor=J.+T.+Sullivan&title=Pharmacokinetics+of+Anakinra+in+Subjects+with+Different+Levels+of+Renal+Function&doi=10.1016%2FS0009-9236%2803%2900094-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of anakinra in subjects with different levels of renal function</span></div><div class="casAuthors">Yang, Bing-Bing; Baughman, Sharon; Sullivan, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Our objective was to assess the effects of decreased renal function and dialysis on anakinra pharmacokinetics.  In 2 sep. studies anakinra (1 mg/kg) was given i.v. to 12 healthy subjects and 20 subjects with end-stage renal disease undergoing dialysis.  In a third study anakinra (100 mg) was given s.c. to 30 subjects who had been assigned to 5 groups according to renal function, as follows: normal (creatinine clearance [CLcr] >80 mL/min), mildly impaired (CLcr = 50-80 mL/min), moderately impaired (CLcr = 30-49 mL/min), severely impaired (CLcr <30 mL/min), and end-stage renal disease undergoing hemodialysis.  Plasma samples were collected up to 96 h after dosing for anakinra measurement by enzyme-linked immunoassay.  The mean plasma clearance (CL) of anakinra after i.v. administration was reduced from 137 ± 21 mL/min in the healthy subjects to approx. 20 mL/min for the subjects with end-stage renal disease (P < .0001).  The removal of anakinra by dialysis was less than 2.5% of the dose administered.  Compared with mean anakinra clearance (CL/F) after s.c. administration in the group with normal renal function (170 ± 37 mL/min), CL/F was reduced by 16% in the mildly impaired group (142 ± 59 mL/min), by 50% in the moderately impaired group (84.5 ± 24.7 mL/min, P < .05), by 70% in the severely impaired group (51.5 ± 8.4 mL/min, P < .05), and by 75% in the group with end-stage renal disease (42.7 ± 4.7 mL/min, P < .05).  A significant correlation between anakinra CL/F and CLcr was obsd. [log(CL/F) = 1.65 + 0.0062 · CLcr; r2 = 0.718].  Anakinra is predominantly cleared renally in humans; the plasma clearance of anakinra decreased with decreasing renal function.  The dialysis process has a minimal effect on the removal of anakinra.  Our results suggest that a dose or schedule adjustment is indicated for persons with severe renal impairment or end-stage renal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojtjGG3lfq-LVg90H21EOLACvtfcHk0lj0aG1TysdJAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFGhsbo%253D&md5=8a84eaa96226bdd9af0634892ab58e7b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2803%2900094-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252803%252900094-8%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.-B.%26aulast%3DBaughman%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DJ.%2BT.%26atitle%3DPharmacokinetics%2520of%2520Anakinra%2520in%2520Subjects%2520with%2520Different%2520Levels%2520of%2520Renal%2520Function%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2003%26volume%3D74%26issue%3D1%26spage%3D85%26epage%3D94%26doi%3D10.1016%2FS0009-9236%2803%2900094-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannenbaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rordorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gram, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody</span>. <i>Clinical Pharmacokinetics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">e1</span>– <span class="NLM_lpage">e18</span>, <span class="refDoi"> DOI: 10.2165/11599820-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.2165%2F11599820-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=22550964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCmu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=e1-e18&author=A.+Chakrabortyauthor=S.+Tannenbaumauthor=C.+Rordorfauthor=P.+J.+Loweauthor=D.+Flochauthor=H.+Gramauthor=S.+Roy&title=Pharmacokinetic+and+Pharmacodynamic+Properties+of+Canakinumab%2C+a+Human+Anti-Interleukin-1%CE%B2+Monoclonal+Antibody&doi=10.2165%2F11599820-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody</span></div><div class="casAuthors">Chakraborty, Abhijit; Tannenbaum, Stacey; Rordorf, Christiane; Lowe, Philip J.; Floch, David; Gram, Hermann; Roy, Sandip</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1-e18</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Canakinumab is a high-affinity human monoclonal anti-interleukin-1β (IL-1β) antibody of the IgG1/κ isotype designed to bind and neutralize the activity of human IL-1β, a pro-inflammatory cytokine.  Canakinumab is currently being investigated on the premise that it would exert anti-inflammatory effects on a broad spectrum of diseases, driven by IL-1β.  This paper focuses on the anal. of the pharmacokinetic and pharmacodynamic data from the canakinumab clin. development program, describing results from the recently approved indication for the treatment of cryopyrin-assocd. periodic syndromes (CAPS) under the trade name ILARIS, as well as diseases such as rheumatoid arthritis, asthma and psoriasis.  Canakinumab displays pharmacokinetic properties typical of an IgG1 antibody.  In a CAPS patient weighing 70 kg, slow serum clearance (0.174 L/day) was obsd. with a low total vol. of distribution at steady state (6.0 L), resulting in a long elimination half-life of 26 days.  The s.c. abs. bioavailability was high (70%).  Canakinumab displays linear pharmacokinetics, with a dose-proportional increase in exposure and no evidence of accelerated clearance or time-dependent changes in pharmacokinetics following repeated administration was obsd.  The pharmacokinetics of canakinumab in various diseases (e.g. CAPS, rheumatoid arthritis, psoriasis or asthma) are comparable to those in healthy individuals.  No sex- or age-related pharmacokinetic differences were obsd. after correction for body wt.  An increase in total IL-1β was obsd. in both healthy subjects and all patient populations following canakinumab dosing, reflecting the ability of canakinumab to bind circulating IL-1β.  The kinetics of total IL-i.p. along with the pharmacokinetics of canakinumab were characterized by a population-based pharmacokinetic-binding model, where the apparent in vivo dissocn. const., signifying binding affinity of canakinumab to circulating IL-1β, was estd. at 1.07±0.173 nmol/L in CAPS patients.  During development of canakinumab a cell line change was introduced.  Pharmacokinetic characterization was performed in both animals and humans to assure that this manufg. change did not affect the pharmacokinetic/pharmacodynamic properties of canakinumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRcbP1lbqGe7Vg90H21EOLACvtfcHk0lj0aG1TysdJAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCmu7jL&md5=781a030dad736dea73fe542428185310</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2165%2F11599820-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11599820-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DTannenbaum%26aufirst%3DS.%26aulast%3DRordorf%26aufirst%3DC.%26aulast%3DLowe%26aufirst%3DP.%2BJ.%26aulast%3DFloch%26aufirst%3DD.%26aulast%3DGram%26aufirst%3DH.%26aulast%3DRoy%26aufirst%3DS.%26atitle%3DPharmacokinetic%2520and%2520Pharmacodynamic%2520Properties%2520of%2520Canakinumab%252C%2520a%2520Human%2520Anti-Interleukin-1%25CE%25B2%2520Monoclonal%2520Antibody%26jtitle%3DClinical%2520Pharmacokinetics%26date%3D2012%26volume%3D51%26spage%3De1%26epage%3De18%26doi%3D10.2165%2F11599820-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lium, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newmark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, P.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy with Etanercept and Anakinra in the Treatment of Patients with Rheumatoid Arthritis who have been Treated Unsuccessfully with Methotrexate</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1412</span>– <span class="NLM_lpage">1419</span>, <span class="refDoi"> DOI: 10.1002/art.20221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fart.20221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=15146410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2004&pages=1412-1419&issue=5&author=M.+C.+Genoveseauthor=S.+Cohenauthor=L.+Morelandauthor=D.+Liumauthor=S.+Robbinsauthor=R.+Newmarkauthor=P.+Bekker&title=Combination+Therapy+with+Etanercept+and+Anakinra+in+the+Treatment+of+Patients+with+Rheumatoid+Arthritis+who+have+been+Treated+Unsuccessfully+with+Methotrexate&doi=10.1002%2Fart.20221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate</span></div><div class="casAuthors">Genovese, Mark C.; Cohen, Stanley; Moreland, Larry; Lium, Deborah; Robbins, Sean; Newmark, Richard; Bekker, Pirow; Block, S.; Borofsky, M.; Box, J.; Brasington, R.; Brodsky, A.; Bulpitt, K.; Caldwell, J.; Coalson, R.; Cush, J.; Deadhar, A.; Divittorio, G.; Fishman, A.; Greenwald, M.; Hurd, E.; Kay, J.; Kavanaugh, A.; Kohen, M.; Maestrello, S.; Malamet, R.; Mandel, D.; Martin, R.; Mathews, S.; Pearson, M.; Poiley, J.; Romano, T.; Roth, S.; Rutstein, J.; Schiff, M.; Schweitz, M.; Shergy, W.; Staley, H.; Sultany, G.; Surbeck, W.; Taborn, J.; Valen, P.; Valente, R.; Wallace, D.; Weidmann, C.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1412-1419</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The aim was to det. the potential for additive or synergistic effects of combination therapy with the selective anti-tumor necrosis factor α agent etanercept and the anti-interleukin-1 agent anakinra.  Two hundred forty-four patients in whom rheumatoid arthritis (RA) was active despite methotrexate therapy were treated with s.c. etanercept only (25 mg twice weekly), full-dosage etanercept (25 mg twice weekly) plus anakinra (100 mg/day), or half-dosage etanercept (25 mg once weekly) plus anakinra (100 mg/day) for 6 mo in a double-blind study at 41 centers in the US.  Patients had never previously received anticytokine therapy.  Patient response was measured with the American College of Rheumatol. (ACR) core set criteria, a health-related quality-of-life questionnaire, and the Disease Activity Score.  Safety was assessed by the no. of adverse events and clin. lab. values.  Plasma concns. of both agents and antibody formation against both agents were also assessed.  Combination therapy with etanercept plus anakinra provided no treatment benefit over etanercept alone, regardless of the regimen, but was assocd. with an increased safety risk.  Thirty-one percent of the patients treated with full-dosage etanercept plus anakinra achieved an ACR 50% response, compared with 41% of the patients treated with etanercept only.  This result was not statistically significant (P = 0.914).  The incidence of serious infections (0% for etanercept alone, 3.7-7.4% for combination therapy), injection-site reactions, and neutropenia was increased with combination therapy.  Combination therapy had no effect on the pharmacokinetics or immunogenicity of either agent.  Combination therapy with etanercept and anakinra provides no added benefit and an increased risk compared with etanercept alone and is not recommended for the treatment of patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotcT2gVGZY8rVg90H21EOLACvtfcHk0liDv2E37eC5Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFykurw%253D&md5=c465011f8a6f2dfd1bd7bc3a0477e51a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fart.20221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.20221%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DMoreland%26aufirst%3DL.%26aulast%3DLium%26aufirst%3DD.%26aulast%3DRobbins%26aufirst%3DS.%26aulast%3DNewmark%26aufirst%3DR.%26aulast%3DBekker%26aufirst%3DP.%26atitle%3DCombination%2520Therapy%2520with%2520Etanercept%2520and%2520Anakinra%2520in%2520the%2520Treatment%2520of%2520Patients%2520with%2520Rheumatoid%2520Arthritis%2520who%2520have%2520been%2520Treated%2520Unsuccessfully%2520with%2520Methotrexate%26jtitle%3DArthritis%2520Rheum.%26date%3D2004%26volume%3D50%26issue%3D5%26spage%3D1412%26epage%3D1419%26doi%3D10.1002%2Fart.20221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaRock, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRock, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizet, V.</span></span> <span> </span><span class="NLM_article-title">IL-1β is an Innate Immune Sensor of Microbial Proteolysis</span>. <i>Science Immunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>), <span class="NLM_elocation-id">eaah3539</span> <span class="refDoi"> DOI: 10.1126/sciimmunol.aah3539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fsciimmunol.aah3539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28331908" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&issue=2&author=C.+N.+LaRockauthor=J.+Toddauthor=D.+L.+LaRockauthor=J.+Olsonauthor=A.+J.+O%E2%80%99Donoghueauthor=A.+A.+B.+Robertsonauthor=M.+A.+Cooperauthor=H.+M.+Hoffmanauthor=V.+Nizet&title=IL-1%CE%B2+is+an+Innate+Immune+Sensor+of+Microbial+Proteolysis&doi=10.1126%2Fsciimmunol.aah3539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1126%2Fsciimmunol.aah3539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciimmunol.aah3539%26sid%3Dliteratum%253Aachs%26aulast%3DLaRock%26aufirst%3DC.%2BN.%26aulast%3DTodd%26aufirst%3DJ.%26aulast%3DLaRock%26aufirst%3DD.%2BL.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%2BJ.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DHoffman%26aufirst%3DH.%2BM.%26aulast%3DNizet%26aufirst%3DV.%26atitle%3DIL-1%25CE%25B2%2520is%2520an%2520Innate%2520Immune%2520Sensor%2520of%2520Microbial%2520Proteolysis%26jtitle%3DScience%2520Immunology%26date%3D2016%26volume%3D1%26issue%3D2%26doi%3D10.1126%2Fsciimmunol.aah3539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span> <span> </span><span class="NLM_article-title">Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19</span>. <i>Frontiers in Immunology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.01021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3389%2Ffimmu.2020.01021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32038653" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1-5&author=A.+Shah&title=Novel+Coronavirus-Induced+NLRP3+Inflammasome+Activation%3A+A+Potential+Drug+Target+in+the+Treatment+of+COVID-19&doi=10.3389%2Ffimmu.2020.01021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.01021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.01021%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DA.%26atitle%3DNovel%2520Coronavirus-Induced%2520NLRP3%2520Inflammasome%2520Activation%253A%2520A%2520Potential%2520Drug%2520Target%2520in%2520the%2520Treatment%2520of%2520COVID-19%26jtitle%3DFrontiers%2520in%2520Immunology%26date%3D2020%26volume%3D11%26spage%3D1%26epage%3D5%26doi%3D10.3389%2Ffimmu.2020.01021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campochiaro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della-Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canetti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oltolini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglioni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassan Din, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boffini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomelleri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovere-Querini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Lucca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinenghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresoldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zangrillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpellini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagna, L.</span></span> <span> </span><span class="NLM_article-title">Interleukin-1 Blockade with High-Dose Anakinra in Patients with COVID-19, Acute Respiratory Distress Syndrome, and Hyperinflammation: A Retrospective Cohort Study</span>. <i>Lancet Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">E325</span>– <span class="NLM_lpage">E331</span>, <span class="refDoi"> DOI: 10.1016/S2665-9913(20)30127-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930127-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32501454" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=E325-E331&issue=6&author=G.+Cavalliauthor=G.+De+Lucaauthor=C.+Campochiaroauthor=E.+Della-Torreauthor=M.+Ripaauthor=D.+Canettiauthor=C.+Oltoliniauthor=B.+Castiglioniauthor=C.+Tassan+Dinauthor=N.+Boffiniauthor=A.+Tomelleriauthor=N.+Farinaauthor=A.+Ruggeriauthor=P.+Rovere-Queriniauthor=G.+Di+Luccaauthor=S.+Martinenghiauthor=R.+Scottiauthor=M.+Tresoldiauthor=F.+Ciceriauthor=G.+Landoniauthor=A.+Zangrilloauthor=P.+Scarpelliniauthor=L.+Dagna&title=Interleukin-1+Blockade+with+High-Dose+Anakinra+in+Patients+with+COVID-19%2C+Acute+Respiratory+Distress+Syndrome%2C+and+Hyperinflammation%3A+A+Retrospective+Cohort+Study&doi=10.1016%2FS2665-9913%2820%2930127-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930127-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930127-2%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DG.%26aulast%3DDe%2BLuca%26aufirst%3DG.%26aulast%3DCampochiaro%26aufirst%3DC.%26aulast%3DDella-Torre%26aufirst%3DE.%26aulast%3DRipa%26aufirst%3DM.%26aulast%3DCanetti%26aufirst%3DD.%26aulast%3DOltolini%26aufirst%3DC.%26aulast%3DCastiglioni%26aufirst%3DB.%26aulast%3DTassan%2BDin%26aufirst%3DC.%26aulast%3DBoffini%26aufirst%3DN.%26aulast%3DTomelleri%26aufirst%3DA.%26aulast%3DFarina%26aufirst%3DN.%26aulast%3DRuggeri%26aufirst%3DA.%26aulast%3DRovere-Querini%26aufirst%3DP.%26aulast%3DDi%2BLucca%26aufirst%3DG.%26aulast%3DMartinenghi%26aufirst%3DS.%26aulast%3DScotti%26aufirst%3DR.%26aulast%3DTresoldi%26aufirst%3DM.%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DLandoni%26aufirst%3DG.%26aulast%3DZangrillo%26aufirst%3DA.%26aulast%3DScarpellini%26aufirst%3DP.%26aulast%3DDagna%26aufirst%3DL.%26atitle%3DInterleukin-1%2520Blockade%2520with%2520High-Dose%2520Anakinra%2520in%2520Patients%2520with%2520COVID-19%252C%2520Acute%2520Respiratory%2520Distress%2520Syndrome%252C%2520and%2520Hyperinflammation%253A%2520A%2520Retrospective%2520Cohort%2520Study%26jtitle%3DLancet%2520Rheumatology%26date%3D2020%26volume%3D2%26issue%3D6%26spage%3DE325%26epage%3DE331%26doi%3D10.1016%2FS2665-9913%2820%2930127-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kernan, K. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canna, S. W</span></span> <span> </span><span class="NLM_article-title">Should COVID-19 Take Advice From Rheumatologists</span>. <i>Lancet Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">E310</span>– <span class="NLM_lpage">E311</span>, <span class="refDoi"> DOI: 10.1016/S2665-9913(20)30129-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930129-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32501452" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=E310-E311&issue=6&author=K.+F+Kernanauthor=S.+W+Canna&title=Should+COVID-19+Take+Advice+From+Rheumatologists&doi=10.1016%2FS2665-9913%2820%2930129-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930129-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930129-6%26sid%3Dliteratum%253Aachs%26aulast%3DKernan%26aufirst%3DK.%2BF%26aulast%3DCanna%26aufirst%3DS.%2BW%26atitle%3DShould%2520COVID-19%2520Take%2520Advice%2520From%2520Rheumatologists%26jtitle%3DLancet%2520Rheumatology%26date%3D2020%26volume%3D2%26issue%3D6%26spage%3DE310%26epage%3DE311%26doi%3D10.1016%2FS2665-9913%2820%2930129-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Roche’s</span> <span> </span><span class="NLM_article-title">Phase III EMPACTA Study Showed Actemra/RoActemra
Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalised
Patients with COVID-19 Associated Pneumonia</span>. <a href="https://www.roche.com/media/releases/med-cor-2020-09-18.htm" class="extLink">https://www.roche.com/media/releases/med-cor-2020-09-18.htm</a> (accessed Sep 27, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Roche%E2%80%99s&title=Phase+III+EMPACTA+Study+Showed+Actemra%2FRoActemra%0AReduced+the+Likelihood+of+Needing+Mechanical+Ventilation+in+Hospitalised%0APatients+with+COVID-19+Associated+Pneumonia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DPhase%2520III%2520EMPACTA%2520Study%2520Showed%2520Actemra%252FRoActemra%250AReduced%2520the%2520Likelihood%2520of%2520Needing%2520Mechanical%2520Ventilation%2520in%2520Hospitalised%250APatients%2520with%2520COVID-19%2520Associated%2520Pneumonia%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guaraldi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meschiari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzi-Lepri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Gaetano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzzolante, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corradi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaniere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabbi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedeschi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartoletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugioni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrangelo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossarizza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pea, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvarani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussini, C.</span></span> <span> </span><span class="NLM_article-title">Tocilizumab in Patients with Severe COVID-19; a Retrospective Cohort Study</span>. <i>Lancet Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">E474</span>– <span class="NLM_lpage">E484</span>, <span class="refDoi"> DOI: 10.1016/S2665-9913(20)30173-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930173-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32835257" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=E474-E484&issue=8&author=G.+Guaraldiauthor=M.+Meschiariauthor=A.+Cozzi-Lepriauthor=J.+Milicauthor=R.+Tonelliauthor=M.+Menozziauthor=E.+Franceschiniauthor=G.+Cuomoauthor=G.+Orlandoauthor=V.+Borghiauthor=A.+Santoroauthor=M.+Di+Gaetanoauthor=C.+Puzzolanteauthor=F.+Carliauthor=A.+Bediniauthor=L.+Corradiauthor=R.+Fantiniauthor=I.+Castaniereauthor=L.+Tabbiauthor=M.+Girardisauthor=S.+Tedeschiauthor=M.+Giannellaauthor=M.+Bartolettiauthor=R.+Pascaleauthor=G.+Dolciauthor=L.+Brugioniauthor=A.+Pietrangeloauthor=A.+Cossarizzaauthor=F.+Peaauthor=E.+Cliniauthor=C.+Salvaraniauthor=M.+Massariauthor=P.+L.+Vialeauthor=C.+Mussini&title=Tocilizumab+in+Patients+with+Severe+COVID-19%3B+a+Retrospective+Cohort+Study&doi=10.1016%2FS2665-9913%2820%2930173-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930173-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930173-9%26sid%3Dliteratum%253Aachs%26aulast%3DGuaraldi%26aufirst%3DG.%26aulast%3DMeschiari%26aufirst%3DM.%26aulast%3DCozzi-Lepri%26aufirst%3DA.%26aulast%3DMilic%26aufirst%3DJ.%26aulast%3DTonelli%26aufirst%3DR.%26aulast%3DMenozzi%26aufirst%3DM.%26aulast%3DFranceschini%26aufirst%3DE.%26aulast%3DCuomo%26aufirst%3DG.%26aulast%3DOrlando%26aufirst%3DG.%26aulast%3DBorghi%26aufirst%3DV.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DDi%2BGaetano%26aufirst%3DM.%26aulast%3DPuzzolante%26aufirst%3DC.%26aulast%3DCarli%26aufirst%3DF.%26aulast%3DBedini%26aufirst%3DA.%26aulast%3DCorradi%26aufirst%3DL.%26aulast%3DFantini%26aufirst%3DR.%26aulast%3DCastaniere%26aufirst%3DI.%26aulast%3DTabbi%26aufirst%3DL.%26aulast%3DGirardis%26aufirst%3DM.%26aulast%3DTedeschi%26aufirst%3DS.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DBartoletti%26aufirst%3DM.%26aulast%3DPascale%26aufirst%3DR.%26aulast%3DDolci%26aufirst%3DG.%26aulast%3DBrugioni%26aufirst%3DL.%26aulast%3DPietrangelo%26aufirst%3DA.%26aulast%3DCossarizza%26aufirst%3DA.%26aulast%3DPea%26aufirst%3DF.%26aulast%3DClini%26aufirst%3DE.%26aulast%3DSalvarani%26aufirst%3DC.%26aulast%3DMassari%26aufirst%3DM.%26aulast%3DViale%26aufirst%3DP.%2BL.%26aulast%3DMussini%26aufirst%3DC.%26atitle%3DTocilizumab%2520in%2520Patients%2520with%2520Severe%2520COVID-19%253B%2520a%2520Retrospective%2520Cohort%2520Study%26jtitle%3DLancet%2520Rheumatology%26date%3D2020%26volume%3D2%26issue%3D8%26spage%3DE474%26epage%3DE484%26doi%3D10.1016%2FS2665-9913%2820%2930173-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furlow, B.</span></span> <span> </span><span class="NLM_article-title">COVACTA Trial Raises Questions About Tocilizumab’s Benefit in COVID-19</span>. <i>Lancet Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">E592</span>, <span class="refDoi"> DOI: 10.1016/S2665-9913(20)30313-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS2665-9913%2820%2930313-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32929415" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2020&pages=E592&issue=10&author=B.+Furlow&title=COVACTA+Trial+Raises+Questions+About+Tocilizumab%E2%80%99s+Benefit+in+COVID-19&doi=10.1016%2FS2665-9913%2820%2930313-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS2665-9913%2820%2930313-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2665-9913%252820%252930313-1%26sid%3Dliteratum%253Aachs%26aulast%3DFurlow%26aufirst%3DB.%26atitle%3DCOVACTA%2520Trial%2520Raises%2520Questions%2520About%2520Tocilizumab%25E2%2580%2599s%2520Benefit%2520in%2520COVID-19%26jtitle%3DLancet%2520Rheumatology%26date%3D2020%26volume%3D2%26issue%3D10%26spage%3DE592%26doi%3D10.1016%2FS2665-9913%2820%2930313-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathinam, V. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span> <span> </span><span class="NLM_article-title">Inflammasome Complexes: Emerging Mechanisms and Effector Functions</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.cell.2016.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27153493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslKitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=792-800&issue=4&author=V.+A.+K.+Rathinamauthor=K.+A.+Fitzgerald&title=Inflammasome+Complexes%3A+Emerging+Mechanisms+and+Effector+Functions&doi=10.1016%2Fj.cell.2016.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammasome Complexes: Emerging Mechanisms and Effector Functions</span></div><div class="casAuthors">Rathinam, Vijay A. K.; Fitzgerald, Katherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">792-800</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Canonical activation of the inflammasome is crit. to promote caspase-1-dependent maturation of the proinflammatory cytokines IL-1β and IL-18, as well as to induce pyroptotic cell death in response to pathogens and endogenous danger signals.  Recent discoveries, however, are beginning to unveil new components of the inflammasome machinery as well as the full spectrum of inflammasome functions, extending their influence beyond canonical functions to regulation of eicosanoid storm, autophagy, and metab.  In addn., the receptor components of the inflammasome can also regulate diverse biol. processes, such as cellular proliferation, gene transcription, and tumorigenesis, all of which are independent of their inflammasome complex-forming capabilities.  Here, we review these recent advances that are shaping our understanding of the complex biol. of the inflammasome and its constituents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThWvwaIho17Vg90H21EOLACvtfcHk0lgEidWyNAmPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslKitrY%253D&md5=f95e0d0bbe9e3c412caaf4b7ed3d9fdd</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DRathinam%26aufirst%3DV.%2BA.%2BK.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26atitle%3DInflammasome%2520Complexes%253A%2520Emerging%2520Mechanisms%2520and%2520Effector%2520Functions%26jtitle%3DCell%26date%3D2016%26volume%3D165%26issue%3D4%26spage%3D792%26epage%3D800%26doi%3D10.1016%2Fj.cell.2016.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GroB, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreier, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ćiković, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodenkamp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Médard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naumann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GroB, O.</span></span> <span> </span><span class="NLM_article-title">The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis and IL-1 Release in the Absence of Caspase-1 Protease Activity</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3846</span>– <span class="NLM_lpage">3859</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2017.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.celrep.2017.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29281832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVeksb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=3846-3859&author=K.+S.+Schneiderauthor=C.+J.+GroBauthor=R.+F.+Dreierauthor=B.+S.+Sallerauthor=R.+Mishraauthor=O.+Gorkaauthor=R.+Heiligauthor=E.+Meunierauthor=M.+S.+Dickauthor=T.+%C4%86ikovi%C4%87author=J.+Sodenkampauthor=G.+M%C3%A9dardauthor=R.+Naumannauthor=J.+Rulandauthor=B.+Kusterauthor=P.+Brozauthor=O.+GroB&title=The+Inflammasome+Drives+GSDMD-Independent+Secondary+Pyroptosis+and+IL-1+Release+in+the+Absence+of+Caspase-1+Protease+Activity&doi=10.1016%2Fj.celrep.2017.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The Inflammasome Drives GSDMD-Independent Secondary Pyroptosis and IL-1 Release in the Absence of Caspase-1 Protease Activity</span></div><div class="casAuthors">Schneider, Katharina S.; Gross, Christina J.; Dreier, Roland F.; Saller, Benedikt S.; Mishra, Ritu; Gorka, Oliver; Heilig, Rosalie; Meunier, Etienne; Dick, Mathias S.; Cikovic, Tamara; Sodenkamp, Jan; Medard, Guillaume; Naumann, Ronald; Ruland, Juergen; Kuster, Bernhard; Broz, Petr; Gross, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3846-3859</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inflammasomes activate the protease caspase-1, which cleaves interleukin-1β and interleukin-18 to generate the mature cytokines and controls their secretion and a form of inflammatory cell death called pyroptosis.  By generating mice expressing enzymically inactive caspase-1C284A, we provide genetic evidence that caspase-1 protease activity is required for canonical IL-1 secretion, pyroptosis, and inflammasome-mediated immunity.  In caspase-1-deficient cells, caspase-8 can be activated at the inflammasome.  Using mice either lacking the pyroptosis effector gasdermin D (GSDMD) or expressing caspase-1C284A, we found that GSDMD-dependent pyroptosis prevented caspase-8 activation at the inflammasome.  In the absence of GSDMD-dependent pyroptosis, the inflammasome engaged a delayed, alternative form of lytic cell death that was accompanied by the release of large amts. of mature IL-1 and contributed to host protection.  Features of this cell death modality distinguished it from apoptosis, suggesting it may represent a distinct form of pro-inflammatory regulated necrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbq43d0I8bIbVg90H21EOLACvtfcHk0liP7QNkgPYp4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVeksb%252FE&md5=71fe5e84799fe99f7d56789f147051d4</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DK.%2BS.%26aulast%3DGroB%26aufirst%3DC.%2BJ.%26aulast%3DDreier%26aufirst%3DR.%2BF.%26aulast%3DSaller%26aufirst%3DB.%2BS.%26aulast%3DMishra%26aufirst%3DR.%26aulast%3DGorka%26aufirst%3DO.%26aulast%3DHeilig%26aufirst%3DR.%26aulast%3DMeunier%26aufirst%3DE.%26aulast%3DDick%26aufirst%3DM.%2BS.%26aulast%3D%25C4%2586ikovi%25C4%2587%26aufirst%3DT.%26aulast%3DSodenkamp%26aufirst%3DJ.%26aulast%3DM%25C3%25A9dard%26aufirst%3DG.%26aulast%3DNaumann%26aufirst%3DR.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DBroz%26aufirst%3DP.%26aulast%3DGroB%26aufirst%3DO.%26atitle%3DThe%2520Inflammasome%2520Drives%2520GSDMD-Independent%2520Secondary%2520Pyroptosis%2520and%2520IL-1%2520Release%2520in%2520the%2520Absence%2520of%2520Caspase-1%2520Protease%2520Activity%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D21%26spage%3D3846%26epage%3D3859%26doi%3D10.1016%2Fj.celrep.2017.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ku, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybuck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randle, J.</span></span> <span> </span><span class="NLM_article-title">Selective Interleukin-1β Converting Enzyme (ICE/Caspase-1) Inhibition with Pralnacasan (HMR 3480/VX-740) Reduces Inflammation and Joint Destruction in Murine Type II Collagen-Induced Arthritis (CIA)</span>. <i>Arthritis Rheumatism</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">S241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=11212168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=S241&issue=9&author=G.+Kuauthor=P.+Fordauthor=S.+Raybuckauthor=M.+Hardingauthor=J.+Randle&title=Selective+Interleukin-1%CE%B2+Converting+Enzyme+%28ICE%2FCaspase-1%29+Inhibition+with+Pralnacasan+%28HMR+3480%2FVX-740%29+Reduces+Inflammation+and+Joint+Destruction+in+Murine+Type+II+Collagen-Induced+Arthritis+%28CIA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKu%26aufirst%3DG.%26aulast%3DFord%26aufirst%3DP.%26aulast%3DRaybuck%26aufirst%3DS.%26aulast%3DHarding%26aufirst%3DM.%26aulast%3DRandle%26aufirst%3DJ.%26atitle%3DSelective%2520Interleukin-1%25CE%25B2%2520Converting%2520Enzyme%2520%2528ICE%252FCaspase-1%2529%2520Inhibition%2520with%2520Pralnacasan%2520%2528HMR%25203480%252FVX-740%2529%2520Reduces%2520Inflammation%2520and%2520Joint%2520Destruction%2520in%2520Murine%2520Type%2520II%2520Collagen-Induced%2520Arthritis%2520%2528CIA%2529%26jtitle%3DArthritis%2520Rheumatism%26date%3D2001%26volume%3D44%26issue%3D9%26spage%3DS241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolphi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verzijl, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Kraan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berg, W.</span></span> <span> </span><span class="NLM_article-title">Pralnacasan, an Inhibitor of Interleukin-1 Converting Enzyme, Reduces Joint Damage in Two Murine Models of Osteoarthritis</span>. <i>Osteo Arthritis and Cartilage</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1016/S1063-4584(03)00153-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2FS1063-4584%2803%2900153-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=13129693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BD3svjsFOhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=738-746&author=K.+Rudolphiauthor=N.+Gerwinauthor=N.+Verzijlauthor=P.+van+der+Kraanauthor=W.+van+den+Berg&title=Pralnacasan%2C+an+Inhibitor+of+Interleukin-1+Converting+Enzyme%2C+Reduces+Joint+Damage+in+Two+Murine+Models+of+Osteoarthritis&doi=10.1016%2FS1063-4584%2803%2900153-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis</span></div><div class="casAuthors">Rudolphi K; Gerwin N; Verzijl N; van der Kraan P; van den Berg W</div><div class="citationInfo"><span class="NLM_cas:title">Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">738-46</span>
        ISSN:<span class="NLM_cas:issn">1063-4584</span>.
    </div><div class="casAbstract">OBJECTIVE:  To study the effect of pralnacasan, the orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE), RU 36384/VRT-18858, on joint damage in two mouse models of knee osteoarthritis (OA).  DESIGN:  In a collagenase-induced OA model, pralnacasan was given orally by gavage to female Balb/c mice at 0, 12.5, 25 and 50 mg/kg twice a day.  In the second study, pralnacasan was tested in male STR/1N mice, which develop OA spontaneously, by administering food-drug mixtures ad libitum at concentrations of 0, 700 and 4200 ppm (mg/kg food).  OA joint damage was assessed by a semi-quantitative histopathological score in both studies.  In the STR/1N mouse study, urinary levels of collagen cross-links hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) were determined by high-pressure liquid chromatography at baseline, after 3 and 6 weeks of treatment and RU 36384/VRT-18858 plasma concentrations was measured after 6 weeks.  RESULTS:  In both studies, the mice developed moderate to severe knee joint OA in the medial joint compartments (tibial plateau and femoral condyle), the non-treated control groups showing median histopathological scores from 18 to 21 of a maximal score of 32.  Pralnacasan was well tolerated.  At the doses of 12.5 and 50 mg/kg in collagenase-induced OA and at the high dose of 4200 ppm in STR/1N mice pralnacasan treatment significantly reduced OA by 13-22%.  In the STR/1N mice, urinary levels of HP cross-links and the ratio of HP/LP, which are indicators of joint damage in OA, were significantly reduced in the high dose group by 59 and 84%, respectively.  CONCLUSIONS:  The ICE inhibitor pralnacasan reduced joint damage in two experimental models of OA and has the potential to become a disease-modifying drug for the treatment of OA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS00eZqsMAAocjl5L8hwNX0fW6udTcc2eZl8RzoQ_aMj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svjsFOhtg%253D%253D&md5=ec8e69c841b711bb5c56cb1f9ac983c3</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS1063-4584%2803%2900153-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1063-4584%252803%252900153-5%26sid%3Dliteratum%253Aachs%26aulast%3DRudolphi%26aufirst%3DK.%26aulast%3DGerwin%26aufirst%3DN.%26aulast%3DVerzijl%26aufirst%3DN.%26aulast%3Dvan%2Bder%2BKraan%26aufirst%3DP.%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DW.%26atitle%3DPralnacasan%252C%2520an%2520Inhibitor%2520of%2520Interleukin-1%2520Converting%2520Enzyme%252C%2520Reduces%2520Joint%2520Damage%2520in%2520Two%2520Murine%2520Models%2520of%2520Osteoarthritis%26jtitle%3DOsteo%2520Arthritis%2520and%2520Cartilage%26date%3D2003%26volume%3D11%26spage%3D738%26epage%3D746%26doi%3D10.1016%2FS1063-4584%2803%2900153-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span> </span><span class="NLM_article-title">Aventis and Vertex Pharmaceuticals Voluntarily
Discontinue Phase
IIb Clinical Trials of Pralnacasan in Rheumatoid Arthritis: Phase
II Activities Temporarily Suspended While Unexpected Toxicology Results
Analyzed</span>. <a href="https://www.sec.gov/Archives/edgar/data/875320/000110465903025360/a03-5139_1ex99d1.htm" class="extLink">https://www.sec.gov/Archives/edgar/data/875320/000110465903025360/a03-5139_1ex99d1.htm</a> (accessed Jun 9, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Aventis+and+Vertex+Pharmaceuticals+Voluntarily%0ADiscontinue+Phase%0AIIb+Clinical+Trials+of+Pralnacasan+in+Rheumatoid+Arthritis%3A+Phase%0AII+Activities+Temporarily+Suspended+While+Unexpected+Toxicology+Results%0AAnalyzed.+https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F875320%2F000110465903025360%2Fa03-5139_1ex99d1.htm+%28accessed+Jun+9%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAventis%2520and%2520Vertex%2520Pharmaceuticals%2520Voluntarily%250ADiscontinue%2520Phase%250AIIb%2520Clinical%2520Trials%2520of%2520Pralnacasan%2520in%2520Rheumatoid%2520Arthritis%253A%2520Phase%250AII%2520Activities%2520Temporarily%2520Suspended%2520While%2520Unexpected%2520Toxicology%2520Results%250AAnalyzed%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wannamaker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charifson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germann, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randle, J. C. R.</span></span> <span> </span><span class="NLM_article-title">(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL-18</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>321</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.111344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1124%2Fjpet.106.111344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=17289835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFehtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=509-516&issue=2&author=W.+Wannamakerauthor=R.+Daviesauthor=M.+Namchukauthor=J.+Pollardauthor=P.+Fordauthor=G.+Kuauthor=C.+Deckerauthor=P.+Charifsonauthor=P.+Weberauthor=U.+A.+Germannauthor=K.+Kuidaauthor=J.+C.+R.+Randle&title=%28S%29-1-%28%28S%29-2-%7B%5B1-%284-Amino-3-chloro-phenyl%29-methanoyl%5D-amino%7D-3%2C3-dimethyl-butanoyl%29-pyrrolidine-2-carboxylic+acid+%28%282R%2C3S%29-2-ethoxy-5-oxo-tetrahydro-furan-3-yl%29-amide+%28VX-765%29%2C+an+Orally+Available+Selective+Interleukin+%28IL%29-Converting+Enzyme%2FCaspase-1+Inhibitor%2C+Exhibits+Potent+Anti-Inflammatory+Activities+by+Inhibiting+the+Release+of+IL-1%CE%B2+and+IL-18&doi=10.1124%2Fjpet.106.111344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-1-((S)-2-{[1-(4-Amino-3-chlorophenyl)methanoyl]amino}-3,3-dimethylbutanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18</span></div><div class="casAuthors">Wannamaker, Woods; Davies, Robert; Namchuk, Mark; Pollard, John; Ford, Pamella; Ku, George; Decker, Caroline; Charifson, Paul; Weber, Peter; Germann, Ursula A.; Kuida, Keisuke; Randle, John C. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">509-516</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">VX-765 is an orally absorbed prodrug of (S)-3-({1-[(S)-1-((S)-2-{[1-(4-amino-3-chlorophenyl)methanoyl]amino}-3,3-dimethyl-butanoyl)pyrrolidin-2-yl]-methanoyl}amino)-4-oxobutyric acid (VRT-043198), a potent and selective inhibitor of interleukin-converting enzyme/caspase-1 subfamily caspases.  VRT-043198 exhibits 100- to 10,000-fold selectivity against other caspase-3 and -6 to -9.  The therapeutic potential of VX-765 was assessed by detg. the effects of VRT-043198 on cytokine release by monocytes in vitro and of orally administered VX-765 in several animal models in vivo.  In cultures of peripheral blood mononuclear cells and whole blood from healthy subjects stimulated with bacterial products, VRT-043198 inhibited the release of interleukin (IL)-1β and IL-18, but it had little effect on the release of several other cytokines, including IL-1α, tumor necrosis factor-α, IL-6 and IL-8.  In contrast, VRT-043198 had little or no demonstrable activity in cellular models of apoptosis, and it did not affect the proliferation of activated primary T cells or T-cell lines.  VX-765 was efficiently converted to VRT-043198 when administered orally to mice, and it inhibited lipopolysaccharide-induced cytokine secretion.  In addn., VX-765 reduced disease severity and the expression of inflammatory mediators in models of rheumatoid arthritis and skin inflammation.  These data suggest that VX-765 is a novel cytokine inhibitor useful for treatment of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUYnZtQc6cNrVg90H21EOLACvtfcHk0lgOSfzmUWluSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFehtLY%253D&md5=f310c20314ee44357acd3027105a8b6a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.111344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.111344%26sid%3Dliteratum%253Aachs%26aulast%3DWannamaker%26aufirst%3DW.%26aulast%3DDavies%26aufirst%3DR.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DFord%26aufirst%3DP.%26aulast%3DKu%26aufirst%3DG.%26aulast%3DDecker%26aufirst%3DC.%26aulast%3DCharifson%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DP.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DKuida%26aufirst%3DK.%26aulast%3DRandle%26aufirst%3DJ.%2BC.%2BR.%26atitle%3D%2528S%2529-1-%2528%2528S%2529-2-%257B%255B1-%25284-Amino-3-chloro-phenyl%2529-methanoyl%255D-amino%257D-3%252C3-dimethyl-butanoyl%2529-pyrrolidine-2-carboxylic%2520acid%2520%2528%25282R%252C3S%2529-2-ethoxy-5-oxo-tetrahydro-furan-3-yl%2529-amide%2520%2528VX-765%2529%252C%2520an%2520Orally%2520Available%2520Selective%2520Interleukin%2520%2528IL%2529-Converting%2520Enzyme%252FCaspase-1%2520Inhibitor%252C%2520Exhibits%2520Potent%2520Anti-Inflammatory%2520Activities%2520by%2520Inhibiting%2520the%2520Release%2520of%2520IL-1%25CE%25B2%2520and%2520IL-18%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26issue%3D2%26spage%3D509%26epage%3D516%26doi%3D10.1124%2Fjpet.106.111344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kudelova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischmannova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matalova, E.</span></span> <span> </span><span class="NLM_article-title">Pharmalogical Caspase Inhibitors: Research Towards Therapeutic Perspectives</span>. <i>J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26348072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVymurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=473-482&issue=4&author=J.+Kudelovaauthor=J.+Fleischmannovaauthor=E.+Adamovaauthor=E.+Matalova&title=Pharmalogical+Caspase+Inhibitors%3A+Research+Towards+Therapeutic+Perspectives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological caspase inhibitors: research towards therapeutic perspectives</span></div><div class="casAuthors">Kudelova, J.; Fleischmannova, J.; Adamova, E.; Matalova, E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">473-482</span>CODEN:
                <span class="NLM_cas:coden">JPHPEI</span>;
        ISSN:<span class="NLM_cas:issn">0867-5910</span>.
    
            (<span class="NLM_cas:orgname">Polish Physiological Society</span>)
        </div><div class="casAbstract">Caspases are key mols. of apoptosis and the inflammatory response.  Up-regulation of the caspase cascade contributes to human pathologies such as neurodegenerative and immune disorders.  Thus, blocking the excessive apoptosis by pharmacol. inhibitors seems promising for therapeutic interventions in such diseases, Caspase inhibitors, both natural and artificial, have been used as research tools and have helped to define the role of the individual caspases in apoptosis and in non-apoptotic processes.  Moreover, some caspase inhibitors have demonstrated their therapeutic efficiency in the redn. of cell death and inflammation in animal models of human diseases, however, no drug based on caspase inhibition has been approved on the market until now.  Thus, the development of therapeutic approaches that specifically target caspases remains a great challenge and is now the focus of intense biol. and clin. interest.  Here, we provide a brief review of recent knowledge about pharmacol. caspase inhibitors with special focus on their proposed clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW1AVlhbjjVrVg90H21EOLACvtfcHk0lgOSfzmUWluSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVymurzF&md5=e4ccc2a8861545154b9bce6882112772</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKudelova%26aufirst%3DJ.%26aulast%3DFleischmannova%26aufirst%3DJ.%26aulast%3DAdamova%26aufirst%3DE.%26aulast%3DMatalova%26aufirst%3DE.%26atitle%3DPharmalogical%2520Caspase%2520Inhibitors%253A%2520Research%2520Towards%2520Therapeutic%2520Perspectives%26jtitle%3DJ.%2520Physiol.%2520Pharmacol.%26date%3D2015%26volume%3D66%26issue%3D4%26spage%3D473%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Vertex</span>. <span> </span><span class="NLM_article-title">Vertex Announces Completion of Phase 2 Study of
VX-765 in People with Epilepsy Who Did Not Respond to Previous Treatment
- Results Support Continued Development of VX-765 in People with Treatment-Resistant
Epilepsy</span>. <a href="https://investors.vrtx.com/static-files/99195d36-42be-4e2a-a2b3-b0d632ba31c7" class="extLink">https://investors.vrtx.com/static-files/99195d36-42be-4e2a-a2b3-b0d632ba31c7</a> (accessed Jun 9, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Vertex&title=Vertex+Announces+Completion+of+Phase+2+Study+of%0AVX-765+in+People+with+Epilepsy+Who+Did+Not+Respond+to+Previous+Treatment%0A-+Results+Support+Continued+Development+of+VX-765+in+People+with+Treatment-Resistant%0AEpilepsy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DVertex%2520Announces%2520Completion%2520of%2520Phase%25202%2520Study%2520of%250AVX-765%2520in%2520People%2520with%2520Epilepsy%2520Who%2520Did%2520Not%2520Respond%2520to%2520Previous%2520Treatment%250A-%2520Results%2520Support%2520Continued%2520Development%2520of%2520VX-765%2520in%2520People%2520with%2520Treatment-Resistant%250AEpilepsy%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, G.</span></span> <span> </span><span class="NLM_article-title">NEK7 is an Essential Mediator of NLRP3 Activation Downstream of Potassium Efflux</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nature16959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature16959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26814970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2016&pages=354-357&author=Y.+Heauthor=M.+Y.+Zengauthor=D.+Yangauthor=B.+Motroauthor=G.+N%C3%BA%C3%B1ez&title=NEK7+is+an+Essential+Mediator+of+NLRP3+Activation+Downstream+of+Potassium+Efflux&doi=10.1038%2Fnature16959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux</span></div><div class="casAuthors">He, Yuan; Zeng, Melody Y.; Yang, Dahai; Motro, Benny; Nunez, Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">7590</span>),
    <span class="NLM_cas:pages">354-357</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammasomes are intracellular protein complexes that drive the activation of inflammatory caspases.  So far, four inflammasomes involving NLRP1, NLRP3, NLRC4 and AIM2 have been described that recruit the common adaptor protein ASC to activate caspase-1, leading to the secretion of mature IL-1β and IL-18 proteins.  The NLRP3 inflammasome has been implicated in the pathogenesis of several acquired inflammatory diseases as well as cryopyrin-assocd. periodic fever syndromes (CAPS) caused by inherited NLRP3 mutations.  Potassium efflux is a common step that is essential for NLRP3 inflammasome activation induced by many stimuli.  Despite extensive investigation, the mol. mechanism leading to NLRP3 activation in response to potassium efflux remains unknown.  Here the authors report the identification of NEK7, a member of the family of mammalian NIMA-related kinases (NEK proteins), as an NLRP3-binding protein that acts downstream of potassium efflux to regulate NLRP3 oligomerization and activation.  In the absence of NEK7, caspase-1 activation and IL-1β release were abrogated in response to signals that activate NLRP3, but not NLRC4 or AIM2 inflammasomes.  NLRP3-activating stimuli promoted the NLRP3-NEK7 interaction in a process that was dependent on potassium efflux.  NLRP3 assocd. with the catalytic domain of NEK7, but the catalytic activity of NEK7 was shown to be dispensable for activation of the NLRP3 inflammasome.  Activated macrophages formed a high-mol.-mass NLRP3-NEK7 complex, which, along with ASC oligomerization and ASC speck formation, was abrogated in the absence of NEK7.  NEK7 was required for macrophages contg. the CAPS-assocd. NLRP3(R258W) activating mutation to activate caspase-1.  Mouse chimeras reconstituted with wild-type, Nek7-/- or Nlrp3-/- hematopoietic cells showed that NEK7 was required for NLRP3 inflammasome activation in vivo.  These studies demonstrate that NEK7 is an essential protein that acts downstream of potassium efflux to mediate NLRP3 inflammasome assembly and activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcHD1JcxOIqrVg90H21EOLACvtfcHk0ljMghiMtyba9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyitbY%253D&md5=ff385d4ed4c8d8861059772c2cb26f19</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnature16959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16959%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DM.%2BY.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DMotro%26aufirst%3DB.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DG.%26atitle%3DNEK7%2520is%2520an%2520Essential%2520Mediator%2520of%2520NLRP3%2520Activation%2520Downstream%2520of%2520Potassium%2520Efflux%26jtitle%3DNature%26date%3D2016%26volume%3D530%26spage%3D354%26epage%3D357%26doi%3D10.1038%2Fnature16959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groß, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettmarshausen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittlein, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, P.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikovic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartjes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smollich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A.B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Supprian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traidl-Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perocchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groß, O.</span></span> <span> </span><span class="NLM_article-title">K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">773</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2016.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2016.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27692612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOmtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=761-773&author=C.+J.+Gro%C3%9Fauthor=R.+Mishraauthor=K.+S.+Schneiderauthor=G.+Medardauthor=J.+Wettmarshausenauthor=D.+C.+Dittleinauthor=H.+Shiauthor=O.+Gorkaauthor=P.-A.+Koenigauthor=S.+Frommauthor=G.+Magnaniauthor=T.+Cikovicauthor=L.+Hartjesauthor=J.+Smollichauthor=A.+A.B.+Robertsonauthor=M.+A.+Cooperauthor=M.+Schmidt-Supprianauthor=M.+Schusterauthor=K.+Schroderauthor=P.+Brozauthor=C.+Traidl-Hoffmannauthor=B.+Beutlerauthor=B.+Kusterauthor=J.+Rulandauthor=S.+Schneiderauthor=F.+Perocchiauthor=O.+Gro%C3%9F&title=K%2B+Efflux-Independent+NLRP3+Inflammasome+Activation+by+Small+Molecules+Targeting+Mitochondria&doi=10.1016%2Fj.immuni.2016.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria</span></div><div class="casAuthors">Gross, Christina J.; Mishra, Ritu; Schneider, Katharina S.; Medard, Guillaume; Wettmarshausen, Jennifer; Dittlein, Daniela C.; Shi, Hexin; Gorka, Oliver; Koenig, Paul-Albert; Fromm, Stephan; Magnani, Giovanni; Cikovic, Tamara; Hartjes, Lara; Smollich, Joachim; Robertson, Avril A. B.; Cooper, Matthew A.; Schmidt-Supprian, Marc; Schuster, Michael; Schroder, Kate; Broz, Petr; Traidl-Hoffmann, Claudia; Beutler, Bruce; Kuster, Bernhard; Ruland, Juergen; Schneider, Sabine; Perocchi, Fabiana; Gross, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">761-773</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Imiquimod is a small-mol. ligand of Toll-like receptor-7 (TLR7) that is licensed for the treatment of viral infections and cancers of the skin.  Imiquimod has TLR7-independent activities that are mechanistically unexplained, including NLRP3 inflammasome activation in myeloid cells and apoptosis induction in cancer cells.  We investigated the mechanism of inflammasome activation by imiquimod and the related mol. CL097 and detd. that K+ efflux was dispensable for NLRP3 activation by these compds.  Imiquimod and CL097 inhibited the quinone oxidoreductases NQO2 and mitochondrial Complex I.  This induced a burst of reactive oxygen species (ROS) and thiol oxidn., and led to NLRP3 activation via NEK7, a recently identified component of this inflammasome.  Metabolic consequences of Complex I inhibition and endolysosomal effects of imiquimod might also contribute to NLRP3 activation.  Our results reveal a K+ efflux-independent mechanism for NLRP3 activation and identify targets of imiquimod that might be clin. relevant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpx4Y3DNW0vbVg90H21EOLACvtfcHk0ljMghiMtyba9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOmtLzJ&md5=e39d1a51cafcecd59f5ab8f2f9d35ff1</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DGro%25C3%259F%26aufirst%3DC.%2BJ.%26aulast%3DMishra%26aufirst%3DR.%26aulast%3DSchneider%26aufirst%3DK.%2BS.%26aulast%3DMedard%26aufirst%3DG.%26aulast%3DWettmarshausen%26aufirst%3DJ.%26aulast%3DDittlein%26aufirst%3DD.%2BC.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DGorka%26aufirst%3DO.%26aulast%3DKoenig%26aufirst%3DP.-A.%26aulast%3DFromm%26aufirst%3DS.%26aulast%3DMagnani%26aufirst%3DG.%26aulast%3DCikovic%26aufirst%3DT.%26aulast%3DHartjes%26aufirst%3DL.%26aulast%3DSmollich%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DA.%2BA.B.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DSchmidt-Supprian%26aufirst%3DM.%26aulast%3DSchuster%26aufirst%3DM.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DBroz%26aufirst%3DP.%26aulast%3DTraidl-Hoffmann%26aufirst%3DC.%26aulast%3DBeutler%26aufirst%3DB.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DPerocchi%26aufirst%3DF.%26aulast%3DGro%25C3%259F%26aufirst%3DO.%26atitle%3DK%252B%2520Efflux-Independent%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Small%2520Molecules%2520Targeting%2520Mitochondria%26jtitle%3DImmunity%26date%3D2016%26volume%3D45%26spage%3D761%26epage%3D773%26doi%3D10.1016%2Fj.immuni.2016.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magupalli, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauenstein, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span> <span> </span><span class="NLM_article-title">Structural Mechanism for NEK7-licensed Activation of NLRP3 Inflammasome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>570</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/s41586-019-1295-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41586-019-1295-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31189953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKgs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=570&publication_year=2019&pages=338-343&author=H.+Sharifauthor=L.+Wangauthor=W.+L.+Wangauthor=V.+G.+Magupalliauthor=L.+Andreevaauthor=Q.+Qiaoauthor=A.+V.+Hauensteinauthor=Z.+Wuauthor=G.+Nunezauthor=Y.+Maoauthor=H.+Wu&title=Structural+Mechanism+for+NEK7-licensed+Activation+of+NLRP3+Inflammasome&doi=10.1038%2Fs41586-019-1295-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome</span></div><div class="casAuthors">Sharif, Humayun; Wang, Li; Wang, Wei Li; Magupalli, Venkat Giri; Andreeva, Liudmila; Qiao, Qi; Hauenstein, Arthur V.; Wu, Zhaolong; Nunez, Gabriel; Mao, Youdong; Wu, Hao</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">570</span>
        (<span class="NLM_cas:issue">7761</span>),
    <span class="NLM_cas:pages">338-343</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome can be activated by stimuli that include nigericin, uric acid crystals, amyloid-β fibrils and extracellular ATP.  The mitotic kinase NEK7 licenses the assembly and activation of the NLRP3 inflammasome in interphase.  Here we report a cryo-electron microscopy structure of inactive human NLRP3 in complex with NEK7, at a resoln. of 3.8 Å.  The earring-shaped NLRP3 consists of curved leucine-rich-repeat and globular NACHT domains, and the C-terminal lobe of NEK7 nestles against both NLRP3 domains.  Structural recognition between NLRP3 and NEK7 is confirmed by mutagenesis both in vitro and in cells.  Modeling of an active NLRP3-NEK7 conformation based on the NLRC4 inflammasome predicts an addnl. contact between an NLRP3-bound NEK7 and a neighboring NLRP3.  Mutations to this interface abolish the ability of NEK7 or NLRP3 to rescue NLRP3 activation in NEK7-knockout or NLRP3-knockout cells.  These data suggest that NEK7 bridges adjacent NLRP3 subunits with bipartite interactions to mediate the activation of the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKz2yqOHis9bVg90H21EOLACvtfcHk0lh5m5_-gE7Xnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKgs7vP&md5=e6d535e4d91e360ce82c1f4327e10e24</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1295-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1295-z%26sid%3Dliteratum%253Aachs%26aulast%3DSharif%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DMagupalli%26aufirst%3DV.%2BG.%26aulast%3DAndreeva%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DQ.%26aulast%3DHauenstein%26aufirst%3DA.%2BV.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DNunez%26aufirst%3DG.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DH.%26atitle%3DStructural%2520Mechanism%2520for%2520NEK7-licensed%2520Activation%2520of%2520NLRP3%2520Inflammasome%26jtitle%3DNature%26date%3D2019%26volume%3D570%26spage%3D338%26epage%3D343%26doi%3D10.1038%2Fs41586-019-1295-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span> <span> </span><span class="NLM_article-title">Oridonin is a Covalent NLRP3 Inhibitor with Strong Anti-Inflammasome Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2550</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04947-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41467-018-04947-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29317637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGqurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-12&issue=2550&author=H.+Heauthor=H.+Jiangauthor=Y.+Chenauthor=J.+Yeauthor=A.+Wangauthor=C.+Wangauthor=Q.+Liuauthor=G.+Liangauthor=X.+Dengauthor=W.+Jiangauthor=R.+Zhou&title=Oridonin+is+a+Covalent+NLRP3+Inhibitor+with+Strong+Anti-Inflammasome+Activity&doi=10.1038%2Fs41467-018-04947-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of pancreatic acinar cell carcinoma by Roux-en-Y Gastric Bypass Surgery</span></div><div class="casAuthors">He, Rui; Yin, Yue; Yin, Wenzhen; Li, Yin; Zhao, Jing; Zhang, Weizhen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Roux-en-Y Gastric Bypass Surgery (RYGB) prevents the occurrence of pancreatic cell acinar carcinoma (ACC) in male and female Ngn3-Tsc1-/- mice.  Ngn3 directed Cre deletion of Tsc1 gene induced the development of pancreatic ACC.  The transgenic mice with sham surgery demonstrated a cancer incidence of 96.7 ± 3.35% and survival rate of 67.0 ± 1.4% at the age of 300 days.  Metastasis to liver and kidney was obsd. in 69.7 ± 9.7% and 44.3 ± 8.01% of these animals, resp.  All animals with RYGB performed at the age of 16 wk survived free of pancreatic ACC up to the age of 300 days.  RYGB significantly attenuated the activation of mTORC1 signaling and inhibition of tumor suppressor genes: p21, p27, and p53 in pancreatic ACC.  Our studies demonstrate that bariatric surgery may limit the occurrence and growth of pancreatic ACC through the suppression of mTORC1 signaling in pancreas.  RYGB shows promise for intervention of both metabolic dysfunction and organ cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMD0P4M0bQ37Vg90H21EOLACvtfcHk0lhnR7GM8283DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGqurbI&md5=fbfeff076ac7a0336e3bce1fce8967bd</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04947-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04947-6%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DR.%26atitle%3DOridonin%2520is%2520a%2520Covalent%2520NLRP3%2520Inhibitor%2520with%2520Strong%2520Anti-Inflammasome%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D2550%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs41467-018-04947-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooftman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaslona, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runtsch, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGettrick, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diskin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundararaj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarotto, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlstrom, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palsson-McDermott, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corr, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K. H.G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R. J.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Board, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L. A.J.</span></span> <span> </span><span class="NLM_article-title">Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.08.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.celrep.2019.08.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31577945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSqtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=151-161&issue=1&author=M.+M.+Hughesauthor=A.+Hooftmanauthor=S.+Angiariauthor=P.+Tummalaauthor=Z.+Zaslonaauthor=M.+C.+Runtschauthor=A.+F.+McGettrickauthor=C.+E.+Suttonauthor=C.+Diskinauthor=M.+Rookeauthor=S.+Takahashiauthor=S.+Sundararajauthor=M.+G.+Casarottoauthor=J.+E.+Dahlstromauthor=E.+M.+Palsson-McDermottauthor=S.+C.+Corrauthor=K.+H.G.+Millsauthor=R.+J.S.+Prestonauthor=N.+Neamatiauthor=Y.+Xieauthor=J.+B.+Baellauthor=P.+G.+Boardauthor=L.+A.J.+O%E2%80%99Neill&title=Glutathione+Transferase+Omega-1+Regulates+NLRP3+Inflammasome+Activation+through+NEK7+Deglutathionylation&doi=10.1016%2Fj.celrep.2019.08.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation</span></div><div class="casAuthors">Hughes, Mark M.; Hooftman, Alexander; Angiari, Stefano; Tummala, Padmaja; Zaslona, Zbigniew; Runtsch, Marah C.; McGettrick, Anne F.; Sutton, Caroline E.; Diskin, Ciana; Rooke, Melissa; Takahashi, Shuhei; Sundararaj, Srinivasan; Casarotto, Marco G.; Dahlstrom, Jane E.; Palsson-McDermott, Eva M.; Corr, Sinead C.; Mills, Kingston H. G.; Preston, Roger J. S.; Neamati, Nouri; Xie, Yiyue; Baell, Jonathan B.; Board, Philip G.; O'Neill, Luke A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-161.e5</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome is a cytosolic complex sensing phagocytosed material and various damage-assocd. mol. patterns, triggering prodn. of the pro-inflammatory cytokines interleukin-1 beta (IL)-β and IL-18 and promoting pyroptosis.  Here, we characterize glutathione transferase omega 1-1 (GSTO1-1), a constitutive deglutathionylating enzyme, as a regulator of the NLRP3 inflammasome.  Using a small mol. inhibitor of GSTO1-1 termed C1-27, endogenous GSTO1-1 knockdown, and GSTO1-1-/- mice, we report that GSTO1-1 is involved in NLRP3 inflammasome activation.  Mechanistically, GSTO1-1 deglutathionylates cysteine 253 in NIMA related kinase 7 (NEK7) to promote NLRP3 activation.  We therefore identify GSTO1-1 as an NLRP3 inflammasome regulator, which has potential as a drug target to limit NLRP3-mediated inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIyA9WP4EQdbVg90H21EOLACvtfcHk0lhnR7GM8283DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSqtrjM&md5=0c3de58791a8b626ec0b2204736f5a3c</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.08.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.08.072%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DM.%2BM.%26aulast%3DHooftman%26aufirst%3DA.%26aulast%3DAngiari%26aufirst%3DS.%26aulast%3DTummala%26aufirst%3DP.%26aulast%3DZaslona%26aufirst%3DZ.%26aulast%3DRuntsch%26aufirst%3DM.%2BC.%26aulast%3DMcGettrick%26aufirst%3DA.%2BF.%26aulast%3DSutton%26aufirst%3DC.%2BE.%26aulast%3DDiskin%26aufirst%3DC.%26aulast%3DRooke%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DSundararaj%26aufirst%3DS.%26aulast%3DCasarotto%26aufirst%3DM.%2BG.%26aulast%3DDahlstrom%26aufirst%3DJ.%2BE.%26aulast%3DPalsson-McDermott%26aufirst%3DE.%2BM.%26aulast%3DCorr%26aufirst%3DS.%2BC.%26aulast%3DMills%26aufirst%3DK.%2BH.G.%26aulast%3DPreston%26aufirst%3DR.%2BJ.S.%26aulast%3DNeamati%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DBoard%26aufirst%3DP.%2BG.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.J.%26atitle%3DGlutathione%2520Transferase%2520Omega-1%2520Regulates%2520NLRP3%2520Inflammasome%2520Activation%2520through%2520NEK7%2520Deglutathionylation%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D29%26issue%3D1%26spage%3D151%26epage%3D161%26doi%3D10.1016%2Fj.celrep.2019.08.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span> <span> </span><span class="NLM_article-title">Regulation of NLRP3 Inflammasome by Phosphorylation</span>. <i>Frontiers in Immunology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">2305</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.02305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3389%2Ffimmu.2018.02305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29403488" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-9&issue=2305&author=N.+Songauthor=T.+Li&title=Regulation+of+NLRP3+Inflammasome+by+Phosphorylation&doi=10.3389%2Ffimmu.2018.02305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02305%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DT.%26atitle%3DRegulation%2520of%2520NLRP3%2520Inflammasome%2520by%2520Phosphorylation%26jtitle%3DFrontiers%2520in%2520Immunology%26date%3D2018%26volume%3D9%26issue%3D2305%26spage%3D1%26epage%3D9%26doi%3D10.3389%2Ffimmu.2018.02305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortimer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadee, K.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Inhibition is Disrupted in a Group of Auto-Inflammatory Disease CAPS Mutations</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1176</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1038/ni.3538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.3538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27548431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlyisLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=1176-1186&issue=10&author=L.+Mortimerauthor=F.+Moreauauthor=J.+A.+MacDonaldauthor=K.+Chadee&title=NLRP3+Inflammasome+Inhibition+is+Disrupted+in+a+Group+of+Auto-Inflammatory+Disease+CAPS+Mutations&doi=10.1038%2Fni.3538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations</span></div><div class="casAuthors">Mortimer, Leanne; Moreau, France; MacDonald, Justin A.; Chadee, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1176-1186</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammasomes are positioned to rapidly escalate the intensity of inflammation by activating interleukin (IL)-1β, IL-18 and cell death by pyroptosis.  However, neg. regulation of inflammasomes remains poorly understood, as is the signaling cascade that dampens inflammasome activity.  We found that rapid NLRP3 inflammasome activation was directly inhibited by protein kinase A (PKA), which was induced by prostaglandin E2 (PGE2) signaling via the PGE2 receptor E-prostanoid 4 (EP4).  PKA directly phosphorylated the cytoplasmic receptor NLRP3 and attenuated its ATPase function.  We found that Ser295 in human NLRP3 was crit. for rapid inhibition and PKA phosphorylation.  Mutations in NLRP3-encoding residues adjacent to Ser295 have been linked to the inflammatory disease CAPS (cryopyrin-assocd. periodic syndromes).  NLRP3-S295A phenocopied the human CAPS mutants.  These data suggest that neg. regulation at Ser295 is crit. for restraining the NLRP3 inflammasome and identify a mol. basis for CAPS-assocd. NLRP3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy0USzArMZsbVg90H21EOLACvtfcHk0lizkmuXTs7qig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlyisLjJ&md5=167971f60f807175bbb69a14158c688d</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fni.3538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3538%26sid%3Dliteratum%253Aachs%26aulast%3DMortimer%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DF.%26aulast%3DMacDonald%26aufirst%3DJ.%2BA.%26aulast%3DChadee%26aufirst%3DK.%26atitle%3DNLRP3%2520Inflammasome%2520Inhibition%2520is%2520Disrupted%2520in%2520a%2520Group%2520of%2520Auto-Inflammatory%2520Disease%2520CAPS%2520Mutations%26jtitle%3DNat.%2520Immunol.%26date%3D2016%26volume%3D17%26issue%3D10%26spage%3D1176%26epage%3D1186%26doi%3D10.1038%2Fni.3538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meszaros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.-t.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fatima
Magliarelli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihlan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig Gamez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goginashvili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielska, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebersold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, R.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase D at the Golgi Controls the NLRP3 Inflammasome Activation</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>214</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2671</span>– <span class="NLM_lpage">2693</span>, <span class="refDoi"> DOI: 10.1084/jem.20162040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1084%2Fjem.20162040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28716882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlemtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2017&pages=2671-2693&issue=9&author=Z.+Zhangauthor=G.+Meszarosauthor=W.-t.+Heauthor=Y.+Xuauthor=H.+de+Fatima%0AMagliarelliauthor=L.+Maillyauthor=M.+Mihlanauthor=Y.+Liuauthor=M.+Puig+Gamezauthor=A.+Goginashviliauthor=A.+Pasquierauthor=O.+Bielskaauthor=B.+Nevenauthor=P.+Quartierauthor=R.+Aebersoldauthor=T.+F.+Baumertauthor=P.+Georgelauthor=J.+Hanauthor=R.+Ricci&title=Protein+Kinase+D+at+the+Golgi+Controls+the+NLRP3+Inflammasome+Activation&doi=10.1084%2Fjem.20162040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase D at the Golgi controls NLRP3 inflammasome activation</span></div><div class="casAuthors">Zhang, Zhirong; Meszaros, Gergo; He, Wan-ting; Xu, Yanfang; Magliarelli, Helena de Fatima; Mailly, Laurent; Mihlan, Michael; Liu, Yansheng; Gamez, Marta Puig; Goginashvili, Alexander; Pasquier, Adrien; Bielska, Olga; Neven, Benedicte; Quartier, Pierre; Aebersold, Rudolf; Baumert, Thomas F.; Georgel, Philippe; Han, Jiahuai; Ricci, Romeo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2671-2693</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The inflammasomes are multiprotein complexs sensing tissue damage and infectious agents to initiate innate immune responses.  Different inflammasomes contg. distinct sensor mols. exist.  The NLRP3 inflammasome is unique as it detects a variety of danger signals.  It has been reported that NLRP3 is recruited to mitochondria-assocd. endoplasmic reticulum membranes (MAMs) and is activated by MAM-derived effectors.  Here, we show that in response to inflammasome activators, MAMs localize adjacent to Golgi membranes.  Diacylglycerol (DAG) at the Golgi rapidly increases, recruiting protein kinase D (PKD), a key effector of DAG.  Upon PKD inactivation, self-oligomerized NLRP3 is retained at MAMs adjacent to Golgi, blocking assembly of the active inflammasome.  Importantly, phosphorylation of NLRP3 by PKD at the Golgi is sufficient to release NLRP3 from MAMs, resulting in assembly of the active inflammasome.  Moreover, PKD inhibition prevents inflammasome autoactivation in peripheral blood mononuclear cells from patients carrying NLRP3 mutations.  Hence, Golgi-mediated PKD signaling is required and sufficient for NLRP3 inflammasome activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Soi3wqOjdLVg90H21EOLACvtfcHk0lizkmuXTs7qig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlemtbk%253D&md5=c2947be57cbac9abeb28d859ecd15188</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1084%2Fjem.20162040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20162040%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DMeszaros%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DW.-t.%26aulast%3DXu%26aufirst%3DY.%26aulast%3Dde%2BFatima%2BMagliarelli%26aufirst%3DH.%26aulast%3DMailly%26aufirst%3DL.%26aulast%3DMihlan%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPuig%2BGamez%26aufirst%3DM.%26aulast%3DGoginashvili%26aufirst%3DA.%26aulast%3DPasquier%26aufirst%3DA.%26aulast%3DBielska%26aufirst%3DO.%26aulast%3DNeven%26aufirst%3DB.%26aulast%3DQuartier%26aufirst%3DP.%26aulast%3DAebersold%26aufirst%3DR.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26aulast%3DGeorgel%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DRicci%26aufirst%3DR.%26atitle%3DProtein%2520Kinase%2520D%2520at%2520the%2520Golgi%2520Controls%2520the%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2017%26volume%3D214%26issue%3D9%26spage%3D2671%26epage%3D2693%26doi%3D10.1084%2Fjem.20162040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Phosphorylation is an Essential Priming Event for Inflammasome Activation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2017.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.molcel.2017.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28943315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGnsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2017&pages=185-197&issue=1&author=N.+Songauthor=Z.-S.+Liuauthor=W.+Xueauthor=Z.-F.+Baiauthor=Q.-Y.+Wangauthor=J.+Daiauthor=X.+Liuauthor=Y.-J.+Huangauthor=H.+Caiauthor=X.-Y.+Zhanauthor=Q.-Y.+Hanauthor=H.+Wangauthor=Y.+Chenauthor=H.-Y.+Liauthor=A.-L.+Liauthor=X.-M.+Zhangauthor=T.+Zhouauthor=T.+Li&title=NLRP3+Phosphorylation+is+an+Essential+Priming+Event+for+Inflammasome+Activation&doi=10.1016%2Fj.molcel.2017.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation</span></div><div class="casAuthors">Song, Nan; Liu, Zhao-Shan; Xue, Wen; Bai, Zhao-Fang; Wang, Qian-Yi; Dai, Jiang; Liu, Xin; Huang, Yi-Jiao; Cai, Hong; Zhan, Xiao-Yan; Han, Qiu-Ying; Wang, Hongxia; Chen, Yuan; Li, Hui-Yan; Li, Ai-Ling; Zhang, Xue-Min; Zhou, Tao; Li, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-197.e6</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Many infections and stress signals can rapidly activate the NLRP3 inflammasome to elicit robust inflammatory responses.  This activation requires a priming step, which is thought to be mainly for upregulating NLRP3 transcription.  However, recent studies report that the NLRP3 inflammasome can be activated independently of transcription, suggesting that the priming process has unknown essential regulatory steps.  Here, we report that JNK1-mediated NLRP3 phosphorylation at S194 is a crit. priming event and is essential for NLRP3 inflammasome activation.  We show that NLRP3 inflammasome activation is disrupted in NLRP3-S194A knockin mice.  JNK1-mediated NLRP3 S194 phosphorylation is crit. for NLRP3 deubiquitination and facilitates its self-assocn. and the subsequent inflammasome assembly.  Importantly, we demonstrate that blocking S194 phosphorylation prevents NLRP3 inflammasome activation in cryopyrin-assocd. periodic syndromes (CAPS).  Thus, our study reveals a key priming mol. event that is a prerequisite for NLRP3 inflammasome activation.  Inhibiting NLRP3 phosphorylation could be an effective treatment for NLRP3-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNwg8-xqO4bVg90H21EOLACvtfcHk0lg-l9muEXCNfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGnsrfN&md5=4baadedcf6fcebbe7e0e77345000f1a6</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2017.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DZ.-S.%26aulast%3DXue%26aufirst%3DW.%26aulast%3DBai%26aufirst%3DZ.-F.%26aulast%3DWang%26aufirst%3DQ.-Y.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.-J.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DZhan%26aufirst%3DX.-Y.%26aulast%3DHan%26aufirst%3DQ.-Y.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.-Y.%26aulast%3DLi%26aufirst%3DA.-L.%26aulast%3DZhang%26aufirst%3DX.-M.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DT.%26atitle%3DNLRP3%2520Phosphorylation%2520is%2520an%2520Essential%2520Priming%2520Event%2520for%2520Inflammasome%2520Activation%26jtitle%3DMol.%2520Cell%26date%3D2017%26volume%3D68%26issue%3D1%26spage%3D185%26epage%3D197%26doi%3D10.1016%2Fj.molcel.2017.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Ray, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkschulte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meissner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Assembly is Regulated by Phosphorylation of the Pyrin Domain</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>214</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1725</span>– <span class="NLM_lpage">1736</span>, <span class="refDoi"> DOI: 10.1084/jem.20160933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1084%2Fjem.20160933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28465465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OgsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2017&pages=1725-1736&issue=6&author=A.+Stutzauthor=C.+Kolbeauthor=R.+Stahlauthor=G.+Horvathauthor=B.+Franklinauthor=O.+van+Rayauthor=R.+Brinkschulteauthor=M.+Geyerauthor=F.+Meissnerauthor=E.+Latz&title=NLRP3+Inflammasome+Assembly+is+Regulated+by+Phosphorylation+of+the+Pyrin+Domain&doi=10.1084%2Fjem.20160933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain</span></div><div class="casAuthors">Stutz, Andrea; Kolbe, Carl-Christian; Stahl, Rainer; Horvath, Gabor L.; Franklin, Bernardo S.; Ray, Olivia van; Brinkschulte, Rebecca; Geyer, Matthias; Meissner, Felix; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1725-1736</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">NLRP3 is a cytosolic pattern recognition receptor that senses microbes and endogenous danger signals.  Upon activation, NLRP3 forms an inflammasome with the adapter ASC, resulting in caspase-1 activation, release of proinflammatory cytokines and cell death.  How NLRP3 activation is regulated by transcriptional and posttranslational mechanisms to prevent aberrant activation remains incompletely understood.  Here, we identify three conserved phosphorylation sites in NLRP3 and demonstrate that NLRP3 activation is controlled by phosphorylation of its pyrin domain (PYD).  Phosphomimetic residues in NLRP3 PYD abrogate inflammasome activation and structural modeling indicates that phosphorylation of the PYD regulates charge-charge interaction between two PYDs that are essential for NLRP3 activation.  Phosphatase 2A (PP2A) inhibition or knock-down drastically reduces NLRP3 activation, showing that PP2A can license inflammasome assembly via dephosphorylating NLRP3 PYD.  These results propose that the balance between kinases and phosphatases acting on the NLRP3 PYD is crit. for NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCB_CjTHBGDLVg90H21EOLACvtfcHk0ljW49DReloLPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OgsbrL&md5=ded2d910f713c60f11d41a766ca8d9ab</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1084%2Fjem.20160933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20160933%26sid%3Dliteratum%253Aachs%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DKolbe%26aufirst%3DC.%26aulast%3DStahl%26aufirst%3DR.%26aulast%3DHorvath%26aufirst%3DG.%26aulast%3DFranklin%26aufirst%3DB.%26aulast%3Dvan%2BRay%26aufirst%3DO.%26aulast%3DBrinkschulte%26aufirst%3DR.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DMeissner%26aufirst%3DF.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DNLRP3%2520Inflammasome%2520Assembly%2520is%2520Regulated%2520by%2520Phosphorylation%2520of%2520the%2520Pyrin%2520Domain%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2017%26volume%3D214%26issue%3D6%26spage%3D1725%26epage%3D1736%26doi%3D10.1084%2Fjem.20160933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Cuellar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweighoffer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuyama, M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of the Adaptor ASC Acts as a Molecular Switch that Controls the Formation of Speck-Like Aggregates and Inflammasome Activity</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1255</span>, <span class="refDoi"> DOI: 10.1038/ni.2749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.2749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24185614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWisbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1247-1255&issue=12&author=H.+Haraauthor=K.+Tsuchiyaauthor=I.+Kawamuraauthor=R.+Fangauthor=E.+Hernandez-Cuellarauthor=Y.+Shenauthor=J.+Mizuguchiauthor=E.+Schweighofferauthor=V.+Tybulewiczauthor=M.+Mitsuyama&title=Phosphorylation+of+the+Adaptor+ASC+Acts+as+a+Molecular+Switch+that+Controls+the+Formation+of+Speck-Like+Aggregates+and+Inflammasome+Activity&doi=10.1038%2Fni.2749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity</span></div><div class="casAuthors">Hara, Hideki; Tsuchiya, Kohsuke; Kawamura, Ikuo; Fang, Rendong; Hernandez-Cuellar, Eduardo; Shen, Yanna; Mizuguchi, Junichiro; Schweighoffer, Edina; Tybulewicz, Victor; Mitsuyama, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1247-1255</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inflammasome adaptor ASC contributes to innate immunity through the activation of caspase-1.  Here we found that signaling pathways dependent on the kinases Syk and Jnk were required for the activation of caspase-1 via the ASC-dependent inflammasomes NLRP3 and AIM2.  Inhibition of Syk or Jnk abolished the formation of ASC specks without affecting the interaction of ASC with NLRP3.  ASC was phosphorylated during inflammasome activation in a Syk- and Jnk-dependent manner, which suggested that Syk and Jnk are upstream of ASC phosphorylation.  Moreover, phosphorylation of Tyr144 in mouse ASC was crit. for speck formation and caspase-1 activation.  Our results suggest that phosphorylation of ASC controls inflammasome activity through the formation of ASC specks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriBevVIrORmrVg90H21EOLACvtfcHk0ljW49DReloLPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWisbvI&md5=2ad63f6ef21b319a29cd41d9b48a2ae2</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fni.2749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2749%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DH.%26aulast%3DTsuchiya%26aufirst%3DK.%26aulast%3DKawamura%26aufirst%3DI.%26aulast%3DFang%26aufirst%3DR.%26aulast%3DHernandez-Cuellar%26aufirst%3DE.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DMizuguchi%26aufirst%3DJ.%26aulast%3DSchweighoffer%26aufirst%3DE.%26aulast%3DTybulewicz%26aufirst%3DV.%26aulast%3DMitsuyama%26aufirst%3DM.%26atitle%3DPhosphorylation%2520of%2520the%2520Adaptor%2520ASC%2520Acts%2520as%2520a%2520Molecular%2520Switch%2520that%2520Controls%2520the%2520Formation%2520of%2520Speck-Like%2520Aggregates%2520and%2520Inflammasome%2520Activity%26jtitle%3DNat.%2520Immunol.%26date%3D2013%26volume%3D14%26issue%3D12%26spage%3D1247%26epage%3D1255%26doi%3D10.1038%2Fni.2749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, I.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun-Nan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojcius, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-C.</span></span> <span> </span><span class="NLM_article-title">Pyk2 Activates the NLRP3 Inflammasome by Directly Phosphorylating ASC and Contributes to Inflammasome-Dependent Peritonitis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">36214</span>, <span class="refDoi"> DOI: 10.1038/srep36214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fsrep36214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27796369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVSitLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=36214&author=I.-C.+Chungauthor=O.+Chun-Nanauthor=S.-N.+Yuanauthor=H.-P.+Liauthor=J.-T.+Chenauthor=H.-R.+Shiehauthor=Y.-J.+Chenauthor=D.+M.+Ojciusauthor=C.-L.+Chuauthor=J.+S.+Yuauthor=Y.-S.+Changauthor=L.-C.+Chen&title=Pyk2+Activates+the+NLRP3+Inflammasome+by+Directly+Phosphorylating+ASC+and+Contributes+to+Inflammasome-Dependent+Peritonitis&doi=10.1038%2Fsrep36214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis</span></div><div class="casAuthors">Chung, I-Che; OuYang, Chun-Nan; Yuan, Sheng-Ning; Li, Hsin-Pai; Chen, Jeng-Ting; Shieh, Hui-Ru; Chen, Yu-Jen; Ojcius, David M.; Chu, Ching-Liang; Yu, Jau-Song; Chang, Yu-Sun; Chen, Lih-Chyang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36214</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inflammasome adaptor protein, ASC, contributes to both innate immune responses and inflammatory diseases via self-oligomerization, which leads to the activation of the protease, caspase-1.  Here, we report that the cytosolic tyrosine kinases, FAK and Pyk2, are differentially involved in NLRP3 and AIM2 inflammasome activation.  The inhibition of FAK and Pyk2 with RNA interference or chem. inhibitors dramatically abolished ASC oligomerization, caspase-1 activation, and IL-1β secretion in response to NLRP3 or AIM2 stimulation.  Pyk2 is phosphorylated by the kinase Syk and relocalizes to the ASC specks upon NLRP3 inflammasome activation.  Pyk2, but not FAK, could directly phosphorylate ASC at Tyr146, and only the phosphorylated ASC could participate in speck formation and trigger IL-1β secretion.  Moreover, the clin.-trial-tested Pyk2/FAK dual inhibitor PF-562271 reduced monosodium urate-mediated peritonitis, a disease model used for studying the consequences of NLRP3 activation.  Our results suggest that although Pyk2 and FAK are involved in inflammasome activation, only Pyk2 directly phosphorylates ASC and brings ASC into an oligomerization-competent state by allowing Tyr146 phosphorylation to participate ASC speck formation and subsequent NLRP3 inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJECFWqBMP-bVg90H21EOLACvtfcHk0li7Ls0Ao7scaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVSitLvJ&md5=aaa6bbbd0e347e2425a9e740efc01399</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fsrep36214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep36214%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DI.-C.%26aulast%3DChun-Nan%26aufirst%3DO.%26aulast%3DYuan%26aufirst%3DS.-N.%26aulast%3DLi%26aufirst%3DH.-P.%26aulast%3DChen%26aufirst%3DJ.-T.%26aulast%3DShieh%26aufirst%3DH.-R.%26aulast%3DChen%26aufirst%3DY.-J.%26aulast%3DOjcius%26aufirst%3DD.%2BM.%26aulast%3DChu%26aufirst%3DC.-L.%26aulast%3DYu%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DY.-S.%26aulast%3DChen%26aufirst%3DL.-C.%26atitle%3DPyk2%2520Activates%2520the%2520NLRP3%2520Inflammasome%2520by%2520Directly%2520Phosphorylating%2520ASC%2520and%2520Contributes%2520to%2520Inflammasome-Dependent%2520Peritonitis%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D36214%26doi%3D10.1038%2Fsrep36214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shichita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, R.</span></span> <span> </span><span class="NLM_article-title">Burton’s Tyrosine Kinase is Essential for NLRP3 Inflammasome Activation and Contributes to Ischaemic Brain Injury</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">7360</span>, <span class="refDoi"> DOI: 10.1038/ncomms8360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fncomms8360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26059659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbit1ersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7360&author=M.+Itoauthor=T.+Shichitaauthor=M.+Okadaauthor=R.+Komineauthor=Y.+Noguchiauthor=A.+Yoshimuraauthor=R.+Morita&title=Burton%E2%80%99s+Tyrosine+Kinase+is+Essential+for+NLRP3+Inflammasome+Activation+and+Contributes+to+Ischaemic+Brain+Injury&doi=10.1038%2Fncomms8360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury</span></div><div class="casAuthors">Ito Minako; Okada Masahiro; Komine Ritsuko; Noguchi Yoshiko; Yoshimura Akihiko; Morita Rimpei; Shichita Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7360</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammasome activation has been implicated in various inflammatory diseases including post-ischaemic inflammation after stroke.  Inflammasomes mediate activation of caspase-1, which subsequently induces secretion of pro-inflammatory cytokines such as IL-1β and IL-18, as well as a form of cell death called pyroptosis.  In this study, we report that Bruton's tyrosine kinase (BTK) is an essential component of the NLRP3 inflammasome, in which BTK physically interacts with ASC and NLRP3.  Inhibition of BTK by pharmacological or genetic means severely impairs activation of the NLRP3 inflammasome.  The FDA-approved BTK inhibitor ibrutinib (PCI-32765) efficiently suppresses infarct volume growth and neurological damage in a brain ischaemia/reperfusion model in mice.  Ibrutinib inhibits maturation of IL-1β by suppressing caspase-1 activation in infiltrating macrophages and neutrophils in the infarcted area of ischaemic brain.  Our study indicates that BTK is essential for NLRP3 inflammasome activation and could be a potent therapeutic target in ischaemic stroke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpx_DiGIJ5y8jl5L8hwNX0fW6udTcc2ebo_lJZUnhn47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbit1ersg%253D%253D&md5=b3062eadbae9cd02ae356cbb8fb54ed2</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fncomms8360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8360%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DM.%26aulast%3DShichita%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DKomine%26aufirst%3DR.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DYoshimura%26aufirst%3DA.%26aulast%3DMorita%26aufirst%3DR.%26atitle%3DBurton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520is%2520Essential%2520for%2520NLRP3%2520Inflammasome%2520Activation%2520and%2520Contributes%2520to%2520Ischaemic%2520Brain%2520Injury%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7360%26doi%3D10.1038%2Fncomms8360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, Z. A.</span>; <span class="NLM_string-name">Liu, X.</span>; <span class="NLM_string-name">Dickhöfer, S.</span>; <span class="NLM_string-name">Kalbacher, H.</span>; <span class="NLM_string-name">Bosch, K.</span>; <span class="NLM_string-name">Andreeva, L.</span>; <span class="NLM_string-name">Marcu, A.</span>; <span class="NLM_string-name">Stevanovic, S.</span>; <span class="NLM_string-name">Mangan, M.</span>; <span class="NLM_string-name">Düwell, P.</span>; <span class="NLM_string-name">Lovotti, M.</span>; <span class="NLM_string-name">Herster, F.</span>; <span class="NLM_string-name">Löffler, M. W.</span>; <span class="NLM_string-name">Shankar, S.</span>; <span class="NLM_string-name">Tapia-Abellán, A.</span>; <span class="NLM_string-name">Wolz, O.-O.</span>; <span class="NLM_string-name">Schilling, N. A.</span>; <span class="NLM_string-name">Kümmerle-Deschner, J.</span>; <span class="NLM_string-name">Wagner, S.</span>; <span class="NLM_string-name">Delor, A.</span>; <span class="NLM_string-name">Grimbacher, B.</span>; <span class="NLM_string-name">Wu, H.</span>; <span class="NLM_string-name">Latz, E.</span>; <span class="NLM_string-name">Weber, A. N. R.</span></span>, <span> </span><span class="NLM_article-title">BTK Operates a Phospho-Tyrosine Switch to Regulate NLRP3 Inflammasome Activity</span> <i>bioRxiv</i> <span class="NLM_year">2019</span>, <span class="refDoi"> DOI: 10.1101/864702</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1101%2F864702" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Z.+A.+Bittner&author=X.+Liu&author=S.+Dickh%C3%B6fer&author=H.+Kalbacher&author=K.+Bosch&author=L.+Andreeva&author=A.+Marcu&author=S.+Stevanovic&author=M.+Mangan&author=P.+D%C3%BCwell&author=M.+Lovotti&author=F.+Herster&author=M.+W.+L%C3%B6ffler&author=S.+Shankar&author=A.+Tapia-Abell%C3%A1n&author=O.-O.+Wolz&author=N.+A.+Schilling&author=J.+K%C3%BCmmerle-Deschner&author=S.+Wagner&author=A.+Delor&author=B.+Grimbacher&author=H.+Wu&author=E.+Latz&author=A.+N.+R.+Weber&title=bioRxiv"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1101%2F864702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1101%252F864702%26sid%3Dliteratum%253Aachs%26aulast%3DBittner%26aufirst%3DZ.%2BA.%26atitle%3DBTK%2520Operates%2520a%2520Phospho-Tyrosine%2520Switch%2520to%2520Regulate%2520NLRP3%2520Inflammasome%2520Activity%26btitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F864702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bedford, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-like Protein Conjugation and the Ubiquitin-Proteasome System as Drug Targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1038/nrd3321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnrd3321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21151032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFChtLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=29-46&author=L.+Bedfordauthor=J.+Loweauthor=L.+R.+Dickauthor=J.+Mayerauthor=J.+E.+Brownell&title=Ubiquitin-like+Protein+Conjugation+and+the+Ubiquitin-Proteasome+System+as+Drug+Targets&doi=10.1038%2Fnrd3321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets</span></div><div class="casAuthors">Bedford, Lynn; Lowe, James; Dick, Lawrence R.; Mayer, R. John; Brownell, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-46</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system (UPS) and ubiquitin-like protein (UBL) conjugation pathways are integral to cellular protein homeostasis.  The growing recognition of the fundamental importance of these pathways to normal cell function and in disease has prompted an in-depth search for small-mol. inhibitors that selectively block the function of these pathways.  However, our limited understanding of the mol. mechanisms and biol. consequences of UBL conjugation is a significant hurdle to identifying drug-like inhibitors of enzyme targets within these pathways.  Here, we highlight recent advances in understanding the role of some of these enzymes and how these new insights may be the key to developing novel therapeutics for diseases including immuno-inflammatory disorders, cancer, infectious diseases, cardiovascular disease and neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkz-kR-1J0ELVg90H21EOLACvtfcHk0liqFV6aAkaCBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFChtLjE&md5=99e49846be907b138ca87bebc5ee91ee</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnrd3321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3321%26sid%3Dliteratum%253Aachs%26aulast%3DBedford%26aufirst%3DL.%26aulast%3DLowe%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26atitle%3DUbiquitin-like%2520Protein%2520Conjugation%2520and%2520the%2520Ubiquitin-Proteasome%2520System%2520as%2520Drug%2520Targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D29%26epage%3D46%26doi%3D10.1038%2Fnrd3321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a Primary Target of Thalidomide Teratogenicity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1350</span>, <span class="refDoi"> DOI: 10.1126/science.1177319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fscience.1177319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20223979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=1345-1350&author=T.+Itoauthor=H.+Andoauthor=T.+Suzukiauthor=T.+Oguraauthor=K.+Hottaauthor=Y.+Imamuraauthor=Y.+Yamaguchiauthor=H.+Handa&title=Identification+of+a+Primary+Target+of+Thalidomide+Teratogenicity&doi=10.1126%2Fscience.1177319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Primary Target of Thalidomide Teratogenicity</span></div><div class="casAuthors">Ito, Takumi; Ando, Hideki; Suzuki, Takayuki; Ogura, Toshihiko; Hotta, Kentaro; Imamura, Yoshimasa; Yamaguchi, Yuki; Handa, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5971</span>),
    <span class="NLM_cas:pages">1345-1350</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects.  Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental defects is unknown.  Here, we identified cereblon (CRBN) as a thalidomide-binding protein.  CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.  Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the assocd. ubiquitin ligase activity.  This study reveals a basis for thalidomide teratogenicity and may contribute to the development of new thalidomide derivs. without teratogenic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPC_7RXLkfabVg90H21EOLACvtfcHk0lgp6_mAnh3ngg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFensrs%253D&md5=4565a67837e0ec34ede2c93c1036f312</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1126%2Fscience.1177319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1177319%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DHotta%26aufirst%3DK.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520Primary%2520Target%2520of%2520Thalidomide%2520Teratogenicity%26jtitle%3DScience%26date%3D2010%26volume%3D327%26spage%3D1345%26epage%3D1350%26doi%3D10.1126%2Fscience.1177319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Py, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakifahmetoglu-Norberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span> <span> </span><span class="NLM_article-title">Deubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2012.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.molcel.2012.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23246432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCku7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=331-338&author=B.+F.+Pyauthor=M.-S.+Kimauthor=H.+Vakifahmetoglu-Norbergauthor=J.+Yuan&title=Deubiquitination+of+NLRP3+by+BRCC3+Critically+Regulates+Inflammasome+Activity&doi=10.1016%2Fj.molcel.2012.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Deubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity</span></div><div class="casAuthors">Py, Benedicte F.; Kim, Mi-Sung; Vakifahmetoglu-Norberg, Helin; Yuan, Junying</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-338</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">NLRP3 is an important pattern recognition receptor involved in mediating inflammasome activation in response to viral and bacterial infections as well as various proinflammatory stimuli assocd. with tissue damage or malfunction.  Upon activation, NLRP3 assembles a multimeric inflammasome complex comprising the adaptor ASC and the effector pro-caspase-1 to mediate the activation of caspase-1.  Although NLRP3 expression is induced by the NF-κB pathway, the posttranscriptional mol. mechanism controlling the activation of NLRP3 remains elusive.  Using both pharmacol. and mol. approaches, we show that the activation of NLRP3 inflammasome is regulated by a deubiquitination mechanism.  We further identify the deubiquitinating enzyme, BRCC3, as a crit. regulator of NLRP3 activity by promoting its deubiquitination and characterizing NLRP3 as a substrate for the cytosolic BRCC3-contg. BRISC complex.  Our results elucidate a regulatory mechanism involving BRCC3-dependent NLRP3 regulation and highlight NLRP3 ubiquitination as a potential therapeutic target for inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4BbAkb645obVg90H21EOLACvtfcHk0lgp6_mAnh3ngg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCku7nL&md5=b84aeaec7e762a36b39abd55d705b30b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DPy%26aufirst%3DB.%2BF.%26aulast%3DKim%26aufirst%3DM.-S.%26aulast%3DVakifahmetoglu-Norberg%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DJ.%26atitle%3DDeubiquitination%2520of%2520NLRP3%2520by%2520BRCC3%2520Critically%2520Regulates%2520Inflammasome%2520Activity%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D49%26spage%3D331%26epage%3D338%26doi%3D10.1016%2Fj.molcel.2012.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lear, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajbhandari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snavely, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulick, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallampalli, R. K.</span></span> <span> </span><span class="NLM_article-title">Lipopolysaccharide Primes the NALP3 Inflammasome by Inhibiting its Ubiquitination and Degradation Mediated by SCF<sup>FBXL2</sup> E3 Ligase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">18123</span>– <span class="NLM_lpage">18133</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1074%2Fjbc.M115.645549" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=18123-18133&issue=29&author=S.+Hanauthor=T.+B.+Learauthor=J.+A.+Jeromeauthor=S.+Rajbhandariauthor=C.+A.+Snavelyauthor=D.+L.+Gulickauthor=K.+f.+Gibsonauthor=C.+Zhouauthor=B.+B.+Chenauthor=R.+K.+Mallampalli&title=Lipopolysaccharide+Primes+the+NALP3+Inflammasome+by+Inhibiting+its+Ubiquitination+and+Degradation+Mediated+by+SCFFBXL2+E3+Ligase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.645549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.645549%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DLear%26aufirst%3DT.%2BB.%26aulast%3DJerome%26aufirst%3DJ.%2BA.%26aulast%3DRajbhandari%26aufirst%3DS.%26aulast%3DSnavely%26aufirst%3DC.%2BA.%26aulast%3DGulick%26aufirst%3DD.%2BL.%26aulast%3DGibson%26aufirst%3DK.%2Bf.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DB.%2BB.%26aulast%3DMallampalli%26aufirst%3DR.%2BK.%26atitle%3DLipopolysaccharide%2520Primes%2520the%2520NALP3%2520Inflammasome%2520by%2520Inhibiting%2520its%2520Ubiquitination%2520and%2520Degradation%2520Mediated%2520by%2520SCFFBXL2%2520E3%2520Ligase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26issue%3D29%26spage%3D18123%26epage%3D18133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-328626, A Clinical
Study to Evaluate KT-1002 for the Treatment of Inflammatory Bowel
Disease, including Ulcerative Colitis and Crohn’s Disease.</i> <a href="https://citeline.informa.com/trials/details/328626?qId=f03d3d1b-94a9-4c09-b53f-543447fe5ea0" class="extLink">https://citeline.informa.com/trials/details/328626?qId=f03d3d1b-94a9-4c09-b53f-543447fe5ea0</a> (accessed Apr 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-328626%2C+A+Clinical%0AStudy+to+Evaluate+KT-1002+for+the+Treatment+of+Inflammatory+Bowel%0ADisease%2C+including+Ulcerative+Colitis+and+Crohn%E2%80%99s+Disease.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F328626%3FqId%3Df03d3d1b-94a9-4c09-b53f-543447fe5ea0+%28accessed+Apr+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-328626%252C%2520A%2520Clinical%250AStudy%2520to%2520Evaluate%2520KT-1002%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Bowel%250ADisease%252C%2520including%2520Ulcerative%2520Colitis%2520and%2520Crohn%25E2%2580%2599s%2520Disease.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span> <span> </span><span class="NLM_article-title">Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 Inflammation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.11.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.cell.2014.11.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25594175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2lsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2015&pages=62-73&author=Y.+Yanauthor=W.+Jiangauthor=L.+Liuauthor=X.+Wangauthor=C.+Dingauthor=Z.+Tianauthor=R.+Zhou&title=Dopamine+Controls+Systemic+Inflammation+through+Inhibition+of+NLRP3+Inflammation&doi=10.1016%2Fj.cell.2014.11.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome</span></div><div class="casAuthors">Yan, Yiqing; Jiang, Wei; Liu, Lei; Wang, Xiaqiong; Ding, Chen; Tian, Zhigang; Zhou, Rongbin</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">62-73</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inflammasomes are involved in diverse inflammatory diseases, so the activation of inflammasomes needs to be tightly controlled to prevent excessive inflammation.  However, the endogenous regulatory mechanisms of inflammasome activation are still unclear.  Here, we report that the neurotransmitter dopamine (DA) inhibits NLRP3 inflammasome activation via dopamine D1 receptor (DRD1).  DRD1 signaling neg. regulates NLRP3 inflammasome via a second messenger cyclic adenosine monophosphate (cAMP), which binds to NLRP3 and promotes its ubiquitination and degrdn. via the E3 ubiquitin ligase MARCH7.  Importantly, in vivo data show that DA and DRD1 signaling prevent NLRP3 inflammasome-dependent inflammation, including neurotoxin-induced neuroinflammation, LPS-induced systemic inflammation, and monosodium urate crystal (MSU)-induced peritoneal inflammation.  Taken together, our results reveal an endogenous mechanism of inflammasome regulation and suggest DRD1 as a potential target for the treatment of NLRP3 inflammasome-driven diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCoi1PYLt3vrVg90H21EOLACvtfcHk0lhyrfY9BXjDmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2lsbc%253D&md5=48b1a2b5a54fef680343cd3294dc6b8e</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.11.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.11.047%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DR.%26atitle%3DDopamine%2520Controls%2520Systemic%2520Inflammation%2520through%2520Inhibition%2520of%2520NLRP3%2520Inflammation%26jtitle%3DCell%26date%3D2015%26volume%3D160%26spage%3D62%26epage%3D73%26doi%3D10.1016%2Fj.cell.2014.11.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span> <span> </span><span class="NLM_article-title">The E3 Ubiquitin Ligase TRIM31 Attenuates NLRP3 Inflammasome Activation by Promoting Proteasomal Degradation of NLRP3</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13727</span>, <span class="refDoi"> DOI: 10.1038/ncomms13727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fncomms13727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27929086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13727&author=H.+Songauthor=B.+Liuauthor=W.+Huaiauthor=Z.+Yuauthor=W.+Wangauthor=J.+Zhaoauthor=L.+Hanauthor=G.+Jiangauthor=L.+Zhangauthor=C.+Gaoauthor=W.+Zhao&title=The+E3+Ubiquitin+Ligase+TRIM31+Attenuates+NLRP3+Inflammasome+Activation+by+Promoting+Proteasomal+Degradation+of+NLRP3&doi=10.1038%2Fncomms13727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3</span></div><div class="casAuthors">Song, Hui; Liu, Bingyu; Huai, Wanwan; Yu, Zhongxia; Wang, Wenwen; Zhao, Jing; Han, Lihui; Jiang, Guosheng; Zhang, Lining; Gao, Chengjiang; Zhao, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13727</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome has a fundamental role in host defense against microbial pathogens and its deregulation may cause diverse inflammatory diseases.  NLRP3 protein expression is a rate-limiting step for inflammasome activation, thus its expression must be tightly controlled to maintain immune homeostasis and avoid detrimental effects.  However, how NLRP3 expression is regulated remains largely unknown.  In this study, we identify E3 ubiquitin ligase TRIM31 as a feedback suppressor of NLRP3 inflammasome.  TRIM31 directly binds to NLRP3, promotes K48-linked polyubiquitination and proteasomal degrdn. of NLRP3.  Consequently, TRIM31 deficiency enhances NLRP3 inflammasome activation and aggravates alum-induced peritonitis in vivo.  Furthermore, TRIM31 deficiency attenuates the severity of dextran sodium sulfate (DSS)-induced colitis, an inflammatory bowel diseases model in which NLRP3 possesses protective roles.  Thus, our research describes a mechanism by which TRIM31 limits NLRP3 inflammasome activity under physiol. conditions and suggests TRIM31 as a potential therapeutic target for the intervention of NLRP3 inflammasome related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5QK_RwuJAsrVg90H21EOLACvtfcHk0lha7KHIO5tPtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamsb7I&md5=e788f0dbe7b67ad95c72efcf19f97e4e</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fncomms13727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13727%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHuai%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DW.%26atitle%3DThe%2520E3%2520Ubiquitin%2520Ligase%2520TRIM31%2520Attenuates%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Promoting%2520Proteasomal%2520Degradation%2520of%2520NLRP3%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13727%26doi%3D10.1038%2Fncomms13727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitoma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tricot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-J.</span></span> <span> </span><span class="NLM_article-title">The E3 Ubiquitin Ligase Tripartite Motif 33 Is Essential for Cytosolic RNA-Induced NLRP3 Inflammasome Activation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">3676</span>– <span class="NLM_lpage">3682</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1401448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1401448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25172487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOnsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=3676-3682&author=L.+Wengauthor=H.+Mitomaauthor=C.+Tricotauthor=M.+Baoauthor=Y.+Liuauthor=Z.+Zhangauthor=Y.-J.+Liu&title=The+E3+Ubiquitin+Ligase+Tripartite+Motif+33+Is+Essential+for+Cytosolic+RNA-Induced+NLRP3+Inflammasome+Activation&doi=10.4049%2Fjimmunol.1401448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">The E3 Ubiquitin Ligase Tripartite Motif 33 Is Essential for Cytosolic RNA-Induced NLRP3 Inflammasome Activation</span></div><div class="casAuthors">Weng, Leiyun; Mitoma, Hiroki; Trichot, Coline; Bao, Musheng; Liu, Ying; Zhang, Zhiqiang; Liu, Yong-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3676-3682</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">NLRP3 is a key component of caspase-activating macromol. protein complexes called inflammasomes.  It has been found that DHX33 is a cytosolic dsRNA sensor for the NLRP3 inflammasome, which induces caspase-1-dependent prodn. of IL-1β and IL-18 upon activation.  However, how the cytosolic dsRNAs induce the interaction between DHX33 and the NLRP3 inflammasome remains unknown.  In this study, we report that TRIM33, a member of the tripartite motif (TRIM) family, can bind DHX33 directly and induce DHX33 ubiquitination via the lysine 218 upon dsRNA stimulation.  Knocking down of TRIM33 abolished the dsRNA-induced NLRP3 inflammasome activation in both THP-1-derived macrophages and human monocyte-derived macrophages.  The ubiquitination of DHX33 by TRIM33 is lysine 63 specific and is required for the formation of the DHX33-NLRP3 inflammasome complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_35cBrT67FLVg90H21EOLACvtfcHk0lha7KHIO5tPtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOnsLjJ&md5=8570f79500d90db7c6ab0ea49cb009be</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1401448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1401448%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DL.%26aulast%3DMitoma%26aufirst%3DH.%26aulast%3DTricot%26aufirst%3DC.%26aulast%3DBao%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.-J.%26atitle%3DThe%2520E3%2520Ubiquitin%2520Ligase%2520Tripartite%2520Motif%252033%2520Is%2520Essential%2520for%2520Cytosolic%2520RNA-Induced%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D3676%26epage%3D3682%26doi%3D10.4049%2Fjimmunol.1401448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. H.</span></span> <span> </span><span class="NLM_article-title">The Deubiquitinating Enzyme, Ubiquitin-Specific Peptidase 50, Regulates Inflammasome Activation by Targeting the ASC Adaptor Protein</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>591</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2F1873-3468.12558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28094437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=591&publication_year=2017&pages=479-490&author=J.+Y.+Leeauthor=D.+Seoauthor=J.+Youauthor=S.+Chungauthor=J.+S.+Parkauthor=J.-H.+Leeauthor=S.+M.+Jungauthor=Y.+S.+Leeauthor=S.+H.+Park&title=The+Deubiquitinating+Enzyme%2C+Ubiquitin-Specific+Peptidase+50%2C+Regulates+Inflammasome+Activation+by+Targeting+the+ASC+Adaptor+Protein&doi=10.1002%2F1873-3468.12558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">The deubiquitinating enzyme, ubiquitin-specific peptidase 50, regulates inflammasome activation by targeting the ASC adaptor protein</span></div><div class="casAuthors">Lee, Jae Young; Seo, Dongyeob; You, Jiyeon; Chung, Sehee; Park, Jin Seok; Lee, Ji-Hyung; Jung, Su Myung; Lee, Youn Sook; Park, Seok Hee</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">591</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-490</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">NOD-like receptor family protein 3 (NLRP3)-mediated inflammasome activation promotes caspase-1-dependent prodn. of interleukin-1β (IL-1β) and requires the adaptor protein ASC.  Compared with the priming and activation mechanisms of the inflammasome signaling pathway, post-translational ubiquitination/deubiquitination mechanisms controlling inflammasome activation have not been clearly addressed.  The authors here demonstrate that the deubiquitinating enzyme USP50 binds to the ASC protein and subsequently regulates the inflammasome signaling pathway by deubiquitinating the lysine 63-linked polyubiquitination of ASC.  USP50 knockdown in human THP-1 cells and mouse bone marrow-derived macrophages shows a significant decrease in procaspase-1 cleavage, resulting in a reduced secretion of IL-1β and interleukin-18 (IL-18) upon treatment with NLRP3 stimuli and a redn. in ASC speck formation and oligomerization.  Thus, the authors elucidate a novel regulatory mechanism of the inflammasome signaling pathway mediated by the USP50 deubiquitinating enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYuk8j74_iFLVg90H21EOLACvtfcHk0ljBUgab_SFoIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kms7k%253D&md5=ec89d85ff5039871a81d88417e944ec1</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12558%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DSeo%26aufirst%3DD.%26aulast%3DYou%26aufirst%3DJ.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DJung%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BH.%26atitle%3DThe%2520Deubiquitinating%2520Enzyme%252C%2520Ubiquitin-Specific%2520Peptidase%252050%252C%2520Regulates%2520Inflammasome%2520Activation%2520by%2520Targeting%2520the%2520ASC%2520Adaptor%2520Protein%26jtitle%3DFEBS%2520Lett.%26date%3D2017%26volume%3D591%26spage%3D479%26epage%3D490%26doi%3D10.1002%2F1873-3468.12558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castano-Rodriguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjuanes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, D.-Y.</span></span> <span> </span><span class="NLM_article-title">Severe Acute Respiratory Syndrome Coronavirus ORF3a Protein Activates the NLRP3 Inflammasome by Promoting TRAF3-Dependent Ubiquitination of ASC</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">8865</span>– <span class="NLM_lpage">8877</span>, <span class="refDoi"> DOI: 10.1096/fj.201802418R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1096%2Ffj.201802418R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31034780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVWnsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=8865-8877&issue=8&author=K.-L.+Siuauthor=K.-S.+Yuenauthor=C.+Castano-Rodriguezauthor=Z.-W.+Yeauthor=M.-L.+Yeungauthor=S.-Y.+Fungauthor=S.+Yuanauthor=C.-P.+Chanauthor=K.-Y.+Yuenauthor=L.+Enjuanesauthor=D.-Y.+Jin&title=Severe+Acute+Respiratory+Syndrome+Coronavirus+ORF3a+Protein+Activates+the+NLRP3+Inflammasome+by+Promoting+TRAF3-Dependent+Ubiquitination+of+ASC&doi=10.1096%2Ffj.201802418R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC</span></div><div class="casAuthors">Siu, Kam-Leung; Yuen, Kit-San; Castano-Rodriguez, Carlos; Ye, Zi-Wei; Yeung, Man-Lung; Fung, Sin-Yee; Yuan, Shuofeng; Chan, Chi-Ping; Yuen, Kwok-Yung; Enjuanes, Luis; Jin, Dong-Yan</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">8865-8877</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus (SARS-CoV) is capable of inducing a storm of proinflammatory cytokines.  In this study, we show that the SARS-CoV open reading frame 3a (ORF3a) accessory protein activates the NLRP3 inflammasome by promoting TNF receptor-assocd. factor 3 (TRAF3)-mediated ubiquitination of apoptosis-assocd. speck-like protein contg. a caspase recruitment domain (ASC).  SARS-CoV and its ORF3a protein were found to be potent activators of pro-IL-1b gene transcription and protein maturation, the 2 signals required for activation of the NLRP3 inflammasome.  ORF3a induced pro-IL-1b transcription through activation of NF-kB, which was mediated by TRAF3-dependent ubiquitination and processing of p105.  ORF3a induced elevation of IL-1b secretion was independent of its ion channel activity or absent in melanoma 2 but required NLRP3, ASC, and TRAF3.  ORF3a interacted with TRAF3 and ASC, colocalized with them in discrete punctate structures in the cytoplasm, and facilitated ASC speck formation.  TRAF3-dependent K63-linked ubiquitination of ASC was more pronounced in SARS-CoV-infected cells or when ORF3a was expressed.  Taken together, our findings reveal a new mechanism by which SARS-CoV ORF3a protein activates NF-kB and the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of p105 and ASC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PzhM5DkKdLVg90H21EOLACvtfcHk0ljBUgab_SFoIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVWnsLrP&md5=f5b36378f985b3e16047b00a0e5e5bde</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1096%2Ffj.201802418R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201802418R%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DK.-L.%26aulast%3DYuen%26aufirst%3DK.-S.%26aulast%3DCastano-Rodriguez%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DZ.-W.%26aulast%3DYeung%26aufirst%3DM.-L.%26aulast%3DFung%26aufirst%3DS.-Y.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DC.-P.%26aulast%3DYuen%26aufirst%3DK.-Y.%26aulast%3DEnjuanes%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DD.-Y.%26atitle%3DSevere%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520ORF3a%2520Protein%2520Activates%2520the%2520NLRP3%2520Inflammasome%2520by%2520Promoting%2520TRAF3-Dependent%2520Ubiquitination%2520of%2520ASC%26jtitle%3DFASEB%2520J.%26date%3D2019%26volume%3D33%26issue%3D8%26spage%3D8865%26epage%3D8877%26doi%3D10.1096%2Ffj.201802418R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-H.</span>; <span class="NLM_string-name">Lee, Y.</span>; <span class="NLM_string-name">Suh, G. Y.</span>; <span class="NLM_string-name">Lee, Y.-S.</span></span>, <span> </span><span class="NLM_article-title">Mul I Suppresses NLRP3 Inflammasome Activation Through Ubiquitination and Degradation of ASC</span>.  <i>bioRxiv</i> <span class="NLM_year">2019</span> <span class="refDoi"> DOI: 10.1101/830380</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1101%2F830380" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=H.-H.+Kim&author=Y.+Lee&author=G.+Y.+Suh&author=Y.-S.+Lee&title=bioRxiv"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1101%2F830380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1101%252F830380%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.-H.%26atitle%3DMul%2520I%2520Suppresses%2520NLRP3%2520Inflammasome%2520Activation%2520Through%2520Ubiquitination%2520and%2520Degradation%2520of%2520ASC%26btitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F830380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campden, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">The Role of Lysosomal Cysteine Cathepsins in NLRP3 Inflammasome Activation</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>670</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2019.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.abb.2019.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30807742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFOqu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=670&publication_year=2019&pages=32-42&author=R.+I.+Campdenauthor=Y.+Zhang&title=The+Role+of+Lysosomal+Cysteine+Cathepsins+in+NLRP3+Inflammasome+Activation&doi=10.1016%2Fj.abb.2019.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation</span></div><div class="casAuthors">Campden, Rhiannon I.; Zhang, Yifei</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">670</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Lysosomal cysteine cathepsins are a family of proteases that are involved in a myriad of cellular processes from proteolytic degrdn. in the lysosome to bone resorption.  These proteins mature following the cleavage of a pro-domain in the lysosome to become either exo- or endo-peptidases.  The cathepsins B, C, L, S and Z have been implicated in NLRP3 inflammasome activation following their activation with ATP, monosodium urate, silica crystals, or bacterial components, among others.  These five cathepsins have both compensatory and independent functions in NLRP3 inflammasome activation.  There is much evidence in the literature to support the release of cathepsin B following lysosomal membrane degrdn. which leads to NLRP3 inflammasome activation.  This is likely due to a hitherto unidentified role of this protein in the cytoplasm, although other interactions with autophagy proteins and within lysosomes have been proposed.  Cathepsin C is involved in the processing of neutrophil IL-1β through processing of upstream proteases.  Cathepsin Z is non-redundantly required for NLRP3 inflammasome activation following nigericin, ATP and monosodium urate activation.  Lysosomal cysteine cathepsins are members of a diverse and complementary family, and likely share both overlapping and independent functions in NLRP3 inflammasome activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQjAezZNN_wbVg90H21EOLACvtfcHk0lhzjnmeKLNYbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFOqu74%253D&md5=1f05b83dc71939a82985ab9b97d46f7b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2019.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2019.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DCampden%26aufirst%3DR.%2BI.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DThe%2520Role%2520of%2520Lysosomal%2520Cysteine%2520Cathepsins%2520in%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2019%26volume%3D670%26spage%3D32%26epage%3D42%26doi%3D10.1016%2Fj.abb.2019.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajamäki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappalainen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öörni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Välimäki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matikainen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovanen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eklund, K. K.</span></span> <span> </span><span class="NLM_article-title">Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>), <span class="NLM_elocation-id">e11765</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0011765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.pone.0011765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20668705" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&issue=7&author=K.+Rajam%C3%A4kiauthor=J.+Lappalainenauthor=K.+%C3%96%C3%B6rniauthor=E.+V%C3%A4lim%C3%A4kiauthor=S.+Matikainenauthor=P.+T.+Kovanenauthor=K.+K.+Eklund&title=Cholesterol+Crystals+Activate+the+NLRP3+Inflammasome+in+Human+Macrophages%3A+A+Novel+Link+between+Cholesterol+Metabolism+and+Inflammation&doi=10.1371%2Fjournal.pone.0011765"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0011765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0011765%26sid%3Dliteratum%253Aachs%26aulast%3DRajam%25C3%25A4ki%26aufirst%3DK.%26aulast%3DLappalainen%26aufirst%3DJ.%26aulast%3D%25C3%2596%25C3%25B6rni%26aufirst%3DK.%26aulast%3DV%25C3%25A4lim%25C3%25A4ki%26aufirst%3DE.%26aulast%3DMatikainen%26aufirst%3DS.%26aulast%3DKovanen%26aufirst%3DP.%2BT.%26aulast%3DEklund%26aufirst%3DK.%2BK.%26atitle%3DCholesterol%2520Crystals%2520Activate%2520the%2520NLRP3%2520Inflammasome%2520in%2520Human%2520Macrophages%253A%2520A%2520Novel%2520Link%2520between%2520Cholesterol%2520Metabolism%2520and%2520Inflammation%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26issue%3D7%26doi%3D10.1371%2Fjournal.pone.0011765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbert, J. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span> <span> </span><span class="NLM_article-title">Multiple Cathepsins Promote Pro-IL-1β Synthesis and NLRP3-Mediated IL-1β Activation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">1685</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1500509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1500509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26195813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12gt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2015&pages=1685-1697&author=G.+M.+Orlowskiauthor=J.+d.+Colbertauthor=S.+Sharmaauthor=M.+Bogyoauthor=S.+A.+Robertsonauthor=K.+L.+Rock&title=Multiple+Cathepsins+Promote+Pro-IL-1%CE%B2+Synthesis+and+NLRP3-Mediated+IL-1%CE%B2+Activation&doi=10.4049%2Fjimmunol.1500509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Cathepsins Promote Pro-IL-1β Synthesis and NLRP3-Mediated IL-1β Activation</span></div><div class="casAuthors">Orlowski, Gregory M.; Colbert, Jeff D.; Sharma, Shruti; Bogyo, Matthew; Robertson, Stephanie A.; Rock, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1685-1697</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Sterile particles induce robust inflammatory responses that underlie the pathogenesis of diseases like silicosis, gout, and atherosclerosis.  A key cytokine mediating this response is IL-1β.  The generation of bioactive IL-1β by sterile particles is mediated by the NOD-like receptor contg. a pyrin domain 3 (NLRP3) inflammasome, although exactly how this occurs is incompletely resolved.  Prior studies have found that the cathepsin B inhibitor, Ca074Me, suppresses this response, supporting a model whereby ingested particles disrupt lysosomes and release cathepsin B into the cytosol, somehow activating NLRP3.  However, reports that cathepsin B-deficient macrophages have no defect in particle-induced IL-1β generation have questioned cathepsin B's involvement.  In this study, we examine the hypothesis that multiple redundant cathepsins (not just cathepsin B) mediate this process by evaluating IL-1β generation in murine macrophages, singly or multiply deficient in cathepsins B, L, C, S and X. Using an activity-based probe, we measure specific cathepsin activity in living cells, documenting compensatory changes in cathepsin-deficient cells, and Ca074Me's dose-dependent cathepsin inhibition profile is analyzed in parallel with its suppression of particle-induced IL-1β secretion.  Also, we evaluate endogenous cathepsin inhibitors cystatins C and B. Surprisingly, we find that multiple redundant cathepsins, inhibited by Ca074Me and cystatins, promote pro-IL-1β synthesis, and to our knowledge, we provide the first evidence that cathepsin X plays a nonredundant role in nonparticulate NLRP3 activation.  Finally, we find cathepsin inhibitors selectively block particle-induced NLRP3 activation, independently of suppressing pro-IL-1β synthesis.  Altogether, we demonstrate that both small mol. and endogenous cathepsin inhibitors suppress particle-induced IL-1β secretion, implicating roles for multiple cathepsins in both pro-IL-1β synthesis and NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohBFbAHtRb3rVg90H21EOLACvtfcHk0ljzoxQb61KPVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12gt7zN&md5=a0e28826ce30c80aa0f9f3d941c6c396</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1500509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1500509%26sid%3Dliteratum%253Aachs%26aulast%3DOrlowski%26aufirst%3DG.%2BM.%26aulast%3DColbert%26aufirst%3DJ.%2Bd.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DBogyo%26aufirst%3DM.%26aulast%3DRobertson%26aufirst%3DS.%2BA.%26aulast%3DRock%26aufirst%3DK.%2BL.%26atitle%3DMultiple%2520Cathepsins%2520Promote%2520Pro-IL-1%25CE%25B2%2520Synthesis%2520and%2520NLRP3-Mediated%2520IL-1%25CE%25B2%2520Activation%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D195%26spage%3D1685%26epage%3D1697%26doi%3D10.4049%2Fjimmunol.1500509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichijo, H.</span></span> <span> </span><span class="NLM_article-title">The Lysosome Rupture-activated TAK1-JNK Pathway Regulates NLRP3 Inflammasome Activation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">32926</span>– <span class="NLM_lpage">32936</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.579961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1074%2Fjbc.M114.579961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25288801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKkt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=32926-32936&issue=47&author=M.+Okadaauthor=A.+Matsuzawaauthor=A.+Yoshimuraauthor=H.+Ichijo&title=The+Lysosome+Rupture-activated+TAK1-JNK+Pathway+Regulates+NLRP3+Inflammasome+Activation&doi=10.1074%2Fjbc.M114.579961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation</span></div><div class="casAuthors">Okada, Masahiro; Matsuzawa, Atsushi; Yoshimura, Akihiko; Ichijo, Hidenori</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">32926-32936</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Lysosome rupture triggers NLRP3 inflammasome activation in macrophages.  However, the underlying mechanism is not fully understood.  Here we showed that the TAK1-JNK pathway, a MAPK signaling pathway, is activated through lysosome rupture and that this activation is necessary for the complete activation of the NLRP3 inflammasome through the oligomerization of an adapter protein, apoptosis-assocd. speck-like protein contg. a caspase recruitment domain (ASC).  We also revealed that the activation of the TAK1-JNK pathway is sustained through Ca2+ ions and that calcium/calmodulin-dependent protein kinase type II functions upstream of the TAK1-JNK pathway and specifically regulates lysosome rupture-induced NLRP3 inflammasome activation.  These data suggest a novel role for the TAK1-JNK pathway as a crit. regulator of NLRP3 inflammasome activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplzjRjZXbuS7Vg90H21EOLACvtfcHk0ljzoxQb61KPVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKkt7rF&md5=a6885a1a5a1ef95eb984777e4dfa808b</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.579961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.579961%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DMatsuzawa%26aufirst%3DA.%26aulast%3DYoshimura%26aufirst%3DA.%26aulast%3DIchijo%26aufirst%3DH.%26atitle%3DThe%2520Lysosome%2520Rupture-activated%2520TAK1-JNK%2520Pathway%2520Regulates%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D47%26spage%3D32926%26epage%3D32936%26doi%3D10.1074%2Fjbc.M114.579961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enkhjargal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaguit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. H.</span></span> <span> </span><span class="NLM_article-title">Dihydrolipoic Acid Inhibits Lysosomal Rupture and NLRP3 Through Lysosome-Associated Membrane Protein-1/Calcium/Calmodulin-Dependent Protein Kinase II/TAK1 Pathways After Subarachnoid Hemorrhage in Rat</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1161/STROKEAHA.117.018593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1161%2FSTROKEAHA.117.018593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29273596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=175-183&issue=1&author=K.+Zhouauthor=B.+Enkhjargalauthor=Z.+Xieauthor=C.+Sunauthor=L.+Wuauthor=J.+Malaguitauthor=S.+Chenauthor=J.+Tangauthor=J.+Zhangauthor=J.+H.+Zhang&title=Dihydrolipoic+Acid+Inhibits+Lysosomal+Rupture+and+NLRP3+Through+Lysosome-Associated+Membrane+Protein-1%2FCalcium%2FCalmodulin-Dependent+Protein+Kinase+II%2FTAK1+Pathways+After+Subarachnoid+Hemorrhage+in+Rat&doi=10.1161%2FSTROKEAHA.117.018593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydrolipoic acid inhibits lysosomal rupture and nlrp3 through lysosome-associated membrane protein-1/calcium/calmodulin-dependent protein kinase ii/tak1 pathways after subarachnoid hemorrhage in rat</span></div><div class="casAuthors">Zhou, Keren; Enkhjargal, Budbazar; Xie, Zhiyi; Sun, Chengmei; Wu, Lingyun; Malaguit, Jay; Chen, Sheng; Tang, Jiping; Zhang, Jianmin; Zhang, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-183</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND AND PURPOSE-: The NLRP3 (nucleotide binding and oligomerization domain-like receptor family pyrin domain-contg. 3) inflammasome is a crucial component of the inflammatory response in early brain injury after subarachnoid hemorrhage (SAH).  In this study, we investigated a role of dihydrolipoic acid (DHLA) in lysosomal rupture, NLRP3 activation, and detd. the underlying pathway.  METHODS-: SAH was induced by endovascular perforation in male Sprague-Dawley rats.  DHLA was administered i.p. 1 h after SAH.  Small interfering RNA for lysosome-assocd. membrane protein-1 and CaMKIIα (calcium/calmodulin-dependent protein kinase II α) was administered through intracerebroventricular 48 h before SAH induction.  SAH grade evaluation, short- and long-term neurol. function testing, Western blot, and immunofluorescence staining expts. were performed.  RESULTS-: DHLA treatment increased the expression of lysosome-assocd. membrane protein-1 and decreased phosphorylated CaMKIIα and NLRP3 inflammasome, thereby alleviating neurol. deficits after SAH.  Lysosome-assocd. membrane protein-1 small interfering RNA abolished the neuroprotective effects of DHLA and increased the level of phosphorylated CaMKIIα, p-TAK1 (phosphorylated transforming growth factor-β-activated kinase), p-JNK (phosphorylated c-Jun-N-terminal kinase), and NLRP3 inflammasome.  CaMKIIα small interfering RNA downregulated the expression of p-TAK1, p-JNK, and NLRP3 and improved the neurobehavior after SAH.  CONCLUSIONS-: DHLA treatment improved neurofunction and alleviated inflammation through the lysosome-assocd. membrane protein-1/CaMKII/TAK1 pathway in early brain injury after SAH.  DHLA may provide a promising treatment to alleviate early brain injury after SAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8EwUm0EBjL7Vg90H21EOLACvtfcHk0liWQgy9xE6cMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2ksrc%253D&md5=3fe7d21a458b66d817c6847279a1168b</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.117.018593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.117.018593%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DK.%26aulast%3DEnkhjargal%26aufirst%3DB.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DMalaguit%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26atitle%3DDihydrolipoic%2520Acid%2520Inhibits%2520Lysosomal%2520Rupture%2520and%2520NLRP3%2520Through%2520Lysosome-Associated%2520Membrane%2520Protein-1%252FCalcium%252FCalmodulin-Dependent%2520Protein%2520Kinase%2520II%252FTAK1%2520Pathways%2520After%2520Subarachnoid%2520Hemorrhage%2520in%2520Rat%26jtitle%3DStroke%26date%3D2018%26volume%3D49%26issue%3D1%26spage%3D175%26epage%3D183%26doi%3D10.1161%2FSTROKEAHA.117.018593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.-C.</span></span> <span> </span><span class="NLM_article-title">Hydroxychloroquine Attenuates Renal Ischemia/Reperfusion Injury by Inhibiting Cathepsin Mediated NLRP3 Inflammasome Activation</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">351</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29298988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSms7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-14&issue=351&author=T.-T.+Tangauthor=M.-M.+Panauthor=Y.+Wenauthor=B.+Wangauthor=Z.-L.+Liauthor=M.+Wuauthor=F.-M.+Wangauthor=S.+D.+Crowleyauthor=B.-C.+Liu&title=Hydroxychloroquine+Attenuates+Renal+Ischemia%2FReperfusion+Injury+by+Inhibiting+Cathepsin+Mediated+NLRP3+Inflammasome+Activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA</span></div><div class="casAuthors">Tang, Jianming; Zhong, Guangsheng; Zhang, Haibo; Yu, Bo; Wei, Fangqiang; Luo, Liming; kang, Yao; Wu, Jianhui; Jiang, Jiaxiang; Li, Yucheng; Wu, Shuqiang; Jia, Yongshi; Liang, Xiaodong; Bi, Aihong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Conventional therapies and novel mol. targeted therapies against breast cancer have gained great advances over the past two decades.  However, poor prognosis and low survival rate are far from expectation for improvement, particularly in patients with triple neg. breast cancer (TNBC).  Here, we found that lncRNA DANCR was significantly overregulated in TNBC tissues and cell lines compared with normal breast tissues or other type of breast cancer.  Knockdown of DANCR suppressed TNBC proliferation both in vitro and in vivo.  Further study of underlying mechanisms demonstrated that DANCR bound with RXRA and increased its serine 49/78 phosphorylation via GSK3β, resulting in activating PIK3CA transcription, and subsequently enhanced PI3K/AKT signaling and TNBC tumorigenesis.  Taken together, our findings identified DANCR as an pro-oncogene and uncovered a new working pattern of lncRNA to mediate TNBC tumorigenesis, which may be a potential therapeutic target for improving treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc1dh6prybH7Vg90H21EOLACvtfcHk0liWQgy9xE6cMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSms7jE&md5=fdca54208fbbe946f8a119cc51288d7f</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DT.-T.%26aulast%3DPan%26aufirst%3DM.-M.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DZ.-L.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.-M.%26aulast%3DCrowley%26aufirst%3DS.%2BD.%26aulast%3DLiu%26aufirst%3DB.-C.%26atitle%3DHydroxychloroquine%2520Attenuates%2520Renal%2520Ischemia%252FReperfusion%2520Injury%2520by%2520Inhibiting%2520Cathepsin%2520Mediated%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26issue%3D351%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Arcy Hart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. R.</span></span> <span> </span><span class="NLM_article-title">Ammonia Inhibits Phagosome-Lysosome Fusion in Macrophages</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1038/286079a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2F286079a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=6993961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADyaL3cXls1Wrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1980&pages=79-80&author=A.+H.+Gordonauthor=P.+D%27Arcy+Hartauthor=M.+R.+Young&title=Ammonia+Inhibits+Phagosome-Lysosome+Fusion+in+Macrophages&doi=10.1038%2F286079a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Ammonia inhibits phagosome-lysosome fusion in macrophages</span></div><div class="casAuthors">Gordon, A. H.; D'Arcy Hart, P.; Young, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5768</span>),
    <span class="NLM_cas:pages">79-80</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">NH3 inhibited phagosome-lysosome fusion (P-LF) induced in mouse peritoneal macrophages by ingestion of Saccharomyces cerevisiae.  Mycobacterium tuberculosis Produced sufficient NH3 (≤20 mM) when grown in vitro to account for most or all of the fusion-inhibitory effect of its culture fluid in this yeast system.  Thus, M. tuberculosis may inhibit P-LF by the prodn. of NH3 or relevant amines within phagosomes of macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx4A85F2voyrVg90H21EOLACvtfcHk0liWQgy9xE6cMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXls1Wrurw%253D&md5=b3da688cb26ebc0c2116a3cd337b41eb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2F286079a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F286079a0%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DA.%2BH.%26aulast%3DD%2527Arcy%2BHart%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DM.%2BR.%26atitle%3DAmmonia%2520Inhibits%2520Phagosome-Lysosome%2520Fusion%2520in%2520Macrophages%26jtitle%3DNature%26date%3D1980%26volume%3D286%26spage%3D79%26epage%3D80%26doi%3D10.1038%2F286079a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heid, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter, R. D.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Reactive Oxygen Species Induces NLRP3-Dependent Lysosmal Damage and Inflammasome Activation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5230</span>– <span class="NLM_lpage">5238</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1301490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24089192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWlsL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=5230-5238&issue=10&author=M.+E.+Heidauthor=P.+A.+Keyelauthor=C.+Kamgaauthor=S.+Shivaauthor=S.+C.+Watkinsauthor=R.+D.+Salter&title=Mitochondrial+Reactive+Oxygen+Species+Induces+NLRP3-Dependent+Lysosmal+Damage+and+Inflammasome+Activation&doi=10.4049%2Fjimmunol.1301490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Reactive Oxygen Species Induces NLRP3-Dependent Lysosomal Damage and Inflammasome Activation</span></div><div class="casAuthors">Heid, Michelle E.; Keyel, Peter A.; Kamga, Christelle; Shiva, Sruti; Watkins, Simon C.; Salter, Russell D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5230-5238</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The nucleotide-binding oligomerization domain-like receptor family, pyrin domain-contg. 3 (NLRP3) inflammasome drives many inflammatory processes and mediates IL-1 family cytokine release.  Inflammasome activators typically damage cells and may release lysosomal and mitochondrial products into the cytosol.  Macrophages triggered by the NLRP3 inflammasome activator nigericin show reduced mitochondrial function and decreased cellular ATP.  Release of mitochondrial reactive oxygen species (ROS) leads to subsequent lysosomal membrane permeabilization (LMP).  NLRP3-deficient macrophages show comparable reduced mitochondrial function and ATP loss, but maintain lysosomal acidity, demonstrating that LMP is NLRP3 dependent.  A subset of wild-type macrophages undergo subsequent mitochondrial membrane permeabilization and die.  Both LMP and mitochondrial membrane permeabilization are inhibited by potassium, scavenging mitochondrial ROS, or NLRP3 deficiency, but are unaffected by cathepsin B or caspase-1 inhibitors.  In contrast, IL-1β secretion is ablated by potassium, scavenging mitochondrial ROS, and both cathepsin B and caspase-1 inhibition.  These results demonstrate interplay between lysosomes and mitochondria that sustain NLRP3 activation and distinguish cell death from IL-1β release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj5uO2tzJX_7Vg90H21EOLACvtfcHk0ljmHpVYtdM_2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWlsL%252FL&md5=f8016a549ebfb06742c3a4140349704a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301490%26sid%3Dliteratum%253Aachs%26aulast%3DHeid%26aufirst%3DM.%2BE.%26aulast%3DKeyel%26aufirst%3DP.%2BA.%26aulast%3DKamga%26aufirst%3DC.%26aulast%3DShiva%26aufirst%3DS.%26aulast%3DWatkins%26aufirst%3DS.%2BC.%26aulast%3DSalter%26aufirst%3DR.%2BD.%26atitle%3DMitochondrial%2520Reactive%2520Oxygen%2520Species%2520Induces%2520NLRP3-Dependent%2520Lysosmal%2520Damage%2520and%2520Inflammasome%2520Activation%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26issue%3D10%26spage%3D5230%26epage%3D5238%26doi%3D10.4049%2Fjimmunol.1301490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorbara, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardin, S. E.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial ROS Fuel the Inflammasome</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1038/cr.2011.20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fcr.2011.20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21283134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BC3MvhtlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=558-560&author=M.+T.+Sorbaraauthor=S.+E.+Girardin&title=Mitochondrial+ROS+Fuel+the+Inflammasome&doi=10.1038%2Fcr.2011.20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial ROS fuel the inflammasome</span></div><div class="casAuthors">Sorbara Matthew T; Girardin Stephen E</div><div class="citationInfo"><span class="NLM_cas:title">Cell research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">558-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToLlA23qka5EkUaC_kzhvyfW6udTcc2ebB17H3qM7uMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvhtlGqug%253D%253D&md5=007c030ae99fce66aa11f93289391f5d</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fcr.2011.20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2011.20%26sid%3Dliteratum%253Aachs%26aulast%3DSorbara%26aufirst%3DM.%2BT.%26aulast%3DGirardin%26aufirst%3DS.%2BE.%26atitle%3DMitochondrial%2520ROS%2520Fuel%2520the%2520Inflammasome%26jtitle%3DCell%2520Res.%26date%3D2011%26volume%3D21%26spage%3D558%26epage%3D560%26doi%3D10.1038%2Fcr.2011.20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span> <span> </span><span class="NLM_article-title">A Role for Mitochondria in NLRP3 Inflammasome Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1038/nature09663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature09663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21124315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2nsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=221-225&author=R.+Zhouauthor=A.+S.+Yazdiauthor=P.+Menuauthor=J.+Tschopp&title=A+Role+for+Mitochondria+in+NLRP3+Inflammasome+Activation&doi=10.1038%2Fnature09663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A role for mitochondria in NLRP3 inflammasome activation</span></div><div class="casAuthors">Zhou, Rong-Bin; Yazdi, Amir S.; Menu, Philippe; Tschopp, Jurg</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">221-225</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An inflammatory response initiated by the NLRP3 inflammasome is triggered by a variety of situations of host 'danger', including infection and metabolic dysregulation.  Previous studies suggested that NLRP3 inflammasome activity is neg. regulated by autophagy and pos. regulated by reactive oxygen species (ROS) derived from an uncharacterized organelle.  Here we show that mitophagy/autophagy blockade leads to the accumulation of damaged, ROS-generating mitochondria, and this in turn activates the NLRP3 inflammasome.  Resting NLRP3 localizes to endoplasmic reticulum structures, whereas on inflammasome activation both NLRP3 and its adaptor ASC redistribute to the perinuclear space where they colocalize with endoplasmic reticulum and mitochondria organelle clusters.  Notably, both ROS generation and inflammasome activation are suppressed when mitochondrial activity is dysregulated by inhibition of the voltage-dependent anion channel.  This indicates that NLRP3 inflammasome senses mitochondrial dysfunction and may explain the frequent assocn. of mitochondrial damage with inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2S_8r04FZELVg90H21EOLACvtfcHk0ljmHpVYtdM_2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2nsLrE&md5=f1a13fa2ad8568fbd6c9467121aa1d9d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnature09663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09663%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DYazdi%26aufirst%3DA.%2BS.%26aulast%3DMenu%26aufirst%3DP.%26aulast%3DTschopp%26aufirst%3DJ.%26atitle%3DA%2520Role%2520for%2520Mitochondria%2520in%2520NLRP3%2520Inflammasome%2520Activation%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D221%26epage%3D225%26doi%3D10.1038%2Fnature09663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakahira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haspel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinam, V. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolinay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englert, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernadas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryter, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, A. M. K.</span></span> <span> </span><span class="NLM_article-title">Autophagy Proteins Regulate Innate Immune Responses by Inhibiting the Release of Mitochondrial DNA Mediated by the NLRP3 Inflammasome</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1038/ni.1980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.1980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21151103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGgtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=222-230&author=K.+Nakahiraauthor=J.+A.+Haspelauthor=V.+A.+K.+Rathinamauthor=S.-J.+Leeauthor=T.+Dolinayauthor=H.+C.+Lamauthor=J.+A.+Englertauthor=M.+Rabinovitchauthor=M.+Cernadasauthor=H.+P.+Kimauthor=K.+A.+Fitzgeraldauthor=S.+W.+Ryterauthor=A.+M.+K.+Choi&title=Autophagy+Proteins+Regulate+Innate+Immune+Responses+by+Inhibiting+the+Release+of+Mitochondrial+DNA+Mediated+by+the+NLRP3+Inflammasome&doi=10.1038%2Fni.1980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome</span></div><div class="casAuthors">Nakahira, Ki-Ichi; Haspel, Jeffrey Adam; Rathinam, Vijay A. K.; Lee, Seon-Jin; Dolinay, Tamas; Lam, Hilaire C.; Englert, Joshua A.; Rabinovitch, Marlene; Cernadas, Manuela; Kim, Hong-Pyo; Fitzgerald, Katherine A.; Ryter, Stefan W.; Choi, Augustine M.-K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-230</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Autophagy, a cellular process for organelle and protein turnover, regulates innate immune responses.  Here we demonstrate that depletion of the autophagic proteins LC3B and beclin 1 enhanced the activation of caspase-1 and secretion of interleukin-1β (IL-1β) and IL-18.  Depletion of autophagic proteins promoted the accumulation of dysfunctional mitochondria and cytosolic translocation of mitochondrial DNA (mtDNA) in response to lipopolysaccharide (LPS) and ATP in macrophages.  Release of mtDNA into the cytosol depended on the NALP3 inflammasome and mitochondrial reactive oxygen species (ROS).  Cytosolic mtDNA contributed to the secretion of IL-1β and IL-18 in response to LPS and ATP.  LC3B-deficient mice produced more caspase-1-dependent cytokines in two sepsis models and were susceptible to LPS-induced mortality.  Our study suggests that autophagic proteins regulate NALP3-dependent inflammation by preserving mitochondrial integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA9JFQ4PVrk7Vg90H21EOLACvtfcHk0lhI1ltSlHzcMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGgtrzE&md5=acce38793034d600b469a8a2b6b4ee0d</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fni.1980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1980%26sid%3Dliteratum%253Aachs%26aulast%3DNakahira%26aufirst%3DK.%26aulast%3DHaspel%26aufirst%3DJ.%2BA.%26aulast%3DRathinam%26aufirst%3DV.%2BA.%2BK.%26aulast%3DLee%26aufirst%3DS.-J.%26aulast%3DDolinay%26aufirst%3DT.%26aulast%3DLam%26aufirst%3DH.%2BC.%26aulast%3DEnglert%26aufirst%3DJ.%2BA.%26aulast%3DRabinovitch%26aufirst%3DM.%26aulast%3DCernadas%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%2BP.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DRyter%26aufirst%3DS.%2BW.%26aulast%3DChoi%26aufirst%3DA.%2BM.%2BK.%26atitle%3DAutophagy%2520Proteins%2520Regulate%2520Innate%2520Immune%2520Responses%2520by%2520Inhibiting%2520the%2520Release%2520of%2520Mitochondrial%2520DNA%2520Mediated%2520by%2520the%2520NLRP3%2520Inflammasome%26jtitle%3DNat.%2520Immunol.%26date%3D2011%26volume%3D12%26spage%3D222%26epage%3D230%26doi%3D10.1038%2Fni.1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-García, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Banaclocha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angosto-Bazarra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torre-Minguela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baroja-Mazo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcón-Vila, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Alarcón, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amores-Iniesta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Sánchez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercole, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Lisorge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Pacheco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Gil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adriouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch-Nolte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luján, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta-Villegas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrilla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Palenciano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrin, P.</span></span> <span> </span><span class="NLM_article-title">P2X7 Receptor Induces Mitochondrial Failure in Monocytes and Compromises NLRP3 Inflammasome Activation During Sepsis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2711</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-10626-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41467-019-10626-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31221993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BB3M3ptVaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2711&author=J.+J.+Mart%C3%ADnez-Garc%C3%ADaauthor=H.+Mart%C3%ADnez-Banaclochaauthor=D.+Angosto-Bazarraauthor=C.+de+Torre-Minguelaauthor=A.+Baroja-Mazoauthor=C.+Alarc%C3%B3n-Vilaauthor=L.+Mart%C3%ADnez-Alarc%C3%B3nauthor=J.+Amores-Iniestaauthor=F.+Mart%C3%ADn-S%C3%A1nchezauthor=G.+A.+Ercoleauthor=C.+M.+Mart%C3%ADnezauthor=A.+Gonz%C3%A1lez-Lisorgeauthor=J.+Fern%C3%A1ndez-Pachecoauthor=P.+Mart%C3%ADnez-Gilauthor=S.+Adriouchauthor=F.+Koch-Nolteauthor=J.+Luj%C3%A1nauthor=F.+Acosta-Villegasauthor=P.+Parrillaauthor=C.+Garc%C3%ADa-Palencianoauthor=P.+Pelegrin&title=P2X7+Receptor+Induces+Mitochondrial+Failure+in+Monocytes+and+Compromises+NLRP3+Inflammasome+Activation+During+Sepsis&doi=10.1038%2Fs41467-019-10626-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis</span></div><div class="casAuthors">Martinez-Garcia Juan Jose; Martinez-Banaclocha Helios; Angosto-Bazarra Diego; de Torre-Minguela Carlos; Baroja-Mazo Alberto; Alarcon-Vila Cristina; Martinez-Alarcon Laura; Amores-Iniesta Joaquin; Martin-Sanchez Fatima; Parrilla Pascual; Pelegrin Pablo; Ercole Giovanni A; Gonzalez-Lisorge Ada; Fernandez-Pacheco Jose; Martinez-Gil Piedad; Acosta-Villegas Francisco; Garcia-Palenciano Carlos; Martinez Carlos M; Adriouch Sahil; Koch-Nolte Friedrich; Lujan Juan; Parrilla Pascual</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2711</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sepsis is characterized by a systemic inflammatory response followed by immunosuppression of the host.  Metabolic defects and mitochondrial failure are common in immunocompromised patients with sepsis.  The NLRP3 inflammasome is important for establishing an inflammatory response after activation by the purinergic P2X7 receptor.  Here, we study a cohort of individuals with intra-abdominal origin sepsis and show that patient monocytes have impaired NLRP3 activation by the P2X7 receptor.  Furthermore, most sepsis-related deaths are among patients whose NLRP3 activation is profoundly altered.  In monocytes from sepsis patients, the P2X7 receptor is associated with mitochondrial dysfunction.  Furthermore, activation of the P2X7 receptor results in mitochondrial damage, which in turn inhibits NLRP3 activation by HIF-1α.  We show that mortality increases in a mouse model of sepsis when the P2X7 receptor is activated in vivo.  These data reveal a molecular mechanism initiated by the P2X7 receptor that contributes to NLRP3 impairment during infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTcVKXbfvKN7GbPKh4T9eAfW6udTcc2eZfDq26Mf7e6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3ptVaisA%253D%253D&md5=c42379ba9783f43d78d277fba2b0c34b</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-10626-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-10626-x%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez-Garc%25C3%25ADa%26aufirst%3DJ.%2BJ.%26aulast%3DMart%25C3%25ADnez-Banaclocha%26aufirst%3DH.%26aulast%3DAngosto-Bazarra%26aufirst%3DD.%26aulast%3Dde%2BTorre-Minguela%26aufirst%3DC.%26aulast%3DBaroja-Mazo%26aufirst%3DA.%26aulast%3DAlarc%25C3%25B3n-Vila%26aufirst%3DC.%26aulast%3DMart%25C3%25ADnez-Alarc%25C3%25B3n%26aufirst%3DL.%26aulast%3DAmores-Iniesta%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADn-S%25C3%25A1nchez%26aufirst%3DF.%26aulast%3DErcole%26aufirst%3DG.%2BA.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DC.%2BM.%26aulast%3DGonz%25C3%25A1lez-Lisorge%26aufirst%3DA.%26aulast%3DFern%25C3%25A1ndez-Pacheco%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADnez-Gil%26aufirst%3DP.%26aulast%3DAdriouch%26aufirst%3DS.%26aulast%3DKoch-Nolte%26aufirst%3DF.%26aulast%3DLuj%25C3%25A1n%26aufirst%3DJ.%26aulast%3DAcosta-Villegas%26aufirst%3DF.%26aulast%3DParrilla%26aufirst%3DP.%26aulast%3DGarc%25C3%25ADa-Palenciano%26aufirst%3DC.%26aulast%3DPelegrin%26aufirst%3DP.%26atitle%3DP2X7%2520Receptor%2520Induces%2520Mitochondrial%2520Failure%2520in%2520Monocytes%2520and%2520Compromises%2520NLRP3%2520Inflammasome%2520Activation%2520During%2520Sepsis%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D2711%26doi%3D10.1038%2Fs41467-019-10626-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pétrilli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dostert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span> <span> </span><span class="NLM_article-title">Activation of the NALP3 Inflammasome is Triggered by Low Intracellular Potassium Concentration</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1583</span>– <span class="NLM_lpage">1589</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4402195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fsj.cdd.4402195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=17599094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptFymurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1583-1589&author=V.+P%C3%A9trilliauthor=S.+Papinauthor=C.+Dostertauthor=A.+Mayorauthor=F.+Martinonauthor=J.+Tschopp&title=Activation+of+the+NALP3+Inflammasome+is+Triggered+by+Low+Intracellular+Potassium+Concentration&doi=10.1038%2Fsj.cdd.4402195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration</span></div><div class="casAuthors">Petrilli, V.; Papin, S.; Dostert, C.; Mayor, A.; Martinon, F.; Tschopp, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1583-1589</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inflammasomes are Nod-like receptor(NLR)- and caspase-1-contg. cytoplasmic multiprotein complexes, which upon their assembly, process and activate the proinflammatory cytokines interleukin (IL)-1β and IL-18.  The inflammasomes harboring the NLR members NALP1, NALP3 and IPAF have been best characterized.  While the IPAF inflammasome is activated by bacterial flagellin, activation of the NALP3 inflammasome is triggered not only by several microbial components, but also by a plethora of danger-assocd. host mols. such as uric acid.  How NALP3 senses these chem. unrelated activators is not known.  Here, we provide evidence that activation of NALP3, but not of the IPAF inflammasome, is blocked by inhibiting K+ efflux from cells.  Low intracellular K+ is also a requirement for NALP1 inflammasome activation by lethal toxin of Bacillus anthracis.  In vitro, NALP inflammasome assembly and caspase-1 recruitment occurs spontaneously at K+ concns. below 90 mM, but is prevented at higher concns.  Thus, low intracellular K+ may be the least common trigger of NALP-inflammasome activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_dQ8Ub0nztrVg90H21EOLACvtfcHk0ljit8livaXIdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptFymurg%253D&md5=2bfb251f0e7b7d90ebed564cbd63c90f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4402195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4402195%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9trilli%26aufirst%3DV.%26aulast%3DPapin%26aufirst%3DS.%26aulast%3DDostert%26aufirst%3DC.%26aulast%3DMayor%26aufirst%3DA.%26aulast%3DMartinon%26aufirst%3DF.%26aulast%3DTschopp%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520the%2520NALP3%2520Inflammasome%2520is%2520Triggered%2520by%2520Low%2520Intracellular%2520Potassium%2520Concentration%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2007%26volume%3D14%26spage%3D1583%26epage%3D1589%26doi%3D10.1038%2Fsj.cdd.4402195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Planillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuffa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Colón, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajendiran, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, G.</span></span> <span> </span><span class="NLM_article-title">K<sup>+</sup> Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1142</span>– <span class="NLM_lpage">1153</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2013.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2013.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23809161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaitb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=1142-1153&author=R.+Mu%C3%B1oz-Planilloauthor=P.+Kuffaauthor=G.+Mart%C3%ADnez-Col%C3%B3nauthor=B.+L.+Smithauthor=T.+M.+Rajendiranauthor=G.+N%C3%BA%C3%B1ez&title=K%2B+Efflux+Is+the+Common+Trigger+of+NLRP3+Inflammasome+Activation+by+Bacterial+Toxins+and+Particulate+Matter&doi=10.1016%2Fj.immuni.2013.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">K+ Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter</span></div><div class="casAuthors">Munoz-Planillo, Raul; Kuffa, Peter; Martinez-Colon, Giovanny; Smith, Brenna L.; Rajendiran, Thekkelnaycke M.; Nunez, Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1142-1153</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome is an important component of the innate immune system.  However, its mechanism of activation remains largely unknown.  We show that NLRP3 activators including bacterial pore-forming toxins, nigericin, ATP, and particulate matter caused mitochondrial perturbation or the opening of a large membrane pore, but this was not required for NLRP3 activation.  Furthermore, reactive oxygen species generation or a change in cell vol. was not necessary for NLRP3 activation.  Instead, the only common activity induced by all NLRP3 agonists was the permeation of the cell membrane to K+ and Na+.  Notably, redn. of the intracellular K+ concn. was sufficient to activate NLRP3, whereas an increase in intracellular Na+ modulated but was not strictly required for inflammasome activation.  These results provide a unifying model for the activation of the NLRP3 inflammasome in which a drop in cytosolic K+ is the common step that is necessary and sufficient for caspase-1 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj2o5NsEXmVLVg90H21EOLACvtfcHk0ljit8livaXIdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaitb3M&md5=5532eee6c2f44c06f67df63ea73f3a1e</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2013.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2013.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DMu%25C3%25B1oz-Planillo%26aufirst%3DR.%26aulast%3DKuffa%26aufirst%3DP.%26aulast%3DMart%25C3%25ADnez-Col%25C3%25B3n%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DB.%2BL.%26aulast%3DRajendiran%26aufirst%3DT.%2BM.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DG.%26atitle%3DK%252B%2520Efflux%2520Is%2520the%2520Common%2520Trigger%2520of%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Bacterial%2520Toxins%2520and%2520Particulate%2520Matter%26jtitle%3DImmunity%26date%3D2013%26volume%3D38%26spage%3D1142%26epage%3D1153%26doi%3D10.1016%2Fj.immuni.2013.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malireddi, R.K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kometani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, T.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, A. B.</span></span> <span> </span><span class="NLM_article-title">The TWIK2 Potassium Efflux Channel in Macrophages Mediates NLRP3 Inflammasome Induced Inflammation</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2018.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2018.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29958799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Smu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=56-65&issue=1&author=A.+Diauthor=S.+Xiongauthor=Z.+Yeauthor=R.K.+S.+Malireddiauthor=S.+Kometaniauthor=M.+Zhongauthor=M.+Mittalauthor=Z.+Hongauthor=T.-D.+Kannegantiauthor=J.+Rehmanauthor=A.+B.+Malik&title=The+TWIK2+Potassium+Efflux+Channel+in+Macrophages+Mediates+NLRP3+Inflammasome+Induced+Inflammation&doi=10.1016%2Fj.immuni.2018.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation</span></div><div class="casAuthors">Di, Anke; Xiong, Shiqin; Ye, Zhiming; Malireddi, R. K. Subbarao; Kometani, Satoshi; Zhong, Ming; Mittal, Manish; Hong, Zhigang; Kanneganti, Thirumala-Devi; Rehman, Jalees; Malik, Asrar B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-65.e4</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Potassium (K+) efflux across the plasma membrane is thought to be an essential mechanism for ATP-induced NLRP3 inflammasome activation, yet the identity of the efflux channel has remained elusive.  Here we identified the two-pore domain K+ channel (K2P) TWIK2 as the K+ efflux channel triggering NLRP3 inflammasome activation.  Deletion of Kcnk6 (encoding TWIK2) prevented NLRP3 activation in macrophages and suppressed sepsis-induced lung inflammation.  Adoptive transfer of Kcnk6-/- macrophages into mouse airways after macrophage depletion also prevented inflammatory lung injury.  The K+ efflux channel TWIK2 in macrophages has a fundamental role in activating the NLRP3 inflammasome and consequently mediates inflammation, pointing to TWIK2 as a potential target for anti-inflammatory therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG6-0jm_OakLVg90H21EOLACvtfcHk0ljit8livaXIdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Smu7vK&md5=81c9a6a77acc1fbda934ede3f5379585</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2018.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2018.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DA.%26aulast%3DXiong%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DMalireddi%26aufirst%3DR.K.%2BS.%26aulast%3DKometani%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DMittal%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DKanneganti%26aufirst%3DT.-D.%26aulast%3DRehman%26aufirst%3DJ.%26aulast%3DMalik%26aufirst%3DA.%2BB.%26atitle%3DThe%2520TWIK2%2520Potassium%2520Efflux%2520Channel%2520in%2520Macrophages%2520Mediates%2520NLRP3%2520Inflammasome%2520Induced%2520Inflammation%26jtitle%3DImmunity%26date%3D2018%26volume%3D49%26issue%3D1%26spage%3D56%26epage%3D65%26doi%3D10.1016%2Fj.immuni.2018.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&issue=1&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+Heeremaauthor=A.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lijJbn_8XQC2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26issue%3D1%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittaluga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lih, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkre, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shustov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vose, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elstrom, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habermann, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munneke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1038/nm.3884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnm.3884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26193343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=922-926&issue=8&author=W.+H.+Wilsonauthor=R.+M.+Youngauthor=R.+Schmitzauthor=Y.+Yangauthor=S.+Pittalugaauthor=G.+Wrightauthor=C.-J.+Lihauthor=P.+M.+Williamsauthor=A.+L.+Shafferauthor=J.+Gerecitanoauthor=S.+de+Vosauthor=A.+Goyauthor=V.+P.+Kenkreauthor=P.+M.+Barrauthor=K.+A.+Blumauthor=A.+Shustovauthor=R.+Advaniauthor=N.+H.+Fowlerauthor=J.+M.+Voseauthor=R.+L.+Elstromauthor=T.+M.+Habermannauthor=J.+C.+Barrientosauthor=J.+McGreivyauthor=M.+Fardisauthor=B.+Y.+Changauthor=F.+Clowauthor=B.+Munnekeauthor=D.+Moussaauthor=D.+M.+Beaupreauthor=L.+M.+Staudt&title=Targeting+B+Cell+Receptor+Signaling+with+Ibrutinib+in+Diffuse+Large+B+Cell+Lymphoma&doi=10.1038%2Fnm.3884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span></div><div class="casAuthors">Wilson, Wyndham H.; Young, Ryan M.; Schmitz, Roland; Yang, Yandan; Pittaluga, Stefania; Wright, George; Lih, Chih-Jian; Williams, P. Mickey; Shaffer, Arthur L.; Gerecitano, John; de Vos, Sven; Goy, Andre; Kenkre, Vaishalee P.; Barr, Paul M.; Blum, Kristie A.; Shustov, Andrei; Advani, Ranjana; Fowler, Nathan H.; Vose, Julie M.; Elstrom, Rebecca L.; Habermann, Thomas M.; Barrientos, Jacqueline C.; McGreivy, Jesse; Fardis, Maria; Chang, Betty Y.; Clow, Fong; Munneke, Brian; Moussa, Davina; Beaupre, Darrin M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">922-926</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The two major subtypes of diffuse large B cell lymphoma (DLBCL)-activated B cell-like (ABC) and germinal center B cell-like (GCB)-arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling.  The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies.  We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling.  In a phase 1/2 clin. trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106).  ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), esp. those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways.  However, the highest no. of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms.  These results support the selective development of ibrutinib for the treatment of ABC DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpryc32RWzm77Vg90H21EOLACvtfcHk0lijJbn_8XQC2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK&md5=d3342e8baa16eb379eed112c21d0b4ba</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnm.3884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3884%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DLih%26aufirst%3DC.-J.%26aulast%3DWilliams%26aufirst%3DP.%2BM.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DGerecitano%26aufirst%3DJ.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DKenkre%26aufirst%3DV.%2BP.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DShustov%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DElstrom%26aufirst%3DR.%2BL.%26aulast%3DHabermann%26aufirst%3DT.%2BM.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DMoussa%26aufirst%3DD.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520B%2520Cell%2520Receptor%2520Signaling%2520with%2520Ibrutinib%2520in%2520Diffuse%2520Large%2520B%2520Cell%2520Lymphoma%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D8%26spage%3D922%26epage%3D926%26doi%3D10.1038%2Fnm.3884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal
Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammeijer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s Tyrosine Kinase in B Cell and Malignancies</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0779-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1186%2Fs12943-018-0779-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29455639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=57&author=S.+Pal%0ASinghauthor=F.+Dammeijerauthor=R.+W.+Hendriks&title=Role+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+B+Cell+and+Malignancies&doi=10.1186%2Fs12943-018-0779-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in B cells and malignancies</span></div><div class="casAuthors">Pal Singh Simar; Dammeijer Floris; Hendriks Rudi W; Pal Singh Simar; Pal Singh Simar; Dammeijer Floris; Dammeijer Floris</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies.  BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells.  Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR).  More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies.  In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions.  Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016.  To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies.  BTK inhibition has molecular effects beyond its classic role in BCR signaling.  These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches.  Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.  As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors.  Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses.  In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp0F3T0LEJd4vKgEt20y1XfW6udTcc2eZdqI6G5cRLHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D&md5=de1ba14dc19e6a123c21b89f1f4133f4</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0779-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0779-z%26sid%3Dliteratum%253Aachs%26aulast%3DPal%2BSingh%26aufirst%3DS.%26aulast%3DDammeijer%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B%2520Cell%2520and%2520Malignancies%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D57%26doi%3D10.1186%2Fs12943-018-0779-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichulik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolz, O.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, T.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickhöfer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daiber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Münzenmayer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kümmerle-Deschner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz-Wachtel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walz, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimbacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. N. R.</span></span> <span> </span><span class="NLM_article-title">Human NACHT, LRR, and PYD Domain-Containing Protein 3 (NLRP3) Inflammasome Activity is Regulated by and Potentially Targetable Through Bruton Tyrosine Kinase</span>. <i>Mechanisms of Allergy/Immunology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2017.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.jaci.2017.01.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=1054-1067&issue=4&author=X.+Liuauthor=T.+Pichulikauthor=O.-O.+Wolzauthor=T.-M.+Dangauthor=A.+Stutzauthor=C.+Dillenauthor=M.+D.+Garciaauthor=H.+Krausauthor=S.+Dickh%C3%B6ferauthor=E.+Daiberauthor=L.+M%C3%BCnzenmayerauthor=S.+Wahlauthor=N.+Rieberauthor=J.+K%C3%BCmmerle-Deschnerauthor=A.+S.+Yazdiauthor=M.+Franz-Wachtelauthor=B.+Macekauthor=M.+Radsakauthor=S.+Vogelauthor=B.+Schulteauthor=J.+S.+Walzauthor=D.+Hartlauthor=E.+Latzauthor=S.+Stilgenbauerauthor=B.+Grimbacherauthor=L.+Millerauthor=C.+Brunnerauthor=C.+Wolzauthor=A.+N.+R.+Weber&title=Human+NACHT%2C+LRR%2C+and+PYD+Domain-Containing+Protein+3+%28NLRP3%29+Inflammasome+Activity+is+Regulated+by+and+Potentially+Targetable+Through+Bruton+Tyrosine+Kinase&doi=10.1016%2Fj.jaci.2017.01.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2017.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2017.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DPichulik%26aufirst%3DT.%26aulast%3DWolz%26aufirst%3DO.-O.%26aulast%3DDang%26aufirst%3DT.-M.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DDillen%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DM.%2BD.%26aulast%3DKraus%26aufirst%3DH.%26aulast%3DDickh%25C3%25B6fer%26aufirst%3DS.%26aulast%3DDaiber%26aufirst%3DE.%26aulast%3DM%25C3%25BCnzenmayer%26aufirst%3DL.%26aulast%3DWahl%26aufirst%3DS.%26aulast%3DRieber%26aufirst%3DN.%26aulast%3DK%25C3%25BCmmerle-Deschner%26aufirst%3DJ.%26aulast%3DYazdi%26aufirst%3DA.%2BS.%26aulast%3DFranz-Wachtel%26aufirst%3DM.%26aulast%3DMacek%26aufirst%3DB.%26aulast%3DRadsak%26aufirst%3DM.%26aulast%3DVogel%26aufirst%3DS.%26aulast%3DSchulte%26aufirst%3DB.%26aulast%3DWalz%26aufirst%3DJ.%2BS.%26aulast%3DHartl%26aufirst%3DD.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DGrimbacher%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DL.%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DWolz%26aufirst%3DC.%26aulast%3DWeber%26aufirst%3DA.%2BN.%2BR.%26atitle%3DHuman%2520NACHT%252C%2520LRR%252C%2520and%2520PYD%2520Domain-Containing%2520Protein%25203%2520%2528NLRP3%2529%2520Inflammasome%2520Activity%2520is%2520Regulated%2520by%2520and%2520Potentially%2520Targetable%2520Through%2520Bruton%2520Tyrosine%2520Kinase%26jtitle%3DMechanisms%2520of%2520Allergy%252FImmunology%26date%3D2017%26volume%3D140%26issue%3D4%26spage%3D1054%26epage%3D1067%26doi%3D10.1016%2Fj.jaci.2017.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staikov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piasecka-Stryczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangond, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolinsky, J.</span></span> <span> </span><span class="NLM_article-title">Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">2406</span>– <span class="NLM_lpage">2147</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa1901981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31075187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2406-2147&issue=25&author=X.+Montalbanauthor=D.+L.+Arnoldauthor=M.+s.+Weberauthor=I.+Staikovauthor=K.+Piasecka-Stryczynskaauthor=J.+Willmerauthor=E.+C.+Martinauthor=F.+Dangondauthor=S.+Syedauthor=J.+Wolinsky&title=Placebo-Controlled+Trial+of+an+Oral+BTK+Inhibitor+in+Multiple+Sclerosis&doi=10.1056%2FNEJMoa1901981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis</span></div><div class="casAuthors">Montalban, Xavier; Arnold, Douglas L.; Weber, Martin S.; Staikov, Ivan; Piasecka-Stryczynska, Karolina; Willmer, Jonathan; Martin, Emily C.; Dangond, Fernando; Syed, Sana; Wolinsky, Jerry S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2406-2417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis.  Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo. methods In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label di-Me fumarate (DMF) as a ref.  The primary end point was the total (cumulative) no. of gadolinium-enhancing lesions identified on T1-weighted magnetic resonance imaging at weeks 12, 16, 20, and 24.  Key secondary end points included the annualized relapse rate and change from baseline in the score on the Expanded Disability Status Scale (EDSS). results A total of 267 patients were randomly assigned to a trial group.  The mean (±SD) total no. of gadolinium-enhancing lesions during weeks 12 through 24 was 3.85 ± 5.44 in the placebo group, 4.06 ± 8.02 in the evobrutinib 25-mg group, 1.69 ± 4.69 in the evobrutinib 75-mg once-daily group, 1.15 ± 3.70 in the evobrutinib 75-mg twice-daily group, and 4.78 ± 22.05 in the DMF group.  The baseline adjusted rate ratios for the total no. of lesions over time as compared with placebo were 1.45 in the evobrutinib 25-mg group (P = 0.32), 0.30 in the evobrutinib 75-mg once-daily group (P = 0.005), and 0.44 in the evobrutinib 75-mg twice-daily group (P = 0.06).  The unadjusted annualized relapse rate at week 24 was 0.37 in the placebo group, 0.57 in the evobrutinib 25-mg group, 0.13 in the evobrutinib 75-mg once-daily group, 0.08 in the evobrutinib 75-mg twice-daily group, and 0.20 in the DMF group.  There was no significant effect of trial group on the change from baseline in the EDSS score.  Elevations in liver aminotransferase values were obsd. with evobrutinib. conclusions Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo.  There was no significant difference with placebo for either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor in the annualized relapse rate or disability progression at any dose.  Longer and larger trials are required to det. the effect and risks of evobrutinib in patients with multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBCts7AZpkC7Vg90H21EOLACvtfcHk0lj0uMTxiVSJcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGqurs%253D&md5=86489e8fe1c2130c8ab46986f0b52881</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901981%26sid%3Dliteratum%253Aachs%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DArnold%26aufirst%3DD.%2BL.%26aulast%3DWeber%26aufirst%3DM.%2Bs.%26aulast%3DStaikov%26aufirst%3DI.%26aulast%3DPiasecka-Stryczynska%26aufirst%3DK.%26aulast%3DWillmer%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DE.%2BC.%26aulast%3DDangond%26aufirst%3DF.%26aulast%3DSyed%26aufirst%3DS.%26aulast%3DWolinsky%26aufirst%3DJ.%26atitle%3DPlacebo-Controlled%2520Trial%2520of%2520an%2520Oral%2520BTK%2520Inhibitor%2520in%2520Multiple%2520Sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D25%26spage%3D2406%26epage%3D2147%26doi%3D10.1056%2FNEJMoa1901981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuckwell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsumoto, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damjanov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedkov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinn, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Bind, Phase II Trial (ANDES Study)</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1435</span>– <span class="NLM_lpage">1446</span>, <span class="refDoi"> DOI: 10.1002/art.41275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fart.41275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGitLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=1435-1446&issue=9&author=S.+Cohenauthor=K.+Tuckwellauthor=T.+R.+Katsumotoauthor=R.+Zhaoauthor=J.+Galanterauthor=C.+Leeauthor=J.+Raeauthor=B.+Tothauthor=N.+Ramamoorthiauthor=J.+A.+Hackneyauthor=A.+Bermanauthor=N.+Damjanovauthor=D.+Fedkovauthor=S.+Jekaauthor=L.+W.+Chinnauthor=M.+J.+Townsendauthor=A.+M.+Morimotoauthor=M.+C.+Genovese&title=Fenebrutinib+versus+Placebo+or+Adalimumab+in+Rheumatoid+Arthritis%3A+A+Randomized%2C+Double-Bind%2C+Phase+II+Trial+%28ANDES+Study%29&doi=10.1002%2Fart.41275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial</span></div><div class="casAuthors">Cohen, Stanley; Tuckwell, Katie; Katsumoto, Tamiko R.; Zhao, Rui; Galanter, Joshua; Lee, Chin; Rae, Julie; Toth, Balazs; Ramamoorthi, Nandhini; Hackney, Jason A.; Berman, Alberto; Damjanov, Nemanja; Fedkov, Dmytro; Jeka, Slawomir; Chinn, Leslie W.; Townsend, Michael J.; Morimoto, Alyssa M.; Genovese, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1435-1446</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA).  Methods : Patients with RA and an inadequate response to methotrexate (MTX) (cohort 1; n = 480) were randomized to receive fenebrutinib (50 mg once daily, 150 mg once daily, or 200 mg twice daily), adalimumab (40 mg every other week), or placebo.  Patients with RA and an inadequate response to tumor necrosis factor inhibitors received fenebrutinib (200 mg twice daily) or placebo.  Both cohorts continued MTX therapy.  Results : In cohort 1, the percentages of patients in whom American College of Rheumatol. 50% improvement criteria (ACR50) was achieved at week 12 were similar in the fenebrutinib 50 mg once daily and placebo groups, and were higher in the fenebrutinib 150 mg once daily group (28%) and 200 mg twice daily group (35%) than in the placebo group (15%) (P = 0.016 and P = 0.0003, resp.).  Fenebrutinib 200 mg twice daily and adalimumab (36%) were comparable (P = 0.81).  Fenebrutinib and adalimumab caused overlapping as well as distinct changes in B cell and myeloid biomarkers.  Conclusion : Fenebrutinib demonstrates efficacy comparable to adalimumab in patients with an inadequate response to MTX, and safety consistent with existing immunomodulatory therapies for RA.  These data support targeting both B and myeloid cells via this novel mechanism for potential efficacy in the treatment of RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovM47ed5ph-7Vg90H21EOLACvtfcHk0lhweaUZlUK74A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGitLjM&md5=4ab180d321fb58498e0d115e9043ebf3</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1002%2Fart.41275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.41275%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DTuckwell%26aufirst%3DK.%26aulast%3DKatsumoto%26aufirst%3DT.%2BR.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DGalanter%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRae%26aufirst%3DJ.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DBerman%26aufirst%3DA.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DFedkov%26aufirst%3DD.%26aulast%3DJeka%26aufirst%3DS.%26aulast%3DChinn%26aufirst%3DL.%2BW.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DMorimoto%26aufirst%3DA.%2BM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DFenebrutinib%2520versus%2520Placebo%2520or%2520Adalimumab%2520in%2520Rheumatoid%2520Arthritis%253A%2520A%2520Randomized%252C%2520Double-Bind%252C%2520Phase%2520II%2520Trial%2520%2528ANDES%2520Study%2529%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2020%26volume%3D72%26issue%3D9%26spage%3D1435%26epage%3D1446%26doi%3D10.1002%2Fart.41275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauernfeind, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnemri, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes-Alnemri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornung, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Recepotrs License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.0901363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19570822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFWgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=787-791&author=F.+Bauernfeindauthor=G.+Horvathauthor=A.+Stutzauthor=E.+S.+Alnemriauthor=K.+MacDonaldauthor=D.+Speertauthor=T.+Fernandes-Alnemriauthor=J.+Wuauthor=B.+G.+Monksauthor=K.+A.+Fitzgeraldauthor=V.+Hornungauthor=E.+Latz&title=Cutting+Edge%3A+NF-%CE%BAB+Activating+Pattern+Recognition+and+Cytokine+Recepotrs+License+NLRP3+Inflammasome+Activation+by+Regulating+NLRP3+Expression&doi=10.4049%2Fjimmunol.0901363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression</span></div><div class="casAuthors">Bauernfeind, Franz G.; Horvath, Gabor; Stutz, Andrea; Alnemri, Emad S.; MacDonald, Kelly; Speert, David; Fernandes-Alnemri, Teresa; Wu, Jianghong; Monks, Brian G.; Fitzgerald, Katherine A.; Hornung, Veit; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">787-791</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The IL-1 family cytokines are regulated on transcriptional and posttranscriptional levels.  Pattern recognition and cytokine receptors control pro-IL-1β transcription whereas inflammasomes regulate the proteolytic processing of pro-IL-1β.  The NLRP3 inflammasome, however, assembles in response to extracellular ATP, pore-forming toxins, or crystals only in the presence of proinflammatory stimuli.  How the activation of gene transcription by signaling receptors enables NLRP3 activation remains elusive and controversial.  In this study, the authors show that cell priming through multiple signaling receptors induces NLRP3 expression, which the authors identified to be a crit. checkpoint for NLRP3 activation.  Signals provided by NF-κB activators are necessary but not sufficient for NLRP3 activation, and a second stimulus such as ATP or crystal-induced damage is required for NLRP3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUf4OrrejQ7Vg90H21EOLACvtfcHk0lhweaUZlUK74A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFWgt78%253D&md5=1b04c9f756bb70d6292bd8bd5507ee1f</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901363%26sid%3Dliteratum%253Aachs%26aulast%3DBauernfeind%26aufirst%3DF.%26aulast%3DHorvath%26aufirst%3DG.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DAlnemri%26aufirst%3DE.%2BS.%26aulast%3DMacDonald%26aufirst%3DK.%26aulast%3DSpeert%26aufirst%3DD.%26aulast%3DFernandes-Alnemri%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DMonks%26aufirst%3DB.%2BG.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DHornung%26aufirst%3DV.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DCutting%2520Edge%253A%2520NF-%25CE%25BAB%2520Activating%2520Pattern%2520Recognition%2520and%2520Cytokine%2520Recepotrs%2520License%2520NLRP3%2520Inflammasome%2520Activation%2520by%2520Regulating%2520NLRP3%2520Expression%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D787%26epage%3D791%26doi%3D10.4049%2Fjimmunol.0901363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning-Bennett, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abuhelwa, A. Y.</span></span> <span> </span><span class="NLM_article-title">Investigational IRAK-4 Inhibitors for the Treatment of Rheumatoid Athritis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1080/13543784.2020.1752660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1080%2F13543784.2020.1752660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=32255710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVWqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=475-482&issue=5&author=M.+D.+Wieseauthor=A.+T.+Manning-Bennettauthor=A.+Y.+Abuhelwa&title=Investigational+IRAK-4+Inhibitors+for+the+Treatment+of+Rheumatoid+Athritis&doi=10.1080%2F13543784.2020.1752660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Wiese, Michael D.; Manning-Bennett, Arkady T.; Abuhelwa, Ahmad Y.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">475-482</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Rheumatoid arthritis (RA) is a chronic inflammatory auto-immune disease that can lead to permanent disability and deformity.  Despite current treatment modalities, many patients are still unable to reach remission.  Interleukin-1 receptor-assocd. kinase 4 (IRAK-4) inhibitors are novel agents designed to suppress immune signaling pathways involved in inflammation and joint destruction in RA.  Four IRAK-4 inhibitors have entered clin. trials.: This review summarizes the current stage of development of IRAK-4 inhibitors in clin. trials, detailing their chem., pharmacokinetics, and therapeutic potential in the treatment of RA.  PubMed, Embase and restricted Google searches were conducted using the term 'IRAK-4', and publicly accessible clin. trial databases were reviewed.: IRAK-4 inhibitors are an exciting therapeutic option in RA management because unlike other targeted disease-modifying agents, they target the innate immune system.  The role of IRAK-4 as a key component of Toll/Interleukin-1 receptor signaling and its potential for a low rate of infectious complications is particularly exciting and this may facilitate their use in combination treatment.  A key aspect of upcoming clin. trials will be the identification of biomarkers predictive of treatment efficacy, which will help to define if and how they will be used in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrpVAIiTis27Vg90H21EOLACvtfcHk0lhweaUZlUK74A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVWqtL8%253D&md5=e0f764411673764a188bb6e2d6bcba24</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1080%2F13543784.2020.1752660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2020.1752660%26sid%3Dliteratum%253Aachs%26aulast%3DWiese%26aufirst%3DM.%2BD.%26aulast%3DManning-Bennett%26aufirst%3DA.%2BT.%26aulast%3DAbuhelwa%26aufirst%3DA.%2BY.%26atitle%3DInvestigational%2520IRAK-4%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Athritis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2020%26volume%3D29%26issue%3D5%26spage%3D475%26epage%3D482%26doi%3D10.1080%2F13543784.2020.1752660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulshian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bober, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlisi, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossetta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=677-682&author=W.+T.+McElroyauthor=Z.+Tanauthor=G.+Hoauthor=S.+Paliwalauthor=G.+Liauthor=M.+W.+Seganishauthor=D.+Tulshianauthor=J.+Tataauthor=T.+O.+Fischmannauthor=C.+Sondeyauthor=H.+Bianauthor=L.+Boberauthor=J.+Jacksonauthor=C.+G.+Garlisiauthor=K.+Devitoauthor=J.+Fossettaauthor=D.+Lundellauthor=X.+Niu&title=Potent+and+Selective+Amidopyrazole+Inhibitors+of+IRAK4+That+Are+Efficacious+in+a+Rodent+Model+of+Inflammation&doi=10.1021%2Facsmedchemlett.5b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation</span></div><div class="casAuthors">McElroy, William T.; Tan, Zheng; Ho, Ginny; Paliwal, Sunil; Li, Guoqing; Seganish, W. Michael; Tulshian, Deen; Tata, James; Fischmann, Thierry O.; Sondey, Christopher; Bian, Hong; Bober, Loretta; Jackson, James; Garlisi, Charles G.; Devito, Kristine; Fossetta, James; Lundell, Daniel; Niu, Xiaoda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-682</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IRAK4 is a crit. upstream kinase in the IL-1R/TLR signaling pathway.  Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders.  A screening campaign identified a pyrazole class of IRAK4 inhibitors that were detd. by X-ray crystallog. to exhibit an unusual binding mode.  SAR efforts focused on the identification of a potent and selective inhibitor with good aq. soly. and rodent pharmacokinetics.  Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogs generally having good rodent oral exposure but poor soly.  N-Alkyl piperidines exhibited excellent soly. and reduced exposure.  Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active.  Piperazine 32 was a potent enzyme inhibitor with good cellular activity.  Compd. 32 reduced the in vivo prodn. of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSA2VYtAf07Vg90H21EOLACvtfcHk0lj270bbz2Hyyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1Sqtrk%253D&md5=2203ad720b478a6e415d7d9df3e82106</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00106%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DG.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSeganish%26aufirst%3DM.%2BW.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DTata%26aufirst%3DJ.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DBober%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DDevito%26aufirst%3DK.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26atitle%3DPotent%2520and%2520Selective%2520Amidopyrazole%2520Inhibitors%2520of%2520IRAK4%2520That%2520Are%2520Efficacious%2520in%2520a%2520Rodent%2520Model%2520of%2520Inflammation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D677%26epage%3D682%26doi%3D10.1021%2Facsmedchemlett.5b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danto, S. I.</span>; <span class="NLM_string-name">Shojaee, N.</span>; <span class="NLM_string-name">Singh, R. S. P.</span>; <span class="NLM_string-name">Manukyan, Z.</span>; <span class="NLM_string-name">Mancuso, J.</span>; <span class="NLM_string-name">Peeva, E.</span>; <span class="NLM_string-name">Vincent, M.</span>; <span class="NLM_string-name">Beebe, J.</span></span> <span> </span><span class="NLM_article-title">In Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate</span>,  <i>2019 ACR/ARP Annual Meeting</i>, <span class="NLM_publisher-loc">Atlanta, GA</span>, November 8–13; Atlanta, Georgia, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+I.+Danto&author=N.+Shojaee&author=R.+S.+P.+Singh&author=Z.+Manukyan&author=J.+Mancuso&author=E.+Peeva&author=M.+Vincent&author=J.+Beebe&title=In+Efficacy+and+Safety+of+the+Selective+Interleukin-1+Receptor+Associated+Kinase+4+Inhibitor%2C+PF-06650833%2C+in+Patients+with+Active+Rheumatoid+Arthritis+and+Inadequate+Response+to+Methotrexate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DDanto%26aufirst%3DS.%2BI.%26atitle%3DIn%2520Efficacy%2520and%2520Safety%2520of%2520the%2520Selective%2520Interleukin-1%2520Receptor%2520Associated%2520Kinase%25204%2520Inhibitor%252C%2520PF-06650833%252C%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%2520and%2520Inadequate%2520Response%2520to%2520Methotrexate%26jtitle%3D2019%2520ACR%252FARP%2520Annual%2520Meeting%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3614</span>– <span class="NLM_lpage">3643</span>, <span class="refDoi"> DOI: 10.1021/jm201271b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201271b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3614-3643&author=R.+Singhauthor=E.+S.+Masudaauthor=D.+G.+Payan&title=Discovery+and+Development+of+Spleen+Tyrosine+Kinase+%28SYK%29+Inhibitors&doi=10.1021%2Fjm201271b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span></div><div class="casAuthors">Singh, Rajinder; Masuda, Esteban S.; Payan, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3614-3643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (SYK) is a member of the cytoplasmic protein tyrosine kinase (PTK) family and has been identified as an important target for the development of therapeutics for the treatment of allergic and autoimmune diseases.  Maladies resulting from chronic inflammation and autoimmune dysfunction include, asthma, rheumatoid arthritis (RA), Crohn's disease, systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP).  SYK has garnered substantial attention because of its importance as a key signal transduction regulator through antigen and Fc receptors in hematopoietic cells.  Recently SYK has entered the mainstream of potential pharmaceutical targets with a no. of inhibitor classes being reported in the literature.  The true potential as a validated target for inhibition by small mols. has been investigated in the last few years, with the emergence of advanced clin. trial data.  Structurally SYK possesses a tandem N-terminal Src homol. 2 domains (SH2), referred to as N-SH2 and C-SH2 domains, followed by a C-terminal kinase domain and most closely related to ZAP-70.  The multiple phosphorylation sites on SYK are fundamental structural prerequisites for its diverse functional activity.  Overall, these phosphorylation sites contribute to maintaining the kinase in an inactivated state.  In addn., they are implicated in events leading to primary activation of the kinase catalytic domain, amplification of this activity, and the orchestrated phosphorylation of multiple substrates.  Utilization of the numerous sites of phosphorylation on SYK leads to the activation of a multitude of signaling networks relevant to immune and autoimmune maladies.  SYK serves as a master regulator of inflammatory responses in a multitude of immune cells and as a result, inhibiting SYK activity dampens inflammation broadly and comprehensively.  The validation of SYK as an effective target for therapeutic intervention in autoimmune and inflammatory disorders has picked up pace over the last decade.  In particular, this has been attributable to the recognition of key biol. findings, coupled with successful small mol. inhibitors of SYK that have shown early indications of clin. efficacy in diverse autoimmune and inflammatory diseases.  SYK as a target has gained reinforcement with the successful completion of several Phase 2 clin. studies in RA, ITP and B-cell lymphoma.  Addnl. clin. studies are under way that may further emphasize the position of SYK as a therapeutically relevant target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp363qA4V4g-rVg90H21EOLACvtfcHk0lj270bbz2Hyyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D&md5=1b51e1b658842f2b562d533edb05e685</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjm201271b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201271b%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Spleen%2520Tyrosine%2520Kinase%2520%2528SYK%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3614%26epage%3D3643%26doi%3D10.1021%2Fjm201271b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Men, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Spleen Tyrosine Kinase Promotes NLR Family Pyrin Domain Containing 3 Inflammasome-Mediated IL-1β Secretion via c-Jun N-Terminal Kinase Activation and Cell Apoptosis During Diabetic Nephropathy</span>. <i>Molecular Medicine Reports</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1995</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.3892/mmr.2018.9164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3892%2Fmmr.2018.9164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29901140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=1995-2008&author=Y.+Qiaoauthor=X.+Tianauthor=L.+Menauthor=S.+Liauthor=Y.+Chenauthor=M.+Xueauthor=Y.+Huauthor=P.+Zhouauthor=G.+Longauthor=Y.+Shiauthor=R.+Liuauthor=Y.+Liuauthor=Z.+Qiauthor=Y.+Cuiauthor=Y.+Shen&title=Spleen+Tyrosine+Kinase+Promotes+NLR+Family+Pyrin+Domain+Containing+3+Inflammasome-Mediated+IL-1%CE%B2+Secretion+via+c-Jun+N-Terminal+Kinase+Activation+and+Cell+Apoptosis+During+Diabetic+Nephropathy&doi=10.3892%2Fmmr.2018.9164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Spleen tyrosine kinase promotes NLR family pyrin domain containing 3 inflammasome-mediated IL-1β secretion via c-Jun N-terminal kinase activation and cell apoptosis during diabetic nephropathy</span></div><div class="casAuthors">Qiao, Yingchun; Tian, Xixi; Men, Li; Li, Shengyu; Chen, Yufeng; Xue, Meiting; Hu, Yahui; Zhou, Pengfei; Long, Guangfeng; Shi, Yue; Liu, Ruiqing; Liu, Yunde; Qi, Zhi; Cui, Yujie; Shen, Yanna</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1995-2008</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Diabetic nephropathy (DN) is a serious complication of diabetes and can cause an increased mortality risk.  It was previously reported that NLR family pyrin domain contg. 3 (NLRP3) inflammasome is involved in the pathogenesis of diabetes.  However, the underlying mechanism is not clearly understood.  In the present study, the effects of spleen tyrosine kinase (Syk) and c-Jun N-terminal kinase (JNK) on the NLRP3 inflammasome were examd. in vivo and in vitro.  Sprague-Dawley rats were injected i.p. with streptozotocin (65 mg/kg) to induce diabetes.  HK2 cells and rat glomerular mesangial cells (RGMCs) were examd. to detect the expression of JNK and NLRP3 inflammasome-assocd. proteins following treatment with a Syk inhibitor or Syk-small interfering (si)RNA in a high glucose condition.  In the present study, it was revealed that the protein and mRNA expression levels of NLRP3 inflammasome-assocd. mols. and the downstream mature interleukin (IL)-1β were upregulated in vivo and in vitro.  The Syk inhibitor and Syk-siRNA suppressed high glucose-induced JNK activation, and subsequently downregulated the activation of the NLRP3 inflammasome and mature IL-1β in HK2 cells and RGMCs.  Therefore, the present results detd. that high glucose-induced activation of the NLRP3 inflammasome is mediated by Syk/JNK activation, which subsequently increased the protein expression level of IL-1β and mature IL-1β.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoNxBctyuDDbVg90H21EOLACvtfcHk0lhLUQ5yLRJ07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjtrbI&md5=cf317a7edf88708cc66649e1f8f8b4b5</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2018.9164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2018.9164%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DMen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DLong%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DSpleen%2520Tyrosine%2520Kinase%2520Promotes%2520NLR%2520Family%2520Pyrin%2520Domain%2520Containing%25203%2520Inflammasome-Mediated%2520IL-1%25CE%25B2%2520Secretion%2520via%2520c-Jun%2520N-Terminal%2520Kinase%2520Activation%2520and%2520Cell%2520Apoptosis%2520During%2520Diabetic%2520Nephropathy%26jtitle%3DMolecular%2520Medicine%2520Reports%26date%3D2018%26volume%3D18%26spage%3D1995%26epage%3D2008%26doi%3D10.3892%2Fmmr.2018.9164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R. J.</span></span> <span> </span><span class="NLM_article-title">Critical Role for NLRP3 in Necrotic Death Triggered by Mycobacterium Tuberculosis</span>. <i>Cell. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1371</span>– <span class="NLM_lpage">1384</span>, <span class="refDoi"> DOI: 10.1111/j.1462-5822.2011.01625.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1111%2Fj.1462-5822.2011.01625.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21740493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWqsbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1371-1384&issue=9&author=K.-W.+Wongauthor=W.+R.+J.+Jacobs&title=Critical+Role+for+NLRP3+in+Necrotic+Death+Triggered+by+Mycobacterium+Tuberculosis&doi=10.1111%2Fj.1462-5822.2011.01625.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis</span></div><div class="casAuthors">Wong, Ka-Wing; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1371-1384</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Induction of necrotic death in macrophages is a primary virulence determinant of Mycobacterium tuberculosis.  The ESX-1 secretion system and its substrate ESAT-6 are required for M. tuberculosis to induce necrosis, but host factors that mediate the ESAT-6-promoted necrosis remain unknown.  Here we report that ESAT-6-promoted necrotic death in THP-1 human macrophages is dependent on the NLRP3 inflammasome, as shown by RNA interference and pharmacol. inhibitions.  Phagosomes contg. ESAT-6-expressing M. tuberculosis recruit markers previously assocd. with damaged phagosomal membrane, such as galectin-3 and ubiquitinated protein aggregates.  In addn., ESAT-6 promoted lysosomal permeabilization by M. tuberculosis.  ESAT-6 mutants defective for ubiquitination were unable to trigger NLRP3 activation and necrotic death.  Furthermore, Syk tyrosine kinase, recently implicated in NLRP3 activation during fungal and malarial infections, was necessary for mediating the ESAT-6-promoted necrosis and NLRP3 activation.  Our results thus link phagosomal damage and Syk activity to NLRP3-mediated necrotic death triggered by M. tuberculosis ESAT-6 during infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0eSC-Ojhsg7Vg90H21EOLACvtfcHk0lhLUQ5yLRJ07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWqsbjM&md5=d297c676ebdbd640d4ce9ffb10116bb3</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1111%2Fj.1462-5822.2011.01625.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1462-5822.2011.01625.x%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.-W.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%2BJ.%26atitle%3DCritical%2520Role%2520for%2520NLRP3%2520in%2520Necrotic%2520Death%2520Triggered%2520by%2520Mycobacterium%2520Tuberculosis%26jtitle%3DCell.%2520Microbiol.%26date%3D2011%26volume%3D13%26issue%3D9%26spage%3D1371%26epage%3D1384%26doi%3D10.1111%2Fj.1462-5822.2011.01625.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poeck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bscheider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dostert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannesschläger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardivel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweighoffer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mocsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span> <span> </span><span class="NLM_article-title">Syk Kinase Signalling Couples to the Nlrp3 Inflammasome for Anti-Fungal Host Defence</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>459</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1038/nature07965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnature07965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19339971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvV2ksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2009&pages=433-436&author=O.+Grossauthor=H.+Poeckauthor=M.+Bscheiderauthor=C.+Dostertauthor=N.+Hannesschl%C3%A4gerauthor=S.+Endresauthor=G.+Hartmannauthor=A.+Tardivelauthor=E.+Schweighofferauthor=V.+Tybulewiczauthor=A.+Mocsaiauthor=J.+Tschoppauthor=J.+Ruland&title=Syk+Kinase+Signalling+Couples+to+the+Nlrp3+Inflammasome+for+Anti-Fungal+Host+Defence&doi=10.1038%2Fnature07965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence</span></div><div class="casAuthors">Gross, Olaf; Poeck, Hendrik; Bscheider, Michael; Dostert, Catherine; Hannesschlaeger, Nicole; Endres, Stefan; Hartmann, Gunther; Tardivel, Aubry; Schweighoffer, Edina; Tybulewicz, Victor; Mocsai, Attila; Tschopp, Juerg; Ruland, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">7245</span>),
    <span class="NLM_cas:pages">433-436</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fungal infections represent a serious threat, particularly in immunocompromised patients.  Interleukin-1β (IL-1β) is a key pro-inflammatory factor in innate antifungal immunity.  The mechanism by which the mammalian immune system regulates IL-1β prodn. after fungal recognition is unclear.  Two signals are generally required for IL-1β prodn.: an NF-κB-dependent signal that induces the synthesis of pro-IL-1β (p35), and a second signal that triggers proteolytic pro-IL-1β processing to produce bioactive IL-1β (p17) via Caspase-1-contg. multiprotein complexes called inflammasomes.  Here we demonstrate that the tyrosine kinase Syk, operating downstream of several immunoreceptor tyrosine-based activation motif (ITAM)-coupled fungal pattern recognition receptors, controls both pro-IL-1β synthesis and inflammasome activation after cell stimulation with Candida albicans.  Whereas Syk signalling for pro-IL-1β synthesis selectively uses the Card9 pathway, inflammasome activation by the fungus involves reactive oxygen species prodn. and potassium efflux.  Genetic deletion or pharmalogical inhibition of Syk selectively abrogated inflammasome activation by C. albicans but not by inflammasome activators such as Salmonella typhimurium or the bacterial toxin nigericin.  Nlrp3 (also known as NALP3) was identified as the crit. NOD-like receptor family member that transduces the fungal recognition signal to the inflammasome adaptor Asc (Pycard) for Caspase-1 (Casp1) activation and pro-IL-1β processing.  Consistent with an essential role for Nlrp3 inflammasomes in antifungal immunity, we show that Nlrp3-deficient mice are hypersusceptible to Candida albicans infection.  Thus, our results demonstrate the mol. basis for IL-1β prodn. after fungal infection and identify a crucial function for the Nlrp3 inflammasome in mammalian host defense in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK4a_GDL8lrrVg90H21EOLACvtfcHk0lhLUQ5yLRJ07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvV2ksLs%253D&md5=7a8d5d412df3bcd7e34dc5e6affe7a42</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1038%2Fnature07965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07965%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DO.%26aulast%3DPoeck%26aufirst%3DH.%26aulast%3DBscheider%26aufirst%3DM.%26aulast%3DDostert%26aufirst%3DC.%26aulast%3DHannesschl%25C3%25A4ger%26aufirst%3DN.%26aulast%3DEndres%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DG.%26aulast%3DTardivel%26aufirst%3DA.%26aulast%3DSchweighoffer%26aufirst%3DE.%26aulast%3DTybulewicz%26aufirst%3DV.%26aulast%3DMocsai%26aufirst%3DA.%26aulast%3DTschopp%26aufirst%3DJ.%26aulast%3DRuland%26aufirst%3DJ.%26atitle%3DSyk%2520Kinase%2520Signalling%2520Couples%2520to%2520the%2520Nlrp3%2520Inflammasome%2520for%2520Anti-Fungal%2520Host%2520Defence%26jtitle%3DNature%26date%3D2009%26volume%3D459%26spage%3D433%26epage%3D436%26doi%3D10.1038%2Fnature07965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Spleen Tyrosine Kinase Inhibitors: A Review of the Patent Literature 2010 - 2013</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.890184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1517%2F13543776.2014.890184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=24555683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=573-595&issue=5&author=P.+Norman&title=Spleen+Tyrosine+Kinase+Inhibitors%3A+A+Review+of+the+Patent+Literature+2010+-+2013&doi=10.1517%2F13543776.2014.890184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">573-595</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The non-receptor tyrosine kinase, spleen tyrosine kinase (Syk), is primarily expressed in hematopoietic cells and appears to be particularly important in B cells.  Syk is involved in signal transduction processes and appears to regulate allergic, inflammatory and autoimmune responses.  It also appears to play a significant role in the development of haematol. malignancies.  Inhibitors of Syk are potentially useful in treating asthma, rheumatoid arthritis, lupus, chronic lymphocytic leukemia and lymphomas.  Areas covered: This article reviews the increasing no. of patent filings between 2010 and 2013 claiming Syk inhibitors and focuses on the multiple structural classes of Syk inhibitors disclosed.  It also comments on recent developments with Syk inhibitors, both clin. results and licensing deals.  Expert opinion: The increased interest in the identification of Syk inhibitors has seen a sharp increase in patent filings claiming such compds.  However, the no. of these is well below that of filings relating to other pro-inflammatory kinases (p38, JAK).  These filings have also claimed an increasingly diverse range of chem. classes moving away from the 2,4-diaminopyrimidine motif present in drugs such as fostamatinib and PRT-06207.  Many of the claimed compds. are Syk inhibitors with potencies considerably better than fostamatinib.  However, good kinase selectivity is also likely to be essential if a Syk inhibitor is to prove useful enough to emulate the JAK inhibitor tofacitinib in gaining marketing authorization.  Recent clin. failures with Syk inhibitors are expected to result in a decrease in the rate of patent filings claiming Syk inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKOmjQYSJAsbVg90H21EOLACvtfcHk0ljcKTwlovNtxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu7o%253D&md5=6db9860a438ced1374f5b8727e3cd420</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.890184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.890184%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DSpleen%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520A%2520Review%2520of%2520the%2520Patent%2520Literature%25202010%2520-%25202013%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26issue%3D5%26spage%3D573%26epage%3D595%26doi%3D10.1517%2F13543776.2014.890184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braselmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlaar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span> <span> </span><span class="NLM_article-title">R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>319</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.109058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1124%2Fjpet.106.109058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=16946104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2006&pages=998-1008&issue=3&author=S.+Braselmannauthor=V.+Taylorauthor=H.+Zhaoauthor=S.+Wangauthor=C.+Sylvainauthor=M.+Baluomauthor=K.+Quauthor=E.+Herlaarauthor=A.+Lauauthor=C.+Youngauthor=B.+R.+Wongauthor=S.+Lovellauthor=T.+Sunauthor=G.+Parkauthor=A.+Argadeauthor=S.+Jurcevicauthor=P.+Pineauthor=R.+Singhauthor=E.+B.+Grossbardauthor=D.+G.+Payanauthor=E.+S.+Masuda&title=R406%2C+an+Orally+Available+Spleen+Tyrosine+Kinase+Inhibitor+Blocks+Fc+Receptor+Signaling+and+Reduces+Immune+Complex-Mediated+Inflammation&doi=10.1124%2Fjpet.106.109058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation</span></div><div class="casAuthors">Braselmann, Sylvia; Taylor, Vanessa; Zhao, Haoran; Wang, Su; Sylvain, Catherine; Baluom, Muhammad; Qu, Kunbin; Herlaar, Ellen; Lau, Angela; Young, Chi; Wong, Brian R.; Lovell, Scott; Sun, Thomas; Park, Gary; Argade, Ankush; Jurcevic, Stipo; Pine, Polly; Singh, Rajinder; Grossbard, Elliott B.; Payan, Donald G.; Masuda, Esteban S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">998-1008</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent compelling evidence has lead to renewed interest in the role of antibodies and immune complexes in the pathogenesis of several autoimmune disorders, such as rheumatoid arthritis.  These immune complexes, consisting of autoantibodies to self-antigens, can mediate inflammatory responses largely through binding and activating the Ig Fc receptors (FcRs).  Using cell-based structure activity relationships with cultured human mast cells, we have identified the small mol. R406 [N4-(2,2-dimethyl-3-oxo-4H-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2- (3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine] as a potent inhibitor of IgE (IgE)- and IgG-mediated activation of Fc receptor signaling (EC50 for degranulation = 56-64 nM).  Here we show that the primary target for R406 is the spleen tyrosine kinase (Syk), which plays a key role in the signaling of activating Fc receptors and the B-cell receptor (BCR).  R406 inhibited phosphorylation of Syk substrate linker for activation of T cells in mast cells and B-cell linker protein/SLP65 in B cells.  R406 bound to the ATP binding pocket of Syk and inhibited its kinase activity as an ATP-competitive inhibitor (Ki = 30 nM).  Furthermore, R406 blocked Syk-dependent FcR-mediated activation of monocytes/macrophages and neutrophils and BCR-mediated activation of B lymphocytes.  R406 was selective as assessed using a large panel of Syk-independent cell-based assays representing both specific and general signaling pathways.  Consistent with Syk inhibition, oral administration of R406 to mice reduced immune complex-mediated inflammation in a reverse-passive Arthus reaction and two antibody-induced arthritis models.  Finally, we report a first-in-human study showing that R406 is orally bioavailable, achieving exposures capable of inhibiting Syk-dependent IgE-mediated basophil activation.  Collectively, the results show R406 potential for modulating Syk activity in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohoeT9BJQAyLVg90H21EOLACvtfcHk0ljcKTwlovNtxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltL7P&md5=18fea516041ea075d2123158f321a186</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.109058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.109058%26sid%3Dliteratum%253Aachs%26aulast%3DBraselmann%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DK.%26aulast%3DHerlaar%26aufirst%3DE.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DB.%2BR.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DArgade%26aufirst%3DA.%26aulast%3DJurcevic%26aufirst%3DS.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26atitle%3DR406%252C%2520an%2520Orally%2520Available%2520Spleen%2520Tyrosine%2520Kinase%2520Inhibitor%2520Blocks%2520Fc%2520Receptor%2520Signaling%2520and%2520Reduces%2520Immune%2520Complex-Mediated%2520Inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D319%26issue%3D3%26spage%3D998%26epage%3D1008%26doi%3D10.1124%2Fjpet.106.109058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pine, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoettler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banquerigo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahn, E.</span></span> <span> </span><span class="NLM_article-title">Inflammation and Bone Erosion are Suppressed in Models of Rheumatoid Arthritis Following Treatment with a Novel Syk Inhibitor</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2007.03.543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.clim.2007.03.543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=17537677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1eltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2007&pages=244-257&issue=3&author=P.+R.+Pineauthor=B.+Changauthor=N.+Schoettlerauthor=M.+L.+Banquerigoauthor=S.+Wangauthor=A.+Lauauthor=F.+Zhaoauthor=E.+B.+Grossbardauthor=D.+G.+Payanauthor=E.+Brahn&title=Inflammation+and+Bone+Erosion+are+Suppressed+in+Models+of+Rheumatoid+Arthritis+Following+Treatment+with+a+Novel+Syk+Inhibitor&doi=10.1016%2Fj.clim.2007.03.543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor</span></div><div class="casAuthors">Pine, Polly R.; Chang, Betty; Schoettler, Nathan; Banquerigo, Mona L.; Wang, Su; Lau, Angela; Zhao, Feifei; Grossbard, Elliott B.; Payan, Donald G.; Brahn, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-257</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in inflammatory cells, is essential for immune complex-mediated signal transduction initiated by activated receptors for IgG.  In collagen-induced arthritis, R788/R406, a novel and potent small mol. Syk inhibitor suppressed clin. arthritis, bone erosions, pannus formation, and synovitis.  Serum anti-collagen type II antibody levels were unaltered, while the half-life of exogenous antibody was extended when co-administered with R406.  Expression of the targeted kinase (Syk) in synovial tissue correlated with the joint level of inflammatory cell infiltrates and was virtually undetectable in treated rats.  Syk inhibition suppressed synovial cytokines and cartilage oligomeric matrix protein (COMP) in serum, suggesting a sensitive and reliable biomarker for R406 activity.  These results highlight the role of activating Fcgamma receptors in inflammatory synovitis and suggest that interruption of the signaling cascade with a novel Syk inhibitor may be a useful addn. to immunosuppressive disease-modifying anti-rheumatic drugs currently used in the treatment of human autoimmune diseases such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Nm2XObIb37Vg90H21EOLACvtfcHk0ligOLyDCb80Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1eltb0%253D&md5=98b5020fb23cc209e5b7c322024748fb</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2007.03.543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2007.03.543%26sid%3Dliteratum%253Aachs%26aulast%3DPine%26aufirst%3DP.%2BR.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DSchoettler%26aufirst%3DN.%26aulast%3DBanquerigo%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DBrahn%26aufirst%3DE.%26atitle%3DInflammation%2520and%2520Bone%2520Erosion%2520are%2520Suppressed%2520in%2520Models%2520of%2520Rheumatoid%2520Arthritis%2520Following%2520Treatment%2520with%2520a%2520Novel%2520Syk%2520Inhibitor%26jtitle%3DClin.%2520Immunol.%26date%3D2007%26volume%3D124%26issue%3D3%26spage%3D244%26epage%3D257%26doi%3D10.1016%2Fj.clim.2007.03.543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bussel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treliński, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homenda, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windyga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivcheva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalafallah, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaja, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovtsov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duliege, A.-M.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1002/ajh.25125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fajh.25125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29696684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ylur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=921-930&issue=7&author=J.+Busselauthor=D.+M.+Arnoldauthor=E.+Grossbardauthor=J.+Mayerauthor=J.+Treli%C5%84skiauthor=W.+Homendaauthor=A.+Hellmannauthor=J.+Windygaauthor=L.+Sivchevaauthor=A.+A.+Khalafallahauthor=F.+Zajaauthor=N.+Cooperauthor=V.+Markovtsovauthor=H.+Zayedauthor=A.-M.+Duliege&title=Fostamatinib+for+the+Treatment+of+Adult+Persistent+and+Chronic+Immune+Thrombocytopenia%3A+Results+of+Two+Phase+3%2C+Randomized%2C+Placebo-Controlled+Trials&doi=10.1002%2Fajh.25125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials</span></div><div class="casAuthors">Bussel, James; Arnold, Donald M.; Grossbard, Elliot; Mayer, Jiri; Trelinski, Jacek; Homenda, Wojciech; Hellmann, Andrzej; Windyga, Jerzy; Sivcheva, Liliya; Khalafallah, Alhossain A.; Zaja, Francesco; Cooper, Nichola; Markovtsov, Vadim; Zayed, Hany; Duliege, Anne-Marie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">921-930</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP).  Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses in a phase 2 ITP study.  In two parallel, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n = 101) or placebo (n = 49) at 100 mg BID for 24 wk with a dose increase in nonresponders to 150 mg BID after 4 wk.  The primary endpoint was stable response (platelets ≥50 000/μL at ≥4 of 6 biweekly visits, weeks 14-24, without rescue therapy).  Baseline median platelet count was 16 000/μL; median duration of ITP was 8.5 years.  Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003).  Overall responses (defined retrospectively as ≥1 platelet count ≥50 000/μL within the first 12 wk on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P = .0006).  Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 wk.  The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%).  Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti-motility agents).  Fostamatinib produced clin.-meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab.  Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXWLFmFwBPrLVg90H21EOLACvtfcHk0ligOLyDCb80Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ylur%252FF&md5=06dff53ac5d8e7752b760844f9f22384</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2Fajh.25125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.25125%26sid%3Dliteratum%253Aachs%26aulast%3DBussel%26aufirst%3DJ.%26aulast%3DArnold%26aufirst%3DD.%2BM.%26aulast%3DGrossbard%26aufirst%3DE.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DTreli%25C5%2584ski%26aufirst%3DJ.%26aulast%3DHomenda%26aufirst%3DW.%26aulast%3DHellmann%26aufirst%3DA.%26aulast%3DWindyga%26aufirst%3DJ.%26aulast%3DSivcheva%26aufirst%3DL.%26aulast%3DKhalafallah%26aufirst%3DA.%2BA.%26aulast%3DZaja%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DMarkovtsov%26aufirst%3DV.%26aulast%3DZayed%26aufirst%3DH.%26aulast%3DDuliege%26aufirst%3DA.-M.%26atitle%3DFostamatinib%2520for%2520the%2520Treatment%2520of%2520Adult%2520Persistent%2520and%2520Chronic%2520Immune%2520Thrombocytopenia%253A%2520Results%2520of%2520Two%2520Phase%25203%252C%2520Randomized%252C%2520Placebo-Controlled%2520Trials%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2018%26volume%3D93%26issue%3D7%26spage%3D921%26epage%3D930%26doi%3D10.1002%2Fajh.25125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magilavy, D. B.</span></span> <span> </span><span class="NLM_article-title">An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1312</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1000500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1056%2FNEJMoa1000500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20879879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WqsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1303-1312&author=M.+E.+Weinblattauthor=A.+Kavanaughauthor=M.+C.+Genoveseauthor=T.+K.+Musserauthor=E.+B.+Grossbardauthor=D.+B.+Magilavy&title=An+Oral+Spleen+Tyrosine+Kinase+%28Syk%29+Inhibitor+for+Rheumatoid+Arthritis&doi=10.1056%2FNEJMoa1000500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">An oral spleen tyrosine kinase (SyK) inhibitor for rheumatoid arthritis</span></div><div class="casAuthors">Weinblatt, Michael E.; Kavanaugh, Arthur; Genovese, Mark C.; Musser, Theresa K.; Grossbard, Elliott B.; Magilavy, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1303-1312</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND  Spleen tyrosine kinase (Syk) is an important modulator of immune signaling.  The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy.  METHODS  We enrolled 457 patients who had active rheumatoid arthritis despite long-term methotrexate therapy in a 6-mo, double-blind, placebo-controlled trial.  The primary outcome was the American College of Rheumatol. (ACR) 20 response (which indicates at least a 20% redn. in the no. of both tender and swollen joints and improvement in at least three of five other criteria) at month 6.  RESULTS  R788, at a dose of 100 mg twice daily and at a dose of 150 mg once daily, was significantly superior to placebo at month 6 (ACR 20 response rates of 67% and 57%, resp., vs. 35%; P < 0.001 for the comparison of both doses with placebo).  It was also significantly superior with respect to ACR 50, which indicates at least a 50% improvement (43% and 32% vs. 19%; P < 0.001 for the comparison of the 100-mg dose with placebo, P = 0.007 for the comparison of the 150-mg dose with placebo) and ACR70 (28% and 14% vs. 10%; P < 0.001 for the comparison of the 100-mg dose with placebo, P = 0.34 for the comparison of the 150-mg dose with placebo).  A clin. significant effect was noted by the end of the first week of treatment.  Adverse effects included diarrhea (in 19% of subjects taking the 100-mg dose of R788 vs. 3% of those taking placebo), upper respiratory infections (14% vs. 7%), and neutropenia (60/% vs. 1%0/).  R788 was assocd. with an increase in systolic blood pressure of approx. 3 mm Hg between baseline and month 1, as compared with a decrease of 2 mm Hg with placebo; 23% of the patients taking R788 vs. 7% of the patients receiving placebo required the initiation of or a change in antihypertensive therapy.  CONCLUSIONS  In this phase 2 study, a Syk inhibitor reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia.  Addnl. studies will be needed to further assess the safety and efficacy of Syk-inhibition therapy in patients with rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv0QGXE3rZiLVg90H21EOLACvtfcHk0ligOLyDCb80Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WqsLfI&md5=f6da21edb34b0fe9858b6d7bbfd6f0b4</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1000500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1000500%26sid%3Dliteratum%253Aachs%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DMusser%26aufirst%3DT.%2BK.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DMagilavy%26aufirst%3DD.%2BB.%26atitle%3DAn%2520Oral%2520Spleen%2520Tyrosine%2520Kinase%2520%2528Syk%2529%2520Inhibitor%2520for%2520Rheumatoid%2520Arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1303%26epage%3D1312%26doi%3D10.1056%2FNEJMoa1000500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-120302, (OSKIRA-2):
A Phase III, Multi-center, Randomised, Double-Blind, Placebo-Controlled,
Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium
in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs
Oral SYK Inhibition in Rheumatoid Arthritis (OSKIRA) - 2 Study.</i> <a href="https://citeline.informa.com/trials/details/120302?qId=c470e1cf-5602-472d-af98-cf9e6aad4f7a" class="extLink">https://citeline.informa.com/trials/details/120302?qId=c470e1cf-5602-472d-af98-cf9e6aad4f7a</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-120302%2C+%28OSKIRA-2%29%3A%0AA+Phase+III%2C+Multi-center%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C%0AParallel+Group+Study+of+Two+Dosing+Regimens+of+Fostamatinib+Disodium%0Ain+Rheumatoid+Arthritis+Patients+with+an+Inadequate+Response+to+DMARDs%0AOral+SYK+Inhibition+in+Rheumatoid+Arthritis+%28OSKIRA%29+-+2+Study.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F120302%3FqId%3Dc470e1cf-5602-472d-af98-cf9e6aad4f7a+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-120302%252C%2520%2528OSKIRA-2%2529%253A%250AA%2520Phase%2520III%252C%2520Multi-center%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%250AParallel%2520Group%2520Study%2520of%2520Two%2520Dosing%2520Regimens%2520of%2520Fostamatinib%2520Disodium%250Ain%2520Rheumatoid%2520Arthritis%2520Patients%2520with%2520an%2520Inadequate%2520Response%2520to%2520DMARDs%250AOral%2520SYK%2520Inhibition%2520in%2520Rheumatoid%2520Arthritis%2520%2528OSKIRA%2529%2520-%25202%2520Study.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-134518 (OSKIRA-3):
A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled,
Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium
in Rheumatoid Arthritis Patients with Inadequate Response to a TNF-alpha
Antagonist.</i> <a href="https://citeline.informa.com/trials/details/120302?qId=c470e1cf-5602-472d-af98-cf9e6aad4f7a" class="extLink">https://citeline.informa.com/trials/details/120302?qId=c470e1cf-5602-472d-af98-cf9e6aad4f7a</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-134518+%28OSKIRA-3%29%3A%0AA+Phase+III%2C+Multi-centre%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C%0AParallel+Group+Study+of+Two+Dosing+Regimens+of+Fostamatinib+Disodium%0Ain+Rheumatoid+Arthritis+Patients+with+Inadequate+Response+to+a+TNF-alpha%0AAntagonist.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F120302%3FqId%3Dc470e1cf-5602-472d-af98-cf9e6aad4f7a+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-134518%2520%2528OSKIRA-3%2529%253A%250AA%2520Phase%2520III%252C%2520Multi-centre%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%250AParallel%2520Group%2520Study%2520of%2520Two%2520Dosing%2520Regimens%2520of%2520Fostamatinib%2520Disodium%250Ain%2520Rheumatoid%2520Arthritis%2520Patients%2520with%2520Inadequate%2520Response%2520to%2520a%2520TNF-alpha%250AAntagonist.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-134522, (OSKIRA-1):
A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled,
Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium
in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate
OSKIRA: Oral Syk Inhibition in Rheumatoid Arthritis.</i> <a href="https://citeline.informa.com/trials/details/134522?qId=ad330157-7712-4ed5-826c-f50e8aadddfc" class="extLink">https://citeline.informa.com/trials/details/134522?qId=ad330157-7712-4ed5-826c-f50e8aadddfc</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-134522%2C+%28OSKIRA-1%29%3A%0AA+Phase+III%2C+Multi-centre%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C%0AParallel+Group+Study+of+Two+Dosing+Regimens+of+Fostamatinib+Disodium%0Ain+Rheumatoid+Arthritis+Patients+with+an+Inadequate+Response+to+Methotrexate%0AOSKIRA%3A+Oral+Syk+Inhibition+in+Rheumatoid+Arthritis.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F134522%3FqId%3Dad330157-7712-4ed5-826c-f50e8aadddfc+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-134522%252C%2520%2528OSKIRA-1%2529%253A%250AA%2520Phase%2520III%252C%2520Multi-centre%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%250AParallel%2520Group%2520Study%2520of%2520Two%2520Dosing%2520Regimens%2520of%2520Fostamatinib%2520Disodium%250Ain%2520Rheumatoid%2520Arthritis%2520Patients%2520with%2520an%2520Inadequate%2520Response%2520to%2520Methotrexate%250AOSKIRA%253A%2520Oral%2520Syk%2520Inhibition%2520in%2520Rheumatoid%2520Arthritis.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-136490, A Long-Term
Extension Study to Assess the Safety and Efficacy of Fostamatinib
Disodium (FosD) in the Treatment of Rheumatoid Arthritis.</i> <a href="https://citeline.informa.com/trials/details/136490?qId=67e62c4f-b508-4d9b-8ef9-37ba0a61c0e1" class="extLink">https://citeline.informa.com/trials/details/136490?qId=67e62c4f-b508-4d9b-8ef9-37ba0a61c0e1</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-136490%2C+A+Long-Term%0AExtension+Study+to+Assess+the+Safety+and+Efficacy+of+Fostamatinib%0ADisodium+%28FosD%29+in+the+Treatment+of+Rheumatoid+Arthritis.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F136490%3FqId%3D67e62c4f-b508-4d9b-8ef9-37ba0a61c0e1+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-136490%252C%2520A%2520Long-Term%250AExtension%2520Study%2520to%2520Assess%2520the%2520Safety%2520and%2520Efficacy%2520of%2520Fostamatinib%250ADisodium%2520%2528FosD%2529%2520in%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span>; <span class="NLM_string-name">Jiang, X.</span>; <span class="NLM_string-name">Qin, D.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Yang, J.</span>; <span class="NLM_string-name">Wu, A.</span>; <span class="NLM_string-name">Huang, F.</span>; <span class="NLM_string-name">Ye, Y.</span>; <span class="NLM_string-name">Wu, J.</span></span>, <span> </span><span class="NLM_article-title">Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</span>.  <i>Frontiers in Pharmacology</i> <span class="NLM_year">2019</span>,  <span class="NLM_volume">10</span> (<span class="NLM_issue">897</span>), <span class="refDoi"> DOI: 10.3389/fphar.2019.00897</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.3389%2Ffphar.2019.00897" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Kang&author=X.+Jiang&author=D.+Qin&author=L.+Wang&author=J.+Yang&author=A.+Wu&author=F.+Huang&author=Y.+Ye&author=J.+Wu&title=Frontiers+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.3389%252Ffphar.2019.00897%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Multiple%2520Dosages%2520of%2520Fostamatinib%2520in%2520Adult%2520Patients%2520With%2520Rheumatoid%2520Arthritis%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26btitle%3DFrontiers%2520in%2520Pharmacology%26date%3D2019%26volume%3D10%26issue%3D897%26doi%3D10.3389%2Ffphar.2019.00897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rolf, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldman-Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellawell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braddock, M.</span></span> <span> </span><span class="NLM_article-title">In Vitro Pharmacological Profiling of R406 Identifies Molecular Targets Underlying the Clinical Effects of Fostamatinib</span>. <i>Pharmacology Res. Perspectives</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e00175</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fprp2.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26516587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&issue=5&author=M.+G.+Rolfauthor=J.+O.+Curwenauthor=M.+Veldman-Jonesauthor=C.+Eberleinauthor=J.+Wangauthor=A.+Harmerauthor=C.+J.+Hellawellauthor=M.+Braddock&title=In+Vitro+Pharmacological+Profiling+of+R406+Identifies+Molecular+Targets+Underlying+the+Clinical+Effects+of+Fostamatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib</span></div><div class="casAuthors">Rolf, Michael G.; Curwen, Jon O.; Veldman-Jones, Margaret; Eberlein, Cath; Wang, Jianyan; Harmer, Alex; Hellawell, Caroline J.; Braddock, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology Research & Perspectives</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e00175/1-e00175/12</span>CODEN:
                <span class="NLM_cas:coden">PRPHCA</span>;
        ISSN:<span class="NLM_cas:issn">2052-1707</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Off-target pharmacol. may contribute to both adverse and beneficial effects of a new drug.  In vitro pharmacol. profiling is often applied early in drug discovery; there are fewer reports addressing the relevance of broad profiles to clin. adverse effects.  Here, we have characterized the pharmacol. profile of the active metabolite of fostamatinib, R406, linking an understanding of drug selectivity to the increase in blood pressure obsd. in clin. studies.  R406 was profiled in a broad range of in vitro assays to generate a comprehensive pharmacol. profile and key targets were further investigated using functional and cellular assay systems.  A combination of traditional literature searches and text-mining approaches established potential mechanistic links between the profile of R406 and clin. side effects.  R406 was selective outside the kinase domain, with only antagonist activity at the adenosine A3 receptor in the range relevant to clin. effects.  R406 was less selective in the kinase domain, having activity at many protein kinases at therapeutically relevant concns. when tested in multiple in vitro systems.  Systematic literature analyses identified KDR as the probable target underlying the blood pressure increase obsd. in patients.  While the in vitro pharmacol. profile of R406 suggests a lack of selectivity among kinases, a combination of classical searching and text-mining approaches rationalized the complex profile establishing linkage between off-target pharmacol. and clin. obsd. effects.  These results demonstrate the utility of in vitro pharmacol. profiling for a compd. in late-stage clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYLaOYcHUvq7Vg90H21EOLACvtfcHk0ljVpYULUWtW8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjurvJ&md5=101df05b530d6928568bd3b8b2f651fa</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fprp2.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.175%26sid%3Dliteratum%253Aachs%26aulast%3DRolf%26aufirst%3DM.%2BG.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DVeldman-Jones%26aufirst%3DM.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHarmer%26aufirst%3DA.%26aulast%3DHellawell%26aufirst%3DC.%2BJ.%26aulast%3DBraddock%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Pharmacological%2520Profiling%2520of%2520R406%2520Identifies%2520Molecular%2520Targets%2520Underlying%2520the%2520Clinical%2520Effects%2520of%2520Fostamatinib%26jtitle%3DPharmacology%2520Res.%2520Perspectives%26date%3D2015%26volume%3D3%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberstock-Debic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gretler, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mant, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurcevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span> <span> </span><span class="NLM_article-title">PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1002/jcph.794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1002%2Fjcph.794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27406873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlSrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=194-210&issue=2&author=G.+Coffeyauthor=A.+Raniauthor=A.+Betzauthor=Y.+Pakauthor=H.+Haberstock-Debicauthor=A.+Pandeyauthor=S.+Hollenbachauthor=D.+D.+Gretlerauthor=T.+Mantauthor=S.+Jurcevicauthor=U.+Sinha&title=PRT062607+Achieves+Complete+Inhibition+of+the+Spleen+Tyrosine+Kinase+at+Tolerated+Exposures+Following+Oral+Dosing+in+Healthy+Volunteers&doi=10.1002%2Fjcph.794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers</span></div><div class="casAuthors">Coffey, Greg; Rani, Aradhana; Betz, Andreas; Pak, Yvonne; Haberstock-Debic, Helena; Pandey, Anjali; Hollenbach, Stanley; Gretler, Daniel D.; Mant, Tim; Jurcevic, Stipo; Sinha, Uma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">194-210</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it an intriguing target for the treatment of inflammatory and autoimmune disorders as well as certain B-cell malignancies.  We have previously reported on the discovery and preclin. characterization of PRT062607, a potent and highly selective inhibitor of SYK that exhibits robust anti-inflammatory activity in a variety of animal models.  Here we present data from our first human studies aimed at characterizing the pharmacokinetics (PK), pharmacodynamics (PD), and safety of PRT062607 in healthy volunteers following single and multiple oral administrations.  PRT062607 demonstrated a favorable PK profile and the ability to completely inhibit SYK activity in multiple whole-blood assays.  The PD half-life in the more sensitive assays was approx. 24 h and returned to predose levels by 72 h.  Selectivity for SYK was obsd. at all dose levels tested.  Anal. of the PK/PD relationship indicated an IC50 of 324 nM for inhibition of B-cell antigen receptor-mediated B-cell activation and 205 nM for inhibition of FcεRI-mediated basophil degranulation.  PRT062607 was safe and well tolerated across the entire range of doses.  Clin. PK/PD was related to in vivo anti-inflammatory activity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concns. may be safely achieved in humans for the treatment of autoimmune disease.  PRT062607 has a desirable PK profile and is capable of safely, potently, and selectively suppressing SYK kinase function in humans following once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCmfMLrtasGbVg90H21EOLACvtfcHk0ljVpYULUWtW8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlSrtw%253D%253D&md5=93d8c5128dbd3d21a51335941f06a8c1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1002%2Fjcph.794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.794%26sid%3Dliteratum%253Aachs%26aulast%3DCoffey%26aufirst%3DG.%26aulast%3DRani%26aufirst%3DA.%26aulast%3DBetz%26aufirst%3DA.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DGretler%26aufirst%3DD.%2BD.%26aulast%3DMant%26aufirst%3DT.%26aulast%3DJurcevic%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DU.%26atitle%3DPRT062607%2520Achieves%2520Complete%2520Inhibition%2520of%2520the%2520Spleen%2520Tyrosine%2520Kinase%2520at%2520Tolerated%2520Exposures%2520Following%2520Oral%2520Dosing%2520in%2520Healthy%2520Volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D57%26issue%3D2%26spage%3D194%26epage%3D210%26doi%3D10.1002%2Fjcph.794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span> </span><span class="NLM_article-title">Trial Trove</span>.  <i>TrialTroveID-174235,
A Phase
II Trial of Syk Inhibitor for Systemic Lupus Erythematosus.</i> <a href="https://citeline.informa.com/trials/details/174235?qId=06f0e751-f3d6-4797-9193-ae485615c160" class="extLink">https://citeline.informa.com/trials/details/174235?qId=06f0e751-f3d6-4797-9193-ae485615c160</a> (accessed Jun 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Trial+Trove.+TrialTroveID-174235%2C%0AA+Phase%0AII+Trial+of+Syk+Inhibitor+for+Systemic+Lupus+Erythematosus.+https%3A%2F%2Fciteline.informa.com%2Ftrials%2Fdetails%2F174235%3FqId%3D06f0e751-f3d6-4797-9193-ae485615c160+%28accessed+Jun+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTrial%2520Trove%26btitle%3DTrialTroveID-174235%252C%250AA%2520Phase%250AII%2520Trial%2520of%2520Syk%2520Inhibitor%2520for%2520Systemic%2520Lupus%2520Erythematosus.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamorska-Dyga, A.</span></span> <span> </span><span class="NLM_article-title">Syk Inhibitors in Clinical Development for Hematological Malignancies</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">145</span>, <span class="refDoi"> DOI: 10.1186/s13045-017-0512-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1186%2Fs13045-017-0512-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28754125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2gsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=145&author=D.+Liuauthor=A.+Mamorska-Dyga&title=Syk+Inhibitors+in+Clinical+Development+for+Hematological+Malignancies&doi=10.1186%2Fs13045-017-0512-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Syk inhibitors in clinical development for hematological malignancies</span></div><div class="casAuthors">Liu, Delong; Mamorska-Dyga, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145/1-145/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells.  Syk was recognized as a crit. element in the B-cell receptor signaling pathway.  Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors.  Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clin. trials.  The second generation compd., entospletinib, showed promising results in clin. trials against B-cell malignancies, mainly chronic lymphoid leukemia.  Syk inhibitors are being evaluated in combination regimens in multiple malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI4gAk4MLv-7Vg90H21EOLACvtfcHk0libLnI7Xa_0GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2gsrbJ&md5=ed423c793913414c2966af15bd4457c4</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1186%2Fs13045-017-0512-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-017-0512-1%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMamorska-Dyga%26aufirst%3DA.%26atitle%3DSyk%2520Inhibitors%2520in%2520Clinical%2520Development%2520for%2520Hematological%2520Malignancies%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D10%26spage%3D145%26doi%3D10.1186%2Fs13045-017-0512-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chavarría-Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vance, R. E.</span></span> <span> </span><span class="NLM_article-title">The NLRP1 Inflammasomes</span>. <i>Immunological Reviews</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>265</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1111/imr.12283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1111%2Fimr.12283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=25879281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1Sqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=2015&pages=22-34&author=J.+Chavarr%C3%ADa-Smithauthor=R.+E.+Vance&title=The+NLRP1+Inflammasomes&doi=10.1111%2Fimr.12283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP1 inflammasomes</span></div><div class="casAuthors">Chavarria-Smith, Joseph; Vance, Russell E.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-34</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Inflammasomes are cytosolic protein complexes that serve as platforms for the recruitment and activation of the pro-inflammatory CASPASE-1 protease.  CASPASE-1 activation leads to processing and maturation of the cytokines interleukin-1β and interleukin-18 and a lytic form of cell death termed pyroptosis.  Inflammasome assembly is initiated by cytosolic sensors in response to microbial infections.  Many of these sensors, including NLRP1 (NLR family, pyrin domain contg. 1), are described to form an inflammasome, but until recently, the mechanism of inflammasome activation and its physiol. functions in host defense have remained unclear.  In the last few years, important advances in our understanding of NLRP1 biol. have been achieved.  In this review, we discuss the activation of NLRP1 by various stimuli, including Bacillus anthracis lethal toxin, Toxoplasma gondii, muramyl dipeptide, and host intracellular ATP depletion.  The role NLRP1 plays in pathogen recognition and resistance during infection is also discussed, as is the regulation of NLRP1 by host and viral proteins.  We conclude by discussing the unexpected differences in the mechanism of NLRP1 inflammasome activation, as compared to the activation of other inflammasomes, such as the NAIP (NLR family, apoptosis inhibitory protein)/NLRC4 inflammasomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqrHKpelBISrVg90H21EOLACvtfcHk0libLnI7Xa_0GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1Sqtb8%253D&md5=4ff66ff30ba1136982dab3cf8d8b8cab</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1111%2Fimr.12283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12283%26sid%3Dliteratum%253Aachs%26aulast%3DChavarr%25C3%25ADa-Smith%26aufirst%3DJ.%26aulast%3DVance%26aufirst%3DR.%2BE.%26atitle%3DThe%2520NLRP1%2520Inflammasomes%26jtitle%3DImmunological%2520Reviews%26date%3D2015%26volume%3D265%26spage%3D22%26epage%3D34%26doi%3D10.1111%2Fimr.12283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, J. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobota, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutertre, C.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginhoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irving, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-F.</span></span> <span> </span><span class="NLM_article-title">Dampened NLRP3-Mediated Inflammation in Bats and Implications for a Special Viral Reservoir Host</span>. <i>Nature Microbiology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1038/s41564-019-0371-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41564-019-0371-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30804542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsVyrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=789-799&author=M.+Ahnauthor=D.+E.+Andersonauthor=Q.+Zhangauthor=C.+W.+Tanauthor=B.+L.+Limauthor=K.+Lukoauthor=M.+Wenauthor=W.+N.+Chiaauthor=S.+Maniauthor=L.+C.+Wangauthor=J.+H.+J.+Ngauthor=R.+M.+Sobotaauthor=C.-A.+Dutertreauthor=F.+Ginhouxauthor=Z.-L.+Shiauthor=A.+T.+Irvingauthor=L.-F.+Wang&title=Dampened+NLRP3-Mediated+Inflammation+in+Bats+and+Implications+for+a+Special+Viral+Reservoir+Host&doi=10.1038%2Fs41564-019-0371-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host</span></div><div class="casAuthors">Ahn, Matae; Anderson, Danielle E.; Zhang, Qian; Tan, Chee Wah; Lim, Beng Lee; Luko, Katarina; Wen, Ming; Chia, Wan Ni; Mani, Shailendra; Wang, Loo Chien; Ng, Justin Han Jia; Sobota, Radoslaw M.; Dutertre, Charles-Antoine; Ginhoux, Florent; Shi, Zheng-Li; Irving, Aaron T.; Wang, Lin-Fa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">789-799</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Bats are special in their ability to host emerging viruses.  As the only flying mammal, bats endure high metabolic rates yet exhibit elongated lifespans.  It is currently unclear whether these unique features are interlinked.  The important inflammasome sensor, NLR family pyrin domain contg. 3 (NLRP3), has been linked to both viral-induced and age-related inflammation.  Here, we report significantly dampened activation of the NLRP3 inflammasome in bat primary immune cells compared to human or mouse counterparts.  Lower induction of apoptosis-assocd. speck-like protein contg. a CARD (ASC) speck formation and secretion of interleukin-1β in response to both 'sterile' stimuli and infection with multiple zoonotic viruses including influenza A virus (-single-stranded (ss) RNA), Melaka virus (PRV3M, double-stranded RNA) and Middle East respiratory syndrome coronavirus (+ssRNA) was obsd.  Importantly, this redn. of inflammation had no impact on the overall viral loads.  We identified dampened transcriptional priming, a novel splice variant and an altered leucine-rich repeat domain of bat NLRP3 as the cause.  Our results elucidate an important mechanism through which bats dampen inflammation with implications for longevity and unique viral reservoir status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTDTFm3XuF_LVg90H21EOLACvtfcHk0liHbCJ95mgwbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsVyrtbo%253D&md5=35f29689eb0fde042b548c36402fed02</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1038%2Fs41564-019-0371-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41564-019-0371-3%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DD.%2BE.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTan%26aufirst%3DC.%2BW.%26aulast%3DLim%26aufirst%3DB.%2BL.%26aulast%3DLuko%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DM.%26aulast%3DChia%26aufirst%3DW.%2BN.%26aulast%3DMani%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%2BC.%26aulast%3DNg%26aufirst%3DJ.%2BH.%2BJ.%26aulast%3DSobota%26aufirst%3DR.%2BM.%26aulast%3DDutertre%26aufirst%3DC.-A.%26aulast%3DGinhoux%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DZ.-L.%26aulast%3DIrving%26aufirst%3DA.%2BT.%26aulast%3DWang%26aufirst%3DL.-F.%26atitle%3DDampened%2520NLRP3-Mediated%2520Inflammation%2520in%2520Bats%2520and%2520Implications%2520for%2520a%2520Special%2520Viral%2520Reservoir%2520Host%26jtitle%3DNature%2520Microbiology%26date%3D2019%26volume%3D4%26spage%3D789%26epage%3D799%26doi%3D10.1038%2Fs41564-019-0371-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichinohe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span> <span> </span><span class="NLM_article-title">Influenza Virus Activates Inflammasomes via its Intracellular M2 Ion Channel</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/ni.1861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fni.1861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=20383149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFaks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=404-410&issue=5&author=T.+Ichinoheauthor=I.+K.+Pangauthor=A.+Iwasaki&title=Influenza+Virus+Activates+Inflammasomes+via+its+Intracellular+M2+Ion+Channel&doi=10.1038%2Fni.1861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus activates inflammasomes via its intracellular M2 ion channel</span></div><div class="casAuthors">Ichinohe, Takeshi; Pang, Iris K.; Iwasaki, Akiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-410</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza virus, a neg.-stranded RNA virus that causes severe illness in humans and animals, stimulates the inflammasome through the Nod-like receptor NLRP3.  However, the mechanism by which influenza virus activates the NLRP3 inflammasome is unknown.  Here the authors show that the influenza virus M2 protein, a proton-selective ion channel important in viral pathogenesis, stimulates the NLRP3 inflammasome pathway.  M2 channel activity was required for the activation of inflammasomes by influenza and was sufficient to activate inflammasomes in primed macrophages and dendritic cells.  M2-induced activation of inflammasomes required its localization to the Golgi app. and was dependent on the pH gradient.  The authors' results show a mechanism by which influenza virus infection activates inflammasomes and identify the sensing of disturbances in intracellular ionic concns. as a previously unknown pathogen-recognition pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkq1MNEoVjp7Vg90H21EOLACvtfcHk0liHbCJ95mgwbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFaks7Y%253D&md5=4b772dca3cb7b7fc9229e40e0636278c</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1038%2Fni.1861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1861%26sid%3Dliteratum%253Aachs%26aulast%3DIchinohe%26aufirst%3DT.%26aulast%3DPang%26aufirst%3DI.%2BK.%26aulast%3DIwasaki%26aufirst%3DA.%26atitle%3DInfluenza%2520Virus%2520Activates%2520Inflammasomes%2520via%2520its%2520Intracellular%2520M2%2520Ion%2520Channel%26jtitle%3DNat.%2520Immunol.%26date%3D2010%26volume%3D11%26issue%3D5%26spage%3D404%26epage%3D410%26doi%3D10.1038%2Fni.1861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scull, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holl, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElvania-TeKippe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taxman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickles, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, J. P.-Y.</span></span> <span> </span><span class="NLM_article-title">The NLRP3 Inflammasome Mediates In Vivo Innate Immunity to Influenza A Virus through Recognition of Viral RNA</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2009.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2009.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19362020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Sqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=556-565&issue=4&author=I.+C.+Allenauthor=M.+A.+Scullauthor=C.+B.+Mooreauthor=E.+K.+Hollauthor=E.+McElvania-TeKippeauthor=D.+J.+Taxmanauthor=E.+H.+Guthrieauthor=R.+J.+Picklesauthor=J.+P.-Y.+Ting&title=The+NLRP3+Inflammasome+Mediates+In+Vivo+Innate+Immunity+to+Influenza+A+Virus+through+Recognition+of+Viral+RNA&doi=10.1016%2Fj.immuni.2009.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA</span></div><div class="casAuthors">Allen, Irving C.; Scull, Margaret A.; Moore, Chris B.; Holl, Eda K.; McElvania-TeKippe, Erin; Taxman, Debra J.; Guthrie, Elizabeth H.; Pickles, Raymond J.; Ting, Jenny P.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The nucleotide-binding domain and leucine-rich-repeat-contg. (NLR) family of pattern-recognition mols. mediate host immunity to various pathogenic stimuli.  However, in vivo evidence for the involvement of NLR proteins in viral sensing has not been widely investigated and remains controversial.  As a test of the physiol. role of the NLR mol. NLRP3 during RNA viral infection, we explored the in vivo role of NLRP3 inflammasome components during influenza virus infection.  Mice lacking Nlrp3, Pycard, or caspase-1, but not Nlrc4, exhibited dramatically increased mortality and a reduced immune response after exposure to the influenza virus.  Utilizing analogs of dsRNA (poly(I:C)) and ssRNA (ssRNA40), we demonstrated that an NLRP3-mediated response could be activated by RNA species.  Mechanistically, NLRP3 inflammasome activation by the influenza virus was dependent on lysosomal maturation and reactive oxygen species (ROS).  Inhibition of ROS induction eliminated IL-1β prodn. in animals during influenza infection.  Together, these data place the NLRP3 inflammasome as an essential component in host defense against influenza infection through the sensing of viral RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYN46-nyFYCLVg90H21EOLACvtfcHk0liSM6A0yn1LSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Sqsr8%253D&md5=b5478e1b5b21ca5531c7ca833fa83ce1</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2009.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2009.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DI.%2BC.%26aulast%3DScull%26aufirst%3DM.%2BA.%26aulast%3DMoore%26aufirst%3DC.%2BB.%26aulast%3DHoll%26aufirst%3DE.%2BK.%26aulast%3DMcElvania-TeKippe%26aufirst%3DE.%26aulast%3DTaxman%26aufirst%3DD.%2BJ.%26aulast%3DGuthrie%26aufirst%3DE.%2BH.%26aulast%3DPickles%26aufirst%3DR.%2BJ.%26aulast%3DTing%26aufirst%3DJ.%2BP.-Y.%26atitle%3DThe%2520NLRP3%2520Inflammasome%2520Mediates%2520In%2520Vivo%2520Innate%2520Immunity%2520to%2520Influenza%2520A%2520Virus%2520through%2520Recognition%2520of%2520Viral%2520RNA%26jtitle%3DImmunity%26date%3D2009%26volume%3D30%26issue%3D4%26spage%3D556%26epage%3D565%26doi%3D10.1016%2Fj.immuni.2009.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tate, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, J. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzog, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansell, A.</span></span> <span> </span><span class="NLM_article-title">Reassessing the Role of the NLRP3 Inflammasome During Pathogenic Influenza A Virus Infection via Temporal Inhibition</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">27912</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1038/srep27912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fsrep27912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28442746" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1-8&issue=27912&author=M.+D.+Tateauthor=J.+D.+H.+Ongauthor=J.+K.+Dowlingauthor=J.+L.+McAuleyauthor=A.+B.+Robertsonauthor=E.+Latzauthor=G.+R.+Drummondauthor=M.+A.+Cooperauthor=P.+J.+Hertzogauthor=A.+Mansell&title=Reassessing+the+Role+of+the+NLRP3+Inflammasome+During+Pathogenic+Influenza+A+Virus+Infection+via+Temporal+Inhibition&doi=10.1038%2Fsrep27912"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fsrep27912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep27912%26sid%3Dliteratum%253Aachs%26aulast%3DTate%26aufirst%3DM.%2BD.%26aulast%3DOng%26aufirst%3DJ.%2BD.%2BH.%26aulast%3DDowling%26aufirst%3DJ.%2BK.%26aulast%3DMcAuley%26aufirst%3DJ.%2BL.%26aulast%3DRobertson%26aufirst%3DA.%2BB.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DDrummond%26aufirst%3DG.%2BR.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DHertzog%26aufirst%3DP.%2BJ.%26aulast%3DMansell%26aufirst%3DA.%26atitle%3DReassessing%2520the%2520Role%2520of%2520the%2520NLRP3%2520Inflammasome%2520During%2520Pathogenic%2520Influenza%2520A%2520Virus%2520Infection%2520via%2520Temporal%2520Inhibition%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D27912%26spage%3D1%26epage%3D8%26doi%3D10.1038%2Fsrep27912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldridge, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellebedy, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamkanfi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webby, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, T.-D.</span></span> <span> </span><span class="NLM_article-title">The Intracellular Sensor NLRP3Mediates Key Innate and Healing Responses to Infleunza A Virus via the Regulation of Caspase-1</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2009.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.immuni.2009.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19362023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Sqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=566-575&author=P.+G.+Thomasauthor=P.+Dashauthor=J.+R.+Aldridgeauthor=A.+H.+Ellebedyauthor=C.+Reynoldsauthor=A.+J.+Funkauthor=W.+J.+Martinauthor=M.+Lamkanfiauthor=R.+J.+Webbyauthor=K.+L.+Boydauthor=P.+C.+Dohertyauthor=T.-D.+Kanneganti&title=The+Intracellular+Sensor+NLRP3Mediates+Key+Innate+and+Healing+Responses+to+Infleunza+A+Virus+via+the+Regulation+of+Caspase-1&doi=10.1016%2Fj.immuni.2009.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1</span></div><div class="casAuthors">Thomas, Paul G.; Dash, Pradyot; Aldridge, Jerry R., Jr.; Ellebedy, Ali H.; Reynolds, Cory; Funk, Amy J.; Martin, William J.; Lamkanfi, Mohamed; Webby, Richard J.; Boyd, Kelli L.; Doherty, Peter C.; Kanneganti, Thirumala-Devi</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">566-575</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Virus-induced interleukin-1β (IL-1β) and IL-18 prodn. in macrophages are mediated via caspase-1 pathway.  Multiple microbial components, including viral RNA, are thought to trigger assembly of the cryopyrin inflammasome resulting in caspase-1 activation.  Here, we demonstrated that Nlrp3-/- and Casp1-/- mice were more susceptible than wild-type mice after infection with a pathogenic influenza A virus.  This enhanced morbidity correlated with decreased neutrophil and monocyte recruitment and reduced cytokine and chemokine prodn.  Despite the effect on innate immunity, cryopyrin-deficiency was not assocd. with any obvious defect in virus control or on the later emergence of the adaptive response.  Early epithelial necrosis was, however, more severe in the infected mutants, with extensive collagen deposition leading to later respiratory compromise.  These findings reveal a function of the cryopyrin inflammasome in healing responses.  Thus, cryopyrin and caspase-1 are central to both innate immunity and to moderating lung pathol. in influenza pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplgvzh5pP-PLVg90H21EOLACvtfcHk0lif9EdINFdovw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Sqsrw%253D&md5=fcfb5b235b4f0316c6d30661747c2b47</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2009.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2009.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DP.%2BG.%26aulast%3DDash%26aufirst%3DP.%26aulast%3DAldridge%26aufirst%3DJ.%2BR.%26aulast%3DEllebedy%26aufirst%3DA.%2BH.%26aulast%3DReynolds%26aufirst%3DC.%26aulast%3DFunk%26aufirst%3DA.%2BJ.%26aulast%3DMartin%26aufirst%3DW.%2BJ.%26aulast%3DLamkanfi%26aufirst%3DM.%26aulast%3DWebby%26aufirst%3DR.%2BJ.%26aulast%3DBoyd%26aufirst%3DK.%2BL.%26aulast%3DDoherty%26aufirst%3DP.%2BC.%26aulast%3DKanneganti%26aufirst%3DT.-D.%26atitle%3DThe%2520Intracellular%2520Sensor%2520NLRP3Mediates%2520Key%2520Innate%2520and%2520Healing%2520Responses%2520to%2520Infleunza%2520A%2520Virus%2520via%2520the%2520Regulation%2520of%2520Caspase-1%26jtitle%3DImmunity%26date%3D2009%26volume%3D30%26spage%3D566%26epage%3D575%26doi%3D10.1016%2Fj.immuni.2009.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, G.</span></span> <span> </span><span class="NLM_article-title">Hyperactivation of the NLRP3 Inflammasome Protects Mice Against Influenza A Virus Infection via IL-1β Mediated Neutrophil Recruitment</span>. <i>Cytokine+</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2019.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.cyto.2019.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=31055218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVCnt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=115-124&author=J.+Niuauthor=S.+Wuauthor=M.+Chenauthor=K.+Xuauthor=Q.+Guoauthor=A.+Luauthor=L.+Zhaoauthor=B.+Sunauthor=G.+Meng&title=Hyperactivation+of+the+NLRP3+Inflammasome+Protects+Mice+Against+Influenza+A+Virus+Infection+via+IL-1%CE%B2+Mediated+Neutrophil+Recruitment&doi=10.1016%2Fj.cyto.2019.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactivation of the NLRP3 inflammasome protects mice against influenza A virus infection via IL-1β mediated neutrophil recruitment</span></div><div class="casAuthors">Niu, Junling; Wu, Shuxian; Chen, Mingkuan; Xu, Ke; Guo, Qiuhong; Lu, Ailing; Zhao, Liping; Sun, Bing; Meng, Guangxun</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-124</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Host innate immune system is crit. for combating invading microbes including Influenza A virus (IAV).  As an important arm of the innate immunity, the NLRP3 inflammasome has been found essential for protecting host against IAV challenge, while the mechanism remained elusive.  Here we found that mice carrying a gain-of-function mutation in the Nlrp3 gene (Nlrp3R258W) are strongly resistant to IAV infection.  Upon H1N1 IAV infection, the Nlrp3R258W mice exhibited decreased wt. loss, increased survival rate and attenuated lung damage compared with WT littermate controls.  Mechanistically, the resistance of Nlrp3R258W mice to IAV infection was dependent on IL-1β-mediated neutrophil recruitment.  Upon IAV infection, mice carrying the Nlrp3R258W mutation produced more IL-1β than WT mice in the lung, which enhanced neutrophil recruitment locally.  The recruited neutrophils facilitated IAV clearance, so that the viral load in Nlrp3R258W mice was lower than that in control mice.  Conversely, neutrophil depletion in Nlrp3R258W mice compromised IAV clearance.  Taken together, our results demonstrate a previously undescribed mechanism by which hyperactivation of the NLRP3 Inflammasome protects mice from IAV infection through IL-1β mediated neutrophil recruitment, thus suggest that pos. fine tuning the physiol. function of NLRP3 inflammasome can be beneficial for a mammalian host against IAV challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0kuu-_n6EX7Vg90H21EOLACvtfcHk0lh6xtp9nIWWAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVCnt7w%253D&md5=35dfd7dc7cfe2edaef4273782f54f97e</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2019.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2019.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DMeng%26aufirst%3DG.%26atitle%3DHyperactivation%2520of%2520the%2520NLRP3%2520Inflammasome%2520Protects%2520Mice%2520Against%2520Influenza%2520A%2520Virus%2520Infection%2520via%2520IL-1%25CE%25B2%2520Mediated%2520Neutrophil%2520Recruitment%26jtitle%3DCytokine%252B%26date%3D2019%26volume%3D120%26spage%3D115%26epage%3D124%26doi%3D10.1016%2Fj.cyto.2019.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stout-Delgado, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirali, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, K. S.</span></span> <span> </span><span class="NLM_article-title">Impaired NLRP3 Inflammasome Function in Elderly Mice during Influenza Infection is Rescued by Treatment with Nigericin</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">2815</span>– <span class="NLM_lpage">2824</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1103051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1103051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=22327078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1GntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2012&pages=2815-2824&author=H.+W.+Stout-Delgadoauthor=S.+E.+Vaughanauthor=A.+C.+Shiraliauthor=R.+J.+Jaramilloauthor=K.+S.+Harrod&title=Impaired+NLRP3+Inflammasome+Function+in+Elderly+Mice+during+Influenza+Infection+is+Rescued+by+Treatment+with+Nigericin&doi=10.4049%2Fjimmunol.1103051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired NLRP3 Inflammasome Function in Elderly Mice during Influenza Infection Is Rescued by Treatment with Nigericin</span></div><div class="casAuthors">Stout-Delgado, Heather W.; Vaughan, Sarah E.; Shirali, Anushree C.; Jaramillo, Richard J.; Harrod, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2815-2824</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The NLRP3 inflammasome is activated in the lung during influenza viral infection; however, the impact of aging on inflammasome function during influenza infection has not been examd.  In this study, we show that elderly mice infected with a mouse-adapted strain of influenza produced lower levels of IL-1β during in vitro and in vivo infection.  Dendritic cells from elderly mice exhibited decreased expression of ASC, NLRP3, and capase-1 but increased expression of pro-IL-1β, pro-IL-18, and pro-IL-33 compared with dendritic cells from young infected mice.  Treatment with nigericin during influenza infection augmented IL-1β prodn., increased caspase-1 activity, and decreased morbidity and mortality in elderly mice.  Our study demonstrates for the first time, to our knowledge, that during influenza viral infection, elderly mice have impaired NLRP3 inflammasome activity and that treatment with nigericin rescues NLRP3 activation in elderly hosts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopYLpyTCR137Vg90H21EOLACvtfcHk0lh6xtp9nIWWAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1GntLs%253D&md5=d65e75a5db34e23c8fe60c6b694d29c6</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1103051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1103051%26sid%3Dliteratum%253Aachs%26aulast%3DStout-Delgado%26aufirst%3DH.%2BW.%26aulast%3DVaughan%26aufirst%3DS.%2BE.%26aulast%3DShirali%26aufirst%3DA.%2BC.%26aulast%3DJaramillo%26aufirst%3DR.%2BJ.%26aulast%3DHarrod%26aufirst%3DK.%2BS.%26atitle%3DImpaired%2520NLRP3%2520Inflammasome%2520Function%2520in%2520Elderly%2520Mice%2520during%2520Influenza%2520Infection%2520is%2520Rescued%2520by%2520Treatment%2520with%2520Nigericin%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D188%26spage%3D2815%26epage%3D2824%26doi%3D10.4049%2Fjimmunol.1103051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNeela, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neill, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeaton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Rachkidy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLoughlin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrilli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrew, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadioglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavelle, E. C.</span></span> <span> </span><span class="NLM_article-title">Pneumolysin Activates the NLRP3 Inflammasome and Promotes Proinflammatory Cytokines Independently of TLR4</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>), <span class="NLM_elocation-id">e1001191</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1001191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1371%2Fjournal.ppat.1001191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21085613" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&issue=11&author=E.+A.+McNeelaauthor=A.+Burkeauthor=D.+R.+Neillauthor=C.+Baxterauthor=V.+E.+Fernandesauthor=D.+Ferreiraauthor=S.+Smeatonauthor=R.+El-Rachkidyauthor=R.+M.+McLoughlinauthor=A.+Moriauthor=B.+Moranauthor=K.+A.+Fitzgeraldauthor=J.+Tschoppauthor=V.+Petrilliauthor=P.+W.+Andrewauthor=A.+Kadiogluauthor=E.+C.+Lavelle&title=Pneumolysin+Activates+the+NLRP3+Inflammasome+and+Promotes+Proinflammatory+Cytokines+Independently+of+TLR4&doi=10.1371%2Fjournal.ppat.1001191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001191%26sid%3Dliteratum%253Aachs%26aulast%3DMcNeela%26aufirst%3DE.%2BA.%26aulast%3DBurke%26aufirst%3DA.%26aulast%3DNeill%26aufirst%3DD.%2BR.%26aulast%3DBaxter%26aufirst%3DC.%26aulast%3DFernandes%26aufirst%3DV.%2BE.%26aulast%3DFerreira%26aufirst%3DD.%26aulast%3DSmeaton%26aufirst%3DS.%26aulast%3DEl-Rachkidy%26aufirst%3DR.%26aulast%3DMcLoughlin%26aufirst%3DR.%2BM.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DMoran%26aufirst%3DB.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26aulast%3DTschopp%26aufirst%3DJ.%26aulast%3DPetrilli%26aufirst%3DV.%26aulast%3DAndrew%26aufirst%3DP.%2BW.%26aulast%3DKadioglu%26aufirst%3DA.%26aulast%3DLavelle%26aufirst%3DE.%2BC.%26atitle%3DPneumolysin%2520Activates%2520the%2520NLRP3%2520Inflammasome%2520and%2520Promotes%2520Proinflammatory%2520Cytokines%2520Independently%2520of%2520TLR4%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26issue%3D11%26doi%3D10.1371%2Fjournal.ppat.1001191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witzenrath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pache, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutbier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabeling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reppe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meixenberger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorhoi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trendelenburg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimesaat, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bereswill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suttorp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, B.</span></span> <span> </span><span class="NLM_article-title">The NLRP3 Inflammasome is Differentially Activated by Pneumolysin Variants and Contributes to Host Defense in Pneumococcal Pneumonia</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1003143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.1003143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21646297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvValtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=434-440&author=M.+Witzenrathauthor=F.+Pacheauthor=D.+Lorenzauthor=U.+Koppeauthor=B.+Gutbierauthor=C.+Tabelingauthor=K.+Reppeauthor=K.+Meixenbergerauthor=A.+Dorhoiauthor=J.+Maauthor=A.+Holmesauthor=G.+Trendelenburgauthor=M.+M.+Heimesaatauthor=S.+Bereswillauthor=M.+van+der+Lindenauthor=J.+Tschoppauthor=T.+J.+Mitchellauthor=N.+Suttorpauthor=B.+Opitz&title=The+NLRP3+Inflammasome+is+Differentially+Activated+by+Pneumolysin+Variants+and+Contributes+to+Host+Defense+in+Pneumococcal+Pneumonia&doi=10.4049%2Fjimmunol.1003143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The NLRP3 Inflammasome Is Differentially Activated by Pneumolysin Variants and Contributes to Host Defense in Pneumococcal Pneumonia</span></div><div class="casAuthors">Witzenrath, Martin; Pache, Florence; Lorenz, Daniel; Koppe, Uwe; Gutbier, Birgitt; Tabeling, Christoph; Reppe, Katrin; Meixenberger, Karolin; Dorhoi, Anca; Ma, Jiangtao; Holmes, Ashleigh; Trendelenburg, George; Heimesaat, Markus M.; Bereswill, Stefan; van der Linden, Mark; Tschopp, Juerg; Mitchell, Timothy J.; Suttorp, Norbert; Opitz, Bastian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">434-440</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Streptococcus pneumoniae is a leading cause of pneumonia, meningitis, and sepsis.  Pneumococci can be divided into >90 serotypes that show differences in the pathogenicity and invasiveness.  We tested the hypotheses that the innate immune inflammasome pathway is involved in fighting pneumococcal pneumonia and that some invasive pneumococcal types are not recognized by this pathway.  We show that human and murine mononuclear cells responded to S. pneumoniae expressing hemolytic pneumolysin by producing IL-1β.  This IL-1β prodn. depended on the NOD-like receptor family, pyrin domain contg. 3 (NLRP3) inflammasome.  Some serotype 1, serotype 8, and serotype 7F bacteria, which have previously been assocd. with increased invasiveness and with prodn. of toxins with reduced hemolytic activity, or bacterial mutants lacking pneumolysin did not stimulate notable IL-1β prodn.  We further found that NLRP3 was beneficial for mice during pneumonia caused by pneumococci expressing hemolytic pneumolysin and was involved in cytokine prodn. and maintenance of the pulmonary microvascular barrier.  Overall, the inflammasome pathway is protective in pneumonia caused by pneumococci expressing hemolytic toxin but is not activated by clin. important pneumococcal sequence types causing invasive disease.  The study indicates that a virulence factor polymorphism may substantially affect the recognition of bacteria by the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTyHkIuuS577Vg90H21EOLACvtfcHk0lj2eX9VrTGhfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvValtL8%253D&md5=8e2ba1fb62ee9126e53fad5ead63b204</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1003143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1003143%26sid%3Dliteratum%253Aachs%26aulast%3DWitzenrath%26aufirst%3DM.%26aulast%3DPache%26aufirst%3DF.%26aulast%3DLorenz%26aufirst%3DD.%26aulast%3DKoppe%26aufirst%3DU.%26aulast%3DGutbier%26aufirst%3DB.%26aulast%3DTabeling%26aufirst%3DC.%26aulast%3DReppe%26aufirst%3DK.%26aulast%3DMeixenberger%26aufirst%3DK.%26aulast%3DDorhoi%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DHolmes%26aufirst%3DA.%26aulast%3DTrendelenburg%26aufirst%3DG.%26aulast%3DHeimesaat%26aufirst%3DM.%2BM.%26aulast%3DBereswill%26aufirst%3DS.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DM.%26aulast%3DTschopp%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DT.%2BJ.%26aulast%3DSuttorp%26aufirst%3DN.%26aulast%3DOpitz%26aufirst%3DB.%26atitle%3DThe%2520NLRP3%2520Inflammasome%2520is%2520Differentially%2520Activated%2520by%2520Pneumolysin%2520Variants%2520and%2520Contributes%2520to%2520Host%2520Defense%2520in%2520Pneumococcal%2520Pneumonia%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D434%26epage%3D440%26doi%3D10.4049%2Fjimmunol.1003143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, A. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout-Delgado, H. W.</span></span> <span> </span><span class="NLM_article-title">NLRP3 Inflammasome Activation in Aged Macrophages is Diminished During <i>Streptococcus Pneumoniae</i> Infection</span>. <i>American Journal of Physiology-Lung Cellular and Molecular Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">L372</span>– <span class="NLM_lpage">L387</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00393.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1152%2Fajplung.00393.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29097427" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2018&pages=L372-L387&author=S.+J.+Choauthor=K.+Rooneyauthor=A.+M.+K.+Choiauthor=H.+W.+Stout-Delgado&title=NLRP3+Inflammasome+Activation+in+Aged+Macrophages+is+Diminished+During+Streptococcus+Pneumoniae+Infection&doi=10.1152%2Fajplung.00393.2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00393.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00393.2017%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DRooney%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DA.%2BM.%2BK.%26aulast%3DStout-Delgado%26aufirst%3DH.%2BW.%26atitle%3DNLRP3%2520Inflammasome%2520Activation%2520in%2520Aged%2520Macrophages%2520is%2520Diminished%2520During%2520Streptococcus%2520Pneumoniae%2520Infection%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Lung%2520Cellular%2520and%2520Molecular%2520Pharmacology%26date%3D2018%26volume%3D314%26spage%3DL372%26epage%3DL387%26doi%3D10.1152%2Fajplung.00393.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plataki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitzel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout-Delgado, H.</span></span> <span> </span><span class="NLM_article-title">Decreased NLRP3 Inflammasome Expression in Aged Lung may Contribute to Increased Susceptibility to Secondary <i>Streptococcus Pneumoniae</i> Infection</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/j.exger.2017.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.exger.2017.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=29203400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCis73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2018&pages=40-46&author=S.+J.+Choauthor=M.+Platakiauthor=D.+Mitzelauthor=G.+Lowryauthor=K.+Rooneyauthor=H.+Stout-Delgado&title=Decreased+NLRP3+Inflammasome+Expression+in+Aged+Lung+may+Contribute+to+Increased+Susceptibility+to+Secondary+Streptococcus+Pneumoniae+Infection&doi=10.1016%2Fj.exger.2017.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased NLRP3 inflammasome expression in aged lung may contribute to increased susceptibility to secondary Streptococcus pneumoniae infection</span></div><div class="casAuthors">Cho, Soo Jung; Plataki, Maria; Mitzel, Dana; Lowry, Gena; Rooney, Kristen; Stout-Delgado, Heather</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-46</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Post-viral pneumococcal pneumonia is a leading morbidity and mortality in older patients (≥ 65 years of age).  The goal of our current study is to understand the impact of chronol. aging on innate immune responses to a secondary, post viral infection with Streptococcus pneumoniae, a causative agent of bacterial pneumonia.  Using aged murine models of infection, our findings demonstrate increased morbidity and mortality in aged mice within 48 h post-secondary S. pneumoniae infection.  Increased susceptibility of aged mice was assocd. with decreased TLR1, TLR6, and TLR9 mRNA expression and diminished IL1β mRNA expression.  Examn. of NLRP3 inflammasome expression illustrated decreased NLRP3 mRNA expression and decreased IL1β prodn. in aged lung in response to secondary S. pneumoniae infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKor62qdna7Vg90H21EOLACvtfcHk0liTQsHaT1_BfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCis73P&md5=844f92d658146ae4dd300908770c61c1</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.exger.2017.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exger.2017.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DPlataki%26aufirst%3DM.%26aulast%3DMitzel%26aufirst%3DD.%26aulast%3DLowry%26aufirst%3DG.%26aulast%3DRooney%26aufirst%3DK.%26aulast%3DStout-Delgado%26aufirst%3DH.%26atitle%3DDecreased%2520NLRP3%2520Inflammasome%2520Expression%2520in%2520Aged%2520Lung%2520may%2520Contribute%2520to%2520Increased%2520Susceptibility%2520to%2520Secondary%2520Streptococcus%2520Pneumoniae%2520Infection%26jtitle%3DExp.%2520Gerontol.%26date%3D2018%26volume%3D105%26spage%3D40%26epage%3D46%26doi%3D10.1016%2Fj.exger.2017.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molony, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malawista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. R.</span></span> <span> </span><span class="NLM_article-title">Reduced Dynamic Range of Antiviral Innate Immune Responses in Aging</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.exger.2017.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.exger.2017.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=28822811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2gtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2018&pages=130-135&issue=1&author=R.+D.+Molonyauthor=A.+Malawistaauthor=R.+R.+Montgomery&title=Reduced+Dynamic+Range+of+Antiviral+Innate+Immune+Responses+in+Aging&doi=10.1016%2Fj.exger.2017.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced dynamic range of antiviral innate immune responses in aging</span></div><div class="casAuthors">Molony, Ryan D.; Malawista, Anna; Montgomery, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">130-135</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The worldwide population aged ≥ 65 years is increasing and the av. life span is expected to increase another 10 years by 2050.  This extended lifespan is assocd. with a progressive decline in immune function and a paradoxical state of low-grade, chronic inflammation that may contribute to susceptibility to viral infection, and reduced responses to vaccination.  Here we review the effects of aging on innate immune responses to viral pathogens including elements of recognition, signaling, and prodn. of inflammatory mediators.  We specifically focus on age-related changes in key pattern recognition receptor signaling pathways, converging on altered cytokine responses, including a notable impairment of antiviral interferon responses.  We highlight an emergent change in innate immunity that arises during aging - the dampening of the dynamic range of responses to multiple sources of stimulation - which may underlie reduced efficiency of immune responses in aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWBTuv1dkmvrVg90H21EOLACvtfcHk0liTQsHaT1_BfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2gtbrI&md5=6a5fa872cf191e85a9139f4fcff9c11c</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.exger.2017.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exger.2017.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DMolony%26aufirst%3DR.%2BD.%26aulast%3DMalawista%26aufirst%3DA.%26aulast%3DMontgomery%26aufirst%3DR.%2BR.%26atitle%3DReduced%2520Dynamic%2520Range%2520of%2520Antiviral%2520Innate%2520Immune%2520Responses%2520in%2520Aging%26jtitle%3DExp.%2520Gerontol.%26date%3D2018%26volume%3D107%26issue%3D1%26spage%3D130%26epage%3D135%26doi%3D10.1016%2Fj.exger.2017.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, P.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresnigt, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lionakis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groß, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naglik, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hube, B.</span></span> <span> </span><span class="NLM_article-title">The Fungal Peptide Toxin Candidalysin Activates the NLRP3 Inflammasome and Causes Cytolysis in Mononuclear Phagocytes</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4260</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06607-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fs41467-018-06607-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=30323213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A280%3ADC%252BB3czpsFCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4260&author=L.+Kasperauthor=A.+Konigauthor=P.-A.+Koenigauthor=M.+S.+Gresnigtauthor=J.+Westmanauthor=R.+A.+Drummondauthor=M.+S.+Lionakisauthor=O.+Gro%C3%9Fauthor=J.+Rulandauthor=J.+R.+Naglikauthor=B.+Hube&title=The+Fungal+Peptide+Toxin+Candidalysin+Activates+the+NLRP3+Inflammasome+and+Causes+Cytolysis+in+Mononuclear+Phagocytes&doi=10.1038%2Fs41467-018-06607-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes</span></div><div class="casAuthors">Kasper Lydia; Konig Annika; Gresnigt Mark S; Hube Bernhard; Koenig Paul-Albert; Ruland Jurgen; Westman Johannes; Drummond Rebecca A; Lionakis Michail S; Drummond Rebecca A; Gross Olaf; Ruland Jurgen; Ruland Jurgen; Ruland Jurgen; Naglik Julian R; Hube Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4260</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Clearance of invading microbes requires phagocytes of the innate immune system.  However, successful pathogens have evolved sophisticated strategies to evade immune killing.  The opportunistic human fungal pathogen Candida albicans is efficiently phagocytosed by macrophages, but causes inflammasome activation, host cytolysis, and escapes after hypha formation.  Previous studies suggest that macrophage lysis by C. albicans results from early inflammasome-dependent cell death (pyroptosis), late damage due to glucose depletion and membrane piercing by growing hyphae.  Here we show that Candidalysin, a cytolytic peptide toxin encoded by the hypha-associated gene ECE1, is both a central trigger for NLRP3 inflammasome-dependent caspase-1 activation via potassium efflux and a key driver of inflammasome-independent cytolysis of macrophages and dendritic cells upon infection with C. albicans.  This suggests that Candidalysin-induced cell damage is a third mechanism of C. albicans-mediated mononuclear phagocyte cell death in addition to damage caused by pyroptosis and the growth of glucose-consuming hyphae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdAjzJJAvn4bFU0A1HOshhfW6udTcc2eZ7nlULlpE0ELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czpsFCrtg%253D%253D&md5=48e1088c5fcb6cc21a3e8e336fbdf161</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06607-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06607-1%26sid%3Dliteratum%253Aachs%26aulast%3DKasper%26aufirst%3DL.%26aulast%3DKonig%26aufirst%3DA.%26aulast%3DKoenig%26aufirst%3DP.-A.%26aulast%3DGresnigt%26aufirst%3DM.%2BS.%26aulast%3DWestman%26aufirst%3DJ.%26aulast%3DDrummond%26aufirst%3DR.%2BA.%26aulast%3DLionakis%26aufirst%3DM.%2BS.%26aulast%3DGro%25C3%259F%26aufirst%3DO.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DNaglik%26aufirst%3DJ.%2BR.%26aulast%3DHube%26aufirst%3DB.%26atitle%3DThe%2520Fungal%2520Peptide%2520Toxin%2520Candidalysin%2520Activates%2520the%2520NLRP3%2520Inflammasome%2520and%2520Causes%2520Cytolysis%2520in%2520Mononuclear%2520Phagocytes%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4260%26doi%3D10.1038%2Fs41467-018-06607-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hise, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomalka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. A.</span></span> <span> </span><span class="NLM_article-title">An Essential Role for the NLRP3 Inflammasome in Host Defense Against the Human Fungal Pathogen <i>Candida Albicans</i></span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2009.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.chom.2009.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19454352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVClu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=487-497&author=A.+G.+Hiseauthor=J.+Tomalkaauthor=S.+Ganesanauthor=K.+Patelauthor=B.+A.+Hallauthor=G.+D.+Brownauthor=K.+A.+Fitzgerald&title=An+Essential+Role+for+the+NLRP3+Inflammasome+in+Host+Defense+Against+the+Human+Fungal+Pathogen+Candida+Albicans&doi=10.1016%2Fj.chom.2009.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans</span></div><div class="casAuthors">Hise, Amy G.; Tomalka, Jeffrey; Ganesan, Sandhya; Patel, Krupen; Hall, Brian A.; Brown, Gordon D.; Fitzgerald, Katherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">487-497</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">C. albicans is an opportunistic fungal pathogen causing life-threatening mucosal and systemic infections in immunocompromised humans.  Using a murine model of mucosal Candida infection, the authors investigated the role of the proinflammatory cytokine IL-1β in host defense to C. albicans.  They found that the synthesis, processing, and release of IL-1β in response to Candida are tightly controlled and first require transcriptional induction, followed by a second signal leading to caspase-1-mediated cleavage of the pro-IL-1β cytokine.  The known fungal pattern recognition receptors TLR2 and Dectin-1 regulate IL-1β gene transcription, whereas the NLRP3-contg. proinflammatory multiprotein complex, the NLRP3 inflammasome, controls caspase-1-mediated cleavage of pro-IL-1β.  Furthermore, the authors show that TLR2, Dectin-1, and NLRP3 are essential for defense against dissemination of mucosal infection and mortality in vivo.  Therefore, in addn. to sensing bacterial and viral pathogens, the NLRP3 inflammasome senses fungal pathogens and is crit. in host defense against Candida.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBcuTfQ1A1BbVg90H21EOLACvtfcHk0lhmRtmVYy32rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVClu7c%253D&md5=b4a08e1bfcc1ac2f3e7c73ab7fd380be</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2009.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2009.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DHise%26aufirst%3DA.%2BG.%26aulast%3DTomalka%26aufirst%3DJ.%26aulast%3DGanesan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DB.%2BA.%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DFitzgerald%26aufirst%3DK.%2BA.%26atitle%3DAn%2520Essential%2520Role%2520for%2520the%2520NLRP3%2520Inflammasome%2520in%2520Host%2520Defense%2520Against%2520the%2520Human%2520Fungal%2520Pathogen%2520Candida%2520Albicans%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2009%26volume%3D5%26spage%3D487%26epage%3D497%26doi%3D10.1016%2Fj.chom.2009.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutterwala, F. S.</span></span> <span> </span><span class="NLM_article-title">Cutting Edge: <i>Candida albicans</i> Hyphae Formation Triggers Activation of the NLRP3 Inflammasome</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">3578</span>– <span class="NLM_lpage">3581</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.4049%2Fjimmunol.0901323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19684085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOmur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=3578-3581&issue=6&author=S.+Jolyauthor=N.+Maauthor=J.+J.+Sadlerauthor=D.+R.+Sollauthor=S.+L.+Casselauthor=F.+S.+Sutterwala&title=Cutting+Edge%3A+Candida+albicans+Hyphae+Formation+Triggers+Activation+of+the+NLRP3+Inflammasome&doi=10.4049%2Fjimmunol.0901323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Cutting Edge: Candida albicans Hyphae Formation Triggers Activation of the Nlrp3 Inflammasome</span></div><div class="casAuthors">Joly, Sophie; Ma, Ning; Sadler, Jeffrey J.; Soll, David R.; Cassel, Suzanne L.; Sutterwala, Fayyaz S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3578-3581</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The proinflammatory cytokine IL-1β plays an important role in antifungal immunity; however, the mechanisms by which fungal pathogens trigger IL-1β secretion are unclear.  In this study we show that infection with Candida albicans is sensed by the Nlrp3 inflammasome, resulting in the subsequent release of IL-1β.  The ability of C. albicans to switch from a unicellular yeast form into a filamentous form is essential for activation of the Nlrp3 inflammasome, as C. albicans mutants incapable of forming hyphae were defective in their ability to induce macrophage IL-1β secretion.  Nlrp3-deficient mice also demonstrated increased susceptibility to infection with C. albicans, which is consistent with a key role for Nlrp3 in innate immune responses to the pathogen C. albicans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYPsaZsfDXGrVg90H21EOLACvtfcHk0ligByMSvrOrfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOmur3E&md5=2637b6909de303851a9f097797fd2d56</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901323%26sid%3Dliteratum%253Aachs%26aulast%3DJoly%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DN.%26aulast%3DSadler%26aufirst%3DJ.%2BJ.%26aulast%3DSoll%26aufirst%3DD.%2BR.%26aulast%3DCassel%26aufirst%3DS.%2BL.%26aulast%3DSutterwala%26aufirst%3DF.%2BS.%26atitle%3DCutting%2520Edge%253A%2520Candida%2520albicans%2520Hyphae%2520Formation%2520Triggers%2520Activation%2520of%2520the%2520NLRP3%2520Inflammasome%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26issue%3D6%26spage%3D3578%26epage%3D3581%26doi%3D10.4049%2Fjimmunol.0901323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiringhelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apetoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesniere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aymeric, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermaelen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaretakis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfettini, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlemmer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasdemir, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Génin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryffel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanellopoulos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschopp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lidereau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitvogel, L.</span></span> <span> </span><span class="NLM_article-title">Activation of the NLRP3 Inflammasome in Dendritic Cells Induces IL-1β-Dependent Adaptive Immunity Against Tumors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1038/nm.2028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1038%2Fnm.2028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=19767732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGjt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1170-1178&issue=10&author=F.+Ghiringhelliauthor=L.+Apetohauthor=A.+Tesniereauthor=L.+Aymericauthor=Y.+Maauthor=C.+Ortizauthor=K.+Vermaelenauthor=T.+Panaretakisauthor=G.+Mignotauthor=E.+Ullrichauthor=J.-L.+Perfettiniauthor=F.+Schlemmerauthor=E.+Tasdemirauthor=M.+Uhlauthor=P.+G%C3%A9ninauthor=A.+Civasauthor=B.+Ryffelauthor=J.+Kanellopoulosauthor=J.+Tschoppauthor=F.+Andr%C3%A9author=R.+Lidereauauthor=N.+M.+McLaughlinauthor=N.+M.+Haynesauthor=M.+J.+Smythauthor=G.+Kroemerauthor=L.+Zitvogel&title=Activation+of+the+NLRP3+Inflammasome+in+Dendritic+Cells+Induces+IL-1%CE%B2-Dependent+Adaptive+Immunity+Against+Tumors&doi=10.1038%2Fnm.2028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors</span></div><div class="casAuthors">Ghiringhelli, Francois; Apetoh, Lionel; Tesniere, Antoine; Aymeric, Laetitia; Ma, Yuting; Ortiz, Carla; Vermaelen, Karim; Panaretakis, Theocharis; Mignot, Gregoire; Ullrich, Evelyn; Perfettini, Jean-Luc; Schlemmer, Frederic; Tasdemir, Ezgi; Uhl, Martin; Genin, Pierre; Civas, Ahmet; Ryffel, Bernhard; Kanellopoulos, Jean; Tschopp, Juerg; Andre, Fabrice; Lidereau, Rosette; McLaughlin, Nicole M.; Haynes, Nicole M.; Smyth, Mark J.; Kroemer, Guido; Zitvogel, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1170-1178</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The therapeutic efficacy of anticancer chemotherapies may depend on dendritic cells (DCs), which present antigens from dying cancer cells to prime tumor-specific interferon-γ (IFN-γ)-producing T lymphocytes.  Here the authors show that dying tumor cells release ATP, which then acts on P2X7 purinergic receptors from DCs and triggers the NOD-like receptor family, pyrin domain contg.-3 protein (NLRP3)-dependent caspase-1 activation complex ('inflammasome'), allowing for the secretion of interleukin-1β (IL-1β).  The priming of IFN-γ-producing CD8+ T cells by dying tumor cells fails in the absence of a functional IL-1 receptor 1 and in Nlpr3-deficient (Nlrp3-/-) or caspase-1-deficient (Casp-1-/-) mice unless exogenous IL-1β is provided.  Accordingly, anticancer chemotherapy turned out to be inefficient against tumors established in purinergic receptor P2rx7-/- or Nlrp3-/- or Casp1-/- hosts.  Anthracycline-treated individuals with breast cancer carrying a loss-of-function allele of P2RX7 developed metastatic disease more rapidly than individuals bearing the normal allele.  These results indicate that the NLRP3 inflammasome links the innate and adaptive immune responses against dying tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGi-AQIhQXaLVg90H21EOLACvtfcHk0ligByMSvrOrfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGjt7rK&md5=78dfc1d52fcccd8fd2081aeb82274599</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1038%2Fnm.2028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2028%26sid%3Dliteratum%253Aachs%26aulast%3DGhiringhelli%26aufirst%3DF.%26aulast%3DApetoh%26aufirst%3DL.%26aulast%3DTesniere%26aufirst%3DA.%26aulast%3DAymeric%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DOrtiz%26aufirst%3DC.%26aulast%3DVermaelen%26aufirst%3DK.%26aulast%3DPanaretakis%26aufirst%3DT.%26aulast%3DMignot%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DE.%26aulast%3DPerfettini%26aufirst%3DJ.-L.%26aulast%3DSchlemmer%26aufirst%3DF.%26aulast%3DTasdemir%26aufirst%3DE.%26aulast%3DUhl%26aufirst%3DM.%26aulast%3DG%25C3%25A9nin%26aufirst%3DP.%26aulast%3DCivas%26aufirst%3DA.%26aulast%3DRyffel%26aufirst%3DB.%26aulast%3DKanellopoulos%26aufirst%3DJ.%26aulast%3DTschopp%26aufirst%3DJ.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DLidereau%26aufirst%3DR.%26aulast%3DMcLaughlin%26aufirst%3DN.%2BM.%26aulast%3DHaynes%26aufirst%3DN.%2BM.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DZitvogel%26aufirst%3DL.%26atitle%3DActivation%2520of%2520the%2520NLRP3%2520Inflammasome%2520in%2520Dendritic%2520Cells%2520Induces%2520IL-1%25CE%25B2-Dependent%2520Adaptive%2520Immunity%2520Against%2520Tumors%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26issue%3D10%26spage%3D1170%26epage%3D1178%26doi%3D10.1038%2Fnm.2028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arbore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spolski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheinheimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ONeill, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coll, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afzali, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Barber, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, C.</span></span> <span> </span><span class="NLM_article-title">T Helper 1 Immunity Requires Complement-Driven NLRP3 Inflammasome Activity in CD4<sup>+</sup>T Cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">6292</span>), <span class="NLM_elocation-id">aad1210</span> <span class="refDoi"> DOI: 10.1126/science.aad1210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fscience.aad1210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=27313051" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2016&issue=6292&author=G.+Arboreauthor=E.+E.+Westauthor=R.+Spolskiauthor=A.+A.+B.+Robertsonauthor=A.+Klosauthor=C.+Rheinheimerauthor=P.+Dutowauthor=T.+M.+Woodruffauthor=Z.+X.+Yuauthor=L.+A.+ONeillauthor=R.+C.+Collauthor=A.+Sherauthor=W.+J.+Leonardauthor=J.+Kohlauthor=P.+Monkauthor=M.+A.+Cooperauthor=M.+Arnoauthor=B.+Afzaliauthor=H.+J.+Lachmannauthor=A.+P.+Copeauthor=K.+D.+Mayer-Barberauthor=C.+Kemper&title=T+Helper+1+Immunity+Requires+Complement-Driven+NLRP3+Inflammasome+Activity+in+CD4%2BT+Cells&doi=10.1126%2Fscience.aad1210"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad1210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad1210%26sid%3Dliteratum%253Aachs%26aulast%3DArbore%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DE.%2BE.%26aulast%3DSpolski%26aufirst%3DR.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%2BB.%26aulast%3DKlos%26aufirst%3DA.%26aulast%3DRheinheimer%26aufirst%3DC.%26aulast%3DDutow%26aufirst%3DP.%26aulast%3DWoodruff%26aufirst%3DT.%2BM.%26aulast%3DYu%26aufirst%3DZ.%2BX.%26aulast%3DONeill%26aufirst%3DL.%2BA.%26aulast%3DColl%26aufirst%3DR.%2BC.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26aulast%3DKohl%26aufirst%3DJ.%26aulast%3DMonk%26aufirst%3DP.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DArno%26aufirst%3DM.%26aulast%3DAfzali%26aufirst%3DB.%26aulast%3DLachmann%26aufirst%3DH.%2BJ.%26aulast%3DCope%26aufirst%3DA.%2BP.%26aulast%3DMayer-Barber%26aufirst%3DK.%2BD.%26aulast%3DKemper%26aufirst%3DC.%26atitle%3DT%2520Helper%25201%2520Immunity%2520Requires%2520Complement-Driven%2520NLRP3%2520Inflammasome%2520Activity%2520in%2520CD4%252BT%2520Cells%26jtitle%3DScience%26date%3D2016%26volume%3D352%26issue%3D6292%26doi%3D10.1126%2Fscience.aad1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span>; <span class="NLM_string-name">Ghosh, S.</span>; <span class="NLM_string-name">Roush, W. R.</span>; <span class="NLM_string-name">Shen, D.-M.</span>; <span class="NLM_string-name">Katz, J.</span>; <span class="NLM_string-name">Seidel, H. M.</span></span> <span> </span><span class="NLM_article-title">Sulphonamides and Compositions Thereof for Treating Conditions Associated with NLRP Activity</span>. WO <span class="NLM_patent">2019/079119</span>, Apr 25, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+Venkatraman&author=S.+Ghosh&author=W.+R.+Roush&author=D.-M.+Shen&author=J.+Katz&author=H.+M.+Seidel&title=Sulphonamides+and+Compositions+Thereof+for+Treating+Conditions+Associated+with+NLRP+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DSulphonamides%2520and%2520Compositions%2520Thereof%2520for%2520Treating%2520Conditions%2520Associated%2520with%2520NLRP%2520Activity%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taxman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, J. P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damania, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Viral NLR Homolog that Inhibits the Inflammasome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>331</i></span> (<span class="NLM_issue">6015</span>),  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1126/science.1199478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1126%2Fscience.1199478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=21252346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsVequw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2011&pages=330-334&issue=6015&author=S.+M.+Gregoryauthor=B.+K.+Davisauthor=J.+A.+Westauthor=D.+J.+Taxmanauthor=S.-i.+Matsuzawaauthor=J.+C.+Reedauthor=J.+P.+Y.+Tingauthor=B.+Damania&title=Discovery+of+a+Viral+NLR+Homolog+that+Inhibits+the+Inflammasome&doi=10.1126%2Fscience.1199478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Viral NLR Homolog that Inhibits the Inflammasome</span></div><div class="casAuthors">Gregory, Sean M.; Davis, Beckley K.; West, John A.; Taxman, Debra J.; Matsuzawa, Shu-ichi; Reed, John C.; Ting, Jenny P. Y.; Damania, Blossom</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">6015</span>),
    <span class="NLM_cas:pages">330-334</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The NLR (nucleotide binding and oligomerization, leucine-rich repeat) family of proteins senses microbial infections and activates the inflammasome, a multiprotein complex that promotes microbial clearance.  Kaposi's sarcoma-assocd. herpesvirus (KSHV) is linked to several human malignancies.  The authors found that KSHV Orf63 is a viral homolog of human NLRP1.  Orf63 blocked NLRP1-dependent innate immune responses, including caspase-1 activation and processing of interleukins IL-1β and IL-18.  KSHV Orf63 interacted with NLRP1, NLRP3, and NOD2.  Inhibition of Orf63 expression resulted in increased expression of IL-1β during the KSHV life cycle.  Furthermore, inhibition of NLRP1 was necessary for efficient reactivation and generation of progeny virus.  The viral homolog subverts the function of cellular NLRs, which suggests that modulation of NLR-mediated innate immunity is important for the lifelong persistence of herpesviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDjH5iE_d2_rVg90H21EOLACvtfcHk0linyww94X-ZNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsVequw%253D%253D&md5=0403fdf36556d47c935d6cb962779c3b</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1126%2Fscience.1199478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1199478%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DS.%2BM.%26aulast%3DDavis%26aufirst%3DB.%2BK.%26aulast%3DWest%26aufirst%3DJ.%2BA.%26aulast%3DTaxman%26aufirst%3DD.%2BJ.%26aulast%3DMatsuzawa%26aufirst%3DS.-i.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DTing%26aufirst%3DJ.%2BP.%2BY.%26aulast%3DDamania%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520a%2520Viral%2520NLR%2520Homolog%2520that%2520Inhibits%2520the%2520Inflammasome%26jtitle%3DScience%26date%3D2011%26volume%3D331%26issue%3D6015%26spage%3D330%26epage%3D334%26doi%3D10.1126%2Fscience.1199478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duraiswami, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornwald, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, P. J.</span></span> <span> </span><span class="NLM_article-title">High Throughput Screening Identifies ATP-Competitive Inhibitors of the NLRP1 Inflammasome</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2739</span>– <span class="NLM_lpage">2743</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=10.1016%2Fj.bmcl.2015.05.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=26022841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2739-2743&issue=14&author=P.+A.+Harrisauthor=C.+Duraiswamiauthor=D.+T.+Fisherauthor=J.+Fornwaldauthor=S.+J.+Hoffmanauthor=G.+Hofmannauthor=M.+Jiangauthor=R.+Lehrauthor=P.+M.+McCormickauthor=L.+Nickelsauthor=B.+Schwartzauthor=Z.+Wuauthor=G.+Zhangauthor=R.+W.+Marquisauthor=J.+Bertinauthor=P.+J.+Gough&title=High+Throughput+Screening+Identifies+ATP-Competitive+Inhibitors+of+the+NLRP1+Inflammasome&doi=10.1016%2Fj.bmcl.2015.05.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput screening identifies ATP-competitive inhibitors of the NLRP1 inflammasome</span></div><div class="casAuthors">Harris, Philip A.; Duraiswami, Chaya; Fisher, Donald T.; Fornwald, James; Hoffman, Sandra J.; Hofmann, Glenn; Jiang, Ming; Lehr, Ruth; McCormick, Patricia M.; Nickels, Leng; Schwartz, Benjamin; Wu, Zining; Zhang, Guofeng; Marquis, Robert W.; Bertin, John; Gough, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2739-2743</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nod-like receptors (NLRs) are cytoplasmic pattern recognition receptors that are promising targets for the development of anti-inflammatory therapeutics.  Drug discovery efforts targeting NLRs have been hampered by their inherent tendency to form aggregates making protein generation and the development of screening assays very challenging.  Herein we report the results of an HTS screen of NLR family member NLRP1 (NLR family, pyrin domain-contg. 1) which was achieved through the large scale generation of recombinant GST-His-Thrombin-NLRP1 protein.  The screen led to the identification of a diverse set of ATP competitive inhibitors with micromolar potencies.  Activity of these hits was confirmed in a FP binding assay, and two homol. models were employed to predict the possible binding mode of the leading series and facilitate further lead-optimization.  These results highlight a promising strategy for the identification of inhibitors of NLR family members which are rapidly emerging as key drivers of inflammation in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb4l4eWn7-vLVg90H21EOLACvtfcHk0lguxhM8ZF-KkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVert78%253D&md5=5c248a57f2ac7178ade9259b6e5adb11</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.032%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DDuraiswami%26aufirst%3DC.%26aulast%3DFisher%26aufirst%3DD.%2BT.%26aulast%3DFornwald%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DS.%2BJ.%26aulast%3DHofmann%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DLehr%26aufirst%3DR.%26aulast%3DMcCormick%26aufirst%3DP.%2BM.%26aulast%3DNickels%26aufirst%3DL.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DBertin%26aufirst%3DJ.%26aulast%3DGough%26aufirst%3DP.%2BJ.%26atitle%3DHigh%2520Throughput%2520Screening%2520Identifies%2520ATP-Competitive%2520Inhibitors%2520of%2520the%2520NLRP1%2520Inflammasome%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D14%26spage%3D2739%26epage%3D2743%26doi%3D10.1016%2Fj.bmcl.2015.05.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01307&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01307%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01307" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667988c3ae5bd1f3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
